

GenCore version 5.1.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 18:50:04 ; Search time 33.2533 Seconds  
(without alignments)  
1232.039 Million cell updates/sec

Title: US-09-830-321A-1  
Perfect score: 852  
Sequence: 1 MELALLGLVWAGVPIQG.....YQKRLRFVWRPHCRGQTGPGC 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_29Jan04.\*  
1: geneseqp1980s.\*  
2: geneseqp1990s.\*  
3: geneseqp2000s.\*  
4: geneseqp2001s.\*  
5: geneseqp2002s.\*  
6: geneseqp2003as.\*  
7: geneseqp2003bs.\*  
8: geneseqp2004s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	852	100.0	145	3 AAB03627	Aab03627 Human pro
2	852	100.0	145	3 AAB12537	Aab12537 Human sec
3	852	100.0	145	4 AAM24100	Aam24100 Human EST
4	852	100.0	145	4 AAE11924	Aae11924 Human CG9
5	852	100.0	150	4 AAM25827	Aam25827 Human pro
6	846	99.3	145	4 AAU09096	Aau09096 Novel hum
7	846	99.3	145	6 ABR44234	Abr44234 Human can
8	846	99.3	145	6 ABR58706	Abr58706 Human can
9	846	99.3	145	6 ABU63124	Abu63124 Human gro
10	624.5	73.3	144	3 AAB12536	Aab12536 Mouse sec
11	624.5	73.3	144	3 AAB11994	Aab11994 Mouse sec
12	500.5	58.7	116	3 AAB24434	Aab24434 Human PRO
13	500.5	58.7	116	3 AAY99450	Aay99450 Human PRO
14	500.5	58.7	116	4 AAB66199	Aab66199 Novel sec
15	500.5	58.7	116	4 AAU12438	Aau12438 Human PRO
16	500.5	58.7	116	6 ABO17882	Abo17882 Novel hum
17	500.5	58.7	116	6 ABU81136	Abu81136 Human PRO
18	500.5	58.7	116	6 ABU66836	Abu66836 Human PRO
19	500.5	58.7	116	6 ABUS9917	Abus9917 Novel sec
20	500.5	58.7	116	6 ABO25107	Abo25107 Human sec
21	500.5	58.7	116	6 ABU67112	Abu67112 Human sec
22	500.5	58.7	116	6 ADA46053	Ada46053 Novel hum
23	500.5	58.7	116	6 ADA76484	Ada76484 Human PRO
24	500.5	58.7	116	6 ADA19134	Ada19134 Human PRO
25	500.5	58.7	116	6 ADA61757	Ada61757 Homo sapi

26	500.5	58.7	116	6 ADB19542	Adb19542 Novel hum
27	500.5	58.7	116	6 ADB28083	Adb28083 Human PRO
28	500.5	58.7	116	6 ADA86562	Ada86562 Novel hum
29	500.5	58.7	116	6 ADB16126	Adb16126 Human PRO
30	500.5	58.7	116	6 ADA47912	Ada47912 Human PRO
31	500.5	58.7	116	6 ABO33692	Abo33692 Novel hum
32	500.5	58.7	116	6 ADA67707	Ada67707 Human PRO
33	500.5	58.7	116	6 ADB30714	Adb30714 Human PRO
34	500.5	58.7	116	6 ADA86010	Ada86010 Novel hum
35	500.5	58.7	116	6 ADA97222	Ada97222 Human PRO
36	500.5	58.7	116	6 ADA79526	Ada79526 Human PRO
37	500.5	58.7	116	6 ADA87665	Ada87665 Novel hum
38	500.5	58.7	116	6 ADB16867	Adb16867 Human PRO
39	500.5	58.7	116	6 ADA91959	Ada91959 Novel hum
40	500.5	58.7	116	6 ADB15022	Adb15022 Human PRO
41	500.5	58.7	116	6 ADB18983	Adb18983 Novel hum
42	500.5	58.7	116	6 ADA94198	Ada94198 Human PRO
43	500.5	58.7	116	6 ADB20094	Adb20094 Novel hum
44	500.5	58.7	116	6 ADB13406	Adb13406 Human PRO
45	500.5	58.7	116	6 ABO43415	Abo43415 Novel hum

## ALIGNMENTS

RESULT 1  
AAB03627 ID AAB03627 standard; protein; 145 AA.  
XX AC AAB03627;  
XX DT 05-OCT-2000 (first entry)  
XX DE Human phospholipase 1 HPPL1.  
XX KW Human; phospholipase 1; HPPL1; cancer; autoimmune disorder; inflammatory disorder; reproductive disorder; infection.  
XX OS Homo sapiens.  
XX FH Key  
XX FT Peptide Location/Qualifiers  
FT Peptide 1..21 /label= putative\_signal\_peptide  
FT Peptide 1..16 /label= putative\_signal\_peptide  
FT Protein 17..145 /label= putative\_mature\_HPPL1  
FT Active-site 21..145 /label= phospholipase\_A2\_active\_site\_signature  
FT Protein 22..145 /label= putative\_mature\_HPPL1  
FT Modified-site 33 /label= potential\_phosphorylation\_site  
FT Region 44..92 /label= active\_site\_histidine\_region  
FT Region 88..140 /label= active\_site\_aspartic\_acid\_region  
FT Modified-site 89 /label= potential\_glycosylation\_site  
FT Modified-site 98 /label= potential\_phosphorylation\_site  
FT Modified-site 102 /label= potential\_phosphorylation\_site  
XX WO200024911-A2.  
XX PD 04-MAY-2000.  
XX PF 27-OCT-1999; 99WO-US025021.  
XX PR 27-OCT-1998; 98US-00181317.  
XX PR 21-JAN-1999; 99US-00234726.

PA (INCY-) INCYTE PHARM INC.  
 XX Hillman JL, Bandman O, Guesler KJ, Corley NC, Baughn MR;  
 PI Azimzai Y, Lal P, Lu DAM;  
 XX WPI: 2000-350750/30.  
 DR N-PSDB; AAA53269.  
 XX Human phospholipase genes and proteins useful to diagnose, prevent or  
 PT treat cancer, autoimmune or inflammatory or reproductive disorders.  
 XX Claim 1; Page 70-71; 80pp; English.  
 XX The present sequence is human phospholipase 1 (HPL1). This protein is  
 CC involved in the hydrolysis of membrane phospholipids. The protein and its  
 CC coding sequence can be used to diagnose and treat the following: cancers  
 CC such as prostate, breast and testicular cancers, autoimmune and  
 CC inflammatory disorders such as AIDS, allergies, anaemia, asthma,  
 CC atherosclerosis, Crohn's disease, diabetes mellitus, emphysema, Graves'  
 CC disease, irritable bowel syndrome, multiple sclerosis, myasthenia gravis,  
 CC psoriasis, rheumatoid arthritis and systemic lupus erythematosus,  
 CC infection caused by viruses, fungi, bacteria, parasites and protozoa, and  
 CC reproductive disorders including infertility, disruptions of the  
 CC menstrual cycle, polycystic ovary syndrome, ectopic pregnancies,  
 CC disruptions of spermatogenesis, cancers within the reproductive tract and  
 CC impotence  
 XX SQ Sequence 145 AA;  
 Query Match 100.0%; Score 852; DB 3; Length 145;  
 Best Local Similarity 100.0%; Pred. No. 7e-77;  
 Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MELALLCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
 Db 1 MELALLCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
 Qy 61 DWCCQTHDCCYDHLTKQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
 Db 61 DWCCQTHDCCYDHLTKQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
 Qy 121 RNLDYQKRLRFYWRPHCRGOTPGC 145  
 Db 121 RNLDYQKRLRFYWRPHCRGOTPGC 145  
 RESULT 2  
 AAB12537  
 ID AAB12537 standard; protein; 145 AA.  
 XX AAB12537;  
 AC AAB12537;  
 XX 02-NOV-2000 (first entry)  
 DT Human secretory phospholipase A2 protein sequence SEQ ID NO:27.  
 DE Secretory phospholipase A2; PLA2; anti-allergic; anti-inflammatory;  
 XX antibacterial; immunosuppressive; tranquilliser; vulnery; anti-rheumatic;  
 KW antithrombotic; septic shock; trauma; pancreatitis; allergic rhinitis;  
 KW chronic rheumatoid arthritis.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX Key Location/Qualifiers  
 FH 1..10 /label= signal  
 FT 21..145 /label= PLA2  
 FT Protein  
 FT  
 FT  
 XX WO200034486-A1.  
 PN 15-JUN-2000.  
 XX  
 XX

PF 07-DEC-1999; 99WO-JP006844.  
 XX  
 XX 09-DEC-1998; 98JP-00349608.  
 XX (SHIO) SHIONOGI & CO LTD.  
 PA Ishizaki J, Suzuki N, Hanasaki K;  
 XX WPI: 2000-423429/36.  
 DR N-PSDB; AAA60878.  
 XX Human secretory phospholipase A2 (PLA2) and its encoded gene for  
 PT diagnosis and treatment of secretory PLA2-associated diseases e.g. septic  
 PT shock, trauma, pancreatitis, allergic rhinitis and chronic rheumatoid  
 PT arthritis.  
 XX Claim 1; Page 41; 45pp; Japanese.  
 XX The present invention describes human secretory phospholipase A2 (PLA2).  
 CC PLA2 has anti-allergic, anti-inflammatory, antibacterial, tranquilliser,  
 CC immunosuppressive, vulnery, anti-rheumatic and antiarthritic activities.  
 CC Human secretory phospholipase A2 (PLA2), the gene encoding it and  
 CC antibodies against it are useful for the diagnosis and treatment of  
 CC secretory PLA2-associated diseases e.g. septic shock, trauma,  
 CC pancreatitis, allergic rhinitis and chronic rheumatoid arthritis. The  
 CC present sequence represents human PLA2  
 XX SQ Sequence 145 AA;  
 Query Match 100.0%; Score 852; DB 3; Length 145;  
 Best Local Similarity 100.0%; Pred. No. 7e-77;  
 Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1 MELALLCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
 Db 1 MELALLCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
 Qy 61 DWCCQTHDCCYDHLTKQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
 Db 61 DWCCQTHDCCYDHLTKQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
 Qy 121 RNLDYQKRLRFYWRPHCRGOTPGC 145  
 Db 121 RNLDYQKRLRFYWRPHCRGOTPGC 145  
 RESULT 3  
 AAM24100  
 ID AAM24100 standard; protein; 145 AA.  
 XX AAM24100;  
 AC AAM24100;  
 XX 12-OCT-2001 (first entry)  
 DT Human EST encoded protein SEQ ID NO: 1625.  
 DE Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;  
 KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;  
 KW diagnostics; forensic test; gene mapping; genetic disorder; biodiversity;  
 KW gene therapy; nutrition.  
 XX Homo sapiens.  
 OS Homo sapiens.  
 XX WO200154477-A2.  
 XX 02-AUG-2001.  
 XX 25-JAN-2001; 2001WO-US002687.  
 XX 25-JAN-2000; 2000US-00491404.  
 PR 17-JUL-2000; 2000US-00617746.  
 PR 03-AUG-2000; 2000US-00631451.  
 PR 15-SEP-2000; 2000US-00663870.  
 PR

```
XX PA (HYSE-) HYSEQ INC.
XX PI Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;
XX PI Cao Y, Drmanac RA, Zhang J, Wehrman T;
XX PI WPI; 2001-476164/51.
XX DR N-PSDB; AAH98759.
XX XX
XX PT Isolated polypeptide for treatment of diseases, diagnostics, raising
XX PT antibodies and research use.
XX PS Claim 20; Page 1102; 1275pp; English.
XX CC The present invention provides the protein and coding sequences of novel
XX CC proteins from a variety of organisms, including human, dog, cat, horse,
XX CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
XX CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
XX CC from the organism of interest. They can be used in diagnostics,
XX CC forensics, gene mapping, identification of mutations, to assess
XX CC biodiversity and for nutritional purposes. The present sequence is a
XX CC protein of the invention
XX SQ Sequence 145 AA;
Query Match 100.0%; Score 852; DB 4; Length 145;
Best Local Similarity 100.0%; Pred. No. 7e-77;
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MELALLCGLVVMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGLGGRQPKDAT 60
Db 1 MELALLCGLVVMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGLGGRQPKDAT 60
Qy 61 DWCCQTHDCCVDHLKTCGCGYKDYRYNFSQGNHCSKGSWCEQQLCACDKEVAFCLK 120
Db 61 DWCCQTHDCCVDHLKTCGCGYKDYRYNFSQGNHCSKGSWCEQQLCACDKEVAFCLK 120
Qy 121 RNLDTYQKRLRFYWRPHCRGQTGPGC 145
Db 121 RNLDTYQKRLRFYWRPHCRGQTGPGC 145
RESULT 4
AAE11924
ID AAE11924 standard; protein; 145 AA.
AC AAE11924;
XX DT 18-DEC-2001 (first entry)
XX DE Human CG95 (or C870) lipase protein.
XX KW Human; apolipoprotein; lipase; lipoprotein receptor; ALLr; angina;
XX KW cardiovascular disease; lipid metabolism; myocardial infarction;
XX KW cerebral ischaemia; arterial thrombosis; thrombolytic; antilipaeamic;
XX KW coronary artery thrombosis; cerebral artery thrombosis; stroke;
XX KW intracardiac thrombosis; gene therapy; cardiovascular; vasodilator;
XX KW neuroprotectant; cerebroprotective.
XX OS Homo sapiens.
XX XX
XX FH Peptide 1..24
XX FT /label= Signal_peptide
XX FT 21..145
XX FT /note= "phospholipase A2 domain"
XX FT 25..145
XX FT /note= "Human mature CG95 (or C870) protein"
XX XX
XX PN WO200179446-A2.
XX XX
XX PD 25-OCT-2001.
XX XX
```

```
PF 16-APR-2001; 2001WO-US012529.
XX XX
XX PR 14-APR-2000; 2000US-0197137P.
XX PR 20-JUN-2000; 2000US-00598042.
XX PR 03-AUG-2000; 2000US-00631451.
XX PR 22-SEP-2000; 2000US-00667298.
XX PR 17-NOV-2000; 2000US-00714936.
XX XX
XX PA (HYSE-) HYSEQ INC.
XX XX
XX PI Ballinger DG, Loeb D, Montgomery JR, Tang TY, Zhou P, Goodrich R;
XX PI Liu C, Asundi V, Zhao QA, Wehrman T, Drmanac RT, Ren F, Qian XB;
XX PI Wang D;
XX XX
XX DR WPI; 2001-611724/70.
XX DR N-PSDB; AAD19218.
XX XX
XX PT Nucleic acids encoding human apolipoproteins, lipases, and lipoprotein
XX PT receptor polypeptides, useful for preventing diagnosing and treating
XX PT lipid metabolism disorders, thrombosis and cardiovascular diseases.
XX XX
XX PS Claim 10; Fig 1; 266pp; English.
XX XX
XX CC The invention relates to polynucleotides encoding proteins CG122, CG179,
XX CC CG95, CG121, CG162, CG27, CG153 and CG168 which are related to proteins
XX CC involved in lipid metabolism and cardiovascular disease such as human
XX CC apolipoproteins, lipases and lipoprotein receptor proteins. These DNA and
XX CC protein sequences are useful for treating or preventing disorders
XX CC associated with apolipoproteins, lipases and lipoprotein receptor (ALLr)
XX CC expression and for treating lipid metabolism, cardiovascular diseases and
XX CC thrombosis. Antibodies against these proteins are useful for determining
XX CC the presence of or predisposition to a disease associated with altered
XX CC levels of these sequences. ALLr polypeptides are also useful for
XX CC identifying agents (agonists and antagonists) that bind to them and cells
XX CC expressing ALLr proteins are useful for identifying a therapeutic agent
XX CC for use in treatment of a pathology related to aberrant expression or
XX CC physiological interactions of this polypeptide. Vectors comprising these
XX CC DNA and protein sequences are also useful for producing ALLr proteins.
XX CC The nucleic acids and polypeptides of the invention are also useful for
XX CC the treatment of occlusive cardiovascular diseases, myocardial
XX CC infarction, cerebral ischaemia, angina, arterial thrombosis, coronary
XX CC artery thrombosis and cerebral artery thrombosis or intracardiac
XX CC thrombosis and stroke. The nucleotides of the invention are used in gene
XX CC therapy. The present sequence is human CG95 (or C870) lipase protein
XX XX
XX SQ Sequence 145 AA;
Query Match 100.0%; Score 852; DB 4; Length 145;
Best Local Similarity 100.0%; Pred. No. 7e-77;
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MELALLCGLVVMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGLGGRQPKDAT 60
Db 1 MELALLCGLVVMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGLGGRQPKDAT 60
Qy 61 DWCCQTHDCCVDHLKTCGCGYKDYRYNFSQGNHCSKGSWCEQQLCACDKEVAFCLK 120
Db 61 DWCCQTHDCCVDHLKTCGCGYKDYRYNFSQGNHCSKGSWCEQQLCACDKEVAFCLK 120
Qy 121 RNLDTYQKRLRFYWRPHCRGQTGPGC 145
Db 121 RNLDTYQKRLRFYWRPHCRGQTGPGC 145
RESULT 5
AAE25827
ID AAE25827 standard; protein; 150 AA.
XX AC AAE25827;
XX XX
XX DT 16-OCT-2001 (first entry)
XX XX
XX DE Human protein sequence SEQ ID NO:1342.
```





DR N-PSDB; AAS14884.  
XX New human proteins, useful for diagnosing, treating, preventing and/or  
PT prognosing disorders related to the proteins, including cardiovascular  
XX disorders, autoimmune disorders and reproductive disorders.  
XX Claim 11; Page 306-307; 318pp; English.  
XX  
XX The invention relates to novel human proteins (NHP) and the nucleic acids  
CC that encode them and antibodies raised against them. The proteins,  
CC antibodies and nucleic acids are useful in the diagnosis, prognosis,  
CC prevention and/or treatment of diseases and/or disorders involving  
CC vasoconstriction, gastrointestinal disorders, cardiovascular disorders  
CC (e.g. hypertension, erectile dysfunction, high blood pressure, coronary  
CC heart disease and arteriosclerosis), anorexia, obesity, bulimia,  
CC cachexia, disorders of small intestine, disorders of reproductive system  
CC (e.g. male infertility and/or impotence), testicular cancer, lung tumours  
CC and other hyperproliferative disorders, disorders of pulmonary system,  
CC central nervous system disorders, bone disorders, neurodegenerative  
CC diseases and behavioural disorders (e.g. Alzheimer's disease, Parkinson's  
CC disease, Huntington's disease, schizophrenia, mania, dementia, paranoia,  
CC panic disorder, learning disabilities, immune system disorders (e.g.  
CC psychoses, autism, sleep disorders), amyotrophic lateral sclerosis,  
CC Hashimoto's thyroiditis), renal and musculo-skeletal system disorders,  
CC central nervous system disorders (e.g. multiple sclerosis, ischaemic  
CC brain injury and/or stroke), infectious diseases, diabetes mellitus,  
CC immunological disorders (e.g. asthma, acquired immunodeficient syndrome  
CC (AIDS), leukaemia, rheumatoid arthritis, inflammatory bowel disease,  
CC sepsis, acne, psoriasis and lupus erythematosus), neural system  
CC disorders, respiratory disorders, olfactory disorders and wound healing.  
XX The present sequence represents an NHP of the invention  
XX  
SQ Sequence 145 AA;  
  
Query Match 99.3%; Score 846; DB 4; Length 145;  
Best Local Similarity 99.3%; Pred. No. 2.8e-76;  
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 1 MELALLGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCHGLGGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCHGLGGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCBOQLCADCKEVAFCLK 120  
Db 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCBOQLCADCKEVAFCLK 120  
  
Qy 121 RNLDYQKRLRFYWRPHCRGQTPGC 145  
Db 121 RNLDYQKRLRFYWRPHCRGQTPGC 145  
  
RESULT 7  
ABR44234  
ID ABR44234 standard; protein; 145 AA.  
XX  
AC ABR44234;  
XX  
DT 18-AUG-2003 (first entry)  
XX  
DE Human secreted group IID phospholipase A2 (sPLA2) enzyme.  
XX  
KW Group IIF secreted phospholipase A2; sPLA2; phosphatidylglycerol; human;  
KW phosphatidylcholine; antibacterial; virucide; cytostatic; vasotropic;  
KW antiinflammatory; vulnary; cardiant; chromosome lp35; transgenic;  
KW enzyme.  
XX  
OS Homo sapiens.  
XX  
PN WO2003033689-A1.  
XX  
PD 24-APR-2003.  
XX  
PF 12-OCT-2001; 2001WO-IB002407.

XX 12-OCT-2001; 2001WO-IB002407.  
PR (CNRS ) CNRS CENT NAT RECH SCT.  
XX  
PA Lazdunski M, Lambeau G, Valentin E;  
PI WPI; 2003-403216/38.  
XX  
DR Novel mammalian secreted group IIF secreted phospholipase A2, useful for  
XX preventing and treating bacterial and viral infections, and cancers.  
PT Disclosure; Fig 1; 33pp; English.  
XX  
XX The invention relates to a mammalian secreted group IIF secreted  
CC phospholipase A2 (sPLA2) (I), where the enzyme is Ca<sup>2+</sup> dependent,  
CC maximally active at pH 7-8 and hydrolyzes phosphatidylglycerol versus  
CC phosphatidylcholine with a 15-fold preference. A pharmaceutical  
CC composition comprising (I) is useful for treating or preventing viral and  
CC bacterial infections, and cancers. A pharmaceutical composition  
CC containing compounds capable of inhibiting catalytic activity of (I),  
CC biologically active compounds that bind sPLA<sub>2</sub> receptors, or a compound  
CC that modulates cell proliferation, cell migration, cell contraction or  
CC apoptosis is useful for treating disease states or disorders involving  
CC group IIF sPLA<sub>2</sub>, such as inflammatory disease, cancers, cardiac and brain  
CC ischaemia, acute lung injury, acute respiratory distress syndrome or  
CC Crohn's disease. Specific antibodies are useful for searching new  
CC secreted mammalian group IIF sPLA<sub>2</sub> or the homologues of the enzyme in  
CC other mammals. The encoding polynucleotides and vectors are useful for  
CC transforming animals and establishing a line of transgenic animals.  
CC Sequences ABR44232-238 represent various human secreted sPLA<sub>2</sub> enzymes  
CC used in alignment studies with the GIIF sPLA<sub>2</sub> enzyme  
XX  
XX Sequence 145 AA;  
  
Query Match 99.3%; Score 846; DB 6; Length 145;  
Best Local Similarity 99.3%; Pred. No. 2.8e-76;  
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 1 MELALLGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCHGLGGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCHGLGGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCBOQLCADCKEVAFCLK 120  
Db 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCBOQLCADCKEVAFCLK 120  
  
Qy 121 RNLDYQKRLRFYWRPHCRGQTPGC 145  
Db 121 RNLDYQKRLRFYWRPHCRGQTPGC 145  
  
RESULT 8  
ABR58706  
ID ABR58706 standard; protein; 145 AA.  
XX  
AC ABR58706;  
XX  
DT 09-JUL-2003 (first entry)  
XX  
DE Human cancer related protein SEQ ID NO:363.  
XX  
KW Human; cancer; diagnosis; screening; modulator; leukaemia; ischaemia;  
KW heart disease; atherosclerosis; endometriosis.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025138-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-US029560.  
XX

PR 17-SEP-2001; 2001US-0323469P.  
PR 20-SEP-2001; 2001US-0323887P.  
PR 13-NOV-2001; 2001US-0350666P.  
PR 08-FEB-2002; 2002US-0355145P.  
PR 08-FEB-2002; 2002US-0355257P.  
PR 12-APR-2002; 2002US-0372246P.  
XX PA (EOSB-) EOS BIOTECHNOLOGY INC.  
XX XX  
XX Afar D, Aziz N, Gish KC, Hevezi PA, Mack DH, Wilson KE;  
XX Zlotnik A;  
XX  
XX WPI; 2003-354600/33.  
DR N-PSDB; ACC72857.  
XX  
XX New genes that are up-regulated or down-regulated in cancers, useful as  
PT markers for diagnosing e.g. cancer, ischemia or heart diseases, or as  
PT therapeutic targets for screening drugs for treating these diseases.  
XX  
XX Claim 12; Page 763; 767pp; English.  
XX  
XX The present invention describes an isolated nucleic acid molecule, which  
CC comprises the sequence of any of the genes that are up-regulated or down-  
CC regulated in specific cancers (e.g. about 1031 genes up-regulated in  
CC acute lymphocytic leukemia). ACC72641 to ACC72860 represent cancer  
CC related gene nucleotide sequences which encode the proteins given in  
CC ABR58521 to ABR58709. Also described: (1) determining the presence or  
CC absence of a pathological cell in a patient; (2) an expression vector  
CC comprising a nucleic acid molecule described above; (3) a host cell  
CC comprising the vector; (4) an isolated polypeptide, which is encoded by  
CC the nucleic acid; (5) an antibody that specifically binds the polypeptide  
CC of (4); (6) specifically targeting a compound to a pathological cell in a  
CC patient by administering to the patient the antibody above; and (7) a  
CC drug screening assay. The nucleic acid is useful as diagnostic markers or  
CC therapeutic targets. In particular, the nucleic acid is useful for  
CC diagnosing a pathology, e.g. cancer (e.g. cancer of the bone marrow,  
CC bladder, brain, breast, cervix, colon/rectum, kidney, lung, ovary,  
CC pancreas, prostate, skin and uterus), wounds, ischaemia, heart diseases,  
CC atherosclerosis and endometriosis. The nucleic acid is also useful in  
CC drug screening, particularly for identifying agents for treating these  
XX pathologies  
XX  
SQ Sequence 145 AA;  
  
Query Match 99.3%; Score 846; DB 6; Length 145;  
Best Local Similarity 99.3%; Pred. No. 2.8e-76;  
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 1 MELALLGLVVMAGVPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
Db 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
  
Qy 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145  
Db 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145  
  
RESULT 9  
ABU63124  
ID ABU63124 standard; protein; 145 AA.  
XX AC ABU63124;  
XX DT 25-SEP-2003 (first entry)  
XX DE Human group IID secreted phospholipase A2.  
XX Human; group IID secreted phospholipase A2; virucide; antibacterial;  
XX cytostatic; antiinflammatory; vasotropic; cerebroprotective; sPLA2;  
KW

KW phosphatidylglycerol hydrolysis; phosphatidylcholine hydrolysis;  
KW viral infection; bacterial infection; cancer; inflammatory disease;  
KW cardiac ischaemia; brain ischaemia; acute lung injury;  
KW acute respiratory distress syndrome; Crohn's disease; enzyme.  
XX  
OS Homo sapiens.  
XX  
XX US2003073087-A1.  
XX  
XX 17-APR-2003.  
XX  
XX 11-OCT-2001; 2001US-00975456.  
XX  
XX 11-OCT-2000; 2000US-0239491P.  
XX  
XX (LAZD/) LAZDUNSKI M.  
XX (LAMB/) LAMBEAU G.  
XX (VALE/) VALENTIN E.  
XX  
XX Lazdunski M, Lambeau G, Valentin E;  
XX  
XX WPI; 2003-567302/53.  
XX  
XX New mammalian secreted group IIF phospholipase A2 or nucleic acid, useful  
PT for treating or preventing viral or bacterial infections, or cancers, or  
PT screening inhibitors of the enzyme for treating e.g. inflammatory  
PT diseases or ischemia.  
XX  
XX Disclosure; Fig 1; 16pp; English.  
XX  
XX The invention describes a mammalian secreted group IIF phospholipase A2  
CC (sPLA2), which is Ca2+-dependent, maximally active at pH of about 7-8,  
CC and hydrolyses phosphatidylglycerol versus phosphatidylcholine with about  
CC a 15-fold preference. The mammalian secreted group IIF sPLA2 protein or  
CC nucleic acid, or a pharmaceutical composition is useful for treating  
CC and/or preventing viral infections, bacterial infections, or cancers. The  
CC inhibitors of sPLA2 or a composition comprising sPLA2 inhibitors is  
CC useful for treating disease states or disorders involving group IIF  
CC sPLA2, e.g. inflammatory diseases, cancer, cardiac and brain ischaemia,  
CC acute lung injury, acute respiratory distress syndrome, or Crohn's  
CC disease. The enzyme is also useful for screening various chemical  
CC compounds for treating these diseases. This is the amino acid sequence  
CC of human group IID phospholipase A2 used to determine a consensus sequence  
XX for human sPLA2s  
XX  
SQ Sequence 145 AA;  
  
Query Match 99.3%; Score 846; DB 6; Length 145;  
Best Local Similarity 99.3%; Pred. No. 2.8e-76;  
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 1 MELALLGLVVMAGVPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
Db 61 DWCCQTHDCCYDHLTKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLK 120  
  
Qy 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145  
Db 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145  
  
RESULT 10  
AAB12536  
ID AAB12536 standard; protein; 144 AA.  
XX AC AAB12536;  
XX DT 02-NOV-2000 (first entry)  
XX DE Mouse secretory phospholipase A2 protein sequence SEQ ID NO:14.



KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;  
KW cytostatic; gene therapy; vaccine.

XX Homo sapiens.

XX WO2000032221-A2.

XX PD 08-JUN-2000.

XX PF 30-NOV-1999; 99WO-US028313.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 16-DEC-1998; 98US-0112850P.

XX PR 12-JAN-1999; 99US-0115554P.

XX PR 08-MAR-1999; 99WO-US005028.

XX PR 12-MAR-1999; 99US-0123957P.

XX PR 28-APR-1999; 99US-0131445P.

XX PR 14-MAY-1999; 99US-0134287P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 23-JUN-1999; 99US-0141037P.

XX PR 20-JUL-1999; 99US-0144758P.

XX PR 26-JUL-1999; 99US-0145698P.

XX PR 01-SEP-1999; 99WO-US020111.

XX PR 08-SEP-1999; 99WO-US020594.

XX PR 13-SEP-1999; 99WO-US020944.

XX PR 15-SEP-1999; 99WO-US021090.

XX PR 15-SEP-1999; 99WO-US021547.

XX PR 05-OCT-1999; 99WO-US023089.

XX PR 29-OCT-1999; 99US-0162506P.

XX (GBTH ) GENENTECH INC.

XX PI Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ;

XX PI Goddard A, Godowski PJ, Gurney AL, Klein RD, Kuo SS, Paoni NF;

XX PI Smith V, Watanabe CK, Williams PM, Wood WI;

XX DR WPI; 2000-412154/35.

XX DR N-PSDB; AAA77684.

XX PT Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing  
XX PT and treating diagnosing a cardiovascular, endothelial or angiogenic  
XX PT disorders in mammals.

XX PS Claim 72; Fig 94; 315pp; English.

XX CC The present invention describes nucleic acids encoding PRO polypeptides  
XX CC useful for preventing, diagnosing and treating diagnosing a  
XX CC cardiovascular, endothelial or angiogenic disorder in mammals by  
XX CC modulating cell proliferation, angiogenesis and cardiovascularisation,  
XX CC and for identifying agonists and antagonists of these processes. The  
XX CC nucleic acids and the proteins they encode may be used in the prevention,  
XX CC treatment and diagnosis of diseases associated with inappropriate PRO  
XX CC expression such as cardiovascular, endothelial or angiogenic disorders in  
XX CC mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For  
XX CC example, the nucleic acids (NAs) and vectors containing them and the PRO  
XX CC polypeptide may be used to treat disorders associated with decreased PRO  
XX CC expression. AAA77510 to AAA77721 and AAB24388 to AAB24435 represent  
XX CC nucleotide and protein sequences used in the exemplification of the  
XX CC present invention

XX SQ Sequence 116 AA;

Query Match 58.7%; Score 500.5; DB 3; Length 116;

Best Local Similarity 82.6%; Pred. No. 5.5e-42;

Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;

Oy 1 MELALLGLVWAGVIPIQGGILNLNMVKVQVTGKMPILSWPYGCHGLGGRGQPKDAT 60  
|||||

Dd 1 MELALLGLVWAGVIPIQGGILNLNMVKVQVTGKMPILSWPYGCHGLGGRGQPKDAT 60  
|||||

Oy 61 DWCCQTHDCCVDHLKTCQCGIYKDN-----NKSSIHQWMD-----LSQRYC 100  
|||||

|||||

Dd 61 DWCCQTHDCCVDHLKTCQCGIYKDN-----NKSSIHQWMD-----LSQRYC 100

RESULT 13

AA999450

ID AAY99450 standard; protein; 116 AA.

XX AC AAY99450;

XX DT 08-AUG-2000 (first entry)

XX DE Human PRO1561 (UNQ768) amino acid sequence SEQ ID NO:378.

XX KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;  
transmembrane; secretion; immunoadhesion; pharmaceutical; screening.

XX OS Homo sapiens.

XX FN WO2000012708-A2.

XX PD 09-MAR-2000.

XX PF 01-SEP-1999; 99WO-US020111.

XX PR 01-SEP-1998; 98US-0098716P.

XX PR 01-SEP-1998; 98US-0098749P.

XX PR 01-SEP-1998; 98US-0098750P.

XX PR 02-SEP-1998; 98US-0098803P.

XX PR 02-SEP-1998; 98US-0098821P.

XX PR 02-SEP-1998; 98US-0098843P.

XX PR 09-SEP-1998; 98US-0099536P.

XX PR 09-SEP-1998; 98US-0099596P.

XX PR 09-SEP-1998; 98US-0099598P.

XX PR 09-SEP-1998; 98US-0099602P.

XX PR 09-SEP-1998; 98US-0099642P.

XX PR 10-SEP-1998; 98US-0099741P.

XX PR 10-SEP-1998; 98US-0099754P.

XX PR 10-SEP-1998; 98US-0099763P.

XX PR 10-SEP-1998; 98US-0099792P.

XX PR 10-SEP-1998; 98US-0099808P.

XX PR 10-SEP-1998; 98US-0099812P.

XX PR 10-SEP-1998; 98US-0099815P.

XX PR 10-SEP-1998; 98US-0099816P.

XX PR 15-SEP-1998; 98US-0100385P.

XX PR 15-SEP-1998; 98US-0100388P.

XX PR 15-SEP-1998; 98US-0100390P.

XX PR 16-SEP-1998; 98US-0100584P.

XX PR 16-SEP-1998; 98US-0100627P.

XX PR 16-SEP-1998; 98US-0100661P.

XX PR 16-SEP-1998; 98US-0100662P.

XX PR 16-SEP-1998; 98US-0100664P.

XX PR 17-SEP-1998; 98US-0100683P.

XX PR 17-SEP-1998; 98US-0100684P.

XX PR 17-SEP-1998; 98US-0100710P.

XX PR 17-SEP-1998; 98US-0100711P.

XX PR 17-SEP-1998; 98US-0100919P.

XX PR 17-SEP-1998; 98US-0100930P.

XX PR 18-SEP-1998; 98US-0100848P.

XX PR 18-SEP-1998; 98US-0100849P.

XX PR 18-SEP-1998; 98US-0101014P.

XX PR 18-SEP-1998; 98US-0101068P.

XX PR 18-SEP-1998; 98US-0101071P.

XX PR 22-SEP-1998; 98US-0101279P.

XX PR 23-SEP-1998; 98US-0101471P.

XX PR 23-SEP-1998; 98US-0101472P.

XX PR 23-SEP-1998; 98US-0101477P.

XX PR 23-SEP-1998; 98US-0101479P.

XX PR 24-SEP-1998; 98US-0101738P.

XX PR 24-SEP-1998; 98US-0101741P.

XX PR 24-SEP-1998; 98US-0101743P.

PR 24-SEP-1998; 98US-0101915P.  
 PR 24-SEP-1998; 98US-0101916P.  
 PR 29-SEP-1998; 98US-0102207P.  
 PR 29-SEP-1998; 98US-0102240P.  
 PR 29-SEP-1998; 98US-0102307P.  
 PR 29-SEP-1998; 98US-0102330P.  
 PR 29-SEP-1998; 98US-0102331P.  
 PR 30-SEP-1998; 98US-0102484P.  
 PR 30-SEP-1998; 98US-0102487P.  
 PR 30-SEP-1998; 98US-0102570P.  
 PR 30-SEP-1998; 98US-0102571P.  
 PR 01-OCT-1998; 98US-0102687P.  
 PR 01-OCT-1998; 98US-0102684P.  
 PR 02-OCT-1998; 98US-0102965P.  
 PR 06-OCT-1998; 98US-0102958P.  
 PR 06-OCT-1998; 98US-0103449P.  
 PR 07-OCT-1998; 98US-0103314P.  
 PR 07-OCT-1998; 98US-0103315P.  
 PR 07-OCT-1998; 98US-0103328P.  
 PR 07-OCT-1998; 98US-0103395P.  
 PR 07-OCT-1998; 98US-0103396P.  
 PR 07-OCT-1998; 98US-0103401P.  
 PR 08-OCT-1998; 98US-0103633P.  
 PR 08-OCT-1998; 98US-0103678P.  
 PR 08-OCT-1998; 98US-0103679P.  
 PR 14-OCT-1998; 98US-0103711P.  
 PR 14-OCT-1998; 98US-0104257P.  
 PR 20-OCT-1998; 98US-0104987P.  
 PR 20-OCT-1998; 98US-0105000P.  
 PR 20-OCT-1998; 98US-0105002P.  
 PR 21-OCT-1998; 98US-0105104P.  
 PR 21-OCT-1998; 98US-0105169P.  
 PR 22-OCT-1998; 98US-0105266P.  
 PR 26-OCT-1998; 98US-0105693P.  
 PR 26-OCT-1998; 98US-0105694P.  
 PR 27-OCT-1998; 98US-0105807P.  
 PR 27-OCT-1998; 98US-0105881P.  
 PR 27-OCT-1998; 98US-0105882P.  
 PR 27-OCT-1998; 98US-0106062P.  
 PR 28-OCT-1998; 98US-0106023P.  
 PR 28-OCT-1998; 98US-0106029P.  
 PR 28-OCT-1998; 98US-0106030P.  
 PR 28-OCT-1998; 98US-0106032P.  
 PR 28-OCT-1998; 98US-0106033P.  
 PR 28-OCT-1998; 98US-0106178P.  
 PR 29-OCT-1998; 98US-0106248P.  
 PR 29-OCT-1998; 98US-0106384P.  
 PR 29-OCT-1998; 98US-0108500P.  
 PR 30-OCT-1998; 98US-0106464P.  
 PR 03-NOV-1998; 98US-0106856P.  
 PR 03-NOV-1998; 98US-0106902P.  
 PR 03-NOV-1998; 98US-0106905P.  
 PR 03-NOV-1998; 98US-0106919P.  
 PR 03-NOV-1998; 98US-0106932P.  
 PR 03-NOV-1998; 98US-0106934P.  
 PR 10-NOV-1998; 98US-0107783P.  
 PR 17-NOV-1998; 98US-0108775P.  
 PR 17-NOV-1998; 98US-0108779P.  
 PR 17-NOV-1998; 98US-0108787P.  
 PR 17-NOV-1998; 98US-0108788P.  
 PR 17-NOV-1998; 98US-0108801P.  
 PR 17-NOV-1998; 98US-0108802P.  
 PR 17-NOV-1998; 98US-0108806P.  
 PR 17-NOV-1998; 98US-0108807P.  
 PR 17-NOV-1998; 98US-0108867P.  
 PR 17-NOV-1998; 98US-0108925P.  
 PR 18-NOV-1998; 98US-0108848P.  
 PR 18-NOV-1998; 98US-0108849P.  
 PR 18-NOV-1998; 98US-0108850P.  
 PR 18-NOV-1998; 98US-0108851P.  
 PR 18-NOV-1998; 98US-0108852P.  
 PR 18-NOV-1998; 98US-0108858P.  
 PR 18-NOV-1998; 98US-0108904P.

XX (GETH ) GENENTECH INC.  
 PA Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;  
 XX WPI; 2000-237871/20.  
 XX N-PSDB; AAA37132.  
 DR New mammalian DNA sequences encoding transmembrane, receptor or secreted  
 PT polypeptides, useful for screening of potential peptide or small  
 PT molecule inhibitors of the relevant receptor/ligand interactions.  
 XX Claim 12; Fig 222; 773pp; English.  
 XX AAA37022 to AAA37144 encode the new isolated human transmembrane,  
 CC receptor or secreted PRO polypeptides given in AA99340 to AA99462. The  
 CC transmembrane and receptor PRO proteins can be used for screening of  
 CC potential peptide or small molecule inhibitors of the relevant  
 CC receptor/ligand interactions. The polypeptides and nucleotide sequences  
 CC encoding then have various industrial applications, including uses as  
 CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR  
 CC primers and hybridisation probes used in the isolation of the PRO  
 CC polypeptides from the present invention  
 XX SQ Sequence 116 AA;  
 Query Match 58.7%; Score 500.5; DB 3; Length 116;  
 Best Local Similarity 82.6%; Pred. No. 5.5e-42;  
 Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
 QY 1 MELALLCGLVVAGVIQGGILNLNKNVKQVTGMPILSYWPGYCHGLGRGQPKDAT 60  
 Db 1 MELALLCGLVVAGVIQGGILNLNKNVKQVTGMPILSYWPGYCHGLGRGQPKDAT 60  
 QY 61 DWCCQTHDCCYDHLTKTQCGIYKXN----NKSSIHCM-----LSQRYC 109  
 Db 61 DWCCQTHDCCYDHLTKTQCGIYKXN----NKSSIHCM-----LSQRYC 109  
 RESULT 14  
 AAB66199  
 ID AAB66199 standard; protein; 116 AA.  
 XX AAB66199;  
 AC AAB66199;  
 XX 02-APR-2001 (first entry)  
 DT Protein of the invention #111.  
 DE Secreted; transmembrane; gene therapy.  
 KW Unidentified.  
 OS WO200078961-A1.  
 PN 28-DEC-2000.  
 PD 18-FEB-2000; 2000WO-US004342.  
 PF 23-JUN-1999; 99US-0141037P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 29-OCT-1999; 99US-0162506P.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000376.  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;  
 PI

```
PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2001-071395/08.
XX Secreted and transmembrane proteins and nucleic acids designated PRO,
PT useful as hybridization probes, in chromosome and gene mapping and gene
PT therapy.
XX Claim 1; Fig 222; 787pp; English.
XX The present invention relates to secreted and transmembrane proteins.
CC These proteins and the DNA encoding them may be used as hybridization
CC probes, in chromosome and gene mapping and in the generation of anti-
CC sense RNA and DNA. They may also be used to generate either
CC transgenic animals or knockout animals which are in turn useful for
CC development and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy
XX Sequence 116 AA;
SQ Query Match 58.7%; Score 500.5; DB 4; Length 116;
Best Local Similarity 82.6%; Pred. No. 5.5e-42;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;
QY 1 MELALLCGLVWVAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGLGGRGPKDAT 60
Db 1 MELALLCGLVWVAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGLGGRGPKDAT 60
QY 61 DWCCQTHCCYDHLTKQTGCGIYKDYRYNFSQGNHCSDKGSWCCEQQLC 109
Db 61 DWCCQTHCCYDHLTKQTGCGIYKDN-----NKSSIHCMD----LSQRYC 100
RESULT 15
AAU12438
ID AAU12438 standard; protein; 116 AA.
XX AC AAU12438;
XX DT 24-OCT-2001 (first entry)
XX DE Human PRO1561 polypeptide sequence.
XX KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW A-peptide; factor VIIa; gene therapy.
XX OS Homo sapiens.
XX PN WO200140466-A2.
XX PD 07-JUN-2001.
XX PF 01-DEC-2000; 2000WO-US032678.
XX PR 01-DEC-1999; 99WO-US028301.
XX PR 01-DEC-1999; 99WO-US028634.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 02-DEC-1999; 99WO-US028564.
XX PR 02-DEC-1999; 99WO-US028565.
XX PR 09-DEC-1999; 99US-0170262P.
XX PR 16-DEC-1999; 99WO-US030095.
XX PR 20-DEC-1999; 99WO-US030911.
XX PR 20-DEC-1999; 99WO-US030999.
XX PR 30-DEC-1999; 99WO-US031243.
XX PR 30-DEC-1999; 99WO-US031274.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000277.
XX PR 06-JAN-2000; 2000WO-US000376.
XX PR 11-FEB-2000; 2000WO-US000365.
```

```
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 05-JUN-2000; 2000US-0209832P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2001-408281/43.
XX N-PSDB; AAS21510.
XX Isolated, secretory and transmembrane PRO polypeptide used to detect
XX other PRO polypeptides, link bioactive molecules to cells expressing PRO
XX polypeptides, and detect the presence of mammalian tumors e.g. lung,
XX breast, prostate, cervical.
XX Claim 12; Fig 534; 813pp; English.
XX AAU12172-AAU12446 represent novel human secretory and transmembrane PRO
XX polypeptides. The PRO polypeptides are useful to detect other PRO
XX polypeptides, to link bioactive molecules to cells expressing PRO
XX polypeptides, to modulate biological activities of cells expressing PRO
XX polypeptides, and to detect the presence of mammalian lung, colon,
XX breast, prostate, rectal, cervical or liver tumours by comparing PRO
XX polypeptide expression in a cell sample to that in a control sample. Some
XX of the 275 sequences are also useful to stimulate the release of tumour
XX necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
XX differentiation of chondrocytes, the proliferation or gene expression in
XX pericyte cells, the release of proteoglycans from cartilage, the
XX proliferation of inner ear utricular supporting cells or of T-
XX lymphocytes, the release of a cytokine from peripheral blood monocytes
XX (PBMCs), or the proliferation of endothelial cells. Some of the PRO
XX polypeptides may modulate glucose or free fatty acid uptake by skeletal
XX muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
XX VIIa. The PRO polypeptides can be used in assays to identify molecules
XX involved in binding interactions. The polynucleotides encoding PRO
XX polypeptides can be used to generate probes, antisense RNA/DNA,
XX transgenic or knock out animals and can be used in gene therapy
XX Sequence 116 AA;
SQ Query Match 58.7%; Score 500.5; DB 4; Length 116;
Best Local Similarity 82.6%; Pred. No. 5.5e-42;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;
QY 1 MELALLCGLVWVAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGLGGRGPKDAT 60
Db 1 MELALLCGLVWVAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGLGGRGPKDAT 60
QY 61 DWCCQTHCCYDHLTKQTGCGIYKDYRYNFSQGNHCSDKGSWCCEQQLC 109
```

Db 61 DWCCQTHDCCYDHLKTQGGIYKDN-----NKSSIHOWD-----LSQRYC 100

Search completed: October 5, 2004, 19:21:29  
Job time : 38.2533 secs

This Page Blank (uspto)



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:10:14 ; Search time 9.08667 Seconds  
(without alignments)  
823.819 Million cell updates/sec

Title: US-09-830-321A-1

Perfect score: 852

Sequence: 1 MELALLGLVWAGVIPIQG.....YOKRLRFYWRHCRQTRQC 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.\*

- 1: /cgn2\_6/ptodata/2/iaa/5A COMB.pap.\*
- 2: /cgn2\_6/ptodata/2/iaa/5B COMB.pap.\*
- 3: /cgn2\_6/ptodata/2/iaa/6A COMB.pap.\*
- 4: /cgn2\_6/ptodata/2/iaa/6B COMB.pap.\*
- 5: /cgn2\_6/ptodata/2/iaa/PCTUS COMB.pap.\*
- 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	401.5	47.1	146	3	US-08-966-317-4
2	401.5	47.1	146	4	US-09-489-770-4
3	400.5	47.0	146	2	US-08-888-497-35
4	400.5	47.0	146	5	US-09-362-230-35
5	400.5	47.0	146	5	PCT-US94-07926-35
6	395.5	46.4	144	1	US-08-186-895-10
7	395.5	46.4	144	2	US-08-888-497-37
8	395.5	46.4	144	4	US-09-362-230-37
9	395.5	46.4	144	5	PCT-US94-07926-37
10	371.5	43.6	146	3	US-08-966-317-3
11	371.5	43.6	146	4	US-09-489-770-3
12	367.5	43.1	124	1	US-08-170-360-4
13	367.5	43.1	124	2	US-08-888-497-39
14	367.5	43.1	124	4	US-09-362-230-39
15	367.5	43.1	124	5	US-09-740-569-2
16	367.5	43.1	124	5	PCT-US94-07926-39
17	360	42.3	125	2	US-08-888-497-42
18	360	42.3	125	4	US-09-362-230-42
19	360	42.3	125	5	PCT-US94-07926-42
20	347	40.7	138	2	US-08-888-497-32
21	347	40.7	138	4	US-09-362-230-32
22	347	40.7	138	5	PCT-US94-07926-32
23	332	39.0	125	1	US-08-170-360-5
24	329.5	38.7	122	1	US-07-734-534A-1
25	328.5	38.6	118	2	US-08-888-497-40
26	328.5	38.6	118	4	US-09-087-094-5
27	328.5	38.6	118	4	US-09-362-230-40

28	328.5	38.6	118	5	PCT-US94-07926-40
29	315.5	37.0	137	2	US-08-888-497-30
30	315.5	37.0	137	4	US-09-362-230-30
31	315.5	37.0	137	5	PCT-US94-07926-30
32	305.5	35.9	117	2	US-08-888-497-44
33	305.5	35.9	117	4	US-09-362-230-44
34	305.5	35.9	117	5	PCT-US94-07926-44
35	295.5	34.7	130	2	US-08-888-497-43
36	295.5	34.7	130	4	US-09-362-230-43
37	295.5	34.7	130	5	PCT-US94-07926-43
38	295.5	34.7	158	4	US-08-888-497-22
39	295.5	34.7	158	5	US-09-362-230-22
40	295.5	34.7	158	5	PCT-US94-07926-22
41	263.5	30.9	165	3	US-08-966-317-1
42	263.5	30.9	165	4	US-09-489-770-1
43	242.5	28.5	148	2	US-08-888-497-36
44	242.5	28.5	148	4	US-09-362-230-36
45	242.5	28.5	148	5	PCT-US94-07926-36

## ALIGNMENTS

RESULT 1  
US-08-966-317-4  
; Sequence 4, Application US/08966317  
; Patent No. 6103469  
; GENERAL INFORMATION:  
; APPLICANT: Hawkins, Phillip R.  
; APPLICANT: Bandman, Olga  
; APPLICANT: Guegler, Karl J.  
; APPLICANT: Shah, Purvi  
; APPLICANT: Corley, Neil C.  
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 PROTEIN  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Incyte Pharmaceuticals, Inc.  
; STREET: 3174 Porter Dr.  
; CITY: Palo Alto  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/966,317  
; FILING DATE: Filed Herewith  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Billings, Lucy J.  
; REGISTRATION NUMBER: 36,749  
; REFERENCE/DOCKET NUMBER: PF-0403 US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-855-0555  
; TELEFAX: 650-845-4166  
; INFORMATION FOR SEQ ID NO: 4:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 146 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; LIBRARY: GenBank  
; CLONE: 204319  
; US-08-966-317-4

11/7/1997 (Ciling)

Query Match 47.1%; Score 401.5; DB 3; Length 146;  
Best Local Similarity 47.9%; Pred. No. 1.1e-34;

	Matches	70; Conservative	23; Mismatches	52; Indels	1; Gaps	1;
QY	1	MELALLCGIIVMA-GVPIOGGIILNKNVQVTKMPILLSYMPYGCGLGGRGQPKDA	59			
Db	1	MKVLLLLNLTMAFGSTIQVGSLLFQOMILFKTGKADVSYGFYGCCHGVGGSGSPKDA	60			
QY	60	TDWCCCTHDCCYDHLKLTGGCGIYKDYVRYNFSQGNHICSDKGSWGEQGLCA	119			
Db	61	TDWCCVTHDCCYNPLEKRGCGTKFLTYKFSYRGSGIISGTSNQDSRKLQCGQDKAAAEFC	120			
QY	120	KRNLDITYQKRLRFYWRPHCRGQTGCG	145			
Db	121	ARNKKSYSLLKYQFYLNKFCRGKTSPC	146			

RESULT 2  
US-09-489-770-4  
; Sequence 4, Application US/09489770  
; Patent No. 639301  
; GENERAL INFORMATION:  
; APPLICANT: Hawkins, Phillip R.  
; APPLICANT: Bandman, Olga  
; APPLICANT: Guegler, Karl J.  
; APPLICANT: Shah, Purvi  
; APPLICANT: Corley, Neil C.  
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 PROTEIN  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Incyte Pharmaceuticals, Inc.  
; STREET: 3174 Porter Dr.  
; CITY: Palo Alto  
; STATE: CA  
; COUNTRY: USA

```

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040

```

PRIOR APPLICATION DATA: 08/966,317

; FILING DATE:  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Billings, Lucy J.  
 ; REGISTRATION NUMBER: 36,749  
 ; REFERENCE/DOCKET NUMBER: PF-0403 US  
 ; TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-855-0555  
TELEFAX: 650-845-4166

; INFORMATION FOR SEQ ID NO: 4:  
: SEQUENCE CHARACTERISTICS:

```

; LENGTH: 146 amino acids
; TYPE: amino acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear

```

IMMEDIATE SOURCE:  
LIBRARY: GenBank

CLONE: 204319  
US-09-489-770-4

Query Match: 47.1%

Best Local Similarity 47.9%;  
Matches 70: Conservative 2

1 METALLCGLVMA-GVIPI

1 MKVLLLLAVVIMAFGSIQV

60 TDWCCQTHDCCYDHLKTQC OV

Figure 1. Schematic diagram of the experimental setup. The subject is seated in a chair and views the screen through a mirror. The screen displays the target (a red dot) and the starting position (a black dot). The subject's hand is positioned at the starting position. The distance between the starting position and the target is 10 cm. The subject is instructed to move the hand to the target as quickly and accurately as possible. The screen is 100 cm high and 100 cm wide. The subject's hand is positioned at the starting position. The distance between the starting position and the target is 10 cm. The subject is instructed to move the hand to the target as quickly and accurately as possible. The screen is 100 cm high and 100 cm wide.

Db  
QY  
Db

TIT	:
TIT	:
TIT	:
NUN	:
COR	:
H	:
H	:
S	:
C	:
S	:
C	:
C	:
Z	:
COR	:
I	:
C	:
C	:
C	:
I	:
CUT	:

PR

“ ”

TE ;  
INFO ;  
SE ;

• •

..

MC  
US-08-8

Query

Best  
Match

Qy

Db

Qy

D'b

Qy

Db

RESULT 4  
US-09-362-230-35  
; Sequence 35, Application US/09362230  
; Patent No. 6352849  
; GENERAL INFORMATION:  
; APPLICANT: Tischfield, Jay A.  
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide  
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences  
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide  
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites  
; NUMBER OF SEQUENCES: 44  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &  
; ADDRESSEE: Russell PA  
; STREET: 200 East Broward Boulevard  
; CITY: Fort Lauderdale  
; STATE: FL  
; COUNTRY: USA  
; ZIP: 33301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/362,230  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/888,497  
; FILING DATE:  
; APPLICATION NUMBER: US 08/097,354  
; FILING DATE: 26-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Manso, Peter J.  
; REGISTRATION NUMBER: 32,264  
; REFERENCE/DOCKET NUMBER: IN21044-5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 305-527-2498  
; TELEFAX: 305-764-4996  
; INFORMATION FOR SEQ ID NO: 35:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 146 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; PCT-US94-07926-35

Query Match 47.0%; Score 400.5; DB 4; Length 146;  
Best Local Similarity 47.9%; Pred. No. 1.4e-34;  
Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;  
  
Qy 1 MELALLGLVYMA-GVPIQGGILNKNMKVQVTKMPILSYWPGCHGGLGRGPKDA 59  
Db 1 MKVLLLLAVVIMAFGSIQVQGSLLFQGMILFKTKRADVSYGYFGCHGCGVGRGSPKDA 60  
  
Qy 60 TDWCCQTHDCCYDHLKTOGGGIYKDYRYNFSQNIHCSDKGWCBOQLCACDKEVAFCL 119  
Db 61 TDWCCVTHDCCYNLRLEKRGCGTKFVTKFSYRGQISCSSTNQDSCKRQQLCQCKAAAEFC 120  
  
Qy 120 KRLNDTYQKRLRFYWRPHCRGQTPGC 145  
Db 121 ARNKSYSLKYQFYFNKFCGKTPSC 146

RESULT 5  
PCT-US94-07926-35  
; Sequence 35, Application PC/TUS9407926  
; GENERAL INFORMATION:  
; APPLICANT: Tischfield, Jay A.

; APPLICANT: Seilhamer, Jeffrey J.  
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide  
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences  
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide  
; NUMBER OF SEQUENCES: 44  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &  
; ADDRESSEE: Russell PA  
; STREET: 200 East Broward Boulevard  
; CITY: Fort Lauderdale  
; STATE: FL  
; COUNTRY: USA  
; ZIP: 33301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US94/07926  
; FILING DATE: 15-JUL-1994  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/097,354  
; FILING DATE: 26-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Manso, Peter J.  
; REGISTRATION NUMBER: 32,264  
; REFERENCE/DOCKET NUMBER: IN21044-5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 305-527-2498  
; TELEFAX: 305-764-4996  
; INFORMATION FOR SEQ ID NO: 35:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 146 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; PCT-US94-07926-35

Query Match 47.0%; Score 400.5; DB 5; Length 146;  
Best Local Similarity 47.9%; Pred. No. 1.4e-34;  
Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;  
  
Qy 1 MELALLGLVYMA-GVPIQGGILNKNMKVQVTKMPILSYWPGCHGGLGRGPKDA 59  
Db 1 MKVLLLLAVVIMAFGSIQVQGSLLFQGMILFKTKRADVSYGYFGCHGCGVGRGSPKDA 60  
  
Qy 60 TDWCCQTHDCCYDHLKTOGGGIYKDYRYNFSQNIHCSDKGWCBOQLCACDKEVAFCL 119  
Db 61 TDWCCVTHDCCYNLRLEKRGCGTKFVTKFSYRGQISCSSTNQDSCKRQQLCQCKAAAEFC 120  
  
Qy 120 KRLNDTYQKRLRFYWRPHCRGQTPGC 145  
Db 121 ARNKSYSLKYQFYFNKFCGKTPSC 146

RESULT 6  
US-08-186-895-10  
; Sequence 10, Application US/08186895  
; Patent No. 5538885  
; GENERAL INFORMATION:  
; APPLICANT: Hollis, Melvyn  
; APPLICANT: Needham, Maurice R.C.  
; APPLICANT: Gooding, Clare  
; APPLICANT: Grosveld, Franklin G.  
; TITLE OF INVENTION: Expression Systems  
; NUMBER OF SEQUENCES: 10  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Cushman, Darby & Cushman  
; STREET: 1615 L Street, N.W.

```

; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20036-5601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/186,895
; FILING DATE: 27-JAN-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/046,383
; FILING DATE: 09-APR-1993
; APPLICATION NUMBER: US/07/810,414
; ATTORNEY/AGENT INFORMATION:
; NAME: Kokulis, Paul N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: FPK/3893/93802/MJW
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-861-3000
; TELEFAX: 202-822-0944
; TELEX: 6714627 CUSH
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 144 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-186-895-10

Query Match 46.4%; Score 395.5; DB 1; Length 144;
Best Local Similarity 47.6%; Pred. No. 4.7e-34;
Matches 69; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY 1 MELALLGLVVMAGVPIQGGILNINMKVQVTGKMPILSYWPGYCHGGLGGRGPKDAT 60
Db 1 MKTLLAVIMIFGLQAHGNLVNFRHMIKLTGKEALSYGFYCHGCGVGRGSPKDAT 60

QY 61 DWCCQTHDCCVDHLTKQCGIYKYDYRYNFSQGNHCSDKGSWCBCQQLCADCKEVAFCLK 120
Db 61 DRCCVTHDCCYKLEKRGCGTKFLSYKFSNBSRITCAKQDS-CRSQLECDKAAATCFA 119

QY 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145
Db 120 RNKTYNKYQYYSNKHCRGSTPRC 144

RESULT 7
US-08-888-497-37
; Sequence 37, Application US/08888497
; Patent No. 5972677
; GENERAL INFORMATION:
; APPLICANT: Tischfield, Jay A.
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSER: Russell PA
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/362,230
; FILING DATE:
; CLASSIFICATION:

; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20036-5601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/651,405
; FILING DATE:
; APPLICATION NUMBER: US 08/097,354
; FILING DATE: 26-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: IN21044-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4996
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 144 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-888-497-37

Query Match 46.4%; Score 395.5; DB 2; Length 144;
Best Local Similarity 47.6%; Pred. No. 4.7e-34;
Matches 69; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY 1 MELALLGLVVMAGVPIQGGILNINMKVQVTGKMPILSYWPGYCHGGLGGRGPKDAT 60
Db 1 MKTLLAVIMIFGLQAHGNLVNFRHMIKLTGKEALSYGFYCHGCGVGRGSPKDAT 60

QY 61 DWCCQTHDCCVDHLTKQCGIYKYDYRYNFSQGNHCSDKGSWCBCQQLCADCKEVAFCLK 120
Db 61 DRCCVTHDCCYKLEKRGCGTKFLSYKFSNBSRITCAKQDS-CRSQLECDKAAATCFA 119

QY 121 RNLDYQKRLRFYWRPHCRGQTGPGC 145
Db 120 RNKTYNKYQYYSNKHCRGSTPRC 144

RESULT 8
US-09-362-230-37
; Sequence 37, Application US/09362230
; Patent No. 6352849
; GENERAL INFORMATION:
; APPLICANT: Tischfield, Jay A.
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSER: Russell PA
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/362,230
; FILING DATE:
; CLASSIFICATION:

```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/888,497
; FILING DATE:
; APPLICATION NUMBER: US 08/097,354
; FILING DATE: 26-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: IN21044-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-527-2496
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 144 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US94-07926-37

Query Match 46.4%; Score 395.5; DB 4; Length 144;
Best Local Similarity 47.6%; Pred. No. 4.7e-34;
Matches 69; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY 1 MELALLGLVWVAGVIPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGPKDAT 60
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
1 MKTLLAVIMIFGLLQAHGNLVNFRMIKLTGKEAALSIFYGCHGCVGGRGSPKDAT 60

QY 61 DWCCOHDCCDHLTKTQGGIYKYDYRYNFSQGNHCSDKGWCCEQQLCACDKEVAFCLK 120
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
61 DRCCVTHDCCYKRLKRGCGTKFLSYKFSNSGSRITCAKQDS-CRSQCECDKAAATCFA 119

QY 121 RNLDTYQKRLRFYRPHCRGOTPGC 145
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
120 RNKTTYKKYQYYSNKHCRGSTPRC 144

RESULT 9
PCT-US94-07926-37
; Sequence 37, Application PC/TUS9407926
; GENERAL INFORMATION:
; APPLICANT: Tischfield, Jay A.
; APPLICANT: Seilhamer, Jeffrey J.
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSEE: Russell PA
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/07926
; FILING DATE: 15-JUL-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/097,354
; FILING DATE: 26-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: IN21044-5
```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-527-2496
; INFORMATION FOR SEQ ID NO: 37:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 144 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US94-07926-37

Query Match 46.4%; Score 395.5; DB 5; Length 144;
Best Local Similarity 47.6%; Pred. No. 4.7e-34;
Matches 69; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY 1 MELALLGLVWVAGVIPIQGGILNLNMVKVQVTGKMPILSYWPGYCHGGLGGRGPKDAT 60
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
1 MKTLLAVIMIFGLLQAHGNLVNFRMIKLTGKEAALSIFYGCHGCVGGRGSPKDAT 60

QY 61 DWCCOHDCCDHLTKTQGGIYKYDYRYNFSQGNHCSDKGWCCEQQLCACDKEVAFCLK 120
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
61 DRCCVTHDCCYKRLKRGCGTKFLSYKFSNSGSRITCAKQDS-CRSQCECDKAAATCFA 119

QY 121 RNLDTYQKRLRFYRPHCRGOTPGC 145
Db : : : : : : : : : : : : : : : : : : : : : : : : : : : :
120 RNKTTYKKYQYYSNKHCRGSTPRC 144

RESULT 10
US-08-966-317-3
; Sequence 3, Application US/08966317
; Patent No. 6103469
; GENERAL INFORMATION:
; APPLICANT: Hawkins, Phillip R.
; APPLICANT: Bandman, Olga
; APPLICANT: Guegler, Karl J.
; APPLICANT: Shah, Purvi
; APPLICANT: Corley, Neil C.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 PROTEIN
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Incyte Pharmaceuticals, Inc.
; STREET: 3174 Porter Dr.
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/966,317
; FILING DATE: Filed Herewith
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Billings, Lucy J.
; REGISTRATION NUMBER: 36,749
; REFERENCE/DOCKET NUMBER: PF-0403 US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-855-0555
; TELEFAX: 650-845-4166
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 146 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
```



```

RESULT 14
US-09-362-230-39
; Sequence 39, Application US/09362230
; Patent No. 6352849
; GENERAL INFORMATION:
; APPLICANT: Tischfield, Jay A.
; APPLICANT: Seilhamer, Jeffrey J.
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences
; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSEE: Russell PA
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/09362,230
; FILING DATE:
; CLASSIFICATION:
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/888,497
; FILING DATE:
; APPLICATION NUMBER: US 08/097,354
; FILING DATE: 26-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: IN21044-5
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4996
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 124 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-362-230-39

Query Match 43.1%; Score 367.5; DB 4; Length 124;
Best Local Similarity 51.6%; Fred. No. 3.4e-31;
Matches 64; Conservative 16; Mismatches 43; Indels 1; Gaps 1;

QY 22 ILNLNKMVKQVTKGMPILSYWPYSGCHGLGRGPKDATWCCOHHCKYDHLKTKGGI 81
Db 2 LVNPHRMIKUTTKGKRALSYGFTYCHGCVGRGSPKDATRCVVTHDCCYKRLKRGCGT 61

QY 82 YKDYRYNFSQGNHCDKGSWCQEQLCACDKEVAFGLKRNLDITYOKRLRFYWRPHCRGQ 141
Db 62 KFLSYFNSGSRITCAKQDS-CRSQLECDKAAATCFARNKITYNKYQYYSNKHCRGS 120

QY 142 TPGC 145
Db 121 TPRC 124

RESULT 15
US-09-740-569-2
; Sequence 2, Application US/09740569
; Patent No. 6475484
; GENERAL INFORMATION:

```





GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:25:05 ; Search time 32.8667 Seconds  
(without alignments)  
1419.702 Million cell updates/sec

Title: US-09-830-321A-1

Perfect score: 852

Sequence: 1 MELALLGLVMAGVIPIQG.....YQKRLRFYWRHCRQGTFC 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1351062 seqs, 321799191 residues

Total number of hits satisfying chosen parameters: 1351062

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:\*

```
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep.*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep.*
13: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep.*
14: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep.*
15: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep.*
16: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep.*
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep.*
18: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep.*
19: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	852	100.0	145	9	US-09-835-996A-6
2	852	100.0	150	12	US-10-296-115-1342
3	846	99.3	145	9	US-09-969-384-17
4	846	99.3	145	10	US-09-975-456B-7
5	500.5	58.7	116	12	US-09-946-374-378
6	500.5	58.7	116	12	US-10-147-493-534
7	500.5	58.7	116	12	US-10-145-127-534
8	500.5	58.7	116	12	US-10-160-503-534
9	500.5	58.7	116	12	US-10-143-118-534
10	500.5	58.7	116	12	US-10-144-993-534
11	500.5	58.7	116	12	US-10-158-787-534
12	500.5	58.7	116	12	US-10-140-024-534
13	500.5	58.7	116	12	US-10-140-808-534
14	500.5	58.7	116	12	US-10-006-485A-378
15	500.5	58.7	116	12	US-10-013-907A-378

16	500.5	58.7	116	12	US-10-015-499A-378
17	500.5	58.7	116	12	US-10-013-910A-378
18	500.5	58.7	116	12	US-10-152-405-534
19	500.5	58.7	116	12	US-10-127-852A-534
20	500.5	58.7	116	12	US-10-127-900A-534
21	500.5	58.7	116	12	US-10-128-685A-534
22	500.5	58.7	116	12	US-10-226-254A-378
23	500.5	58.7	116	12	US-10-131-820A-534
24	500.5	58.7	116	12	US-10-142-886-534
25	500.5	58.7	116	12	US-10-146-728-534
26	500.5	58.7	116	12	US-10-146-786-534
27	500.5	58.7	116	12	US-10-147-499-534
28	500.5	58.7	116	12	US-10-157-798-534
29	500.5	58.7	116	12	US-10-015-395A-378
30	500.5	58.7	116	14	US-10-028-072-534
31	500.5	58.7	116	14	US-10-121-049-534
32	500.5	58.7	116	14	US-10-123-904-534
33	500.5	58.7	116	14	US-10-140-470-534
34	500.5	58.7	116	14	US-10-175-746-534
35	500.5	58.7	116	14	US-10-176-918-534
36	500.5	58.7	116	14	US-10-176-921-534
37	500.5	58.7	116	14	US-10-137-865-534
38	500.5	58.7	116	14	US-10-140-474-534
39	500.5	58.7	116	14	US-10-142-431-534
40	500.5	58.7	116	14	US-10-143-114-534
41	500.5	58.7	116	14	US-10-140-002-534
42	500.5	58.7	116	14	US-10-006-856A-378
43	500.5	58.7	116	14	US-10-142-419-534
44	500.5	58.7	116	14	US-10-123-262-534
45	500.5	58.7	116	14	US-10-142-423-534

#### ALIGNMENTS

#### RESULT 1

```
US-09-835-996A-6
; Sequence 6, Application US/09835996A
; Patent No. US20020142953A1
; GENERAL INFORMATION:
; APPLICANT: Ballinger, Dennis
; APPLICANT: Loeb, Debra
; APPLICANT: Montgomery, Julie
; APPLICANT: Tang, Y. Tom
; APPLICANT: Zhou, Ping
; APPLICANT: Goodrich, Ryle
; APPLICANT: Liu, Chenghua
; APPLICANT: Asundi, Vinod
; APPLICANT: Zhao, Qing
; APPLICANT: Wehrman, Tom
; APPLICANT: Drmanac, Radoje
; APPLICANT: Ren, Feiyan
; APPLICANT: Qian, Xiaohong
; APPLICANT: Wang, Dunrui
; TITLE OF INVENTION: MATERIALS AND METHODS RELATING TO LIPID METABOLISM
; FILE REFERENCE: 28110/35915A
; CURRENT APPLICATION NUMBER: US/09/835,996A
; PRIOR FILING DATE: 2001-04-16
; PRIOR APPLICATION NUMBER: US 60/197,137
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: US 09/714,936
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: US 09/667,298
; PRIOR FILING DATE: 2000-09-22
; PRIOR APPLICATION NUMBER: US 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: US 09/598,042
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6
; LENGTH: 145
; TYPE: PRT
```

```
; ORGANISM: Homo sapiens
US-09-835-996A-6

Query Match      100.0%; Score 852; DB 9; Length 145;
Best Local Similarity 100.0%; Pred. No. 1.6e-81;
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||
DB 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||

QY 61 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||
DB 61 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||

QY 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||
DB 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||

RESULT 2
US-10-296-115-1342
; Sequence 1342, Application US/10296115
; Publication No. US20040053248A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq Inc
; TITLE OF INVENTION: No. US20040053248A1el Nucleic Acids and Polypeptides
; FILE REFERENCE: 784PCT
; CURRENT APPLICATION NUMBER: US/10/296,115
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US09/488,725
; PRIOR FILING DATE: 2000-01-21
; PRIOR APPLICATION NUMBER: US09/552,317
; PRIOR FILING DATE: 2000-04-25
; NUMBER OF SEQ ID NOS: 1478
; SEQ ID NO 1342
; LENGTH: 150
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-296-115-1342

Query Match      100.0%; Score 852; DB 12; Length 150;
Best Local Similarity 100.0%; Pred. No. 1.6e-81;
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||
DB 6 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 65
   |||||||

QY 61 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||
DB 66 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 125
   |||||||

QY 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||
DB 126 RNLDYQKRLRFYWRPHCRGQTPGC 150
   |||||||

RESULT 3
US-09-969-384-17
; Sequence 17, Application US/09969384
; Publication No. US20020192749A1
; GENERAL INFORMATION:
; APPLICANT: Moore, et al.
; TITLE OF INVENTION: Human Gene Polynucleotides, Polypeptides, and Antibodies
; FILE REFERENCE: PT055PI
; CURRENT APPLICATION NUMBER: US/09/969,384
; CURRENT FILING DATE: 2001-10-03
; PRIOR APPLICATION NUMBER: PCT/US01/10542
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: 60/236,384
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/194,118

; PRIOR FILING DATE: 2000-04-03
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 17
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-969-384-17

Query Match      99.3%; Score 846; DB 9; Length 145;
Best Local Similarity 99.3%; Pred. No. 6.7e-81;
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||
DB 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||

QY 61 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||
DB 61 DWCCQTHDCCYDHLKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||

QY 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||
DB 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||

RESULT 4
US-09-975-456B-7
; Sequence 7, Application US/09975456B
; Publication No. US20030073087A1
; GENERAL INFORMATION:
; APPLICANT: LAZDUNSKI, MICHEL
; APPLICANT: LAMBEAU, GERARD
; APPLICANT: VALENTIN, EMMANUEL
; TITLE OF INVENTION: NOVEL MAMMALIAN SECRETED GROUP IIF PHOSPHOLIPASE A2
; FILE REFERENCE: 1478-R-00
; CURRENT APPLICATION NUMBER: US/09/975,456B
; CURRENT FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: 60/239,491
; PRIOR FILING DATE: 2000-10-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patent In version 2.1
; SEQ ID NO 7
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-975-456B-7

Query Match      99.3%; Score 846; DB 10; Length 145;
Best Local Similarity 99.3%; Pred. No. 6.7e-81;
Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||
DB 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYGCCHGCGGGRGQPKDAT 60
   |||||||

QY 61 DWCCQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||
DB 61 DWCCQTHDCCYDHLKTQCGSIYKDYRYNFSQGNHCSDKGSWCEQQQLCADCDEKVAFCCLK 120
   |||||||

QY 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||
DB 121 RNLDYQKRLRFYWRPHCRGQTPGC 145
   |||||||

RESULT 5
US-09-946-374-378
; Sequence 378, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
```

APPLICANT: Baton, Dan L.  
APPLICANT: Ferrara, Napoleone  
APPLICANT: Fong, Sherman  
APPLICANT: Gao, Wei-Qiang  
APPLICANT: Goddard, Audrey  
APPLICANT: Godowski, Paul J.  
APPLICANT: Grimaldi, Christopher J.  
APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth J.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
APPLICANT: Roy, Margaret Ann  
APPLICANT: Smith, Victoria  
APPLICANT: Stewart, Timothy A.  
APPLICANT: Tumas, Daniel  
APPLICANT: Watanabe, Colin K.  
APPLICANT: Williams, P. Mickey  
APPLICANT: Wood, William I.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
TITLE OF INVENTION: Acids Encoding the Same  
FILE REFERENCE: P2830PIC1  
CURRENT APPLICATION NUMBER: US/09/946,374  
CURRENT FILING DATE: 2001-09-04  
PRIOR APPLICATION NUMBER: 60/098716  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098723  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098749  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098750  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098803  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/098821  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/098843  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/099536  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099596  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099598  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099602  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099642  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099741  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099754  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099763  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099792  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099808  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099812  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099815  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099816  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/100385  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100388  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100390  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100584  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100627  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100661  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100662  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100664  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100683  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100684  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100710  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100711  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100848  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/100849  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/100919  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100930  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/101014  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101068  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101071  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101279  
PRIOR FILING DATE: 1998-09-22  
PRIOR APPLICATION NUMBER: 60/101471  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101472  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101474  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101475  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101476  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101477  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101479  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101738  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101741  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101743  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101915  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101916  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/102207  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102240  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102307  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102330  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102331  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102484  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102487  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102570  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102571  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102684

;; PRIOR FILING DATE: 1998-10-01  
;; PRIOR APPLICATION NUMBER: 60/102687  
;; PRIOR FILING DATE: 1998-10-01  
;; PRIOR APPLICATION NUMBER: 60/102965  
;; PRIOR FILING DATE: 1998-10-02  
;; PRIOR APPLICATION NUMBER: 60/103258  
;; PRIOR FILING DATE: 1998-10-06  
;; PRIOR APPLICATION NUMBER: 60/103314  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103315  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103328  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103395  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103396  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103401  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103449  
;; PRIOR FILING DATE: 1998-10-06  
;; PRIOR APPLICATION NUMBER: 60/103633  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103678  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103679  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103711  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/104257  
;; PRIOR FILING DATE: 1998-10-14  
;; PRIOR APPLICATION NUMBER: 60/104987  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105000  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105002  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105104  
;; PRIOR FILING DATE: 1998-10-21  
;; PRIOR APPLICATION NUMBER: 60/105169  
;; PRIOR FILING DATE: 1998-10-22  
;; PRIOR APPLICATION NUMBER: 60/105266  
;; PRIOR FILING DATE: 1998-10-22  
;; PRIOR APPLICATION NUMBER: 60/105693  
;; PRIOR FILING DATE: 1998-10-26  
;; PRIOR APPLICATION NUMBER: 60/105694  
;; PRIOR FILING DATE: 1998-10-26  
;; PRIOR APPLICATION NUMBER: 60/105807

Query Match 58.7%; Score 500.5; DB 10; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
  
Qy 1 MELALLGLVVMAGVIPIQGGILNKNMKVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVIPIQGGILNKNMKVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQGGIYKDYRYNFSQGNHCSDKGSWCEQQLC 109  
Db 61 DWCCQTHDCCYDHLTKTQGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 6  
US-10-147-493-534  
; Sequence 534, Application US/10147493  
; Publication No. US2004029217A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang

;; APPLICANT: Gerritsen, Mary E.  
;; APPLICANT: Goddard, Audrey  
;; APPLICANT: Godowski, Paul J.  
;; APPLICANT: Gurney, Austin L.  
;; APPLICANT: Sherwood, Steven  
;; APPLICANT: Smith, Victoria  
;; APPLICANT: Stewart, Timothy A.  
;; APPLICANT: Tumas, Daniel  
;; APPLICANT: Watanabe, Colin K  
;; APPLICANT: Wood, William  
;; APPLICANT: Zhang, Zemin  
;; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
;; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
;; FILE REFERENCE: P3330R1C345  
;; CURRENT APPLICATION NUMBER: US/10/147,493  
;; CURRENT FILING DATE: 2002-05-17  
;; Prior Application removed - See File Wrapper or Palm  
;; NUMBER OF SEQ ID NOS: 550  
;; SEQ ID NO 534  
;; LENGTH: 116  
;; TYPE: PRT  
;; ORGANISM: Homo Sapien  
US-10-147-493-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
  
Qy 1 MELALLGLVVMAGVIPIQGGILNKNMKVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
Db 1 MELALLGLVVMAGVIPIQGGILNKNMKVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60  
  
Qy 61 DWCCQTHDCCYDHLTKTQGGIYKDYRYNFSQGNHCSDKGSWCEQQLC 109  
Db 61 DWCCQTHDCCYDHLTKTQGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 7  
US-10-145-127-534  
; Sequence 534, Application US/10145127  
; Publication No. US20040033558A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
; FILE REFERENCE: P3330R1C252  
; CURRENT APPLICATION NUMBER: US/10/145,127  
; CURRENT FILING DATE: 2002-05-13  
; Prior Application removed - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 550  
; SEQ ID NO 534  
; LENGTH: 116  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-145-127-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;

```
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;

Qy 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60
Db 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60

Qy 61 DWCCQTHDCCYDHLTKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLC 109
Db 61 DWCCQTHDCCYDHLTKTQCGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 8
US-10-160-503-534
; Sequence 534, Application US/10160503
; Publication No. US20040033559A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC446
; CURRENT APPLICATION NUMBER: US/10/160,503
; CURRENT FILING DATE: 2002-05-30
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 534
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-160-503-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;

Qy 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60
Db 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60

Qy 61 DWCCQTHDCCYDHLTKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLC 109
Db 61 DWCCQTHDCCYDHLTKTQCGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 9
US-10-143-118-534
; Sequence 534, Application US/10143118
; Publication No. US20040038335A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC261
; CURRENT APPLICATION NUMBER: US/10/144,993
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 534
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-143-118-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;
```

```
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC228
; CURRENT APPLICATION NUMBER: US/10/143,118
; CURRENT FILING DATE: 2002-05-09
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 534
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-143-118-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;

Qy 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60
Db 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPGCHGCGRGQPKDAT 60

Qy 61 DWCCQTHDCCYDHLTKTQCGGIYKDYRYNFSQGNHCSDKGSWCEQQLC 109
Db 61 DWCCQTHDCCYDHLTKTQCGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 10
US-10-144-993-534
; Sequence 534, Application US/10144993
; Publication No. US20040038336A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330RIC261
; CURRENT APPLICATION NUMBER: US/10/144,993
; CURRENT FILING DATE: 2002-05-13
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 534
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-144-993-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;
```

QY 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
Db 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
QY 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 109  
Db 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 100

RESULT 11  
US-10-158-787-534  
; Sequence 534, Application US/10158787  
; Publication No. US20040039164A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
; FILE REFERENCE: P3330R1C449  
; CURRENT APPLICATION NUMBER: US/10/158,787  
; CURRENT FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: 60/049911  
; PRIOR FILING DATE: 1997-06-18  
; PRIOR APPLICATION NUMBER: 60/056974  
; PRIOR FILING DATE: 1997-08-26  
; PRIOR APPLICATION NUMBER: 60/059113  
; PRIOR FILING DATE: 1997-09-17  
; PRIOR APPLICATION NUMBER: 60/059115  
; PRIOR FILING DATE: 1997-09-17  
; PRIOR APPLICATION NUMBER: 60/059117  
; PRIOR FILING DATE: 1997-09-17  
; PRIOR APPLICATION NUMBER: 60/059122  
; PRIOR FILING DATE: 1997-09-17  
; PRIOR APPLICATION NUMBER: 60/059184  
; PRIOR FILING DATE: 1997-09-17  
; PRIOR APPLICATION NUMBER: 60/059263  
; PRIOR FILING DATE: 1997-09-18  
; PRIOR APPLICATION NUMBER: 60/059352  
; PRIOR FILING DATE: 1997-09-19  
; PRIOR APPLICATION NUMBER: 60/059588  
; PRIOR FILING DATE: 1997-09-19  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 550  
; SEQ ID NO 534  
; LENGTH: 116  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-158-787-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
QY 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
Db 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
QY 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 109

Db 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 100

RESULT 12  
US-10-140-024-534  
; Sequence 534, Application US/10140024  
; Publication No. US20040058424A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin  
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; TITLE OF INVENTION: ACIDS ENCODING THE SAME  
; FILE REFERENCE: P3330R1C69  
; CURRENT APPLICATION NUMBER: US/10/140,024  
; CURRENT FILING DATE: 2002-05-06  
; Prior Application removed - See Palm or File Wrapper  
; NUMBER OF SEQ ID NOS: 550  
; SEQ ID NO 534  
; LENGTH: 116  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-10-140-024-534

Query Match 58.7%; Score 500.5; DB 12; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
QY 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
Db 1 METALLCGLVVWAGVIPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCHGGRGQPKDAT 60  
QY 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 109  
Db 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCMD-----LSQRYC 100

RESULT 13  
US-10-140-808-534  
; Sequence 534, Application US/10140808  
; Publication No. US20030017563A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William

```
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C182
; CURRENT APPLICATION NUMBER: US/10/140,808
; PRIOR FILING DATE: 2002-05-07 10:140,808
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 534
; LENGTH: 116
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-140-808-534

Query Match      58.7%; Score 500.5; DB 12; Length 116;
Best Local Similarity 82.6%; Pred. No. 1.1e-44;
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;

QY 1 MELLALCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGYCHGCGRGQPKDAT 60
Db 1 MELLALCGLVVMAGVPIQGGILNLNMVKQVTGKMPILSYWPGYCHGCGRGQPKDAT 60

QY 61 DWCCQTHDCYDHLTKTQGGIYKDYRYNFSQGNHCHSDKGSWCQQLC 109
Db 61 DWCCQTHDCYDHLTKTQGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 14
US-10-006-485A-378
; Sequence 378, Application US/10006485A
; Publication No. US20030064062A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas P.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C9
; CURRENT APPLICATION NUMBER: US/10/006,485A
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09

; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
```

Fri Oct 8 10:22:30 2004

;; PRIOR FILING DATE: 1998-09-24  
;; PRIOR APPLICATION NUMBER: 60/101741  
;; PRIOR FILING DATE: 1998-09-24  
;; PRIOR APPLICATION NUMBER: 60/101743  
;; PRIOR FILING DATE: 1998-09-24  
;; PRIOR APPLICATION NUMBER: 60/101915  
;; PRIOR FILING DATE: 1998-09-24  
;; PRIOR APPLICATION NUMBER: 60/101916  
;; PRIOR FILING DATE: 1998-09-24  
;; PRIOR APPLICATION NUMBER: 60/102207  
;; PRIOR FILING DATE: 1998-09-29  
;; PRIOR APPLICATION NUMBER: 60/102240  
;; PRIOR FILING DATE: 1998-09-29  
;; PRIOR APPLICATION NUMBER: 60/102307  
;; PRIOR FILING DATE: 1998-09-29  
;; PRIOR APPLICATION NUMBER: 60/102330  
;; PRIOR FILING DATE: 1998-09-29  
;; PRIOR APPLICATION NUMBER: 60/102331  
;; PRIOR FILING DATE: 1998-09-29  
;; PRIOR APPLICATION NUMBER: 60/102484  
;; PRIOR FILING DATE: 1998-09-30  
;; PRIOR APPLICATION NUMBER: 60/102487  
;; PRIOR FILING DATE: 1998-09-30  
;; PRIOR APPLICATION NUMBER: 60/102570  
;; PRIOR FILING DATE: 1998-09-30  
;; PRIOR APPLICATION NUMBER: 60/102571  
;; PRIOR FILING DATE: 1998-09-30  
;; PRIOR APPLICATION NUMBER: 60/102684  
;; PRIOR FILING DATE: 1998-10-01  
;; PRIOR APPLICATION NUMBER: 60/102687  
;; PRIOR FILING DATE: 1998-10-01  
;; PRIOR APPLICATION NUMBER: 60/102965  
;; PRIOR FILING DATE: 1998-10-02  
;; PRIOR APPLICATION NUMBER: 60/103258  
;; PRIOR FILING DATE: 1998-10-06  
;; PRIOR APPLICATION NUMBER: 60/103314  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103315  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103328  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103395  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103396  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103401  
;; PRIOR FILING DATE: 1998-10-07  
;; PRIOR APPLICATION NUMBER: 60/103449  
;; PRIOR FILING DATE: 1998-10-06  
;; PRIOR APPLICATION NUMBER: 60/103633  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103678  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103679  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/103711  
;; PRIOR FILING DATE: 1998-10-08  
;; PRIOR APPLICATION NUMBER: 60/104257  
;; PRIOR FILING DATE: 1998-10-14  
;; PRIOR APPLICATION NUMBER: 60/104987  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105000  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105002  
;; PRIOR FILING DATE: 1998-10-20  
;; PRIOR APPLICATION NUMBER: 60/105104  
;; PRIOR FILING DATE: 1998-10-21  
;; PRIOR APPLICATION NUMBER: 60/105169  
;; PRIOR FILING DATE: 1998-10-22  
;; PRIOR APPLICATION NUMBER: 60/105266  
;; PRIOR FILING DATE: 1998-10-22  
;; PRIOR APPLICATION NUMBER: 60/105693  
;; PRIOR FILING DATE: 1998-10-26

;; PRIOR APPLICATION NUMBER: 60/105694  
;; PRIOR FILING DATE: 1998-10-26  
;; PRIOR APPLICATION NUMBER: 60/105807  
;; PRIOR FILING DATE: 1998-10-27  
;; PRIOR APPLICATION NUMBER: 60/105891  
;; PRIOR FILING DATE: 1998-10-27  
;; PRIOR APPLICATION NUMBER: 60/105882  
;; PRIOR FILING DATE: 1998-10-27  
;; PRIOR APPLICATION NUMBER: 60/106023  
;; PRIOR FILING DATE: 1998-10-28

Query Match 58.7%; Score 500.5; DB 12; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
QY 1 MELALLCGLVVMAGVPIQGGILNLNKMKVQVTGKMPILSYWPYGCGLGGRGQPKDAT 60  
Db 1 MELALLCGLVVMAGVPIQGGILNLNKMKVQVTGKMPILSYWPYGCGLGGRGQPKDAT 60  
QY 61 DWCCQTHDCCYDHLKTQCGGIYKYDYRYNFSQGNHCHSDKGSWCEQQLC 109  
Db 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCM-----LSQRYC 100

RESULT 15

US-10-013-907A-378  
; Sequence 378, Application US/10013907A  
; Publication No. US20030064925A1  
; GENERAL INFORMATION:  
; APPLICANT: Baker, Kevin P.  
; APPLICANT: Botstein, David  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Eaton, Dan I.  
; APPLICANT: Ferrara, Napoleone  
; APPLICANT: Fong, Sherman  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Grimaldi, Christopher J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Hillan, Kenneth J.  
; APPLICANT: Pan, James  
; APPLICANT: Paoni, Nicholas P.  
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
; FILE REFERENCE: P2830P1C34  
; CURRENT APPLICATION NUMBER: US/10/013,907A  
; PRIOR FILING DATE: 2001-12-10  
; PRIOR APPLICATION removed - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 477  
; SEQ ID NO 378  
; LENGTH: 116  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-013-907A-378

Query Match 58.7%; Score 500.5; DB 12; Length 116;  
Best Local Similarity 82.6%; Pred. No. 1.1e-44;  
Matches 90; Conservative 4; Mismatches 6; Indels 9; Gaps 2;  
QY 1 MELALLCGLVVMAGVPIQGGILNLNKMKVQVTGKMPILSYWPYGCGLGGRGQPKDAT 60  
Db 1 MELALLCGLVVMAGVPIQGGILNLNKMKVQVTGKMPILSYWPYGCGLGGRGQPKDAT 60  
QY 61 DWCCQTHDCCYDHLKTQCGGIYKYDYRYNFSQGNHCHSDKGSWCEQQLC 109  
Db 61 DWCCQTHDCCYDHLKTQCGGIYKDN-----NKSSIHCM-----LSQRYC 100

Search completed: October 5, 2004, 19:41:12  
Job time : 34.8667 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:21:45 ; Search time 9.86 Seconds  
(without alignments)  
1414.561 Million cell updates/sec

Title: US-09-830-321A-1

Perfect score: 852

Sequence: 1 MELALLGLVVMAGVIPIQG.....YQKRLRFYWRPHCRGQTGPGC 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_78:\*  
1: PIR1:\*  
2: PIR2:\*  
3: PIR3:\*  
4: PIR4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	401.5	47.1	146	A35493	phospholipase A2 (
2	399.5	46.9	146	A33394	phospholipase A2 (
3	395.5	46.4	144	1 PSHUYF	phospholipase A2 (
4	389.5	45.7	146	2 JU0283	phospholipase A2 (
5	389	45.7	145	2 I48093	phospholipase A2 (
6	365.5	42.9	146	2 I48342	phospholipase A2 (
7	347	40.7	138	2 A49959	phospholipase A2 (
8	335.5	39.4	138	1 PSRSBT	phospholipase A2 (
9	335.5	39.4	138	1 I51381	phospholipase A2 (
10	332	39.0	125	2 JX0052	phospholipase A2 (
11	331.5	38.9	138	1 PSRSB2	phospholipase A2 (
12	328.5	38.6	138	2 JCI342	phospholipase A2 (
13	320.5	37.6	122	2 S13900	phospholipase A2 (
14	319.5	37.5	137	2 S68429	myotoxin precursor
15	316.5	37.1	122	1 PSTVXF	phospholipase A2 (
16	314.5	36.9	138	2 S10992	ammodytin L precur
17	313.5	36.8	138	2 E48188	phospholipase A2 (
18	312.5	36.7	121	1 PC4024	phospholipase A2 h
19	312.5	36.7	122	1 PSABA	phospholipase A2 (
20	311.5	36.6	122	2 JX0063	phospholipase A2 (
21	311.5	36.6	138	2 D48188	phospholipase A2 (
22	310	36.4	138	2 S59522	phospholipase A2 (
23	309.5	36.3	138	2 S59522	phospholipase A2 (
24	307.5	36.1	121	1 PSSNAM	phospholipase A2 h
25	305.5	35.9	138	1 PSVTAC	phospholipase A2 (
26	305.5	35.9	138	2 S10333	ammodytoxin B prec
27	305.5	35.9	138	2 I51386	phospholipase A2 (
28	304.5	35.7	138	1 PSVIAA	phospholipase A2 (
29	302	35.4	138	2 I50098	phospholipase a2 -

#### RESULT 1

A35493

phospholipase A2 (EC 3.1.1.4) II precursor - rat

C:Species: Rattus norvegicus (Norway rat)

C>Date: 14-Sep-1990 #sequence revision 18-Nov-1992 #text\_change 18-Jun-1999

C:Accession: A35493; S11388; S71310

R:Komada, M.; Kudo, I.; Inoue, K.

Biochem. Biophys. Res. Commun. 168, 1059-1065, 1990

A:Title: Structure of gene coding for rat group II phospholipase A-2.

A:Reference number: A35493; MUID:90267443; PMID:2346480

A:Accession: A35493

A>Status: Preliminary

A:Molecule type: DNA

A:Residues: 1-146 <K0M>

A:Cross-references: GB:M37127; NID:G204318; PIDN:AAA41223.1; PID:G204319

A:Note: The authors translated the codon TAT for residue 42 as Thr

R:Kusunoki, C.; Satoh, C.; Kobayashi, M.; Niwa, M.

Biochim. Biophys. Acta 1087, 95-97, 1990

A:Title: Structure of genomic DNA for rat platelet phospholipase A(2).

A:Reference number: S11388; MUID:90381322; PMID:2400792

A:Accession: S11388

A>Status: Preliminary

A:Molecule type: DNA

A:Residues: 1-146 <KUS>

A:Cross-references: EMBL:X51529; NID:G56930; PIDN:CAA35909.1; PID:G56931

R:Aarsman, A.J.; Schalkwijk, C.G.; Neys, F.W.; Iijima, N.; Wherrett, J.R.; van den Bosch,

Arch. Biochem. Biophys. 331, 95-103, 1996

A:Title: Purification and characterization of Ca(2+)-dependent phospholipases A(2) from r

A:Reference number: S71310; MUID:96268465; PMID:8660688

A:Accession: S71310

A:Molecule type: protein

A:Residues: 22-29, 'X', '31-32, 'X', '34 <AAR>

A:Experimental source: kidney

C:Superfamily: phospholipase A2

C:Keywords: carboxylic ester hydrolase; lipid degradation

F:68,113/Active site: His, Asp #status predicted

Query Match

Best Local Similarity 47.1%; Score 401.5; DB 2; Length 146;

Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY

1 MELALLGLVVMAGVIPIQG.....YQKRLRFYWRPHCRGQTGPGC 59

Db

1 MKVLLLVAVINAFSGIQVGSLLFFGQMILPKTKRRADVSYFGYCHGCGVGRSGPKDA 60

QY

60 TDWCCTQTHDCCTDHLKTKTCGTYKDYRYNFFSQGNHCSDKGSCWCEQQCLCACDKEVAFCL 119

Db

61 TDWCCTQTHDCCTDHLKTKTCGTYKDYRYNFFSQGNHCSDKGSCWCEQQCLCACDKEVAFCL 120

QY

120 KKNLDITYQKRLRFYWRPHCRGQTGPGC 145

Db

121 ARNKXSYSLKQFYLNKFKCKGKTPSC 146

## RESULT 2

A33394

phospholipase A2 (BC 3.1.1.4) precursor (version 1) - rat

C:Species: Rattus norvegicus (Norway rat)

C:Date: 29-Jan-1990 #sequence\_revision 29-Jan-1990 #text\_change 20-Jun-2000

C:Accession: A33394; J00131

R:Ishizaki, J.; Ohara, O.; Nakamura, E.; Tamaki, M.; Ono, T.; Kanda, A.; Yoshida, N.; Te

Biochem. Biophys. Res. Commun. 162, 1030-1036, 1989

A:Title: cDNA cloning and sequence determination of rat membrane-associated phospholipase

A:Reference number: A33394; MUID:89350908; PMID:2764915

A:Accession: A33394

A:Status: preliminary

A:Molecule type: mRNA

A:Residues: 1-146 &lt;ISH&gt;

A:Cross-references: GB:M25148

R:Komada, M.; Kudo, I.; Mizushima, H.; Kitamura, N.; Inoue, K.

J. Biochem. 106, 545-547, 1989

A:Title: Structure of cDNA coding for rat platelet phospholipase A2.

A:Reference number: J00131; MUID:90110043; PMID:2606907

A:Accession: J00131

A:Molecule type: mRNA

A:Residues: 1-146 &lt;XOM&gt;

A:Cross-references: GB:D00523; NID:g220857; PIDN:BAA00410.1; PID:g220858

C:Superfamily: phospholipase A2

C:Keywords: carboxylic ester hydrolase

F:1-21/Domain: signal sequence #status predicted &lt;SIG&gt;

F:22-146/Product: phospholipase A2 #status predicted &lt;MAT&gt;

F:68,113/Active site: His, Asp #status predicted

Query Match 46.9%; Score 399.5; DB 2; Length 146;

Best Local Similarity 47.9%; Pred. No. 1.7e-29;

Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

Qy 1 MELALLGLVYVA-GVPIQGLINLNMVKVQTKMPILSWPVGCHGLGGRQPKDA 59

Dy 1 MKVLLLAWVINAFAGSIQVQGSLLFEGQMLFKTKRADVSYGFYGCYGVGRGSPKDA 60

Qy 60 TDWCCTHDCVHLKTCGGYKDYVNFSGNHCSDKGSWCEQQI-CACDKVEAFCL 119

Dy 61 TDWCCTHDCVHLKTCGGYKDYVNFSGNHCSDKGSWCEQQI-CACDKVEAFCL 120

Qy 120 KRLDITYQKRLFYWRHRCGTGTC 145

Dy 121 ARNKKSYSLKQFYENKFCGKGTGTC 146

## RESULT 3

P5HUYF

phospholipase A2 (BC 3.1.1.4) IIA precursor [validated] - human

N:Alternate names: phosphatidylcholine 2-acylhydrolase; placental PLA2; platelet-secreted

C:Species: Homo sapiens (man)

C:Date: 31-Mar-1993 #sequence\_revision 31-Mar-1993 #text\_change 15-Sep-2000

A:Accession: A32862; B32862; A60266; A32847; A60263; A31350; P70056; A32913; A60265; A61

R:Kramer, R.M.; Hession, C.; Johansen, B.; Hayes, G.; McGray, P.; Chow, E.P.; Tizard, R.

J. Biol. Chem. 264, 5768-5775, 1989

A:Title: Structure and properties of a human non-pancreatic phospholipase A-2.

A:Reference number: A32862; MUID:89174633; PMID:2925633

A:Accession: A32862

A:Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-144 &lt;KRA&gt;

A:Accession: B32862

A:Molecule type: protein

A:Residues: 21-39 &lt;KRA&gt;

A&gt;Note: this protein was also detected in platelets

R:Kramer, R.M.; Johansen, B.; Hession, C.; Pepinsky, R.B.

Adv. Exp. Med. Biol. 275, 35-53, 1990

A:Title: Structure and properties of a secreted phospholipase A-2 from human platelets

A:Reference number: A60266; MUID:91050834; PMID:2239446

A:Accession: A60266

A:Status: not compared with conceptual translation

A:Molecule type: DNA

A:Residues: 1-144 <KR3>

R:Seilhamer, J.J.; Pruzanski, W.; Vadas, P.; Plant, S.; Miller, J.A.; Kloss, J.; Johnson, J. Biol. Chem. 264, 5335-5338, 1989

A:Title: Cloning and recombinant expression of phospholipase A-2 present in rheumatoid A:Reference number: A32847; MUID:89174566; PMID:2925608

A:Accession: A32847

A:Molecule type: mRNA

A:Residues: 1-144 <SEI>

A:Cross-references: GB:J04704; EMBL:M242430; NID:q190888; PIDN:AAA36550.1; PID:q190889

R:Crowl, R.; Stoner, C.; Stoller, T.; Pan, Y.C.; Conroy, R.

Adv. Exp. Med. Biol. 279, 173-184, 1990

A:Title: Isolation and characterization of cDNA clones from human placenta coding for phospholipase A2

A:Reference number: A60263; MUID:91263879; PMID:1710870

A:Accession: A60263

A:Status: not compared with conceptual translation

A:Molecule type: mRNA

A:Residues: 1-144 <CRO>

R:Lai, C.Y.; Wada, K.

Biochem. Biophys. Res. Commun. 157, 488-493, 1988

A:Title: Phospholipase A-2 from human synovial fluid: purification and structural homology

A:Reference number: A31350; MUID:89076274; PMID:3202859

A:Accession: A31350

A:Molecule type: protein

A:Residues: 21-33 <LAI>

R:Hara, S.; Kudo, I.; Matsuta, K.; Miyamoto, T.; Inoue, K.

J. Biochem. 104, 326-328, 1988

A:Title: Amino acid composition and NH2-terminal amino acid sequence of human phospholipase A2

A:Reference number: P70056; MUID:89197814; PMID:3240982

A:Accession: P70056

A:Molecule type: protein

A:Residues: 21-46, 'X', 48-54 <HAR>

R:Kanda, A.; Ono, T.; Yoshida, N.; Tojo, H.; Okamoto, M.

Biochem. Biophys. Res. Commun. 163, 42-48, 1989

A:Title: The primary structure of a membrane-associated phospholipase A-2 from human spl

A:Reference number: A32913; MUID:89374261; PMID:2775276

A:Accession: A32913

A:Molecule type: protein

A:Residues: 21-144 <KAN>

R:Parks, T.P.; Lukas, S.; Hoffman, A.F.

Adv. Exp. Med. Biol. 275, 55-81, 1990

A:Title: Purification and characterization of a phospholipase A-2 from human osteoarthritis

A:Reference number: A60265; MUID:91050835; PMID:2146857

A:Accession: A60265

A:Molecule type: protein

A:Residues: 21-45, 'X', <PAR>

R:Recklies, A.D.; White, C.

Arthritis Rheum. 34, 1106-1115, 1991

A:Title: Phospholipase A-2 is a major component of the salt-extractable pool of matrix p

A:Reference number: A61201; MUID:92029121; PMID:1930329

A:Accession: A61201

A:Molecule type: protein

A:Residues: 21-40 <REC>

A:Experimental source: adult articular cartilage

R:Green, J.A.; Smith, G.M.; Buchta, R.; Lee, R.; Ho, K.Y.; Rajkovic, I.A.; Scott, K.F.

Inflammation 15, 355-366, 1991

A:Title: Circulating phospholipase A-2 activity associated with sepsis and septic shock

A:Reference number: A61634; MUID:92098137; PMID:1757123

A:Accession: A61634

A:Molecule type: protein

A:Residues: 21-44 <GRE>

R:Wery, J.P.; Schevitz, R.W.; Clawson, D.K.; Bobbitt, J.L.; Dow, E.R.; Gamboa, G.; Goods

Teater, C.; Warrick, M.W.; Jones, N.D.

submitted to the Brookhaven Protein Data Bank, May 1992

A:Reference number: A51043; PDB:1B8C

A:Contents: annotation; X-ray crystallography, 2.2 angstroms, residues 21-144

R:Wery, J.P.; Schevitz, R.W.; Clawson, D.K.; Bobbitt, J.L.; Dow, E.R.; Gamboa, G.; Goods

Teater, C.; Warrick, M.W.; Jones, N.D.

Nature 352, 79-82, 1991

A:Title: Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase

A:Reference number: A58514; MUID:91287826; PMID:2062381

A:Contents: annotation; X-ray crystallography

C:Genetics:





RESULT 10  
JX0052 phospholipase A2 (EC 3.1.1.4) - rat  
N:Alternate names: phosphatidylcholine 2-acylhydrolase  
C:Species: Rattus norvegicus (Norway rat)  
C>Date: 30-Jun-1992 #sequence revision 30-Jun-1992 #text change 24-Jul-1997  
C:Accession: JX0052; A1438; A26924; A38247; A28618; A33506  
R:Hayakawa, M.; Kudo, I.; Tomita, M.; Nojima, S.; Inoue, K.  
J. Biochem. 104, 767-772, 1988  
A:Title: The primary structure of rat platelet phospholipase A2.  
A:Reference number: JX0052; MUID:89174508; PMID:3235451  
A:Accession: JX0052  
A:Molecule type: protein  
A:Residues: 1-125 <HA2>  
A:Experimental source: Wistar  
R:Hayakawa, M.; Kudo, I.; Tomita, M.; Inoue, K.  
J. Biochem. 103, 263-266, 1988  
A:Title: Purification and characterization of membrane-bound phospholipase A-2 from rat  
A:Reference number: A41438; MUID:88227898; PMID:3372490  
A:Accession: A41438  
A>Status: preliminary  
A:Molecule type: protein  
A:Residues: 'X', 2-19 <HA2>  
R:Hayakawa, M.; Horigome, K.; Kudo, I.; Tomita, M.; Nojima, S.; Inoue, K.  
J. Biochem. 101, 1311-1314, 1987  
A:Title: Amino acid composition and NH-2-terminal amino acid sequence of rat platelet se  
A:Reference number: A26924; MUID:88007474; PMID:3654593  
A:Accession: A26924  
A:Molecule type: protein  
A:Residues: 'X', 2-25 <HA3>

**A;Title:** The origin of the diversity of crotoxin isoforms in the re

A:Accession: S45647  
A:Status: nucleic acid sequence not shown

A:Molecule type: mRNA

A:Residues: 17-138 <FAU>

A:Cross-references: EMBL:X16100

A:Accession: S46598

A:Molecule type: protein

A:Residues: 17-51 <FA2>

C:Comment: Crotoxin is a beta-neurotoxin.

C:Complex: heterodimer of acidic and basic chains

C:Function:

A:Description: catalyzes hydrolysis of 1,2-diacyl-sn-glycero-3-phosphocholine to 1-acyl-

A>Note: the reaction is strongly enhanced when the phospholipid is condensed into a micelle

C:Superfamily: phospholipase A2

C:Keywords: calcium; carboxylic ester hydrolase; heterodimer; lipid degradation; metallo

F:1-16/Domain: signal sequence #status predicted <SIG>

F:17-138/Product: crotoxin basic chain 2 #status experimental <MAT>

F:20-80/Binding site: micellar substrate (Gln, Tyr) #status predicted

F:42-131,44-60,59-111,65-138,66-104,73-97,91-102/Disulfide bonds: #status predicted

F:43,45,47,64/Binding site: calcium (Tyr, Gly, Asp) #status predicted

F:63,105/Active site: His, Asp #status predicted

Query Match 38.9%; Score 331.5; DB 1; Length 138;

Best Local Similarity 44.1%; Pred. No. 2.7e-23;

Matches 60; Conservative 21; Mismatches 52; Indels 3; Gaps 2;

QY 10 VVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCGRGQPKDATDWCCTHDC 69

Db 6 IVALLVGVESLLQFNKMKETERNVFFAFCYCYCGGQGRPKDATDCCFVHDC 65

QY 70 CYDHLKTCGCGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLRNLDTYQKRLFYWRP 129

Db 66 CYG--KLAKNTKWDIYRSLKSGYITCG-KGTWCKEQICEDRVAAECRLRSLSYKNE 122

QY 130 LRFYWRPHRCRGQTGTC 145

Db 123 VMFYDPSRCREPSETC 138

RESULT 12

JCI342

C:Species: Agkistrodon halys (halys viper)

C:Date: 09-Oct-1997 #sequence\_revision 07-Nov-1997 #text\_change 13-Nov-1998

A:Accession: JCI342

A:Residues: 1-138 <PAN>

A:Title: Cloning of the BPA2 gene from Agkistrodon halys Pallas.

A:Reference number: JCI342

A:Contents: Snake venom

A:Molecule type: mRNA

A:Residues: 1-138 <PAN>

A:Note: the authors translated the codon GAC for residue 54 as Asn

C:Superfamily: phospholipase A2

C:Keywords: carboxylic ester hydrolase

F:1-16/Domain: signal sequence #status predicted <SIG>

F:17-138/Product: phospholipase A2 #status predicted <MAT>

Query Match 38.6%; Score 328.5; DB 2; Length 138;

Best Local Similarity 43.4%; Pred. No. 5e-23;

Matches 59; Conservative 24; Mismatches 50; Indels 3; Gaps 2;

QY 10 VVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCGRGQPKDATDWCCTHDC 69

Db 6 IVALLVGVESLLQFNKMKETERNVFFAFCYCYCGGQGRPKDATDCCFVHDC 65

QY 70 CYDHLKTCGCGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLRNLDTYQKRLFYWRP 129

Db 66 CYE--KLTCGDPKWDYTYSKNGTIVCGGDDP-CKKEVCECDKAAICFRDLNLTQYKR 122

QY 130 LRFYWRPHRCRGQTGTC 145

Db 123 YMTYPNLCSSKSEKC 138

RESULT 13

SI3900

phospholipase A2 (EC 3.1.1.4) - Bothrops asper

C:Species: Bothrops asper

C:Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 31-Oct-1997

A:Accession: SI3900

R:Francis, B.; Gutierrez, J.M.; Lomonte, B.; Kaiser, I.I.

Arch. Biochem. Biophys. 284, 352-359, 1991

A:Title: Myotoxin II from Bothrops asper (Terciopelo) venom is a lysine-49 phospholipase

A:Reference number: SI3900; MUID:91112832; PMID:1899180

A:Accession: SI3900

A:Status: preliminary

A:Molecule type: protein

A:Residues: 1-122 <FRA>

C:Superfamily: phospholipase A2

C:Keywords: carboxylic ester hydrolase

Query Match 37.6%; Score 320.5; DB 2; Length 122;

Best Local Similarity 50.4%; Pred. No. 2.4e-22;

Matches 58; Conservative 15; Mismatches 39; Indels 3; Gaps 2;

QY 22 ILNLNKMVKQVTGKMPILSYWPYCHGCGRGQPKDATDWCCTHDCYDHLKTCGCGI 81

Db 2 LFLGKMLQETGKMPAKSYGAYGNCVGLGRGPKDATDRCYVHKCCYK--KLTCGNP 59

QY 82 YKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLRNLDTYQKRLFYWRP 136

Db 60 KXDYRYSWKDKTIIVCGNNNS--CLKELCECDKAVAICLRENLTYNKYRYLYKP 113

RESULT 14

S68429

myotoxin precursor - southern copperhead

C:Species: Agkistrodon contortrix contortrix (southern copperhead)

C:Date: 15-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change 18-Jun-1999

A:Accession: S68429; S74296

R:de Araujo, H.S.S.; White, S.P.; Ownby, C.L.

Arch. Biochem. Biophys. 326, 21-30, 1996

A:Title: cDNA cloning and sequence analysis of a lysine-49 phospholipase A(2) myotoxin

A:Reference number: S68429; MUID:96154243; PMID:8579368

A:Accession: S68429

A:Molecule type: mRNA

A:Residues: 1-137 <DEA>

A:Cross-references: EMBL:U21335; NID:9809484; PIDN:AAC59887.1; PID:9809485

A:Accession: S74296

A:Molecule type: protein

A:Residues: 17-36 <DER>

C:Superfamily: phospholipase A2

F:1-16/Domain: signal sequence #status predicted <SIG>

F:17-137/Product: myotoxin #status experimental <MAT>

Query Match 37.5%; Score 319.5; DB 2; Length 137;

Best Local Similarity 45.4%; Pred. No. 3.3e-22;

Matches 59; Conservative 20; Mismatches 48; Indels 3; Gaps 2;

QY 10 VVMAGVPIQGGILNLNKMVKQVTGKMPILSYWPYCHGCGRGQPKDATDWCCTHDC 69

Db 6 IVALLVGVESLLQFNKMKETERNVFFAFCYCYCGGQGRPKDATDCCFVHDC 65

QY 70 CYDHLKTCGCGIYKDYRYNFSQGNHCSDKGSWCEQQLCACDKEVAFCLRNLDTYQKRLFYWRP 129

Db 66 CYK--KLTCNHNKTDYRYSWKNAIICEKNP--CLKEMCECDKAVAICLRENLDYNNK 122

QY 130 LRFYWRPHRCRGQTGTC 139

Db 123 YKAYPFKCK 132

RESULT 15

Search completed: October 5, 2004, 19:36:26  
Job time : 10.86 secs

**This Page Blank (uspto)**



GenCore version 5.1.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:13:29 ; Search time 5.8 Seconds  
(without alignments)  
1301.754 Million cell updates/sec

Title: US-09-830-321A-1

Perfect score: 852

Sequence: 1 MELALLGLVVMAGVIPIQG.....YQKRLRFYWRPHCRGQTGDC 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_42:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	846	99.3	145	1 PA2D HUMAN	Q9unk4 homo sapien
2	624.5	73.3	144	1 PA2D MOUSE	Q9wvf6 mus musculus
3	399.5	46.9	146	1 PA2A RAT	P14423 rattus norv
4	395.5	46.4	144	1 PA2A HUMAN	P14555 homo sapien
5	389	45.7	145	1 PA2M CAVPO	P47711 cavia porce
6	371.5	43.6	146	1 PA2A MOUSE	P31482 mus musculus
7	352	41.3	168	1 PA2F HUMAN	Q9szm2 homo sapien
8	347	40.7	138	1 PA25 HUMAN	P39877 homo sapien
9	340.5	40.0	138	1 PA23 BOTAS	Q9pve3 bothrops as
10	336	39.4	122	1 PA22 BOTMO	Q91834 bothrops mo
11	336	39.4	168	1 PA2F MOUSE	Q9gzt4 mus musculus
12	335.5	39.4	138	1 PA2B CRODU	P07517 crotalus du
13	332	39.0	138	1 PA2W TRIFL	Q02517 trimeresuru
14	331.5	38.9	138	1 PA2C CRODU	P24027 crotalus du
15	330.5	38.8	138	1 PA2H AGKAC	O57385 agkistrodon
16	330	38.7	137	1 PA25 MOUSE	P97391 mus musculus
17	330	38.7	138	1 PA2Y TRIFL	Q90y77 trimeresuru
18	329	38.6	138	1 PA2Q TRIFL	Q81i90 trimeresuru
19	328.5	38.6	121	1 PA22 BOTAS	P24605 bothrops as
20	328.5	38.6	138	1 PA24 AGKRP	O42187 agkistrodon
21	328.5	38.6	142	1 PA2A AGKRP	Q9ul33 mus musculus
22	320.5	37.6	119	1 PA2M BOTNE	Q91at9 bothrops ne
23	319.5	37.5	137	1 PA2H AGKCL	P49121 agkistrodon
24	318.5	37.4	121	1 PA22 BOTPI	P82287 bothrops pi
25	317.5	37.3	122	1 PA2A TRIFL	P5264 trimeresuru
26	317.5	37.3	122	1 PA2B TRIFL	P59265 trimeresuru
27	317.5	37.3	138	1 PA21 ECHCO	Q90zz9 echis color
28	316.5	37.1	122	1 PA21 TRIFL	P06860 trimeresuru
29	315.5	37.0	137	1 PA25 RAT	P51433 rattus norv
30	314.5	36.9	121	1 PA21 BOTPI	P58393 bothrops pi
31	313.5	36.8	138	1 PA2L VIPAA	P17935 vipera ammo
32	312.5	36.7	121	1 PA2B BOTUR	Q90249 bothrops ja
33	312.5	36.7	122	1 PA21 AGKHA	P04417 agkistrodon

34	311.5	36.6	122	1 PA23 AGKHP	P14421 agkistrodon
35	311.5	36.6	138	1 PA2F AGKRH	Q9pvf3 agkistrodon
36	311.5	36.6	138	1 PA2P TRIFL	P20381 trimeresuru
37	310	36.4	138	1 PA2P TRIFL	Q92147 trimeresuru
38	309.5	36.3	138	1 PA2A TRIMU	Q90w39 trimeresuru
39	308.5	36.2	122	1 PA29 AGKHP	O42188 agkistrodon
40	308.5	36.2	142	1 PA2E HUMAN	Q9nz87 homo sapien
41	308	36.2	138	1 PA2E HUMAN	Q8jly9 trimeresuru
42	307.5	36.1	121	1 PA28 DABRR	P59071 daboia rusa
43	307.5	36.1	121	1 PA2H AGKPI	P04361 agkistrodon
44	307.5	36.1	137	1 PA2H CERGO	Q8uvu7 cerrophidio
45	306.5	36.0	137	1 PA2H CROAT	Q8uvz7 crotalus at

#### ALIGNMENTS

RESULT 1  
PA2D HUMAN  
ID PA2D HUMAN STANDARD; PRT; 145 AA.  
AC Q9UNK4; Q9UK01;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Group IID secretory phospholipase A2 precursor (EC 3.1.1.4)  
DE (Phosphatidylcholine 2-acylhydrolase GIID) (GIID sPLA2) (PLA2IID)  
DE (sPLA2)-IID) (Secretory-type PLA, stroma-associated homolog).  
GN PLA2G2D OR SPLASH.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A., VARIANT GLY-80, AND CHARACTERIZATION.  
RX MEDLINE=99386983; PubMed=10455175;  
RA Ishizaki J., Suzuki N., Higashino K.-I., Yokota Y., Ono T.,  
RA Kawamoto K., Fujii N., Arita H., Hanasaki K.;  
RT "Cloning and characterization of novel mouse and human secretory  
phospholipase A2s";  
RL J. Biol. Chem. 274:24973-24979 (1999).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=21040292; PubMed=11196711;  
RA Shakhov A.N., Rubtsov A.V., Lyakhov I.G., Tumanov A.V.,  
RA Nedospasov S.A.;  
RT "SPLASH (PLA2) IID), a novel member of phospholipase A2 family, is  
associated with lymphotoxin-deficiency";  
RL Genes Immun. 1:191-199 (2000).  
RN [3]  
RP SEQUENCE FROM N.A.  
RA Wallis J.;  
RL Submitted (OCT-2000) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Pancreas, and Spleen;  
RX MEDLINE=22388257; PubMed=12477932;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Raha S.S., Joquellano N.A., Toshiyuki S., Carninci P., Prange C.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
FAhey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,  
Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.E.,  
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences".

RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

CC -1- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. L-alpha-1-palmitoyl-2-linoleoyl phosphatidylethanolamine is more efficiently hydrolyzed than the other phospholipids examined.

CC -1- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-acylglycerophosphocholine + a fatty acid anion.

CC -1- COFACTOR: Binds 1 calcium ion per subunit.

CC -1- SUBCELLULAR LOCATION: Secreted (Potential).

CC -1- TISSUE SPECIFICITY: Broadly expressed.

CC -1- MISCELLANEOUS: Maximally active at neutral to alkaline pH and with 2 mM Ca(2+).

CC -1- SIMILARITY: Belongs to the phospholipase A2 family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/) or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL; AF112982; AAD51390.1; -

DR EMBL; AF188625; AAF09020.1; -

DR EMBL; AL158172; CAC13159.1; -

DR EMBL; BC025706; AAH25706.1; -

DR HSSP; P14555; IPOD.

DR Genew; HGNC:9033; PLA2G2D.

DR MIM; 605630; -

DR GO; GO:0005576; C:extracellular; TAS.

DR GO; GO:0004624; P:secreted phospholipase A2 activity; TAS.

DR GO; GO:0006934; P:inflammatory response; TAS.

DR GO; GO:0006644; P:phospholipid metabolism; TAS.

DR InterPro; IPR001211; PhospholipaseA2.

DR Pfam; PF00068; phoslip; 1.

DR PRINTS; PR00389; PHPLIPASEA2.

DR ProDom; PD000303; PhospholipaseA2; 1.

DR SMART; SM00085; PA2c; 1.

DR PROSITE; PS00119; PA2\_ASP; 1.

DR PROSITE; PS00118; PA2\_HIS; 1.

KW Hydrolase; Lipid degradation; Signal; Calcium; Polymorphism.

FT SIGNAL 1 20

FT CHAIN 21 145

FT ACT\_SITE 67 112

FT ACT\_SITE 112 112

FT DISULFID 46 138

FT DISULFID 48 64

FT DISULFID 63 118

FT DISULFID 69 145

FT DISULFID 70 111

FT DISULFID 79 104

FT DISULFID 97 109

FT CARBOHYD 89 89

FT METAL 47 47

FT METAL 49 49

FT METAL 51 51

FT METAL 68 68

FT VARIANT 80 80

FT SEQUENCE 145 AA; 16546 MW; CF3A49DE516BD1EF CRC64; /FTId=VAR\_012741.

Query Match 99.3%; Score 846; DB 1; Length 145;

Best Local Similarity 99.3%; Pred. No. 1.7e-78;

Matches 144; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 MELALLCGLVVWAGVIPIQGGHILNKNWQVTKGMPILSYWPGYCHGGRGQPKDAT 60

DB 1 MELALLCGLVVWAGVIPIQGGHILNKNWQVTKGMPILSYWPGYCHGGRGQPKDAT 60

QY 61 DWCCQTHDCCYDLHKTGCGGIYKDYRYNPSQGNHCSKGSWCEQQLCACDKEVAFCLK 120

DB 61 DWCCQTHDCCYDLHKTGCGGIYKDYRYNPSQGNHCSKGSWCEQQLCACDKEVAFCLK 120

QY 121 RNLDTYQKRLRFYWRPHCRGQTGFC 145

DB 121 RNLDTYQKRLRFYWRPHCRGQTGFC 145

RESULT 2

PA2D MOUSE

ID PA2D MOUSE STANDARD; PRT; 144 AA.

AC Q9WVF6; Q9JLK0;

DT 28-FEB-2003 (Rel. 41, Created)

DT 28-FEB-2003 (Rel. 41, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Group IID secretory phospholipase A2 precursor (EC 3.1.1.4)

DE (Phosphatidylcholine 2-acylhydrolase GIIID) (GIID sPLA2) (PLA2IID)

DE (sPLA2)-IID) (Secretory-type PLA, stroma-associated homolog).

GN PLA2G2D OR PLA2A2 OR SPLASH.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI\_TaxID=10090;

RP SEQUENCE FROM N.A. (ISOFORM 1), AND CHARACTERIZATION.

RC STRAIN=BALB/c;

RE MEDLINE=99386983; PubMed=10455175; \*

RA Ishizaki J., Suzuki N., Higashino K.-I., Yokota Y., Ono T.,

RA Kawamoto K., Fujii N., Arita H., Hanasaki K.;

RT "Cloning and characterization of novel mouse and human secretory phospholipase A2s."

RL J. Biol. Chem. 274:24973-24979(1999).

RN [2]

RP SEQUENCE FROM N.A. (ISOFORM 1).

RE MEDLINE=99315857; PubMed=10383420;

RA Valentin E., Koduri R.S., Scimeca J.-C., Carle G., Gelb M.H.,

RA Lazdunski M., Lambeau G.;

RT "Cloning and recombinant expression of a novel mouse-secreted phospholipase A2."

RL J. Biol. Chem. 274:19152-19160(1999).

RN [3]

RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).

RC STRAIN=C57BL/6 X 129;

RE MEDLINE=21040292; PubMed=11196711;

RA Shakhov A.N., Rubtsov A.V., Lyakhov I.G., Tumanov A.V.,

RA Nedospasov S.A.;

RT "SPLASH (PLA2)IID), a novel member of phospholipase A2 family, is associated with lymphotoxin-deficiency."

RL Genes Immun. 1:191-199(2000).

RN [4]

RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 2).

RC STRAIN=C57BL/6J; TISSUE=Thymus;

RE MEDLINE=21085660; PubMed=11217851;

RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,

RA Aizawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,

RA Saito T., Okazaki Y., Gojohori T., Bono H., Kasukawa T., Saito R.,

RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,

RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,

RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,

RA Schriml L.M., Stauble F., Suzuki R., Tomita M., Wagner L., Washio I.,

RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,

RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,

RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,

RA Gustinich S., Hill D., Hofmann M., Hume D.A., Kamiya M., Lee N.H.,

RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,

RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,

RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,

RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,

RA Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohtsuki S.,

RA Hayashizaki Y.;

RT "Functional annotation of a full-length mouse cDNA collection.";  
 RL Nature 409:685-690(2001).  
 CC -!- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the 2-  
 CC acyl groups in 3-sn-phosphoglycerides. L-alpha-1-palmitoyl-2-  
 CC linoleoyl phosphatidylethanolamine is more efficiently hydrolyzed  
 CC than the other phospholipids examined.  
 CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
 CC acylglycerophosphocholine + a fatty acid anion.  
 CC -!- COFACTOR: Binds 1 calcium ion per subunit.  
 CC -!- SUBCELLULAR LOCATION: Secreted (isoform 1) and Cytoplasmic  
 CC (isoform 2) (Potential).  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=2;  
 CC Name=1;  
 CC IsoId=Q9WVF6-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=Q9WVF6-2; Sequence=VSP 004508;  
 CC -!- TISSUE SPECIFICITY: Expressed in several tissues including  
 CC pancreas, spleen, thymus, skin, lung, and ovary.  
 CC -!- SIMILARITY: Belongs to the phospholipase A2 family.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; AF112983; AAD51391.1; -;  
 CC EMBL; AF124374; AAD24773.1; -;  
 CC EMBL; AF188624; AAF09019.1; -;  
 CC EMBL; AF169407; AAF42987.1; -;  
 CC EMBL; AF169408; AAF42988.1; -;  
 CC EMBL; AK018005; BAB31033.1; -;  
 CC EMBL; AK004232; -; NOT\_ANNOTATED\_CDS.  
 CC HSSP; P24605; 1CLP.  
 CC MGB; MGI:1341796; Pla2g2d.  
 CC InterPro; IPR001211; PhospholipaseA2.  
 CC Pfam; PF00068; phoslip; 1.  
 CC PRINTS; PR00389; PHPLIPASEA2.  
 CC ProDom; PD000303; PhospholipaseA2; 1.  
 CC SMART; SM00085; PA2C; 1.  
 CC PROSITE; PS00119; PA2\_ASP; 1.  
 CC PROSITE; PS00118; PA2\_HIS; 1.  
 CC Hydrolase; Lipid degradation; Signal; Calcium; Alternative splicing.  
 CC SIGNAL 1 19  
 CC CHAIN 20 144  
 CC ACT\_SITE 66 66  
 CC ACT\_SITE 111 111  
 CC DISULFID 45 137  
 CC DISULFID 47 63  
 CC DISULFID 62 117  
 CC DISULFID 68 144  
 CC DISULFID 69 110  
 CC DISULFID 78 103  
 CC DISULFID 96 108  
 CC CARBOHYD 99 99  
 CC METAL 46 46  
 CC METAL 48 48  
 CC METAL 50 50  
 CC METAL 67 67  
 CC VARSPLIC 1 26  
 CC SEQUENCE 144 AA; 16164 MW; 7697ADA07F8D270A CRC64;  
 CC Query Match 73.3%; Score 624.5; DB 1; Length 144;  
 CC Best Local Similarity 71.0%; Pred. No. 3.8e-56;  
 CC Matches 103; Conservative 14; Mismatches 27; Indels 1; Gaps 1;

QY 1 MELALLCGLVVMAGVPIQGGILNKNKVKQVTKMPILSYWPGYCHGGLGGGQPKDAT 60  
 Db 1 MELALLCGL-LIAGTATQGGILNKNKVMTHMTGKRAFFSYWPGYCHGGLGGGQPKDAT 59  
 QY 61 DMCCQTHDCCYDHLTKTQGGIYKDYRYNFSOGNIHCSKSWCEQOLCACDKEVAFCLK 120  
 Db 60 DMCCQKHDCCYAHLKIDGKSLTDNYKYSISQGTTCSDNGSMCEQOLCACDKEVAFCLK 119  
 QY 121 RNLDYQKRLRYWPHRCGQTPGC 145  
 Db 120 QNLDSYNKRLYYWRPCKGKTPAC 144  
 RESULT 3  
 PA2A\_RAT STANDARD; PRT; 146 AA.  
 AC PL4423;  
 DT 01-JAN-1990 (Rel. 13, Created)  
 DT 01-FEB-1991 (Rel. 17, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Phospholipase A2, membrane associated precursor (EC 3.1.1.4)  
 DE (Phosphatidylcholine 2-acylhydrolase) (Group IIA phospholipase A2)  
 DE (GIIC sPLA2).  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Sprague-Dawley; TISSUE=platelet;  
 RX MEDLINE=90110043; PubMed=2606907;  
 RA Komada M., Kudo I., Mizushima H., Kitamura N., Inoue K.;  
 RT "Structure of cDNA coding for rat platelet phospholipase A2.";  
 RL J. Biochem. 106:545-547(1989).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Spleen;  
 RX MEDLINE=90267443; PubMed=2346480;  
 RA Komada M., Kudo I., Inoue K.;  
 RT "Structure of gene coding for rat group II phospholipase A2.";  
 RL Biochem. Biophys. Res. Commun. 168:1059-1065(1990).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=89350908; PubMed=2764915;  
 RA Ishizaki J., Ohara O., Nakamura E., Tamaki M., Ono T., Kanda A.,  
 RA Yoshida N., Teraoka H., Tojo H., Okamoto M.;  
 RT "cDNA cloning and sequence determination of rat membrane-associated  
 RT phospholipase A2.";  
 RL Biochem. Biophys. Res. Commun. 162:1030-1036(1989).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Sprague-Dawley; TISSUE=Liver;  
 RX MEDLINE=90381322; PubMed=2400792;  
 RA Kusunoki C., Satoh S., Kobayashi M., Niwa M.;  
 RT "Structure of genomic DNA for rat platelet phospholipase A2.";  
 RL Biochim. Biophys. Acta 1087:95-97(1990).  
 RN [5]  
 RP SEQUENCE OF 22-146.  
 RC STRAIN=Wistar; TISSUE=platelet;  
 RX MEDLINE=89174508; PubMed=3235451;  
 RA Hayakawa M., Kudo I., Tomita M., Nojima S., Inoue K.;  
 RT "The primary structure of rat platelet phospholipase A2.";  
 RL J. Biochem. 104:767-772(1988).  
 RN [6]  
 RP SEQUENCE OF 22-57.  
 RC TISSUE=Spleen;  
 RX MEDLINE=88186890; PubMed=3356705;  
 RA Ono T., Tojo H., Kuramitsu S., Kagamiyama H., Okamoto M.;  
 RT "Purification and characterization of a membrane-associated  
 RT phospholipase A2 from rat spleen. Its comparison with a cytosolic  
 RT phospholipase A2 S-1.";  
 RL J. Biol. Chem. 263:5732-5738(1988).

[7]
RN SEQUENCE OF 22-46.
RP TISSUE=Platelet;
RX MEDLINE=88007474; PubMed=3654593;
RA Hayakawa M., Horigome K., Kudo I., Tomita M., Notima S., Inoue K.;
RT "Amino acid composition and NH2-terminal amino acid sequence of rat
platelet secretory phospholipase A2.";
RL J. Biochem. 101:1311-1314(1987).
[8]
RN SEQUENCE OF 22-45.
RP TISSUE=Liver;
RX MEDLINE=89255484; PubMed=2722857;
RA Aarsman A.J., de Jong J.G.N., Arnoldussen E., Neys F.W.,
van Wassenaer P.D., van den Bosch H.;
RT "Immunofluorescence purification, partial sequence, and subcellular
localization of rat liver phospholipase A2.";
RL J. Biol. Chem. 264:10008-10014(1989).
CC -!- FUNCTION: Thought to participate in the regulation of the
phospholipid metabolism in biomembranes including eicosanoid
biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-
acyl groups in 3-sn-phosphoglycerides.
CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
acylglycerophosphocholine + a fatty acid anion.
CC -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).
CC -!- SUBCELLULAR LOCATION: Membrane-associated.
CC -!- MISCELLANEOUS: Group II phospholipase A2 is found in many cells
and also extracellularly. The membrane-bound and secreted forms
are identical and are encoded by a single gene.
CC -!- SIMILARITY: Belongs to the phospholipase A2 family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).
CC
EMBL; D00523; BAA00410.1; -
DR EMBL; M37127; AAA41223.1; -
DR EMBL; M25148; AAA41920.1; -
DR EMBL; X51529; CAA35909.1; -
DR PIR; A33394; A33394.
DR HSP; P44555; IPOD.
DR InterPro; IPR001211; PhospholipaseA2.
DR Pfam; PF00068; phoslip; 1.
DR PRINTS; PR00389; PHPLIPASEA2.
DR ProDom; PD00303; PhospholipaseA2; 1.
DR SMART; SM00085; PA2c; 1.
DR PROSITE; PS00118; PA2\_HIS; 1.
DR PROSITE; PS00119; PA2\_ASP; 1.
KW Hydrolase; Lipid degradation; Membrane; Signal; Calcium.
FT SIGNAL 1 21
FT CHAIN 22 146
FT ACT\_SITE 68 68
FT ACT\_SITE 113 113
FT DISULFID 47 139
FT DISULFID 49 65
FT DISULFID 64 119
FT DISULFID 70 146
FT DISULFID 71 112
FT DISULFID 80 105
FT DISULFID 98 110
FT METAL 48 48
FT METAL 50 50
FT METAL 52 52
FT METAL 69 69
FT METAL 135 135
FT VARIANT 22 22
FT CONFLICT 22 22
FT CONFLICT 63 63

FT CONFLICT 69 69 D -> E (IN REF. 5).
FT CONFLICT 78 78 R -> S (IN REF. 5).
FT CONFLICT 85 85 L -> V (IN REF. 3).
FT CONFLICT 121 121 A -> S (IN REF. 5).
SQ SEQUENCE 146 AA; 16294 MW; 60DDC9E79BF109F7 CRC64;
Query Match 46.9%; Score 399.5; DB 1; Length 146;
Best Local Similarity 47.9%; Pred. No. 2e-33;
Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;
QY 1 MELALLGLVMA-GVPIQGGILNLMKWKQVTKMPILSYWPFYCHGCGRGPCKDA 59
Db 1 MKVILLAVVIMAFSGISQVGSLLFCQMILFKTKRADVSIFYGCHGCGRGPCKDA 60
QY 60 TDMCCQTHDCCYDHLTKQGGIYKYNYRNFQSNHCHSKGSCWCEQOLCACDKEVAFCL 119
Db 61 TDMCCVTHDCCYNLEKRGCGTRFLTYKFSYRGQISCSNQNDSCKQLQCQCKAAAEFC 120
QY 120 KRNLDYQKRLRFWRHCHRGQTPGC 145
Db 121 ARNKKSYSLKYQFYFNPCKRGKTPSC 146
RESULT 4
PA2A HUMAN STANDARD; PRT; 144 AA.
AC P14555; Q9UCD2;
DT 01-JAN-1990 (Rel. 13, Created)
DT 01-APR-1990 (Rel. 14, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Phospholipase A2, membrane associated precursor (RC 3.1.1.4)
DE (Phosphatidylcholine 2-acylhydrolase) (Group IIA phospholipase A2)
DE (GIIC sPLA2) (Non-pancreatic secretory phospholipase A2) (NFS-PLA2).
GN PLA2G2A OR PLA2B OR RASFA-A OR PLA2L.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
OX NCBI\_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Rheumatoid arthritic synovial fluid;
RX MEDLINE=89174566; PubMed=2525608;
RA Seilhamer J.J., Fruzanski W., Vadas P., Plant S., Miller J.A.,
Kloss J., Johnson L.K.;
RT "Cloning and recombinant expression of phospholipase A2 present in
rheumatoid arthritic synovial fluid.";
RL J. Biol. Chem. 264:5335-5338(1989).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=89174633; PubMed=2525633;
RA Kramer R.M., Hession C., Johansen B., Hayes G., McGray P., Chow E.P.,
Tizard R., Pepinsky R.B.;
RT "Structure and properties of a human non-pancreatic phospholipase
A2.";
RL J. Biol. Chem. 264:5768-5775(1989).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=91050834; PubMed=2239446;
RA Kramer R.M., Johansen B., Hession C., Pepinsky R.B.;
RT "Structure and properties of a secreted phospholipase A2 from human
platelets.";
RL Adv. Exp. Med. Biol. 275:35-53(1990).
RN [4]
RP SEQUENCE FROM N.A.
RC TISSUE=Prostate;
RX MEDLINE=2238257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins P.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalley D.E.,  
RA Schnurch A., Schein J.E., Jones S.J.M., Marra M.A.,  
RT "Generation and initial analysis of more than 15,000 full-length  
RT human and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [5]  
RN SEQUENCE OF 21-144.  
RN  
RN TISSUE=Splice;  
RN MEDLINE=89374261; PubMed=2775276;  
RA Kanda A., Ono T., Yoshida N., Tojo H., Okamoto M.;  
RT "The primary structure of a membrane-associated phospholipase A2 from  
RT human spleen.";  
RL Biochem. Biophys. Res. Commun. 163:42-48(1989).  
RN [6]  
RN SEQUENCE OF 21-54.  
RN  
RN TISSUE=Synovial fluid;  
RN MEDLINE=89197814; PubMed=3240982;  
RA Hara S., Kudo I., Matsuta K., Miyamoto T., Inoue K.;  
RT "Amino acid composition and NH2-terminal amino acid sequence of human  
RT phospholipase A2 purified from rheumatoid synovial fluid.";  
RL J. Biochem. 104:326-328(1988).  
RN [7]  
RN SEQUENCE OF 21-33.  
RN  
RN TISSUE=Synovial fluid;  
RN MEDLINE=89076274; PubMed=3202859;  
RA Lai C.Y., Wada K.;  
RT "Phospholipase A2 from human synovial fluid: purification and  
RT structural homology to the placental enzyme.";  
RL Biochem. Biophys. Res. Commun. 157:488-493(1988).  
RN [8]  
RN SEQUENCE OF 21-75.  
RN  
RN TISSUE=ileal mucosa;  
RN MEDLINE=94002200; PubMed=8399335;  
RA Minami T., Tojo H., Shinomura Y., Matsuzawa Y., Okamoto M.;  
RT "Purification and characterization of a phospholipase A2 from human  
RT ileal mucosa.";  
RL Biochim. Biophys. Acta 1170:125-130(1993).  
RN [9]  
RN X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).  
RP MEDLINE=91287826; PubMed=2062381;  
RX Wery J.-P., Schevitz R.W., Clawson D.K., Bobbitt J.L., Dow E.R.,  
RA Gamboa G., Goodson T. Jr., Hermann R.B., Kramer R.M., McClure D.B.,  
RA Mihelich E.D., Putnam J.E., Sharp J.D., Stark D.H., Teater C.,  
RA Warrick M.W., Jones N.D.;  
RT "Structure of recombinant human rheumatoid arthritic synovial fluid  
RT phospholipase A2 at 2.2-A resolution.";  
RL Nature 352:79-82(1991).  
RN [10]  
RN X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).  
RP MEDLINE=92054586; PubMed=1948070;  
RX Scott D.L., White S.P., Browning J.L., Rosa J.J., Gelb M.H.,  
RA Sigler P.B.;  
RT "Structures of free and inhibited human secretory phospholipase A2  
RT from inflammatory exudate.";  
RL Science 254:1007-1010(1991).  
RN [11]  
RN X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).  
RP MEDLINE=95393225; PubMed=7664108;  
RX Schevitz R.W., Bach N.J., Carlson D.G., Chirgadze N.Y., Clawson D.K.,  
RA Dillard R.D., Drahaim S.E., Hartley L.W., Jones N.D., Mihelich E.D.,  
RA Olkowski J.L., Snyder D.W., Dand S.C., Wery J.-P.;  
RT "Structure-based design of the first potent and selective inhibitor  
RT of human non-pancreatic secretory phospholipase A2.";  
RL Nat. Struct. Biol. 2:458-465(1995).  
RN [12]

RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).  
RX MEDLINE=98207049; PubMed=9538252;  
RA Kitadokoro K., Hagishita S., Sato T., Ohtan M., Miki K.;  
RT "Crystal structure of human secretory phospholipase A2-IIA complex  
RT with the potent indolizine inhibitor 120-1032.";  
RL J. Biochem. 123:619-623(1998).  
RN  
RN -1- FUNCTION: Thought to participate in the regulation of the  
RN phospholipid metabolism in biomembranes including eicosanoid  
RN biosynthesis. Catalyzes the calcium-dependent hydrolysis of the 2-  
RN acyl groups in 3-sn-phosphoglycerides.  
RN -1- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
RN acylglycerophosphocholine + a fatty acid anion.  
RN -1- COFACTOR: Binds 1 calcium ion per subunit.  
RN -1- SUBCELLULAR LOCATION: Membrane-associated.  
RN -1- MISCELLANEOUS: Group II phospholipase A2 is found in many cells  
RN and also extracellularly. The membrane-bound and secreted forms  
RN are identical and are encoded by a single gene.  
RN -1- SIMILARITY: Belongs to the phospholipase A2 family.  
RN  
RN This SWISS-PROT entry is copyright. It is produced through a collaboration  
RN between the Swiss Institute of Bioinformatics and the EMBL outstation -  
RN the European Bioinformatics Institute. There are no restrictions on its  
RN use by non-profit institutions as long as its content is in no way  
RN modified and this statement is not removed. Usage by and for commercial  
RN entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
RN or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
RN  
RN EMBL; M22430; AAA36550.1; -;  
RN EMBL; M22431; AAA36549.1; -;  
RN EMBL; BC005919; AAH05919.1; -;  
RN PIR; A32862; PSHUVF  
RN PDB; 1AYP; 31-JUL-95.  
RN PDB; 1BBC; 31-OCT-93.  
RN PDB; 1POD; 31-OCT-93.  
RN PDB; 1FOE; 31-OCT-93.  
RN PDB; 1KVO; 07-JUL-97.  
RN PDB; 1DB4; 12-NOV-99.  
RN PDB; 1DB5; 12-NOV-99.  
RN PDB; 1DCY; 12-NOV-99.  
RN Genew; HGNC:9031; PLA2G2A.  
RN MIM; 172411; -;  
RN GO; GO:0004623; F:phospholipase A2 activity; TAS.  
RN InterPro: IPR001211; PhospholipaseA2.  
RN Pfam; PF00068; phoslip; 1.  
RN PRINTS; PR00389; PHPLIPASEA2.  
RN PRODom; PD000303; PhospholipaseA2; 1.  
RN SMART; SM00085; PA2C; 1.  
RN PROSITE; PS00118; PA2\_HIS; 1.  
RN PROSITE; PS00119; PA2\_ASP; 1.  
RN Hydrolase; Lipid degradation; Membrane; Signal; Calcium;  
RN 3D-structure.  
RN SIGNAL 1 20  
RN CHAIN 21 144 PHOSPHOLIPASE A2, MEMBRANE ASSOCIATED.  
RN ACT SITE 67 67 BY SIMILARITY.  
RN ACT SITE 111 111 BY SIMILARITY.  
RN DISULFID 46 137  
RN DISULFID 48 64  
RN DISULFID 63 117  
RN DISULFID 69 144  
RN DISULFID 70 110  
RN DISULFID 79 103  
RN DISULFID 97 108  
RN METAL 47 47  
RN METAL 49 49  
RN METAL 51 51  
RN METAL 68 68  
RN HELIX 22 33  
RN HELIX 37 40  
RN TURN 41 41  
RN TURN 45 47  
RN HELIX 59 75  
RN TURN 76 78  
RN TURN 88 91  
RN STRAND 88 91  
RN  
RN CALCIIUM (VIA CARBONYL OXYGEN).  
RN CALCIIUM (VIA CARBONYL OXYGEN).  
RN CALCIIUM (VIA CARBONYL OXYGEN).  
RN CALCIIUM.

Fri Oct 8 10:22:31 2004

us-09-830-321a-1.rsp

```

FT TURN 92 93
FT STRAND 94 97
FT HELIX 102 120
FT TURN 121 121
FT HELIX 122 124
FT TURN 127 128

Query Match 46.4%; Score 395.5; DB 1; Length 144;
Best Local Similarity 47.6%; Pred. No. 4.9e-33;
Matches 69; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTKMFIISYWPYGCCHGLGGRGQPKDA 60
Db 1 MKTLLLAIVIMIFELLQAHGNLVNFMKILTTGKEAALSFGVFGCHGVGGRGSPKDA 60
QY 61 DWCCQTHDCYDHLKTCGCGIYKDYRYNFSQGNHSCDKSGWCEQQLCACDKEVAFCL 120
Db 61 DRCCVTHDCYKRLKEGCGTKFLSYKFSNSGSRITCAKQDS-CRSQLCEDCAAATCFA 119
QY 121 RNLDTYOKRLRFYWRPHCRGQTGTC 145
Db 120 RNKTTYNKQYYSNKHCRGSTPRC 144

RESULT 5
PA2M CAVPO STANDARD; PRT; 145 AA.
ID PA2M CAVPO
AC PA4711;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Phospholipase A2, membrane associated precursor (EC 3.1.1.4)
DE (Phosphatidylcholine 2-acylhydrolase) (Group IIA phospholipase A2)
DE (GIIC sPLA2)
GN PLA2G2A.
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriognathi; Caviidae; Cavia.
OX NCBI_TaxID=10141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Hartley; TISSUE=Macrophage;
RX MEDLINE=95340522; PubMed=7615534;
RA Vial D., Senozale-Pose M., Havet N., Molio L., Vargaftig B.B.,
RA Touqui L.;
RT "Expression of the type-II phospholipase A2 in alveolar macrophages.
RT Down-regulation by an inflammatory signal.";
RL J. Biol. Chem. 270:17327-17332(1995).
CC -!- FUNCTION: Thought to participate in the regulation of the
CC phospholipid metabolism in biomembranes including eicosanoid
CC biosynthesis (By similarity). Catalyzes the calcium-dependent
CC hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides.
CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
CC acylglycerophosphocholine + a fatty acid anion.
CC -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).
CC -!- SUBCELLULAR LOCATION: Membrane-associated.
CC -!- TISSUE SPECIFICITY: Alveolar macrophages, and at much lower levels
CC in peripheral blood monocytes and peritoneal macrophages.
CC -!- SIMILARITY: Belongs to the phospholipase A2 family.

This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).

EMBL; X82631; CAA57953.1; --
PIR; I48093; I48093.
HSP; P14555; IPOD.
InterPro; IPR001211; PhospholipaseA2.
Pfam; PF00068; phoslip; 1.

```

---

```

DR PRINTS; PRO0389; PHPLIPASEA2.
DR PRODOM; PD000303; PhospholipaseA2; 1.
DR SMART; SM00085; PA2C; 1.
DR PROSITE; PS00118; PA2_HIS; 1.
DR PROSITE; PS00119; PA2_ASP; 1.
KW Hydrolase; Lipid degradation; Membrane; Signal; Calcium.
FT SIGNAL 1 20
FT CHAIN 21 145
FT ACT_SITE 67 67
FT ACT_SITE 112 112
FT DISULFID 46 138
FT DISULFID 48 64
FT DISULFID 63 118
FT DISULFID 69 145
FT DISULFID 70 111
FT DISULFID 79 104
FT DISULFID 97 109
FT METAL 47 47
FT METAL 49 49
FT METAL 51 51
FT METAL 68 68
SQ SEQUENCE 145 AA; 16153 MW; 13F22C96594D304D CRC64;

Query Match 45.7%; Score 389; DB 1; Length 145;
Best Local Similarity 49.3%; Pred. No. 2.2e-32;
Matches 72; Conservative 20; Mismatches 52; Indels 2; Gaps 2;

QY 1 MELALLCGLVVMAGVPIQGGILNLNKMVKQVTKMFIISYWPYGCCHGLGGRGQPKDA 59
Db 1 MKTLLLAIVIMIFELLQAHGNLVNFMKILTTGKEAALSFGVFGCHGVGGRGSPKDA 59
QY 60 TDWCCQTHDCYDHLKTCGCGIYKDYRYNFSQGNHSCDKSGWCEQQLCACDKEVAFCL 119
Db 60 TDRCCVTHDCYDHLKTCGCGIYKDYRYNFSQGNHSCDKSGWCEQQLCACDKEVAFCL 119
QY 120 RNLDTYOKRLRFYWRPHCRGQTGTC 145
Db 120 RNLDTYOKRLRFYWRPHCRGQTGTC 145

RESULT 6
PA2A MOUSE STANDARD; PRT; 146 AA.
ID PA2A MOUSE
AC P31482; Q60871;
DT 01-JUL-1993 (Rel. 26, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Phospholipase A2, membrane associated precursor (EC 3.1.1.4)
DE (Phosphatidylcholine 2-acylhydrolase) (Group IIA phospholipase A2)
DE (GIIC sPLA2) (Enhancing factor) (EF).
GN PLA2G2A.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BA1B/c;
RC Mulherkar R.;
RL Submitted (OCT-1994) to the EMBL/GenBank/DBJ databases.
RN [2]
RN SEQUENCE FROM N.A., AND POLYMORPHISM.
RC STRAIN=BA1B/c, and CD-1; TISSUE=Intestine;
RC MEDLINE=95403435; PubMed=7673223;
RX Kennedy B.P., Payette P., Mudgett J., Vadas P., Pruzanski W.,
RX Yvan M., Tang C., Rancourt D.E., Cromlish W.;
RX "A natural disruption of the secretory group II phospholipase A2 gene
RX in inbred mouse strains.";
RL J. Biol. Chem. 270:22378-22385(1995).
RN [3]

```

RP SEQUENCE FROM N.A.  
 RC STRAIN=C3H;  
 RX MacPhee M., Chepenik K.P., Liddell R.A., Nelson K.K., Siracusa L.D.,  
 RA Buchberg A.M.;  
 RA "The secretory phospholipase A2 gene is a candidate for the Mom1  
 RT locus, a major modifier of ApcMin-induced intestinal neoplasia";  
 RL Cell 81:957-966(1995).  
 [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=FVB/N; TISSUE=Colon;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettner M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RA "Generation and initial analysis of more than 15,000 full-length human  
 RT and mouse cDNA sequences";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 [5]  
 RP SEQUENCE OF 22-146 FROM N.A.  
 RC STRAIN=BALB/c; TISSUE=Small intestine;  
 RX MEDLINE=94029955; PubMed=8267767;  
 RA Mulherkar R., Rao R.S., Wagie A.S., Patki V., Deo M.G.;  
 RA "Enhancing factor, a Paneth cell specific protein from mouse small  
 RT intestines: predicted amino acid sequence from RT-PCR amplified cDNA  
 RL and its expression";  
 RL Biochem. Biophys. Res. Commun. 195:1254-1263(1993).  
 [6]  
 RP ERATUM.  
 RX MEDLINE=94071967; PubMed=8250944;  
 RA Mulherkar R., Rao R.S., Wagie A.S., Patki V., Deo M.G.;  
 RA Biochem. Biophys. Res. Commun. 197:351-352(1993).  
 [7]  
 RP PRELIMINARY SEQUENCE OF 22-41.  
 RC TISSUE=Small intestine;  
 RX MEDLINE=93146172; PubMed=8425615;  
 RA Mulherkar R., Rao R., Rao L., Patki V., Chauhan V.S., Deo M.G.;  
 RA "Enhancing factor protein from mouse small intestines belongs to the  
 RT phospholipase A2 family";  
 RL FEBS Lett. 317:263-266(1993).  
 CC -1- FUNCTION: May play a role in cell proliferation, by increasing the  
 CC binding of EGF to the cells and thereby modulating its action. In  
 CC doing so, this isozyme binds to a membrane-associated receptor  
 CC distinct from the EGF receptor and which could be a heparan-  
 CC sulfate proteoglycan located on the cell membrane.  
 CC -1- FUNCTION: P2 catalyzes the calcium-dependent hydrolysis of the 2-  
 CC acyl groups in 3-sn-phosphoglycerides.  
 CC -1- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
 CC acylglycerophosphocholine + a fatty acid anion.  
 CC -1- COFACTOR: Binds 1 calcium ion per subunit (By similarity).  
 CC -1- SUBCELLULAR LOCATION: Membrane-associated.  
 CC -1- TISSUE SPECIFICITY: Mainly in the Paneth cells adjacent to the  
 CC stem population in the small intestines. Also expressed in  
 CC regenerating liver and hyperplastic esophageal epithelium.  
 CC -1- POLYMORPHISM: In strains 129/Sv, B10.RII and C57BL/6, a  
 CC polymorphism causes a frameshift and premature truncation of the  
 CC protein, rendering it inactive. Strains BALB/c, C3H/He, DBA/1,  
 CC DBA/2, MRL and NZB/BN contain the normal protein while strain CD-  
 CC 1 is heterozygous for the mutation.

CC -1- SIMILARITY: Belongs to the phospholipase A2 family.  
 CC  
 CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; X74266; CAA52325.1; -;  
 CC EMBL; U23358; AAC52252.1; -;  
 CC EMBL; U28244; AAB06315.1; ALT INIT.  
 CC EMBL; BC045156; AHA45156.1; -;  
 CC PIR; I48342; I48342;  
 CC FIR; S29495; S29495.  
 CC HSSP; P14555; IPOD.  
 CC MGD; MGI:104642; P1a2g2a.  
 CC InterPro; IPR001211; PhospholipaseA2.  
 CC Pfam; PF00068; phoslip; 1  
 CC PRINTS; PR00389; PHPLIPASEA2.  
 CC ProDom; PD000303; PhospholipaseA2; 1.  
 CC SMART; SM00085; PA2C; 1.  
 CC PROSITE; PS00118; PA2\_HIS; 1.  
 CC PROSITE; PS00119; PA2\_ASP; 1.  
 CC Hydrolase; Lipid degradation; Calcium; Growth regulation; Signal;  
 CC Membrane; Polymorphism.  
 CC SIGNAL 1 21  
 CC CHAIN 22 146 PHOSPHOLIPASE A2, MEMBRANE ASSOCIATED.  
 CC ACT\_SITE 68 68 BY SIMILARITY.  
 CC ACT\_SITE 113 113 BY SIMILARITY.  
 CC DISULFID 47 133 BY SIMILARITY.  
 CC DISULFID 49 65 BY SIMILARITY.  
 CC DISULFID 64 119 BY SIMILARITY.  
 CC DISULFID 70 146 BY SIMILARITY.  
 CC DISULFID 71 112 BY SIMILARITY.  
 CC DISULFID 80 105 BY SIMILARITY.  
 CC DISULFID 98 110 BY SIMILARITY.  
 CC METAL 48 48 CALCIUM (VIA CARBONYL OXYGEN)  
 CC METAL 50 50 (BY SIMILARITY).  
 CC METAL 52 52 CALCIUM (VIA CARBONYL OXYGEN)  
 CC METAL 69 69 (BY SIMILARITY).  
 CC METAL 69 69 CALCIUM (VIA CARBONYL OXYGEN)  
 CC CONFLICT 19 19 V -> D (IN REF. 1).  
 CC CONFLICT 86 86 K -> T (IN REF. 1).  
 CC SEQUENCE 146 AA; 16145 MW; AB904F6B3B1BA5C7 CRC64;  
 CC  
 CC Query Match 43.6%; Score 371.5; DB 1; Length 146;  
 CC Best Local Similarity 47.3%; Pred. No. 1.3e-30;  
 CC Matches 69; Conservative 19; Mismatches 57; Indels 1; Gaps 1;  
 CC  
 CC Qy 1 MELALLGLVMA-GVPIQGGIINLNMKVQTKMPILSYWPGYCHGLGGRGQPKDA 59  
 CC Db 1 MKVLLLAASIMAFSGTQVGNATQFCGEMRLTKGKAEISYAFYGCYCHGLGGRGSPDA 60  
 CC Qy 60 TDMCCQTHDCYDHLTKTQGGYKDYKYNFNSQNHCHSDKGSWCEQOLCACDKEVAFCL 119  
 CC Db 61 TDRCCVTHDCYKSLKSGGKTKLLKYKHQSGQTCSANQNSQKRLCQCDKAAAEFCF 120  
 CC Qy 120 KRNLDYQKELRFRWPHRCGQTPGC 145  
 CC Db 121 ARNKTYSLKYQFPNMFCKGKPKC 146  
 CC  
 CC RESULT 7  
 CC PA2F HUMAN  
 CC ID PA2F HUMAN STANDARD; PRT; 168 AA.  
 CC AC Q9BZM2; Q9H506;  
 CC DT 28-FEB-2003 (Rel. 41, Created)  
 CC DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 CC DT 10-OCT-2003 (Rel. 42, Last annotation update)





CC EMBL; U03090; AAC2886.1; -;  
 DR EMBL; AL158172; CAC13158.1; -;  
 DR PIR; A49959; A49959.  
 DR HSSP; P14421; 1A2A.  
 DR Genew; HGNC:9038; PLA2G5.  
 DR MIM; 601192; -;  
 DR GO; GO:000576; C:extracellular; TAS.  
 DR GO; GO:0004625; F:calcium-dependent secreted phospholipase A2...; TAS.  
 DR GO; GO:0006644; P:phospholipid metabolism; TAS.  
 DR InterPro; IPR001211; PhospholipaseA2.  
 DR Pfam; PF00068; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD00303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00118; PA2\_HIS; 1.  
 DR PROSITE; PS00119; PA2\_ASP; 1.  
 DR KW Hydrolyase; Lipid degradation; Calcium; Signal.  
 FT SIGNAL 1 20  
 FT CHAIN 21 138  
 FT ACT\_SITE 67 67  
 FT ACT\_SITE 111 111  
 FT DISULFID 46 137  
 FT DISULFID 48 64  
 FT DISULFID 63 117  
 FT DISULFID 70 110  
 FT DISULFID 79 103  
 FT DISULFID 97 108  
 FT METAL 47 47  
 FT METAL 49 49  
 FT METAL 51 51  
 FT METAL 68 68  
 FT SEQUENCE 138 AA; 15674 MW; 15674 MW; 0D17DC76E55F42BC CRC64;  
 SQ  
 Query Match 40.7%; Score 347; DB 1; Length 138;  
 Best Local Similarity 43.6%; Pred. No. 3.7e-28;  
 Matches 58; Conservative 27; Mismatches 36; Indels 12; Gaps 2;  
 YQ 12 MAGVIP-----LOGGIILNLMVKVQVTKMPILSYWPGCHGLGRGQPKDAT 60  
 Db 1 MKGLPLANFLACVSPAVAGLLDLKMKIEKVTGNALTNFYGYCYCGWGRGT 60  
 YQ 61 DWCCQTHDCVYHLKTCGGYKDYRYNFSQNIHCSDKGSWCEQQLCACDKEVAFCLK 120  
 Db 61 DWCCWAHDHCYGRLEKGNIRTSQYKRFANGVVTCT-EPGPFCHVNLCACDRKLVTCLK 119  
 YQ 121 RNLDTYQKRLRFY 133  
 Db 120 RNLRSYNPQYQYF 132

RESULT 9  
 PA23\_BOTAS STANDARD; PRT; 138 AA.  
 AC Q9PVE3;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Phospholipase A2 homolog 3 precursor (Myotoxin III) (M1-3-3).  
 OS Bothrops asper (Terciopelo).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidodonta; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Bothrops.  
 OC NCBI\_TaxID=8722;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Venom gland;  
 RA Pescatori M., Grasso A., Rufini S.;  
 RT "Molecular cloning of a K-42 PLA2-like myotoxin from the snake  
 RT Bothrops asper.";

RL Submitted (NOV-1998) to the EMBL/GenBank/DBJ databases.  
 CC -!- FUNCTION: Myotoxic protein that lacks enzymatic activity (By  
 CC similarity).  
 CC -!- SUBCELLULAR LOCATION: Secreted (By similarity).  
 CC -!- MISCELLANEOUS: Does not bind calcium as one of the calcium binding  
 CC ligands is lost (Asp->Lys in position 64) (Probable).  
 CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group II  
 CC subfamily.  
 CC  
 CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC EMBL; AF109911; AAF14241.1; -;  
 DR HSSP; P24605; 1CLP.  
 DR InterPro; IPR001211; PhospholipaseA2.  
 DR Pfam; PF00068; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD00303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00119; PA2\_ASP; 1.  
 DR PROSITE; PS00118; PA2\_HIS; 1.  
 DR KW Toxin; Signal; Multigene family.  
 FT SIGNAL 1 16  
 FT CHAIN 17 138  
 FT ACT\_SITE 63 63  
 FT ACT\_SITE 105 105  
 FT DISULFID 42 132  
 FT DISULFID 44 60  
 FT DISULFID 59 111  
 FT DISULFID 65 138  
 FT DISULFID 66 104  
 FT DISULFID 73 97  
 FT DISULFID 91 102  
 FT SEQUENCE 138 AA; 15559 MW; AF7491F7E3049BF2 CRC64;  
 SQ  
 Query Match 40.0%; Score 340.5; DB 1; Length 138;  
 Best Local Similarity 47.4%; Pred. No. 1.7e-27;  
 Matches 64; Conservative 21; Mismatches 43; Indels 7; Gaps 4;  
 YQ 10 VWAGVPIQGGIILNLMVKVQVTKMPILSYWPGCHGLGRGQPKDATWCQTHDC 69  
 Db 9 VLVGV---EGSLVELGKMLQETGKNPVTSGAYGNCVGLGRGPKDATDRCCYVHKC 65  
 YQ 70 CYDHLKTQGGYKDYRYNFSQNIHCSDKGSWCEQQLCACDKEVAFCLKRNLDYQKR 129  
 Db 66 CYK--KLTGCPKPKDYRSYKDKTIVCGNN--CLKELCECDKAVAICLRKLDYNNK 122  
 YQ 130 LR-FYWRPHCRGQTP 143  
 Db 123 YKNNYLPFCCKADP 137  
 RESULT 10  
 PA22\_BOTMO STANDARD; PRT; 122 AA.  
 AC Q9I834;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Phospholipase A2 homolog 2 (Myotoxin II) (MjTX-II) (M-VI).  
 OS Bothrops moojeni (Lance-headed viper) (Caissaca).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidodonta; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Bothrops.  
 OC NCBI\_TaxID=98334;  
 RN [1]  
 RP SEQUENCE OF 1-52, AND CHARACTERIZATION.  
 RC TISSUE=Venom;

RX MEDLINE=98299483; PubMed=9637370;  
 RA Soares A.M., Rodrigues V.M., Honsi-Brandeburgo M.I., Toyama M.H.,  
 RA Lombardi F.R., Arni R.K., Giglio J.R.;  
 RT "A rapid procedure for the isolation of the Lys-49 myotoxin II from  
 RT Bothrops moojeni (caissaca) venom: biochemical characterization,  
 RT crystallization, myotoxic and edematogenic activity.";  
 RL Toxicon 36:503-514(1998).  
 RN [2]  
 RP SEQUENCE OF 15-122 FROM N.A.  
 RC TISSUE=Venom gland;  
 RA Soares A.M., Ward R.J., Rodrigues-Simioni L., Lomonte B.,  
 RA Gutierrez J.M., Guerra-Sa R., Rodrigues V., Fontes M.R.M., Arni R.K.,  
 RA Giglio J.R.;  
 RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP X-RAY CRYSTALLOGRAPHY.  
 RC TISSUE=Venom;  
 RA de Azevedo W.F., Ward R.J., Lombardi F.R., Giglio J.R., Soares A.M.,  
 RA Fontes M.R.M., Arni R.K.;  
 RT "Crystal structure of myotoxin-II: a myotoxic phospholipase A2  
 RT homologue from Bothrops moojeni venom.";  
 RL Protein Pept. Lett. 4:329-334(1997).  
 CC -!- FUNCTION: Displays myotoxin and edema-inducing activities. Lacks  
 CC PA2 enzymatic activity as well as of hemorrhagic, anticoagulant  
 CC and coagulant activities.  
 CC -!- SUBUNIT: Homodimer.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- MISCELLANEOUS: Does not bind calcium as one of the calcium binding  
 CC ligands is lost (Asp->Iys in position 48).  
 CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group II  
 CC subfamily.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC  
 CC EMBL; AF145759; AAF66702.1; -.  
 DR HSP; P82287; 10LL.  
 DR InterPro; IPR001211; PhospholipaseA2.  
 DR Pfam; PF00068; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD000303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00119; PA2 ASP; 1.  
 DR PROSITE; PS00118; PA2 HIS; 1.  
 DR Toxin; Multigene family.  
 KW ACT\_SITE 47 47 BY SIMILARITY.  
 FT ACT\_SITE 89 89 BY SIMILARITY.  
 FT DISULFID 26 116 BY SIMILARITY.  
 FT DISULFID 28 44 BY SIMILARITY.  
 FT DISULFID 43 95 BY SIMILARITY.  
 FT DISULFID 49 122 BY SIMILARITY.  
 FT DISULFID 50 88 BY SIMILARITY.  
 FT DISULFID 57 81 BY SIMILARITY.  
 FT DISULFID 75 86 BY SIMILARITY.  
 FT CONFLICT 18 18 A -> V (IN REF. 2).  
 SQ SEQUENCE 122 AA; 13887 MW; 120AA53FAB3009CB CRC64;  
 Query Match 39.4%; Score 336; DB 1; Length 122;  
 Best Local Similarity 50.4%; Pred. No. 4.1e-27;  
 Matches 62; Conservative 15; Mismatches 42; Indels 4; Gaps 3;  
 QY 22 ILNLMKWKQVTKGMPILSYWPYCHGCGGGRGQPKDATTWCQTHDCYDHLKHTGGCGI 81  
 Db 2 LPELGMUQLQETGKPKAKSYGVYGCNCGVGRGKPKDATTDRCCYVHKCCYK--KLGGCDP 59  
 QY 82 YKDYRYNFSQGNHSCDKGSCEQQLCACDKEVAFLKRLNLDYOKRLRF-YWRPHCRG 140  
 Db 60 KDRYSYSWDKTIVGNNNS-CLKELCECDKAVAICLRLNLDYNNKRYNYLKPFCCK 118

QY 141 QTP 143  
 Db 119 ADP 121  
 RESULT 11  
 PA2F MOUSE STANDARD; PRT; 168 AA.  
 ID -PA2F MOUSE  
 AC OSQZT4;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Group IIF secretory phospholipase A2 precursor (EC 3.1.1.4)  
 DE (Phosphatidylcholine 2-acylhydrolase GIIF) (GIIF SPLA2) (SPLA(2)-IIF).  
 GN PLA2G2F.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20002639; PubMed=10531313;  
 RA Valentin E., Ghomashchi P., Gelb M.H., Lazdunski M., Lambeau G.;  
 RT "On the diversity of secreted phospholipases A2. Cloning, tissue  
 RT distribution, and functional expression of two novel mouse group II  
 RT enzymes.";  
 RL J. Biol. Chem. 274:31195-31202(1999).  
 CC -!- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the 2-  
 CC acyl groups in 3-sn-phosphoglycerides. Hydrolyzes  
 CC phosphatidylglycerol versus phosphatidylcholine with a 15-fold  
 CC preference (by similarity).  
 CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
 CC acylglycerophosphocholine + a fatty acid anion.  
 CC -!- COFACTOR: Binds 1 calcium ion per subunit.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the phospholipase A2 family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
 CC or send an email to license@isb-sib.ch).  
 CC  
 CC EMBL; AF166099; AAF04500.2; -.  
 DR HSP; P00593; 4BP2.  
 DR MGD; MGI:1349661; Pla2g2f.  
 DR InterPro; IPR001211; PhospholipaseA2.  
 DR Pfam; PF00068; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD000303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00119; PA2 ASP; FALSE\_NEG.  
 DR PROSITE; PS00118; PA2 HIS; 1.  
 KW Hydrolyase; Lipid degradation; Signal; Calcium.  
 FT SIGNAL 1 20 POTENTIAL.  
 FT CHAIN 21 168 GROUP IIF SECRETORY PHOSPHOLIPASE A2.  
 FT ACT\_SITE 67 67 BY SIMILARITY.  
 FT ACT\_SITE 114 114 BY SIMILARITY.  
 FT DISULFID 46 138 BY SIMILARITY.  
 FT DISULFID 48 64 BY SIMILARITY.  
 FT DISULFID 63 120 BY SIMILARITY.  
 FT DISULFID 69 145 BY SIMILARITY.  
 FT DISULFID 70 113 BY SIMILARITY.  
 FT DISULFID 79 106 BY SIMILARITY.  
 FT DISULFID 98 111 BY SIMILARITY.  
 FT CARBOHYD 92 102 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 102 92 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT CARBOHYD 144 144 N-LINKED (GLCNAC. . .) (POTENTIAL).  
 FT METAL 47 47 CALCIUM (VIA CARBONYL OXYGEN)  
 (BY SIMILARITY).



Db 6 IVAVLLVGVGEGHLLQNKMIKTRKNAIPFFAFYCYGCGWGRGPKDATDRCCFVHDC 65  
QY 70 CYDHLKTOGCGIYKYDYRYNFSQGNTHCSKSGWCEQQLCACKEVAFCLKRNLDITYQKR 129  
Db 66 CYG--KLAKNTKWDIYPIYSLKSGYITCG-KGTWCEBEQICECDRVAACLRSLSTYKYG 122  
QY 130 LRFYWRPHCRGQTGPGC 145  
Db 123 YMEYDPSRCRGPSETC 138  
RESULT 13  
PA2W TRIFL STANDARD; PRT; 138 AA.  
AC Q02517;  
DT 01-FEB-1994 (Rel. 28, Created)  
DT 01-FEB-1994 (Rel. 28, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Phospholipase A2 isozyme PL-X' precursor (EC 3.1.1.4)  
DE (Phosphatidylcholine 2-acylhydrolase).  
OS Trimeresurus flavoviridis (Habu).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
OC Viperidae; Crotalinae; Trimeresurus.  
OX NCBI\_TaxID=88087;  
RN [1]  
RP SEQUENCE FROM N.A.  
RT TISSUE=Venom gland;  
RX MEDLINE=92409555; PubMed=1528861;  
RA Ogawa T., Oda N., Nakashima K.-I., Sasaki H., Hattori M., Sasaki Y.,  
RA Kinara H., Ohno M.;  
RT "Unusually high conservation of untranslated sequences in cDNAs for  
RT Trimeresurus flavoviridis phospholipase A2 isozymes."  
RL Proc. Natl. Acad. Sci. U.S.A. 89:8557-8561(1992).  
CC -!- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the  
CC 2-acyl groups in 3-sn-phosphoglycerides.  
CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
CC acylglycerophosphocholine + a fatty acid anion.  
CC -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.  
CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group II  
CC subfamily.  
-----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
-----  
CC EMBL; D10721; BAA01564.1; -.  
DR HSSP; P51972; IYAP.  
DR InterPro; IPR001211; PhospholipaseA2.  
DR Pfam; PF00668; phoslip; 1.  
DR PRINTS; PR00389; PHPLIPASEA2.  
DR ProDom; PD000303; PhospholipaseA2; 1.  
DR SMART; SM00085; PA2c; 1.  
DR PROSITE; PS00119; PA2 ASP; 1.  
DR PROSITE; PS00118; PA2 HIS; 1.  
KW Hydrolase; Lipid degradation; Calcium; Multigene family; Signal.  
FT SIGNAL 1 16 PHOSPHOLIPASE A2 ISOZYME PL-X'.  
FT CHAIN 17 138 BY SIMILARITY.  
FT ACT\_SITE 63 63 BY SIMILARITY.  
FT ACT\_SITE 105 105 BY SIMILARITY.  
FT ACT\_SITE 42 131 BY SIMILARITY.  
FT DISULFID 44 60 BY SIMILARITY.  
FT DISULFID 59 111 BY SIMILARITY.  
FT DISULFID 65 138 BY SIMILARITY.  
FT DISULFID 66 104 BY SIMILARITY.  
FT DISULFID 73 97 BY SIMILARITY.

FT DISULFID 91 102 BY SIMILARITY.  
FT METAL 43 43 CALCIUM (VIA CARBONYL OXYGEN)  
FT METAL 45 45 (BY SIMILARITY).  
FT METAL 45 45 CALCIUM (VIA CARBONYL OXYGEN)  
FT METAL 47 47 (BY SIMILARITY).  
FT METAL 47 47 CALCIUM (VIA CARBONYL OXYGEN)  
FT METAL 64 64 (BY SIMILARITY).  
FT METAL 64 64 CALCIUM (BY SIMILARITY).  
SQ SEQUENCE 138 AA; 15733 MW; 471B01878CCAIED1 CRC64;  
Query Match 39.0%; Score 332; DB 1; Length 138;  
Best Local Similarity 46.3%; Pred. No. 1.2e-26;  
Matches 63; Conservative 19; Mismatches 48; Indels 6; Gaps 3;  
QY 10 VVMAGVIPIQGGILNLNKMVKVQTKMPILSYVPYCHGLGGRGPKDATDRCCFVHDC 69  
Db 9 VLLVGV---EGHLLQFRKMIKMTGKEPIVSAYFYCYGCGKGRGPKDATDRCCFVHDC 65  
QY 70 CYDHLKTOGCGIYKYDYRYNFSQGNTHCSKSGWCEQQLCACKEVAFCLKRNLDITYQKR 129  
Db 66 CYE--KVTGCDPRKWDIYTYTSSENGDIVCGGDNPCYKEVCECDKAAALCFEDNLKTYKKR 122  
QY 130 LRFYWRPHCRGQTGPGC 145  
Db 123 YMEYDPSRCRGPSETC 138  
RESULT 14  
PA2C CRODU STANDARD; PRT; 138 AA.  
AC P24027;  
DT 01-MAR-1992 (Rel. 21, Created)  
DT 01-MAR-1992 (Rel. 21, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Phospholipase A2 CB2 precursor (EC 3.1.1.4) (Crotoxin basic chain 2)  
DE (Phosphatidylcholine 2-acylhydrolase).  
OS Crotalus durissus terrificus (South American rattlesnake).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
OC Viperidae; Crotalinae; Crotalus.  
OX NCBI\_TaxID=8732;  
RN [1]  
RP SEQUENCE FROM N.A.  
RT TISSUE=Venom gland;  
RX MEDLINE=91198145; PubMed=2015302;  
RA Bouchier C., Boulain J.-C., Bon C., Menez A.;  
RT "Analysis of cDNAs encoding the two subunits of crotoxin, a  
RT phospholipase A2 neurotoxin from rattlesnake venom: the acidic non  
RT enzymatic subunit derives from a phospholipase A2-like precursor.";  
RL Biochim. Biophys. Acta 1088:401-408(1991).  
RN [2]  
RP SEQUENCE OF 17-49.  
RT TISSUE=Venom;  
RX MEDLINE=94307256; PubMed=8033889;  
RA Faure G., Choumet V., Bouchier C., Camoin L., Guillaume J.-L.,  
RA Monégier B., Vuilhorgne M., Bon C.;  
RT "The origin of the diversity of crotoxin isoforms in the venom of  
RT Crotalus durissus terrificus."  
RL Eur. J. Biochem. 223:161-164(1994).  
CC -!- FUNCTION: PA2 catalyzes the calcium-dependent hydrolysis of the 2-  
CC acyl groups in 3-sn-phosphoglycerides. Inhibits neuromuscular  
CC transmission by blocking acetylcholine release from the nerve  
CC termini. Acts presynaptically.  
CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
CC acylglycerophosphocholine + a fatty acid anion.  
CC -!- COFACTOR: Binds 1 calcium ion per subunit (By similarity).  
CC -!- SUBUNIT: Crotoxin consists of 2 subunits: CA and CB. CA is acidic,  
CC nontoxic, without enzymatic activity and comprises 3 peptides that  
CC are crosslinked by 7 disulfide bridges. CB is basic, toxic, has  
CC phospholipase A2 activity and is composed of a single chain.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group II  
CC subfamily.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X16100; CAA34227.1; -;  
 DR HSP; S15068; PRRS2.  
 DR HSP; P14421; IAZA.  
 DR InterPro: IPR001211; PhospholipaseA2.  
 DR Pfam: PF00668; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD000303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00119; PA2 ASP; 1.  
 DR PROSITE; PS00118; PA2\_HIS; 1.  
 KW Hydrolase; Lipid degradation; Calcium; Signal; Multigene family.  
 FT SIGNAL 1 16  
 FT CHAIN 17 138 PHOSPHOLIPASE A2 CB2.  
 FT ACT\_SITE 63 63 BY SIMILARITY.  
 FT ACT\_SITE 105 105 BY SIMILARITY.  
 FT DISULFID 42 131 BY SIMILARITY.  
 FT DISULFID 44 60 BY SIMILARITY.  
 FT DISULFID 59 111 BY SIMILARITY.  
 FT DISULFID 65 138 BY SIMILARITY.  
 FT DISULFID 66 104 BY SIMILARITY.  
 FT DISULFID 73 97 BY SIMILARITY.  
 FT DISULFID 91 102 BY SIMILARITY.  
 FT METAL 43 43 CALCIUM (VIA CARBONYL OXYGEN)  
 FT METAL 45 45 (BY SIMILARITY).  
 FT METAL 47 47 CALCIUM (VIA CARBONYL OXYGEN)  
 FT METAL 64 64 (BY SIMILARITY).  
 FT METAL 64 64 CALCIUM (VIA CARBONYL OXYGEN)  
 FT SEQUENCE 138 AA; 15968 MW; 935D12258D47B058 CRC64;  
 Query Match 38.9%; Score 331.5; DB 1; Length 138;  
 Best Local Similarity 44.1%; Pred. No. 1.3e-26;  
 Matches 60; Conservative 21; Mismatches 52; Indels 3; Gaps 2;  
 QY 10 VMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGGLGRGQPKDADTWCQTHDC 69  
 Db 6 IVALLVGVGSLFELGKMTWQETGKNPVKNYGLYGCNGVGRGFLDATDRCCFVHDC 65  
 QY 70 CYDHLKTQGGIYKDYRYNFSQNIHCSDKGSCBQOLCACDKEVAFCLKRNLDITYQKR 129  
 Db 66 CYG--KLAKNTKWDIYRSLKSGYITCG-KGTWCKEQICECDRAAECLRRSLSTYKNE 122  
 QY 130 LRFYWRPHCRGQTGPGC 145  
 Db 123 YMFYPSRCRPSPTC 138  
 RESULT 15  
 ID PA2H AGKAC STANDARD; PRT; 138 AA.  
 AC OS7385; Q8UVZ5;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Phospholipase A2 homolog Dac-K491I precursor.  
 OS Agkistrodon acutus (Hundred-pace snake) (Deinagkistrodon acutus).  
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 CC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 CC Viperidae; Crotalinae; Deinagkistrodon.  
 CX NCBI\_TaxID=36307;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Venom gland;

RX MEDLINE=99183869; PubMed=10084123;  
 RA Fan C.Y., Qian Y.C., Yang S.L., Gong Y.;  
 RT "cDNA cloning and sequence analysis of Lys-49 phospholipase A2 from  
 RT Agkistrodon acutus.";  
 RL Genet. Anal. 15:15-18(1999).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Venom gland;  
 RX MEDLINE=21478853; PubMed=11594738;  
 RA Tsai I.-H., Chen Y.-H., Wang Y.-M., Tu M.-C., Tu A.T.;  
 RT "Purification, sequencing, and phylogenetic analyses of novel Lys-49  
 RT phospholipases A(2) from the venoms of rattlesnakes and other pit  
 RT vipers";  
 RL Arch. Biochem. Biophys. 394:236-244(2001).  
 CC -!- FUNCTION: Myotoxic protein that lacks PA2 enzymatic activity.  
 CC -!- SUBCELLULAR LOCATION: Secreted (By similarity).  
 CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.  
 CC -!- MISCELLANEOUS: Does not bind calcium as one of the calcium binding  
 CC ligands is lost (Asp->Lys in position 64).  
 CC -!- SIMILARITY: Belongs to the phospholipase A2 family. Group II  
 CC subfamily.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; AJ223188; CAA11159.1; -;  
 DR EMBL; AF269132; AAL36975.1; -;  
 DR PDB; IMC2; 2I-AUG-02.  
 DR PDB; IMG6; 04-SEP-02.  
 DR InterPro: IPR001211; PhospholipaseA2.  
 DR Pfam; PF00068; phoslip; 1.  
 DR PRINTS; PR00389; PHPLIPASEA2.  
 DR ProDom; PD000303; PhospholipaseA2; 1.  
 DR SMART; SM00085; PA2C; 1.  
 DR PROSITE; PS00119; PA2 ASP; 1.  
 DR PROSITE; PS00118; PA2\_HIS; 1.  
 KW Toxin; Signal; 3D-structure.  
 FT SIGNAL 1 16 BY SIMILARITY.  
 FT CHAIN 17 138 PHOSPHOLIPASE A2 HOMOLOG DAC-K491I.  
 FT ACT\_SITE 63 63 BY SIMILARITY.  
 FT ACT\_SITE 105 105 BY SIMILARITY.  
 FT DISULFID 42 131 BY SIMILARITY.  
 FT DISULFID 44 60 BY SIMILARITY.  
 FT DISULFID 59 111 BY SIMILARITY.  
 FT DISULFID 65 138 BY SIMILARITY.  
 FT DISULFID 73 97 BY SIMILARITY.  
 FT DISULFID 91 102 BY SIMILARITY.  
 FT DISULFID 130 130 BY SIMILARITY.  
 FT CONFLICT 130 130 S -> L (IN REF. 2).  
 FT SEQUENCE 138 AA; 15777 MW; 1353CD8C8F54DA99 CRC64;  
 Query Match 38.8%; Score 330.5; DB 1; Length 138;  
 Best Local Similarity 43.4%; Pred. No. 1.7e-26;  
 Matches 59; Conservative 21; Mismatches 53; Indels 3; Gaps 2;  
 QY 10 VMAGVPIQGGILNLNKKVQVTKMPILSYWPGCHGGLGRGQPKDADTWCQTHDC 69  
 Db 6 IVALLVGVGSLFELGKMTWQETGKNPVKNYGLYGCNGVGRGFLDATDRCCFVHDC 65  
 QY 70 CYDHLKTQGGIYKDYRYNFSQNIHCSDKGSCBQOLCACDKEVAFCLKRNLDITYQKR 129  
 Db 66 CYG--KLTKDCKKORYSYKWKNAIVCG-KNQPCQEMCECDKAFACLRENLDITYKS 122  
 QY 130 LRFYWRPHCRGQTGPGC 145  
 Db 123 FRYHLKPSCKTSEQ 138

us-09-830-321a-1.rsp

Fri Oct 8 10:22:31 2004

Search completed: October 5, 2004, 19:25:30  
Job time : 6.8 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 18:51:24 ; Search time 28.8067 Seconds  
(without alignments)  
1588.179 Million cell updates/sec

Title: US-09-830-321A-1

Perfect score: 852

Sequence: 1 MELALLGLVWVAGVPIQG.....YQKRLRFYWRPHCRGQTGCG 145

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 seqs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL\_25.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phage.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*  
15: sp\_rvirus.\*  
16: sp\_bacteriap.\*  
17: sp\_archaeap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	400.5	47.0	146	11 Q91Y34	Q91Y34 rattus norv
2	389	45.7	154	11 Q9QX68	Q9QX68 mesocricetu
3	352	41.3	168	4 Q8N217	Q8N217 homo sapien
4	347	40.7	187	4 Q8N435	Q8N435 homo sapien
5	336	39.4	210	11 Q8CE14	Q8CE14 mus musculus
6	334	39.2	137	13 Q804D7	Q804D7 bothrops ja
7	330	38.7	202	11 Q8BJ93	Q8BJ93 mus musculus
8	314	36.9	138	13 Q805A3	Q805A3 trimeresu
9	312.5	36.7	136	13 Q7T3S7	Q7T3S7 echis carin
10	309	36.3	138	13 Q805A2	Q805A2 trimeresu
11	306.5	36.0	138	13 Q7T1D5	Q7T1D5 vipera beru
12	296.5	34.8	150	11 Q8K0Y1	Q8K0Y1 mus musculus
13	295.5	34.7	138	13 Q7ZZQ1	Q7ZZQ1 vipera russ
14	294	34.5	138	13 Q8AXY1	Q8AXY1 bothrops ja
15	289.5	34.0	138	13 Q7T1C6	Q7T1C6 vipera aspi
16	283.5	33.3	138	13 Q7T2R1	Q7T2R1 vipera russ

17	274.5	32.2	138	13 Q7T1D1	Q7T1D1 vipera beru
18	269.5	31.6	138	13 Q7T1D4	Q7T1D4 vipera aspi
19	269.5	31.6	138	13 Q7T1D3	Q7T1D3 vipera aspi
20	269.5	31.6	138	13 Q7T1D2	Q7T1D2 vipera aspi
21	261.5	30.7	138	13 Q800C2	Q800C2 crotalus vi
22	260.5	30.6	138	13 Q800C4	Q800C4 crotalus vi
23	260.5	30.6	138	13 Q800C1	Q800C1 crotalus vi
24	259.5	30.5	138	13 Q7ZTA7	Q7ZTA7 crotalus vi
25	255.5	30.0	138	13 Q800C3	Q800C3 crotalus vi
26	255.5	30.0	141	11 Q8C5Y6	Q8C5Y6 mus musculu
27	251.5	29.5	130	13 Q7T3T5	Q7T3T5 vipera russ
28	246	28.9	138	13 Q7ZTA8	Q7ZTA8 crotalus vi
29	244	28.6	138	13 Q7ZTA6	Q7ZTA6 crotalus vi
30	234	27.5	147	13 Q7ZM60	Q7ZM60 rana catesb
31	222.5	26.1	147	13 Q7T2Q5	Q7T2Q5 bungarus fl
32	221.5	26.0	156	5 Q8WS88	Q8WS88 adamsia car
33	218.5	25.6	147	13 Q7T2Q4	Q7T2Q4 bungarus fl
34	210.5	24.7	146	13 Q7T1R0	Q7T1R0 bungarus fl
35	208	24.4	142	13 Q802I1	Q802I1 bungarus ca
36	199	23.4	453	11 Q80ZM2	Q80ZM2 mus musculu
37	198.5	23.3	146	13 Q8AXW2	Q8AXW2 bungarus mu
38	197.5	23.2	144	11 Q8K130	Q8K130 mus musculu
39	196.5	23.1	145	13 Q8AXW0	Q8AXW0 bungarus mu
40	196	23.0	149	13 Q9YH62	Q9YH62 dicentrarch
41	196	23.0	149	13 Q57313	Q57313 pegrus majo
42	192.5	22.6	167	5 Q86DU7	Q86DU7 polyandroca
43	192	22.5	177	5 Q8IML0	Q8IML0 drosophila
44	189.5	22.2	146	13 Q8AXW7	Q8AXW7 micrurus co
45	189	22.2	137	13 Q8AY48	Q8AY48 bungarus ca

#### ALIGNMENTS

#### RESULT 1

Q91Y34	PRELIMINARY;	PRT;	146 AA.
ID Q91Y34			
AC Q91Y34			
DT 01-DEC-2001 (TRENBLrel. 19, Created)			
DT 01-DEC-2001 (TRENBLrel. 19, Last sequence update)			
DT 01-OCT-2003 (TRENBLrel. 25, Last annotation update)			
DE Platelet phospholipase A2 precursor (Fragment).			
OS Rattus norvegicus (Rat)			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus;			
OX NCBI_TaxID=10116;			
RN [1]			
RP SEQUENCE FROM N.A.			
RC STRAIN=Wistar; TISSUE=Blood;			
RA Liu T.T., Liang N.S., Meng Z.Q., Xie Y.A., Kuang Z.P., Li Y.;			
RT "Cloning and sequence determination of rat platelet phospholipase A2			
RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.			
DR EMBL; AF365363; AAK52061.1; -			
DR GO; GO:0005509; F:calcium ion binding; IEA.			
DR GO; GO:0004623; F:phospholipase A2 activity; IEA.			
DR GO; GO:0016042; F:lipid catabolism; IEA.			
DR InterPro; IPR001211; PhospholipaseA2.			
DR Pfam; PF00068; phoslip; 1.			
DR PRINTS; PR00389; PHPLIPASEA2.			
DR ProDom; PD000303; PhospholipaseA2; 1.			
DR SMART; SM00085; PA2c; 1.			
DR PROSITE; PS00119; PA2_ASP; 1.			
DR PROSITE; PS00118; PA2_HIS; 1.			
KW SIGNAL.			
FT SIGNAL	1	21	POTENTIAL.
FT CHAIN	22	>146	PLATELET PHOSPHOLIPASE A2.
FT NON_TER	146	146	
SQ SEQUENCE	146 AA;	16306 MW;	60C1C9EC85DCBD67 CRC64;

Query Match 47.0%; Score 400.5; DB 11; Length 146;  
Best Local Similarity 47.9%; Pred. No. 3e-38;  
Matches 70; Conservative 23; Mismatches 52; Indels 1; Gaps 1;

→



QY 3 LALLCGLVVMAGVPIQGGILNLNMVKQVTKMPILSYWPYGCCHGLGGGPKDATDW 62

```

QY 130 LRFYWRPHCRGQTP 143
Db 123 YRYHLKPFCKKADP 136

RESULT 7
Q805A3 PRELIMINARY; PRT; 202 AA.
AC Q805A3;
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Calcium-dependent phospholipase A2 precursor.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=BALB/C; PubMed=12466851;
RX MEDLINE=22354683;
RA The FANTOM Consortium,
RA the RIKEN Genome Exploration Research Group Phase I & II Team;
RT "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs.";
RL Nature 420:563-573 (2002).
DR EMBL; AK090021; BAC41050.1; -.
DR GO; GO:0005509; F:calcium ion binding; IEA.
DR GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR GO; GO:0016042; P:lipid catabolism; IEA.
DR InterPro; IPR001211; PhospholipaseA2.
DR Pfam; PF00068; phoslip; 1.
DR PRINTS; PR00389; PHPLIPASEA2.
DR ProDom; PD000303; PhospholipaseA2; 1.
DR SMART; SM00085; PA2C; 1.
DR PROSITE; PS00119; PA2_ASP; 1.
DR PROSITE; PS00118; PA2_HIS; 1.
SQ SEQUENCE 202 AA; 22770 MW; BDBA97C09F64F7C4 CRC64;

Query Match 38.7%; Score 330; DB 11; Length 202;
Best Local Similarity 44.3%; Pred. No. 6.1e-30;
Matches 58; Conservative 24; Mismatches 43; Indels 6; Gaps 2;

QY 8 GLVWMA-----GVPIQGIILNLMKWKQVTGKMPILSYWPGCHGCGRGQPKDATDW 62
Db 3 GLLTLAWFLACSVAPVGGELLEKSNIEKVTGNNAFNYGFCYCGWGRGTPKDGTDW 62

QY 63 CQTHDCCYDHLKTQCGGIYKDYRYNFSQGNHSCDKGSWCEQQIACDKEVAFCLKRN 122
Db 63 CQCHEDRCYQGLEEKDCAIRTSYDRTYINGLVIC-EHDSFCFMRLCADRLKLVYCLRRN 121

QY 123 LDTYQKRLRFY 133
Db 122 LWTYNPLFYQY 132

RESULT 8
Q805A3 PRELIMINARY; PRT; 138 AA.
AC Q805A3;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Phospholipase A2.
GN PLA-N.
OS Trimeresurus flavoviridis (Habu).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC Viperidae; Crotalinae; Trimeresurus.
CX NCBI_TaxID=88087;
RN [1]
RP SEQUENCE FROM N.A.

```

```

RA Chijiwa T., Hamai S., Tsubouchi S., Ogawa T., Deshimaru M.,
RA Oda-Ueda N., Hattori S., Kihara H., Tsunazawa S., Ohno M.;
RT "Interisland mutation of a novel phospholipase A2 from Trimeresurus
RT flavoviridis venom and evolution of crotalinae group II phospholipase
RT A2."
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB102728; BAC56892.1; -.
DR GO; GO:0005509; F:calcium ion binding; IEA.
DR GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR GO; GO:0016042; P:lipid catabolism; IEA.
DR InterPro; IPR001211; PhospholipaseA2.
DR Pfam; PF00068; phoslip; 1.
DR PRINTS; PR00389; PHPLIPASEA2.
DR ProDom; PD000303; PhospholipaseA2; 1.
DR SMART; SM00085; PA2C; 1.
DR PROSITE; PS00119; PA2_ASP; 1.
DR PROSITE; PS00118; PA2_HIS; 1.
SQ SEQUENCE 138 AA; 15617 MW; A2F7B5A23897ECC5 CRC64;

Query Match 36.9%; Score 314; DB 13; Length 138;
Best Local Similarity 44.9%; Pred. No. 2.8e-28;
Matches 61; Conservative 19; Mismatches 50; Indels 6; Gaps 3;

QY 10 VVMAGVPIQGIILNLMKWKQVTGKMPILSYWPGCHGCGRGQPKDATDWCCQTHDC 69
Db 9 VLLVGV---EGLLQFNMKIMTKNGFFPYTSYCYCGWGRGKPKDATDRCCFVHDC 65

QY 70 CYDHLKTQCGGIYKDYRYNFSQGNHSCDKGSWCEQQIACDKEVAFCLKRNLDTYOKR 129
Db 66 CYE--KLTDSPKSDIYSYWKTVIIGGE-GTECEKQICECDRAAAVCFQGNLRTYKKK 122

QY 130 LRFYWRPHCRGQTPGC 145
Db 123 YMFYDFELCTDPTTEKC 138

RESULT 9
Q7T3S7 PRELIMINARY; PRT; 136 AA.
AC Q7T3S7;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Phospholipase A2 (EC 3.1.1.4).
OS Echis carinatus (Saw-scaled viper).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC Viperidae; Viperinae; Echis.
CX NCBI_TaxID=40353;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Venom gland;
RA Jasti J., Murugan P., Alagiri S., Singh T.P.;
RT "X-ray structure of acidic phospholipase A2 from Indian saw-scaled-
RT viper (Echis carinatus) with a potent platelet aggregation inhibition
RT activity."
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY268946; AAP41217.1; -.
KW Hydrolase.
SQ SEQUENCE 136 AA; 15523 MW; 39699DA1D01271BA CRC64;

Query Match 36.7%; Score 312.5; DB 13; Length 136;
Best Local Similarity 41.2%; Pred. No. 4.2e-28;
Matches 56; Conservative 22; Mismatches 53; Indels 5; Gaps 3;

QY 10 VVMAGVPIQGIILNLMKWKQVTGKMPILSYWPGCHGCGRGQPKDATDWCCQTHDC 69
Db 6 IVAVMLIAVEGNLYQFGRMINWRTGKLPILSYSGYCYCGWGGQGPDKDATDRCCLVHDC 65

QY 70 CYDHLKTQCGGIYKDYRYNFSQGNHSCDKGSWCEQQIACDKEVAFCLKRNLDTYOKR 129
Db 66 CY--TRVGDCSPKMTLYSYRFENGDIICDNKOP--CKRAVCECDREAAICLGENVNTYDKK 122

```

RX	MEDLINE=22707820; PubMed=12823540;
RA	Guillemin I., Bouchier C., Garrigues T., Wisner A., Choumet V.;
RT	"Sequences and structural organization of phospholipase A2 genes from
RT	Vipera aspis aspis, V. aspis zinnikeri and Vipera berus berus venom.
RT	Identification of the origin of a new viper population based on
RT	amoditycation II heterogeneity.";
RL	Eur. J. Biochem. 270:2697-2706(2003).
DR	EMBL; AY158636; AA59982.1; -
SQ	SEQUENCE 138 AA; 15716 MW; 79B9F9E0D16C9CCB CRC64;
Query Match 36.0%; Score 306.5; DB 13; Length 138;	
Best Local Similarity 37.5%; Pred. No. 2.1e-27;	
Matches 51; Conservative 27; Mismatches 55; Indels 3; Gaps 2;	
QY	10 VVMAGVPIPGGILNLNKKVKQTGMPTLSWPGCHGLGRGPKDATMCCQTHDC 69
Db	6 IVAVLMLMGVEGNLFQFGNNINHMVGKHAVMSLYSGYCGWGQKPQDATRCCFVHDC 65
QY	70 CYDHLTKTGGIGYKYDYRYNFSGNIHCSDKSWCEQQLCACDKVEAFCLKNLDTYQKR 129
Db	66 CYG--RANGCDPKLSTYSYNFONGNIVCGNKYG--CLRHIICEDRVAAICFQNMMTYNKK 122
QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YKNYSNSNCQNSDKC 138
RESULT 12	
Q8KOY1	PRELIMINARY; PRT; 150 AA.
ID	Q8KOY1;
AC	Q8KOY1;
DT	01-OCT-2002 (TrEMBLrel. 22, Created)
DT	01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	Similar to phospholipase A2, group IIC.
OS	Mus musculus (Mouse).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX	NCBI_TaxID=10090;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Kidney;
RA	Straussberg R.;
RL	Submitted (May-2002) to the EMBL/GenBank/DDBJ databases.
DR	EMBL; BC029347; AAH29347.1; -
DR	GO; GO:0005509; F:calcium ion binding; IEA.
DR	GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR	GO; GO:0016042; P:lipo catabolism; IEA.
DR	InterPro; IPRO01211; PhospholipaseA2.
DR	Pfam; PF00068; phoslip; 1.
DR	PRINTS; PR00389; PHPLIPASEA2.
DR	ProDom; PD000303; PhospholipaseA2; 1.
DR	SMART; SM00085; PA2c; 1.
DR	PROSITE; PS00119; PA2_ASP; 1.
DR	PROSITE; PS00118; PA2_HIS; 1.
SQ	SEQUENCE 150 AA; 16985 MW; 6548C632B1C2ECEP CRC64;
Query Match 34.8%; Score 296.5; DB 11; Length 150;	
Best Local Similarity 45.3%; Pred. No. 3.3e-26;	
Matches 53; Conservative 14; Mismatches 45; Indels 5; Gaps 2;	
QY	27 KMWKVQVTGKMPILSYWPYCHGLGRGPKDATMCCQTHDCYDHKLKGCGIYKDYY 86
Db	27 RMVXHTGRSAFFSYGYGVCYGLGGKGLPVDAITDRCCWAHDCCYHKLKEYGCQPINAY 86
QY	87 RYNFSGNIHC---DKGSWCEQQLCADKEVAFLKRNLDTYQKLR--FYWRPHC 138
Db	87 QFTVINGTVTCGCTVASSCLGQKACECDKQSVYCFKENLATYEKAFQLFPTEPC 143
RESULT 13	
Q7ZZQ1	PRELIMINARY; PRT; 138 AA.
ID	Q7ZZQ1;

RX	MEDLINE=22707820; PubMed=12823540;
RA	Guillemin I., Bouchier C., Garrigues T., Wisner A., Choumet V.;
RT	"Sequences and structural organization of phospholipase A2 genes from
RT	Vipera aspis aspis, V. aspis zinnikeri and Vipera berus berus venom.
RT	Identification of the origin of a new viper population based on
RT	amoditycation II heterogeneity.";
RL	Eur. J. Biochem. 270:2697-2706(2003).
DR	EMBL; AY158636; AA59982.1; -
SQ	SEQUENCE 138 AA; 15716 MW; 79B9F9E0D16C9CCB CRC64;
Query Match 36.0%; Score 306.5; DB 13; Length 138;	
Best Local Similarity 37.5%; Pred. No. 2.1e-27;	
Matches 51; Conservative 27; Mismatches 55; Indels 3; Gaps 2;	
QY	10 VVMAGVPIPGGILNLNKKVKQTGMPTLSWPGCHGLGRGPKDATMCCQTHDC 69
Db	6 IVAVLMLMGVEGNLFQFGNNINHMVGKHAVMSLYSGYCGWGQKPQDATRCCFVHDC 65
QY	70 CYDHLTKTGGIGYKYDYRYNFSGNIHCSDKSWCEQQLCACDKVEAFCLKNLDTYQKR 129
Db	66 CYG--RANGCDPKLSTYSYNFONGNIVCGNKYG--CLRHIICEDRVAAICFQNMMTYNKK 122
QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YKNYSNSNCQNSDKC 138
RESULT 12	
Q8KOY1	PRELIMINARY; PRT; 150 AA.
ID	Q8KOY1;
AC	Q8KOY1;
DT	01-OCT-2002 (TrEMBLrel. 22, Created)
DT	01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	Similar to phospholipase A2, group IIC.
OS	Mus musculus (Mouse).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX	NCBI_TaxID=10090;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Kidney;
RA	Straussberg R.;
RL	Submitted (May-2002) to the EMBL/GenBank/DDBJ databases.
DR	EMBL; BC029347; AAH29347.1; -
DR	GO; GO:0005509; F:calcium ion binding; IEA.
DR	GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR	GO; GO:0016042; P:lipo catabolism; IEA.
DR	InterPro; IPRO01211; PhospholipaseA2.
DR	Pfam; PF00068; phoslip; 1.
DR	PRINTS; PR00389; PHPLIPASEA2.
DR	ProDom; PD000303; PhospholipaseA2; 1.
DR	SMART; SM00085; PA2c; 1.
DR	PROSITE; PS00119; PA2_ASP; 1.
DR	PROSITE; PS00118; PA2_HIS; 1.
SQ	SEQUENCE 138 AA; 15803 MW; A2F103123897ECC5 CRC64;
Query Match 36.3%; Score 309; DB 13; Length 138;	
Best Local Similarity 44.1%; Pred. No. 1.1e-27;	
Matches 60; Conservative 19; Mismatches 51; Indels 6; Gaps 3;	
QY	10 VVMAGVPIPGGILNLNKKVKQTGMPTLSWPGCHGLGRGPKDATMCCQTHDC 69
Db	9 VLVAVG---EGNLLQFNKIKIMTKNGPPFYTSYCYCGWGGRGPKDATRCCFVHDC 65
QY	70 CYDHLTKTGGIGYKYDYRYNFSGNIHCSDKSWCEQQLCACDKVEAFCLKNLDTYQKR 129
Db	66 CYB--KLTDCPSKSDIYSWKVTGVIIIGE-GTECBKQICECDRAAAVCGQLRTYKKN 122
QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YMFYPDFLCDTPTEKC 138
RESULT 11	
Q7TIDS	PRELIMINARY; PRT; 138 AA.
ID	Q7TIDS;
AC	Q7TIDS;
DT	01-OCT-2003 (TrEMBLrel. 25, Created)
DT	01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT	

RX	MEDLINE=22707820; PubMed=12823540;
RA	Guillemin I., Bouchier C., Garrigues T., Wisner A., Choumet V.;
RT	"Sequences and structural organization of phospholipase A2 genes from
RT	Vipera aspis aspis, V. aspis zinnikeri and Vipera berus berus venom.
RT	Identification of the origin of a new viper population based on
RT	amoditycation II heterogeneity.";
RL	Eur. J. Biochem. 270:2697-2706(2003).
DR	EMBL; AY158636; AAN59982.1; -
SQ	SEQUENCE 138 AA; 15716 MW; 79B9F9E0D16C9CCB CRC64;
Query Match 36.0%; Score 306.5; DB 13; Length 138;	
Best Local Similarity 37.5%; Pred. No. 2.1e-27;	
Matches 51; Conservative 27; Mismatches 55; Indels 3; Gaps 2;	
QY	10 VVMAGVPIPGGILNLNKKVKQTGMPTLSWPGCHGLGRGPKDATMCCQTHDC 69
Db	6 IVAVLMLMGVEGNLFQFGNNINHMVGKHAVMSLYSGYCGWGQGPQDATRCCFVHDC 65
QY	70 CYDHLTKTGGIGYKYDYRYNFSGNIHCSDKSWCEQQLCACDKVEAFCLKNLDTYQKR 129
Db	66 CYG--RANGCDPKLSTYSYNFONGNIVCGNKYG--CLRHIICEDRVAAICFQNMMTYNKK 122
QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YKNYSNSNCQNSDKC 138
RESULT 12	
Q8KOY1	PRELIMINARY; PRT; 150 AA.
ID	Q8KOY1;
AC	Q8KOY1;
DT	01-OCT-2002 (TrEMBLrel. 22, Created)
DT	01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	Similar to phospholipase A2, group IIC.
OS	Mus musculus (Mouse).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX	NCBI_TaxID=10090;
RN	[1]
RP	SEQUENCE FROM N.A.
RC	TISSUE=Kidney;
RA	Strausberg R.;
RL	Submitted (May-2002) to the EMBL/GenBank/DDBJ databases.
DR	EMBL; BC029347; AAH29347.1; -
DR	GO; GO:0005509; F:calcium ion binding; IEA.
DR	GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR	GO; GO:0016042; P:lipo catabolism; IEA.
DR	InterPro; IPRO01211; PhospholipaseA2.
DR	Pfam; PF00068; phoslip; 1.
DR	PRINTS; PR00389; PHPLIPASEA2.
DR	ProDom; PD000303; PhospholipaseA2; 1.
DR	SMART; SM00085; PA2c; 1.
DR	PROSITE; PS00119; PA2_ASP; 1.
DR	PROSITE; PS00118; PA2_HIS; 1.
SQ	SEQUENCE 150 AA; 16985 MW; 6548C632B1C2ECEP CRC64;
Query Match 34.8%; Score 296.5; DB 11; Length 150;	
Best Local Similarity 45.3%; Pred. No. 3.3e-26;	
Matches 53; Conservative 14; Mismatches 45; Indels 5; Gaps 2;	
QY	27 KMWKVQVTGKMPILSYWPYGHCHGLGRGPKDATMCCQTHDCYDHKLKGCGIYKDYY 86
Db	27 RMVXHTVGRSAFFSYGYGVGYGLGGKGLPVDAITDRCCWAHDCCYHKLKEYGCQPINAY 86
QY	87 RYNFSGNIHCSDKSWCEQQLCADKEVAFLKNLDTYQKLR--FYWRPHC 138
Db	87 QFTVNGTVTCGCTVASSCLGQKACECDKQSVYCFKENLATYEKAFQLFPTEPQC 143
RESULT 13	
Q7ZZQ1	PRELIMINARY; PRT; 138 AA.
ID	Q7ZZQ1;

QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YKSY--EDCTEEVQEC 136
RESULT 10	
Q805A2	PRELIMINARY; PRT; 138 AA.
ID	Q805A2;
AC	Q805A2;
DT	01-JUN-2003 (TrEMBLrel. 24, Created)
DT	01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	PLA-N(O).
GN	PLA2.
OS	Trimeresurus flavoviridis (Habu).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC	Viperidae; Crotalinae; Trimeresurus.
OX	NCBI_TaxID=88087;
RN	[1]
RP	SEQUENCE FROM N.A.
RA	Chijiwa T., Hamai S., Tsubouchi S., Ogawa T., Deshimaru M.,
RA	Oda-Ueda N., Hattori S., Kihara H., Tsunazawa S., Ohno M.;
RT	"Interisland mutation of a novel phospholipase A2 from Trimeresurus
RT	flavoviridis venom and evolution of crotalinae group II phospholipase
RT	A2.";
RL	Submitted (Feb-2003) to the EMBL/GenBank/DDBJ databases.
DR	EMBL; AB102729; BAC56893.1; -
DR	GO; GO:0005509; F:calcium ion binding; IEA.
DR	GO; GO:0004623; F:phospholipase A2 activity; IEA.
DR	GO; GO:0016042; P:lipo catabolism; IEA.
DR	InterPro; IPRO01211; PhospholipaseA2.
DR	Pfam; PF00068; phoslip; 1.
DR	PRINTS; PR00389; PHPLIPASEA2.
DR	ProDom; PD000303; PhospholipaseA2; 1.
DR	SMART; SM00085; PA2c; 1.
DR	PROSITE; PS00119; PA2_ASP; 1.
DR	PROSITE; PS00118; PA2_HIS; 1.
SQ	SEQUENCE 138 AA; 13803 MW; A2F103123897ECC5 CRC64;
Query Match 36.3%; Score 309; DB 13; Length 138;	
Best Local Similarity 44.1%; Pred. No. 1.1e-27;	
Matches 60; Conservative 19; Mismatches 51; Indels 6; Gaps 3;	
QY	10 VVMAGVPIPGGILNLNKKVKQTGMPTLSWPGCHGLGRGPKDATMCCQTHDC 69
Db	9 VLVAVG---EGNLLQFNKMIKIMTKNGPPFTYSYCYCGWGGRGPKDATRCCFVHDC 65
QY	70 CYDHLTKTGGIGYKYDYRYNFSGNIHCSDKSWCEQQLCACDKVEAFCLKNLDTYQKR 129
Db	66 CYR--KLTDCPSKSDIYSWKVTGVIICGE-GTECBKQICECDRAAAVCGQLRTYKKN 122
QY	130 LRFYWRPHCRGTGPGC 145
Db	123 YMFYPDFLCDTPTEKC 138
RESULT 11	
Q7T1D5	PRELIMINARY; PRT; 138 AA.
ID	Q7T1D5;
AC	Q7T1D5;
DT	01-OCT-2003 (TrEMBLrel. 25, Created)
DT	01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT	01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE	Phospholipase A2.
GN	PLA2VB.
OS	Vipera berus (Common viper).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC	Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;
OC	Viperidae; Viperinae; Vipera.
OX	NCBI_TaxID=31156;
RN	[1]
RP	SEQUENCE FROM N.A.



Fri Oct 8 10:22:32 2004

us-09-830-321a-1.rspt

Page 7

Db 123 YRELSSRCRQTSEQC 138

Search completed: October 5, 2004, 19:24:02  
Job time : 30.8067 secs

Page Blank (uspto)

GenCore version 5.1.6  
 Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 18:50:04 ; Search time 138.747 Seconds  
 (without alignments)  
 1232.039 Million cell updates/sec

Title: US-09-830-321A-2  
 Perfect score: 3235  
 Sequence: 1 MIFVLSPTALCLERVASH.....EQLEALRQAVRRQRPH 605

Scoring table: BLOSUM62  
 Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
 Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
 Maximum Match 100%  
 Listing first 45 summaries

Database : A\_Geneseq\_29Jan04.\*  
 1: geneseqp1980s.\*  
 2: geneseqp1980s.\*  
 3: geneseqp2000s.\*  
 4: geneseqp2001s.\*  
 5: geneseqp2002s.\*  
 6: geneseqp2003s.\*  
 7: geneseqp2003bs.\*  
 8: geneseqp2004s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Query			DB ID	Description
	Score	Match	Length		
1	3235	100.0	605	3 AAB03628	Human pho
2	2767.5	85.5	778	5 AAU10696	Human CPL
3	2767.5	85.5	778	6 ABG76482	Human par
4	2767.5	85.5	797	5 AAU10697	ABG76482 N-t
5	2767.5	85.5	797	6 ABG76483	Human cyt
6	2767.5	85.5	913	3 AAY51557	Human PLA
7	2767.5	85.5	913	4 AAB74635	Phospholi
8	2767.5	85.5	913	4 AAB82415	Human pho
9	2765.5	85.5	533	3 AAB21140	Human pho
10	2700	83.5	1020	4 ABG05871	Human cyt
11	2610.5	80.7	1040	4 ABG20154	Novel hum
12	2509.5	77.6	483	2 AAW75067	Novel hum
13	2509.5	77.6	483	2 AAW75067	Human sec
14	2509.5	77.6	483	6 ABO01943	Human sec
15	2509.5	77.6	483	6 ABO02008	Novel hum
16	1492	46.1	802	5 AAE22843	Human pho
17	1492	46.1	818	7 ADB61634	Human 818
18	1492	46.1	1026	5 ABB07497	Human lip
19	1492	46.1	1045	7 ADC10174	Human MOV
20	1455	45.0	1746	4 ABG05869	Novel hum
21	1243.5	38.4	996	5 ABB78290	Amino aci
22	1139.5	35.2	849	5 ABB09144	Human pho
23	1139.5	35.2	849	7 ADE08121	Novel pho
24	1138	35.2	853	5 ABB09149	Mouse pho
25	1127	34.8	854	5 ABB09147	Mouse pho

## SUMMARIES

RESULT 1  
 AAB03628  
 ID AAB03628 standard; protein; 605 AA.  
 XX AC AAB03628;  
 XX DT 05-OCT-2000 (first entry)  
 XX DE Human phospholipase 2 HPPL2.  
 KW Human; phospholipase 2; HPPL2; cancer; autoimmune disorder;  
 KW inflammatory disorder; reproductive disorder; infection.  
 XX OS Homo sapiens.  
 FH Key Location/Qualifiers  
 FT Modified-site 72  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 78  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 104  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 186  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 282  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 293  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 397  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 426  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 430  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 440  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 456  
 FT Modified-site /label= potential\_glycosylation\_site  
 FT Modified-site 506  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 518  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 540  
 FT Modified-site /label= potential\_phosphorylation\_site  
 FT Modified-site 550  
 FT Modified-site /label= potential\_glycosylation\_site  
 FT Modified-site 552  
 FT Modified-site /label= potential\_phosphorylation\_site

## ALIGNMENTS

26	1123.5	34.7	1600	4	AAE05958	Human pho
27	1112	34.4	848	5	ABB07494	Human lip
28	1101.5	34.0	1624	4	AAE05956	Human pho
29	1031.5	31.9	798	5	AAE22833	Human pho
30	1022	31.6	1497	4	ABG20153	Novel hum
31	886.5	27.4	188	4	ABG20150	Novel hum
32	629.5	19.5	438	4	ABG20151	Novel hum
33	619	19.1	749	2	AAE26501	Cytosolic
34	619	19.1	749	2	AAE54090	PLA2 phos
35	619	19.1	749	2	AAE63757	Human pho
36	619	19.1	749	2	AAE97751	Human pho
37	619	19.1	749	2	AAW11607	Human pho
38	619	19.1	749	2	AAW14650	Human pho
39	619	19.1	749	3	AAW59631	Human pho
40	619	19.1	749	5	AAO15549	Human pho
41	619	19.1	749	6	ABU03480	Human cyt
42	619	19.1	749	7	AD862603	Angiogene
43	616.5	19.1	611	3	ABE21142	Human Pro
44	611.5	18.9	749	5	AAE22834	Human pho
45	599.5	18.5	748	5	AAE23054	Human pho

Modified-site 566 /label= potential\_phosphorylation\_site

WO200024911-A2.

04-MAY-2000.

27-OCT-1999; 99WO-US025021.

27-OCT-1998; 98US-00181317.

21-JAN-1999; 99US-00234726.

(INCYTE) INCYTE PHARM INC.

Hillman JL, Bandman O, Guegler KJ, Corley NC, Baughn MR;

Azimzai Y, Lal P, Lu DAM;

WPI; 2000-350750/30.

DR N-PSDB; AAAS3270.

Human phospholipase genes and proteins useful to diagnose, prevent or treat cancer, autoimmune or inflammatory or reproductive disorders.

Disclosure; Page 71-72; 80pp; English.

The present sequence is human phospholipase 2 (HPPL2). This protein is involved in the hydrolysis of membrane phospholipids. The protein and its coding sequence can be used to diagnose and treat the following: cancers such as prostate, breast and testicular cancers, autoimmune and inflammatory disorders such as AIDS, allergies, anaemia, asthma, atherosclerosis, Crohn's disease, diabetes mellitus, emphysema, Graves' disease, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, psoriasis, rheumatoid arthritis and systemic lupus erythematosus, infection caused by viruses, fungi, bacteria, parasites and protozoa, and reproductive disorders including infertility, disruptions of the menstrual cycle, polycystic ovary syndrome, ectopic pregnancies, disruptions of spermatogenesis, cancers within the reproductive tract and impotence

Sequence 605 AA;

Query Match 100.0%; Score 3235; DB 3; Length 605;  
Best Local Similarity 100.0%; Pred. No. 4.3e-292;  
Matches 605; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MIFVELSPTALCLERVASHLTDTGLLVLCFPCAPCPFFPFEMESLSVAQGVQRDLGS 60  
1 MIFVELSPTALCLERVASHLTDTGLLVLCFPCAPCPFFPFEMESLSVAQGVQRDLGS 60  
61 LQPPPLGKFRFSCLSLPSWDYRLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQL 120  
61 LQPPPLGKFRFSCLSLPSWDYRLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQL 120  
121 DGDLODEIPVVAIMATGGIRAMTSLYQLAGLGLDCVYITGASGTWALANLY 180  
121 DGDLODEIPVVAIMATGGIRAMTSLYQLAGLGLDCVYITGASGTWALANLY 180  
181 EDPEWSQKDLAGTELLKTQVTNKNLGVLAAPSOQLRYROELARLGLVPSCTNLWALI 240  
181 EDPEWSQKDLAGTELLKTQVTNKNLGVLAAPSOQLRYROELARLGLVPSCTNLWALI 240  
241 NEALLHDEPHDKLSQREALSQGNPLPYCALNTKGSLTTFEFGWCEFPYEVGFP 300  
241 NEALLHDEPHDKLSQREALSQGNPLPYCALNTKGSLTTFEFGWCEFPYEVGFP 300  
301 KYGAFIPSELFSGEFFWQMLMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWR 360  
301 KYGAFIPSELFSGEFFWQMLMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWR 360  
361 WVRNQNANLDEQVPLKIEEPPSTAGRIAEFFDILLTWRLAQATHNPLRGLHFKDYQ 420  
361 WVRNQNANLDEQVPLKIEEPPSTAGRIAEFFDILLTWRLAQATHNPLRGLHFKDYQ 420

QY 421 HPHFSTWKATTLDDGLPNQITPSEPHCLLDVGLINTSCLPLQPTRDVLILSLDYNLH 480  
Db 421 HPHFSTWKATTLDDGLPNQITPSEPHCLLDVGLINTSCLPLQPTRDVLILSLDYNLH 480  
QY 481 GAFQQLQLLGRFCQEQGIFPPISPSPEQLOPRECHTFSDPTCPGAPAVLHPSGVRRT 540  
Db 481 GAFQQLQLLGRFCQEQGIFPPISPSPEQLOPRECHTFSDPTCPGAPAVLHPSGVRRT 540  
QY 541 PEEAAGEVNLSSSDSPYHYTKVYSQEDVDKLLHLTHYVNCNNQQLLEALRQAVRRR 600  
Db 541 PEEAAGEVNLSSSDSPYHYTKVYSQEDVDKLLHLTHYVNCNNQQLLEALRQAVRRR 600  
QY 601 QRRPH 605  
Db 601 QRRPH 605

RESULT 2

AAU10696

ID AAU10696 standard; protein; 778 AA.

XX AC AAU10696;

XX 25-FEB-2002 (first entry)

XX Human cPLA2-beta enzyme.

XX DE  
XX KW Calcium-independent cytosolic phospholipase A2-beta; cPLA2-beta;  
XX KW U937 cell; membrane phospholipid turnover; intracellular signalling;  
XX KW arachidonic acid cascade; inflammatory disorder; rheumatoid arthritis;  
XX KW psoriasis; asthma; inflammatory bowel disease; antiinflammatory.

XX OS Homo sapiens.

XX PN US6287838-B1.

XX PD 11-SEP-2001.

XX PF 13-DEC-1999; 99US-00460145.

XX PR 24-JAN-1997; 97US-00788975.

XX (GENY) GENETICS INST INC.

XX Kriz R, Song C;

XX WPI: 2002-054342/07.

XX N-PSDB; AAS17362.

XX Novel cytosolic phospholipase A2-beta enzyme encoding polynucleotide,  
PT useful for producing the enzyme for use in assays to discover enzyme  
PT antagonists.

XX Claim 1; Col 15-19; 19pp; English.

XX The present invention relates to a novel calcium-independent cytosolic  
XX phospholipase A2 (cPLA2)-beta enzyme and the cDNA sequence encoding it.  
XX The cDNA clone is isolated from U937 cells. The cPLA2 enzyme is active in  
XX membrane phospholipid turnover and in regulation of intracellular  
XX signalling mediated by the arachidonic acid cascade. The invention  
XX describes a method for producing phospholipase enzymes which can be used  
XX to identify inhibitors of their function. The inhibitors can be used to  
XX treat inflammatory disorders such as rheumatoid arthritis, psoriasis,  
XX asthma, and inflammatory bowel disease. The present sequence represents  
XX human cPLA2-beta enzyme

XX SQ Sequence 778 AA;

Query Match 85.5%; Score 2767.5; DB 5; Length 778;

Best Local Similarity 87.6%; Pred. No. 2.5e-248;

Matches 537; Conservative

QY 24 TGLVLVLCFPCAPCPFFPFEMESLSVAQGVQRDLGSLQPPPLGKFRFSCLSLPSWDYR 83







CC are useful as research or diagnostic tools, and to study phospholipase  
 CC A2 activity and inflammatory conditions. The present sequence represents  
 CC the cPLA2-beta protein  
 XX  
 SQ Sequence 797 AA;

Query Match 85.5%; Score 2767.5; DB 6; Length 797;  
 Best Local Similarity 87.6%; Pred. No. 2.6e-248;  
 Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;  
 QY 24 TGLLVLCFPCAPCPFFFFMESISVAQAQVQWRDLGSLQPPPLGFKFSCLSLPSWDYR 83  
 Db 203 TGTFRFHCPA-C-----WQEQ-LSI-----RLQDAPEEQKAPLSALPGSQVVR 244  
 QY 84 -----LRELA VRLGFGPCAEQAFSLRRKQVVAALRQALQDGD 123  
 Db 245 LVFTTSQBLMRVELKKEAGRELAVRLGFGPCAEQAFSLRRKQVVAALRQALQDGD 304  
 QY 124 LQDEIPVVAIMATGGIRAMTSLYGQLAGLKGELGLDCVSYITGASGSTWALANLYEDP 183  
 Db 305 LQDEIPVVAIMATGGIRAMTSLYGQLAGLKGELGLDCVSYITGASGSTWALANLYEDP 364  
 QY 184 EWSQKDLAGTTELLKTQVTKNKLGVLPASQOLQRYQELAEARLGYPCFTNLWALINEA 243  
 Db 365 EWSQKDLAGTTELLKTQVTKNKLGVLPASQOLQRYQELAEARLGYPCFTNLWALINEA 424  
 QY 244 LLHDEPHDKLSQREALSHGQNPLPIYCALNTKQSLTTTFEGWCEFSFVEVGFPPKYG 303  
 Db 425 LLHDEPHDKLSQREALSHGQNPLPIYCALNTKQSLTTTFEGWCEFSFVEVGFPPKYG 484  
 QY 304 AFIPSELFGSEFFMGQMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWRWVR 363  
 Db 485 AFIPSELFGSEFFMGQMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWRWVR 544  
 QY 364 NQANLDEKQVPLKIEEPPSTAGRIAEFTDLLTWRLAQATHNRLGLHFKDYFQHPH 423  
 Db 545 NQANLDEKQVPLKIEEPPSTAGRIAEFTDLLTWRLAQATHNRLGLHFKDYFQHPH 604  
 QY 424 FSTWKATTLGDLNQLTSPSEPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAF 483  
 Db 605 FSTWKATTLGDLNQLTSPSEPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAF 664  
 QY 484 QQLQLGRFCQEQGIPPPISPEEQLOPRECHTFSDPTCPGAPAVLHF-----533  
 Db 665 QQLQLGRFCQEQGIPPPISPEEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 724  
 QY 534 -SSGVRRTPEAAAGENVLSSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNOQLLEAL 592  
 Db 725 SAPGVRTPEAAAGENVLSSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNOQLLEAL 784  
 QY 593 RQAVQRRQRPPH 605  
 Db 785 RQAVQRRQRPPH 797

RESULT 6  
 AA51557  
 ID AA51557 standard; protein; 913 AA.  
 XX  
 AC AA51557;  
 XX  
 DT 18-MAY-2000 (first entry)  
 XX  
 DE Human PLA2 protein.  
 XX  
 KW PLA2; phospholipase A2; phosphatide 2-acyl hydrolase; human; therapy;  
 XX arachidonic acid; lysophospholipid; Alzheimer's disease.  
 OS Homo sapiens.  
 XX US6025178-A.  
 PN 15-SEP-2000.

XX 28-MAR-1997; 97US-00827208.  
 XX 29-MAR-1996; 96US-0014608P.  
 XX (ELIL ) LILLY & CO ELI.  
 XX Sharp JD, Striffler BA, Choi XC, Kramer RM, Pickard RT;  
 DR WPI; 2000-181816/16.  
 XX N-PSDB; AA288756, AA288757.  
 XX An isolated amino acid having phospholipase (PL)A2 activity is useful in  
 PT assays to identify inhibitors having a therapeutic benefit, such as  
 PT inhibiting the central role of PLA2 in the inflammatory component of  
 PT Alzheimer's disease.  
 XX Claim 1; Col 53-58; 32pp; English.  
 PS This invention describes a novel human phospholipase A2 (PLA2) protein  
 CC (I) and its encoding nucleic acid. The amino acid (I) releases  
 CC arachidonic acid in specific tissues characterized by unique membrane  
 CC phospholipids, by generating lysophospholipid species which are  
 CC deleterious to membrane integrity or by remodeling of unsaturated species  
 CC of membrane phospholipids through deacylation/reacylation mechanisms. The  
 CC amino acid is useful in assays to identify inhibitors having a  
 CC therapeutic benefit, such as inhibiting the central role of PLA2 in the  
 CC inflammatory component of Alzheimer's disease. The amino acid (I) allows  
 CC sensitive and rapid screening and identification of inhibitors of  
 CC phospholipase A2. This sequence represents the human PLA2 protein (also  
 CC known as phosphatide 2-acyl hydrolase)  
 XX Sequence 913 AA;

Query Match 85.5%; Score 2767.5; DB 3; Length 913;  
 Best Local Similarity 87.6%; Pred. No. 3.2e-248;  
 Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;  
 QY 24 TGLLVLCFPCAPCPFFFFMESISVAQAQVQWRDLGSLQPPPLGFKFSCLSLPSWDYR 83  
 Db 319 TGTFRFHCPA-C-----WQEQ-LSI-----RLQDAPEEQKAPLSALPGSQVVR 360  
 QY 84 -----LRELA VRLGFGPCAEQAFSLRRKQVVAALRQALQDGD 123  
 Db 361 LVFTTSQBLMRVELKKEAGRELAVRLGFGPCAEQAFSLRRKQVVAALRQALQDGD 420  
 QY 124 LQDEIPVVAIMATGGIRAMTSLYGQLAGLKGELGLDCVSYITGASGSTWALANLYEDP 183  
 Db 421 LQDEIPVVAIMATGGIRAMTSLYGQLAGLKGELGLDCVSYITGASGSTWALANLYEDP 480  
 QY 184 EWSQKDLAGTTELLKTQVTKNKLGVLPASQOLQRYQELAEARLGYPCFTNLWALINEA 243  
 Db 481 EWSQKDLAGTTELLKTQVTKNKLGVLPASQOLQRYQELAEARLGYPCFTNLWALINEA 540  
 QY 244 LLHDEPHDKLSQREALSHGQNPLPIYCALNTKQSLTTTFEGWCEFSFVEVGFPPKYG 303  
 Db 541 LLHDEPHDKLSQREALSHGQNPLPIYCALNTKQSLTTTFEGWCEFSFVEVGFPPKYG 600  
 QY 304 AFIPSELFGSEFFMGQMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWRWVR 363  
 Db 601 AFIPSELFGSEFFMGQMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPQFWRWVR 660  
 QY 364 NQANLDEKQVPLKIEEPPSTAGRIAEFTDLLTWRLAQATHNRLGLHFKDYFQHPH 423  
 Db 661 NQANLDEKQVPLKIEEPPSTAGRIAEFTDLLTWRLAQATHNRLGLHFKDYFQHPH 720  
 QY 424 FSTWKATTLGDLNQLTSPSEPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAF 483  
 Db 721 FSTWKATTLGDLNQLTSPSEPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAF 780  
 QY 484 QQLQLGRFCQEQGIPPPISPEEQLOPRECHTFSDPTCPGAPAVLHF-----533  
 Db 781 QQLQLGRFCQEQGIPPPISPEEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 840

QY 534 -SSGVRRTPEEAAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLTHYNVNNQOLLEAL 592  
Db 841 SAPGVRRTPEEAAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLTHYNVNNQOLLEAL 900  
QY 593 ROAVORRRORRPH 605  
Db 901 ROAVORRRORRPH 913

RESULT 7  
AAB74635  
ID AAB74635 standard; protein; 913 AA.  
AC AAB74635;  
XX  
DT 23-MAY-2001 (first entry)  
XX  
DE Phospholipase A2 (PLA2) protein sequence SEQ ID NO:3.  
XX  
KW Phospholipase A2; PLA2; antiinflammatory; inflammatory condition;  
KW rheumatoid arthritis; psoriasis; asthma; cytosolic PLA2; cPLA2.  
XX  
OS Homo sapiens.  
XX  
XX US6197569-B1.  
XX  
XX 06-MAR-2001.  
XX  
XX 07-FEB-2000; 2000US-00500358.  
XX  
XX 29-MAR-1996; 96US-0014608P.  
PR 19-MAR-1997; 97US-0041264P.  
PR 28-MAR-1997; 97US-00827208.  
XX  
XX (ELIL ) LILLY & CO ELI.

XX Chou XC, Kramer RM, Pickard RT, Sharp JD, Striffler BA;  
XX WPI; 2001-256372/26.  
XX N-PSDB; AAF74998, AAF74999.  
XX  
XX Novel nucleic acid molecules encoding phospholipase A2 enzyme, useful in  
XX screening assays for identifying compounds that inhibit or block  
XX phospholipase A2 enzyme activity.  
XX  
XX Claim 1; Col 53-58; 32pp; English.

XX The present invention describes an isolated polynucleotide (I),  
XX comprising a 3085 base pair phospholipase A2 (PLA2) sequence (given in  
XX AAF74999), encoding a 913 residue phospholipase A2 protein sequence  
XX (given in AAB74635), or a nucleotide sequence which hybridises under  
XX stringent conditions to the above mentioned nucleotide sequence. Also  
XX described are: (1) an isolated polynucleotide (II) comprising an 8517  
XX base pair sequence, given in AAF74998; (2) an expression vector (III)  
XX comprising (I) and an expression control sequence; (3) a host cell  
XX transformed with (III); (4) an expression vector (IV) comprising (II)  
XX operably linked to an expression control sequence; and (5) a host cell  
XX operably linked to an expression control sequence. The host cells  
XX inhibit or block cytosolic PLA2 (cPLA2) enzyme activity. The host cells  
XX transformed or transfected with cPLA2 enzymes in large  
XX quantities which are useful in screening assays for discovering agents  
XX that inhibit PLA2. The inhibitors identified are useful for treating  
XX inflammatory conditions such as rheumatoid arthritis, psoriasis, or  
XX asthma. (I) is also useful in the detection of mutant genomic DNA which  
XX has been digested with restriction enzymes and run on an electrophoretic  
XX gel by hybridising to the genomic DNA

XX Sequence 913 AA;

Query Match 85.5%; Score 2767.5; DB 4; Length 913;  
Best Local Similarity 87.6%; Pred. No. 3.2e-248;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLCFPCAPCPFFFFEMESLSVAQACQVQRWDLGSLQPPPLGPKRFSCLSLPSSWDYR 83  
Db 319 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSCGVYR 360  
QY 84 -----IRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 123  
Db 361 LVEFTSQEPIRMVELKKEAGRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 420  
QY 124 LOEDEIPVVAIMATGGGIRAMTSLYQLAGLKGELGLDCVSYITGASGWTWALANIYEDP 183  
Db 421 LOEDEIPVVAIMATGGGIRAMTSLYQLAGLKGELGLDCVSYITGASGWTWALANIYEDP 480  
QY 184 EMSQKDLAGPTTELLKTQVTNKNLGVLAPOSQLORYROELAEARLGLPSCFTNLWALINEA 243  
Db 481 EMSQKDLAGPTTELLKTQVTNKNLGVLAPOSQLORYROELAEARLGLPSCFTNLWALINEA 540  
QY 244 LHDEPHDKLSDOREALSHGONPLPIYCALNTKGOSLTTFEGEWCERFSPYEVGFPKY 303  
Db 541 LHDEPHDKLSDOREALSHGONPLPIYCALNTKGOSLTTFEGEWCERFSPYEVGFPKY 600  
QY 304 AFIPSELFGSEFTMGQMKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSPQFWRWVR 363  
Db 601 AFIPSELFGSEFTMGQMKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSPQFWRWVR 660  
QY 364 NQANLKEQVPLKIEBPSTAGRIAEFFTDLLTWRLAQATHNLFGLHFKDYFOHPH 423  
Db 661 NQANLKEQVPLKIEBPSTAGRIAEFFTDLLTWRLAQATHNLFGLHFKDYFOHPH 720  
QY 424 FSTWKATTLGDLNQLTPSEPHCLLDVGYLINTSCLPLQPTRDVDLLSLDNLHGAF 483  
Db 721 FSTWKATTLGDLNQLTPSEPHCLLDVGYLINTSCLPLQPTRDVDLLSLDNLHGAF 780  
QY 484 QQLQLGRFCQEQGIPFPPIPSPEEQLOPRECHTFSDPTCPGAPAVLHF----- 533  
Db 781 QQLQLGRFCQEQGIPFPPIPSPEEQLOPRECHTFSDPTCPGAPAVLHF----- 840  
QY 534 -SSGVRRTPEEAAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLTHYNVNNQOLLEAL 592  
Db 841 SAPGVRRTPEEAAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLTHYNVNNQOLLEAL 900  
QY 593 ROAVORRRORRPH 605  
Db 901 ROAVORRRORRPH 913  
RESULT 8  
AAB82415  
ID AAB82415 standard; protein; 913 AA.  
AC AAB82415;  
XX  
DT 06-AUG-2001 (first entry)  
XX  
DE Human phospholipase A2.  
XX  
KW Phospholipase A2; PLA2; bPLA2; PLA2-beta; inhibitor; screening;  
KW antiinflammatory; human; Alzheimer's disease; therapy.  
XX  
OS Homo sapiens.  
XX  
XX US6242206-B1.  
XX  
XX 05-JUN-2001.  
XX  
XX 07-FEB-2000; 2000US-00498809.  
XX  
XX 29-MAR-1996; 96US-0014608P.  
PR 19-MAR-1997; 97US-0041264P.  
PR 28-MAR-1997; 97US-00827208.  
XX  
XX (ELIL ) LILLY & CO ELI.

PI Chou X, Kramer RM, Pickard RT, Sharp JD, Striffler BA;  
XX  
DR WPI: 2001-366537/38.  
DR N-FSDS: AAF90487, AAF90488.

PT Assays to evaluate the effectiveness of inhibitors of phospholipase A2, used to screen candidate compounds, comprise recombinant expression of a novel phospholipase A2.

PS Claim 1(a); Col 53-58; 32pp; English.

The present sequence is that of a novel human phospholipase A2 (PLA2, also referred to bPLA2 or PLA2-beta). PLA2 liberates arachidonic acid from phospholipids, leading to the production of eicosanoids involved in inflammatory reaction. A claimed assay for evaluating the effectiveness of a compound as an inhibitor of PLA2 involves culturing a cell transformed with an expression vector comprising PLA2 genomic DNA or cDNA (see AAF90487-98), isolating the PLA2, contacting it with a candidate compound, and determining whether the PLA2 activity has been inhibited. The assay provides rapid and efficient screening for new antiinflammatory drugs that inhibit the arachidonic acid cascade. These may be especially useful in the treatment of the inflammatory component of Alzheimer's disease

Sequence 913 AA:

Query Match	85.5%	Score 2767.5	DB 4	Length 913
Best Local Similarity	87.6%	Pred. No. 3.2e-248		
Matches 537	Conservative	5	Mismatches 22	Indels 49
			Gaps	6
QY	24	TGLLVLCFAPACPFPPFFEFMESVSAQAQVQWRDLGSLQPPPLGFKRFKXCSLSPSSWDYR	83	
Db	319	TGTRFPCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALFPGQVVR	360	
QY	84	-----LRELAVRLGFGPCAEQAFLSRKQVVAALRQALQLDGD	123	
Db	361	LVFPTSQBELMRVELKKAEGLRELAVRLGFGPCAEQAFLSRKQVVAALRQALQLDGD	420	
QY	124	LQDEIPVVAIMATGGGIRAMTSLYGQAGLKGELGILDCVSYITGASGSFWALANIYEDP	183	
Db	421	LQDEIPVVAIMATGGGIRAMTSLYGQAGLKGELGILDCVSYITGASGSFWALANIYEDP	480	
QY	184	EWSQKLAGPTTELLKTQVTKNKLGVLAQSLQRYRQELAEARLGYPCSFCTNLWALINEA	243	
Db	481	EWSQKLAGPTTELLKTQVTKNKLGVLAQSLQRYRQELAEARLGYPCSFCTNLWALINEA	540	
QY	244	LLHDEPHDKLSQREALSHGQNPPIYCALNTKGSLTTTFBGEWCFSPEYVGFPKYG	303	
Db	541	LLHDEPHDKLSQREALSHGQNPPIYCALNTKGSLTTTFBGEWCFSPEYVGFPKYG	600	
QY	304	AFIPSELFGSEFFMGQMKRLPESRICFLEGIWSNLYAANLQDSLWASEPQFDRWVR	363	
Db	601	AFIPSELFGSEFFMGQMKRLPESRICFLEGIWSNLYAANLQDSLWASEPQFDRWVR	660	
QY	364	QNAQLDKQVPLKIEEPPSTAGRIAEFFTDLLTWRLPAAQTHNLRGLHFHKDYFOHPH	423	
Db	661	QNAQLDKQVPLKIEEPPSTAGRIAEFFTDLLTWRLPAAQTHNLRGLHFHKDYFOHPH	720	
QY	424	FSTWKATTLDLGNPLQITPSBPHCLLDVGYLINTSCLPLQPTRDVLTLISLDYNLHGAF	483	
Db	721	FSTWKATTLDLGNPLQITSEPHCLLDVGYLINTSCLPLQPTRDVLTLISLDYNLHGAF	780	
QY	484	QQLQLGFRFCOEGIPPEPIPSPEEQLOPRECHTFSDPTCPGAPAVLHF	533	
Db	781	QQLQLGFRFCOEGIPPEPIPSPEEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSFREY	840	
QY	534	-SSGVRRTPEAAAGEVNLSSSDSPHYHTKYTSQEDVDKLLHLTHYNVCNNQEQLEAL	592	
Db	841	SAPGVRRTPEAAAGEVNLSSSDSPHYHTKYTSQEDVDKLLHLTHYNVCNNQEQLEAL	900	
QY	593	QOAVQRRRQRAPH	605	
Db	901	QOAVQRRRQRAPH	913	

RESULT 9	
AAAB21140	
TD	AAAB21140 standard; protein; 533 AA.
XX	
XX	
AC	AAAB21140;
XX	
DT	19-JAN-2001 (first entry)
XX	
XX	
DE	Human cytosolic phospholipase A2 cPLA2 beta.

KW Human; cytosolic phospholipase A2 beta; cPLA2 beta; asthma; arthritis; inflammatory disease; crystal structure.

OS Homo sapiens.

XX  
PN  
WO200047763-A1.XX  
PD 17-AUG-2000XX  
PF  
14-FEB-2000:

XX  
DD 15 FEB 1966

XX  
XXXXXX

XX  
GENETICS INST. INC.

Dessein A, Somers WS, Stahl ML, Seehra JS, XX

UR  
XX  
WPI; 2000-558219/51.

PT New crystalline cytosolic phospholipase A2 (cPLA2) for identifying a  
PT species which is an agonist or antagonist of cPLA2 activity or binding  
PT that can be used to prevent or treat inflammation or inflammatory-related  
PT conditions.

XX  
PS Disclosure; Fig 4; 71pp: English.

The present sequence is the human cytosolic phospholipase A2 (cPLA2) beta protein. The invention concerns the elucidation of the crystal structure of the protein and its use in drug design. The protein can be used to identify treatments for inflammation-related conditions such as rheumatoid arthritis, psoriasis, asthma, inflammatory bowel disease, and diseases such as osteoporosis, colitis, myelogenous leukaemia, diabetes, wasting and atherosclerosis.

Sequence 533 AA:

Query Match	85.5%	Score 2765.5;	DB 3;	Length 533;
Best Local Similarity	97.6%	Pred. No. 2.1e-248;		
Matches 520; Conservative		1; Mismatches	1;	Indels 11; Gaps 1;

Qy	84	LRELAVRLGFGPCAEEQAFLSRRKQVVAAALROALQDLQDEIPVVAIMATGGGIRA	143
Db	1	LRELAVRLGFGPCAEEQAFLSRRKQVVAAALROALQDLQDEIPVVAIMATGGGIRA	60
Qy	144	MTSLYQGLAGLKEGLLDCVSYITGASGSTWALANLYDEPWSQOKLAGTTELLKQTQVTK	203
Db	61	MTSLYQGLAGLKEGLLDCVSYITGASGSTWALANLYDEPWSQOKLAGTTELLKQTQVTK	120
Qy	204	NKLGVLAPSOLOQRYOEIAERALGLPSCFTNLWALINEALLHDEPHDKLSQOREALSH	263
Db	121	NKLGVLAPSOLOQRYOEIAERALGLPSCFTNLWALINEALLHDEPHDKLSQOREALSH	180
Qy	264	GQNPLPIYCALNTKGSLTTFEFGEWCESPVEVGPKYGAFTPSLFGSEFFPMGQIMKR	323
Db	181	GQNPLPIYCALNTKGSLTTFEFGEWCESPVEVGPKYGAFTPSLFGSEFFPMGQIMKR	240
Qy	324	LPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVVRNQANLDKEQVPLLKIEEPPS	383
Db	241	LPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVVRNQANLDKEQVPLLKIEEPPS	300
Qy	384	TAGRTAEPTDILLTRPFLAQATHNFIURLHFHKDYFQHPHFSTWKATITDGLPNLOITPSE	443

301 TAGRIAEFTDILLTRPQAQTHNLRGLHFKDFQHEHFTWKTATLLDGLPNQLTPSE 360  
444 PHLCILLDVGYLINTSCILPQLQTRVDLILSLDYNLHGAFQQLLGRFCQGGIPFPPI 503  
361 PHLCILLDVGYLINTSCILPQLQTRVDLILSLDYNLHGAFQQLLGRFCQGGIPFPPI 420  
504 SPSPEQLQPRECHTSDDTCGAPAVLHF-----SSGVRTPEEAAAGVNL 552  
421 SPSPEQLQPRECHTSDDTCGAPAVLHF-----SSGVRTPEEAAAGVNL 480  
553 SSDSPHYTKVTSQSDVDKLLHLTHYVNCNNOEQLLEALRQAVRRQRPH 605  
481 SSDSPHYTKVTSQSDVDKLLHLTHYVNCNNOEQLLEALRQAVRRQRPH 533

RESULT 10  
ABG05871  
ID ABG05871 standard; protein; 1020 AA.  
XX AC ABG05871;  
XX AC  
DT 13-FEB-2002 (first entry)  
XX Novel human diagnostic protein #5862.  
DE Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX food supplement; medical imaging; diagnostic; genetic disorder.  
XX Homo sapiens.  
XX OS  
XX WO200175067-A2.  
XX FN  
XX PD  
XX 11-OCT-2001.  
XX PF  
XX 30-MAR-2001; 2001WO-US008631.  
XX PR  
XX 31-MAR-2000; 2000US-00540217.  
XX PR  
XX 23-AUG-2000; 2000US-00649167.  
XX XX  
XX (HYSE-) HYSEQ INC.  
XX PA  
XX Drmanac RT, Liu C, Tang YT;  
XX PI  
XX N-PSDB; AAS70058.  
XX WPI; 2001-639362/73.  
XX DR  
XX N-PSDB; AAS70058.  
XX PT  
XX New isolated polynucleotide and encoded polypeptides, useful in  
XX diagnostics, forensics, gene mapping, identification of mutations  
XX responsible for genetic disorders or other traits and to assess  
XX biodiversity.  
XX Claim 20; SEQ ID NO 36230; 103pp; English.

The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping, and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical imaging of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have application in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG00010-ABG0377 represent novel human diagnostic amino acid sequences of the invention. Note: The sequence data for this patent did not appear in the printed specification, but was obtained in

CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 1020 AA;  
Query Match 83.5%; Score 2700; DB 4; Length 1020;  
Best Local Similarity 86.4%; Pred. No. 7.5e-242;  
Matches 532; Conservative 5; Mismatches 27; Indels 52; Gaps 9;  
24 TGLLVLCFCAPCPFFFFEFMESLSVAQAGVQWRDGLSLOPPPLGFKRFSCLSPSSWDYR 83  
423 TGTFRHCPA-C-----WEQE-LSI-----LQDAPEQKAPLSALPSGVVR 464  
84 -----LRELAIVLGFPCAEQAFLSRRKQVVAALRALQALDGD 123  
465 LVFPTSQEPLMRVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRALQALDGD 524  
124 LOEDEIPVVAIMATGGIRAMTSLYQLAGLKEGLLDCVSYITGASGWTWALANLYEDP 183  
525 LOEDEIPVVAIMATGGIRAMTSLYQLAGLKEGLLDCVSYITGASGWTWALANLYEDP 584  
184 EMSQKDLAGTELLKTQVTKNKLGVLAPOLOQRYRQELAEARLGYSCFTNLWALNEA 243  
585 EMSQKDLAGTELLKTQVTKNKLGVLAPOLOQRYRQELAEARLGYSCFTNLWALNEA 644  
244 LLHDEPHDKLSQREALSHGQNPPIYCALNTKGQSLTTFEGCEWCFSPYEVGFPKYG 303  
645 LLHDEPHDKLSQREALSHGQNPPIYCALNTKGQSLTTFEGCEWCFSPYEVGFPKYG 704  
304 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWRWV- 362  
705 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWRWVS 764  
363 RNQANLDEKQVPLLKIEEPPSTAGRIAEFFTDLLTWRLAQATNFLRGLH-FHKDYFQH 421  
765 RNQANLDEKQVPLLKIEEPPSTAGRIAEFFTDLLTWRLAQATNFLRGLRISFHKDYFQH 824  
422 PHFSTWKATLLDGLPNQLTPSEPHCLLDVGY-LINTSCLPLLOTRDVLILSLDYNLH 480  
825 PHFSTWKATLLDGLPNQLTPSEPHCLLDGGYTLINTSCLPLLOTRDVLILSLDYNLH 884  
481 GAFQOLQLLGRFCQGGIPFPPIPSPEQLOPRECHTSDDTCGAPAVLHF----- 533  
885 GAFQOLQLLGRFCQGGIPFPPIPSPEQLOPRECHTSDDTCGAPAVLHFPLVSDSF 944  
534 ----SSGVRTPEEAAAGVNLSSSDSPHYTKVTSQSDVDKLLHLTHYVNCNNOEQL 589  
945 REYSAPGVRRTPPEAAAGVNLSSSDSPHYTKVTSQSDVDKLLHLTHYVNCNNOEQL 1004  
590 EALRQAVQRRQRPH 605  
1005 EALRQAVQRRQRPH 1020

RESULT 11  
ABG20154  
ID ABG20154 standard; protein; 1040 AA.  
XX AC ABG20154;  
XX AC  
DT 18-FEB-2002 (first entry)  
XX Novel human diagnostic protein #20145.  
XX DE  
XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX food supplement; medical imaging; diagnostic; genetic disorder.  
XX Homo sapiens.  
XX OS  
XX WO200175067-A2.  
XX PD  
XX 11-OCT-2001.  
XX XX

30-MAR-2001; 2001WO-US008631.  
31-MAR-2000; 2000US-00540217.  
23-AUG-2000; 2000US-00649167.  
(HYSE-) HYSBQ INC.  
Drmanac RT, Liu C, Tang YT;  
WPI; 2001-639362/73.  
N-PSDB; AAS84341.  
New isolated polynucleotide and encoded polypeptides, useful in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits and to assess  
biodiversity.  
Claim 20; SEQ ID NO 50513; 103pp; English.  
The invention relates to isolated polynucleotide (I) and polypeptide (II)  
sequences. (I) is useful as hybridisation probes, polymerase chain  
reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
and in recombinant production of (II). The polynucleotides are also used  
in diagnostics as expressed sequence tags for identifying expressed  
genes. (I) is useful in gene therapy techniques to restore normal  
activity of (II) or to treat disease states involving (II). (II) is  
useful for generating antibodies against it, detecting or quantitating a  
polypeptide in tissue, as molecular weight markers and as a food  
supplement. (II) and its binding partners are useful in medical imaging  
of sites expressing (II). (I) and (II) are useful for treating disorders  
involving aberrant protein expression or biological activity. The  
polypeptide and polynucleotide sequences have applications in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits to assess biodiversity  
and to produce other types of data and products dependent on DNA and  
amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
amino acid sequences of the invention. Note: The sequence data for this  
patent did not appear in the printed specification, but was obtained in  
electronic format directly from WIPO at  
ftp.wipo.int/pub/published\_pct\_sequences  
Sequence 1040 AA;  
Query Match 80.7%; Score 2610.5; DB 4; Length 1040;  
Best Local Similarity 84.3%; Pred. No. 1.7e-233;  
Matches 520; Conservative 7; Mismatches 35; Indels 55; Gaps 11;  
24 TGLLVLCPCAPCPFFFFEMESLSVAQAGVQWRDLGSLQPPPLGFKPSCLSLPSWDYR 83  
430 TGTFRHCPA-C-----WEQE-LSi-----RLQDAPEQLKAPLSALPSGQVVR 471  
84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAAALRQALQDGD 123  
472 LVFPTSQEPLMRVELKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAAALRQALQDGD 531  
124 LQDEIPVVAIMATGGIRAMTSLYGQAGLKEGLDVCVSYITGASGWTALANLYEDP 183  
532 LQDEIPVVAIMATGGIRAMTSLYGQAGLKEGLDVCVSYITGASGWTALANLYEDP 591  
184 EWSQKDLAGTTELLKTQVTNKNLGVLAAPSQLOQRYOELAEARLGYPCSTNWLALINEA 243  
592 EWSQKDLAGTTELLKTQVTNKNLGVLAAPSQLOQRYOELAEARLGYPCSTNWLALINEA 651  
244 LLHDEPHDKLSQREALSQGNPLPTCYALNTKGSLTTFEGMCEPSPYGVGPKYG 303  
652 LLHDEPHDKLSQREALSQGNPLPTCYALNTKGSLTTFEGMCEPSPYGVGPKYG 711  
304 APTSELFGSEFFMGQMLKGLPSRCTFEGISWNLVYANLQSLYWASEPQFWRWV- 362  
712 APTSELFGSEFFMGQMLKGLPSRCTFEGISWNLVYANLQSLYWASEPQFWRWVS 771  
363 RNQANLDKEQVPLKLTIEEPPSTAGRIAEFTDILLTWRLAQATQNFGRSIFHKDYFOH 421  
|||||

Db 772 RNQANLDKEQVPLKLTIEEPPSTAGRIAEFTDILLTWRLAQATQNFGRSIFHKDYFOH 831  
Qy 422 PHESTWKATTDGLPNQLTPESEPHLCLLDVGY-LINTSCLEPLLOPTEDVDLLIISLDYNLH 480  
Db 832 PHESTWKATTDGLPNQLTPESEPHLCLLDGGYTLINTSCLEPLLOPTEDVDLLIISLDYNLH 891  
Qy 481 GAFQOQLLGRFCQEQGIFPPPIPSPEBQLOP-RECHTFSDFTCGAPAVLHF----- 533  
Db 892 GAFQOQLLGRFCQEQGIFPPPIPSPEBQLOPWRSCHTFSDPTCFGAPAVLHFPLVSDS 951  
Qy 534 -----SSGVRRTPEAAAGEVNLSSDSPHYHTKVTSQEDVDKLLHLTHYNNVNNQEQ 588  
Db 952 FREYSAPGVRRTPEAAAGEVNLSSDSPHYHTKVTSQEDVDKLLHLTHYNNVNNQEQ 1011  
Qy 589 LEAL--RQAVQRRQR 603  
Db 1012 LGRLCAPGSANGRRQRK 1028  
RESULT 12  
AAW75132  
ID AAW75132 standard; protein; 483 AA.  
XX  
AC AAW75132;  
XX  
DT 25-MAR-2003 (revised)  
DT 28-JAN-1999 (first entry)  
XX  
DE Human secreted protein encoded by gene 11 clone HCENJ40.  
XX  
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;  
diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;  
developmental abnormality; foetal deficiency; blood; allergy; renal;  
immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;  
inflammation; ischaemic shock; Alzheimer's disease; testenosis; AIDS;  
cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;  
osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;  
endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT Misc-difference 29  
FT Misc-difference /label= unknown  
FT Misc-difference 483  
FT Misc-difference /label= unknown  
XX  
FN WO9839446-A2.  
XX  
PD 11-SEP-1998.  
XX  
PF 06-MAR-1998; 98WO-US004482.  
XX  
PR 07-MAR-1997; 97US-0038621P.  
PR 07-MAR-1997; 97US-0040161P.  
PR 07-MAR-1997; 97US-0040162P.  
PR 07-MAR-1997; 97US-0040163P.  
PR 07-MAR-1997; 97US-0040333P.  
PR 07-MAR-1997; 97US-0040334P.  
PR 07-MAR-1997; 97US-0040336P.  
PR 11-APR-1997; 97US-0040626P.  
PR 11-APR-1997; 97US-0043311P.  
PR 11-APR-1997; 97US-0043312P.  
PR 11-APR-1997; 97US-0043313P.  
PR 11-APR-1997; 97US-0043314P.  
PR 11-APR-1997; 97US-0043315P.  
PR 11-APR-1997; 97US-0043568P.  
PR 11-APR-1997; 97US-0043569P.  
PR 11-APR-1997; 97US-0043576P.  
PR 11-APR-1997; 97US-0043578P.  
PR 11-APR-1997; 97US-0043580P.  
PR 11-APR-1997; 97US-0043669P.  
PR 11-APR-1997; 97US-0043670P.

```
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;
XX PI Bednarij DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;
XX PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;
XX PI Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;
XX WPI; 1998-609887/51.
XX N-PSDB; AAV34229.
XX DR New isolated human genes and the secreted polypeptides they encode -
XX DR N-PSDB; AAV34229.
XX PT useful for diagnosis and treatment of e.g. cancers, neurological
XX PT disorders, immune diseases, inflammation or blood disorders.
XX PS Claim 1; Page 326-327; 447pp; English.
XX XX This sequence represents a secreted human protein encoded by the gene
XX CC clone detailed in the descriptor line. The gene can be used to generate
XX CC fusion proteins by linking to the gene to a human immunoglobulin Fc
XX CC portion (e.g. AAV34145) for increasing the stability of the fused protein
XX CC as compared to the human protein only. The invention relates to 70 novel
XX CC genes and their fragments (nucleic acid sequences: AAV34154-V34276; amino
XX CC acid sequences AAW75057-W75179) which are useful for preventing, treating
XX CC or ameliorating medical conditions e.g. by protein or gene therapy. Also,
XX CC pathological conditions can be diagnosed by determining the amount of the
XX CC new polypeptides in a sample or by determining the presence of mutations
XX CC in the new polynucleotides. Specific uses are described for each of the
XX CC 70 polynucleotides, based on which tissues they are most highly expressed
XX CC in (see AAV34154 for described uses). (Updated on 25-MAR-2003 to correct
XX CC PF field.) (Updated on 25-MAR-2003 to correct PI field.)
XX SQ Sequence 483 AA;
Query Match 77.6%; Score 2509.5; DB 2; Length 483;
Best Local Similarity 96.9%; Pred. No. 1.3e-224;
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;
QY 135 MATGGIRAMTSLYGQLAGLKGELGDCVSYITGASGSTMALANLYDEPWSQKDLAFT 194
Db 1 MATGGIRAMTSLYGQLAGLKGELGDCVSYITGASGSTMALANLYDEPWSQKDLAFT 60
QY 195 ELLKTQVTKNKLGVLAQSLQRYQELAEARLGYPSCTNLWALINEALLHDEPHDKL 254
Db 61 ELLKTQVTKNKLGVLAQSLQRYQELAEARLGYPSCTNLWALINEALLHDEPHDKL 120
QY 255 SDQREALSHGQNPLPIYCALNTKGSLTTFEFGWCESFPEVGPFGYGAFTPSLFGSE 314
Db 121 SDQREALSHGQNPLPIYCALNTKGSLTTFEFGWCESFPEVGPFGYGAFTPSLFGSE 180
QY 315 FPMQIMKRLPESRICFLEGIWSNLYAANLQDSLYWASEPQFWDWRVNRQANLKEQVP 374
Db 181 FPMQIMKRLPESRICFLEGIWSNLYAANLQDSLYWASEPQFWDWRVNRQANLKEQVP 240
QY 375 LKIEEPPSTAGRIAEFFDILLTWPLAQATNHLRGLHFHKDYFOHPHFSTWKATLDG 434
Db 241 LKIEEPPSTAGRIAEFFDILLTWPLAQATNHLRGLHFHKDYFOHPHFSTWKATLDG 300
QY 435 LPNQLTPSPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAFCQQLLGRFCQ 494
Db 301 LPNQLTPSPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAFCQQLLGRFCQ 360
QY 495 EQGIPPPISPSPPEEQLOPRECHTFSDPTCPGAPAVLHFLVSDSPREVSAPGVRTPEE 543
Db 361 EQGIPPPISPSPPEEQLOPRECHTFSDPTCPGAPAVLHFLVSDSPREVSAPGVRTPEE 420
QY 544 AAAGEVNLSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNQQLLEALQAVQRQR 603
Db 421 AAAGEVNLSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNQQLLEALQAVQRQR 480
QY 604 PH 605
Db 481 PH 482
```



RESULT 13  
AAW75067  
ID AAW75067 standard; protein; 483 AA.  
AC AAW75067;  
XX  
DT 25-MAR-2003 (revised)  
DT 28-JAN-1999 (first entry)  
XX  
XX Human secreted protein encoded by gene 11 clone HCENJ40.  
XX  
KW Human; secreted protein; fusion protein; gene therapy; protein therapy;  
KW diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia;  
KW developmental abnormality; foetal deficiency; blood; allergy; renal;  
KW immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma;  
KW inflammation; ischaemic shock; Alzheimer's disease; restenosis; AIDS;  
KW cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus;  
KW osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion;  
KW endocrine; metabolism; regulation; malabsorption; gastritis; neoplasm.  
XX  
OS Homo sapiens.  
XX  
XX Key Location/Qualifiers  
XX PH Misc-difference 29 /label= unknown  
XX FT Misc-difference 483  
XX FT Misc-difference 483 /label= unknown  
XX  
XX W09839446-A2.  
XX  
XX PD 11-SEP-1998.  
XX  
XX PF 06-MAR-1998; 98WO-US004482.  
XX  
XX 07-MAR-1997; 97US-0038621P.  
XX 07-MAR-1997; 97US-0040161P.  
XX 07-MAR-1997; 97US-0040162P.  
XX 07-MAR-1997; 97US-0040163P.  
XX 07-MAR-1997; 97US-0040333P.  
XX 07-MAR-1997; 97US-0040334P.  
XX 07-MAR-1997; 97US-0040336P.  
XX 11-APR-1997; 97US-0040626P.  
XX 11-APR-1997; 97US-0043311P.  
XX 11-APR-1997; 97US-0043312P.  
XX 11-APR-1997; 97US-0043313P.  
XX 11-APR-1997; 97US-0043314P.  
XX 11-APR-1997; 97US-0043315P.  
XX 11-APR-1997; 97US-0043588P.  
XX 11-APR-1997; 97US-0043589P.  
XX 11-APR-1997; 97US-0043576P.  
XX 11-APR-1997; 97US-0043578P.  
XX 11-APR-1997; 97US-0043580P.  
XX 11-APR-1997; 97US-0043669P.  
XX 11-APR-1997; 97US-0043670P.  
XX 11-APR-1997; 97US-0043671P.  
XX 11-APR-1997; 97US-0043672P.  
XX 11-APR-1997; 97US-0043674P.  
XX 23-MAY-1997; 97US-0047492P.  
XX 23-MAY-1997; 97US-0047500P.  
XX 23-MAY-1997; 97US-0047501P.  
XX 23-MAY-1997; 97US-0047502P.  
XX 23-MAY-1997; 97US-0047503P.  
XX 23-MAY-1997; 97US-0047581P.  
XX 23-MAY-1997; 97US-0047582P.  
XX 23-MAY-1997; 97US-0047583P.  
XX 23-MAY-1997; 97US-0047584P.  
XX 23-MAY-1997; 97US-0047585P.  
XX 23-MAY-1997; 97US-0047586P.  
XX 23-MAY-1997; 97US-0047587P.  
XX 23-MAY-1997; 97US-0047588P.  
XX 23-MAY-1997; 97US-0047589P.  
XX

PR 23-MAY-1997; 97US-0047590P.  
PR 23-MAY-1997; 97US-0047592P.  
PR 23-MAY-1997; 97US-0047593P.  
PR 23-MAY-1997; 97US-0047594P.  
PR 23-MAY-1997; 97US-0047595P.  
PR 23-MAY-1997; 97US-0047596P.  
PR 23-MAY-1997; 97US-0047597P.  
PR 23-MAY-1997; 97US-0047598P.  
PR 23-MAY-1997; 97US-0047599P.  
PR 23-MAY-1997; 97US-0047600P.  
PR 23-MAY-1997; 97US-0047601P.  
PR 23-MAY-1997; 97US-0047612P.  
PR 23-MAY-1997; 97US-0047613P.  
PR 23-MAY-1997; 97US-0047615P.  
PR 23-MAY-1997; 97US-0047617P.  
PR 23-MAY-1997; 97US-0047618P.  
PR 23-MAY-1997; 97US-0047632P.  
PR 23-MAY-1997; 97US-0047633P.  
PR 06-JUN-1997; 97US-0048964P.  
PR 06-JUN-1997; 97US-0048974P.  
PR 22-AUG-1997; 97US-0056630P.  
PR 22-AUG-1997; 97US-0056631P.  
PR 22-AUG-1997; 97US-0056632P.  
PR 22-AUG-1997; 97US-0056636P.  
PR 22-AUG-1997; 97US-0056637P.  
PR 22-AUG-1997; 97US-0056662P.  
PR 22-AUG-1997; 97US-0056664P.  
PR 22-AUG-1997; 97US-0056845P.  
PR 22-AUG-1997; 97US-0056862P.  
PR 22-AUG-1997; 97US-0056864P.  
PR 22-AUG-1997; 97US-0056872P.  
PR 22-AUG-1997; 97US-0056874P.  
PR 22-AUG-1997; 97US-0056875P.  
PR 22-AUG-1997; 97US-0056877P.  
PR 22-AUG-1997; 97US-0056878P.  
PR 22-AUG-1997; 97US-0056879P.  
PR 22-AUG-1997; 97US-0056880P.  
PR 22-AUG-1997; 97US-0056881P.  
PR 22-AUG-1997; 97US-0056882P.  
PR 22-AUG-1997; 97US-0056884P.  
PR 22-AUG-1997; 97US-0056886P.  
PR 22-AUG-1997; 97US-0056887P.  
PR 22-AUG-1997; 97US-0056888P.  
PR 22-AUG-1997; 97US-0056889P.  
PR 22-AUG-1997; 97US-0056892P.  
PR 22-AUG-1997; 97US-0056893P.  
PR 22-AUG-1997; 97US-0056894P.  
PR 22-AUG-1997; 97US-0056903P.  
PR 22-AUG-1997; 97US-0056908P.  
PR 22-AUG-1997; 97US-0056909P.  
PR 22-AUG-1997; 97US-0056910P.  
PR 22-AUG-1997; 97US-0056911P.  
PR 05-SEP-1997; 97US-0057650P.  
PR 05-SEP-1997; 97US-0057761P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;  
XX Bednarik DP, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JW;  
XX Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;  
XX Moore PA, Shi Y, Lafleur DW, Li Y, Zeng Z, Kyaw H;  
XX WPI; 1998-609887/51.  
XX N-PSDB; AAV34164.  
XX  
XX New isolated human genes and the secreted polypeptides they encode -  
XX useful for diagnosis and treatment of e.g. cancers, neurological  
XX disorders, immune diseases, inflammation or blood disorders.  
XX  
XX Claim 1; Page 285-287; 447pp; English.

CC This sequence represents a secreted human protein encoded by the gene  
CC clone detailed in the descriptor line. The gene can be used to generate  
CC fusion proteins by linking to the gene to a human immunoglobulin Fc  
CC portion (e.g. AAV34145) for increasing the stability of the fused protein  
CC as compared to the human protein only. The invention relates to 70 novel  
CC genes and their fragments (nucleic acid sequences: AAV34154-V34276; amino  
CC acid sequences AAV75057-W75179) which are useful for preventing, treating  
CC or ameliorating medical conditions e.g. by protein or gene therapy. Also,  
CC pathological conditions can be diagnosed by determining the amount of the  
CC new polypeptides in a sample or by determining the presence of mutations  
CC in the new polynucleotides. Specific uses are described for each of the  
CC 70 polynucleotides, based on which tissues they are most highly expressed  
CC in (see AAV34154 for described uses). (Updated on 25-MAR-2003 to correct  
CC PF field.) (Updated on 25-MAR-2003 to correct PI field.)  
XX  
SQ Sequence 483 AA;

Query Match 77.6%; Score 2509.5; DB 2; Length 483;  
Best Local Similarity 96.9%; Pred. No. 1.3e-224;  
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;  
QY 135 MATGGGIRAMTSYGLQAGLKLGLDCVYITGASGWTWALANLYDEPWSQKDLAAPT 194  
Db 1 MATGGGIRAMTSYGLQAGLKLGLDCVYITGASGWTWALANLYDEPWSQKDLAAPT 60  
QY 195 ELLKTQVTKNKLGLVAPSOLORYQOELARLGVSCFTNLWALINEALLHDEPHDKL 254  
Db 61 ELLKTQVTKNKLGLVAPSOLORYQOELARLGVSCFTNLWALINEALLHDEPHDKL 120  
QY 255 SDQREALSHGONPLIYCALNTKQSITTFEFGWCEFSPEYVGPKYGAIPSELFGSE 314  
Db 121 SDQREALSHGONPLIYCALNTKQSITTFEFGWCEFSPEYVGPKYGAIPSELFGSE 180  
QY 315 FFMGQMKRLPESRICFLEGWNSNLYANLQDSLYWASEPQFNDWRVNRQANLDKEQVP 374  
Db 181 FFMGQMKRLPESRICFLEGWNSNLYANLQDSLYWASEPQFNDWRVNRQANLDKEQVP 240  
QY 375 LKKEBPSTAGRIAEFTDILLTWPLAQATHNLRGLHFKDYFOHPHFSTWKATTLDG 434  
Db 241 LKKEBPSTAGRIAEFTDILLTWPLAQATHNLRGLHFKDYFOHPHFSTWKATTLDG 300  
QY 435 LPNQLTPSEPHCLLDVGLINTSCLPLQPTRDVDLILSLDYNLHGAFQQLIGRFCC 494  
Db 301 LPNQLTPSEPHCLLDVGLINTSCLPLQPTRDVDLILSLDYNLHGAFQQLIGRFCC 360  
QY 495 EQGIFPPISPSPBQLOPRECHTSDPTCPGAPVLPF-----SSGVRTPEE 543  
Db 361 EQGIFPPISPSPBQLOPRECHTSDPTCPGAPVLPF-----SSGVRTPEE 420  
QY 544 AAAGEVNLSSDSPHYTKVTSQEDVDKLLHLTHVNCNBOLEALRQAVQRRQR 603  
Db 421 AAAGEVNLSSDSPHYTKVTSQEDVDKLLHLTHVNCNBOLEALRQAVQRRQR 480  
QY 604 PH 605  
Db 481 PH 482

RESULT 14  
AB001943  
ID AB001943 standard; protein; 483 AA.  
XX  
AC AB001943;  
XX  
DE 12-AUG-2003 (first entry)  
XX  
DE Novel human secreted protein #11.  
XX  
KW Human; immunoglobulin G; IgG; fragment of crystallisation; Fc;  
KW immune system disorder; haematopoietic cell disorder;  
KW immunologic deficiency disorder; ataxia telangiectasia; HIV infection;  
KW Wiskott-Aldrich disorder; thrombocytopenia; haemoglobinuria;  
KW blood coagulation disorder; blood platelet disorder; autoimmune disorder;

KW Addison's disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;  
KW glomerulonephritis; Grave's disease; allergic reaction;  
KW graft-versus-host disease; hyperproliferative disorder; neoplasm;  
KW infectious disease; nervous system disease; spinal cord disorder;  
KW head trauma; stroke; tissue regeneration; congenital defect; trauma;  
KW wound; burn; incision; ulcer; age disease; osteoporosis;  
KW periodontal disease; liver failure; catabolism; anabolism; metabolism;  
KW food additive; preservative; secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX US2003027132-A1.  
XX  
XX 06-FEB-2003.  
XX  
XX 04-SEP-1998; 98US-00148545.  
XX  
XX 07-MAR-1997; 97US-0038621P.  
XX 07-MAR-1997; 97US-0040161P.  
XX 07-MAR-1997; 97US-0040162P.  
XX 07-MAR-1997; 97US-0040163P.  
XX 07-MAR-1997; 97US-0040333P.  
XX 07-MAR-1997; 97US-0040334P.  
XX 07-MAR-1997; 97US-0040336P.  
XX 07-MAR-1997; 97US-0040626P.  
XX 11-APR-1997; 97US-0043311P.  
XX 11-APR-1997; 97US-0043312P.  
XX 11-APR-1997; 97US-0043313P.  
XX 11-APR-1997; 97US-0043314P.  
XX 11-APR-1997; 97US-0043315P.  
XX 11-APR-1997; 97US-0043568P.  
XX 11-APR-1997; 97US-0043569P.  
XX 11-APR-1997; 97US-0043576P.  
XX 11-APR-1997; 97US-0043578P.  
XX 11-APR-1997; 97US-0043580P.  
XX 11-APR-1997; 97US-0043669P.  
XX 11-APR-1997; 97US-0043670P.  
XX 11-APR-1997; 97US-0043671P.  
XX 11-APR-1997; 97US-0043672P.  
XX 11-APR-1997; 97US-0043674P.  
XX 23-MAY-1997; 97US-0047492P.  
XX 23-MAY-1997; 97US-0047500P.  
XX 23-MAY-1997; 97US-0047501P.  
XX 23-MAY-1997; 97US-0047502P.  
XX 23-MAY-1997; 97US-0047503P.  
XX 23-MAY-1997; 97US-0047581P.  
XX 23-MAY-1997; 97US-0047582P.  
XX 23-MAY-1997; 97US-0047583P.  
XX 23-MAY-1997; 97US-0047584P.  
XX 23-MAY-1997; 97US-0047585P.  
XX 23-MAY-1997; 97US-0047586P.  
XX 23-MAY-1997; 97US-0047587P.  
XX 23-MAY-1997; 97US-0047588P.  
XX 23-MAY-1997; 97US-0047589P.  
XX 23-MAY-1997; 97US-0047590P.  
XX 23-MAY-1997; 97US-0047592P.  
XX 23-MAY-1997; 97US-0047593P.  
XX 23-MAY-1997; 97US-0047594P.  
XX 23-MAY-1997; 97US-0047595P.  
XX 23-MAY-1997; 97US-0047596P.  
XX 23-MAY-1997; 97US-0047597P.  
XX 23-MAY-1997; 97US-0047598P.  
XX 23-MAY-1997; 97US-0047599P.  
XX 23-MAY-1997; 97US-0047600P.  
XX 23-MAY-1997; 97US-0047601P.  
XX 23-MAY-1997; 97US-0047612P.  
XX 23-MAY-1997; 97US-0047613P.  
XX 23-MAY-1997; 97US-0047614P.  
XX 23-MAY-1997; 97US-0047615P.  
XX 23-MAY-1997; 97US-0047617P.  
XX 23-MAY-1997; 97US-0047618P.  
XX 23-MAY-1997; 97US-0047632P.  
XX 23-MAY-1997; 97US-0047633P.

PR 06-JUN-1997; 97US-0048964P.  
 PR 06-JUN-1997; 97US-0048974P.  
 PR 22-AUG-1997; 97US-0056630P.  
 PR 22-AUG-1997; 97US-0056631P.  
 PR 22-AUG-1997; 97US-0056632P.  
 PR 22-AUG-1997; 97US-0056633P.  
 PR 22-AUG-1997; 97US-0056636P.  
 PR 22-AUG-1997; 97US-0056637P.  
 PR 22-AUG-1997; 97US-0056662P.  
 PR 22-AUG-1997; 97US-0056664P.  
 PR 22-AUG-1997; 97US-0056845P.  
 PR 22-AUG-1997; 97US-0056862P.  
 PR 22-AUG-1997; 97US-0056864P.  
 PR 22-AUG-1997; 97US-0056872P.  
 PR 22-AUG-1997; 97US-0056874P.  
 PR 22-AUG-1997; 97US-0056875P.  
 PR 22-AUG-1997; 97US-0056877P.  
 PR 22-AUG-1997; 97US-0056879P.  
 PR 22-AUG-1997; 97US-0056880P.  
 PR 22-AUG-1997; 97US-0056881P.  
 PR 22-AUG-1997; 97US-0056882P.  
 PR 22-AUG-1997; 97US-0056884P.  
 PR 22-AUG-1997; 97US-0056886P.  
 PR 22-AUG-1997; 97US-0056887P.  
 PR 22-AUG-1997; 97US-0056888P.  
 PR 22-AUG-1997; 97US-0056889P.  
 PR 22-AUG-1997; 97US-0056892P.  
 PR 22-AUG-1997; 97US-0056893P.  
 PR 22-AUG-1997; 97US-0056894P.  
 PR 22-AUG-1997; 97US-0056903P.  
 PR 22-AUG-1997; 97US-0056908P.  
 PR 22-AUG-1997; 97US-0056909P.  
 PR 22-AUG-1997; 97US-0056910P.  
 PR 22-AUG-1997; 97US-0056911P.  
 PR 05-SEP-1997; 97US-0057650P.  
 PR 05-SEP-1997; 97US-0057761P.  
 PR 06-MAR-1998; 98WO-US004482.  
 XX  
 PA (RUBE//) RUBEN S M.  
 PA (ROSE//) ROSEN C A.  
 PA (FISC//) FISCHER C L.  
 PA (SOPP//) SOPPET D R.  
 PA (CART//) CARTER K C.  
 PA (BEDN//) BEDNARIK D R.  
 PA (ENDR//) ENDRESS G A.  
 PA (YUGG//) YU G.  
 PA (NIJJ//) NI J.  
 PA (FENG//) FENG P.  
 PA (YOUN//) YOUNG P E.  
 PA (GREE//) GREENE J M.  
 PA (FERE//) FERRIE A M.  
 PA (DUAN//) DUAN R.  
 PA (HUJJ//) HU J.  
 PA (FLOR//) FLORENCE K A.  
 PA (OLSE//) OLSEN H S.  
 PA (EBNE//) EBNER R.  
 PA (BREW//) BREWER L A.  
 PA (SHIY//) SHI Y.  
 XX  
 PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;  
 PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;  
 PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;  
 PI Shi Y;  
 XX  
 DR WPI; 2003-466138/44.  
 DR N-PSDB; ACD08035.  
 XX  
 PT Novel isolated human secreted HODAZ50 polypeptide useful for diagnosing  
 PT or treating deficiencies or disorders of the immune system, autoimmune  
 PT disorders, hyperproliferative disorders, and infectious diseases.  
 XX  
 PS Claim 11; Page 177-178; 243pp; English.

XX The invention describes an isolated human secreted HODAZ50 polypeptide  
 CC (I) comprising a sequence at least 95% identical to a sequence selected  
 CC from polypeptide fragment of any one of the 123 polypeptide sequences  
 CC (PS) fully defined in the specification and having biological activity,  
 CC polypeptide domain or epitope of PS, secreted form of PS, full-length  
 CC protein of PS, or variant, allelic variant or species homologue of PS.  
 CC (I) or a polynucleotide (II) encoding (I) is useful for preventing,  
 CC treating, or ameliorating a medical condition in a mammalian subject. (I)  
 CC or (II) is also useful for diagnosing a pathological condition or a  
 CC susceptibility to a pathological condition in a subject. (I) is useful  
 CC for identifying a binding partner which involves contacting the  
 CC polypeptide with the binding partner and determining whether the binding  
 CC partner affects the activity of the polypeptide. (I) or (II) is useful  
 CC for diagnosing or treating deficiencies or disorders of the immune  
 CC system, deficiencies or disorders of haematopoietic cells, to treat  
 CC Wiskott-Aldrich disorders, ataxia telangiectasia, HIV infection,  
 CC immunologic deficiency disorders, thrombocytopenia or haemoglobinuria, blood  
 CC coagulation disorders, blood platelet disorders, autoimmune disorders  
 CC (e.g., Addison's disease, haemolytic anaemia, rheumatoid arthritis, blood  
 CC dermatitis, glomerulonephritis, Grave's disease), allergic reactions,  
 CC graft-versus-host disease, hyperproliferative disorders (e.g., neoplasms  
 CC located in the abdomen, bone, breast, digestive system, liver, pancreas,  
 CC peritoneum, endocrine glands), infectious diseases (e.g., viral,  
 CC bacterial, fungal or parasitic infection), central and peripheral nervous  
 CC system diseases (e.g., spinal cord disorders, head trauma or stroke), to  
 CC differentiate, proliferate and attract cells leading to the regeneration  
 CC of tissues to repair, replace or protect tissue damaged by congenital  
 CC defects, trauma (wounds, burns, incisions, or ulcers) age disease (e.g.,  
 CC osteoporosis, periodontal disease, liver failure) or surgery. (I) or (II)  
 CC is useful to modulate mammalian characteristics, to modulate mammalian  
 CC metabolism affecting catabolism, anabolism, processing, utilisation, and  
 CC storage of energy, to change a mammal's mental state or physical state,  
 CC or as a food additive or preservative, such as to increase or decrease  
 CC storage capabilities, fat content, lipid, protein, carbohydrate,  
 CC vitamins, minerals, cofactors or other nutritional components. This is  
 CC the amino acid sequence of a novel human secreted protein  
 XX  
 SQ Sequence 483 AA;

Query Match 77.6%; Score 2509.5; DB 6; Length 483;  
 Best Local Similarity 96.9%; Pred. No. 1.3e-224;  
 Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;  
 QY 135 MATGGGIRAMTSYGLAGLKEGLDVCVYITGASGTSWALANLYXDPWSQDLAAPT 194  
 Db 1 MATGGGIRAMTSYGLAGLKEGLDVCVYITGASGTSWALANLYXDPWSQDLAAPT 60  
 QY 195 ELLKTQVTKNKLGLVAPSOLORYQRLAERARLYGSCFTNLWALINEALLHDEPHDKL 254  
 Db 61 ELLKTQVTKNKLGLVAPSOLORYQRLAERARLYGSCFTNLWALINEALLHDEPHDKL 120  
 QY 255 SDQREALSHGQNPLPIYCALNTKGQSLITTFEGWCEFSPEYVGPKYGFISELPGSE 314  
 Db 121 SDQREALSHGQNPLPIYCALNTKGQSLITTFEGWCEFSPEYVGPKYGFISELPGSE 180  
 QY 315 FFMQMLKRLPESRICFLEGINLSNLYAANLQDSLWASEPSQFDRWVRNQANLDEQVP 374  
 Db 181 FFMQMLKRLPESRICFLEGINLSNLYAANLQDSLWASEPSQFDRWVRNQANLDEQVP 240  
 QY 375 LKIEPPPTAGRIAEFFDTLTWRPLAQATNIFLGLHFHKDYFOHPHFSTWKATLDG 434  
 Db 241 LKIEPPPTAGRIAEFFDTLTWRPLAQATNIFLGLHFHKDYFOHPHFSTWKATLDG 300  
 QY 435 LPNQLTPSPHPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAFQQLGRFCQ 494  
 Db 301 LPNQLTPSPHPHCLLDVGYLINTSCPLLPQTRDVLILSLDYNLHGAFQQLGRFCQ 360  
 QY 495 EGGIFPPPTSPSPBQLOPRECHTSDPTCPGAPAVLHF-----SSGVRTPPE 543  
 Db 361 EGGIFPPPTSPSPBQLOPRECHTSDPTCPGAPAVLHFPLVSDSPRESAFCVRTPPE 420  
 QY 544 AAAGEVNLSDDSPHYTKVTSQEDVDKLLHLYNNVCNQEQLLEALRQAVRRQR 603

Db	421	AAAGEVNLSSDSPHYTKYTSQEDVDKLLHLTHYVNCNQQLLEALRQAVRRQR	480
Qy	604	PH 605	
Db	481	PH 482	
RESULT 15			
ABO02008			
ID	ABO02008	standard; protein; 483 AA.	
AC	ABO02008;		
XX	12-AUG-2003	(first entry)	
XX	Novel human secreted protein #76.		
XX	Human; immunoglobulin G; IGG; fragment of crystallisation; Fc;		
KW	immune system disorder; haematopoietic cell disorder;		
KW	immunologic deficiency disorder; taxia telangiectasia; HIV infection;		
KW	Wiskott-Aldrich disorder; thrombocytopenia; haemoglobinuria;		
KW	blood coagulation disorder; blood platelet disorder; autoimmune disorder;		
KW	Adison's disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;		
KW	glomerulonephritis; Grave's disease; allergic reaction;		
KW	graft-versus-host disease; hyperproliferative disorder; neoplasm;		
KW	infectious disease; nervous system disease; spinal cord disorder;		
KW	head trauma; stroke; tissue regeneration; congenital defect; trauma;		
KW	wound; burn; incision; ulcer; age disease; osteoporosis;		
KW	periodontal disease; liver failure; catabolism; anabolism;		
KW	food additive; preservative; secreted protein.		
XX	Homo sapiens.		
XX	US2003027132-A1.		
XX	06-FEB-2003.		
XX	04-SEP-1998;	98US-00148545.	
XX	07-MAR-1997;	97US-0038621P.	
PR	07-MAR-1997;	97US-0040162P.	
PR	07-MAR-1997;	97US-0040163P.	
PR	07-MAR-1997;	97US-0040333P.	
PR	07-MAR-1997;	97US-0040334P.	
PR	07-MAR-1997;	97US-0040336P.	
PR	07-MAR-1997;	97US-0043311P.	
PR	11-APR-1997;	97US-0043312P.	
PR	11-APR-1997;	97US-0043313P.	
PR	11-APR-1997;	97US-0043314P.	
PR	11-APR-1997;	97US-0043315P.	
PR	11-APR-1997;	97US-0043568P.	
PR	11-APR-1997;	97US-0043569P.	
PR	11-APR-1997;	97US-0043576P.	
PR	11-APR-1997;	97US-0043578P.	
PR	11-APR-1997;	97US-0043580P.	
PR	11-APR-1997;	97US-0043665P.	
PR	11-APR-1997;	97US-0043670P.	
PR	11-APR-1997;	97US-0043671P.	
PR	11-APR-1997;	97US-0043672P.	
PR	11-APR-1997;	97US-0043674P.	
PR	23-MAY-1997;	97US-0047492P.	
PR	23-MAY-1997;	97US-0047500P.	
PR	23-MAY-1997;	97US-0047501P.	
PR	23-MAY-1997;	97US-0047502P.	
PR	23-MAY-1997;	97US-0047503P.	
PR	23-MAY-1997;	97US-0047581P.	
PR	23-MAY-1997;	97US-0047582P.	
PR	23-MAY-1997;	97US-0047583P.	
PR	23-MAY-1997;	97US-0047584P.	
PR	23-MAY-1997;	97US-0047585P.	
PR	23-MAY-1997;	97US-0047586P.	
PR	23-MAY-1997;	97US-0047587P.	
PR	23-MAY-1997;	97US-0047588P.	
PR	23-MAY-1997;	97US-0047589P.	
PR	23-MAY-1997;	97US-0047590P.	
PR	23-MAY-1997;	97US-0047591P.	
PR	23-MAY-1997;	97US-0047592P.	
PR	23-MAY-1997;	97US-0047593P.	
PR	23-MAY-1997;	97US-0047594P.	
PR	23-MAY-1997;	97US-0047595P.	
PR	23-MAY-1997;	97US-0047596P.	
PR	23-MAY-1997;	97US-0047597P.	
PR	23-MAY-1997;	97US-0047598P.	
PR	23-MAY-1997;	97US-0047599P.	
PR	23-MAY-1997;	97US-0047600P.	
PR	23-MAY-1997;	97US-0047601P.	
PR	23-MAY-1997;	97US-0047612P.	
PR	23-MAY-1997;	97US-0047613P.	
PR	23-MAY-1997;	97US-0047614P.	
PR	23-MAY-1997;	97US-0047615P.	
PR	23-MAY-1997;	97US-0047617P.	
PR	23-MAY-1997;	97US-0047618P.	
PR	23-MAY-1997;	97US-0047632P.	
PR	23-MAY-1997;	97US-0047633P.	
PR	06-JUN-1997;	97US-0048964P.	
PR	06-JUN-1997;	97US-0048974P.	
PR	22-AUG-1997;	97US-0056630P.	
PR	22-AUG-1997;	97US-0056631P.	
PR	22-AUG-1997;	97US-0056632P.	
PR	22-AUG-1997;	97US-0056636P.	
PR	22-AUG-1997;	97US-0056637P.	
PR	22-AUG-1997;	97US-0056652P.	
PR	22-AUG-1997;	97US-0056664P.	
PR	22-AUG-1997;	97US-0056845P.	
PR			

PA (GEE/) GREENE J M.  
PA (FERR/) FERRIE A M.  
PA (DUAN/) DUAN R.  
PA (HUJ/) HU J.  
PA (FLO/) FLORENCE K A.  
PA (OLSE/) OLSEN H S.  
PA (EBNE/) EBNER R.  
PA (BREW/) BREWER L A.  
PA (SHIY/) SHI Y.  
XX  
PI Ruben SM, Rosen CA, Fischer CL, Soppet DR, Carter KC;  
PI Bednarik DR, Endress GA, Yu G, Ni J, Feng P, Young PE, Greene JM;  
PI Ferrie AM, Duan R, Hu J, Florence KA, Olsen HS, Ebner R, Brewer LA;  
PI Shi Y;  
XX  
DR WPI; 2003-466138/44.  
DR N-PSDB; ACD08100.  
XX  
PT Novel isolated human secreted HODAZ50 polypeptide useful for diagnosing  
PT or treating deficiencies or disorders of the immune system, autoimmune  
PT disorders, hyperproliferative disorders, and infectious diseases.  
XX  
PS Claim 11; Page 210; 243pp; English.

CC The invention describes an isolated human secreted HODAZ50 polypeptide  
CC (I) comprising a sequence at least 95% identical to a sequence selected  
CC from polypeptide fragment of any one of the 123 polypeptide sequences  
CC (PS) fully defined in the specification and having biological activity,  
CC polypeptide domain or epitope of PS, secreted form of PS, full-length  
CC protein of PS, or variant, allelic variant or species homologue of PS.  
CC (II) or a polynucleotide (II) encoding (I) is useful for preventing,  
CC treating, or ameliorating a medical condition in a mammalian subject.  
CC or (II) is also useful for diagnosing a pathological condition or a  
CC susceptibility to a pathological condition in a subject. (I) is useful  
CC for identifying a binding partner which involves contacting the  
CC polypeptide with the binding partner and determining whether the binding  
CC partner affects the activity of the polypeptide. (I) or (II) is useful  
CC for diagnosing or treating deficiencies or disorders of the immune  
CC system, deficiencies or disorders of haematopoietic cells, to treat  
CC immunologic deficiency disorders, ataxia telangiectasia, HIV infection,  
CC Wiskott-Aldrich disorders, thrombocytopenia or haemoglobinuria, blood  
CC coagulation disorders, blood platelet disorders or autoimmune disorders  
CC (e.g., Addison's disease, haemolytic anaemia, rheumatoid arthritis,  
CC dermatitis, glomerulonephritis, Grave's disease), allergic reactions,  
CC graft-versus-host disease, hyperproliferative disorders (e.g., neoplasms  
CC located in the abdomen, bone, breast, digestive system, liver, pancreas,  
CC peritoneum, endocrine glands), infectious diseases (e.g., viral,  
CC bacterial, fungal or parasitic infection), central and peripheral nervous  
CC system diseases (e.g., spinal cord disorders, head trauma or stroke), to  
CC differentiate, proliferate and attract cells leading to the regeneration  
CC of tissues to repair, replace or protect tissue damaged by congenital  
CC defects, trauma (wounds, burns, incisions, or ulcers) age disease (e.g.,  
CC osteoporosis, periodontal disease, liver failure) or surgery. (I) or (II)  
CC is useful to modulate mammalian characteristics, to modulate mammalian  
CC metabolism affecting catabolism, anabolism, processing, utilisation, and  
CC storage of energy, to change a mammal's mental state or physical state,  
CC or as a food additive or preservative, such as to increase or decrease  
CC storage capabilities, fat content, lipid, protein, carbohydrate, or  
CC vitamins, minerals, cofactors or other nutritional components. This is  
CC the amino acid sequence of a novel human secreted protein

XX Sequence 483 AA;

Query Match 77.6%; Score 2509.5; DB 6; Length 483;  
Best Local Similarity 96.9%; Pred. No. 1.3e-224;  
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;  
QY 135 MATGGGTRAMTSYLGQLAGLKEGLLDVSYTGASGTSWALANLYDEPWSQKDLAGPT 194  
Db 1 MATGGGTRAMTSYLGQLAGLKEGLLDVSYTGASGTSWALANLYDEPWSQKDLAGPT 60  
QY 195 ELLKTQVTKNKLGVLPASQVRYQELAEARLGYPCFTNLWALINEALLHDEPHDKL 254  
|||||

Db 61 ELLKTQVTKNKLGVLPASQVRYQELAEARLGYPCFTNLWALINEALLHDEPHDKL 120  
QY 255 SDQREALSHGQNPPIYCALNTKGQSLTTTFEGEWCEFSYEVGFPKYGAFIPSELFGSE 314  
Db 121 SDQREALSHGQNPPIYCALNTKGQSLTTTFEGEWCEFSYEVGFPKYGAFIPSELFGSE 180  
QY 315 FFMGQLMKLPESRICFLEGIWSNLVAANLQDSLYWASEPSQFWDWRVNRQANLDEQVP 374  
Db 181 FFMGQLMKLPESRICFLEGIWSNLVAANLQDSLYWASEPSQFWDWRVNRQANLDEQVP 240  
QY 375 LKIEPPPTAGRIAEFFTDLLTWRLAQATHNFGHLHFKDYFOHPHFTWKATLDG 434  
Db 241 LKIEPPPTAGRIAEFFTDLLTWRLAQATHNFGHLHFKDYFOHPHFTWKATLDG 300  
QY 435 LPNQLTPSEPHCLLDVGYLINTSCIPLLQPTRDVLILSLDYNLHGAFOQLQLGRFCQ 494  
Db 301 LPNQLTPSEPHCLLDVGYLINTSCIPLLQPTRDVLILSLDYNLHGAFOQLQLGRFCQ 360  
QY 495 EOGIEPPPTISPSPELOQPRECHTSDPTCPGAPAVLHP-----SSGVRTPEE 543  
Db 361 EOGIEPPPTISPSPELOQPRECHTSDPTCPGAPAVLHP-----SSGVRTPEE 420  
QY 544 AAAGEVNLSSSDSPVHYTKVTSQEDVDKLLHLTHYVNCNNOELLEALRQAVRRQR 603  
Db 421 AAAGEVNLSSSDSPVHYTKVTSQEDVDKLLHLTHYVNCNNOELLEALRQAVRRQR 480  
QY 604 PH 605  
Db 481 PH 482

Search completed: October 5, 2004, 19:21:35  
Job time : 144.747 secs

**This Page Blank (uspto)**

Result No.	Score	Query Match	Length	DB	ID	SUMMARIES	
						Description	
1	2767.5	85.5	778	3	US-09-460-145-2	Sequence 2, Appl	
2	2767.5	85.5	778	4	US-09-895-547-2	Sequence 2, Appl	
3	2767.5	85.5	797	3	US-09-460-145-4	Sequence 4, Appl	
4	2767.5	85.5	797	4	US-09-895-547-4	Sequence 4, Appl	
5	2767.5	85.5	913	3	US-08-827-208-3	Sequence 3, Appl	
6	2767.5	85.5	913	3	US-09-500-358-3	Sequence 3, Appl	
7	2767.5	85.5	913	3	US-09-498-809-3	Sequence 3, Appl	
8	2509.5	77.6	483	4	US-09-148-545-144	Sequence 144, Appl	
9	2509.5	77.6	483	4	US-09-148-545-209	Sequence 209, Appl	
10	619	19.1	749	1	US-08-046-508-2	Sequence 2, Appl	
11	498.5	15.4	541	3	US-09-045-185-2	Sequence 2, Appl	
12	490.5	15.2	541	3	US-08-890-615-2	Sequence 2, Appl	
13	490.5	15.2	541	4	US-09-246-290A-2	Sequence 2, Appl	
14	208	6.4	638	4	US-09-687-538B-4	Sequence 4, Appl	
15	208	6.4	654	4	US-09-437-687A-2	Sequence 2, Appl	
16	208	6.4	654	4	US-10-263-250-2	Sequence 2, Appl	
17	203.5	6.3	90	4	US-09-621-976-4397	Sequence 2, Appl	
18	200.5	6.2	640	4	US-09-687-538B-2	Sequence 4397, A	
19	200	6.2	87	4	US-09-205-258-342	Sequence 2, Appl	
20	198.5	6.1	66	4	US-09-621-976-5606	Sequence 342, Appl	
21	195.5	6.0	552	3	US-09-295-186-10	Sequence 5606, A	
22	195.5	6.0	573	3	US-09-295-186-11	Sequence 10, Appl	
23	193	6.0	397	5	FCT-US95-47111A-121	Sequence 11, Appl	
24	189	5.8	117	4	US-09-621-976-4623	Sequence 121, Appl	
25	188	5.8	627	4	US-09-687-538B-6	Sequence 4623, A	
26	186.5	5.8	648	4	US-09-437-687A-16	Sequence 6, Appl	
27	186.5	5.8	648	4	US-10-263-250-16	Sequence 16, Appl	

```

184 TGTFRHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGQVVR 225
84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 123
226 LVFPTSQEPMLMRVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 285
124 LQDEIPIVVAIMATGGGIRAMTSLYGQLAGLKEGLDCCVSYITGASGSTWALANLYEDP 183
286 LQDEIPIVVAIMATGGGIRAMTSLYGQLAGLKEGLDCCVSYITGASGSTWALANLYEDP 345
184 EWSQKDLAGTELLKTQVTKNKLGVLAQPSQIQRYRQELAEARLGYPCFTNLWALINEA 243
346 EWSQKDLAGTELLKTQVTKNKLGVLAQPSQIQRYRQELAEARLGYPCFTNLWALINEA 405
244 LLHDEPHDKLSQREALSQGNPLPIYCALNTKGOSLTTFEGCEWCFEFSYEVGFPKYG 303
406 LLHDEPHDKLSQREALSQGNPLPIYCALNTKGOSLTTFEGCEWCFEFSYEVGFPKYG 465
304 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 363
466 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 525
364 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPAQATHNPLRGLHFKDYFQHPH 423
526 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPAQATHNPLRGLHFKDYFQHPH 585
424 FSTWKATTLGIPNQLTSEPHCLLDVGYLINTSCPLLOTPRDVDLILSLDYNLHGAF 483
586 FSTWKATTLGIPNQLTSEPHCLLDVGYLINTSCPLLOTPRDVDLILSLDYNLHGAF 645
484 QQLQLGRFCOEQGIPIPPPIPSPEEQLOPRECHTFSPTCPGAPAVLHF-----533
646 QQLQLGRFCOEQGIPIPPPIPSPEEQLOPRECHTFSPTCPGAPAVLHFPLVSDSFREY 705
534 -SSGVRRTPEAAAGEVNLSSSDSPYHTKVITYSDQEDVDKLLHLYHNVNVCNQEQLLEAL 592
706 SAPGVRRTPEAAAGEVNLSSSDSPYHTKVITYSDQEDVDKLLHLYHNVNVCNQEQLLEAL 765
593 RQAVORRRQRPH 605
766 RQAVORRRQRPH 778

```

RESULT 2

```

US-09-895-547-2
; Sequence 2, Application US/09895547
; Patent No. 6482625
; GENERAL INFORMATION:
; APPLICANT: Kriz, Ron
; Song, Chuangzheng
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/895,547
; FILING DATE: 29-Jun-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/460,145
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.

```

```

; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15289
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 778 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-895-547-2

```

```

Query Match      85.5%; Score 2767.5; DB 4; Length 778;
Best Local Similarity 87.6%; Pred. No. 2.1e-268;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLECPAPCPFFFFEMESLSVAQAGVQWMDLGSLOPPPLGFKRFSCLSLSSWDYR 83
DB 184 TGTFRHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGQVVR 225
QY 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 123
DB 226 LVFPTSQEPMLMRVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 285
QY 124 LQDEIPIVVAIMATGGGIRAMTSLYGQLAGLKEGLDCCVSYITGASGSTWALANLYEDP 183
DB 286 LQDEIPIVVAIMATGGGIRAMTSLYGQLAGLKEGLDCCVSYITGASGSTWALANLYEDP 345
QY 184 EWSQKDLAGTELLKTQVTKNKLGVLAQPSQIQRYRQELAEARLGYPCFTNLWALINEA 243
DB 346 EWSQKDLAGTELLKTQVTKNKLGVLAQPSQIQRYRQELAEARLGYPCFTNLWALINEA 405
QY 244 LLHDEPHDKLSQREALSQGNPLPIYCALNTKGOSLTTFEGCEWCFEFSYEVGFPKYG 303
DB 406 LLHDEPHDKLSQREALSQGNPLPIYCALNTKGOSLTTFEGCEWCFEFSYEVGFPKYG 465
QY 304 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 363
DB 466 AFIPSELFSGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 525
QY 364 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPAQATHNPLRGLHFKDYFQHPH 423
DB 526 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPAQATHNPLRGLHFKDYFQHPH 585
QY 424 FSTWKATTLGIPNQLTSEPHCLLDVGYLINTSCPLLOTPRDVDLILSLDYNLHGAF 483
DB 586 FSTWKATTLGIPNQLTSEPHCLLDVGYLINTSCPLLOTPRDVDLILSLDYNLHGAF 645
QY 484 QQLQLGRFCOEQGIPIPPPIPSPEEQLOPRECHTFSPTCPGAPAVLHF-----533
DB 646 QQLQLGRFCOEQGIPIPPPIPSPEEQLOPRECHTFSPTCPGAPAVLHFPLVSDSFREY 705
QY 534 -SSGVRRTPEAAAGEVNLSSSDSPYHTKVITYSDQEDVDKLLHLYHNVNVCNQEQLLEAL 592
DB 706 SAPGVRRTPEAAAGEVNLSSSDSPYHTKVITYSDQEDVDKLLHLYHNVNVCNQEQLLEAL 765
QY 593 RQAVORRRQRPH 605
DB 766 RQAVORRRQRPH 778

```

RESULT 3

```

US-09-460-145-4
; Sequence 4, Application US/09460145
; Patent No. 6287838
; GENERAL INFORMATION:
; APPLICANT: Kriz, Ron
; Song, Chuangzheng
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES
; NUMBER OF SEQUENCES: 9

```



;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Genetics Institute, Inc.  
;; STREET: 87 CambridgePark Drive  
;; CITY: Cambridge  
;; STATE: MA  
;; COUNTRY: USA  
;; ZIP: 02140  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; FILING DATE: US/09/460,145  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/788,975  
;; FILING DATE:  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brown, Scott A.  
;; REGISTRATION NUMBER: 32,724  
;; REFERENCE/DOCKET NUMBER: G15289  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 498-8224  
;; TELEFAX: (617) 876-5851  
;; INFORMATION FOR SEQ ID NO: 4:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 797 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS:  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;;  
;; US-09-460-145-4

Query Match 85.5%; Score 2767.5; DB 3; Length 797;  
Best Local Similarity 87.6%; Pred. No. 2.2e-268;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLCFPCAPCPFFFFEMESLSVAQAGVQWRDLGSLQRPPLGFKRPSCLSLPSSWDYR 83  
DB 203 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGGQVVR 244

QY 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 123  
DB 245 LVFPTSQEPMLRMVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 304

QY 124 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 183  
DB 305 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 364

QY 184 EWSQKDLAGPTELLKTQVTKNKGVLAPSOLQRYQELAEARLGYPSCTNLWALINEA 243

Query Match 85.5%; Score 2767.5; DB 4; Length 797;  
Best Local Similarity 87.6%; Pred. No. 2.2e-268;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLCFPCAPCPFFFFEMESLSVAQAGVQWRDLGSLQRPPLGFKRPSCLSLPSSWDYR 83  
DB 203 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGGQVVR 244

QY 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 123  
DB 245 LVFPTSQEPMLRMVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 304

QY 124 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 183  
DB 305 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 364

QY 184 EWSQKDLAGPTELLKTQVTKNKGVLAPSOLQRYQELAEARLGYPSCTNLWALINEA 243

;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Genetics Institute, Inc.  
;; STREET: 87 CambridgePark Drive  
;; CITY: Cambridge  
;; STATE: MA  
;; COUNTRY: USA  
;; ZIP: 02140  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; FILING DATE: US/09/460,145  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/788,975  
;; FILING DATE:  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brown, Scott A.  
;; REGISTRATION NUMBER: 32,724  
;; REFERENCE/DOCKET NUMBER: G15289  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 498-8224  
;; TELEFAX: (617) 876-5851  
;; INFORMATION FOR SEQ ID NO: 4:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 797 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS:  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;;  
;; US-09-460-145-4

Query Match 85.5%; Score 2767.5; DB 3; Length 797;  
Best Local Similarity 87.6%; Pred. No. 2.2e-268;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLCFPCAPCPFFFFEMESLSVAQAGVQWRDLGSLQRPPLGFKRPSCLSLPSSWDYR 83  
DB 203 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGGQVVR 244

QY 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 123  
DB 245 LVFPTSQEPMLRMVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 304

QY 124 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 183  
DB 305 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 364

QY 184 EWSQKDLAGPTELLKTQVTKNKGVLAPSOLQRYQELAEARLGYPSCTNLWALINEA 243

;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Genetics Institute, Inc.  
;; STREET: 87 CambridgePark Drive  
;; CITY: Cambridge  
;; STATE: MA  
;; COUNTRY: USA  
;; ZIP: 02140  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; FILING DATE: US/09/460,145  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/788,975  
;; FILING DATE:  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Brown, Scott A.  
;; REGISTRATION NUMBER: 32,724  
;; REFERENCE/DOCKET NUMBER: G15289  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 498-8224  
;; TELEFAX: (617) 876-5851  
;; INFORMATION FOR SEQ ID NO: 4:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 797 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS:  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
;;  
;; US-09-460-145-4

Query Match 85.5%; Score 2767.5; DB 4; Length 797;  
Best Local Similarity 87.6%; Pred. No. 2.2e-268;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLCFPCAPCPFFFFEMESLSVAQAGVQWRDLGSLQRPPLGFKRPSCLSLPSSWDYR 83  
DB 203 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALPSGGQVVR 244

QY 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 123  
DB 245 LVFPTSQEPMLRMVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 304

QY 124 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 183  
DB 305 LQDEIIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDCVSYITGASGTWALANLYEDP 364

QY 184 EWSQKDLAGPTELLKTQVTKNKGVLAPSOLQRYQELAEARLGYPSCTNLWALINEA 243

```

Db 365 EWQKOLAGTELLKTQVTKNKLGLVAPSQLQRYRQELAEARLGYSCFTNLWALINEA 424
QY 244 LLHDEPHDKLSQREALSHGQNPPLIYCALNTKGOSLITTFEGCEWCEFSYEVGFPKYG 303
Db 425 LLHDEPHDKLSQREALSHGQNPPLIYCALNTKGOSLITTFEGCEWCEFSYEVGFPKYG 484
QY 304 AFIPSELFSGEFGFMQMLKRLPESRICFLEGIWNLVAANLQDSLYWASESPQFWDWRVR 363
Db 485 AFIPSELFSGEFGFMQMLKRLPESRICFLEGIWNLVAANLQDSLYWASESPQFWDWRVR 544
QY 364 NOANLDEQVPLLKIEEPPSTAGRIAEFFDTLLTWRLPAQATHNPLRGLHFKDYFQHPH 423
Db 545 NOANLDEQVPLLKIEEPPSTAGRIAEFFDTLLTWRLPAQATHNPLRGLHFKDYFQHPH 604
QY 424 FSTWKATLDGLNQLPSEPHCLLDVGYLINTSCPLPQTPTRDVLILSLDYNLHGAF 483
Db 605 FSTWKATLDGLNQLPSEPHCLLDVGYLINTSCPLPQTPTRDVLILSLDYNLHGAF 664
QY 484 QOLQLGRFCOEQIGIPPPISPSPEEQLOPRECHTFSDPTCPGAPAVLHF----- 533
Db 665 QOLQLGRFCOEQIGIPPPISPSPEEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSPREY 724
QY 534 -SSGVRRTPEAAAGEVNLSSDSPYHYTKVYTSQEDVDKLLHLTHYVNCNNQOLLEAL 592
Db 725 SAPGVRRTPEAAAGEVNLSSDSPYHYTKVYTSQEDVDKLLHLTHYVNCNNQOLLEAL 784
QY 593 ROAVORRRQRPH 605
Db 785 ROAVORRRQRPH 797

```

RESULT 5

```

US-08-827-208-3
; Sequence 3, Application US/08827208
; Patent No. 6025178
; GENERAL INFORMATION:
; APPLICANT: Chiou, Xue-Chiou C.
; APPLICANT: Kramer, Ruth M.
; APPLICANT: Pickard, Richard T.
; APPLICANT: Sharp, John D.
; APPLICANT: Strifler, Beth A.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: United States of America
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/827,208
; FILING DATE: 28-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/014,608
; FILING DATE: 29-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/041,264
; FILING DATE: 19-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaylo, Paul J.
; REGISTRATION NUMBER: 36,808
; REFERENCE/DOCKET NUMBER: X-10610
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 276-0756

```

```

; TELEFAX: (317) 276-3861
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 913 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-827-208-3

Query Match      85.5%; Score 2767.5; DB 3; Length 913;
Best Local Similarity 87.6%; Pred. No. 2.7e-268;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLIVLFCPCAPCPFFFEFEMESLSVAQAGVQWRDLGSLQPPPLGFKFSCLSFSSWDYR 83
Db 319 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEQLKAPLSALFSGQVVR 360
QY 84 -----LRLAVLRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 123
Db 361 LVFPTSQEPMLMRVELKEAGLRLAVLRLGFGPCAEQAFLSRRKQVVAALRQALQDGD 420
QY 124 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLLDCVSIITGASGTWALANLYEDP 183
Db 421 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLLDCVSIITGASGTWALANLYEDP 480
QY 184 EWSQKDLAGTELLKTQVTKNKLGLVAPSQLQRYRQELAEARLGYSCFTNLWALINEA 243
Db 481 EWSQKDLAGTELLKTQVTKNKLGLVAPSQLQRYRQELAEARLGYSCFTNLWALINEA 540
QY 244 LLHDEPHDKLSQREALSHGQNPPLIYCALNTKGOSLITTFEGCEWCEFSYEVGFPKYG 303
Db 541 LLHDEPHDKLSQREALSHGQNPPLIYCALNTKGOSLITTFEGCEWCEFSYEVGFPKYG 600
QY 304 AFIPSELFSGEFGFMQMLKRLPESRICFLEGIWNLVAANLQDSLYWASESPQFWDWRVR 363
Db 601 AFIPSELFSGEFGFMQMLKRLPESRICFLEGIWNLVAANLQDSLYWASESPQFWDWRVR 660
QY 364 NOANLDEQVPLLKIEEPPSTAGRIAEFFDTLLTWRLPAQATHNPLRGLHFKDYFQHPH 423
Db 661 NOANLDEQVPLLKIEEPPSTAGRIAEFFDTLLTWRLPAQATHNPLRGLHFKDYFQHPH 720
QY 424 FSTWKATLDGLNQLPSEPHCLLDVGYLINTSCPLPQTPTRDVLILSLDYNLHGAF 483
Db 721 FSTWKATLDGLNQLPSEPHCLLDVGYLINTSCPLPQTPTRDVLILSLDYNLHGAF 780
QY 484 QOLQLGRFCOEQIGIPPPISPSPEEQLOPRECHTFSDPTCPGAPAVLHF----- 533
Db 781 QOLQLGRFCOEQIGIPPPISPSPEEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSPREY 840
QY 534 -SSGVRRTPEAAAGEVNLSSDSPYHYTKVYTSQEDVDKLLHLTHYVNCNNQOLLEAL 592
Db 841 SAPGVRRTPEAAAGEVNLSSDSPYHYTKVYTSQEDVDKLLHLTHYVNCNNQOLLEAL 900
QY 593 ROAVORRRQRPH 605
Db 901 ROAVORRRQRPH 913

```

RESULT 6

```

US-09-500-358-3
; Sequence 3, Application US/09500358
; Patent No. 6197569
; GENERAL INFORMATION:
; APPLICANT: Chiou, Xue-Chiou C.
; APPLICANT: Kramer, Ruth M.
; APPLICANT: Pickard, Richard T.
; APPLICANT: Sharp, John D.
; APPLICANT: Strifler, Beth A.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company

```

```
STREET: Lilly Corporate Center
CITY: Indianapolis
STATE: Indiana
COUNTRY: United States of America
ZIP: 46285
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/500,358
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/827,208
FILING DATE: 28-MAR-1997
APPLICATION NUMBER: US 60/014,608
FILING DATE: 29-MAR-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/041,264
FILING DATE: 19-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Gaylo, Paul J.
REGISTRATION NUMBER: 36,808
REFERENCE/DOCKET NUMBER: X-10610
TELECOMMUNICATION INFORMATION:
TELEPHONE: (317) 276-0756
TELEFAX: (317) 276-3861
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 913 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-500-358-3

Query Match 85.5%; Score 2767.5; DB 3; Length 913;
Best Local Similarity 87.6%; Pred. No. 2.7e-268;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

Qy 24 TGLLVLCFPCPFFPFEMESLSVAQAGVQWRDLSLQPPPLGFKRFSCLSLPSSWDYR 83
Db 319 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGQVVR 360
Qy 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 420
Db 361 LVFPTSQEPLMRVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 420
Qy 124 LOEDEIPVWATMATTGGIRAMTSYGLAGLKEGLLDCVSYITGASGSTWALANLYEDP 183
Db 421 LOEDEIPVWATMATTGGIRAMTSYGLAGLKEGLLDCVSYITGASGSTWALANLYEDP 480
Qy 184 EWSQKDLAGTELLKTVTKNKLGLVAPLSQQRQELAEARLGYPCFTNLWALINEA 243
Db 481 EWSQKDLAGTELLKTVTKNKLGLVAPLSQQRQELAEARLGYPCFTNLWALINEA 540
Qy 244 LLHDEPHDKLSDQREALSHGQNPPIYCALNTKQSLTTFEFGWCBSFSPYEVGFPKYG 303
Db 541 LLHDEPHDKLSDQREALSHGQNPPIYCALNTKQSLTTFEFGWCBSFSPYEVGFPKYG 600
Qy 304 AFIPSELPSEFFFMQMKRLPESRICFTEGLWSNLYAANLODSIYMASSEPSQFWDWVR 363
Db 601 AFIPSELPSEFFFMQMKRLPESRICFTEGLWSNLYAANLODSIYMASSEPSQFWDWVR 660
Qy 364 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPQAQTHNPLRGLHFHKDYFOHPH 423
Db 661 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPQAQTHNPLRGLHFHKDYFOHPH 720
Qy 424 FSTWKATTLGDLNPLTSPBPHCLLDVGYLINTSCLPLQPTRDVLILSLDYNLHGAF 483
Db 721 FSTWKATTLGDLNPLTSPBPHCLLDVGYLINTSCLPLQPTRDVLILSLDYNLHGAF 780

104 QY 484 QQLQLGRFCOEQIGIPPPISPSPPEEQLOPRECHTFSDPTCPGAPVHLHF----- 533
105 DB 781 QQLQLGRFCOEQIGIPPPISPSPPEEQLOPRECHTFSDPTCPGAPVHLHFPLVSDSPREY 840
106 QY 534 -SSGVRRTPEAAAGEVNLSSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNQQLLEAL 592
107 DB 841 SAPGVRRTPEAAAGEVNLSSSDSPYHYTKVTSQEDVDKLLHLTHYVNCNNQQLLEAL 900
108 QY 593 RQAVQRRRRRPH 605
109 DB 901 RQAVQRRRRRPH 913

RESULT 7
US-09-498-809-3
; Sequence 3, Application US/09498809
; Patent No. 6242206
; GENERAL INFORMATION:
; APPLICANT: Chiou, Xue-Chiou C.
; APPLICANT: Kramer, Ruth M.
; APPLICANT: Pickard, Richard T.
; APPLICANT: Sharp, John D.
; APPLICANT: Strifler, Beth A.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED
; NUCLEIC ACID COMPOUNDS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: United States of America
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/09/498,809
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/827,208
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/041,264
; FILING DATE: 19-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaylo, Paul J.
; REGISTRATION NUMBER: 36,808
; REFERENCE/DOCKET NUMBER: X-10610
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 276-0756
; TELEFAX: (317) 276-3861
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 913 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-498-809-3

Query Match 85.5%; Score 2767.5; DB 3; Length 913;
Best Local Similarity 87.6%; Pred. No. 2.7e-268;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

Qy 24 TGLLVLCFPCPFFPFEMESLSVAQAGVQWRDLSLQPPPLGFKRFSCLSLPSSWDYR 83
Db 319 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGQVVR 360
Qy 84 -----LRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 420
Db 361 LVFPTSQEPLMRVELKKEAGLRELAVRLGFGPCAEQAFLSRRKQVVAALRQALQLDGD 420
Qy 124 LOEDEIPVWATMATTGGIRAMTSYGLAGLKEGLLDCVSYITGASGSTWALANLYEDP 183
Db 421 LOEDEIPVWATMATTGGIRAMTSYGLAGLKEGLLDCVSYITGASGSTWALANLYEDP 480
Qy 184 EWSQKDLAGTELLKTVTKNKLGLVAPLSQQRQELAEARLGYPCFTNLWALINEA 243
Db 481 EWSQKDLAGTELLKTVTKNKLGLVAPLSQQRQELAEARLGYPCFTNLWALINEA 540
Qy 244 LLHDEPHDKLSDQREALSHGQNPPIYCALNTKQSLTTFEFGWCBSFSPYEVGFPKYG 303
Db 541 LLHDEPHDKLSDQREALSHGQNPPIYCALNTKQSLTTFEFGWCBSFSPYEVGFPKYG 600
Qy 304 AFIPSELPSEFFFMQMKRLPESRICFTEGLWSNLYAANLODSIYMASSEPSQFWDWVR 363
Db 601 AFIPSELPSEFFFMQMKRLPESRICFTEGLWSNLYAANLODSIYMASSEPSQFWDWVR 660
Qy 364 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPQAQTHNPLRGLHFHKDYFOHPH 423
Db 661 NQANLDKEQVPLLKIEEPPSTAGRIAEFFTDLLTWRLPQAQTHNPLRGLHFHKDYFOHPH 720
Qy 424 FSTWKATTLGDLNPLTSPBPHCLLDVGYLINTSCLPLQPTRDVLILSLDYNLHGAF 483
Db 721 FSTWKATTLGDLNPLTSPBPHCLLDVGYLINTSCLPLQPTRDVLILSLDYNLHGAF 780
```

```

Db 361 LVFTSDEPLMRVELKKEAGIREIAVRLGRGPCABEQAFISRRKQVVAALRQALQDGD 420
QY 124 LQDEIPVVAIMATGGIRAMTSYLGQAGKELGLLDCVSYITGASGSTWALANLYEDP 183
Db 421 LQDEIPVVAIMATGGIRAMTSYLGQAGKELGLLDCVSYITGASGSTWALANLYEDP 480
QY 184 EWSQDLAGTELLKTQVTKNKLGVLAAPSQIQRYRQELARARLGYPSCTNMLWALINEA 243
Db 481 EWSQDLAGTELLKTQVTKNKLGVLAAPSQIQRYRQELARARLGYPSCTNMLWALINEA 540
QY 244 LLHDEPHDKLSDOREALSHGONPLPYCALNTKGSITTFEGEMWCEFSYEVGFPKYG 303
Db 541 LLHDEPHDKLSDOREALSHGONPLPYCALNTKGSITTFEGEMWCEFSYEVGFPKYG 600
QY 304 AFIPSEFGSEFFMGQMLKRLPESRICFLEGIWNLNLYAANLQDSLYWASEPSQFWRWVR 363
Db 601 AFIPSEFGSEFFMGQMLKRLPESRICFLEGIWNLNLYAANLQDSLYWASEPSQFWRWVR 660
QY 364 NOANLDEQVPLKIEBPPSTAGRIABFFTDLLTWRLPQAQTHNPLRGLHFKDYFOHPH 423
Db 661 NOANLDEQVPLKIEBPPSTAGRIABFFTDLLTWRLPQAQTHNPLRGLHFKDYFOHPH 720
QY 424 FSTWKATTLQGLNQLPSPHCLLDVGYLINTSCLPLLOPTRDVDLILSLDYNLHGAF 483
Db 721 FSTWKATTLQGLNQLPSPHCLLDVGYLINTSCLPLLOPTRDVDLILSLDYNLHGAF 780
QY 484 QQLQLGRFCQEQIGIPPPISPSPEEQIQPRECHTFSDPTCPGAPAVLHF----- 533
Db 781 QQLQLGRFCQEQIGIPPPISPSPEEQIQPRECHTFSDPTCPGAPAVLHFPLVSDSPREY 840
QY 534 -SSGVRTPTEAAAGEVNLSSDSPPYHYTKVTSQEDVDKLLHLTHNVNVCNNQQLLEAL 592
Db 841 SAPGVRTPTEAAAGEVNLSSDSPPYHYTKVTSQEDVDKLLHLTHNVNVCNNQQLLEAL 900
QY 593 ROAVORRRORRPH 605
Db 901 ROAVORRRORRPH 913

RESULT 8
US-09-148-545-144
; Sequence 144, Application US/09148545
; Patent No. 6590075
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: P2001p1
; CURRENT APPLICATION NUMBER: US/09/148,545
; CURRENT FILING DATE: 1998-09-04
; EARLIER APPLICATION NUMBER: PCT/US98/04482
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,161
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/047,615
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,600
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,597
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,592
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,502
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,633
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,583
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,617
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,618
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,503
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,592
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,581
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,584
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,500
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,587
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,492
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,598
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,613
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,582
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,596
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,612
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,632
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,601
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,580
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,568
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,314
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,569
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,311
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,671
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,674
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,669
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,312
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,313
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,672
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,315
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/048,974
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/056,886
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,877
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,889
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,893
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,630

```

```
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,878
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,662
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,872
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,882
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,637
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,903
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,888
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,879
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,880
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,894
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,911
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,636
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,874
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,910
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,864
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,631
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,845
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,892
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/047,595
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/057,761
; EARLIER FILING DATE: 05-Sep-1997
; EARLIER APPLICATION NUMBER: 60/047,599
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,588
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,585
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,586
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22

; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,880
; EARLIER FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 144
; LENGTH: 483

Query Match          77.6%; Score 2509.5; DB 4; Length 483;
Best Local Similarity 96.9%; Pred. No. 7.3e-243;
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;

QY 135 MATGGIRAMTSLYGQAGLKEGLDLCVSYITGASGSTWALANLYEDPWSQKDLAGPT 194
DB 1 MATGGIRAMTSLYGQAGLKEGLDLCVSYITGASGSTWALANLYEDPWSQKDLAGPT 60
QY 195 ELTKTQVTNKLGVLAAPSQLOQRYROELABRARLGYPCSTNLWALINEALLHDEPHDKL 254
DB 61 ELTKTQVTNKLGVLAAPSQLOQRYROELABRARLGYPCSTNLWALINEALLHDEPHDKL 120
QY 255 SDREALSHGQNPPIYCALNTKGSLTTFEGWCEFGSPYEVGPKYGAFIPSELPFGE 314
DB 121 SDREALSHGQNPPIYCALNTKGSLTTFEGWCEFGSPYEVGPKYGAFIPSELPFGE 180
QY 315 FFWGQMLMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVNRQANLDKEQVP 374
DB 181 FFWGQMLMKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVNRQANLDKEQVP 240
QY 375 LKIEEPPSTAGRIAEFFTDLLTWRPLAQATHNPLRGLHFKDYFOHPHSTWKATTLDG 434
DB 241 LKIEEPPSTAGRIAEFFTDLLTWRPLAQATHNPLRGLHFKDYFOHPHSTWKATTLDG 300
QY 435 LPNLTSEPHCLLDVGYLINTSCLPLLOPTRDVLTLSDYNLHGAFQQLLGRFCQ 494
DB 301 LPNLTSEPHCLLDVGYLINTSCLPLLOPTRDVLTLSDYNLHGAFQQLLGRFCQ 360
QY 495 EQGIPFPPIGPSPEEQLPRECHTFSDPTCPGAPAVLHF-----SSGVRRTPEE 543
DB 361 EQGIPFPPIGPSPEEQLPRECHTFSDPTCPGAPAVLHFPLVSDSFREYSAPGVRRTPEE 420
QY 544 AAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLYNNVNNQOEQLLEALRAQVQRORR 603
DB 421 AAAGEVNLSSSDSPHYTKVTSQEDVDKLLHLYNNVNNQOEQLLEALRAQVQRORR 480
QY 604 PH 605
DB 481 PH 482

RESULT 9
US-09-148-545-209
; Sequence 209, Application US/09148545
; Patent No. 6590075
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: PZ001PI
; CURRENT APPLICATION NUMBER: US/09/148,545
```

;	EARLIER	APPLICATION	NUMBER:	60/043,671
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,674
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,669
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,312
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,313
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,672
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/043,315
;	EARLIER	FILING	DATE:	1997-04-11
;	EARLIER	APPLICATION	NUMBER:	60/048,974
;	EARLIER	FILING	DATE:	1997-06-06
;	EARLIER	APPLICATION	NUMBER:	60/056,886
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,877
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,889
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,893
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,630
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,878
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,662
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,872
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,882
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,637
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,903
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,888
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,879
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,880
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,894
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,911
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,636
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,874
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,910
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,864
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,631
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,845
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/056,892
;	EARLIER	FILING	DATE:	1997-08-22
;	EARLIER	APPLICATION	NUMBER:	60/047,595
;	EARLIER	FILING	DATE:	1997-05-23
;	EARLIER	APPLICATION	NUMBER:	60/057,761
;	EARLIER	FILING	DATE:	05-Sep-1997
;	EARLIER	APPLICATION	NUMBER:	60/047,599
;	EARLIER	FILING	DATE:	1997-05-23
;	EARLIER	APPLICATION	NUMBER:	60/047,598
;	EARLIER	FILING	DATE:	1997-05-23
;	EARLIER	APPLICATION	NUMBER:	60/047,585
;	EARLIER	FILING	DATE:	1997-05-23
;	EARLIER	APPLICATION	NUMBER:	60/047,586

```

; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,590
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,594
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 209
; LENGTH: 483

Query Match
Best Local Similarity 77.6%; Score 2509.5; DB 4; Length 483;
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;

QY 135 MATGGIRAMTSLYGQAGLKGELGLDVCYSYITGASGSTWALANLYDEPWSQKLAGPT 194
DB 1 MATGGIRAMTSLYGQAGLKGELGLDVCYSYITGASGSTWALANLYDEPWSQKLAGPT 60

QY 195 ELKTKQVTKNKGVLAPSOLQRYQRLAERARLGYPSCFTNLWALINEALLHDEPHDKL 254
DB 61 ELKTKQVTKNKGVLAPSOLQRYQRLAERARLGYPSCFTNLWALINEALLHDEPHDKL 120

QY 255 SQREALS HQNPLPIYCAINTKGQSLTTFEGWCEFPSEYEGFPKYGAFIPSELFQSE 314
DB 121 SQREALS HQNPLPIYCAINTKGQSLTTFEGWCEFPSEYEGFPKYGAFIPSELFQSE 180

QY 315 FPMQMLKLPESRICFLREGIWSNLYAANLQDSLYWASEPQFWRWVRNQANLKEQVP 374
DB 181 FPMQMLKLPESRICFLREGIWSNLYAANLQDSLYWASEPQFWRWVRNQANLKEQVP 240

QY 375 LKIEEPPSTAGRIAEFFTDLLTWRLAQATNFLRGLHFKDYFOHPHFTWKATLLDG 434
DB 241 LKIEEPPSTAGRIAEFFTDLLTWRLAQATNFLRGLHFKDYFOHPHFTWKATLLDG 300

QY 435 LPNQITPSPHCLLDVGYLINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLLGRFCQ 494

```

```

DB 301 LPNQITPSPHCLLDVGYLINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLLGRFCQ 360
QY 495 EQGIPTPSPHCLLDVGYLINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLLGRFCQ 543
DB 361 EQGIPTPSPHCLLDVGYLINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLLGRFCQ 420
QY 544 AAAGEVNLSSSDSPHYHTKVYTSQEDVDKLLHLTHYVNCNQEOLLEALRQAVORRQR 603
DB 421 AAAGEVNLSSSDSPHYHTKVYTSQEDVDKLLHLTHYVNCNQEOLLEALRQAVORRQR 480
QY 604 PH 605
DB 481 PH 482

RESULT 10
US-08-046-508-2
; Sequence 2, Application US/08046508
; Patent No. 5328842
; GENERAL INFORMATION:
; APPLICANT: Chou et al.
; TITLE OF INVENTION: COMPOUNDS, VECTORS AND METHODS FOR
; TITLE OF INVENTION: EXPRESSING HUMAN CYTOSOLIC PHOSPHOLIPASE A2
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patent Division/RSM
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: USA
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Macintosh
; OPERATING SYSTEM: Macintosh
; SOFTWARE: Microsoft Word
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/046,508
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph A. Jones
; REGISTRATION NUMBER: 26,472
; REFERENCE/DOCKET NUMBER: X-8477
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 317-276-5183
; TELEFAX: 317-276-1294
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 749 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-046-508-2

Query Match
Best Local Similarity 19.1%; Score 619; DB 1; Length 749;
Matches 174; Conservative 125; Mismatches 238; Indels 106; Gaps 22;

QY 44 ESLVAQAGVQWRDLGSLQPPPLGPKRFSCLSLPSSWDYRLRELA----VRLGFGPCAE 99
DB 100 EFLGTATFTVSSMKYGEKEVFFINQVTEWLEMS-----LEVSCPLDRSMALCDGE 154

QY 100 QAFLSRRKQVAAALRQAL---QLDGDILQEDDEIPVVAIMATGGIRAMTSLYGQLAGLKE 156
DB 155 KTFROQRKEHIRESMKLLGPKNSGSLHSARDVPVVAIILGSGGFRAMVGFSGVMKALYE 214

QY 157 LGLLDCVYITGASSTWALANLYDEPWSQKLAGPTL---LKTQVTKNKGVLAPSQ 213
DB 215 SGILDCATYVAGLSGSTMSTLYSHGPDPEK---GPEEINELMKNVSHNLLLTPOK 271

QY 214 LQRYQELAERARLGYPSCFTNLWA-LINEALLHDEPHDKLSDQREALSHGQNPLPIYC 272

```

```

Db 272 VKRYVESLWKKSSQPTFTDIFGMLIGETLIHNMNT-TLSSLKEKVNTAQCPPLPT 330
Qy 273 AINTKGQSLTTFEGEWCEFSYEVGPKYGAIFSELFGSEFFMGQMKRLPESRICFL 332
Db 331 CLHVK-PDVSELMAFADWVEFSYEIGMAKYGTMAPDLFGSKFFGTGVVKKYEENPDLHFL 389
Qy 333 EGIWENLYA-----ANLQDSLYWASEPSQFWDWRVRNQANLKDQOVPL 376
Db 390 MGWCSAFSILNRLVGLSGSQSRGSTWEEEL-----ENITTKHIVNSDSDSD 439
Qy 377 KIEEPPSTAGRIA--EFTFD-----LTPWPLAQATHNFLRGLHPH 415
Db 440 ESHEPKGTENEDAGSDYQSDNQASWHRMIALVSDSALFNTRGKAGKVNFMGLNLN 499
Qy 416 KDYFOHP--HSTWKAATILDGL-----PNQ-----LTPSEPHCLLDVGYLINTSCL 460
Db 500 TSYPLSPLSDFATQSDDELDAADPDEFERIEYELDVKSXKIHVVDSGLTFLNLPYP 559
Qy 461 PLLQPTRDVLJLSDYNLHGA-----FQQLQLGRFCQEQGIPPPISPSPSEEQLOPRE 515
Db 560 LILRPQGVDLIISDFARSPPSPFKELLALAEKWKAKMNLPPFKIDPYVFDREGLKE 619
Qy 516 CHTFSDPTCP-----CAPAVLHF-----SSGV-RTPEEAAAAGEVNL-SSSDSPY 558
Db 620 CVYFK-PKNPDMKDCPTIHFVLANINPRKYKAPGVPRETEEKEIADFDIDDPESPF 678
Qy 559 HYTKVTSQEDVDKLLHLTHYVNCNQEQLLEALQCAVQRREQ 601
Db 679 STNFQYENQAFKRLHLMHFNTLANNIDVKEAMVESIEYRQ 721

```

RESULT 11

```

US-09-045-185-2
; Sequence 2, Application US/09045185
; Patent No. 6103510
; GENERAL INFORMATION:
; APPLICANT: Kramer, Ruth M.
; APPLICANT: Pickard, Richard T.
; APPLICANT: Sharp, John D.
; APPLICANT: Striffler, Beth A.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: United States of America
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/045,185
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaylo, Paul J.
; REGISTRATION NUMBER: 36,808
; REFERENCE/DOCKET NUMBER: P-11369
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 276-0756
; TELEFAX: (317) 276-3861
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 541 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

```

```

US-09-045-185-2
Query Match 15.4%; Score 498.5; DB 3; Length 541;
Best Local Similarity 27.8%; Pred. No. 4.9e-41;
Matches 158; Conservative 86; Mismatches 190; Indels 135; Gaps 23;
Qy 98 BEQAFLSRRKQVAAALRQALQDGLQDEIPVVAIMATGGIRAMTSLYQQLAGLKL 157
Db 15 EEKAAVERRRHLVLAALKL-----RIEADAFVAVLGGGGLRAHIACTGLVSEMKEQ 69
Qy 158 GLLDVCVSIITGASGWTALANIYE---DPEWSQKDLAGTELLKTQVTKNKLGVLAPOSQ 214
Db 70 GLLDVAVTYLAGVSGSTWAISSLYTNDGMEALEAD-----LKRFTROEW-----DL 116
Qy 215 QRYRQELAEARLGYPSCTNLWA-LINEALLHSDPHDKLSDOREALSHGONPLPIYCA 273
Db 117 AKSLQKTQAARSENYS-LTDFWYMWVLSKQTRPELPEH-LSNMKKPVEEGTLPIPIFAA 174
Qy 274 ----INTKGQSLTTFEGEWCEFSYEVGPKYGAIFSELFGSEFFMGQMKRLPESRI 329
Db 175 IDNDLQPSWQEARAPE--TWFEFTPHAGFPALGAFVSIHFGSKFKGRLVTHPERDL 232
Qy 330 CFLEIGWNS-----LYA--ANLQDSLY 349
Db 233 TELRLGWSALGNTVEIREYIFDQURNLTLKGLMRAVANAKSIGHLIFARLLRQESSQ 292
Qy 350 W-----AGEPSQFW-----DRVRNQANLKDQOVPLLKIEEPPSTAGRIAEEFF 392
Db 293 GEHPPEDEGEPEHTWLTMLENWT--TSLEKQEQP-----HEDPERKGSLSNLMDFVK 346
Qy 393 -TDLLTWRLAQATHNFLRGLHFKDYFQHPHFSTWKATTDGLPNQLTPSPHICLLDV 451
Db 347 KTGICASKWEGTTHNFL-----YKH-----GGIRDKIMSSRKKHLHLDVA 386
Qy 452 GYLINTSCLPLQPTDVLJLSDYNLHGAFOQLQLGRFCQEQGIPPPISPSPSEEQ 511
Db 387 GLAINTFPFLVLPPTREVHLILSDFDSAGDPEETIRATDYCRHKIPFPQVE---EABL 443
Qy 512 Q-----PRECHTFSDPTCPGAPAVLHFSSGVRRTF---EAAAAGEVNLSSSDSPYHYTKV 563
Db 444 DLMSKAPASCYLLKGET---GPVVMHF-----PLENIDAGGDLAEWSDTYDTFKLAD 493
Qy 564 TYSQEDVDKLLHLTHYVNCNQEQLLEAL 592
Db 494 TYTLDVAVVLLALAKKNVRENKKILREL 522

```

RESULT 12

```

US-08-890-615-2
; Sequence 2, Application US/08890615
; Patent No. 6121031
; GENERAL INFORMATION:
; APPLICANT: Song, Chuansheng
; APPLICANT: Kriz, Ron
; APPLICANT: Knopf, John
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-GAMMA ENZYMES
; TITLE OF INVENTION: AND POLYNUCLEOTIDES ENCODING SAME
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,615
; FILING DATE:

```



```

; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G1300
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-498-8224
; TELEFAX: 617-876-5851
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 541 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Active-site
; LOCATION: 6..242
; FEATURE:
; NAME/KEY: Active-site
; LOCATION: 366..535
;
US-08-890-615-2

```

```

Query Match      15.2%; Score 490.5; DB 3; Length 541;
Best Local Similarity 27.6%; Pred. No. 3.1e-40;
Matches 157; Conservative 86; Mismatches 191; Indels 135; Gaps 23;

```

```

QY 98 EQAFLSRRKQVVAALRQALQDGLDQDEIPVVAIMATGGIRAMTSLYQGLAGLKE 157
Db 15 EKAVERRRRLHLKALKL-----RIEADAPVAVVLGGGGLRAHIAACGLVLSMK 69
QY 158 GLLDVCYSITGASGTSWALANLYE---DPEWSOKLAGTTELLKTQVTKNKLGV 214
Db 70 GLLDVAVTLGAVSGTSWALSSLYTNDGMEALD-----LKHFTQEW-----DL 116
QY 215 QYRQELAEARLGLVPSCTNLA-LINEALHDEPHDKLSQREALSHGONPLPIYCA 273
Db 117 AKSLQKTIQAARSENYS-LTDFWAYVVISQTRPELPEH-LSNMKKPVVEEGLTPY 174
QY 274 ----LNTKQSLLTFEFGWCFSFVEGPKYGFAPISLFGSEFFMGQMLKRLPES 329
Db 175 INDNLQPSWQEARPE--TWFEFTPHAGFSALGAFVSTHFGSKFKGRLVTRTHPE 232
QY 330 CFLEGISWN-----LVA--ANLQDSLY 349
Db 233 TFLRGLWSALGNTEVIREYIFDQLRNLTGLMRRANAKSIGHLIFARLLRLQESS 292
QY 350 W-----ASPPSQFW-----DRVRNQANLDKEQVPLLKIEEPPSTAGRIA 392
Db 293 GEHPPEDEGGPEHTWLTMLENWT--TSLEKQEQP---HEDPERKGSLSNLMDFVK 346
QY 393 -TDLLTWRPLAQATHNRLGLHFHKDYFOHPHFSTWKTATLDGLNQLTPSEPHCL 451
Db 347 KTGICASKWEGTTHNFI-----YKH-----GGIRDKIMSSRKHLLHVD 386
QY 452 GYLINTSCLPLLOPTRDVLILSDYNLHGAQQQLLGRFCQEQIIPPPISPSPEOL 511
Db 387 GLAINTPPELVLPPTREVHLLISDFESAGDPETIRATTDYCRHKIPPPQVE---E 443
QY 512 Q-----PRECHTFSPTCPGAPAVLHFSFGVRRTP---EEAAGEVNLSSSDSP 563
Db 444 DLWSKAPASCYILKGET---GPVVIHF-----PLFNIDACGGDIEAWSDTYDF 493
QY 564 TYSQEDVDKLLHLTHVYVNCNQEQQLLEAL 592
Db 494 TYTLDDVVVLLALAKKNVRENKKILREL 522

```

```

RESULT 13
US-09-246-290A-2
; Sequence 2, Application US/09246290A
; Patent No. 6440683
; GENERAL INFORMATION:

```

```

; APPLICANT: Song, Chuanzheng
; APPLICANT: Kriz, Ronald
; APPLICANT: Knopf, John
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-GAMMA ENZYMES
; FILE REFERENCE: AND POLYNUCLEOTIDES ENCODING SAME
; CURRENT APPLICATION NUMBER: US/09/246,290A
; CURRENT FILING DATE: 1999-02-08
; PRIOR APPLICATION NUMBER: US 08/890,615
; PRIOR FILING DATE: 1997-07-09
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FASTSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 541
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: ACT_SITE
; LOCATION: (6)....(242)
; NAME/KEY: ACT_SITE
; LOCATION: (366)....(535)
;
US-09-246-290A-2

```

```

Query Match      15.2%; Score 490.5; DB 4; Length 541;
Best Local Similarity 27.6%; Pred. No. 3.1e-40;
Matches 157; Conservative 86; Mismatches 191; Indels 135; Gaps 23;

```

```

QY 98 EQAFLSRRKQVVAALRQALQDGLDQDEIPVVAIMATGGIRAMTSLYQGLAGLKE 157
Db 15 EKAVERRRRLHLKALKL-----RIEADAPVAVVLGGGGLRAHIAACGLVLSMK 69
QY 158 GLLDVCYSITGASGTSWALANLYE---DPEWSOKLAGTTELLKTQVTKNKLGV 214
Db 70 GLLDVAVTLGAVSGTSWALSSLYTNDGMEALD-----LKHFTQEW-----DL 116
QY 215 QYRQELAEARLGLVPSCTNLA-LINEALHDEPHDKLSQREALSHGONPLPIYCA 273
Db 117 AKSLQKTIQAARSENYS-LTDFWAYVVISQTRPELPEH-LSNMKKPVVEEGLTPY 174
QY 274 ----LNTKQSLLTFEFGWCFSFVEGPKYGFAPISLFGSEFFMGQMLKRLPES 329
Db 175 INDNLQPSWQEARPE--TWFEFTPHAGFSALGAFVSTHFGSKFKGRLVTRTHPE 232
QY 330 CFLEGISWN-----LVA--ANLQDSLY 349
Db 233 TFLRGLWSALGNTEVIREYIFDQLRNLTGLMRRANAKSIGHLIFARLLRLQESS 292
QY 350 W-----ASPPSQFW-----DRVRNQANLDKEQVPLLKIEEPPSTAGRIA 392
Db 293 GEHPPEDEGGPEHTWLTMLENWT--TSLEKQEQP---HEDPERKGSLSNLMDFVK 346
QY 393 -TDLLTWRPLAQATHNRLGLHFHKDYFOHPHFSTWKTATLDGLNQLTPSEPHCL 451
Db 347 KTGICASKWEGTTHNFI-----YKH-----GGIRDKIMSSRKHLLHVD 386
QY 452 GYLINTSCLPLLOPTRDVLILSDYNLHGAQQQLLGRFCQEQIIPPPISPSPEOL 511
Db 387 GLAINTPPELVLPPTREVHLLISDFESAGDPETIRATTDYCRHKIPPPQVE---E 443
QY 512 Q-----PRECHTFSPTCPGAPAVLHFSFGVRRTP---EEAAGEVNLSSSDSP 563
Db 444 DLWSKAPASCYILKGET---GPVVIHF-----PLFNIDACGGDIEAWSDTYDF 493
QY 564 TYSQEDVDKLLHLTHVYVNCNQEQQLLEAL 592
Db 494 TYTLDDVVVLLALAKKNVRENKKILREL 522

```

```

RESULT 14
US-09-687-538B-4
; Sequence 4, Application US/09687538B
; Patent No. 6514739
; GENERAL INFORMATION:

```

```

; APPLICANT: Udagawa, Hiroaki
; APPLICANT: Frandsen, Torben
; APPLICANT: Nielsen, Tom
; APPLICANT: Kauppinen, Markus
; APPLICANT: Christensen, Soeren
; TITLE OF INVENTION: Lysophospholipase
; FILE REFERENCE: 5958.210-US
; CURRENT APPLICATION NUMBER: US/09/687,538B
; CURRENT FILING DATE: 1999-10-20
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 638
; TYPE: PRT
; ORGANISM: Aspergillus niger
US-09-687-538B-4

Query Match      6.4%; Score 208; DB 4; Length 638;
Best Local Similarity 20.1%; Pred. No. 9e-12;
Matches 108; Conservative 74; Mismatches 156; Indels 200; Gaps 26;

QY 129 IPVVAIMATGGIRAMTSLYGLAGLKE-----GLDCVSYITGASGSTMALA 177
Db 114 IPNIAAASGGYRALTYGAGALKAFDSRSDNATNSGQLGGLQATYVSGLSGGSWLVG 173
QY 178 NLY-----EDPEWSQKDLAGPTTELLKTQVTKNKLGLVLAPSQ 213
Db 174 SMFVNFSIGELQASEKVMRFDKSLLEGPNFDHIQIVSTVEYWK-DIT----- 221
QY 214 LQRYQELAEARLGVPCFTNLWA-----LINE-----ALLHDEPHDKH 253
Db 222 -----EEVDGKANAGFNTSFTDYWGRALSYQLVNASDDKGGPDYTWSSIALMDD----- 270
QY 254 LSDQREALSHGQNLPIYCA-LNTKGO-----SLTTFEFGECFSPYEVGPKYGATP 307
Db 271 -----FKNGYPMPIVVADGRNPEGIIVETNATYVENVK-EFGSPD-----PSVYAFAP 319
QY 308 SELFGESEFMGLMKRLPESRIC-----FLEGIWSNLYAANLQDSLYWASEPSQFWD 359
Db 320 LQYLSGRFENG-----IPNGICVSGFDNAGFMGSSSLF-----NQF-- 359
QY 360 RWRNQAANDKEQVPLKTEBPPSTAGTAEFTDLLTWRLPAQATHNRLGLHFHKDYF 419
Db 360 -----LLQINSTSIEPT-----LKDAFTDIL-EDLGERNDDI-----AVYS 394
QY 420 QHPFSTWKATLTDGLPNQLTPSEHLCLLDVGYL-----INTSCLPILQPTRDVDLIL 473
Db 395 PNP-FSGYRDS-----SEDYATAKDLDVVDGCGEDGENIPLHPLIQPERAVDVIF 442
QY 474 SLDYNLHGAF---QQLGLGRFCQEQGIPFPPIPSPEBQLQPRBCHTSDPTCPGAPAV 530
Db 443 AIDSSADTDYWPNGTSLVATY-----ERSLEPSIANGTAFPAVDPQNTF 487
QY 531 LHFSSGVRTPEAAAGEVNLSS-----DSPHYHT-----KVYSQEDVDKLL 574
Db 488 VNL--GLNSRPTFFGCDPKNISGTAPLVLYLPNSPYTDNSFSTFKLTYSDEERDSVI 543

```

RESULT 15

```

US-09-437-687A-2
; Sequence 2, Application US/09437687A
; Patent No. 6489154
; GENERAL INFORMATION:
; APPLICANT: Randy M. Berka
; APPLICANT: Michael W. Rey
; APPLICANT: Tony Byun
; APPLICANT: Ryoko Itami
; APPLICANT: No. 6489154iko Tsutsumi
; TITLE OF INVENTION: Polypeptides Having Lysophospholipase
; TITLE OF INVENTION: Activity And Nucleic Acids Encoding Same
; FILE REFERENCE: 5713, 200-US
; CURRENT APPLICATION NUMBER: US/09/437,687A

```

```

; CURRENT FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: 09/189,486
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 654
; TYPE: PRT
; ORGANISM: Fusarium venenatum
US-09-437-687A-2

Query Match      6.4%; Score 208; DB 4; Length 654;
Best Local Similarity 21.7%; Pred. No. 9.4e-12;
Matches 146; Conservative 82; Mismatches 216; Indels 230; Gaps 35;

QY 36 PFFPFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSS-----WDYRLRE 86
Db 4 PLVFTLWITSSAIAAPD-----DAGLVAAPATG-KSLSTRALPDSGGYAPKVVDCPSTR 58
QY 87 LAVRLGFGPCABEQAFLSRRKQVAAALRQALQ-----LDGD--LOEDE-----IPVVA 133
Db 59 PKIRLADGLSDQEEAWVRRNRNTIDPMKDLLSRVNIISGFDAAEKWIKNNKNNATALPNA 118
QY 134 IMATGGGIRAMTSLYGLAGLKE-----GLDCVSYITGASGSTMALANLVED--- 182
Db 119 IAASGGYRALMNGAGFTISAADSRNNEGPIISGLLQSSLYLAGSGGGLVGSIIFANNPT 178
QY 183 --PEWSQK-----LAGPTTELLKTQVTKNKLGLVLAPSQLQRYROELAEARLUG 228
Db 179 TPDLOKQKSDIWAFFRSIFKGP-----EASGLNVLNTAKYWDIDKDTVEKADG 230
QY 229 YPSCFTNLWALINEALLHDEPHDKHLSQREA-----LHGQNPLPIYCA- 273
Db 231 WNTLTLDWM---GRAL-----SYQLIDASEGGPAYTFSSIADTGNFKDADTPFILVAD 281
QY 274 -----LNTKQSLTTFEFGECFSPYEVGPKYGATIPSELFSSEFFMGOLMKR 323
Db 282 GRAPQQRIVSLNATYVFNPFEGFTWPTS-----YG-FAPVEYIGSNFTNGTIEK- 331
QY 324 LPESRIC-----FLEGIWSNLYAANLQDSLYWASEPSQFWRWRNQAANDKEQVPL 375
Db 332 ---GGECVRGFPQFGVMTGSSSLFNQFLNNITKGE-----ENDIFS 372
QY 376 LKIEPPSTAGTAEFTDLLTWRLPAQATHNRLGLHFH-----KDYFOHPHFSTWKAT- 430
Db 373 L-----VVKAIQGLFVALDITNDEDIADYSNP-FYQWNVTG 407
QY 431 -TLDGLPNQLTPSEHLCLLDVGY-LINTSCLPILQPTRDVDLILSLDYN----- 478
Db 408 KSYNAKDHQLT-----LVQGGEDLQNIPLHPLIQPRGVVDIIFAISSADTDNNWPN 460
QY 479 --LHGAFQOL-QLLGRFCQEQGIPFPPIPSPE-----EOLOPR-----ECHTFSDPT 523
Db 461 TAIIRATYDRVDSLSG-----NGTQFPSI-PSAETINEKLNQRPITLFGCDADNFTLSDGK 514
QY 524 CPGAPAVLHFFSGVRTPEAAAGEVNLSSSPHYHTKVYSQEDVDKLLHLTHYVNCN 583
Db 515 AP-PPLVFI-----PNAPYTFLSNVSTFD-----LSYSIPERDSI----- 549
QY 584 NOEQLLEALRQAVQ 597
Db 550 ----ILNALNGATQ 559

```

Search completed: October 5, 2004, 19:24:58  
Job time : 41.9133 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:25:05 ; Search time 137.133 Seconds  
(without alignments)  
1419.702 Million cell updates/sec

Title: US-09-830-321A-2

Perfect score: 3235

Sequence: 1 MIFVELSPITALCLERVASH.....EQLLEALRQAVQRRRRQRP 605

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1351062 seqs, 321799191 residues

Total number of hits satisfying chosen parameters: 1351062

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications AA:\*

1: /cgn2\_6/ptodata/2/pubpaa/US07\_PUBCOMB.pep.\*  
2: /cgn2\_6/ptodata/2/pubpaa/PCT\_NEW\_PUB.pep.\*  
3: /cgn2\_6/ptodata/2/pubpaa/US05\_NEW\_PUB.pep.\*  
4: /cgn2\_6/ptodata/2/pubpaa/US06\_PUBCOMB.pep.\*  
5: /cgn2\_6/ptodata/2/pubpaa/US07\_NEW\_PUB.pep.\*  
6: /cgn2\_6/ptodata/2/pubpaa/PCTUS\_PUBCOMB.pep.\*  
7: /cgn2\_6/ptodata/2/pubpaa/US08\_NEW\_PUB.pep.\*  
8: /cgn2\_6/ptodata/2/pubpaa/US08\_PUBCOMB.pep.\*  
9: /cgn2\_6/ptodata/2/pubpaa/US09A\_PUBCOMB.pep.\*  
10: /cgn2\_6/ptodata/2/pubpaa/US09B\_PUBCOMB.pep.\*  
11: /cgn2\_6/ptodata/2/pubpaa/US09C\_PUBCOMB.pep.\*  
12: /cgn2\_6/ptodata/2/pubpaa/US09\_NEW\_PUB.pep.\*  
13: /cgn2\_6/ptodata/2/pubpaa/US10A\_PUBCOMB.pep.\*  
14: /cgn2\_6/ptodata/2/pubpaa/US10B\_PUBCOMB.pep.\*  
15: /cgn2\_6/ptodata/2/pubpaa/US10C\_PUBCOMB.pep.\*  
16: /cgn2\_6/ptodata/2/pubpaa/US10C\_NEW\_PUB.pep.\*  
17: /cgn2\_6/ptodata/2/pubpaa/US60\_NEW\_PUB.pep.\*  
18: /cgn2\_6/ptodata/2/pubpaa/US60\_PUBCOMB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2767.5	85.5	778	14	US-10-266-388-2
2	2767.5	85.5	797	14	US-10-266-388-4
3	2767.5	85.5	1012	16	US-10-408-765A-638
4	2509.5	77.6	483	9	US-09-981-876-144
5	2509.5	77.6	483	9	US-09-981-876-209
6	2509.5	77.6	483	10	US-09-148-545-144
7	2509.5	77.6	483	10	US-09-148-545-209
8	1492	46.1	1026	12	US-10-332-426-6
9	1243.5	38.4	996	16	US-10-467-248-1
10	1139.5	35.2	849	15	US-10-380-873B-1
11	1138	35.2	853	15	US-10-380-873B-38
12	1127	34.8	854	15	US-10-380-873B-22
13	1112	34.4	848	12	US-10-332-426-3
14	619	19.1	749	12	US-10-211-462-50
15	619	19.1	749	12	US-10-157-898-2
16	619	19.1	749	12	US-10-157-898-4
17	619	19.1	749	12	US-10-157-898-6
18	619	19.1	749	12	US-10-157-898-8
19	619	19.1	749	12	US-10-157-898-10
20	619	19.1	749	12	US-10-157-898-12
21	619	19.1	749	12	US-10-157-898-14
22	619	19.1	749	12	US-10-157-898-16
23	619	19.1	749	12	US-10-157-898-18
24	619	19.1	749	12	US-10-157-898-20
25	619	19.1	749	12	US-10-157-898-22
26	619	19.1	749	12	US-10-157-898-24
27	619	19.1	749	12	US-10-157-898-26
28	619	19.1	749	12	US-10-157-898-28
29	619	19.1	749	12	US-10-157-898-30
30	619	19.1	749	12	US-10-157-898-32
31	619	19.1	749	12	US-10-157-898-34
32	619	19.1	749	12	US-10-157-898-36
33	619	19.1	749	12	US-10-157-898-38
34	619	19.1	749	12	US-10-157-898-40
35	619	19.1	749	12	US-10-157-898-42
36	619	19.1	749	12	US-10-157-898-44
37	619	19.1	749	12	US-10-157-898-46
38	619	19.1	749	12	US-10-157-898-48
39	619	19.1	749	12	US-10-157-898-50
40	619	19.1	749	12	US-10-157-898-52
41	619	19.1	749	12	US-10-157-898-54
42	619	19.1	749	12	US-10-157-898-56
43	619	19.1	749	12	US-10-157-898-58
44	619	19.1	749	12	US-10-157-898-60
45	619	19.1	749	12	US-10-157-898-62

Sequence	2, Appli	Sequence 118, App	Sequence 93, Appli	Sequence 127, App	Sequence 296, App	Sequence 297, App	Sequence 4, Appli	Sequence 917, App	Sequence 26, Appli	Sequence 3, Appli	Sequence 1, Appli	Sequence 8, Appli	Sequence 5, Appli	Sequence 295, App	Sequence 1210, Ap	Sequence 1020, Ap	Sequence 1682, Ap	Sequence 242280,	Sequence 2181, Ap	Sequence 1959, Ap	Sequence 4272, Ap	Sequence 1940, Ap	Sequence 1949, Ap	Sequence 245, App	Sequence 107, App	Sequence 2008, Ap	Sequence 4, Appli	Sequence 2, Appli	Sequence 911, App	
16	619	19.1	749	13	US-10-062-730-2																									
17	619	19.1	749	14	US-10-021-660-118																									
18	593.5	18.5	748	12	US-10-157-898-4																									
19	490.5	15.2	541	12	US-10-211-462-93																									
20	490.5	15.2	541	14	US-10-021-660-127																									
21	490.5	15.2	541	16	US-10-741-601-296																									
22	490.5	15.2	541	16	US-10-741-601-297																									
23	461	14.3	597	14	US-10-181-612-4																									
24	419	13.0	180	12	US-10-296-115-917																									
25	368.5	11.4	261	15	US-10-380-873B-26																									
26	361	11.2	454	15	US-10-380-873B-3																									
27	358	11.1	442	16	US-10-468-519-1																									
28	347.5	10.7	441	16	US-10-468-519-8																									
29	344	10.6	445	16	US-10-468-519-5																									
30	339	10.5	384	16	US-10-741-601-295																									
31	232	7.2	151	14	US-10-017-161-1210																									
32	232	7.2	151	15	US-10-292-798-1020																									
33	220	6.8	150	15	US-10-094-749-1682																									
34	217	6.7	135	12	US-10-424-599-242280																									
35	216	6.7	101	15	US-10-094-749-2181																									
36	211	6.5	137	12	US-10-276-774-1959																									
37	211	6.5	157	15	US-10-108-260A-4272																									
38	210	6.5	157	12	US-10-276-774-1940																									
39	208.5	6.4	137	12	US-10-276-774-1949																									
40	208.5	6.4	183	9	US-09-989-920-245																									
41	208.5	6.4	361	9	US-09-995-494-107																									
42	208	6.4	97	12	US-10-276-774-2008																									
43	208	6.4	638	14	US-10-309-437-4																									
44	208	6.4	654	14	US-10-263-250-2																									
45	206	6.4	213	12	US-10-296-115-911																									

#### ALIGNMENTS

RESULT 1  
US-10-266-388-2  
; Sequence 2, Application US/10266388  
; Publication No. US20030124702A1  
; GENERAL INFORMATION:  
; APPLICANT: Kriz, Ron  
; Song, Chuanzheng  
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute, Inc.  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/266,388  
; FILING DATE: 07-Oct-2002  
; CLASSIFICATION: <Unknown>  
; PRIORITY DATA:  
; APPLICATION NUMBER: US/09/895,547  
; FILING DATE: 29-Jun-2001  
; APPLICATION NUMBER: 09/460,145  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brown, Scott A.  
; REGISTRATION NUMBER: 32,724  
; REFERENCE/DOCKET NUMBER: G15289  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 498-8224  
; TELEFAX: (617) 876-5851  
; INFORMATION FOR SEQ ID NO: 2:

```

;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 778 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-266-388-2

Query Match      85.5%; Score 2767.5; DB 14; Length 778;
Best Local Similarity 87.6%; Pred. No. 1.2e-254;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLVLFPCAPCPFFPFEMESLSVAQAGVQWMDLGSLOPPPLGPKRFSCLSLPSSWDYR 83
DB 184 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGVVR 225

QY 84 -----LRELAVRLGFGPCABEQAFLSRRKOVVAAALRQALQLDGD 123
DB 226 LVFPTSQELMRVELKKEAGRELAVRLGFGPCABEQAFLSRRKOVVAAALRQALQLDGD 285

QY 124 LOEDEIPVVAIMATGGIRAMTSYGLAGLKGELGLDCVSYITGASGTWALANLYEDP 183
DB 286 LOEDEIPVVAIMATGGIRAMTSYGLAGLKGELGLDCVSYITGASGTWALANLYEDP 345

QY 184 EWSQKDLAAGPTTELLKTQVTKNKGVLAPSQLQRYQELAEARLGYPCFTNLMALINEA 243
DB 346 EWSQKDLAAGPTTELLKTQVTKNKGVLAPSQLQRYQELAEARLGYPCFTNLMALINEA 405

QY 244 LLHDEPHDKLSQDREALSHGONPLPIYCALNTKGOSLTTFEFGWCESFSPVEVGFPKYG 303
DB 406 LLHDEPHDKLSQDREALSHGONPLPIYCALNTKGOSLTTFEFGWCESFSPVEVGFPKYG 465

QY 304 AFIPSELFSGSEFFFMQMLKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVR 363
DB 466 AFIPSELFSGSEFFFMQMLKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVR 525

QY 364 NOANLDKEQVPLLKIEEPPSTAGTAEFFTDLLTWRLAQATHNPLRGLHFKHGYFQHPH 423
DB 526 NOANLDKEQVPLLKIEEPPSTAGTAEFFTDLLTWRLAQATHNPLRGLHFKHGYFQHPH 585

QY 424 FSTWKATTLTDLGNLTSEPHCLLDVGYLINTSCLPLQTPTRDVLILSLDYNLHGAF 483
DB 586 FSTWKATTLTDLGNLTSEPHCLLDVGYLINTSCLPLQTPTRDVLILSLDYNLHGAF 645

QY 484 QQLQLGRFCOEQGIPIPPPIGSPSEQLQPRECHTFSDPTCPGAPAVLHF----- 533
DB 646 QQLQLGRFCOEQGIPIPPPIGSPSEQLQPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 705

QY 534 -SSGVRRTPEAAAGEVNLSSSDSPYHTKVTYSQEDVDKLLHLTHYNVNCNQEQLLEAL 592
DB 706 SAPGVRRTPPEAAAGEVNLSSSDSPYHTKVTYSQEDVDKLLHLTHYNVNCNQEQLLEAL 765

QY 593 QAVQRRRQRREPH 605
DB 766 QAVQRRRQRREPH 778

```

RESULT 2

```

US-10-266-388-4
; Sequence 4, Application US/10266388
; Publication No. US20030124702A1
; GENERAL INFORMATION:
; APPLICANT: Kriz, Ron
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESS: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA

```

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/10/266,388
; FILING DATE: 07-Oct-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/895,547
; FILING DATE: 29-Jun-2001
; APPLICATION NUMBER: 09/460,145
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15289
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 777 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-10-266-388-4

```

```

Query Match      85.5%; Score 2767.5; DB 14; Length 797;
Best Local Similarity 87.6%; Pred. No. 1.2e-254;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLVLFPCAPCPFFPFEMESLSVAQAGVQWMDLGSLOPPPLGPKRFSCLSLPSSWDYR 83
DB 203 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGVVR 244

QY 84 -----LRELAVRLGFGPCABEQAFLSRRKOVVAAALRQALQLDGD 123
DB 245 LVFPTSQELMRVELKKEAGRELAVRLGFGPCABEQAFLSRRKOVVAAALRQALQLDGD 304

QY 124 LOEDEIPVVAIMATGGIRAMTSYGLAGLKGELGLDCVSYITGASGTWALANLYEDP 183
DB 305 LOEDEIPVVAIMATGGIRAMTSYGLAGLKGELGLDCVSYITGASGTWALANLYEDP 364

QY 184 EWSQKDLAAGPTTELLKTQVTKNKGVLAPSQLQRYQELAEARLGYPCFTNLMALINEA 243
DB 365 EWSQKDLAAGPTTELLKTQVTKNKGVLAPSQLQRYQELAEARLGYPCFTNLMALINEA 424

QY 244 LLHDEPHDKLSQDREALSHGONPLPIYCALNTKGOSLTTFEFGWCESFSPVEVGFPKYG 303
DB 425 LLHDEPHDKLSQDREALSHGONPLPIYCALNTKGOSLTTFEFGWCESFSPVEVGFPKYG 484

QY 304 AFIPSELFSGSEFFFMQMLKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVR 363
DB 485 AFIPSELFSGSEFFFMQMLKRLPESRICFLEGIWSNLYAANLQDSLYWASEPSQFWDWRVR 544

QY 364 NOANLDKEQVPLLKIEEPPSTAGTAEFFTDLLTWRLAQATHNPLRGLHFKHGYFQHPH 423
DB 545 NOANLDKEQVPLLKIEEPPSTAGTAEFFTDLLTWRLAQATHNPLRGLHFKHGYFQHPH 604

QY 424 FSTWKATTLTDLGNLTSEPHCLLDVGYLINTSCLPLQTPTRDVLILSLDYNLHGAF 483
DB 605 FSTWKATTLTDLGNLTSEPHCLLDVGYLINTSCLPLQTPTRDVLILSLDYNLHGAF 664

QY 484 QQLQLGRFCOEQGIPIPPPIGSPSEQLQPRECHTFSDPTCPGAPAVLHF----- 533
DB 665 QQLQLGRFCOEQGIPIPPPIGSPSEQLQPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 724

QY 534 -SSGVRRTPEAAAGEVNLSSSDSPYHTKVTYSQEDVDKLLHLTHYNVNCNQEQLLEAL 592

```



; PRIOR APPLICATION NUMBER: 60/047,596  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,612  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,632  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,601  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/043,580  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,568  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,314  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,569  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,311  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,671  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,674  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,669  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,312  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,313  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,672  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,315  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/048,974  
 ; PRIOR FILING DATE: 1997-06-06  
 ; PRIOR APPLICATION NUMBER: 60/056,886  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,877  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,889  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,893  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,630  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,878  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,662  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,872  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,882  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,637  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,903  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,888  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,879  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,880  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,894  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,911  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,636  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,874  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,910  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,864

; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,631  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,845  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,892  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/047,595  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/057,761  
 ; PRIOR FILING DATE: 05-Sep-1997  
 ; PRIOR APPLICATION NUMBER: 60/047,599  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,588  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,585  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,586  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,590  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,594  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,589  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,593  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/047,614  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/043,578  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/043,576  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/047,501  
 ; PRIOR FILING DATE: 1997-05-23  
 ; PRIOR APPLICATION NUMBER: 60/043,670  
 ; PRIOR FILING DATE: 1997-04-11  
 ; PRIOR APPLICATION NUMBER: 60/056,632  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,664  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,876  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,881  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,909  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,875  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,862  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,887  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/056,908  
 ; PRIOR FILING DATE: 1997-08-22  
 ; PRIOR APPLICATION NUMBER: 60/048,964  
 ; PRIOR FILING DATE: 1997-06-06  
 ; PRIOR APPLICATION NUMBER: 60/057,650  
 ; PRIOR FILING DATE: 1997-09-05  
 ; PRIOR APPLICATION NUMBER: 60/056,884  
 ; PRIOR FILING DATE: 1997-08-22  
 ; NUMBER OF SEQ ID NOS: 280  
 ; SOFTWARE: Patent In Ver. 2.0  
 ; SEQ ID NO 144  
 ; LENGTH: 483

Query Match 77.6%; Score 2509.5; DB 9; Length 483;

Best Local Similarity 96.9%; Pred. No. 2.4e-230;

Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;

Qy 135 MATGGIRAMTSLYGQLAGLGLDCVSYITGASGTWALNLYEDPEWSQKDLAGPT 194

Db 1 MATGGIRAMTSLYGQLAGLGLDCVSYITGASGTWALNLYEDPEWSQKDLAGPT 60

QY 195 ELLKTOVTKNKGVLAPSOLQRYROELABRARLGYPCSTNLMALINEALLHDEPHDKL 254  
|||  
Db 61 ELLKTOVTKNKGVLAPSOLQRYROELABRARLGYPCSTNLMALINEALLHDEPHDKL 120  
|||  
QY 255 SDOREALSHGQNPPIYCALNTKGQSLTTFEGWCEFSFYEVGPKYGAFIPSELFSGE 314  
|||  
Db 121 SDOREALSHGQNPPIYCALNTKGQSLTTFEGWCEFSFYEVGPKYGAFIPSELFSGE 180  
|||  
QY 315 FWMQMKLPSRICFLEGIWSNLYAANLQSLYASPSQFWDNRVNRQANLQKEQVP 374  
|||  
Db 181 FWMQMKLPSRICFLEGIWSNLYAANLQSLYASPSQFWDNRVNRQANLQKEQVP 240  
|||  
QY 375 LKIEPSPSTAGRIAEFFDILLTWRLAQATHNFRGLHFKHFKDYFOHPHFSWTWKTLLDG 434  
|||  
Db 241 LKIEPSPSTAGRIAEFFDILLTWRLAQATHNFRGLHFKHFKDYFOHPHFSWTWKTLLDG 300  
|||  
QY 435 LPNQTPSPPHCLLDVGYLINTSCLPLLOPTRDNDVLLSLDYNLHGAFQQLLGRFCQ 494  
|||  
Db 301 LPNQTPSPPHCLLDVGYLINTSCLPLLOPTRDNDVLLSLDYNLHGAFQQLLGRFCQ 360  
|||  
QY 495 EOGIPFPPIPSPELOQRECHTSFSDPTCPGAPAVLHF-----SSGVRTPEE 543  
|||  
Db 361 EOGIPFPPIPSPELOQRECHTSFSDPTCPGAPAVLHFPLVSDSPREYSAPGVRTPEE 420  
|||  
QY 544 AAGEVNLSSDSPHYTKVTSQEDVDKLLHLTHYVNCNBOLEALRQAVQRRQR 603  
|||  
Db 421 AAGEVNLSSDSPHYTKVTSQEDVDKLLHLTHYVNCNBOLEALRQAVQRRQR 480  
|||  
QY 604 PH 605  
|||  
Db 481 PH 482  
|||

## RESULT 5

US-09-981-876-209  
; Sequence 209, Application US/09981876  
; Patent No. US2002016469A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 70 Human Secreted Proteins  
; FILE REFERENCE: PZ001P1  
; CURRENT APPLICATION NUMBER: US/09/981,876  
; CURRENT FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: 09/148,545  
; PRIOR FILING DATE: 1998-09-04  
; PRIOR APPLICATION NUMBER: 60/040,162  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,333  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/038,621  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,161  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,626  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,334  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,336  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/040,163  
; PRIOR FILING DATE: 1997-03-07  
; PRIOR APPLICATION NUMBER: 60/047,615  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,600  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,597  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,502  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,633  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,583

; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,617  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,618  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,503  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,592  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,581  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,584  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,500  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,587  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,492  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,598  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,613  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,582  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,596  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,612  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,632  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,601  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/043,580  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,568  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,314  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,569  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,311  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,671  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,674  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,669  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,312  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,313  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,672  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,315  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/048,974  
; PRIOR FILING DATE: 1997-06-06  
; PRIOR APPLICATION NUMBER: 60/056,886  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,877  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,889  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,893  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,630  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,878  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,662  
; PRIOR FILING DATE: 1997-08-22

; PRIOR APPLICATION NUMBER: 60/056,872  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,882  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,637  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,903  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,888  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,879  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,880  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,894  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,911  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,636  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,874  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,910  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,864  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,631  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,845  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,892  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/047,595  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/057,761  
; PRIOR FILING DATE: 05-Sep-1997  
; PRIOR APPLICATION NUMBER: 60/047,599  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,588  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,585  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,586  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,590  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,594  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,589  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,593  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/047,614  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/043,578  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/043,576  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/047,501  
; PRIOR FILING DATE: 1997-05-23  
; PRIOR APPLICATION NUMBER: 60/043,670  
; PRIOR FILING DATE: 1997-04-11  
; PRIOR APPLICATION NUMBER: 60/056,632  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,664  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,876  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,881  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,909  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,875

; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,862  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,887  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/056,908  
; PRIOR FILING DATE: 1997-08-22  
; PRIOR APPLICATION NUMBER: 60/048,964  
; PRIOR FILING DATE: 1997-06-06  
; PRIOR APPLICATION NUMBER: 60/057,650  
; PRIOR FILING DATE: 1997-09-05  
; PRIOR APPLICATION NUMBER: 60/056,884  
; PRIOR FILING DATE: 1997-08-22  
; NUMBER OF SEQ ID NOS: 280  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 209  
; LENGTH: 483  
  
Query Match 77.6%; Score 2509.5; DB 9; Length 483;  
Best Local Similarity 96.9%; Pred. No. 2.4e-230;  
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;  
  
QY 135 MATGGIRAMTSLYCOLAGLKLGLDCVSYITGASGSTMALANLYEDPWSQKDLGPT 194  
Db 1 MATGGIRAMTSLYCOLAGLKLGLDCVSYITGASGSTMALANLYEDPWSQKDLGPT 60  
QY 195 ELLKTQVTKNKLGVLPASQLORYQELAEARLGYPSCTNLWALINEALLHDEPHDKL 254  
Db 61 ELLKTQVTKNKLGVLPASQLORYQELAEARLGYPSCTNLWALINEALLHDEPHDKL 120  
QY 255 SDQREALSHGQNPPIYCALNTKQSLTTFEFGWCESPYEVGPKYGAFIPSELFGSE 314  
Db 121 SDQREALSHGQNPPIYCALNTKQSLTTFEFGWCESPYEVGPKYGAFIPSELFGSE 180  
QY 315 FPMGQMKRLPESRICFLEGWNSNLYAANLQDSLWASEPSQFWDWRVNRQANLKEQVP 374  
Db 181 FPMGQMKRLPESRICFLEGWNSNLYAANLQDSLWASEPSQFWDWRVNRQANLKEQVP 240  
QY 375 LKIEEPPSTAGRIAEFFTDLLTWPLAQATHFLRGLHFHKDYFQHPHFSTWKATTLDG 434  
Db 241 LKIEEPPSTAGRIAEFFTDLLTWPLAQATHFLRGLHFHKDYFQHPHFSTWKATTLDG 300  
QY 435 LPNQLTPSEPHCLLDVGYLINTSCPLQLQPTROVDLILSLDYNLHGAPQQLGLGRFCQ 494  
Db 301 LPNQLTPSEPHCLLDVGYLINTSCPLQLQPTROVDLILSLDYNLHGAPQQLGLGRFCQ 360  
QY 495 EQGIPEPPISSPERLOPBRCHTSDPTCGAPAVLHF-----SSGVRTPEE 543  
Db 361 EQGIPEPPISSPERLOPBRCHTSDPTCGAPAVLHF-----SSGVRTPEE 420  
QY 544 AAAGEVNLSSSDSPYHYTKVTYSQEDVDKLLHLTHYVNCNNQQLLEALRQAVRRQR 603  
Db 421 AAAGEVNLSSSDSPYHYTKVTYSQEDVDKLLHLTHYVNCNNQQLLEALRQAVRRQR 480  
QY 604 PH 605  
Db 481 PH 482  
  
RESULT 6  
US-09-148-545-144  
; Sequence 144, Application US/09148545  
; Publication No. US20030027132A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 70 Human Secreted Proteins  
; FILE REFERENCE: PZ001PI  
; CURRENT APPLICATION NUMBER: US/09/148,545  
; CURRENT FILING DATE: 1998-09-04  
; EARLIER APPLICATION NUMBER: PCT/US98/04482  
; EARLIER FILING DATE: 1998-03-06  
; EARLIER APPLICATION NUMBER: 60/040,162  
; EARLIER FILING DATE: 1997-03-07



1	EARLIER FILING DATE: 1997-04-11
2	EARLIER APPLICATION NUMBER: 60/043,312
3	EARLIER FILING DATE: 1997-04-11
4	EARLIER APPLICATION NUMBER: 60/043,313
5	EARLIER FILING DATE: 1997-04-11
6	EARLIER APPLICATION NUMBER: 60/043,672
7	EARLIER FILING DATE: 1997-04-11
8	EARLIER APPLICATION NUMBER: 60/043,315
9	EARLIER FILING DATE: 1997-04-11
10	EARLIER APPLICATION NUMBER: 60/048,974
11	EARLIER FILING DATE: 1997-06-06
12	EARLIER APPLICATION NUMBER: 60/056,886
13	EARLIER FILING DATE: 1997-08-22
14	EARLIER APPLICATION NUMBER: 60/056,877
15	EARLIER FILING DATE: 1997-08-22
16	EARLIER APPLICATION NUMBER: 60/056,889
17	EARLIER FILING DATE: 1997-08-22
18	EARLIER APPLICATION NUMBER: 60/056,893
19	EARLIER FILING DATE: 1997-08-22
20	EARLIER APPLICATION NUMBER: 60/056,630
21	EARLIER FILING DATE: 1997-08-22
22	EARLIER APPLICATION NUMBER: 60/056,878
23	EARLIER FILING DATE: 1997-08-22
24	EARLIER APPLICATION NUMBER: 60/056,862
25	EARLIER FILING DATE: 1997-08-22
26	EARLIER APPLICATION NUMBER: 60/056,637
27	EARLIER FILING DATE: 1997-08-22
28	EARLIER APPLICATION NUMBER: 60/056,903
29	EARLIER FILING DATE: 1997-08-22
30	EARLIER APPLICATION NUMBER: 60/056,888
31	EARLIER FILING DATE: 1997-08-22
32	EARLIER APPLICATION NUMBER: 60/056,879
33	EARLIER FILING DATE: 1997-08-22
34	EARLIER APPLICATION NUMBER: 60/056,880
35	EARLIER FILING DATE: 1997-08-22
36	EARLIER APPLICATION NUMBER: 60/056,894
37	EARLIER FILING DATE: 1997-08-22
38	EARLIER APPLICATION NUMBER: 60/056,911
39	EARLIER FILING DATE: 1997-08-22
40	EARLIER APPLICATION NUMBER: 60/056,636
41	EARLIER FILING DATE: 1997-08-22
42	EARLIER APPLICATION NUMBER: 60/056,874
43	EARLIER FILING DATE: 1997-08-22
44	EARLIER APPLICATION NUMBER: 60/056,910
45	EARLIER FILING DATE: 1997-08-22
46	EARLIER APPLICATION NUMBER: 60/056,864
47	EARLIER FILING DATE: 1997-08-22
48	EARLIER APPLICATION NUMBER: 60/056,631
49	EARLIER FILING DATE: 1997-08-22
50	EARLIER APPLICATION NUMBER: 60/056,845
51	EARLIER FILING DATE: 1997-08-22
52	EARLIER APPLICATION NUMBER: 60/056,892
53	EARLIER FILING DATE: 1997-08-22
54	EARLIER APPLICATION NUMBER: 60/047,595
55	EARLIER FILING DATE: 1997-05-23
56	EARLIER APPLICATION NUMBER: 60/057,761
57	EARLIER FILING DATE: 05-Sep-1997
58	EARLIER APPLICATION NUMBER: 60/047,599
59	EARLIER FILING DATE: 1997-05-23
60	EARLIER APPLICATION NUMBER: 60/047,586
61	EARLIER FILING DATE: 1997-05-23
62	EARLIER APPLICATION NUMBER: 60/047,590
63	EARLIER FILING DATE: 1997-05-23
64	EARLIER APPLICATION NUMBER: 60/047,594
65	EARLIER FILING DATE: 1997-05-23

```

; EARLIER APPLICATION NUMBER: 60/047,589
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,593
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,614
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,578
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/043,576
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/047,501
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/043,670
; EARLIER FILING DATE: 1997-04-11
; EARLIER APPLICATION NUMBER: 60/056,632
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,664
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,876
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,881
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,909
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,875
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,862
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,887
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/056,908
; EARLIER FILING DATE: 1997-08-22
; EARLIER APPLICATION NUMBER: 60/048,964
; EARLIER FILING DATE: 1997-06-06
; EARLIER APPLICATION NUMBER: 60/057,650
; EARLIER FILING DATE: 1997-09-05
; EARLIER APPLICATION NUMBER: 60/056,884
; EARLIER FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 144
; LENGTH: 483

Query Match          77.6%; Score 2509.5; DB 10; Length 483;
Best Local Similarity 96.9%; Pred. No. 2.4e-230;
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;

QY 135 MATGGIRAMTSLYGQLAGLKEGLDLCVSYITGASGSGTWTALANLYDEPWSQKLAGPT 194
DB 1 MATGGIRAMTSLYGQLAGLKEGLDLCVSYITGASGSGTWTALANLYKDPWSQKLAGPT 60
QY 195 ELKTKQVTKNKGVLAPSOQRYROFLAERARLGYPCFTNLWALINEALLHDEPHDKL 254
DB 61 ELKTKQVTKNKGVLAPSOQRYROFLAERARLGYPCFTNLWALINEALLHDEPHDKL 120
QY 255 SQREALSHGQNLPIYCAINTKGSLTTFFGEWCESPVEYGPVKYGAIPSELFGSE 314
DB 121 SQREALSHGQNLPIYCAINTKGSLTTFFGEWCESPVEYGPVKYGAIPSELFGSE 180
QY 315 FPMQIMKELPSRICFLEGIWSNLYAANLQSLYASPSQFWDNRWNQANLKEQVP 374
DB 181 FPMQIMKELPSRICFLEGIWSNLYAANLQSLYASPSQFWDNRWNQANLKEQVP 240
QY 375 LKIEPPTAGRIAEFFDILLTWPLAQATNFRLGLHFHFKDYFOHPHFTWKTATLDG 434
DB 241 LKIEPPTAGRIAEFFDILLTWPLAQATNFRLGLHFHFKDYFOHPHFTWKTATLDG 300
QY 435 LPNQLTPSEPHCLLDVGVLYINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLIGRFQ 494
DB 301 LPNQLTPSEPHCLLDVGVLYINTSCLPLLOPTRDVLILSLDYNLHGAFCQQLIGRFQ 360
QY 495 EQGIPEPPIPSPELOQRECHTSDDTCGAPAVLHF-----SSQVRTPEE 543
;

```

---

```

Db 361 EQGIPEPPIPSPELOQRECHTSDDTCGAPAVLHFPLVSDSFREYSAPGVRTPEE 420
QY 544 AAAGEVNLSSDSPHYTKVTSQSDVDKLLHLHLTHYVNCNNOEQLEALRQAVQRRQR 603
;
Db 421 AAAGEVNLSSDSPHYTKVTSQSDVDKLLHLHLTHYVNCNNOEQLEALRQAVQRRQR 480
QY 604 PH 605
;
Db 481 PH 482
;
RESULT 7
US-09-148-545-209
; Sequence 209, Application US/09148545
; Publication No. US20030027132A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: 70 Human Secreted Proteins
; FILE REFERENCE: PZ001P1
; CURRENT APPLICATION NUMBER: US/09/148,545
; CURRENT FILING DATE: 1998-09-04
; EARLIER APPLICATION NUMBER: PCT/US98/04482
; EARLIER FILING DATE: 1998-03-06
; EARLIER APPLICATION NUMBER: 60/040,162
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,333
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/038,621
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,161
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,626
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,334
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,336
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/040,163
; EARLIER FILING DATE: 1997-03-07
; EARLIER APPLICATION NUMBER: 60/047,615
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,600
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,597
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,502
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,633
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,583
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,617
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,618
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,503
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,592
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,581
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,584
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,500
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,587
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,492
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,598
; EARLIER FILING DATE: 1997-05-23
; EARLIER APPLICATION NUMBER: 60/047,613
; EARLIER FILING DATE: 1997-05-23

```

EARLIER APPLICATION NUMBER: 60/047,582  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,596  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,612  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,632  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,601  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/043,580  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,568  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,314  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,569  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,311  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,671  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,674  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,669  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,312  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,313  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,672  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,315  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/048,974  
EARLIER FILING DATE: 1997-06-06  
EARLIER APPLICATION NUMBER: 60/056,886  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,877  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,889  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,893  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,630  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,878  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,662  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,872  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,882  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,637  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,903  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,888  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,879  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,880  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,894  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,911  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,636  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,874  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,910

EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,864  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,631  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,845  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,892  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/047,595  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/057,761  
EARLIER FILING DATE: 05-Sep-1997  
EARLIER APPLICATION NUMBER: 60/047,599  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,588  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,585  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,586  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,590  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,594  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,589  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,593  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,614  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/043,578  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,576  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/047,501  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/043,670  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/056,632  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,664  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,876  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,881  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,909  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,875  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,862  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,887  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/056,908  
EARLIER FILING DATE: 1997-08-22  
EARLIER APPLICATION NUMBER: 60/048,964  
EARLIER FILING DATE: 1997-06-06  
EARLIER APPLICATION NUMBER: 60/057,650  
EARLIER FILING DATE: 1997-09-05  
EARLIER APPLICATION NUMBER: 60/056,884  
EARLIER FILING DATE: 1997-08-22  
NUMBER OF SEQ ID NOS: 280  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 209  
LENGTH: 483

Query Match 77.6%; Score 2509.5; DB 10; Length 483;  
Best Local Similarity 96.9%; Pred. No. 2.4e-230;  
Matches 467; Conservative 2; Mismatches 2; Indels 11; Gaps 1;

```
Db 1 MATGGIRAMTSLYQLAGKELGDCXSYITGASGTWALANLYKDPWSDQLAGPT 60
Qy 195 ELLKTQVTKNKLGVLAPOLORYQELAEARLGYPSCTNLWALINEALLHDPHDHL 254
Db 61 ELLKTQVTKNKLGVLAPOLORYQELAEARLGYPSCTNLWALINEALLHDPHDHL 120
Qy 255 SDQREALSHGQNPLPIYCALNTKQSLTTFBFGWCEPSPYEVGPKYGAFTPSLFGSE 314
Db 121 SDQREALSHGQNPLPIYCALNTKQSLTTFBFGWCEPSPYEVGPKYGAFTPSLFGSE 180
Qy 315 FFMQMLKRLPESRICFLEGWNSNLYAANLQDSLYWASEPQFMDRWVRNQNALDKQVP 374
Db 181 FFMQMLKRLPESRICFLEGWNSNLYAANLQDSLYWASEPQFMDRWVRNQNALDKQVP 240
Qy 375 LKTEEPSTAGRTAEFTDILLTWPLAQATHNLRGLHFKHDXFQHPHSTWKAATLDG 434
Db 241 LKTEEPSTAGRTAEFTDILLTWPLAQATHNLRGLHFKHDXFQHPHSTWKAATLDG 300
Qy 435 LPNOLTPSEPHCLLDVGYLINTSCPLPQLQPTRDVLILSLDYNLHGAFQQLLGRFCQ 494
Db 301 LPNOLTPSEPHCLLDVGYLINTSCPLPQLQPTRDVLILSLDYNLHGAFQQLLGRFCQ 360
Qy 495 EQGIPFPISPSPEQLQPRECHTSDPTCPGAPAVLHP-----SSGVRTPEE 543
Db 361 EQGIPFPISPSPEQLQPRECHTSDPTCPGAPAVLHP-----SSGVRTPEE 420
Qy 544 AAGAEVNLSSSDSPHYTKVTSQSDVDKLLHLTHYNNCNOEQLLEALRQAVRRRR 603
Db 421 AAGAEVNLSSSDSPHYTKVTSQSDVDKLLHLTHYNNCNOEQLLEALRQAVRRRR 480
Qy 604 PH 605
Db 481 PH 482
```

## RESULT 8

```
US-10-332-426-6
; Sequence 6, Application US/10332426
; Publication No. US20040029136A1
; GENERAL INFORMATION:
; APPLICANT: INCYTE GENOMICS, INC.; TANG, Y. Tom;
; APPLICANT: AZIMZAI, Yalda; DAS, Debopriya;
; APPLICANT: THORNTON, Michael; LU, Dyung Aina M.;
; APPLICANT: TRIBOULEY, Catherine M.; YUE, Henry;
; APPLICANT: GANDHI, Ameena R.; CHAWLA, Narinder K.;
; APPLICANT: KHAN, Farrah A.; LU, Yan;
; APPLICANT: YAO, Monique G.; HAFALIA, April J. A.;
; APPLICANT: ELLIOTT, Vicki S.; ARVIZU, Chandra S.;
; APPLICANT: LAL, Preeti; RAMKUMAR, Jayalaxmi;
; APPLICANT: NGUYEN, Daniel B.; BAUGHN, Mariah R.
; TITLE OF INVENTION: LIPID METABOLISM MOLECULES
; FILE REFERENCE: PI-0152 USN
; CURRENT APPLICATION NUMBER: US/10/332,426
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US 60/216,803
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 60/216,801
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 60/218,233
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 60/220,046
; PRIOR FILING DATE: 2000-07-21
; PRIOR APPLICATION NUMBER: US 60/220,739
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/222,824
; PRIOR FILING DATE: 2000-08-04
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PERL Program
; SEQ ID NO 6
; LENGTH: 1026
; TYPE: PRT
; ORGANISM: Homo sapiens
```

## FEATURE:

```
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No. US20040029136A1 7477093CD1
US-10-332-426-6
```

```
Query Match 46.1%; Score 1492; DB 12; Length 1026;
Best Local Similarity 51.6%; Pred. No. 1.3e-13;
Matches 296; Conservative 92; Mismatches 152; Indels 34; Gaps 8;
Qy 61 LOPPLGFKRFSCLSPSSWDYRLR-----ELAVRLGFGPCAEQAFLSRRKQVAA 112
Db 452 LRPLTIGKEVTMDYPAFNPAGVRLQLKAEQCEELAVHLGNLCAEEQAFLSRRKQVAA 511
Qy 113 ALRQALQDLQDEDEIPVVAIMATGGGIRAMTSLYQLAGLKEGLLDCVSYITGASG 172
Db 512 ALKQALQDLQDEDEVPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVYTSFGS 571
Qy 173 TWALANLYYEDPWSQDLAGTELLKTQVTKNKLGVLAPOLORYQELAEARLGYPS 232
Db 572 TWTWALYGDPEWSQDLAGEPIRYAREHLAKSKLEVFSPERLASYRRELELRAEQGHPT 631
Qy 233 FTNLWALINEALLHDPHDHLSDQREALSHGQNPLPIYCALNTKQSLTTFEGWCEP 292
Db 632 FVDLWALVLESMLHGQVMDQKLSQRAALRGQNPLPLYLSLVKNNLETLDFKEWVEF 691
Qy 293 SPYEVGPKYGAFTPSLFGSEFFMGQMLKRLPESRICFLEGWNSNLYAANLQDSLYWAS 352
Db 692 SPYEVGFLKYGAFVPELFGSEFFMGRLMRRIPEPRICFLEAIMSNIFSLNLLDAWYDIT 751
Qy 353 EPSQFMDRWVRNQA-NLJKEQVPLL-----KIEB---PPSTAGRIAEFFTDLLTWPLA 402
Db 752 SSGESWKQHIKDKTRSLKE--PLTTSQTSRLEASWLOQGT--LAQAFGLTGRPLH 807
Qy 403 QATHNLRGLHFKHDXFQHPHSTWKAATLDGLPNQLTPESEPHCLLDVGYLINTSCPL 462
Db 808 QPSNPLFQGLQHLQDYCSHKDFSTWADYQDLSMPSQLTPKEPRCLVDAAYFINITSSPM 867
Qy 463 LQPTRDVLILSLDYNLHGAFQQLQGLGRFQEQGIPFPISPSPEQLQPRECHTSDPT 522
Db 868 PRPGRRLDILLSDYSLSAPFEALQOTELYCRARGLPFRVPEPSQDQHPRECHLFSDP 927
Qy 523 TCGGAPAVLHP-----SSGVRTPEEAAAGAEVNLSSSDSPHYTKVTSQSDVD 571
Db 928 ACPEAPILLHPLVNNASFKDHSAPGVQSPAELOQGGQDVTGATCTYLSNMTYKEEDPE 987
Qy 572 KLLHLTHYNNCNOEQLLEALRQAVRRR-QRRP 604
Db 988 LLRLSDYNNVQTSQAILQALRTALKHRTLEARP 1021
```

## RESULT 9

```
US-10-467-248-1
; Sequence 1, Application US/10467248
; Publication No. US20040086905A1
; GENERAL INFORMATION:
; APPLICANT: DAS, Debopriya; YAO, Monique G.;
; APPLICANT: ARVIZU, Chandra S.; BAUGHN, Mariah R.;
; APPLICANT: LU, Yan; HAFALIA, April J.A.;
; APPLICANT: CHAWLA, Narinder K.; GRIFFIN, Jennifer A.;
; APPLICANT: LU, Dyung Aina M.; YUE, Henry;
; APPLICANT: DING, Li; ELLIOTT, Vicki S.;
; APPLICANT: FORTSYTHE, Ian J.; RAMKUMAR, Jayalaxmi;
; APPLICANT: GANDHI, Ameena R.; ISON, Craig H.;
; APPLICANT: WARREN, Bridget M.; TANG, Y. Tom;
; APPLICANT: EMERLING, Brooke M.; HONCHELL, Cynthia D.;
; APPLICANT: LYNE, Michael; BARROSO, Ines
; TITLE OF INVENTION: LIPID-ASSOCIATED MOLECULES
; FILE REFERENCE: PI-0358 USN
; CURRENT APPLICATION NUMBER: US/10/467,248
; CURRENT FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: PCT/US02/03813
; PRIOR FILING DATE: 2002-02-06
; PRIOR APPLICATION NUMBER: US 60/266,910
```

```

; PRIOR FILING DATE: 2001-02-06
; PRIOR APPLICATION NUMBER: US 60/276,891
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: US 60/276,855
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: US 60/279,760
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: US 60/283,818
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: US 60/285,405
; PRIOR FILING DATE: 2001-04-20
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PERL Program
; SEQ ID NO 1
; LENGTH: 996
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Incyte ID No: 7472774CDI
; US-10-467-248-1

Query Match      38.4%; Score 1243.5; DB 16; Length 996;
Best Local Similarity 44.8%; Pred. No. 6.6e-109;
Matches 261; Conservative 86; Mismatches 187; Indels 49; Gaps 9;

QY 56 RDGSGIQQPLPGKFRSCLS-----LPSSWDYRL-----RELAVRLGFGPCABEQ 101
Db 419 RKKGPIISQ-----LDCLSDGQVMTLPVGSYELHMKSTPCPETLDVRLGFLSPAELE 472
QY 102 FLSSRKQVAAALROALQDGLQDEIRPVVAIMATGGIRAMTSLYXGQLAGLKEGLD 161
Db 473 FLQKKVVAKALKVQLQEDLQEDVPIAIAMATGGIRMTSMYCHLLGLQKLNLD 532
QY 162 CVSYITGASGSTWALANLYEDPEWSQKDLAGPTTELLKTQVTKNGLVLAPELQORQEL 221
Db 533 CASYITGLSGATWTMATLYRDPDWSKNLPAIFEARRHVVKDKLPFLFPDQLRKFOEEL 592
QY 222 ABRARIGYPCFTNLWALINEALLHDEPHDKSLDQREALSHGQNPPIYCALNTKQSL 281
Db 593 RORSQEGYRVTFTDFWGLLIETCLGDRNECKLSQDRAALSQGNPLPIYLTINVKDD-- 650
QY 282 TTFEGGWCFCFSPVEVGFPGYKAFIPSELFGSEFPMQMKRLPESRICFLEGWSNLYA 341
Db 651 VSNQDVWFVFEFSPVEVGLQKIGAFIPSELFGSEFPMGLVKRIPESRICYMWGLMSSIFS 710
QY 342 ANLQDSLYWASEPQFWDVRVNRQANLDKQVPLLKIEEPPSTAGRIAE----- 390
Db 711 LNLDDAMNLSHTSEFFHRTWREKVQ--DIEDEPIL--PEIPKCDANILETTVVIPIGSLWS 767
QY 391 -FTDILLTWPLAQATHNLFGLHFKDYQHPHFSTWKAATLIDGLPNQLTSPSEPHICLL 449
Db 768 NSFREILTHRSFVSEFHNFLSGLQLHTNYLQNGQFSRWKQTVLDPGFPNQLTESANHICLL 827
QY 450 DVGVLINTSCPLIQLPQTRDVLILSLDYNLHGAFQQLQLGRFCOEQIPPPISPSPEE 509
Db 828 DTAFFVNSYPPILRPKADLIHLNYCAGSQTKPLQTCYEYCTVQVNPFPKYE-LPDE 886
QY 510 QLOPRECHTSDPTCPGAPAVLHF-----SSGVRRTPEAAAGEVNLSSSDSPY 558
Db 887 NENLKECVLMENPQEPDAPITVTFPPLINDTPRKYKAPGVRSPEELEGQGVDIYGPKTPY 946
QY 559 HYTKVTYSQEDVDKLLHLYTHVNCNQEOLLEALROAVORRQ 601
Db 947 ATKELTVTEATFDKLVKLSYNNILNNKDTLLQALRLAVEKKR 989

RESULT 10
US-10-380-873B-1
; Sequence 1, Application US/10380873B
; Publication No. US20040014089A1
; GENERAL INFORMATION:
; APPLICANT: Hiromasa MIYAJI, et al.

```

```

; TITLE OF INVENTION: Polypeptide having phospholipase A2 activity
; FILE REFERENCE: 2139.34
; CURRENT APPLICATION NUMBER: US/10/380,873B
; PRIOR FILING DATE: 2003-07-09
; PRIOR APPLICATION NUMBER: JP 00/146466
; PRIOR FILING DATE: 2000-09-19
; PRIOR APPLICATION NUMBER: JP 01/284044
; PRIOR FILING DATE: 2001-05-16
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 1
; LENGTH: 849
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-380-873B-1

Query Match      35.2%; Score 1139.5; DB 15; Length 849;
Best Local Similarity 41.8%; Pred. No. 4.4e-99;
Matches 250; Conservative 94; Mismatches 213; Indels 41; Gaps 9;

QY 43 MESLSVAQAG-----VQMRDLGS-----LQPPPLGFKFRSCLSLPSSWDYRLR----- 85
Db 250 MELLAAGVSGPSTELBAQTSKLGEGGILLSSDPLGQEQSVAGLGGQEQVALSKMVKEMSS 309
QY 86 -ELAVRLGFGPCABEQAFLSRRKQVAAALROALQDGLQDEIRPVVAIMATGGIRAM 144
Db 310 GDLDLRLGFLDLSGQEQEFLDRRKQVVKALQVVLGSLSEALDSQVVPVAVLGGGGGTRAM 369
QY 145 TSYLQGLAGLKEGLDLCVSYITGASGSTWALANLYEDPEWSQKDLAGPTTELLKTQVTKN 204
Db 370 SSSYGLSLAGLQELGLDITVTLSCVSGSTWCISTLYRDPAWSQVALQGPTRIAQVHVCCS 429
QY 205 KLGVLAPSQORVROELAEARLGYSCFTNLWALINEALLHDEPHDKSLDQREALSHG 264
Db 430 KMGALSTERLQYTYQELGVRSRSHSVSLDMLGLVEXLYLLEENPAKLSDDQEAVRQ 489
QY 265 QNPLPIYCALNTKQSLTTFEGGWCFCFSPVEVGFPGYKAFIPSELFGSEFPMQMKRL 324
Db 490 QNPIYTSVNVNR-TNLSGEDFAEWCEFTFYEVGFPGYKAVVPELFGSELFGRLILQLQ 548
QY 325 PESRICFLEGWSNLYAANLQDSLYWASEPQFWDVRVNRQANL-DKEQVPLLKIEEPP- 382
Db 549 PEPRICVLCQMGWSAFATSLDEIFLKTAGSGLSFLWYRGSVNITDDCQKP--QLHNPSR 605
QY 383 -----STAGRIAEFFTDLLTWPLAQATHNLFGLHFKDYQHPHFSTWKAATLIDGLP 436
Db 607 LRTRLITPQFPFQAVLIDIFTSRFTSAQSFNTRGLCHDKDYVAGREFVAKDTHPDAPF 666
QY 437 NQLTSPSEPHICLLDVGYLINTSCPLIQLPQTRDVLILSLDYNLHGAFQQLQLGRFCOEQ 496
Db 667 NQLTPMRDCLYLVGDFAINSPFPPLALLPQRAVDLILSPDYSLEAPEVLMKTEKYCLDR 726
QY 497 GIDFPPIPSPEBQLOPRECHTSDPTCPGAPAVLHF-----SSGV-RTPEEA 544
Db 727 GIDFPPISEVGPEDVEEARECYLFAKEDRPSPIVLFHFLVNRFTFRTHLAPGVERQTAEEK 786
QY 545 AAGEVNLSSDSPHYTKVTYSQEDVDKLAHLHLYTHVNCNQEOLLEALROAVORROR 602
Db 787 AFGDFVINRDEPTPYGMNFTYEQDFYRLVALSKYNNVNLNNVETLKCALQLALDRHQAR 844

RESULT 11
US-10-380-873B-38
; Sequence 38, Application US/10380873B
; Publication No. US20040014089A1
; GENERAL INFORMATION:
; APPLICANT: Hiromasa MIYAJI, et al.
; TITLE OF INVENTION: Polypeptide having phospholipase A2 activity
; FILE REFERENCE: 2139.34
; CURRENT APPLICATION NUMBER: US/10/380,873B
; CURRENT FILING DATE: 2003-07-09
; PRIOR APPLICATION NUMBER: JP 00/146466
; PRIOR FILING DATE: 2000-09-19

```

; PRIOR APPLICATION NUMBER: JP 01/284044  
 ; PRIOR FILING DATE: 2001-05-16  
 ; NUMBER OF SEQ ID NOS: 47  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 38  
 ; LENGTH: 853  
 ; TYPE: PRT  
 ; ORGANISM: Mus musculus  
 ; US-10-380-873B-38

Query Match 35.2%; Score 1138; DB 15; Length 853;  
 Best Local Similarity 42.4%; Pred. No. 6.2e-99;  
 Matches 235; Conservative 102; Mismatches 189; Indels 28; Gaps 7;  
 QY 74 LSLPSSWDYRLRELAVRLGFGPCAEEQAFLSRRKQVVAALRQALQDGLQDEIPVVA 133  
 Db 295 VSLRMKADSSGDLRLGLFDLDCGQEFLDKQKQVASKALQRMVGLSEALHCDQVPVVA 354  
 QY 134 IMATGGGIRAMTSLYQLAGLKLGLDVCYSYITGASGTWALANLYEDPEWSQKDLAGP 193  
 Db 355 VLGGSGGTAMTSLYGLAGLQBLGLDVAVTLSGVSGSWCISTLYRDPWSQKALQGP 414  
 QY 194 TELTKQVTKNKLGLVLAPSQLORYOELAEARLGYPCFTNLWALINEALLHDEPHDK 253  
 Db 415 IKYASERVCSKGLMLSPKQFEYYSREKRAWESRHSMSFTDLWGLIIEYFLNQEENPAK 474  
 QY 254 LSPQREALSHGONPLPIYCALNTKGSLTTFEGEWCFSPEYVGPFGKYGAFIPSELFGS 313  
 Db 475 LSPQETVSGQGNPYPIYASINVH-KNISGDDFAEWCEFTPEYVGPFGKYGAVYPTLFGS 533  
 QY 314 EFPWGLMKELPSRSCFLGINSNLYANLQDSLYWASEPQFWRWVRNQANLDKXQVPLKIEEPPSTA 373  
 Db 534 EFPWGLHFWPEPRICYLQGMGSAFAASLYEFLKGLGLSLFLDWHRGSVSV-TDDW 592  
 QY 374 PLIKIEEPPSTAGRI-----AEFFTDLTLTWRLAQATHNPLRGLHFKDYFQHPHF-- 424  
 Db 593 PLKRLKQDPTLPTLPTMSSFSQAVLDIFTSITCAQTFNTRGLCMKYDTARKDQFVV 652  
 QY 425 --STWKATL---DGLPNQLTPSEPHCLLDVGYLINTCLPLQPTRDVLLSLDYLNL 479  
 Db 653 SEDAMSHNYGVDPACPNQLTPMKDFSLVDGGFAINSPFVLQVQRAVDLIVSFDYSL 712  
 QY 480 HGAFOQLLGRCCQOGTFFPPIPSPEQLOPRECHTFSDPTCGAPAVLHF-----SSGV 533  
 Db 713 EGEFEVLQVTEKYCRDRGIPFPRIEVDPKDSEDPRECYLFAEADPCSPVLHFLPVNRT 772  
 QY 534 -----SSGV-RRTPPEAAAGEVNLSSDGPYHYTKVTSQEDVDKLLHLTHYVNCNQQEQ 587  
 Db 773 FRTHLAPGVERTAEKAFGDFIINGPDTAYGMDFTEYEPKEFDRLVTLRYNLNNKET 832  
 QY 588 LLEALRQAVRRRQ 601  
 Db 833 IRHALQALDRRRQ 846

RESULT 12  
 US-10-380-873B-22  
 ; Sequence 22, Application US/10380873B  
 ; Publication No. US20040014089A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Hiromasa MIYAJI, et al.  
 ; TITLE OF INVENTION: Polypeptide having phospholipase A2 activity  
 ; FILE REFERENCE: 2139.34  
 ; CURRENT APPLICATION NUMBER: US/10/380,873B  
 ; PRIOR FILING DATE: 2003-07-09  
 ; PRIOR APPLICATION NUMBER: JP 00/146466  
 ; PRIOR FILING DATE: 2000-09-19  
 ; PRIOR APPLICATION NUMBER: JP 01/284044  
 ; PRIOR FILING DATE: 2001-05-16  
 ; NUMBER OF SEQ ID NOS: 47  
 ; SOFTWARE: PatentIn Ver. 2.0  
 ; SEQ ID NO 22  
 ; LENGTH: 854

; TYPE: PRT  
 ; ORGANISM: Mus musculus  
 ; US-10-380-873B-22  
 Query Match 34.8%; Score 1127; DB 15; Length 854;  
 Best Local Similarity 42.6%; Pred. No. 7e-98;  
 Matches 231; Conservative 100; Mismatches 183; Indels 28; Gaps 7;  
 QY 86 ELAVRLGFGPCAEEQAFLSRRKQVVAALRQALQDGLQDEIPVVAIWATGGGIRAMT 145  
 Db 308 DLDRLGFDLDCGQEFLDKQKQVASKALQRMVGLSEALHCDQVPVVAIVGSGGTAMT 367  
 QY 146 SLYGQLAGLKLGLDVCYSYITGASGTWALANLYEDPEWSQKDLAGTPTLLKTQVTKN 205  
 Db 368 SLYGSLAGLQELGLDVAVTLSGVSGSWCISTLYRDPWSQKALQPIKYASERVCSK 427  
 QY 206 LGVLAPSQLORYOELAEARLGYPCFTNLWALINEALLHDEPHDKLSQREALSHGQ 265  
 Db 428 IGLMSPKQFEYYSREKRAWESRHSMSFTDLWGLIIEYFLNQEENPAKLSQOQETVSGQ 487  
 QY 266 NPLPIYCALNTKGSLTTFEGEWCFSPEYVGPFGKYGAFIPSELFGSEFFMGOLMKRLP 325  
 Db 488 NPYPIYASINVH-KNISGDIYFAEWCEFTPEYVGPFGKYGAVYPTLFGSEFFMGRLHFWP 546  
 QY 326 ESRICFLEGIWNSNLYANLQDSLYWASEPQFWRWVRNQANLDKXQVPLKIEEPPSTA 385  
 Db 547 EPRICYLQGMGSAFAASLYEFLKGLGLSLFLDWHRGSVSV-TDDWPKLRQDPTRLP 605  
 QY 386 GRI-----AEFFTDLTLTWRLAQATHNPLRGLHFKDYFQHPHF-----STWKATL-- 432  
 Db 606 TRLFTPMSSFSQAVLDIFTSITCAQTFNTRGLCMKYDTARKDQFVWSEDAWHSNHYG 665  
 QY 433 -DGLPNQLTPSEPHCLLDVGYLINTCLPLQPTRDVLLSLDYLNLHGAFOQLQLGR 491  
 Db 666 PDACPNQLTPMKDFSLVDGGFAINSPFVLQVQRAVDLIVSFDISLESGPFEVLQVTEK 725  
 QY 492 FQEOGIPFPPIPSPEQLOPRECHTFSDPTCGAPAVLHF-----SSGV-RR 539  
 Db 726 YCRDRGIPFPRIEVDPKDSEDPRECYLFAEADPCSPVLHFLPVNRTFRTHLAPGVRRQ 785  
 QY 540 TPEAAAGEVNLSSDGPYHYTKVTSQEDVDKLLHLTHYVNCNQBOLLEALRQAVRR 599  
 Db 786 TAEKAFGDFIINGPDTAYGMDFTEYEPKEFDRLVTLRYNLNNKETIRHALQALDRR 845  
 QY 600 RQ 601  
 Db 846 RQ 847

RESULT 13  
 US-10-332-426-3  
 ; Sequence 3, Application US/10332426  
 ; Publication No. US20040029136A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: INCYTE GENOMICS, INC.; TANG, Y. Tom;  
 ; APPLICANT: AZIMZAI, Yalda; DAS, Debopriya;  
 ; APPLICANT: THORNTON, Michael; LU, Dying Aina M.;  
 ; APPLICANT: TRIBOULET, Catherine M.; YUE, Henry;  
 ; APPLICANT: GANDHI, Ameena R.; CHAWLA, Narinder K.;  
 ; APPLICANT: KHAN, Farrah A.; LU, Yan;  
 ; APPLICANT: YAO, Monique G.; HAFALIA, April J. A.;  
 ; APPLICANT: BELLITT, Vicki S.; ARVIZU, Chandra S.;  
 ; APPLICANT: IAL, Preeti; RAMKUMAR, Jayalaxmi;  
 ; APPLICANT: NGUYEN, Dannie B.; BAUGHN, Mariah R.  
 ; TITLE OF INVENTION: LIPID METABOLISM MOLECULES  
 ; FILE REFERENCE: PI-0152 USN  
 ; CURRENT APPLICATION NUMBER: US/10/332,426  
 ; CURRENT FILING DATE: 2003-01-06  
 ; PRIOR APPLICATION NUMBER: US 60/216,803  
 ; PRIOR FILING DATE: 2000-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/216,801  
 ; PRIOR FILING DATE: 2000-07-07  
 ; PRIOR APPLICATION NUMBER: US 60/218,233

```
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: US 60/220,046
; FILE REFERENCE: 018501-00620005
; CURRENT APPLICATION NUMBER: US 60/220,739
; PRIOR FILING DATE: 2000-07-21
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/222,824
; PRIOR FILING DATE: 2000-08-04
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PERL Program
; SEQ ID NO 3
; LENGTH: 848
; TYPE: PRT
; ORGANISM: Homo sapiens
; NAME/KEY: misc_feature
; OTHER INFORMATION: incyte ID No. US20040029136A1 1281946CDI
US-10-332-426-3

Query Match      34.4%; Score 1112; DB 12; Length 848;
Best Local Similarity 41.2%; Pred. No. 1.9e-96;
Matches 247; Conservative 97; Mismatches 211; Indels 44; Gaps 11;

QY 43 MSLSLVAQAQ-----VQWRDLGS-----IQPPLGKFRFSC-----LSLPSSWDYR 83
Db 250 MELLAAVQSPSAEAEQAQTKLGGGILLSSPLG-QEEQCSVALGEGEGVALSMVTVEMS 308
QY 84 LRELAVRLGFGPCAERQAFSLRKKQVVAALRQALQOLDGDLQEDFIPVVAIMATGGIRA 143
Db 309 SGBLDURLGFDLSDGQEFDRRRKQVSKALQQLVGLSEALDSGQVPVAVLGGGGGTRA 368
QY 144 MTSLYQLAGLKLGLLDCVSYITGASGSTWALANLYDEPWQKDLAGTTELLKTKQVTK 203
Db 369 MSSLYSGLAGLBGLLDVTYLSVSGSTWCTSTLYRDPANQVALQGPRAQVHVS 428
QY 204 NKLGVLAPSOQYRQELAEARLGYPSCTNLMWALINEALLHDEPHDKLSQREALSH 263
Db 429 SKMGALSTERLQYTBELGVRERSGHSVSLDLWGLLVEYLLYQEEENPAKLSQOKAVRQ 488
QY 264 GNPPLIYCALNTKQSLITFEFGECERSPYEYVGPYKCAFIPSELFGSEFPMGOLMKR 323
Db 489 GQNPYPIYTSVNVYR-TNLGSEDFA-WCEFTPYKVPKYGAYVTELFSGELFMGRLLQL 546
QY 324 LPESRICFLEGIWSNLYAANLQDSLYWASEPQFWRDVRVWNOANL-DKEQVPLLKIEEP 382
Db 547 QEPERICYLQGMWSAFATSLDIFLTKTAGSGLSFLEWYRGVNIITDCKP--QLHNPS 604
QY 383 -----STAGIAEFTDLLWRPLAQATHNLFRLGHFKDYFQHPHFSTWKATLDGL 435
Db 605 RLKRLTLTPQSPQAVLDIIFTSRFTSAQSFNFTRGILCLHKDYVAGREFVAKDTHPDAF 664
QY 436 PNOLTPSEPHCLLDVGYLINTSCLPLLOPTRDVLTLSDYNLHGAFOQLLGRPCOE 495
Db 665 PNOLTPMRDCLYLVGGFALNSFPFALPLQRAVDLILSPDYSLEAPFEVLKMKTEKYCLD 724
QY 496 QGIPFPPIPSPEQLOPQRECHTFSDPTCPGAPAVLHF-----SSGV-RRTPEE 543
Db 725 RGIPFPISEVGPEDVEARECYLFAKAEDPRSPVLHFLPVNTRFTHLAPGVERTAE 764
QY 544 AAGEVNLSSDSPHYHVKTYTGOEDVDKLLHLYTHVNCNNQOLLEALRQAVORRQ 602
Db 785 KAFGDFVINRPTPYGMNFTYPEQDFYRLVALSRVNLNNVETLKCALQLALDRHOAR 843

RESULT 14
US-10-211-462-50
; Sequence 50, Application US/10211462
; Publication No. US20040033495A1
; GENERAL INFORMATION:
; APPLICANT: Murray, Richard
; APPLICANT: Glynn, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Aziz, Natasha
; APPLICANT: Eos Biotechnology, Inc.
```

```
; TITLE OF INVENTION: Methods of Diagnosis of Angiogenesis, Compositions and
; TITLE OF INVENTION: Methods of Screening for Angiogenesis Modulators
; FILE REFERENCE: 018501-00620005
; CURRENT APPLICATION NUMBER: US/10/211,462
; CURRENT FILING DATE: 2003-02-13
; PRIOR APPLICATION NUMBER: US 09/784,356
; PRIOR FILING DATE: 2001-02-14
; PRIOR APPLICATION NUMBER: US 09/791,390
; PRIOR FILING DATE: 2001-02-22
; PRIOR APPLICATION NUMBER: US 60/310,025
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/334,244
; PRIOR FILING DATE: 2001-11-29
; NUMBER OF SEQ ID NOS: 230
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 50
; LENGTH: 749
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-211-462-50

Query Match      19.1%; Score 619; DB 12; Length 749;
Best Local Similarity 27.1%; Pred. No. 1.9e-49;
Matches 174; Conservative 125; Mismatches 238; Indels 106; Gaps 22;

QY 44 ESLSVAQAQVQWRDLGSLQPPPLGKFRFSCLSLPSSWDYRLRELA---VRLGFGPCAEE 99
Db 100 ETLGTRATFTVSSMKVGEKEVEFIFNQVTMVELEMS-----LEVSCPDRLRSMALCDOE 154
QY 100 QAFLSRRKQVAAALRQAL---QLDGDLOEDFIPVVAIMATGGIRAMTSLYQLAGLKE 156
Db 155 KTFRQQRKEHIRESMKLLGPKNSEGLHSARDVPVVAIILGSGGPRAMVFGSGVMKALYE 214
QY 157 LGLLDCVSYITGASGSTWALANLYDEPWQKDLAGTTEL---LKTQVTKNLKGLVLAPSQ 213
Db 215 SGILDCAITYVAGLSGTWTMYSTLYSHPDPEK---GPERINEELMKNVSHNPLLLTPOK 271
QY 214 LQRYRELAERARLGYPSCTNLMW-LINEALLHDEPHDKLSDOREALSHGQNPPIYC 272
Db 272 VKRYVESLWKXSSGGQVTFDTIFGLMIGETLIHNRMT-TLSSLKEKVNATACPLPLFT 330
QY 273 ALNTKQQSITTFEFGECERSPYEYVGPYKCAFIPSELFGSEFPMGOLMKRLPESRICFL 332
Db 331 CLHVK-PDVSELMAFDWVEFSPYEIGMAKYGTFTMAPDLFGSKFFMGTVVKKYEENPLHFL 389
QY 333 EGIWSNLYA-----ANLQDSLYWASEPQFWRDVRVWNOANLDEQVPLL 376
Db 390 MGWYGSFAFSLFNRLVGLVSGSOSRGSTMBEEL-----ENITTKHIVSNDSSDD--- 439
QY 377 KTEPEPSTAGRIA--EFTFD-----LLTWRPLAQATHNLFRLGHFH 415
Db 440 ESHEPKGTENEDAGSYQSDNQASWTHRMIMALVDSALFNTEGRAGKVVHFMGLNLN 499
QY 416 KQYFQHP--HFSTWKATLDGL-----PNQ-----LTPSEPHCLLDVGYLINTSCL 460
Db 500 TSVPLSPLSDFATQDSFDDDELDAADVADPEFERIYEPDLVSKKTHVVDVSGLTFNLYP 559
QY 461 PLLOPTRDVLTLSDYNLHGA-----FOOLQLGRFCOEQIGIPFPPIPSPEQLOP 515
Db 560 LILRQGRVDLILSIFDSARPSSPPKELLAEKWAQMNKLPFPKIDPFYVDFREGLKE 619
QY 516 CHTFSDPTCP---GAPAVLHF-----SSGV-RRTPEEAAAGVNL--SSSDSPY 558
Db 620 CVYFK-PKNPDMEKOCPTIHFVLANINFRKYKAPGVPRETEEEKIADPIDFDDPESPF 678
QY 559 HYTKVTYSQEDVDKLLHLYTHVNCNNQOLLEALRQAVORRQ 601
Db 679 STENFOYPNQAFKRLHDLMHFNTLNNIDVKEAMVESIEYRRQ 721

RESULT 15
US-10-157-898-2
; Sequence 2, Application US/10157898
```

```

; Publication No. US20030225011A1
; GENERAL INFORMATION:
; APPLICANT: DAVID, Samuel
; APPLICANT: KALYVAS, Athena
; TITLE OF INVENTION: PHOSPHOLIPASE A2 EXPRESSION AND ACTIVITY AND USE THEREOF FOR DIAG
; TITLE OF INVENTION: PROGNOSTICATION, PREVENTION AND TREATMENT OF NEURAL INFLAMMATORY
; TITLE OF INVENTION: DEMYELINATING DISEASE
; FILE REFERENCE: 85827-36
; CURRENT APPLICATION NUMBER: US/10/157,898
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patent version 3.1
; SEQ ID NO 2
; LENGTH: 749
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-157-898-2

Query Match      19.1%; Score 619; DB 12; Length 749;
Best Local Similarity 27.1%; Pred. No. 1.9e-49;
Matches 174; Conservative 125; Mismatches 238; Indels 106; Gaps 22;

QY 44 ESLSVAQGVQVRDLGSLQPPPLGKRFKFSCLSLPSSWDYRLRLA-----VRLGFGPCABE 99
Db 100 ETILGTATFTVSSMKVGEKVPFIFNQVTVMVLEMS-----DEVCSCLPDLRFSMALCDQE 154

QY 100 QAFLSRRKQWAAALRQAL---QLDGDLOEDEIPVVAIMATGGGIRAMTSLYGOLAGLKE 156
Db 155 KTFRQQRKEHIRESMKKLGPKNSEGLHSARDVPVVAIIIGSGGGFRAMVGFSGVMKALYE 214

QY 157 LGLLDCVSYITGASGTWALANLYEDPEWSQKDLAGTEL---LKTQVTNKLGLVLAPSQ 213
Db 215 SGILDCATYVAGLSGTWTMTSLYSHPDPEK---GPEEBELMKNVSHNPLLLTPQK 271

QY 214 LQRYQELAEARLGPSCFTNLWA--LINEALLHDEPHDKLSQDREALSHGQNPPIYC 272
Db 272 VRYVESLWKKSSGQFVTTFDIFGMLIGETLIHNMT--TSSSLKEKVTACQPLPFT 330

QY 273 ALNTKQSILTFEFGWCFCFSYEVGPKYGAIPSELFSGSFFFMQMLMKRLPESRICFL 332
Db 331 CLHVK--PDVSELMFADWVFSVEIGMAKYGTFMADPLFGSKFFMGTVVKYEEENPLHEL 389

QY 333 EGIWSNLYA-----ANQDSLYWASEPSQFWDNRWVRNQANLDKEQVPLL 376
Db 390 MGWGSFAFSLFNRLVGVSGSQSRGSTMBEEL-----ENITTKHIVSNDSDSD-- 439

QY 377 KIEEPSTAGRIA--BFTD-----LLTWRLPAQATHNRLGLHFEH 415
Db 440 ESHEPKGTENEDAGSDYQSDNQASWIHRMIMALVSDSALFNTREGRAGKVHNFMLGILN 499

QY 416 KDYFQHP--HFSTWKATTLDLG-----PNQ-----LTPSEPHLCLLDVGYLINTSCL 460
Db 500 TSYPLSPLSDFATQDSFDDDELDAADVADFEFRIYEPDLVKSKIHVVDSGLTFNLPPY 559

QY 461 PLLQPTRVDLILSLDYNLHGA-----FOQLLGRFCOEGQIPPPPIPSPEEQLOPRE 515
Db 560 LILRQRGVLDLIISDFSRPSDSSPPFKELLIAEKWAKWNKLPFKIDPIYVDFREGLKE 619

QY 516 CHTFSDPTCP---GAPAVLHF-----SSGV--RRTPEEAAAAGVNL--SSSDSPY 558
Db 620 CIVFK--PKNPFMEKDCPTIIHFVLANINFKRYKAGVPRTEEEKIEADFDIDDPESPF 678

QY 559 HYTKYTSQEDVDKLLHLTHYVNNQEQLEALRAQVQRKQ 601
Db 679 STFNFQYPNQAFKRLHDLMHFNTLNNIDVIKEAMVESIEYRQ 721

```

Search completed: October 5, 2004, 19:41:16  
Job time : 141.133 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:21:45 ; Search time 41.14 Seconds  
(without alignments)  
1414.581 Million cell updates/sec

Title: US-09-830-321A-2  
Perfect score: 3235  
Sequence: 1 MIFVELSPTLALCLERVASH.....EQLEALRQAVQRQRPH 605

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : PIR 78.\*  
1: pir1.\*  
2: pir2.\*  
3: pir3.\*  
4: pir4.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	619	19.1	749	1 A39329	phospholipase A2 (
2	602	18.6	749	1 B39898	phospholipase A2 (
3	596	18.4	748	1 I50699	cytosolic phosphol
4	572	17.7	741	2 B54908	phospholipase A2 c
5	498.5	15.4	541	2 T13162	cytosolic phosphol
6	198	6.1	627	4 A40201	artifact-warning s
7	193.5	6.0	613	4 C40201	artifact-warning s
8	186	5.7	673	2 T50281	probable lysophosp
9	184	5.7	686	2 S66693	hypothetical prote
10	177	5.5	612	2 S29318	lysophospholipase
11	170	5.3	46	2 I54375	gene NF2 protein -
12	162	5.0	664	2 S53037	PLB1 protein - yea
13	160	4.9	39	2 I54374	gene NF2 protein -
14	159.5	4.9	623	2 T40891	probable lysophosp
15	159	4.9	624	2 T38006	probable lysophosp
16	158	4.9	53	2 A42442	integrin beta-1 ch
17	154	4.8	754	2 T18238	lysophospholipase
18	151	4.7	613	2 T38007	probable lysophosp
19	140	4.3	644	2 T37800	probable lysophosp
20	136	4.2	706	2 S53035	probable lysophosp
21	124	3.8	100	2 A46010	X-linked retinopat
22	122.5	3.8	673	4 F40201	artifact-warning s
23	122	3.8	536	2 S62110	lysophospholipase
24	118.5	3.7	1749	2 S75071	lysophospholipase
25	105	3.2	431	2 JC4805	hypothetical prote
26	103.5	3.2	597	4 E40201	core protein F - p
27	103	3.2	432	2 T10894	artifact-warning s
28	101.5	3.1	946	2 I38100	neuronal pentraxin
29	101	3.1	372	2 T25621	rho-GTPase-activat
					hypothetical prote

30	101	3.1	1188	2	D86311	protein Fl13.20 [i
31	100.5	3.1	1461	2	B70588	probable polykeid
32	100	3.1	252	2	B82181	exidoeductase, sh
33	99.5	3.1	1026	2	G81751	oxidoxyribonuclea
34	99.5	3.1	2611	2	T14591	actinomycin synthe
35	99	3.1	690	2	D75487	v-type ATP syntha
36	99	3.1	4687	1	A39638	plectin - rat
37	98.5	3.0	440	2	A26359	decay-accelerating
38	97	3.0	852	1	GNLUGA	poi polyprotein -
39	96	3.0	361	2	AD1079	Glucosamine-fructo
40	96	3.0	624	2	T39102	hypothetical prote
41	96	3.0	781	2	S37032	gene LL5 protein -
42	96	3.0	873	1	TVFVF	protein-tyrosine k
43	96	3.0	883	2	A49733	[heparan sulfate] -
44	95.5	3.0	569	2	C86934	probable membrane
45	95.5	3.0	613	2	AC2962	hypothetical prote

## ALIGNMENTS

### RESULT 1

A39329  
phospholipase A2 (EC 3.1.1.4), cytosolic - human  
C;Species: Homo sapiens (man)  
C;Date: 10-Sep-1999 #sequence revision 10-Sep-1999 #text\_change 20-Apr-2000  
C;Accession: A39329; A39898; A54198; S68898  
R;Sharp, J.D.; White, D.L.; Chiou, X.G.; Goodson, T.; Gamboa, G.C.; McClure, D.; Burchett, J. Biol. Chem. 266, 14850-14853, 1991  
A;Title: Molecular cloning and expression of human Ca(2+)-sensitive cytosolic phospholipase A2  
A;Reference number: A39329; MUID:91331987; PMID:1869522  
A;Accession: A39329  
A;Molecule type: mRNA  
A;Residues: 1-749 <SHA>  
A;Cross-references: GB:M68874; NID:G190003; PIDN:AAA60105.1; PID:G190004  
R;Clark, J.D.; Lin, L.L.; Kriz, R.W.; Ramesha, C.S.; Sultzman, L.A.; Lin, A.Y.; Milona, R. Cell 65, 1043-1051, 1991  
A;Title: A novel arachidonic acid-selective cytosolic PLA-2 contains a Ca(2+)-dependent t  
A;Reference number: A39898; MUID:91256305; PMID:1904318  
A;Accession: A39898  
A;Molecule type: mRNA  
A;Residues: 1-749 <CLA>  
A;Cross-references: GB:M72393; NID:G190006; PIDN:AAB00789.1; PID:G190007  
A;Note: part of this sequence was confirmed by protein sequencing  
R;Li, B.; Copp, L.; Castelhan, A.L.; Feng, R.; Stahl, M.; Yuan, Z.; Krantz, A. Biochemistry 33, 8594-8603, 1994  
A;Title: Inactivation of a cytosolic phospholipase A-2 by thiol-modifying reagents: cyste  
A;Reference number: A54198; MUID:94304876; PMID:8031794  
A;Accession: A54198  
A;Molecule type: protein  
A;Residues: 319-338; 'X', 340-345; 'X', 347-358 <LJA>  
A;Note: modification of preferred modification site Cys-324 abolished enzymatic activity  
R;Gordon, R.D.; Leighton, I.A.; Campbell, D.G.; Cohen, P.; Creaney, A.; Wilton, D.C.; Mas Eur. J. Biochem. 238, 690-697, 1996  
A;Title: Cloning and expression of cytosolic phospholipase A(2) (cPLA(2)) and a naturally results in an increase in specific activity.  
A;Reference number: S68897; MUID:96300233; PMID:8706669  
A;Accession: S68898  
A;Molecule type: protein  
A;Residues: 497-507 <GOR>  
C;Comment: This cytosolic phospholipase A2 translocates to membrane vesicles in response  
C;Genetics:  
A;Gene: GDB:PLA2C4A; PLA2G4  
A;Cross-references: GDB:134687; OMIM:600522  
A;Map position: 1q25-1q25  
C;Superfamily: cytosolic phospholipase A2  
C;Keywords: calcium; carboxylic ester hydrolase; cytosol; inflammation; phosphoprotein F;505/Binding site: phosphate (Ser) (covalent) #status experimental

Query Match 19.1%; Score 619; DB 1; Length 749;  
Best Local Similarity 27.1%; Pred. No. 1.1e-39;  
Matches 174; Conservative 125; Mismatches 238; Indels 106; Gaps 22;



QY	218	QOELAEARLGVPSCTNLWA-LINEALLHDEPHDKLSQDREALSHGQNPLFIYCALNT	276
Db	276	IEALWNKSSGQPVFTDIFGMLIGETLIHNR-MOTTLDMKEKVSEAQCALPFTCLHV	334
QY	277	KGQSUTTFEFEGBCFESPYEVCFPKYGAFIPSELFGSBEFFMQLMKRLPESICIFLEGW	336
Db	335	K-PDVSELMFADWBEFSYEIGMAKYGTMSPDLFSGKPFMTGTVKKYSENPLHLMGYW	393
QY	337	SNLYAANLQDSILYWASEFSQFWRDWRVQANLDKEQVPLLK-----EPP	381
Db	394	GSAFSILFNVLGVGNS-----QNKGTPEEELNIRLKLHVSNDSSDESOHP	444
QY	382	PSTAGRIA-----EFTDLL-----TWRLPAQAATHNPLRGLHFKDYQF	420
Db	445	KGTESENANEYQSSQBSQVORMLMALVGDALSALFNTREGRAGKVHNFMGLGNLNSCYPL	504
QY	421	HP--HFSWKATLIDGL-----PNQ-----LTPSEPHCLDLDVGYLINTSCLPLQP	465
Db	505	SPLADLLTQESVEEBELDAADVPDEFERIYPLDVKSKTHIVDSGLTFNLPYLLILP	564
QY	466	TRDVDLILSLDYNLHGA-----FOQLLLGRFCQOGTIPPPISPSPEQLQPRECHTF-	519
Db	565	QRGVDLIISDFSAKPSDSSPPFKIEALLAEKWAQKNKLPFPKIDPNVDFRGLKCYCYFK	624
QY	520	-----SDPTCPGAPAVLHF-----SSGV-RRTPPEAAAGEVNL-SSSDSPYHYT	561
Db	625	PKDTSSEKDC--P7IIHFVLINFRYKAGPLPRESKEEKDFADFDIDPDNTPFSTF	681
QY	562	KV7YSQEDVDKLLH7HYNVNCOBQLLEALQAVORRRQ	601
Db	682	NFOYPNEAFKRLHDLMEFTLNLLDVIKQAMMESIEYRKE	721

RESULT 4  
B54908  
phospholipase A2 cytosolic - zebra fish  
C:Species: Brachydanio rerio (zebra fish)  
C:Date: 07-Aug-1997 #sequence\_revision 09-Aug-1997 #text\_change 31-Oct-1997  
C:Accession: B54908  
R:Nalefski, E.A.; Sultzman, L.A.; Martin, D.M.; Kriz, R.W.; Towler, P.S.; Knopf, J.L.; C  
J. Biol. Chem. 269, 18239-18249, 1994  
A:Title: Delineation of two functionally distinct domains of cytosolic phospholipase A2,  
A:Reference number: A54908; MUID:94299545; PMID:8027085  
A:Accession: B54908  
A>Status: preliminary; translated from GB/EMBL/DBDJ  
A:Molecule type: mRNA  
A:Residues: 1-741 <NAL2>  
A:Cross-references: EMBL:U10329  
C:Superfamily: cytosolic phospholipase A2

Query Match	17.7%	Score 572;	DB 2;	Length 741;
Best Local Similarity	26.5%	Pred. No. 4.8e-36;		
Matches 154;	Conservative 115;	Mismatches 236;	Indels 76;	Gaps 17;
QY	89	VRLGFGCAEEQAFLSRRKQVAAALPQALQLDG----	DLQDEIPIVVAIMATGGGIRAM	144
Db	138	LRFSMTLCDQEKLFQMTRDRVMLSIKKLKUMENRFLPSPREVPVFIATILGGGGFRAM		197
QY	145	TSYIGQIAGLKEGLGLLDCVSYITGASGTSWALANLYEDPQSQDLAPTEL---	LKTQV	201
Db	198	VGFGVMKALYESGVFCATVYAGLSGTSWMSMLYSHPEPAK----	GPGDINKELMNRV	254
QY	202	TKNKLGVLAQSOLQRYQEQLAERARLGYPCSFNLWA-	LINEALLHDEPHDKLSDOREA	260
Db	255	NNPLKULLPQNIINRYKVALMKKKSAGQVTFDIFGMLIGETLIPGR--	MNKLSSLLKKG	313
QY	261	LSHQNPPLIYCALNTKGQSILITPEFGECFSPSYEVGPKYGAFISELPFGSEFFMGQL		320
Db	314	INEQSPLPFTCLHVK-PDVSELWFADWVEFSPYEIGMAKYGTMFSGPLFGSKPFMGSV		372
QY	321	MKRLPESRICFLEGIWNLY-----	AAANQDSLYWASEPSQFWDWRVNRQ	365

```

Db      373 VKQYENPLHFLMGVWGSAFSLFNRLVLGKETTSSSTWEEBLEQIKPEHIVGDSDADNE 432
QY      366 ANLDK--EQVPLLKIEPPSTAGIAIEFTDILL-----TWRLAQATHNLRGLGHHF 415
Db      433 BETRGGTESADAEDERQHAQASWQVRLTSTMGDTTLFTTREGRAKVHNFMLGLNLN 492
QY      416 KDYFOHPHFSTWKAATLDGLPNQLT-PSE-----PHLCILDVGYLINTSCPL 462
Db      493 STLPPSPFGSIHTQSLSEEVDAVTDPEFERIYELDVKSKKHVVDSGLTFLNLPYPLI 552
QY      463 LQPTEDVDLILSLDNLHCA-----FOQLQLGRFCQEGIGIPPPISPSPERQLQPRECH 517
Db      553 LRCQGVDLIISFDSARPSDSSPPFKELLAEKWARMNKLPPPKIDSKVDFREGLKECY 612
QY      518 TF----SDPTCPGAPAVLHF-----SSGV-RRTPPEAAAGEVNL-SSSDSPYHY 560
Db      613 VFPAKGDKNC---PTIIHFVLINFRNFKAGVPRDSKDIEFGDFIDFEPASPYST 669
QY      561 TKVTYSQEDVDKLLHLTHYNVCNQOEQLLEALRQAVQRRRQ 601
Db      670 FNFYNNQAFKRLHDLMEFNTLNNIEVKEAIKDSILLRRE 710

RESULT 5
TI3162
cytosolic phospholipase A2 gamma - human
N:Alternate names: protein DKFZp586C0423.1
C:Species: Homo sapiens (man)
C:Date: 13-Aug-1999 #sequence_revision 13-Aug-1999 #text_change 17-Nov-2000
C:Accession: TI3162; T08799
R:Pickard, R.T.; Striffler, B.A.; Kramer, R.M.; Sharp, J.D.
A:Title: Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2
A:Reference number: Z17618; MUID:99185108; PMID:10085124
A:Accession: TI3162
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-541 <PIC>
A:Cross-references: EMBL:AF065214; NID:g3811344; PID:g3811345; PIDN:AAC78835.1
R:Ansorge, W.; Wirkner, U.; Mewes, H.W.; Gassenhuber, J.; Wiemann, S.
submitted to the Protein Sequence Database, May 1999
A:Reference number: Z16472
A:Accession: T08799
A:Molecule type: mRNA
A:Residues: 443-541 <ANS>
A:Cross-references: EMBL:AL050193
A:Experimental source: adult uterus; clone DKFZp586C0423
C:Genetics:
A:Gene: cPLA2 gamma
A:Map position: 19
A>Note: DKFZp586C0423.1

Query Match          15.4%; Score 498.5; DB 2; Length 541;
Best Local Similarity 27.8%; Pred.No.1.5e-30;
Matches 158; Conservative 86; Mismatches 190; Indels 135; Gaps 23;

QY      98  BEQAFLSRRKQVAAALRQALQDLGDEIPVVAIMATGGGIRAMTSLYGOLAGLKEEL 157
Db      15  EEKAAVERRLHLVKALKKL-----RIEADRAPVAVLVGSGGLRAHATCLGLVLSMKEQ 69
QY      158  GLLDVCYITGASGSTWALANLYE---DPWESQKDLAGTPELLTKTQVTKNKLGLVLAQSOL 214
Db      70  GLLDVAVTYLAGVSGSTWAISSLYTNDGDMEALEAD-----LKHRTFRQEW-----DL 116
QY      215  QRYQELAEARLARGYPCFTNLWA-LINEALLHDEPHDKLSQREALSHGQNPLPIYCA 273
Db      117  AKSLQKTIOARSSENYSLTDFWYMWVISKQTRLELPESH-LSNMKKPVVEGTLPIYPIFAA 174
QY      274  ----LNTKGSLTTFEFGWCEFGSPYEVGPKYGAFIPSELFGSFFFMQMKRLPESRI 329
Db      175  IDNDLQPSWQEARAPE--TWFEFTPHHGFPALGAFVSIHFGSKFKKGLRVHTPERDL 232
QY      330  CFLEGIWSN-----LYA--ANLQDSLIY 349

```



Db 222 NYNDLRKEIDQKHAGFDCSLTDLW-----SRKLVDABERGPGITYSYMRN 272  
QY 261 ---LSHQNLPIYCA-----LNTKQSLTTFEGWCEPSPYEVGPKYCAFI 306  
Db 273 QSWFNADYPIPIIVADSRLEBETAIPANTSIEFFTAIEFGTW-----DNGIK---AFI 323  
QY 307 PSELFGSEFFWQMKRLPESRIC-----FLEGISWNLNLAANLQDSLYWASEPQFW 358  
Db 324 PMEYVGT-----HLLDGVDPDKSCIHNVDAGFWMGTSATLFSFLD-----W 367  
QY 359 DRWVRQANLQKQVPLLKIEEPPSTAGRIABFTDLLTWRLPAAQATHNFLGLHFHKD- 417  
Db 368 NENVKKN-----DITYDIL-----HAILEDLSKHQDD 394  
QY 418 --VFQPH--FSTWKATTLQGLNQLTPSRPH--LCLLDVGY-LINTSCLPILQPTDQVD 470  
Db 395 IAYPNPYQNTTNSVNVAF-----EPYTDILVDGGEDRENPLPLHLPQRFVD 447  
QY 471 LILSLD--YNLHGAFOQLLGRFCQBGQIFPPISPSPBEQLOPRCHTFSD-----PTC 524  
Db 448 VFAIDSTYN-----DPYGWPLGSSIVATYERVVTFNANKSVDRVGFYI 492  
QY 525 PGAPAVLHSSGVRT-----PREAAGEVNLSSDSP-----YHYTKVTYSQE 568  
Db 493 PDENTIISLGLNTRPTFFGCDGKNTTAGNHVDVNDNTPPLLVYFPNYPWTYYSNISTFMS 552  
QY 569 DVBKLLHLTHYVC-----NNQQLLEALRQA-VORRRQR 603  
Db 553 MDDKMANGILEAFMSTTQNNESFAVCLACAIQRLSRK 593

RESULT 9  
S66693  
hypotheical protein YOL011w - yeast (Saccharomyces cerevisiae)  
N/Alternate names: hypotheical protein G2349  
C/Species: Saccharomyces cerevisiae  
C/Date: 12-Jul-1996 #sequence\_revision 12-Jul-1996 #text\_change 19-Apr-2002  
C/Accession: S66693  
R/Hughes, B.; Pohl, T.M.  
submitted to the Protein Sequence Database, July 1996  
A/Reference number: S66685  
A/Accession: S66693  
A/Molecule type: DNA  
A/Residues: 1-686 <HUG>  
A/Cross-references: EMBL:Z74753; NID:G1419780; PIDN:CAA99010.1; PID:G1419781; GSPDB:GN00  
A/Experimental source: strain S288C  
C/Genetics:  
A/Gene: SGD:PLB3; MIPS:YOL011w  
A/Cross-references: SGD:S0005371  
A/Map position: 15L  
C/Superfamily: yeast lysophospholipase

Query Match 5.7%; Score 184; DB 2; Length 686;  
Best Local Similarity 21.0%; Pred. No. 4.7e-06;  
Matches 129; Conservative 80; Mismatches 192; Indels 214; Gaps 31;  
QY 99 EOAFLSRRKQVAAALRQAL-----QLDGLQDEIPVVAIMATGGGIRA 143  
Db 57 ESALREKRNKVTVALKDFLTRATNFSDESSEVLKLFNDGSENIPKTIADAVSGGGYRS 116  
QY 144 MTSLYQLAGLKL-----GLLDCVSYITGASGSTWALANL----- 179  
Db 117 MLTGAGVLAAMNRTGAYEHLGLLQSTLYLSGASGNNLVGTLALNNWTSVQDILNN 176  
QY 180 --YEDPWSKD--LAGPTLLKTQVTKNL-GVLAPOLOQRYRELAE---RAELGYP 230  
Db 177 MQNDDSIWLDLSIVTPGGINIFKTAQRWDHISNAVESKQADYNTSLADIWGRA-LAY- 234  
QY 231 SCFTNLWALINE-----ALLHDEPHDKLSQREALSHGQNPPLIYCA-----LNTKQ 279  
Db 235 ----NFFPSLNRRGIGLWTSIRDFP-----VFQNAEMFPFPIISVADGRYPGTKVI 280  
QY 280 SLTTFEGWCEPSPYEVGF--PKYGAFIPSELFSGEFFMQLMKR-----LPESRICFLE 333

Db 281 NLNATVF-----ENPEMGSGWDFSLNSFANVKYLGTVNSGVPLERKCTAGFNAGFIM 336  
QY 334 GIWSNLYAANLQDSLYWASEPQFWDRWRVNOANLQDEQVPLLKIEEP--PSTAGRIA-- 389  
Db 337 GTSSTLF-----NQF-----LLRINSTHLPSPFITLARH 365  
QY 390 -----EFFTDLITWRPLAQATHNFLRGLHFHKDYFOHPHFWKATILDGLPNQLTPSE 443  
Db 366 FLKDLSDQDFNDIAVYSPNPFKTKFL-----DSDY-----SIYDSD 403  
QY 444 PHLCILDVGY-LINTSCLPILQPTDQVDLILSLDYN-----LHGAFQQLQLL 489  
Db 404 -SFLVDGGEDDENVPVLPIQKERVDDIIFAVDNSADMLANPDPGSSLVHVERQFVK 462  
QY 490 GRFCQBGQIFPPISPSPBEQLOPRCHTF-----SDPTCPGA-----PAVL 531  
Db 463 G-----QMSFPYVP-----DTNTEVNLGLNKKPTFFGCDANNTDLOQVIPPVV 507  
QY 532 HFSSGVRRTPEEAAAGEVNLSSDSPHYHYTKVTYSQED-----VDKLLHLTHYVNCNQE 587  
Db 508 YLPN-----AEYSPNSQSAF-----KLSYSESQRRSMIQNGFEIATRNFTDDE 553  
QY 588 LLEALRQAVORRRQR 602  
Db 554 FMGCVGCAIIRKQ 568

## RESULT 10

S29318  
lysophospholipase (EC 3.1.1.5) precursor [validated] - Penicillium notatum (fragment)  
C/Species: Penicillium notatum  
C/Date: 10-Mar-1994 #sequence\_revision 10-Mar-1994 #text\_change 19-Jan-2001  
C/Accession: S29318; S39881; S22045  
R/Masuda, N.; Kitamura, N.; Saito, K.  
Eur. J. Biochem. 202, 783-787, 1991  
A/Title: Primary structure of protein moiety of Penicillium notatum phospholipase B deduc  
A/Reference number: S29318; MUID:92111525; PMID:1722456  
A/Accession: S29318  
A/Molecule type: mRNA  
A/Residues: 1-612 <MAL>  
A/Cross-references: EMBL:X60348; NID:G3183; PIDN:CAA42906.1; PID:G3184  
A/Accession: S39881  
A/Molecule type: protein  
A/Residues: 10-20; 185-199 <MA2>  
C/Superfamily: yeast lysophospholipase  
C/Keywords: carboxylic ester hydrolase; glycoprotein  
F/1-9/Domain: signal sequence (fragment) #status predicted <SIG>  
F/10-612/Product: lysophospholipase #status experimental <MAT>  
F/41,81,116,223,267,306,335,427,440,446,477,498,536,532,567,571/Binding site: carbohydrat

Query Match 5.5%; Score 177; DB 2; Length 612;  
Best Local Similarity 21.3%; Pred. No. 1.4e-05;  
Matches 108; Conservative 60; Mismatches 162; Indels 178; Gaps 23;  
QY 51 AGVWRDLGSLQPPPLGFKFPCSLSPSSWDYRLRELAVRLGFCPCAEQAFLSRRKQV 110  
Db 5 AGVQ-----RALPNAPDY-----VPTSVSCPASRPTVRSAAKLTSTNLSWEVRGKT 53  
QY 111 AAALRQ-----ALQLDGLD-QEDEIPVVAIMATGGIRAMTSLYGLQAGLKL 157  
Db 54 LSALKDFFGHVKGVDYDVGAYLDKXSGNSSSLPNIGIAVSGGWRALMNGAGAVKAFDSR 113  
QY 158 -----GLLDCVSYITGASGSTWALANL----- 180  
Db 114 TDNATATGHLGILLQATYISGLSGSWLLGSIYINNFTTVDKLTQTHEAGSVQMGNSII 173  
QY 181 EDPEWSKDLAGTELLKTQVTKNLGVLAPOLOQRYRELAE-----RAELGYPSCFTNL 236  
Db 174 EGPD-----AGTIQLLDS-----AGYYKDLADAVDGKKAGGDTTLTDI 212  
QY 237 WALLINEALLHDSFHD-----HKLSQREALSHGQNPPLIYCALNTK-----GQSLTTF 284

```
Db 213 WGRALSYQMFNASNGSLSYTWSSIAADTPE-FQDGYPMFPFVVADVGRNPGELVIGSNSTVY 271
QY 285 EGEWCERSPEYGVGPKYCAFTPELFGSEFFMGQMKLPESRIC-----FLEGIM 336
Db 272 EFNPM-EFTFD---PTTFGVPELVLSKFEFGS-----LPSNESCIRGFDAGFVIGHS 323
QY 337 SNLYAANLDSLYWASEPQFQFDRWRNRQANLDKEQVPLLKIEEPPSTAGRIAEFTDLL 396
Db 324 SSLFNQFL-L-QINTTSLPSFKIDVFNGLFDLDKSNQDASVDNPN----- 368
QY 397 TWRIPLAQATHNLRGLHFKHVFQHPHFTWKTATLDGLPNQLTPSEPHLC-LLDV---- 451
Db 369 -----FYK-YNEH-----SSPYAAQKLLDWDVG 390
QY 452 ---GYLINTSCLPLLOPTRDVLILSLD 476
Db 391 GEDGQ--NVPLHLPIQPERHVDVIFAVD 416

RESULT 11
I54375
gene NF2 protein - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 01-Nov-1996 #sequence_revision 01-Nov-1996 #text_change 20-Aug-1999
C:Accession: I54375
R:Arakawa, H.; Hayashi, N.; Nagase, H.; Ogawa, M.; Nakamura, Y.
Hum. Mol. Genet. 3, 565-568, 1994
A>Title: Alternative splicing of the NF2 gene and its mutation analysis of breast and co
A:Reference number: I54375; MUID:94348501; PMID:8069299
A:Accession: I54375
A>Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-46 <RES>
A:Cross-references: GB:S73853; NID:G688372; PIDN:AAB31736.1; PID:G688373
C:Genetics:
A:Gene: GDB:NF2
A:Cross-references: GDB:120232; OMIM:101000
A:Map position: 22q12.2-22q12.2
C:Superfamily: Integrin beta chain; laminin-type EGF-like homology

Query Match 5.3%; Score 170; DB 2; Length 46;
Best Local Similarity 76.7%; Pred. No. 1.2e-06;
Matches 33; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 41 FEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYR 83
Db 4 FNCESCSVTLAGVQWRDLGLQLPLPKFKRFSCLSPSSWDYR 46

RESULT 12
S53037
PLB1 protein - yeast (Saccharomyces cerevisiae)
N/Alternate names: protein YM270.10c; protein YMR008c
C:Species: Saccharomyces cerevisiae
C>Date: 08-Jul-1995 #sequence_revision 01-Sep-1995 #text_change 18-Jun-1999
C:Accession: S53037; A53647
R:Devlin, K.; Churcher, C.M.
submitted to the EMBL Data Library, March 1995
A:Reference number: S53028
A:Accession: S53037
A:Molecule type: DNA
A:Residues: 1-664 <DEV>
A:Cross-references: EMBL:Z48613; NID:G728645; PIDN:CAA8523.1; PID:G728655; MIPS:YMR008c
A:Experimental source: strain AB972
R:Lee, K.S.; Patton, J.L.; Fido, M.; Hines, L.K.; Kohlwein, S.D.; Palttauf, F.; Henry, S.
J. Biol. Chem. 269, 19725-19730, 1994
A>Title: The Saccharomyces cerevisiae PLB1 gene encodes a protein required for lysophosph
A:Reference number: A53647; MUID:94327513; PMID:8051052
A:Accession: A53647
A:Molecule type: DNA
A:Residues: 1-31, 'S', 33-493, 'D', 495-664 <LEE>
A:Cross-references: GB:I23089; NID:G437731; PIDN:AAA61611.1; PID:G437732
A>Note: the authors translated the codon GAC for residue 494 as Glu
```

```
C:Genetics:
A:Gene: SGD:PLB1
A:Cross-references: SGD:S0004610; MIPS:YMR008c
A:Map position: 13L
C:Superfamily: yeast lysophospholipase
C:Keywords: transmembrane protein
F:648-664/Domain: transmembrane #status predicted <TM>

Query Match 5.0%; Score 162; DB 2; Length 664;
Best Local Similarity 21.5%; Pred. No. 0.00022;
Matches 96; Conservative 64; Mismatches 170; Indels 116; Gaps 20;

QY 89 VRLGFGPCAEQAFLSRR-----KQVVAALRQALQDGL-----QEDEIPVVALM 135
Db 43 VREASGLSDNETEWLKKRDATYKKAHSLFNATSNFSDTSLSTLFGSNSSNMPKIAVA 102
QY 136 ATGGGIRAMTSLYQGLAGLKL-----GLDDCVSYITCAGSTWALANLYEDPEW 185
Db 103 CSGGGYRAMLSGAGMLAAMDNRDGANEHGLGLGGLQGATYLAGLSGNWLTSLAWN-NW 161
QY 186 SQKDLAGPTELLKTQVTKNKLGLVAPSQLQRYR-----QELAERARLGYPSCTNL 236
Db 162 TSVQALVDNMTTESNSIWDISHSILTPDGINIFKTGSRWDDISDDVDQDKDAGFNISLADV 221
QY 237 WALINEAL-----LHDEPHDKLSDQREA--LSHGQNPLPI-----YCALNTKGQSL 281
Db 222 W---GRALAYNFWPSLHRGGVGYTWSTLRADVFKNGEMFPFITVADGRYPGTTVINLA 278
QY 282 TTFEFGCEPSEFPGYVGF--PKYGAFIPSELFGSEFFQMGLMKRLPESRICFLEGWSNL 339
Db 279 TLF-----EFNFFEMGSDPTLNAFTDVKYLGTVNNGK-----PVNKGQCIAGFDNTG 327
QY 340 YAANLQDSLYWASEPQFQFDRWRNRQANLDKEQVPLLKIEEPPSTAGRIAEFTDLLTWR 399
Db 328 FITATSTSLF-----NQF-----LLRLNS-----TDLPSF- 352
QY 400 PLQAATHNLRGLHFKH-----YFQHPHSTWKTATLDGLPNQLTPSEPHLCILDV 451
Db 353 -IANLATDFLEDLSNDSDDIAIYAPNPFKEANFLQKNAT-----SSIIESE-YLFLVDG 404
QY 452 GY-LINTSCLPLLOPTRDVLILSLD 476
Db 405 GEDNQNIPLVPLLLQKERELDVIFALD 430

RESULT 13
I54374
gene NF2 protein - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 20-Aug-1999
C:Accession: I54374
R:Pykett, M.J.; Murphy, M.; Harnish, P.R.; George, D.L.
Hum. Mol. Genet. 3, 559-564, 1994
A>Title: The neurofibromatosis 2 (NF2) tumor suppressor gene encodes multiple alternativ
A:Reference number: I54374; MUID:94348500; PMID:8069298
A:Accession: I54374
A>Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-39 <RES>
A:Cross-references: GB:L27065; NID:G463120; PIDN:AAA62422.1; PID:G463121
C:Genetics:
A:Gene: GDB:NF2
A:Cross-references: GDB:120232; OMIM:101000
A:Map position: 22q12.2-22q12.2
C:Superfamily: Integrin beta chain; laminin-type EGF-like homology

Query Match 4.9%; Score 160; DB 2; Length 39;
Best Local Similarity 79.5%; Pred. No. 5.4e-06;
Matches 31; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 45 SLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYR 83
Db 1 SCSVTLAGVQWRDLGLQLPLPKFKRFSCLSPSSWDYR 39
```



**This Page Blank (uspto)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 19:13:29 ; Search time 24.2 Seconds  
(without alignments)  
1301.754 Million cell updates/sec

Title: US-09-830-321A-2

Perfect score: 3235

Sequence: 1 MIFVLSPTALCLERVASH.....EQLEALRQAVRRRQRPH 605

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt\_42\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	619	19.1	749	1 PA24_HUMAN	P47712 homo sapien
2	611.5	18.9	749	1 PA24_HORSE	O77793 equus cabal
3	599.5	18.5	748	1 PA24_MOUSE	P47713 mus musculus
4	596	18.4	748	1 PA24_CHICK	P49147 gallus gall
5	594	18.4	752	1 PA24_RAT	P50393 rattus norv
6	572	17.7	741	1 PA24_BRARE	P50392 brachydanio
7	226.5	7.0	591	1 ALU8_HUMAN	P39195 homo sapien
8	199.5	6.2	587	1 ALU2_HUMAN	P39189 homo sapien
9	199.5	6.2	593	1 ALU7_HUMAN	P39194 homo sapien
10	198	6.1	587	1 ALU3_HUMAN	P39190 homo sapien
11	192.5	6.0	593	1 ALU6_HUMAN	P39193 homo sapien
12	191	5.9	585	1 ALU5_HUMAN	P39192 homo sapien
13	186	5.7	673	1 PLB4_SCHPO	O99327 schizosacch
14	184	5.7	686	1 PLB3_YEAST	O08108 saccharomyc
15	182	5.6	591	1 ALU1_HUMAN	P39188 homo sapien
16	177.5	5.5	649	1 PLB1_TORDE	Q11121 torulaspora
17	177	5.5	612	1 PLB1_PENCH	P39457 penicillium
18	172.5	5.3	659	1 PLB1_CANGA	O8tg07 candida gla
19	165.5	5.1	608	1 PLB2_CANAL	O93795 candida alb
20	164	5.1	605	1 PLB1_CANAL	Q9uwi6 candida alb
21	164	5.1	626	1 PLB_NEUCR	O42790 neurospora
22	162	5.0	640	1 PLB_KULLA	O59863 kluyveromyc
23	162	5.0	664	1 PLB1_YEAST	P39105 saccharomyc
24	159.5	4.9	633	1 PLB5_SCHPO	O9y7n6 schizosacch
25	159	4.9	624	1 PLB2_SCHPO	O19857 schizosacch
26	154	4.8	754	1 PLB3_CANAL	Q9uvx1 candida alb
27	151	4.7	613	1 PLB1_SCHPO	P78854 schizosacch
28	146.5	4.5	695	1 PLB2_CANGA	O8tg06 candida gla
29	143.5	4.4	603	1 ALU4_HUMAN	P39191 homo sapien
30	140	4.3	644	1 PLB6_SCHPO	Q9uth5 schizosacch
31	136	4.2	706	1 PLB2_YEAST	Q03674 saccharomyc
32	122	3.8	536	1 SP01_YEAST	P35411 saccharomyc
33	105	3.2	431	1 VGF_BPPHK	Q38041 bacterioph

34	103	3-2	432	1	NPX2_RAT	P97738 rattus norv
35	101.5	3-1	946	1	RHG4_HUMAN	P98171 homo sapien
36	100.5	3-1	1138	1	RDL3_ARATH	Q8w3k0 arabidopsis
37	99.5	3-1	664	1	Y4FB_RHISN	P55440 rhizobium s
38	99.5	3-1	1026	1	EX5B_CHLMU	Q9plt8 chlamydia m
39	99	3-1	690	1	VATI_DEIRA	Q9rwh3 deinococcus
40	99	3-1	4473	1	PLE1_CRIGR	Q9j155 cricetus
41	99	3-1	4687	1	PLE1_RAT	P30427 rattus norv
42	98.5	3-0	2208	1	POLN_MANCV	Q69014 manchester
43	98	3-0	438	1	SGCE_HUMAN	O43556 homo sapien
44	97	3-0	852	1	POL_BLVAV	P25059 bovine leuk
45	96.5	3-0	772	1	LMBT_HUMAN	Q9y468 homo sapien

ALIGNMENTS

RESULT 1  
PA24\_HUMAN  
ID PA24\_HUMAN STANDARD; PRT; 749 AA.  
AC P47712;  
DT 01-FEB-1996 (Rel. 33, Created)  
DT 01-FEB-1996 (Rel. 33, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Cytosolic phospholipase A2 (CPLA2) [Includes: Phospholipase A2  
[EC 3.1.1.4] (Phosphatidylcholine 2-acylhydrolase); Lysophospholipase  
[EC 3.1.1.5]].  
DE PLA2G4A OR PLA2G4 OR CPLA2.  
GN Homo sapiens (Human).  
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
RX MEDLINE=91256305; PubMed=1904318;  
RA Clark J.D., Lin L.-L., Kriz R.W., Ramesha C.S., Sultzman L.A.,  
Lin A.Y., Milona N., Knopf J.L.;  
RT "A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-  
dependent translocation domain with homology to PKC and GAP.";  
RL Cell 65:1043-1051(1991).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91311987; PubMed=1869522;  
RA Sharp J., White D., Chiu G., Goodson T., Gamboa G., McClure D.,  
Burgett S., Hoskins J., Skatrud P., Sportsman J., Becker G., Kang L.,  
Roberts E., Kramer R.;  
RT "Molecular cloning and expression of human Ca(2+)-sensitive cytosolic  
phospholipase A2.";  
RL J. Biol. Chem. 266:14850-14853(1991).  
RN [3]  
RP SEQUENCE OF 1-186 FROM N.A.  
RA Howden P.;  
RL Submitted (MAY-1999) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP MUTAGENESIS OF SER-505, AND PHOSPHORYLATION BY MAP KINASE.  
RX MEDLINE=93145328; PubMed=8381049;  
RA Lin L.-L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., Davis R.J.;  
RT "cPLA2 is phosphorylated and activated by MAP kinase.";  
RL Cell 72:269-278(1993).  
RN [5]  
RP MUTAGENESIS OF SER-228.  
RX MEDLINE=94299545; PubMed=8027085;  
RA Sharp J.D.;  
RL Unpublished results, cited by:  
RL Nalefski E.A., Sultzman L.A., Martin D.M., Kriz R.W., Towler P.S.,  
Knopf J.L., Clark J.D.;  
RL J. Biol. Chem. 269:18239-18249(1994).  
RN [6]  
RP INTERACTION WITH HTATIP.  
RX MEDLINE=21309279; PubMed=11416127;  
RA Sheridan A.M., Force T., Yoon H.J., O'Leary E., Choukroun G.,  
Taheri M.R., Bonventre J.V.;  
RT "PLIP, a novel splice variant of Tip60, interacts with group IV

FT	DOMAIN	5	106	C2 DOMAIN.
FT	MOD_RES	505	505	PHOSPHORYLATION (BY MAPK) .
FT	MOD_RES	228	228	S->A: ABOLISHES BOTH PHOSPHOLIPASE AND LYSOPHOSPHATASE ACTIVITY.
FT	MUTAGEN	505	505	S->A: DECREASES AGONIST-STIMULATED RELEASE OF ARACHIDONIC ACID.
FT	SEQUENCE	749 AA;	85210 MW;	9F9CDCA98231C70 CRC64;
Query Match			19.1%;	Score 619; DB 1; Length 749;
Best Local Similarity			27.1%;	Pred. No. 4.4e+04;
Matches 174;			Conservative 125;	Mismatches 238; Indels 106; Gaps 44
QY				44 ELSVQAQGVQNRDLGSLQPLGPKRFSCLSPSSWDYRLRELA---VELGRGPCAAE 99
DB				100 ETLTGTAFTVSSMKVGEKKEVPFIHQVTEVLEMS-----LEVCCPDURFSMALCDQE 154
QY				100 QAFSLRRKQVVAALQAL---QLDGLQDEIPVVAIMATGGGIRAMTSIYLGOLAGLKE 156
DB				155 KTRFQRKEHIRESMKKLPGKNSGLHSARDVPVAILGGGFRAMVGSVMKALYE 214
QY				157 LGLLDCVSYITGASGWTWALANIYEDPEWSQKDLAGPTL---LKTQVTKNKLGVILARSQ 213
DB				215 SGILDCAITYAGLSGTSWYMSLTLYSHDFPEK---GPEEINEELMKNVSHNPLLLLTPOK 271
QY				214 LQRYRQELAEARLGVPSCTNLWA-LINLALLHDEPHDKLSQREALSHGQNPPLTYC 272
DB				272 VKRYVESLWKKSSGQVPTFDIFGMLIGETLIHNRMT-TLSLSEKVKWTAQCELPFLT 330
QY				273 ALNTKGQSILATTFBGEWCFEFSPEYGVFPKYGAFIPSELFSGEFFGQMLKBLPSRICFL 332
DB				331 CLHVK-PDVSELWFADWVEFSPEYIGMAKYGTFWAPDLFGSKFFMGTVVKKYEENPLHFL 389
QY				333 EGTWSNLYA-----ANLQDSLYWASPSQFWRWVRNQANLDEQVPLL 376
DB				390 MGWGSAFSILFNRLVGVSGSQSRGSTMEEEL-----ENITTKHIVSNDSDSD--- 439
QY				377 KIEPPPTAGRIA-BEFTD-----LITWRPLAQATINFLRGLHFH 415
DB				440 ESHEPKTENEDAGSDYQSDNQASWIHRMIALVSDSALFNTRREGRACKVHFMGLNLIN 499
QY				416 KDYFQHP-HFSTWKATTLDEL-----PNO-----LTSEPHCLLDVGYLINTSCL 460
DB				500 TSYPLSPSLDFATQSDSDDDELDAADPDEFERIEYELDVKSKKHIVVDSGLTFLNLPYP 559
QY				461 PLLQPTQVDVLILSDYNLHGA---FQQLQLLRFCQEQGIPPPPIPSPEEQIQPRE 515
DB				560 LILSPQGVVDLIISDFESARPSDSSPPKELLAEKAWKMKLPFKIDPYVDFREGLKE 619
QY				516 CHTFSDPTCP---GAPAVLHF-----SSGV-RRTPTEAAAGENVL-SSSDSPY 558
DB				620 CYVFK-PKNPDMEXDCPTIIHFVLINANFRKYKAPGPRETEEEKIADFIDFDDPESP 678
QY				559 HYTKVTSQEDVDKLLHITHYVNCNQOLLEALQAVQRRO 601
DB				679 STFNQVFNQAPKRLHMLHENTLNNIDVIKEAMVESIEYRQ 721
RESULT 2				
PA24_HORSE				
ID	PA24_HORSE	STANDARD;	PRT;	749 AA.
AC	O77793;			
DT	15-JUL-1999	(Rel. 38, Created)		
DT	15-JUL-1999	(Rel. 38, Last sequence update)		
DT	28-FEB-2003	(Rel. 41, Last annotation update)		
DE	Cytosolic phospholipase A2 (CPLA2)	[includes: Phospholipase A2		
DE	(EC 3.1.1.4)	(Phosphatidylcholine 2-acylhydrolase);		
DE	(EC 3.1.1.5)]			
GN	PLA2G4A OR PLA2G4 OR CPLA2.			
OS	Equus caballus (Horse).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Perissodactyla; Equidae; Equus.			
OX	NCBI_TaxID=9796;			
RN	[1]			

SEQUENCE FROM N.A.  
 TISSUE=Neutrophils;  
 RA Larsson Forsell P.K.A., Lindberg A., Karlsson S., Lindgren J.A.,  
 RA Claesson H.-E.;  
 RT "Purification, characterization and cDNA sequencing of calcium-  
 dependent cytosolic phospholipase A2 from equine neutrophils.";  
 RL Submitted (SEP-1998) to the EMBL/GenBank/DBJ databases.  
 CC -!- FUNCTION: Selectively hydrolyzes arachidonyl phospholipids in the  
 CC sn-2 position releasing arachidonic acid. Together with its  
 CC lysophospholipid activity, it is implicated in the initiation of  
 CC the inflammatory response.  
 CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
 CC acylglycerophosphocholine + a fatty acid anion.  
 CC -!- CATALYTIC ACTIVITY: 2-lysophosphatidylcholine + H(2)O =  
 CC glycerophosphocholine + a fatty acid anion.  
 CC -!- ENZYME REGULATION: Stimulated by agonists such as ATP, EGF,  
 CC thrombin and bradykinin as well as by cytosolic Ca(2+) (By  
 CC similarity).  
 CC -!- SUBCELLULAR LOCATION: Cytoplasmic. Translocates to membrane  
 CC vesicles in a calcium-dependent fashion (By similarity).  
 CC -!- DOMAIN: The N-terminal C2 domain, by its association with lipid  
 CC membranes, mediates the regulation of CPLA2 by presenting the  
 CC active site to its substrate in response to elevations of  
 CC Cytosolic Ca(2+) (By similarity).  
 CC -!- PTM: Activated by phosphorylation on a serine residue (By  
 CC similarity).  
 CC -!- SIMILARITY: Contains 1 C2 domain.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement. (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).

EMBL; AF092539; AAC61774.1; -  
 DR HSSP; P47712; IBCI.  
 DR InterPro; IPR000008; C2.  
 DR InterPro; IPR008973; C2\_CaLB.  
 DR InterPro; IPR002642; PLAC.  
 DR Pfam; PF00168; C2; 1.  
 DR Pfam; PF01735; PLA2\_B; 1.  
 DR SMART; SM00239; C2; 1.  
 DR SMART; SM00022; PLAC; 1.  
 DR PROSITE; PS00004; C2\_DOMAIN\_2; 1.  
 KW Hydrolase; Lipid degradation; Calcium; Phosphorylation.  
 FT DOMAIN 1 178 PHOSPHOLIPID BINDING (PROBABLE).  
 FT DOMAIN 5 106 C2 DOMAIN.  
 FT MOD\_RES 505 505 PHOSPHORYLATION (BY MAPK) (BY  
 FT SIMILARITY).  
 SQ SEQUENCE 749 AA; 85454 MW; 493A67DF28D50FE0 CRC64;

Query Match 18.9%; Score 611.5; DB 1; Length 749;  
 Best Local Similarity 27.8%; Pred. No. 1.7e-39;  
 Matches 165; Conservative 121; Mismatches 212; Indels 95; Gaps 21;  
 89 VRLGFGCAEQAFLSRKQVAAALRQAL---QLDGLQDEIPVATMATGGIRAWT 145  
 144 LRFSNALCDQETFRQQRKENNKMKLLGPKSEGLYSTRDVPVWALGSGGGFRAMV 203  
 146 SLYGLAGLKEGLDLCVSYITGASGSTWALANEDPEWSQKDLAGPTEL---LKTQVT 202  
 204 GFSGVKALYESGILDCAITLAGLSSGSSWYMTLSHDPFPEK---GPEINKELMKVVS 260  
 203 KNLGLVAPSLQVRYQELAEARARYGSCFTNLWA-LINEALLHDEPHDKLSQREAL 261  
 261 YDPLLLTPQIKRYVESLWKKSSGQPVTFDIFGLMIGETLIHNRMT-TLSSLKENV 319  
 262 SHGQNPLPYCALNTKGQSLITTFEGCEPSPYGVGPKYCAFIPTSELPFGSEFPMGVM 321  
 320 NTAQCLPLFTLCHVK-PDVSELMFADWVFSPYBIGMAKYGTGFMAPDLFGSKFPMGTVV 378

QY 322 KRLPESRICFEGINSLNLYAANLQDSLYWASEPSQFQDRWVRNQANLDKEQVLL----- 376  
 DB 379 KYEENPLHLFMGVGWSAFSILFNRLVGVSGS-----QNGSTMEBELENITAKHI 429  
 QY 377 -----KIEEPPSTAGRIAE--FFTD-LLTW-RPL-----AQAT 405  
 DB 430 VNSDSSDSDSEGEKPTENEDAEIRDYQNDNQASVHMLMALVSDSALENTREGKGV 489  
 QY 406 HNFLRGLHFKHFOYQHP--HFSTWKAATLDGL-----LTPSEPHICLLD 450  
 DB 490 HNFMLGLNLNTSYPLSPFLNFTTQESLDDDDDAVADPDEFERIEPLDVKSKIHVD 549  
 QY 451 VGLINTSCLPLQLOPTRDVDLILSLDYNLHGA-----FOQLQLGRPCQEQGIPFPISP 505  
 DB 550 SGUTFNLPYPLILRPGQVVDLILISFDSARPSSPPFKELLALAEKWKMKLFPFKIDP 609  
 QY 506 SPEEQQPRECHTFSDPTCP---GAPAVLHF-----SSGV-RRTPEAAAGEV 549  
 DB 610 YVFDREGLKECVFK-PKNPDVEKDCPTIIHFVLANINFRKYKAPGVPRETKEELADF 668  
 QY 550 NL-SSDSPHYTKVYSQEDVDKLLHLTHYVNNQEQQLLEALQAVQRRRQ 601  
 DB 669 DIFDDPESPSTFNFQYPNQAFKRLHDLMEFNTLNNIDVIKNAWVESIEYRRQ 721  
 RESULT 3  
 PA24\_MOUSE STANDARD; PRT; 748 AA.  
 ID PA24\_MOUSE  
 DT 01-FEB-1996 (Rel. 33, Created)  
 DT 01-FEB-1996 (Rel. 33, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Cytosolic phospholipase A2 (CPLA2) [Includes: Phospholipase A2  
 DE (EC 3.1.1.4) [Phosphatidylcholine 2-acylhydrolase]; Lysophospholipase  
 DE (EC 3.1.1.5)].  
 GN PLA2G4A OR PLA2G4 OR CPLA2.  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91256305; PubMed=1904318;  
 RA Clark J.D., Lin L.-L., Kriz R.W., Ramesha C.S., Sultzman L.A.,  
 RA Lin A.Y., Wilona N., Knopf J.L.;  
 RT "A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-  
 RL Cell 65:1043-1051(1991).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=breast tumor;  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altshul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hong F.,  
 RA Diachenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Udwin T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalon D.K., Muzny N.J., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Fahey J., Helton E., Kettman M., Madan A.C., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A.C., Young J.W., Green E.D., Dickson M.C.,  
 RA Blakesley R.W., Touchman J.W., Shevchenko Y., Bouffard G.G.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalish D.E.,  
 RA Schnerker A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length  
 RL human and mouse cDNA sequences.";  
 Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 CC -!- FUNCTION: Selectively hydrolyzes arachidonyl phospholipids in the



```
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U10329; AAA53228.1; -.
CC PIR; I50699; I50699.
CC HSSP; P47712; IBC1.
CC InterPro; IPR000008; C2.
CC InterPro; IPR008973; C2_CaLB.
CC Pfam; PF00168; C2; 1.
CC Pfam; PF01735; PLA2 B; 1.
CC SMART; SM00239; C2_1.
CC SMART; SM00222; PLA2; 1.
CC PROSITE; PS50004; C2_DOMAIN 2; 1.
KW Hydrolyase; Lipid degradation; Calcium; Phosphorylation.
FT DOMAIN 1 178 PHOSPHOLIPID BINDING.
FT DOMAIN 5 106 C2 DOMAIN
FT MOD_RES 505 505 PHOSPHORYLATION (BY MAPK) (BY
FT SIMILARITY).
SQ SEQUENCE 748 AA; 84978 MW; 996A5256CA032F75 CRC64;
Query Match 18.4%; Score 596; DB 1; Length 748;
Best Local Similarity 25.9%; Pred. No. 2.7e-38;
Matches 166; Conservative 129; Mismatches 245; Indels 100; Gaps 20;
QY 44 ESLVSAQAQGVQRDQSGLOPPGLGKFRFSCLSPPSWDYRLRELAVRLGFGPCAERQAF 103
DB 100 ETLGWATFPISLKLGEKEVQLTFNNVTMTLESLV-CSSTDRLFSMALCDEKKFR 158
QY 104 SRKQVVAALQAQLQDGD---LQDEIPVVAIMATGGIRAMTSLYQLAGLKGELGL 160
DB 159 QQRKNIMOSMKFFGEENSKNLTTSRDVFVAVLGGSGGFRAMVGFAGVMKALYESGLV 218
QY 161 DCVSYITGASGWTALANLYDEPWSQKDLAGPTL---LKTQVTKNLGVLAPSOLQRY 217
DB 219 DCATYIAGLSGWTMYSTLYSHDPFEK---GPKNEQLMSVSNPLLLTPQVKRY 275
QY 218 RELAEARLGVPSCTNLA-LINEALLHDPHDKLSDOREALSHGQNPLPIYCALNT 276
DB 276 IEALWNKSGSGOPVTFTDFGLIGETLIHNR-MDTTSLDMKEKVEAQCALPLFTCLHV 334
QY 277 KQSLTTFEGWCESPVEVGFPPKYGATPELFGSEFFMQLMKRLPESRICFLEGW 336
DB 335 K-PDVSLELFAQWVEFSPYEIGNAKYGTGFMSPDLFGSKFFMGTVVKKYGENPLHFLMGV 393
QY 337 SNLYAANLDQSLYAWSEPSQFWDWRVNRQANLDKEQVPLLKI-----EPP 381
DB 394 GSASFILNRLVGVNS-----QNKGTWEELENIKHLVNSDSSDESQHP 444
QY 382 PSTAGRIA-----EFTDLL-----TWRLAQATHNRLRGLHFHKDYFQ 420
DB 445 KGTENSEANEYQNSQESWQVQRMALVGDGSAFNTRGRAGKVHFMGLNLNSCYPL 504
QY 421 HP--HFSTWKATTLQGL-----PQK-----LTPSEPHCLLDVGYLINTSCLP 465
DB 505 SPLADLLTQESVEEDLDAADDPDEFRIYPLDVKSKKHIVDSGLTFNLPYPLILRP 564
QY 466 TRVDLLILSLDNLHGA-----FQQLQLLGRQCQEGIPFPISPSPERQLQPRECHTF 519
DB 565 QRGVDLIISFDSARPSDSSPPFKELLAEKAKKNKLPFPKIDNVFREGLEKCYVPK 624
QY 520 -----SDTPCQAPAVLHF-----SSGV-RRTEPEAAAGEVNI--SSSDSPHYHT 561
DB 625 PKDTSEKDC--PTIHFVLANINFRKYKAPGLPRESKEKDFADFDIDDPNTPFSFF 681
QY 562 KVTYSQEDVDKLLHLYHNVQNCQQLLEALQAQVRRRQ 601
DB 682 NFQYPNEAFKRLHDLMEFNLTNNLDVIOAMMESIEYRKE 721
RESULT 5
PA24 RAT
ID PA24 RAT
AC P50393;
STANDARD; PRT; 752 AA.
```

DT 01-OCT-1996 (Rel. 34, Created)  
DT 01-OCT-1996 (Rel. 34, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Cytosolic phospholipase A2 (CPLA2) [includes: Phospholipase A2  
DE (EC 3.1.1.4) (Phosphatidylcholine 2-acylhydrolase); Lysophospholipase  
DE (EC 3.1.1.5)]  
GN PLA2G4A OR PLA2G4 OR CPLA2.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=101116;  
RN [1]  
RP SEQUENCE FROM N.A.  
RT TISSUE=Brain;  
RA Owada Y., Tominaga T., Yoshimoto T., Kondo H.;  
RT "Molecular cloning of rat cDNA for cytosolic phospholipase A2 and the  
RT increased gene expression in the dentate gyrus following transient  
RT forebrain ischemia."  
RL Brain Res. Mol. Brain Res. 25:364-368(1994).  
RN [2]  
RP  
RP ERRATUM  
RX MEDLINE=95206125; PubMed=7898324;  
RA Owada Y., Tominaga T., Yoshimoto T., Kondo H.;  
RL Brain Res. Mol. Brain Res. 27:355-355(1994).  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Sprague-Dawley; TISSUE=Pancratic islets;  
RX MEDLINE=98223459; PubMed=9555100;  
RA Ma Z., Ramanadham S., Hu Z., Turk J.;  
RT "Cloning and expression of a group IV cytosolic Ca2+-dependent  
RT phospholipase A2 from rat pancreatic islets. Comparison of the  
RT expressed activity with that of an islet group VI cytosolic Ca2+-  
RT independent phospholipase A2."  
RL Biochim. Biophys. Acta 1391:384-400(1998).  
CC -!- FUNCTION: Selectively hydrolyzes arachidonyl phospholipids in the  
CC sn-2 position releasing arachidonic acid. Together with its  
CC lysophospholipid activity, it is implicated in the initiation of  
CC the inflammatory response.  
CC -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-  
CC acylglycerophosphocholine + a fatty acid anion.  
CC -!- CATALYTIC ACTIVITY: 2-lysophosphatidylcholine + H(2)O =  
CC glycerophosphocholine + a fatty acid anion.  
CC -!- ENZYME REGULATION: Stimulated by agonists such as ATP, EGF,  
CC thrombin and bradykinin as well as by cytosolic Ca(2+).  
CC -!- SUBCELLULAR LOCATION: Cytoplasmic. Translocates to membrane  
CC vesicles in a calcium-dependent fashion (By similarity).  
CC -!- TISSUE SPECIFICITY: In brain tissue, expressed in low levels in  
CC olfactory mitral and granule cells, in hippocampal pyramidal  
CC cells and in dentate and cerebellar granule cells.  
CC -!- INDUCTION: Levels of rat CPLA2 are increased in dentate granule  
CC cells during ischemia.  
CC -!- DOMAIN: The N-terminal C2 domain, by its association with lipid  
CC membranes, mediates the regulation of CPLA2 by presenting the  
CC active site to its substrate in response to elevations of  
CC cytosolic Ca(2+) (By similarity).  
CC -!- PTM: Activated by phosphorylation on a serine residue (By  
CC similarity).  
CC -!- SIMILARITY: Contains 1 C2 domain.  
CC  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/  
CC or send an email to license@isb-sib.ch).  
CC  
CC EMBL; S77829; AAB33847.1; -;  
CC EMBL; U38376; AAC21591.1; -;  
CC HSSP; P47712; IBC1.  
CC InterPro; IPR000008; C2.  
CC InterPro; IPR008973; C2\_CaLB.  
CC InterPro; IPR002642; PLA2.



```

Db 138 LRFSTMLCDQKLFMTQTRDRVLMISIKKLLKMNPRFLPSPREVPITAILGGGFRAM 197
QY 145 TSLYGOLAGLKEUGLDCVSYITGASGTSWALANLYEDPWSOKDLAGTEL---LKTQV 201
Db 198 VGFSGVMKALYESGVDFCAIYVAGLSGSTMWMLSYHPEFPAK---GPGDINKELMNRV 254
QY 202 TKMKGLVLAPOQLORYQELAEARLGYPCFTNLWA-LINEALLHDEPHDKLSQOREA 260
Db 255 SNNPLKLLPQINIRYVKALWKKSAGQPTVTFDIFQMLIGETLIFGR-WNLIKSLIKGK 313
QY 261 LSHQNPPIYCALNTKGOSLTTFEFGECWCFSPYVGPFGAPISLFGSEFFMQGL 320
Db 314 INEGOSPLPLFTCLHVK-PDVSLMEADWVEFSYBGMKAYGTFSPLFGSKFFMGSV 372
QY 321 MKRLPESRICEFLEGIWSNLY-----AANLQDSLYWASEPSQFWDVRVRNQ 365
Db 373 VKQYENPHLPLMGWGSFAFSLFNVLGVKETTSSSTMEEELEQIKPEHIVGDDSDADNE 432
QY 366 ANLDK---EQVPLLKIEPPSTAGIAEFTDILL-----TWRLAQATHNPLRGLHFH 415
Db 433 EETQRGTSADAEDQRQHAQASWQVRLTSMGTTLFTTREGRAKGVHNPMLGLNLN 492
QY 416 KYDFQHPHSTKATYLDGLPNOLT-PSE-----PHLCULDVGYYLNTSCLEPL 462
Db 493 STLFPSPFGSITHOTSLEEVDAVTDPEFERIYEPDVKSKKHVVDGSLTFNLPYPLI 552
QY 463 LQPTRVDVLTSLDYNLHGA-----FOQLQLLRFCQEQIIPPPIPSPEQLOPRECH 517
Db 553 LRCQGVDLIIIFDSFARSDDSPFPKELLAEKWMKMLPPPKIDSKVDFREGLUKEY 612
QY 518 TF-----SDPTCPGAPAVLHF-----SSGV-RRTPPEAAAGEVNL-SSSDSPYHY 560
Db 613 VFEPKAKGDKNC---PTLIHFVLANINFRNFKAGVPRDSKDIIEFGDFDIFDEPASPYST 669
QY 561 TKVTSYQEDVDKLLHLTHVNCNQELLEALRQAVQRRQ 601
Db 670 FNFKNYNQAFKRLHOLMEFTNLNIEVIEKAIKDSILLRRE 710

RESULT 7
ALU8 HUMAN
ID ALU8 HUMAN STANDARD; PRT; 591 AA.
AC P39195;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Alu subfamily SX sequence contamination warning entry.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
[1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95021758; PubMed=7935834;
RA Claverie J.-M.; Makalowski W.;
RT "Alu alert.";
RL Nature 371:752-752 (1994).
[2]
RP CONCEPT.
RX MEDLINE=92241891; PubMed=1572661;
RA Claverie J.-M.;
RT "Identifying coding exons by similarity search: alu-derived and other
RT potentially misleading protein sequences.";
RL Genomics 12:838-841 (1992).
[3]
RN ALU FAMILIES CLASSIFICATION.
RP MEDLINE=88333009; PubMed=3138422;
RA Quentin Y.;
RT "The Alu family developed through successive waves of fixation
RT closely connected with primate lineage history.";
RL J. Mol. Evol. 27:194-202 (1988).
[4]

```

```

RP ALU FAMILIES CLASSIFICATION.
RX MEDLINE=91178815; PubMed=1706781;
RA Jurka J.; Milosavljevic A.;
RT "Reconstruction and analysis of human Alu genes.";
RL J. Mol. Evol. 32:105-121 (1991).
CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF. 3 AND REF. 4) INDICATE
CC THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING
CC CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX
CC FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU
CC REPEATS.
CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP
CC CODON, 'XX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.
CC -!- CAUTION: This Alu entry is provided in order to avoid the further
CC pollution of protein sequence databases with Alu-derived amino
CC acid sequences.
CC -!- CAUTION: Alu repetitive sequences are interspersed in human and
CC primate genomes with an average spacing of 4 kb. Some of them are
CC actively transcribed by pol III. Normal transcripts may contain
CC Alu-derived sequences in 5' or 3' untranslated regions. However,
CC cDNA libraries also contain partial and/or rearranged cDNAs
CC ligated with Alu-derived sequence in any orientation. Although Alu
CC elements (especially situated on the complementary strand) have a
CC great potential to create additional/alternative exons,
CC consideration should be given to the possibility that the presence
CC of an Alu in an open reading frame may have resulted from a
CC cloning artifact or may be due to misinterpretation of sequencing
CC data. This point has been overlooked on several occasions, with
CC the consequence of erroneous Alu-derived amino acid sequences
CC being reported.
CC -!- CAUTION: Any significant similarity of a putative protein sequence
CC with an Alu-translated entry must be taken as a warning that a
CC part of Alu repeat may have been artifactually included in the
CC coding nucleotide sequence.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U14574; -; NOT_ANNOTATED_CDS.
CC DR Hypothetical protein.
CC FT DOMAIN 1 96 FRAME-1.
CC FT DOMAIN 100 195 FRAME-2.
CC FT DOMAIN 100 195 FRAME-3.
CC FT DOMAIN 298 393 FRAME-4.
CC FT DOMAIN 397 492 FRAME-5.
CC FT DOMAIN 496 591 FRAME-6.
CC SQ SEQUENCE 591 AA; 64395 MW; AC8154AD8A6BB280 CRC64;

Query Match 7.0%; Score 226.5; DB 1; Length 591;
Best Local Similarity 65.3%; Pred. No. 8.8e-10;
Matches 47; Conservative 1; Mismatches 17; Indels 7; Gaps 1;

QY 32 PAPCPFFPFMEISLVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYRLRE----- 86
Db 488 PASARXXXFFETESRSVAQAGVQWRDLGSLQPPPPGFKRFSCLSLPSSWDYRPPRPN 547
QY 87 --LAVRLGFGPC 96
Db 548 FCIFSRDGVSPC 559

RESULT 8
ALU2 HUMAN
ID ALU2 HUMAN STANDARD; PRT; 587 AA.
AC P39189;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Alu subfamily SB sequence contamination warning entry.

```

OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OK NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=95021758; PubMed=7935834;  
 RA Claverie J.-M., Makalowski W.;  
 RT "Alu alert.";  
 RL Nature 371:752-752(1994).  
 RN [2]  
 RP CONCEPT.  
 RX MEDLINE=92241891; PubMed=1572661;  
 RA Claverie J.-M.;  
 RT "Identifying coding exons by similarity search: alu-derived and other  
 RT potentially misleading protein sequences.";  
 RL Genomics 12:838-841(1992).  
 RN [3]  
 RP ALU FAMILIES CLASSIFICATION.  
 RX MEDLINE=88333009; PubMed=3138422;  
 RA Quentin Y.;  
 RT "The Alu family developed through successive waves of fixation  
 RT closely connected with primate lineage history.";  
 RL J. Mol. Evol. 27:194-202(1988).  
 RN [4]  
 RP ALU FAMILIES CLASSIFICATION.  
 RX MEDLINE=91178815; PubMed=1706781;  
 RA Jurka J., Milosavljevic A.;  
 RT "Reconstruction and analysis of human Alu genes.";  
 RL J. Mol. Evol. 32:105-121(1991).  
 CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF.3 AND REF.4) INDICATE  
 CC THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING  
 CC CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX  
 CC FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU  
 CC REPEATS.  
 CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP  
 CC CODON, 'XXX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.  
 CC -!- CAUTION: This Alu entry is provided in order to avoid the further  
 CC pollution of protein sequence databases with Alu-derived amino  
 CC acid sequences.  
 CC -!- CAUTION: Alu repetitive sequences are interspersed in human and  
 CC primate genomes with an average spacing of 4 kb. Some of them are  
 CC actively transcribed by pol III. Normal transcripts may contain  
 CC Alu-derived sequences in 5' or 3' untranslated regions. However,  
 CC cDNA libraries also contain partial and/or rearranged cDNAs  
 CC ligated with Alu-derived sequence in any orientation. Although Alu  
 CC elements (especially situated on the complementary strand) have a  
 CC great potential to create additional/alternative exons,  
 CC of an Alu in an open reading frame may have resulted from a  
 CC cloning artifact or may be due to misinterpretation of sequencing  
 CC data. This point has been overlooked on several occasions, with  
 CC the consequence of erroneous Alu-derived amino acid sequences  
 CC being reported.  
 CC -!- CAUTION: Any significant similarity of a putative protein sequence  
 CC with an Alu-translated entry must be taken as a warning that a  
 CC part of Alu repeat may have been artifactually included in the  
 CC coding nucleotide sequence.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; U14568; -; NOT ANNOTATED\_CDS.  
 CC -----  
 DR Hypothetical protein.  
 KW 1 96 FRAME-1.  
 FT DOMAIN 100 194 FRAME-2.  
 FT DOMAIN 198 292 FRAME-3.  
 FT DOMAIN 296 391 FRAME-4.

FT DOMAIN 395 489 FRAME-5.  
 FT DOMAIN 493 587 FRAME-6.  
 SQ SEQUENCE 587 AA; 63703 MW; 3EAAB3E3E329203 CRC64;  
 Query Match 6.2%; Score 199.5; DB 1; Length 587;  
 Best Local Similarity 65.6%; Pred. No. 1.1e-07; Indels 7; Gaps 1;  
 Matches 42; Conservative 1; Mismatches 14;  
 QY 40 FFEMESLSVAQGVQWRDLGSLQPPPLGFKFSCISLSPSSWDYRLRE-----LAVRLG 92  
 Db 493 FFETESRSVAQGVQWRDLGSLQPPPGFTFSCISLSPSSWDYRPPRPPANFCIFSRDG 552  
 QY 93 FGPC 96  
 Db 553 VSPC 556  
 RESULT 9  
 ID ALU7 HUMAN STANDARD; PRT; 593 AA.  
 AC P39194;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Alu subfamily SQ sequence contamination warning entry.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=95021758; PubMed=7935834;  
 RA Claverie J.-M., Makalowski W.;  
 RT "Alu alert.";  
 RL Nature 371:752-752(1994).  
 RN [2]  
 RP CONCEPT.  
 RX MEDLINE=92241891; PubMed=1572661;  
 RA Claverie J.-M.;  
 RT "Identifying coding exons by similarity search: alu-derived and other  
 RT potentially misleading protein sequences.";  
 RL Genomics 12:838-841(1992).  
 RN [3]  
 RP ALU FAMILIES CLASSIFICATION.  
 RX MEDLINE=88333009; PubMed=3138422;  
 RA Quentin Y.;  
 RT "The Alu family developed through successive waves of fixation  
 RT closely connected with primate lineage history.";  
 RL J. Mol. Evol. 27:194-202(1988).  
 RN [4]  
 RP ALU FAMILIES CLASSIFICATION.  
 RX MEDLINE=91178815; PubMed=1706781;  
 RA Jurka J., Milosavljevic A.;  
 RT "Reconstruction and analysis of human Alu genes.";  
 RL J. Mol. Evol. 32:105-121(1991).  
 CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF.3 AND REF.4) INDICATE  
 CC THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING  
 CC CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX  
 CC FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU  
 CC REPEATS.  
 CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP  
 CC CODON, 'XXX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.  
 CC -!- CAUTION: This Alu entry is provided in order to avoid the further  
 CC pollution of protein sequence databases with Alu-derived amino  
 CC acid sequences.  
 CC -!- CAUTION: Alu repetitive sequences are interspersed in human and  
 CC primate genomes with an average spacing of 4 kb. Some of them are  
 CC actively transcribed by pol III. Normal transcripts may contain  
 CC Alu-derived sequences in 5' or 3' untranslated regions. However,  
 CC cDNA libraries also contain partial and/or rearranged cDNAs  
 CC ligated with Alu-derived sequence in any orientation. Although Alu  
 CC elements (especially situated on the complementary strand) have a  
 CC great potential to create additional/alternative exons,  
 CC of an Alu in an open reading frame may have resulted from a  
 CC cloning artifact or may be due to misinterpretation of sequencing  
 CC data. This point has been overlooked on several occasions, with  
 CC the consequence of erroneous Alu-derived amino acid sequences  
 CC being reported.  
 CC -!- CAUTION: Any significant similarity of a putative protein sequence  
 CC with an Alu-translated entry must be taken as a warning that a  
 CC part of Alu repeat may have been artifactually included in the  
 CC coding nucleotide sequence.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 CC EMBL; U14568; -; NOT ANNOTATED\_CDS.  
 CC -----  
 DR Hypothetical protein.  
 KW 1 96 FRAME-1.  
 FT DOMAIN 100 194 FRAME-2.  
 FT DOMAIN 198 292 FRAME-3.  
 FT DOMAIN 296 391 FRAME-4.



consideration should be given to the possibility that the presence of an Alu in an open reading frame may have resulted from a cloning artifact or may be due to misinterpretation of sequencing data. This point has been overlooked on several occasions, with the consequence of erroneous Alu-derived amino acid sequences being reported.

-!- CAUTION: Any significant similarity of a putative protein sequence with an Alu-translated entry must be taken as a warning that a part of Alu repeat may have been artifactually included in the coding nucleotide sequence.

-----

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

-----

EMBL; U14573; -; NOT\_ANNOTATED\_CDS.

KW Hypothetical protein.

FT DOMAIN 1 97 FRAME-1.

FT DOMAIN 101 196 FRAME-2.

FT DOMAIN 200 295 FRAME-3.

FT DOMAIN 299 395 FRAME-4.

FT DOMAIN 399 494 FRAME-5.

FT DOMAIN 498 593 FRAME-6.

SQ SEQUENCE 593 AA; 64417 MW; 54A4F50F33A6089F CRC64;

Query Match 6.2%; Score 199.5; DB 1; Length 593;  
Best Local Similarity 63.1%; Pred. No. 1.1e-07;  
Matches 41; Conservative 1; Mismatches 16; Indels 7; Gaps 1;

QY 39 FFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYRLRE-----LAVRL 91  
Db 299 FLFRSFLVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYRRPPRPNANFCIFSRD 358

QY 92 GFGPC 96  
Db 359 GVSPC 363

RESULT 10

ALU3 HUMAN

ID ALU3 HUMAN STANDARD; PRT; 587 AA.

AC P39190;

DT 01-FEB-1995 (Rel. 31, Created)

DT 01-FEB-1995 (Rel. 31, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Alu subfamily SBI sequence contamination warning entry.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI\_TaxID=9606;

FN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=95021758; PubMed=7935834;

RA Claverie J.-M., Makalowski W.;

RT "Alu alert.";

RL Nature 371:752-752(1994).

RN [2]

RP CONCEPT.

RX MEDLINE=92241891; PubMed=1572661;

RA Claverie J.-M.;

RT "Identifying coding exons by similarity search: alu-derived and other potentially misleading protein sequences.";

RL Genomics 12:838-841(1992).

RN [3]

RP ALU FAMILIES CLASSIFICATION.

RX MEDLINE=88333009; PubMed=3138422;

RA Quentin Y.;

RT "The Alu family developed through successive waves of fixation closely connected with primate lineage history.";

J. Mol. Evol. 27:194-202(1988).

[4] ALU FAMILIES CLASSIFICATION.

RX MEDLINE=91178815; PubMed=1706781;

RA Jurka J., Milosavljevic A.;

RT "Reconstruction and analysis of human Alu genes.";

RL J. Mol. Evol. 32:105-121(1991)

CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF.3 AND REF.4) INDICATE THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU REPEATS.

CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP CODON, 'XX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.

CC -!- CAUTION: This Alu entry is provided in order to avoid the further pollution of protein sequence databases with Alu-derived amino acid sequences.

CC -!- CAUTION: Alu repetitive sequences are interspersed in human and primate genomes with an average spacing of 4 kb. Some of them are actively transcribed by pol III. Normal transcripts may contain Alu-derived sequences in 5' or 3' untranslated regions. However, cDNA libraries also contain partial and/or rearranged cDNAs ligated with Alu-derived sequence in any orientation. Although Alu elements (especially situated on the complementary strand) have a great potential to create additional/alternative exons, consideration should be given to the possibility that the presence of an Alu in an open reading frame may have resulted from a cloning artifact or may be due to misinterpretation of sequencing data. This point has been overlooked on several occasions, with the consequence of erroneous Alu-derived amino acid sequences being reported.

CC -!- CAUTION: Any significant similarity of a putative protein sequence with an Alu-translated entry must be taken as a warning that a part of Alu repeat may have been artifactually included in the coding nucleotide sequence.

-----

This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

-----

EMBL; U14569; -; NOT\_ANNOTATED\_CDS.

KW Hypothetical protein.

FT DOMAIN 1 96 FRAME-1.

FT DOMAIN 100 194 FRAME-2.

FT DOMAIN 198 292 FRAME-3.

FT DOMAIN 296 391 FRAME-4.

FT DOMAIN 395 489 FRAME-5.

FT DOMAIN 493 587 FRAME-6.

SQ SEQUENCE 587 AA; 63573 MW; 85C4155726DEF235 CRC64;

Query Match 6.1%; Score 198; DB 1; Length 587;  
Best Local Similarity 86.4%; Pred. No. 1.4e-07;  
Matches 38; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 40 FFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYR 83  
Db 493 FFETESRSVAQAGVQWRDLGSLQAPPFPPTFFSCLSLPSSWDYR 536

RESULT 11

ALU6 HUMAN

ID ALU6 HUMAN STANDARD; PRT; 593 AA.

AC P39193;

DT 01-FEB-1995 (Rel. 31, Created)

DT 01-FEB-1995 (Rel. 31, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Alu subfamily SP sequence contamination warning entry.

OS Homo sapiens (Human)

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Fri Oct 8 10:22:34 2004

```
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95021758; PubMed=7935834;
RA Claverie J.-M., Makalowski W.;
RT "Alu alert.";
RL Nature 371:752-752(1994).
RN [2]
RP CONCEPT.
RX MEDLINE=92241891; PubMed=1572661;
RA Claverie J.-M.;
RT "Identifying coding exons by similarity search: alu-derived and other
potentially misleading protein sequences.";
RL Genomics 12:838-841(1992).
RN [3]
RP ALU FAMILIES CLASSIFICATION.
RX MEDLINE=88333009; PubMed=3138422;
RA Quentin Y.;
RT "The Alu family developed through successive waves of fixation
closely connected with primate lineage history.";
RL J. Mol. Evol. 27:194-202(1988).
RN [4]
RP ALU FAMILIES CLASSIFICATION.
RX MEDLINE=91178815; PubMed=1706781;
RA Jurka J., Milosavljevic A.;
RT "Reconstruction and analysis of human Alu genes.";
RL J. Mol. Evol. 32:105-121(1991).
CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF.3 AND REF.4) INDICATE
THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING
CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX
FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU
REPEATS.
CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP
CODON, 'XXX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.
CC -!- CAUTION: This Alu entry is provided in order to avoid the further
pollution of protein sequence databases with Alu-derived amino
acid sequences.
CC -!- CAUTION: Alu repetitive sequences are interspersed in human and
primate genomes with an average spacing of 4 kb. Some of them are
actively transcribed by pol III. Normal transcripts may contain
Alu-derived sequences in 5' or 3' untranslated regions. However,
cDNA libraries also contain partial and/or rearranged cDNAs
ligated with Alu-derived sequence in any orientation. Although Alu
elements (especially situated on the complementary strand) have a
great potential to create additional/alternative exons,
consideration should be given to the possibility that the presence
of an Alu in an open reading frame may have resulted from a
cloning artifact or may be due to misinterpretation of sequencing
data. This point has been overlooked on several occasions, with
the consequence of erroneous Alu-derived amino acid sequences
being reported.
CC -!- CAUTION: Any significant similarity of a putative protein sequence
with an Alu-translated entry must be taken as a warning that a
part of Alu repeat may have been artifactually included in the
coding nucleotide sequence.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U14572; ; NOT_ANNOTATED_CDS.
DR Hypothetical protein.
KW DOMAIN 1 97 FRAME-1.
FT DOMAIN 101 196 FRAME-2.
FT DOMAIN 200 295 FRAME-3.
FT DOMAIN 299 395 FRAME-4.
FT DOMAIN 399 494 FRAME-5.
FT DOMAIN 498 593 FRAME-6.
FT
```

```
SQ SEQUENCE 593 AA; 64603 MW; 136EF344AACD12A2 CRC64;
Query Match 6.0%; Score 192.5; DB 1; Length 593;
Best Local Similarity 61.5%; Pred. No. 3.8e-07;
Matches 40; Conservative 1; Mismatches 17; Indels 7; Gaps 1;
QY 39 FFFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSLPSSWDYRLRE-----LAVRL 91
Db 299 FFLRRSFALVAQAGVQWRDLGSPQPPPPGFKRFSCLSLPSSWDYRHAPPRANFCIFSRD 358
QY 92 GFGPC 96
Db 359 GVSPC 363
RESULT 12
ALU5 HUMAN
ID ALU5 HUMAN STANDARD; PRT; 585 AA.
AC P39192;
DT 01-FEB-1995 (Rel. 31, Created)
DT 01-FEB-1995 (Rel. 31, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Alu subfamily SC sequence contamination warning entry.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=95021758; PubMed=7935834;
RA Claverie J.-M., Makalowski W.;
RT "Alu alert.";
RL Nature 371:752-752(1994).
RN [2]
RP CONCEPT.
RX MEDLINE=92241891; PubMed=1572661;
RA Claverie J.-M.;
RT "Identifying coding exons by similarity search: alu-derived and other
potentially misleading protein sequences.";
RL Genomics 12:838-841(1992).
RN [3]
RP ALU FAMILIES CLASSIFICATION.
RX MEDLINE=88333009; PubMed=3138422;
RA Quentin Y.;
RT "The Alu family developed through successive waves of fixation
closely connected with primate lineage history.";
RL J. Mol. Evol. 27:194-202(1988).
RN [4]
RP ALU FAMILIES CLASSIFICATION.
RX MEDLINE=91178815; PubMed=1706781;
RA Jurka J., Milosavljevic A.;
RT "Reconstruction and analysis of human Alu genes.";
RL J. Mol. Evol. 32:105-121(1991).
CC -!- MISCELLANEOUS: VARIOUS ANALYSES (SEE REF.3 AND REF.4) INDICATE
THAT ALU REPEATS FALL INTO 8 SUBFAMILIES. THEREFORE, 8 ALU WARNING
CONSENSUS SEQUENCES HAVE BEEN CONSTITUTED THAT CONTAIN ALL SIX
FRAMES CONCEPTUAL TRANSLATIONS OF EACH OF THESE CLASSES OF ALU
REPEATS.
CC -!- MISCELLANEOUS: ISOLATED 'X' INDICATES THE PRESENCE OF A STOP
CODON, 'XXX' IS USED TO SEPARATE THE VARIOUS TRANSLATION PHASES.
CC -!- CAUTION: This Alu entry is provided in order to avoid the further
pollution of protein sequence databases with Alu-derived amino
acid sequences.
CC -!- CAUTION: Alu repetitive sequences are interspersed in human and
primate genomes with an average spacing of 4 kb. Some of them are
actively transcribed by pol III. Normal transcripts may contain
Alu-derived sequences in 5' or 3' untranslated regions. However,
cDNA libraries also contain partial and/or rearranged cDNAs
ligated with Alu-derived sequence in any orientation. Although Alu
elements (especially situated on the complementary strand) have a
great potential to create additional/alternative exons,
consideration should be given to the possibility that the presence
of an Alu in an open reading frame may have resulted from a
cloning artifact or may be due to misinterpretation of sequencing
data. This point has been overlooked on several occasions, with
the consequence of erroneous Alu-derived amino acid sequences
being reported.
```

```

CC cloning artifact or may be due to misinterpretation of sequencing
CC data. This point has been overlooked on several occasions, with
CC the consequence of erroneous Alu-derived amino acid sequences
CC being reported.
CC
CC -!- CAUTION: Any significant similarity of a putative protein sequence
CC with an Alu-translated entry must be taken as a warning that a
CC part of Alu repeat may have been artifactually included in the
CC coding nucleotide sequence.
CC
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; U14571; -; NOT ANNOTATED_CDS.
CC
DR HYPOTHETICAL protein.
KW DOMAIN 1 95 FRAME-1.
FT DOMAIN 99 193 FRAME-2.
FT DOMAIN 197 291 FRAME-3.
FT DOMAIN 295 389 FRAME-4.
FT DOMAIN 393 487 FRAME-5.
FT DOMAIN 491 585 FRAME-6.
SQ SEQUENCE 585 AA; 63957 MW; 46EE8C4F493650A7 CRC64;

Query Match 5.9%; Score 191; DB 1; Length 585;
Best Local Similarity 31.7%; Pred. No. 4.9e-07;
Matches 71; Conservative 20; Mismatches 63; Indels 70; Gaps 10;

QY 39 FPFMEISLVAQGVQWRDYGSLQPPPLGPKRPSCLSLPSSWDYRLRE-----LAVRL 91
Db 393 FFXDGVSL-CRQAGVQWRDYGSLQPPPPGPKRPSCLSLPSSWDYRRAPPANFCIFSRD 451
QY 92 GFGECAEEQAFLSRRKQVAAALRQALQDLQDEDEIPVVAIMATGGGIRAMTSLYGQL 151
Db 452 GVSPFCWP-----GWSRLDLVIRPPPPKVL-----GLQXATAPGXX 489
QY 152 AGL-----KEGLIDCVSYITGAGSTWALANL-----YEDPEWSOKLAGPTE----- 195
Db 490 XFFETESRSVARLEC-----SGAISAHCNRLPGSSDSPASASRVAGTGTGARHHAQLI 542
QY 196 ---LLKT---QVTKNKLGVLPASQLQRYRQELAEARLGVPSCF 233
Db 543 FVLVETGFHHVQDGLDLT-----SXSARLGLPKCW 575

RESULT 13
PLB4 SCHPO
ID ID PLB4 SCHPO STANDARD; PRT; 673 AA.
AC Q9P327;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Putative lysophospholipase C977.09c precursor (EC 3.1.1.5)
DE (Phospholipase B)
GN SPAC977.09C OR SPAC1348.10C.
OS Schizosaccharomyces pombe (Fission yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
ON NCBI_TaxID=4896;
OX [1]
RN SEQUENCE FROM N.A.
RP STRAIN=972;
RX MEDLINE=21848401; PubMed=11859360;
RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouras J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Felwell T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jacobs K.,

```

116 QAL-----QLDGLQDEIPVVAIMATGGIPAMTSLYQGLAKE-----LGILL 160  
 109 SFISKTLINVLDRKVVNSDGRIGIAFSGGLRAMVNGGAFNAFDRPESDPLSGLL 168  
 161 DCVSYITGASSTWALANLYEDPEWSQDLAPTELLKTQVTKKGLVLA-----SQL 214  
 169 QSAMYISGLSGSLVGSV-----AINNFNIT-YLRDNVWNLHSEVFAHGDVNIENL 221  
 215 QRY---ROELAEARLGYSCFTLWALINLHALLHDEPHDKLSQREA----- 260  
 222 NYNDLRKEIDQKHAGDCSLTDLW-----GRAL-----SRKLVAERGGPGITYSSMRN 272  
 261 ---LSHGQNPPIYCA-----LNTKQSITTEFECEWCEFSFVEYGFPGYGAFI 306  
 273 QSWFNADYPPIIIVADSRLEETAIPANTSIFFETAYEFTW-----DNGIK---AFI 323  
 307 PSELFSGEFFMGQMKRPFESRIC-----FLEGIWSNLYAANLQDSLYWASEPSPFW 358  
 324 PNEYVGT-----HLLDGVPPDKSCIHNVDNAGFVMTSATLNSFLD-----W 367  
 359 DRWRNQNANLQDSLYWASEPSPAGRIABFFTDLLTWRLAQATHNGLHFKHD- 417  
 368 NENVKKN-----DTYYDIL-----HALLDLSKHQDD 394  
 418 ---YFOHPH---PSTWATLIDGLPNQITPSEPH---LCLLDVGY-LINTSCLPLLOTRDVD 470  
 395 IAPENPNQNTYSNTSVNAF-----EPYDIDLVDGGDRDNIPLWELLHQRVD 447  
 471 LITLSD---YNLHGAFAQLQLGRFCQEQGIPFPISPSPEEQLOPRECHTFSD---PTC 524  
 448 VFAIDSYN-----DPYGMPLGSSIVATYERVVTFNANKSVDRGFPYI 492  
 525 GPAPAVLHPSGVRRT-----PEEAAAGEVNLSSDSP-----YHYTKVYSOE 568  
 493 PENTIISLGLNTRPTFFGCDGKNTAGNHVDNNTPTLLVYFPNYPWTYISNISTFMS 552  
 569 DVDKLLHLTHYNVC-----NNOEQLEALRQA-VORRRORR 603  
 553 MODKMWANGILENAFMTSTONNESFAVCLALIQSLERK 593

RESULT 14  
 FLB3\_YEAST STANDARD; PRT; 686 AA.  
 AC Q08108;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Lysophospholipase 3 precursor (EC 3.1.1.5) (Phospholipase B 3).  
 GN FLB3 OR YOLO11W.  
 OS Saccharomyces cerevisiae (Baker's yeast).  
 OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;  
 OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.  
 OX NCBI\_TaxID=4932;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Hughes B., Pohl T.M.;  
 RL Submitted (JUL-1996) to the EMBL/GenBank/DBJ databases.  
 CC -1- FUNCTION: Catalyzes the release of fatty acids from  
 CC lysophospholipids.  
 CC -1- CATALYTIC ACTIVITY: 2-lysophosphatidylcholine + H(2)O =  
 CC glycerophosphocholine + a fatty acid anion.  
 CC -1- SUBCELLULAR LOCATION: Secreted (Potential).  
 CC -1- SIMILARITY: Belongs to the lysophospholipase family.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

EMBL; Z74753; CAA99010.1; --  
 PIR; S66693; S66693.  
 GenOnline; 143433; --  
 SGD; S0005371; P1B3.  
 DR GO; GO:0005615; C:extracellular space; IDA.  
 DR GO; GO:0004622; F:lysophospholipase activity; IMP.  
 DR GO; GO:0006660; P:phosphatidylserine catabolism; IDA.  
 DR GO; GO:0030384; P:phosphoinositide metabolism; IDA.  
 DR InterPro; IPR002642; PLAC.  
 DR Pfam; PF01735; PLAC\_2; 1.  
 DR SMART; SM00022; PLAC; 1.  
 KW Lipid degradation; Hydrolase; Glycoprotein; Signal.  
 FT SIGNAL 1 26  
 FT CHAIN 27 686  
 FT DOMAIN 627 643  
 FT POLY-SER.  
 FT CARBOHYD 56 56  
 FT CARBOHYD 82 82  
 FT CARBOHYD 129 129  
 FT CARBOHYD 166 166  
 FT CARBOHYD 221 221  
 FT CARBOHYD 283 283  
 FT CARBOHYD 313 313  
 FT CARBOHYD 351 351  
 FT CARBOHYD 495 495  
 FT CARBOHYD 519 519  
 FT CARBOHYD 547 547  
 FT CARBOHYD 571 571  
 FT CARBOHYD 588 588  
 FT CARBOHYD 614 614  
 FT CARBOHYD 686 686  
 SQ SEQUENCE 686 AA; 75076 MW; 95A2DF41BF3E20F CRC64;

Query Match 5.7%; Score 184; DB 1; Length 686;  
 Best Local Similarity 21.0%; Pred. No. 2.1e-06;  
 Matches 129; Conservative 80; Mismatches 192; Indels 214; Gaps 31;

QY 99 EQAFLSRRKQVVAALRQAL-----QLDGLQDEIPVVAIMATGGIARA 143  
 DB 57 ESAMLEKRNKVTSAVKDFLTRATANFSDSSEVLSKLFNDGENSELPKIAVAVSGGYRS 116  
 QY 144 MTSLYGQLAGLAKEL-----GLDCVSYITGASSTWALANL----- 179  
 DB 117 MUTGAGVLAMDNRTGAYEHGGLGQLQSTTYLSGASGGLVGLTALANWTSVQDILNN 176  
 QY 180 ---YEDPEWSQKD---LAGTELLKTQVTKNKL-GVLAPSOLORYOELAE---RAELGYP 230  
 DB 177 MQNDDSIWLSDSIVTPGGINIFKTAKRWDHISNAVESKQADYNTSLADIWGRA-LAY- 234  
 QY 231 SCFTNLWALINE-----ALLHDEPHDKLSQREALSHGQNPPIYCA---LNTKQ 279  
 DB 235 ---NFFPSLNRGGIGLITWSSIRDFP-----VFQNAEMPPFISVADGRYPGTVKI 280  
 QY 280 SLTTFEFGWCWCFSPYEVGF--PKYGAFIPSELFSEFFMGQMKR---LPESRICFLE 333  
 DB 281 NLNATVF---BENPEMGSWDPSLNSFANVKYLGTVNSGVPLERKCKTAGFDNAGFIM 336  
 QY 334 GWSNLYAANLQDSLYWASEPSPQFWRWRNQNANLQKEQVPLLKIEEP--PSTAGRIA-- 389  
 DB 337 GTSSTLTF-----NQF-----LLRINSTHLPSTFTRLARH 365  
 QY 390 -----EFFTDLLTWRLAQATHNGLHFKHDYFQHPHSTWKTATLIDGLPNQITPSE 443  
 DB 366 FLKDLSDQDFNDIAVYSENPFKDTKFL-----DSDY-----TT-----SIVSDS 403  
 QY 444 PHLCLLDVGY-LINTSCLPLLOTRDVDLTLSDYN-----LHGAFAQLQLL 489  
 DB 404 -SLFLVDGGEDDENVPVPLIQKERVVDIIFAVDNGADMRLAWPDGSSLVHYTERQVVK 462  
 QY 490 GRFCQEQGIPFPISPSPEEQLOPRECHTF-----SDPTCPGA-----PAVL 531  
 DB 463 G-----QGMSPFPYVP-----DTNTFNLGLNKKPTFFGCDANLTLQVIPPV 507  
 QY 532 HFSSGVRRTEEEAAAGEVNLSSDSPVHYTKVYSQED-----VDKLLHLTHYNVNNQEQ 587



**THIS Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: October 5, 2004, 18:51:24 ; Search time 120.193 Seconds  
(without alignments)  
1588.179 Million cell updates/sec

Title: US-09-830-321a-2

Perfect score: 3235

Sequence: 1 MIFVESPTALCLERVASH.....EQLLEALROAVRRQRREH 605

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1017041 segs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- SPTREMBL.25.\*  
1: sp\_archaea.\*  
2: sp\_bacteria.\*  
3: sp\_fungi.\*  
4: sp\_human.\*  
5: sp\_invertebrate.\*  
6: sp\_mammal.\*  
7: sp\_mhc.\*  
8: sp\_organelle.\*  
9: sp\_phage.\*  
10: sp\_plant.\*  
11: sp\_rodent.\*  
12: sp\_virus.\*  
13: sp\_vertebrate.\*  
14: sp\_unclassified.\*  
15: sp\_rvirus.\*  
16: sp\_bacteriap.\*  
17: sp\_archaeap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2767.5	85.5	1012	4 Q9UKV7	Q9ukv7 homo sapien
2	2767.5	85.5	1012	4 Q95712	Q95712 homo sapien
3	1931.5	59.7	439	11 Q80VV8	Q80vv8 mus musculus
4	1492	46.1	818	4 Q86XP0	Q86xp0 homo sapien
5	1141.5	35.3	845	4 Q81UP3	Q81up3 homo sapien
6	1127	34.8	841	11 Q80VV9	Q80vv9 mus musculus
7	708	21.9	356	11 Q8BX44	Q8bx44 mus musculus
8	685	21.2	372	11 Q80V08	Q80vq8 mus musculus
9	639.5	19.8	748	6 Q8TT38	Q8tt38 oryctolagus
10	622	19.2	749	13 Q7T0T9	Q7t0t9 xenopus lae
11	595.5	18.5	740	11 Q9DBX5	Q9dbx5 mus musculus
12	498.5	15.4	541	4 Q8UP65	Q8up65 homo sapien
13	490.5	15.2	541	4 Q75457	Q75457 homo sapien
14	397.5	12.3	216	4 Q8N176	Q8n176 homo sapien
15	371.5	11.5	530	11 Q7TN01	Q7tn01 mus musculus
16	239	7.4	634	3 Q9F8L1	Q9p8l1 cryptococcu

17	227.5	7.0	637	3 Q9P8P2	Q9p8p2 cryptococcu
18	227	7.0	634	3 Q8X0Z4	Q8x0z4 cryptococcu
19	225	7.0	634	3 Q8WMC5	Q8wmc5 homo sapien
20	221	6.8	634	3 Q96WX0	Q96wx0 cryptococcu
21	211	6.5	157	4 Q8N845	Q8n845 homo sapien
22	205	6.3	163	4 Q96MM0	Q96mm0 homo sapien
23	200	6.2	135	6 Q95XE1	Q95kel macaca fasc
24	199	6.2	158	4 Q8NAL9	Q8nal9 homo sapien
25	198	6.1	61	4 Q9UI48	Q9ui48 homo sapien
26	196.5	6.1	138	4 Q8N874	Q8n874 homo sapien
27	194.5	6.0	162	4 Q9H5D5	Q9h5d5 homo sapien
28	194	6.0	86	4 Q8N5B5	Q8n5b5 homo sapien
29	192	5.9	122	6 Q9BGM3	Q9bgw3 macaca fasc
30	192	5.9	152	4 Q9NX85	Q9nx85 homo sapien
31	190.5	5.9	151	4 Q9HA67	Q9ha67 homo sapien
32	187	5.8	208	4 Q9NM14	Q9nm14 homo sapien
33	185	5.7	101	4 Q7Z4P3	Q7z4p3 homo sapien
34	185	5.7	375	4 Q60448	Q60448 homo sapien
35	184.5	5.7	35	4 Q8N7M7	Q8n7m7 homo sapien
36	183	5.7	160	4 Q7Z8L3	Q7z8l3 pichia jadi
37	182	5.6	162	4 Q9BYA5	Q9bya5 homo sapien
38	178.5	5.5	66	4 Q96HL9	Q96hl9 homo sapien
39	177	5.5	125	4 Q9H842	Q9h842 homo sapien
40	176	5.4	118	4 Q9H387	Q9h387 homo sapien
41	175.5	5.4	164	4 Q9UQD6	Q9uqd6 homo sapien
42	175	5.4	244	4 Q9H700	Q9h700 homo sapien
43	175	5.4	434	4 Q8N2I3	Q8n2i3 homo sapien
44	175	5.4	506	4 Q9H6L7	Q9h6l7 homo sapien
45	174	5.4	126	4 Q8N1G7	Q8n1g7 homo sapien

## ALIGNMENTS

RESULT 1

Q9UKV7 PRELIMINARY; PRT; 1012 AA.  
ID Q9UKV7  
AC Q9UKV7  
DT 01-MAY-2000 (TREMBLrel. 13, Created)  
DT 01-MAY-2000 (TREMBLrel. 13, Last sequence update)  
DT 01-OCT-2003 (TREMBLrel. 25, Last annotation update)  
DE Cytosolic phospholipase A2 beta.  
OS Homo sapiens (Human)  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OC NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=99287906; PubMed=10358058;  
RA Song C., Chang X.J., Bean K.M., Proia M.S., Knopf J.L., Kriz R.W.;  
RT "Molecular characterization of cytosolic phospholipase A2-beta.,"  
RL J. Biol. Chem. 274:17063-17067(1999)  
CC -|- SIMILARITY: CONTAINS 1 C2 DOMAIN.  
DR EMBL; AF121908; AAD32135.1; -  
DR HSP; P04410; 1A25.  
DR GO; GO:0004620; P:phospholipase activity; IEA.  
DR GO; GO:0009395; P:phospholipid catabolism; IEA.  
DR InterPro; IPR000008; C2.  
DR InterPro; IPR008973; C2 CaLB.  
DR InterPro; IPR002642; PLAc.  
DR InterPro; IPR003347; TF\_JmjC.  
DR Pfam; PF00168; C2; 1.  
DR Pfam; PF01735; PLA2\_B; 1.  
DR SMART; SM00239; C2; 1.  
DR SMART; SM00558; JmjC; 1.  
DR SMART; SM00022; PLAc; 1.  
DR PROSITE; PS00004; C2 DOMAIN 2; 1.  
SQ SEQUENCE 1012 AA; 114154 MW; 1A9D3269BA457797 CRC64;

Query Match 85.5%; Score 2767.5; DB 4; Length 1012;  
Best Local Similarity 87.6%; Pred. No. 6.4e-231;  
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

Fri Oct 8 10:22:34 2004

us-09-830-321a-2.rspt

```

QY 24 TGLLVLECPAPCPFFFFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSPSSWDYR 83
DB 418 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGGQVR 459
QY 84 -----LRELAVRLGFGCAEQAFLSRRKQVVAAALRQALQDGD 123
DB 460 LVFPTSQEPMLMRVBLKEAGLRELAVRLGFGCAEQAFLSRRKQVVAAALRQALQDGD 519
QY 124 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDVCVSYITGASGWTWALANLYEDP 183
DB 520 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDVCVSYITGASGWTWALANLYEDP 579
QY 184 EWSQKDLAPTELLKTQVTKNKLGVLAAPSOLQRYQELAEARLGYPCFTNLWALINEA 243
DB 580 EWSQKDLAPTELLKTQVTKNKLGVLAAPSOLQRYQELAEARLGYPCFTNLWALINEA 639
QY 244 LLHDEPHDKLSQDREALSHGQNPPIYCALNTKGSLTTFEGEWCFFSPYEVGFPPKYG 303
DB 640 LLHDEPHDKLSQDREALSHGQNPPIYCALNTKGSLTTFEGEWCFFSPYEVGFPPKYG 699
QY 304 AFIPSELFGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 363
DB 700 AFIPSELFGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 759
QY 364 NQANLDKEQVPLKLEPPSTAGRIAEFFTDLLTWRLPAQATHNFIHFKDYFOHPH 423
DB 760 NQANLDKEQVPLKLEPPSTAGRIAEFFTDLLTWRLPAQATHNFIHFKDYFOHPH 819
QY 424 FSTWKATTLGDLNPQITPSEPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAF 483
DB 820 FSTWKATTLGDLNPQITPSEPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAF 879
QY 484 QQLQLLGRFCQOGIPFPPIPSPEQLOPRECHTFSDPTCPGAPAVLHF-----533
DB 880 QQLQLLGRFCQOGIPFPPIPSPEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 939
QY 534 -SSGVRRTPEEAAAGEVNLSSDSPHYHTKVTSQEDVDKLHLTHYNNVNNQOEQLLEAL 592
DB 940 SAPGVRRTPEEAAAGEVNLSSDSPHYHTKVTSQEDVDKLHLTHYNNVNNQOEQLLEAL 999
QY 593 ROAVQRRRRRPH 605
DB 1000 ROAVQRRRRRPH 1012

RESULT 2
ID O95712 PRELIMINARY; PRT; 1012 AA.
AC O95712;
DT 01-MAY-1999 (TREMBlrel. 10, Created)
DT 01-MAY-1999 (TREMBlrel. 10, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Cytosolic phospholipase A2 beta.
GN CPLA2 BETA.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=99185108; PubMed=10085124;
RA Pickard R.T., Striffler B.A., Kramer R.M., Sharp J.D.;
RT "Molecular cloning of two new human paralogs of 85-Kda cytosolic
RT phospholipase A2.";
RL J. Biol. Chem. 274:8823-8831 (1999).
CC -I- SIMILARITY: CONTAINS 1 C2 DOMAIN.
EMBL: AF065215; AAC78836.1; -.
DR HSP; P04410; IAA25.
DR Gnew; HGNC:9036; PLA2G4B.
DR GO:0004627; F:calcium-dependent cytosolic phospholipase A. . .; TAS.
DR InterPro; IPR000008; C2.
DR InterPro; IPR008973; C2 CaLB.
DR InterPro; IPR002642; PLAC.

```

```

DR InterPro; IPR003347; TF_JmJC.
DR Pfam; PF00168; C2; 1.
DR Pfam; PF01735; PLA2 B; 1.
DR SMART; SM00239; C2; 1.
DR SMART; SM00558; JmJC; 1.
DR SMART; SM00022; PLAC; 1.
DR PROSITE; PS00004; C2_DOMAIN_2; 1.
SQ SEQUENCE 1012 AA; 114120 MW; 989EDB4AD3CF19DD CRC64;

Query Match      85.5%; Score 2767.5; DB 4; Length 1012;
Best Local Similarity 87.6%; Pred. No. 6.4e-231;
Matches 537; Conservative 5; Mismatches 22; Indels 49; Gaps 6;

QY 24 TGLLVLECPAPCPFFFFEMESLSVAQAGVQWRDLGSLQPPPLGFKRFSCLSPSSWDYR 83
DB 418 TGTFRFHCPA-C-----WEQE-LSI-----RLQDAPEEQKAPLSALPSGGQVR 459
QY 84 -----LRELAVRLGFGCAEQAFLSRRKQVVAAALRQALQDGD 123
DB 460 LVFPTSQEPMLMRVBLKEAGLRELAVRLGFGCAEQAFLSRRKQVVAAALRQALQDGD 519
QY 124 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDVCVSYITGASGWTWALANLYEDP 183
DB 520 LOEDEIPVVAIMATGGGIRAMTSLYGQLAGLKEGLDVCVSYITGASGWTWALANLYEDP 579
QY 184 EWSQKDLAPTELLKTQVTKNKLGVLAAPSOLQRYQELAEARLGYPCFTNLWALINEA 243
DB 580 EWSQKDLAPTELLKTQVTKNKLGVLAAPSOLQRYQELAEARLGYPCFTNLWALINEA 639
QY 244 LLHDEPHDKLSQDREALSHGQNPPIYCALNTKGSLTTFEGEWCFFSPYEVGFPPKYG 303
DB 640 LLHDEPHDKLSQDREALSHGQNPPIYCALNTKGSLTTFEGEWCFFSPYEVGFPPKYG 699
QY 304 AFIPSELFGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 363
DB 700 AFIPSELFGSEFFMGQMLKRLPESRICFLEGIWNSLYAANLQDSLYWASEPSQFWDWRVR 759
QY 364 NQANLDKEQVPLKLEPPSTAGRIAEFFTDLLTWRLPAQATHNFIHFKDYFOHPH 423
DB 760 NQANLDKEQVPLKLEPPSTAGRIAEFFTDLLTWRLPAQATHNFIHFKDYFOHPH 819
QY 424 FSTWKATTLGDLNPQITPSEPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAF 483
DB 820 FSTWKATTLGDLNPQITPSEPHCLLDVGYLINTSCLPLQPTRDVDLILSLDYNLHGAF 879
QY 484 QQLQLLGRFCQOGIPFPPIPSPEQLOPRECHTFSDPTCPGAPAVLHF-----533
DB 880 QQLQLLGRFCQOGIPFPPIPSPEQLOPRECHTFSDPTCPGAPAVLHFPLVSDSFREY 939
QY 534 -SSGVRRTPEEAAAGEVNLSSDSPHYHTKVTSQEDVDKLHLTHYNNVNNQOEQLLEAL 592
DB 940 SAPGVRRTPEEAAAGEVNLSSDSPHYHTKVTSQEDVDKLHLTHYNNVNNQOEQLLEAL 999
QY 593 ROAVQRRRRRPH 605
DB 1000 ROAVQRRRRRPH 1012

RESULT 3
ID Q80VV8 PRELIMINARY; PRT; 439 AA.
AC Q80VV8;
DT 01-JUN-2003 (TREMBlrel. 24, Created)
DT 01-JUN-2003 (TREMBlrel. 24, Last sequence update)
DT 01-OCT-2003 (TREMBlrel. 25, Last annotation update)
DE Similar to phospholipase A2, group IVB (Cytosolic) (Fragment).
OS Mus musculus (Mouse)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX STRAIN=FVB/N; TISSUE=Salivary gland;

```



RA Strausberg R.;  
 RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BC042758; AAH42758.1; -.  
 DR PIR; PT0721; PT0721.  
 DR GO; GO:0004620; F:phospholipase activity; IEA.  
 DR GO; GO:0009395; P:phospholipid catabolism; IEA.  
 DR InterPro; IPR002642; Pfam.  
 DR Pfam; PF01735; PLA2\_B; 1.  
 DR NON TER 1  
 SQ SEQUENCE 439 AA; 50464 MW; EA9041FA820F5F10 CRC64;

Query Match 59.78; Score 1931.5; DB 11; Length 439;  
 Best Local Similarity 82.54; Pred. No. 6.9e-159;  
 Matches 358; Conservative 30; Mismatches 35; Indels 11; Gaps 1;

QY 181 EDPEWQKDLGTELLKTQVTKNKLGVLAAPSOLQRYQELARARLGYSCETNLWALI 240  
 Db 1 EDPEWQKDLGTEVTLKQVTKSKLGVLAAPSOLQRYQELARARLGHPTCTNLWALI 60

QY 241 NEALLHDEPHDKLSQREALSHGONPLPIYCALNTKGQSLTTFEGWCEFSYEVGPP 300  
 Db 61 NEALLHDKPEHKLSQREALSRGONPLPIYCALNSKEQSLTFEGWCEFSYEVGPP 120

QY 301 KYGARTPSLFGSEFMGQMKELPSRICFLGINSNLVAANLQSLYWASEPQFWR 360  
 Db 121 KYGARTPSLFGSEFMGRLVKQLPESRICFLGINSNLFAASLQSLYWSSEPSQFWR 180

QY 361 WVRNQNLDKEQVPLKIEPPSTAGRIAEFFDILLTWPLAQATHNGLRGLHFKDYQ 420  
 Db 181 WAQDQANLDKEQVPLKIAEPPSTAGRIAEFFDILLTWPLAQATHNGLRGLHFKDYQ 240

QY 421 HPHFSTWKAATLDGPNQTPSEPHCLLDVGYLINTSLPQTPRDVLDLILSLDYNLH 480  
 Db 241 NSHFSAWKASLDLPNQLTAEPHCLLDVGYLINTSCPELLQTPRDVLDLILSLDYNLY 300

QY 481 GAFQQLLGRFCOEGIPFPISPSPELOQPRECHTSDPTCPGAPAVLHF 533  
 Db 301 GAFQQLLGRFCOEGIPFPISPSPELOQPRECHTSDPTCPGAPAVLHF 360

QY 534 ----SSGVRTPEAAAGVNLSSDSPHYTKVTSQEDVDKLLHLYNNVNNQEQLL 589  
 Db 361 QDYSAPGVPTSEKXAGEVNLSSDSPHYTKVTSQEDVDKLLHLYNNVNNQEQRLR 420

QY 590 EALRAQVQRRRR 603  
 Db 421 EAMHQAQVQRRRRK 434

RESULT 4  
 Q86XP0  
 ID Q86XP0 PRELIMINARY; PRT; 818 AA.  
 AC Q86XP0;  
 DT 01-JUN-2003 (TremBLrel. 24, Created)  
 DT 01-JUN-2003 (TremBLrel. 24, Last sequence update)  
 DT 01-OCT-2003 (TremBLrel. 25, Last annotation update)  
 DE Cytosolic phospholipase A2 delta.  
 GN CPLA2 DELTA.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Imai Y.; Chiba H.;  
 RT "cytosolic phospholipase A2 homolog (cPLA2delta).";  
 RL Submitted (AUG-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AB090876; BAC67158.1; -.  
 DR GO; GO:0004620; F:phospholipase activity; IEA.  
 DR GO; GO:0009395; P:phospholipid catabolism; IEA.  
 DR InterPro; IPR000008; C2.  
 DR InterPro; IPR002642; C2\_CaLB.  
 DR Pfam; PF00168; C2; 1.

DR Pfam; PF01735; PLA2\_B; 1.  
 DR SMART; SM00239; C2; 1.  
 DR SMART; SM00022; PLAC; 1.  
 DR PROSITE; PS00004; C2\_DOMAIN\_2; 1.  
 SQ SEQUENCE 818 AA; 91955 MW; E5ADF3478FDAB180 CRC64;

Query Match 46.14; Score 1492; DB 4; Length 818;  
 Best Local Similarity 51.64; Pred. No. 2.6e-120;  
 Matches 296; Conservative 92; Mismatches 152; Indels 34; Gaps 8;

QY 61 LQPEPLGFKRFSCLSPSSWDYRLR-----ELAVRLGFGCAEQAFSLRRKQVAA 112  
 Db 244 LRPLTIGKEVTMDVPAPNAPGVQLQKAECPPELAVHLGNLCABEQAFSLRRKQVAA 303

QY 113 ALBQALQDLQDEDEIPVVAIMATGGIRAMTSLYGQLAGLKGELGLDCVSYITGASGS 172  
 Db 304 ALKQALQLDRDLQDEDEVPVVGIMATGGGARAMTSLYGHLLALQKGLDLCVSYITGASGS 363

QY 173 TWALANLYEDPEWSOKDLGAPTELLKTQVTKNKLGVLAAPSOLQRYQELARARLGYVSC 232  
 Db 364 TWTMAHLYGDPEWSQDRDLGPIRYAREHLAKSKLEVPSPERLASYRRELELRAEQGHPTT 423

QY 233 FTMWALINEALLHDPHDKLSQREALSHGONPLPIYCALNTKGQSLTTFEGWCEFS 292  
 Db 424 FVDLWALVLESLHGVMDQKLSGQRAALRGONPLPLYSLNKNNLETLLDFKEWVEF 483

QY 293 SPYEVGFPYKGAFTISELFGSEFMGQMKELPSRICFLGINSNLVAANLQSLYWAS 352  
 Db 484 SPYEVGFLYKGAFTVPELFGSEFMGRLMRRIPPEPRICFLEALWNI FSLNLLDANVDLT 543

QY 353 EFSQFQDRWRNQA-NLDKEQVPLL-----KLEE---PPSTAGRIAEFFDILLTWPLA 402  
 Db 544 SGSEWQKIKOKTKRSELEKE--PLTSGTSSKLEASWLOFGTA--LAQAFKGLTGRPLH 599

QY 403 QATHNFRGLHFKDYFQHPHFSTWKAATLDGPNQTPSEPHCLLDVGYLINTSLCLPL 462  
 Db 600 QRSNPLQGLQHQDYCSHKDFSTWADYQDSMPSQLTKPEPRCLCLVDAAVINTSSPSM 659

QY 463 LQPTDVLILSLDYNLHGAFOQLQLLGRFCOEGIPFPISPSPELOQPRECHTSDPT 522  
 Db 660 FRPGRRLDILSFDYSLGAPPEALQOTELYCRARGLPFRVPEPSQDQHPRECHLFS 719

QY 523 TCPGAPAVLHF-----SSGVRTPEAAAGVNLSSDSPHYTKVTSQEDVDKLLHLYNNV 571  
 Db 720 ACPEAPILLHPLVNASFKDHSAPGVQSPALQSGQVDLTGATCPTLSNNTYKEEDFE 779

QY 572 KLLHLTHYNNVNNQEQLLAEALRAQVQRRR-ORRP 604  
 Db 780 RLLRLSDYNNVQTSQGAILLQALRTALKHRTLEARP 813

RESULT 5  
 Q8IUP3  
 ID Q8IUP3 PRELIMINARY; PRT; 845 AA.  
 AC Q8IUP3;  
 DT 01-MAR-2003 (TremBLrel. 23, Created)  
 DT 01-MAR-2003 (TremBLrel. 23, Last sequence update)  
 DT 01-OCT-2003 (TremBLrel. 25, Last annotation update)  
 DE Similar to phospholipase A2, group IVB (Cytosolic) (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Strausberg R.;  
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; BC035335; AAH35335.1; -.  
 DR GO; GO:0004620; F:phospholipase activity; IEA.  
 DR GO; GO:0009395; P:phospholipid catabolism; IEA.  
 DR InterPro; IPR000008; C2.  
 DR InterPro; IPR008973; C2\_CaLB.





```
Db 100 ETGCTATPTSSMKVGGKKEVPFFNFQNTQMILEMSLEVCSPPD-----LRFSMALCD 152
QY 98 EEOAFLSRKQVAAALRQAL---OLDGDLQEDIPVVAIMATGGIRAMTSLYGLQAGL 154
Db 153 QEKAFRQQRKENIKENMKLGPCKSEGLYSTRDVPVVAAILGSGGFRAMVGFSGVMKAL 212
QY 155 KELGLDCVSVITGASSTWALANLYDEPWSOKDLAPTEL---LKTQVTKNKLGVLP 211
Db 213 YESGILDCAITYAGLSSGTWNTSLYSHDPPEK---GPQENBELMKVNSHNPLLLTTP 269
QY 212 SOLQRYRELAERARLGVSPCFNLNWA-LINEALLHDEPHDKLSQDREALSHGNPLPI 270
Db 270 QKVRYVESLWKXSSGQPVFTDFMGLGETLIHNRMHT-TLSSLKEKVSSAQCPPLP 328
QY 271 YCALNTKQSLTTFEFGWCFSFSPYVGFPGYKAFIPSELFGSEFFMGQMKRLPESRIC 330
Db 329 FTCLHVK-PDVSSELMAFADWVEFSYIEIGMAKYGTMAPDLFGSKFFMGTVVKYBENPLH 387
QY 331 FLEGWNLNLYAANLQDSLYWASEPQFWDWRVNRQANLDKEOVPLL----- 376
Db 388 FLMGVWGSFSLFNRVLGVSGS-----HNKGTWEELEENITAXHIVNSDSSD 438
QY 377 -KIEPPPTAGRIA--EPFTD-LLTW--RPL-----AQATHNFRGLHF 414
Db 439 DESQEPKTEGEDAEREYQNDHQASVHMLMALVSDSALFNTRREGRAGKVHFMGLNL 498
QY 415 HKDY-----FOHPHFTWKAATLDGPNQ-----LTPSEPHCLLDVGYLINTSCL 460
Db 499 NTSYPLSPURDFTQESFDDDELDAVADPDEPERIYEPDLVKSXKIHVVDSGLTFNLPYP 558
QY 461 PLOPTRDVLLILSLDYNLHGA-----FOQLQLGRFCOEQGIPIPPISPEEQLOPRE 515
Db 559 LILRFRQGVLLIISDFARSPTSPPFKELLAEKWKAKNKLPPKIDPIYVFDREGLKE 618
QY 516 CHTFSDPTCP---GAPAVLHF-----SSGV-RRTPEEAAAGVNL-SSSDSPY 558
Db 619 CVVFK-PKNPDVEKDCPIIIHFVLANINFRKYKPGVPRETKEEIBADFDIPDDPESPF 677
QY 559 HYTKVTSQEDVDKLLHLTHYVNNQOEQLLEALROAVORRRQ 601
Db 678 STNFQYQNAQAFKRLHLMFYNTLNNIDVICKDAMVESIEYRRQ 720

RESULT 10
Q770T9 PRELIMINARY; PRT; 749 AA.
AC Q770T9;
DT 01-OCT-2003 (T-EMBLrel. 25, Created)
DT 01-OCT-2003 (T-EMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (T-EMBLrel. 25, Last annotation update)
DE Hypothetical protein.
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Spleen;
RX MEDLINE=22341132; PubMed=12454917;
RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W.,
RA Richardson P.;
RA "Genetic and genomic tools for Xenopus research: The NIH Xenopus
RT initiative.";
RL Dev. Dyn. 225:384-391 (2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Spleen;
RX MEDLINE=22388257; PubMed=12477932;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.W., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
```

```
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RL and mouse cDNA sequences.";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RP SEQUENCE FROM N.A.
RC TISSUE=Spleen;
RA Klein S., Strausberg R.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC056041; AAH56041.1;
KW Hypothetical protein.
SQ SEQUENCE 749 AA; 85282 MW; CE769904144C4DE2 CRC64;

Query Match 19.2%; Score 622; DB 13; Length 749;
Best Local Similarity 27.6%; Pred. No. 7.9e-45;
Matches 177; Conservative 113; Mismatches 219; Indels 132; Gaps 22;

QY 59 GSLQPPPLGFKRFS-----CLSLPSSWDYRLRELAVRLGFGCAEEQAFLSRRKQVAA 112
Db 115 GEKKQVPPTFNKVTMELFEFSLEVCSSTD-----LRFSMALCDEKFLPROKKNKVIN 167
QY 113 ALRQAL--QLDGLQED--EIPVVAIMATGGIRAMTSLYGLQAGLKEGLDCVSYITG 168
Db 168 GLRKLGPKTQDLNSTSDVFIAGLSSGGFRAMVGFSGVMKALYESGLDCATYVAG 227
QY 169 ASGSTWALANLYDEPWSOKDLAPTEL---LKTQVTKNKLGVLAISOIQRQELAE 225
Db 228 LSGSTWYMTSLYSHDPDFTK---GPKEINKELMHNVSYNPLLLLTPOKRYVYEAELWKX 284
QY 226 RLGYPSCFNLWA-LINEALLHDEPHDKLSQDREALSHGNPLTYCALNTKQSLTTF 284
Db 285 SSGQPVFTFDIFAMLIGETLIKDR-WNRKLSEHKEKINDGQCDPLFTCLHVK-PDVS 342
QY 285 EFGWCEFSYEVGFPKYGAFIPSELFGSEFFMGQMKRLPESRICFLEGINSLNLA 344
Db 343 MFADWVEFSYIEIGMAKYGTFFMPGLFGSKFFMGTVIKKYEENPLHFFMGVMSAFSILI 402
QY 345 QDSLYWASEPQFWDWRVNRQANLDKEQVPLLK-----IIEPSTAGRIA 389
Db 403 NRVLGVSN-----NSKGTMBEEIEENLKPHEILGNDSDDSDDEMQEPKGTENAKA 452
QY 390 E---FTDLLTW--RPL-----AQATHNFRGLHFKHYQFHPHFSTWK 428
Db 453 EEEYLNRNQASVQVRMLMAILGDSALFNTRREGRAGKVHFMGLNLTNLSYPS 506
QY 429 ATTLDGLPNQLTSPSEPHL-----CLLDVGYLINTSCLPLLQ 464
Db 507 ---LSGLCTQOSMEEDLDAVADPDEFEQIYEPLDVSKKIHIVDSGLTNLPYLILR 563
QY 465 PTDVDVLLSLDYNLHGA-----FOQLQLGRFCOEQGIPIPPISPEEQLOPRECHTF 519
Db 564 PQRGVDLIISDFARSPTSPPFKELLAEKWKAKNKLPPKIDPIYVFDREGLKECYIF 623
QY 520 S-----DPTCPGAPVILHF-----SSGV-RRTPEEAAAGVNL-SSSDSPYHY 560
Db 624 KPKNVTSVEKDC---PTVIHFVLANLQPNFKAPGVPRETKEESADFDIPDDPTPST 680
QY 561 TKVTSQEDVDKLLHLTHYVNNQOEQLLEALROAVORRRQ 601
Db 681 ENFQYPNVAFKQLHDLMEFNTLNNINVIKQAMVESIEYRRQ 721
```



```

Db 70 GLLDAVITLAVGSGTWAISLYTNDGMEALD-----LKHRTFQEW-----DL 116
QY 215 QRYQELAEARLGYPCSTNLWA-LINEALLHDEPHDKLSDOREALSHGONPLPIYCA 273
Db 117 AKSLQKTIQAARSENYS-LTDFWAMVWISKQTRRELPESH-LSNMKKPVBEGLTPYPIFAA 174
QY 274 ----LNTKGSLTTFEGEWCEFPYEGPKYGAIFISELFGSEFFMGOLMKRLPESRI 329
Db 175 IDNDLQPSWQARAPD--TWFEFTPHAGFALGAFVSI THFGSKFKKGRIVRTHPERDL 232
QY 330 CFLEGINW-----LYA--ANLQDSLY 349
Db 233 TFLRGLWSALGNTVEIREYIFDQLNLTLKGLWRAVANAKSIGHLIFARLLRLQESSQ 292
QY 350 W-----ASEPSQW-----DRWRNOANLDKEQVLLKTEBPPSTAGRIAEFF----- 392
Db 293 GEHPPPEDEGEPHTWLTMLENTR--TSLEKQEQP-----HEDPERKGSLSNLMDFVK 346
QY 393 -TDLLTWPLAQATHNRLGLHFKDYFQHPHFSTWKATTLDLGLNQLTPSEPHCLLDV 451
Db 347 KTGICASKWEGTTHNFI-----YKH-----GGIRDKIMSSRKHLHLVDA 386
QY 452 GYLINTSCLPLLOPTRDNDLILSLDYNLHGAFQQLLGRFCQEQGIPPPPIPSPEEQ 511
Db 387 GLAINTPPLVLPPTREVHLLILSDFDSAGDPETIRATTDYCRHKIPPPQVE---EABL 443
QY 512 Q-----PRECHTFSDPTCGAPAVLHFFSGVGRTP---EAAAGEVNLSSDSPHYTKV 563
Db 444 DLWSKAPASCYILKGET---GPVWHF-----PLFNIDACGGDIEAWSDTYDTFKLAD 493
QY 564 TYSQEDVDKLLHLYTHYVNCNOEQLEAL 592
Db 494 TYTLDVVLLALAKKNVRENKKILREL 522

```

## RESULT 13

```

O75457 PRELIMINARY; PRT; 541 AA.
ID O75457;
AC O75457;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Cytosolic phospholipase A2-gamma.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Skeletal muscle;
RX MEDLINE=98371032; PubMed=9705332;
RA Underwood K.W., Song C., Kriz R.W., Chang X.J., Knopf J.L., Lin L.L.;
RT "A novel calcium-independent phospholipase A2, cPLA2-gamma, that is
RT prenylated and contains homology to cPLA2.";
RL J. Biol. Chem. 273:21926-21932(1998).
DR EMBL; AF058921; AAC32823.1; -.
DR Genew; HGNC:9037; PLA2G4C.
DR GO; GO:0016020; C:membrane; TAS.
DR GO; GO:0004628; F:calcium-independent cytosolic phospholipase. .; TAS.
DR InterPro; IPR002642; PLAC.
DR Pfam; PF01735; PLA2 B; 1.
DR SMART; SM00022; PLAC; 1.
SQ SEQUENCE 541 AA; 60920 MW; BBB972A611FB5237 CRC64;

```

```

Query Match 15.2%; Score 490.5; DB 4; Length 541;
Best Local Similarity 27.6%; Pred. No. 1.3e-33;
Matches 157; Conservative
QY 98 EEOAFLSRRKQVVAALRQALQLDGDIQDEIPVWALMATGGGTRAMTSYLGOLAGLKL 157
Db 15 EEKAAVERRRHLVILKALKL-----RIEAEAPVAVVIGSGGGGURAHIAICLVISEMKQ 69

```

```

QY 158 GLLDCVSYITGASGTWALANLYE---DPEWSQDKLAGPTELLKTQVTKNKLGVLAQSQL 214
Db 70 GLLDAVITLAVGSGTWAISLYTNDGMEALD-----LKHRTFQEW-----DL 116
QY 215 QRYQELAEARLGYPCSTNLWA-LINEALLHDEPHDKLSDOREALSHGONPLPIYCA 273
Db 117 AKSLQKTIQAARSENYS-LTDFWAMVWISKQTRRELPESH-LSNMKKPVBEGLTPYPIFAA 174
QY 274 ----LNTKGSLTTFEGEWCEFPYEGPKYGAIFISELFGSEFFMGOLMKRLPESRI 329
Db 175 IDNDLQPSWQARAPD--TWFEFTPHAGFALGAFVSI THFGSKFKKGRIVRTHPERDL 232
QY 330 CFLEGINW-----LYA--ANLQDSLY 349
Db 233 TFLRGLWSALGNTVEIREYIFDQLNLTLKGLWRAVANAKSIGHLIFARLLRLQESSQ 292
QY 350 W-----ASEPSQW-----DRWRNOANLDKEQVLLKTEBPPSTAGRIAEFF----- 392
Db 293 GEHPPPEDEGEPHTWLTMLENTR--TSLEKQEQP-----HEDPERKGSLSNLMDFVK 346
QY 393 -TDLLTWPLAQATHNRLGLHFKDYFQHPHFSTWKATTLDLGLNQLTPSEPHCLLDV 451
Db 347 KTGICASKWEGTTHNFI-----YKH-----GGIRDKIMSSRKHLHLVDA 386
QY 452 GYLINTSCLPLLOPTRDNDLILSLDYNLHGAFQQLLGRFCQEQGIPPPPIPSPEEQ 511
Db 387 GLAINTPPLVLPPTREVHLLILSDFDSAGDPETIRATTDYCRHKIPPPQVE---EABL 443
QY 512 Q-----PRECHTFSDPTCGAPAVLHFFSGVGRTP---EAAAGEVNLSSDSPHYTKV 563
Db 444 DLWSKAPASCYILKGET---GPVWHF-----PLFNIDACGGDIEAWSDTYDTFKLAD 493
QY 564 TYSQEDVDKLLHLYTHYVNCNOEQLEAL 592
Db 494 TYTLDVVLLALAKKNVRENKKILREL 522

```

## RESULT 14

```

O8N176 PRELIMINARY; PRT; 216 AA.
ID O8N176;
AC O8N176;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Similar to phospholipase A2, group IVB (Cytosolic).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC034571; AAH34571.1; -.
SQ SEQUENCE 216 AA; 24371 MW; 6198D0A387F1071B CRC64;

```

```

Query Match 12.3%; Score 397.5; DB 4; Length 216;
Best Local Similarity 39.5%; Pred. No. 3.6e-26;
Matches 92; Conservative 37; Mismatches 75; Indels 29; Gaps 8;
QY 317 MGOLMKRLPESRICFLEGINSNLYANLQDSLWASEPQFWRWRVWNA-NLDKQVPL 375
Db 1 MGRLMRRIPRIPCFLAIAWSNIFSLNLLDAWYDLTSSGSESWKQHKDKTRSEK--PL 58
QY 376 L-----KIEE---PPSTAGRIAEFFTDLLTWPLAQATHNRLGLHFKDYFQHPHFST 425
Db 59 TTSGTSRLSEASWLQGTGTA--LQAQKFGTLTGRLHQRSPNFLOGLHODYCSHKDFST 116
QY 427 WKATTLDLGLNQLTPSEPHCLLDVGYLINTSCLPLLOPTRDNDLILSLDYNLHGAFQQL 486
Db 117 WADYQLDSMPSQLTPKEPRCLVDAAYFINTSSPSMFRPGRRLLDILSFDYLSAPFE-- 174

```



**This Page Blank (uspto)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 12:49:19 ; Search time 1674.58 Seconds  
(without alignments)  
10556.917 Million cell updates/sec

Title: US-09-830-321A-4

Perfect score: 592

Sequence: 1 ttgtcctccactgctgtg.....cccagctcccccggaacc 592

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues

Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

EST:\*

1: em\_estba:\*

2: em\_esthum:\*

3: em\_estin:\*

4: em\_estmu:\*

5: em\_estov:\*

6: em\_estpl:\*

7: em\_estro:\*

8: em\_hc:\*

9: gb\_est1:\*

10: gb\_est2:\*

11: gb\_hc:\*

12: gb\_est3:\*

13: gb\_est4:\*

14: gb\_est5:\*

15: em\_estfun:\*

16: em\_estom:\*

17: em\_gss\_hum:\*

18: em\_gss\_inv:\*

19: em\_gss\_pln:\*

20: em\_gss\_vrt:\*

21: em\_gss\_fun:\*

22: em\_gss\_mam:\*

23: em\_gss\_mus:\*

24: em\_gss\_pro:\*

25: em\_gss\_rtd:\*

26: em\_gss\_phg:\*

27: em\_gss\_vrl:\*

28: gb\_gss1:\*

29: gb\_gss2:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	587.2	99.2	726	14	CD691591 EST81114 h
2	527.6	89.1	680	12	BI836812
3	436.4	73.7	438	29	AY417051
4	436.4	73.7	438	29	AY417052

5	427.2	72.2	463	12	BM153087
6	323	54.6	461	14	CB481980
7	308.6	52.1	424	14	CD687559
8	296.6	50.1	623	13	BY752231
9	296	50.0	1582	11	AK018005
10	289.8	49.0	438	29	AY417053
11	268.8	45.4	460	9	AI430241
12	268.8	45.4	501	9	AA762051
13	265.8	44.9	601	13	BQ418599
14	265.8	44.9	998	13	BY704474
15	265.8	44.9	1206	11	AK004232
16	259.8	43.9	484	12	BM106914
17	259.6	43.9	472	10	BE138146
18	252.8	42.7	629	14	CB437446
19	249.4	42.1	603	14	CB451900
20	247.4	41.8	432	10	BB850720
21	240.6	40.6	388	10	BF150826
22	234.2	39.6	367	10	BB869347
23	225	38.0	352	13	BY221065
24	219.4	37.1	359	13	BY214853
25	213.6	36.1	339	13	BY215822
26	210	35.5	558	12	BM363855
27	208	35.1	334	13	BY216497
28	201.4	34.0	360	13	BY211786
29	194	32.8	356	10	BB868695
30	192.6	32.5	340	13	BY216553
31	187	31.6	442	9	AI769633
32	179.4	30.3	392	10	AW659630
33	140.4	23.7	233	10	AW418175
34	135.6	22.9	643	14	CB453372
35	131.8	22.3	224	13	BY008213
36	124	20.9	554	29	CE203341
37	121.2	20.5	416	29	AY417601
38	119.6	20.2	417	29	AY417600
39	119.6	20.2	688	14	CK003597
40	117.4	19.8	521	10	AW660275
41	117.4	19.8	558	10	AW658438
42	117.4	19.8	567	10	AW658432
43	117.4	19.8	579	12	BI540965
44	115.8	19.6	570	12	BI975432
45	114.8	19.4	544	10	BE015249

#### ALIGNMENTS

CD691591 726 bp mRNA linear EST 25-JUN-2003  
EST81114 human nasopharynx Homo sapiens cDNA, mRNA sequence.  
CD691591  
CD691591.1 GI:32213459  
EST.  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 726)  
Liu, X.-Q., Zhou, Y., Zhang, L.-J., Xu, H., Chen, H.-K., Pan, Z.-G. and Zeng, Y.-X.  
Transcriptional Gene Expression Profile of Human Nasopharynx  
Unpublished (2003)  
Contact: Yixin Zeng  
Cancer Center  
Sun Yat-sen University  
651 Dongfeng Road East, Guangzhou 510060, China  
Tel: 86-1380-9770-743  
Fax: 86-20-8775-4506  
Email: yxzeng@gzsums.edu.cn.  
Location/Qualifiers  
1. .726  
/organism="Homo sapiens"  
/mol\_type="mRNA"

/db\_xref="taxon:9606"  
/tissue\_type="normal nasopharynx"  
/clone\_lib="human nasopharynx"  
/note="ESTs generated from a normal nasopharynx cDNA library from southern Chinese"

ORIGIN  
Query Match 99.2%; Score 587.2; DB 14; Length 726;  
Best Local Similarity 99.5%; Pred. No. 1.8e-133;  
Matches 589; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1 TCTGCTCCACTGCTGCTGGATCATGGAATTCGCACTGCTGCTGGCTGGTGGT 60  
Db 45 TCTGCTCCACTGCTGCTGGATCATGGAATTCGCACTGCTGCTGGCTGGTGGT 104  
Qy 61 GATGCTGGTGTGATTCGAATCCAGGGCGGGATCTGAACTGCAACAAAGATGTCACGA 120  
Db 105 GATGCTGGTGTGATTCGAATCCAGGGCGGGATCTGAACTGCAACAAAGATGTCACGA 164  
Qy 121 AGTACTGGGAAATGCCATCTCTCTACTGCGCTACGCTACGCTGCTACTGGGACTAGG 180  
Db 165 AGTACTGGGAAATGCCATCTCTCTACTGCGCTACGCTACGCTGCTACTGGGACTAGG 224  
Qy 181 TGGCAGAGGCCAACCCAAAGATGCCAGGATGCTGCTGCCAGACCCATGCTGCTGCTA 240  
Db 225 TGGCAGAGGCCAACCCAAAGATGCCAGGATGCTGCTGCCAGACCCATGCTGCTGCTA 284  
Qy 241 TGACACCTGAAGACCCAGGGGTGGGATCTACAGGACTATACAGATACAACTTTTC 300  
Db 285 TGACACCTGAAGACCCAGGGGTGGGATCTACAGGACTATACAGATACAACTTTTC 344  
Qy 301 CGAGGGGAACATCCACTGCTCTGCAAGGGAAGCTGCTGAGCAGCAGCTGCTGTCCTG 360  
Db 345 CGAGGGGAACATCCACTGCTCTGCAAGGGAAGCTGCTGAGCAGCAGCTGCTGTCCTG 404  
Qy 361 TGACAGAGAGTGGCTCTGCTCTGAAGGCGCACTTGACACCTACCAAGCGACTGGC 420  
Db 405 TGGCAGAGAGTGGCTCTGCTCTGAAGGCGCACTTGACACCTACCAAGCGACTGGC 464  
Qy 421 TTTTCTACTGGCGGCCCACTGCGGGGGGAGAGCTGCGGCTCCCACTCAGTATCTAACCTGAACAGC 540  
Db 465 TTTTCTACTGGCGGCCCACTGCGGGGGGAGAGCTGCGGCTCCCACTCAGTATCTAACCTGAACAGC 524  
Qy 481 TACCTGTTCTCAGCAGGCTGCTGGCATCCCACTCAGTATCTAACCTGAACAGC 540  
Db 525 TACCTGTTCTCAGCAGGCTGCTGGCATCCCACTCAGTATCTAACCTGAACAGC 584  
Qy 541 CTGGCTTTTCAAACTCCGGGGGGAGTAGTCCCACTCCCGGAAACCC 592  
Db 585 CTGGCTTTTCAAACTCCGGGGGGAGTAGTCCCACTCCCGGAAACCC 636

RESULT 2  
BI836812 680 bp mRNA linear EST 04-OCT-2001  
LOCUS 603084703F1 NIH\_MGC\_120 Homo sapiens cDNA clone IMAGE:5223912 5',  
DEFINITION mRNA sequence.  
ACCESSION BI836812  
VERSION BI836812.1 GI:15948362  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 680)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-remail.nih.gov  
Tissue Procurement: Life Technologies, Inc.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov  
Plate: LIAM11563 row: e column: 01  
High quality sequence start: 4  
High quality sequence stop: 680.  
Location/Qualifiers  
FEATURES  
source 1..680  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:5223912"  
/lab\_host="DH10B"  
/clone\_lib="NIH\_MGC\_120"  
/note="Organ: pooled pancreas and spleen; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: EcoRV (destroyed); RNA source anonymous pool of spleen and pancreas from 28 yo male. Library is oligo-dT primed and directionally cloned (EcoRV site is destroyed upon cloning). Average insert size 1.5 kb, insert size range 1-2.5 kb. Library is normalized, and enriched for full-length clones and was constructed by C. Gruber (Invitrogen). Research Genetics tracking code 025. Note: this is a NIH\_MGC Library."

ORIGIN

Query Match 89.1%; Score 527.6; DB 12; Length 680;  
Best Local Similarity 98.6%; Pred. No. 7.7e-119;  
Matches 574; Conservative 0; Mismatches 4; Indels 4; Gaps 4;  
Qy 12 TGCTCTGTGCTGGATCATGGAATTCGCACTGCTGCTGGCTGGTGGTGGTGGTGG 71  
Db 1 TGCTCTGTGCTGGATCATGGAATTCGCACTGCTGCTGGCTGGTGGTGGTGGTGG 60  
Qy 72 TGATTTCCAAATCCAAAGATGCTGAACTGAACTGAACTGAACTGAACTGAACTG 131  
Db 61 TGATTTCCAAATCCAAAGATGCTGAACTGAACTGAACTGAACTGAACTGAACTG 119  
Qy 132 AAATGCCATCT 191  
Db 120 AAATGCCATCT 179  
Qy 192 AACCCAAAGATGCCAGGACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 251  
Db 180 AACCCAAAGATGCCAGGACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 239  
Qy 252 AGACCCAGGGGTGGGCACTCTACAGGACTATTTACAGATACAACTTTTCCAGGGGAACA 311  
Db 240 AGACCCAGGGGTGGGCACTCTACAGGACTATTTACAGATACAACTTTTCCAGGGGAACA 298  
Qy 312 TCCACTGCTCTGACAAAGGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 371  
Db 299 TCCACTGCTCTGACAAAGGAAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 358  
Qy 372 TGGCCCTTCTGCTGAGCGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCT 431  
Db 359 TGGCCCTTCTGCTGAGCGCACTGCACTGCACTGCACTGCACTGCACTGCACTGCT 418  
Qy 432 GGCCCCCACTGCGGGGGG-CAGACCCCTTGGGTGCTAGAAAGCCCAACCCCTCTACCCCTGTTTC 490  
Db 419 GGCCCCCACTGCGGGGGG-CAGACCCCTTGGGTGCTAGAAAGCCCAACCCCTCTACCCCTGTTTC 478  
Qy 491 CTCAGCATGAGCTCTGGCATGCCCATCTCAGTATCTTAACCTGAACAGCTGCTGCTTTTC 550  
Db 479 CTCAGCATGAGCTCTGGCATGCCCATCTCAGTATCTTAACCTGAACAGCTGCTGCTTTTC 537  
Qy 551 AAACACTCCCGGGGGAGTAGTCCCGCTCCCGGAAACCC 592  
Db 538 AAACACTCCCGGGGGAGTAGTCCCGCTCCCGGAAACCC 579

RESULT 3  
AY417051

LOCUS  
DEFINITION Homo sapiens PLA2G2D gene, VIRTUAL TRANSCRIPT, partial sequence, GSS 17-DEC-2003  
AY417051 genomic survey sequence.  
ACCESSION AY417051  
VERSION AY417051.1 GI:39773011  
KEYWORDS GSS.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE  
AUTHORS Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.  
TITLE Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios  
JOURNAL Science 302 (5652), 1960-1963 (2003)  
PUBMED 14671302  
REFERENCE 2 (bases 1 to 438)  
AUTHORS Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.  
TITLE Direct Submission  
JOURNAL Submitted (16-NOV-2003) Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA  
COMMENT This sequence was made by sequencing genomic exons and ordering them based on alignment  
FEATURES  
source Location/Qualifiers  
1..438  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
<1..>438  
/gene="PLA2G2D"  
/locus\_tag="HCM6095"

ORIGIN  
Query Match 73.7%; Score 436.4; DB 29; Length 438;  
Best Local Similarity 99.8%; Pred. No. 1.6e-96;  
Matches 437; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 ATGGAACCTTGCACTGCTGTGGGCTGTGATGGCTGTGATTCCTCAATCCAGGC 88  
Db 1 ATGGAACCTTGCACTGCTGTGGGCTGTGATGGCTGTGATTCCTCAATCCAGGC 60

QY 89 GGGATCTCTGAACCTGAACAGATGCTCAAGCAAGTGAAGTGGGAAATGCCATCTCTCC 148  
Db 61 GGGATCTCTGAACCTGAACAGATGCTCAAGCAAGTGAAGTGGGAAATGCCATCTCTCC 120

QY 149 TACTGGCCCTACGGCTGTCACTGGCGACTAGTGGCAGAGGCCAACCAAGATGCCACG 208  
Db 121 TACTGGCCCTACGGCTGTCACTGGCGACTAGTGGCAGAGGCCAACCAAGATGCCACG 180

QY 209 GACTGGTGTGCGACACCCATGCTGTGCTATGACCACTGAGAGGAGTGGCGGCG 268  
Db 181 GACTGGTGTGCGACACCCATGCTGTGCTATGACCACTGAGAGGAGTGGCGGCG 240

QY 329 GGAAGCTGGTGTGAGCAGACCTGCTGTGCTGTGACAGAGGAGTGGCGGCG 388  
Db 301 GGAAGCTGGTGTGAGCAGACCTGCTGTGCTGTGACAGAGGAGTGGCGGCG 360

QY 449 CAGACCCCTGGTGGTGTAG 466  
|||||

Db 421 CAGACCCCTGGTGGTGTAG 438

RESULT 4  
AY417052  
LOCUS  
DEFINITION Pan troglodytes PLA2G2D gene, VIRTUAL TRANSCRIPT, partial sequence, GSS 17-DEC-2003  
AY417052 genomic survey sequence.  
ACCESSION AY417052  
VERSION AY417052.1 GI:39773012  
KEYWORDS GSS.  
SOURCE Pan troglodytes (chimpanzee)  
ORGANISM Pan troglodytes

REFERENCE  
AUTHORS Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.  
TITLE Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios  
JOURNAL Science 302 (5652), 1960-1963 (2003)  
PUBMED 14671302  
REFERENCE 2 (bases 1 to 438)  
AUTHORS Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Ferriera, S., Wang, G., Zheng, X.H., White, T.J., Sninsky, J.J., Adams, M.D. and Cargill, M.  
TITLE Direct Submission  
JOURNAL Submitted (16-NOV-2003) Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA  
COMMENT This sequence was made by sequencing genomic exons and ordering them based on alignment  
FEATURES  
source Location/Qualifiers  
1..438  
/organism="Pan troglodytes"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9598"  
<1..>438  
/gene="PLA2G2D"  
/locus\_tag="HCM6095"

ORIGIN  
Query Match 73.7%; Score 436.4; DB 29; Length 438;  
Best Local Similarity 99.8%; Pred. No. 1.6e-96;  
Matches 437; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 ATGGAACCTTGCACTGCTGTGGGCTGTGATGGCTGTGATTCCTCAATCCAGGC 88  
Db 1 ATGGAACCTTGCACTGCTGTGGGCTGTGATGGCTGTGATTCCTCAATCCAGGC 60

QY 89 GGGATCTCTGAACCTGAACAGATGCTCAAGCAAGTGAAGTGGGAAATGCCATCTCTCC 148  
Db 61 GGGATCTCTGAACCTGAACAGATGCTCAAGCAAGTGAAGTGGGAAATGCCATCTCTCC 120

QY 149 TACTGGCCCTACGGCTGTCACTGGCGACTAGTGGCAGAGGCCAACCAAGATGCCACG 208  
Db 121 TACTGGCCCTACGGCTGTCACTGGCGACTAGTGGCAGAGGCCAACCAAGATGCCACG 180

QY 209 GACTGGTGTGCGACACCCATGCTGTGCTATGACCACTGAGAGGAGTGGCGGCG 268  
Db 181 GACTGGTGTGCGACACCCATGCTGTGCTATGACCACTGAGAGGAGTGGCGGCG 240

QY 269 ATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGAAACATCCACTGCTCTGACAAG 328  
Db 241 ATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGAAACATCCACTGCTCTGACAAG 300

QY 329 GGAAGCTGGTGTGAGCAGACCTGCTGTGCTGTGACAGAGGAGTGGCGGCG 388  
Db 301 GGAAGCTGGTGTGAGCAGACCTGCTGTGCTGTGACAGAGGAGTGGCGGCG 360

QY 389 CGCAACCTGGACACCTACCAGAGGAGTGGTTCCTACTGGCGGCCCACTGCCGGGG 448  
|||||

```

||||| 361 CGCAACTGGACACTACCAAGCGACTGCTTCTACTGGCGGCCCACTGCGGGG 420
|||||
||||| 449 CAGACCCCTGGGTGCTAG 466
|||||
||||| 421 CAGACCCCTGGGTGCTAG 438
|||||

RESULT 5
BML153087
LOCUS
DEFINITION
  TCBAP1Q13560 Pediatric pre-B cell acute lymphoblastic leukemia
  Baylor-HGSC project-TCBA Homo sapiens cDNA clone TCBAP1356, mRNA
  sequence.
ACCESSION
  BML153087
VERSION
  BML153087.1 GI:17177919
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
ORGANISM
  Homo sapiens
REFERENCE
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS
  Wei,Y., Tsang,Y.T.M., Mei,G., Ku,J.M., Ali-Osman,F.R. Jr.,
  Gunaratne,P.H., Muzny,D., Bouck,J., Gibbs,R.A. and Margolin,J.F.
  Pediatric Leukemia cDNA Sequencing Project (2001)
  Unpublished (2001)
JOURNAL
  Contact: Dr. Judith F. Margolin
  Texas Children's Cancer Center and Human Genome Sequencing Center
  at Baylor College of Medicine
  1102 Bates, MC3-3320 Houston, TX 77030, USA
  Tel: 832-824-4536
  Fax: 832-825-4038
  Email: clones@ccc.org
  Seq primer: M13 primer.
  Location/Qualifiers
    1..463
    /organism="Homo sapiens"
    /mol_type="mRNA"
    /db_xref="taxon:9606"
    /clone="TCBAP1356"
    /sex="male"
    /tissue_type="leukopheresis"
    /cell_type="pre-B cell"
    /dev_stage="pediatric 2 years"
    /lab_host="DH10B"
    /clone_lib="pediatric pre-B cell acute lymphoblastic
    leukemia Baylor-HGSC project-TCBA"
    /note="Vector: lambda PSB; Site 1: BamHI; Site 2: EcoRI;
    First strand cDNA was primed with an anchored
    XhoI-oligo(dT) primer [5'GGAGGACTCGAGCGCGCGAGGAG(T)VN
    3'; V=A,C,G; N=A,C,G,T] and then dG tailed. Second strand
    was primed with a BamHI-dC primer
    [5'AGAGACTCGATCCGCGCGCGCAATAATAAT(C) 3'].
    Double-stranded cDNA was then digested with BamHI and XhoI
    and directionally cloned into the BamHI and SalI sites of
    lambda PSB vector. Library went through one round of
    normalization. Library was constructed by Wei Yu at RIKEN
    of Japan (Carninci P, Westover A, Nishiyama Y, Ohsumi T,
    Itoh M, Nagaoaka S, Sasakin, Okazaki Y, Muramatsu M,
    Schneider C, Hayashizaki Y, High efficiency selection of
    full-length cDNA by improved biotinylated cap trapper.,
    DNA Res 4: 1, 61-6, Feb 28, 1997)"
  DNA Res 4: 1, 61-6, Feb 28, 1997"

FEATURES
  source
  1..463
  /organism="Homo sapiens"
  /mol_type="mRNA"
  /db_xref="taxon:9606"
  /clone="TCBAP1356"
  /sex="male"
  /tissue_type="leukopheresis"
  /cell_type="pre-B cell"
  /dev_stage="pediatric 2 years"
  /lab_host="DH10B"
  /clone_lib="pediatric pre-B cell acute lymphoblastic
  leukemia Baylor-HGSC project-TCBA"
  /note="Vector: lambda PSB; Site 1: BamHI; Site 2: EcoRI;
  First strand cDNA was primed with an anchored
  XhoI-oligo(dT) primer [5'GGAGGACTCGAGCGCGCGAGGAG(T)VN
  3'; V=A,C,G; N=A,C,G,T] and then dG tailed. Second strand
  was primed with a BamHI-dC primer
  [5'AGAGACTCGATCCGCGCGCGCAATAATAAT(C) 3'].
  Double-stranded cDNA was then digested with BamHI and XhoI
  and directionally cloned into the BamHI and SalI sites of
  lambda PSB vector. Library went through one round of
  normalization. Library was constructed by Wei Yu at RIKEN
  of Japan (Carninci P, Westover A, Nishiyama Y, Ohsumi T,
  Itoh M, Nagaoaka S, Sasakin, Okazaki Y, Muramatsu M,
  Schneider C, Hayashizaki Y, High efficiency selection of
  full-length cDNA by improved biotinylated cap trapper.,
  DNA Res 4: 1, 61-6, Feb 28, 1997)"

ORIGIN
  Query Match 72.2%; Score 427.2; DB 12; Length 463;
  Best Local Similarity 99.3%; Pred. No. 2.9e-94;
  Matches 429; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGCTGCTGGGATCATGGAACCTTGCACTGCTGTGGGTGGTGGT 60
Db 32 TCTGCTCCACTGCTGCTGCTGGGATCATGGAACCTTGCACTGCTGTGGGTGGTGGT 91
QY 61 GATGGCTGGTGTGATTCCAATCCAGGCGGGATCCCTGAACCTGAACAGATGTCAGCA 120

```

```

||||| 92 GATGGTTTTGTGATCCAAATCCAGGCGGGGATCCTGAACCTGAACAGATGGTCAAGCA 151
|||||
||||| 121 AGTGACTGGGAAATGCCATCTCTCTACTGCGCCCTACGGCTGTCTACTCGGACTAGG 180
|||||
||||| 152 AGTGACTGGGAAATGCCATCTCTCTACTGCGCCCTACGGCTGTCTACTCGGACTAGG 211
|||||
||||| 181 TGGCAGAGGGCCAAACCCAAAGATGCCAGGACTGTGTGTCGACACCCATGACTGTGCTA 240
|||||
||||| 212 TGGCAGAGGGCCAAACCCAAAGATGCCAGGACTGTGTGTCGACACCCATGACTGTGCTA 271
|||||
||||| 241 TGACCACTGAAGACCCAGGGGTGGGCATCTTACAAGGACTATTACAGATACAATTTC 300
|||||
||||| 272 TGACCACTGAAGACCCAGGGGTGGGCATCTTACAAGGACTATTACAGATACAATTTC 331
|||||
||||| 301 CCAGGGGAACATCCACTGCTCTGACAGGGGAAGCTGTGTGTCGACGACGCTGTGTGCTG 360
|||||
||||| 332 CCAGGGGAACATCCACTGCTCTGACAGGGGAAGCTGTGTGTCGACGACGCTGTGTGCTG 391
|||||
||||| 361 TGACAGAGAGTGCGCTTCTGCTGAAGCGCAACTGGACACCTACAGAGCGACTGG 420
|||||
||||| 392 TGACAGAGAGTGCGCTTCTGCTGAAGCGCAACTGGACACCTACAGAGCGACTGG 451
|||||
||||| 421 TTTCTACTGGCG 432
|||||
||||| 452 TTTCTACTGGCG 463
|||||

RESULT 6
CB481980
LOCUS
DEFINITION
  jns85.C09.f jns Sus scrofa cDNA 5', mRNA sequence.
ACCESSION
  CB481980
VERSION
  CB481980.1 GI:29288366
KEYWORDS
  EST.
SOURCE
  Sus scrofa (pig)
ORGANISM
  Sus scrofa
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE
  1 (bases 1 to 461)
  Neilan,J.G., Kutish,G.F., Lu,Z., Zsak,A. and Rock,D.L.
  Sequence analysis of African swine fever virus infected and
  non-infected porcine macrophage cDNA libraries
  Unpublished (2003)
  Contact: Neilan JG
  Plum Island Animal Disease Center
  US Department of Agriculture, Agricultural Research Service
  PO Box 848, Greenport, NY 11944-848, USA
  Tel: 631 323 3133
  Fax: 631 323 3044
  Email: jneilan@piadc.ars.usda.gov
  Single pass sequencing. Bases called with phred v0.020425.c and
  trimmed with the aid of the trim alt option. Vector identified by
  cross match v0.90329 and Lucy v1.17p.
  Seq primer: M13 Forward.
  Location/Qualifiers
    1..461
    /organism="Sus scrofa"
    /mol_type="mRNA"
    /db_xref="taxon:9823"
    /tissue_type="lymphoid"
    /cell_type="macrophage"
    /lab_host="DH10B"
    /clone_lib="jns"
    /note="Vector: pSPORT1; Site 1: NotI; Site 2: SalI;
    Library made from pools of polyA selected RNA. Macrophages
    were derived from peripheral blood mononuclear cells
    cultured for 48 hrs on plastic in the presence of 30% L929
    supernatant."

ORIGIN
  Query Match 54.6%; Score 323; DB 14; Length 461;
  Best Local Similarity 84.8%; Pred. No. 1.2e-68;

```

Matches 362; Conservative 0; Mismatches 65; Indels 0; Gaps 0;

QY 2 CTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 61  
 Db 427 CTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 61

QY 62 ATGGCTGGTGTGATTCGAATCCAGGCGGGATCCTGAACTGGAACAGATGGTCAAGCAA 121  
 Db 367 TTTGCTGGTGTGATTCGAATCCAGGCGGGATCCTGAACTGGAACAGATGGTCAAGCAA 308

QY 122 GTGACTGGGAAATGCCATCCTCTCTACTGCTGGCTTACGGCTGTCTACTGCGACTAGGT 181  
 Db 307 GTGACCGGGAAGTGGCTCTTCTCTCTATTTGGCTTACGGCTGTCTACTGGAATCGGT 248

QY 182 GGCAGAGGCCCAACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCCATGCTGCTAT 241  
 Db 247 GGCAGAGGTGAACCCAAAGATGCCAGACTGGTGTGCTGCGAGACCCATGCTGCTAT 188

QY 242 GACCACTGAAGACCCAGGGGTGGGATCTCAAGGACTATTACAGATCAACACTTTTCC 301  
 Db 187 AGTCACCTGAAGGGCCATGGCTCGGCACCACTTTGGACCACTACAGATACACTTTTCC 128

QY 302 CAGGGGAACATCAGCTCTGTGCAAGGGAAGTGGTGTGAGCAGCAGCTGTGTGCTGT 361  
 Db 127 CAGGGGACCGTCCAGTGTCTGTGCAAGGGGAGTGGTGTGAGCAGCAGCTGTGTGCTGT 68

QY 362 GACAAGAGGTGGCTTTCTGCTTGAAGCGCAACTGGACACTTACAGAGGAGCTGCGT 421  
 Db 67 GACAAGGGGTGGCTTTCTGCTGATGAAGCGCAACTGGACACTTACAGAGGAGCTGCGT 8

QY 422 TTCTACT 428  
 Db 7 TACTACT 1

RESULT 7  
 CD687559  
 LOCUS  
 DEFINITION  
 EST4080 human nasopharynx Homo sapiens cDNA, mRNA sequence.  
 ACCESSION  
 CD687559  
 VERSION  
 CD687559.1 GI:32205515  
 KEYWORDS  
 EST.  
 SOURCE  
 Homo sapiens (human)  
 ORGANISM  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE  
 1 (bases 1 to 424)  
 AUTHORS  
 Liu, X.-Q., Zhou, Y., Zhang, L.-J., Xu, H., Chen, H.-K., Pan, Z.-G. and  
 Zeng, Y.-X.  
 TITLE  
 Transcriptional Gene Expression Profile of Human Nasopharynx  
 JOURNAL  
 Unpublished (2003)  
 COMMENT  
 Contact: Yixin Zeng  
 Cancer Center  
 Sun Yat-sen University  
 651 Dongfeng Road East, Guangzhou 510060, China  
 Tel: 86-1380-9770-743  
 Fax: 86-20-8775-4506  
 Email: yxzeng@zsums.edu.cn.  
 FEATURES  
 Location/Qualifiers  
 1..424  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /tissue\_type="normal nasopharynx"  
 /clone\_lib="human nasopharynx"  
 /note="ESTs generated from a normal nasopharynx cDNA library from southern Chinese"

ORIGIN  
 Query Match 52.1%; Score 308.6; DB 14; Length 424;  
 Best Local Similarity 96.3%; Pred. No. 3.9e-65;  
 Matches 369; Conservative 0; Mismatches 9; Indels 5; Gaps 5;

QY 1 TCTGCTCCACTGCTCTGTGCTGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 60  
 Db 42 TCTGCTCCACTGCTCTGTGCTGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 101

QY 61 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCCTGAACTGGAACAGATGGTCAAGCAA 120  
 Db 102 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCCTGAACTGGAACAGATGGTCAAGCAA 161

QY 121 AGTACTGGGAAATGCCATCCTCTCTACTGCTGGCTTACGGCTGTCTACTGCGACTAGG 180  
 Db 162 AGTACTGGGAAATGCCATCCTCTCTACTGCTGGCTTACGGCTGTCTACTGCGACTAGG 221

QY 181 TGGCAGAGGCC-AACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCCATGCTGCT 239  
 Db 222 TGGAGAGGCCGAAGCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCCATGCTGCT 281

QY 240 ATGACCACCTGGAAGACCCAGGGGTGGG-CATCTCAAGGA-CTATTACAGATA-CAACT 296  
 Db 282 ATGACCACCTGGAAGACCCAGGGGTGGGATCTCAAGGAGATATTACAGATAGCACT 341

QY 297 TTTCCAGGGGAACATCCATCTGCTCTGCAAGGGAAGTGGTGTGAGCAGCA-GCTGTGT 355  
 Db 342 TTTCCAGGGGAACATCCATCTGCTCTGCAAGGGAAGTGGTGTGAGCAGCATGCTGT 401

QY 356 GCCTGTGACAAGAGGTGGCTT 378  
 Db 402 GCCTGTGACAAGAGGTGGCTT 424

BY752231 623 bp mRNA linear EST 17-DEC-2002  
 BY752231 RIKEN full-length enriched, activated spleen Mus musculus  
 CDNA clone F830213F07 5', mRNA sequence.  
 BY752231  
 BY752231.1 GI:27183012  
 EST.  
 Mus musculus (house mouse)  
 Mus musculus  
 ACCESSION  
 VERSION  
 BY752231  
 KEYWORDS  
 EST.  
 SOURCE  
 Mus musculus  
 ORGANISM  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE  
 1 (bases 1 to 623)  
 AUTHORS  
 Okazaki, Y., Furuno, M., Kasukawa, T., Adachi, J., Bono, H., Kondo, S.,  
 Nikaido, I., Otsu, N., Saito, R., Suzuki, H., Yamanaka, I.,  
 Kiyosawa, H., Yagi, K., Tomaru, Y., Hasegawa, Y., Nogami, A.,  
 Schonbach, C., Gojobori, T., Baldarelli, R., Hill, D.P., Bult, C.,  
 Hume, D.A., Quackenbush, J., Schriml, L.M., Kanapin, A., Matsuda, H.,  
 Batalov, S., Beisel, K.W., Blake, J.A., Bradt, D., Bruscia, V.,  
 Chothia, C., Corbani, L.E., Cousins, S., Dalla, E., Dragani, T.A.,  
 Fletcher, C.F., Forrest, A., Frazer, K.S., Gaasterland, T.,  
 Gariboldi, M., Gibsi, C., Godzik, A., Gough, J., Grimmond, S.,  
 Gustincich, S., Hirokawa, N., Jackson, I.J., Jarvis, E.D., Kanai, A.,  
 Kawaji, H., Kawasawa, Y., Kedzierski, R.M., King, B.L., Konagaya, A.,  
 Kurochkin, I.V., Lee, Y., Lenhard, B., Lyons, P.A., Maglott, D.R.,  
 Maltais, L., Marchionni, L., McKenzie, L., Miki, H., Nagashima, T.,  
 Numata, K., Okido, T., Pavan, W.J., Pertea, G., Pesole, G.,  
 Petrovsky, N., Pillai, R., Pontius, J.U., Qi, D., Ramachandran, S.,  
 Ravasi, T., Reed, J.C., Reid, J., Ring, B.Z., Ringwald, M.,  
 Sandelin, A., Schneider, C., Semple, C.A., Setou, M., Shimada, K.,  
 Sultana, R., Takenaka, Y., Taylor, M.S., Teasdale, R.D., Tomita, M.,  
 Vekardo, R., Wagner, L., Wahlestedt, C., Wang, Y., Watanabe, Y.,  
 Wells, C., Wilming, L.G., Wynshaw-Boris, A., Yanagisawa, M., Yang, I.,  
 Yang, L., Yuan, Z., Zavolan, M., Zhu, Y., Zimmer, A., Carninci, P.,  
 Hayatsu, N., Hirozane-Kishikawa, T., Konno, H., Nakamura, M.,  
 Sakazume, N., Sato, K., Shiraki, T., Waki, K., Kawai, J., Aizawa, K.,  
 Arakawa, T., Fukuda, S., Hara, A., Hashizume, W., Imotani, K., Ishii, Y.,  
 Itoh, M., Kagawa, I., Miyazaki, A., Sakai, K., Sasaki, D., Shibata, K.,  
 Shinagawa, A., Yasunishi, A., Yoshino, M., Waterston, R., Lander, E.S.,  
 Rogers, J., Birney, E. and Hayashizaki, Y.  
 ANALYSIS of the mouse transcriptome based on functional annotation  
 of 60,770 full-length cDNAs  
 Nature 420, 563-573 (2002)  
 22354683

RESULT 8  
 BY752231  
 LOCUS  
 DEFINITION  
 BY752231 RIKEN full-length enriched, activated spleen Mus musculus  
 ACCESSION  
 VERSION  
 BY752231  
 KEYWORDS  
 EST.  
 SOURCE  
 Mus musculus (house mouse)  
 ORGANISM  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE  
 1 (bases 1 to 623)  
 AUTHORS  
 Okazaki, Y., Furuno, M., Kasukawa, T., Adachi, J., Bono, H., Kondo, S.,  
 Nikaido, I., Otsu, N., Saito, R., Suzuki, H., Yamanaka, I.,  
 Kiyosawa, H., Yagi, K., Tomaru, Y., Hasegawa, Y., Nogami, A.,  
 Schonbach, C., Gojobori, T., Baldarelli, R., Hill, D.P., Bult, C.,  
 Hume, D.A., Quackenbush, J., Schriml, L.M., Kanapin, A., Matsuda, H.,  
 Batalov, S., Beisel, K.W., Blake, J.A., Bradt, D., Bruscia, V.,  
 Chothia, C., Corbani, L.E., Cousins, S., Dalla, E., Dragani, T.A.,  
 Fletcher, C.F., Forrest, A., Frazer, K.S., Gaasterland, T.,  
 Gariboldi, M., Gibsi, C., Godzik, A., Gough, J., Grimmond, S.,  
 Gustincich, S., Hirokawa, N., Jackson, I.J., Jarvis, E.D., Kanai, A.,  
 Kawaji, H., Kawasawa, Y., Kedzierski, R.M., King, B.L., Konagaya, A.,  
 Kurochkin, I.V., Lee, Y., Lenhard, B., Lyons, P.A., Maglott, D.R.,  
 Maltais, L., Marchionni, L., McKenzie, L., Miki, H., Nagashima, T.,  
 Numata, K., Okido, T., Pavan, W.J., Pertea, G., Pesole, G.,  
 Petrovsky, N., Pillai, R., Pontius, J.U., Qi, D., Ramachandran, S.,  
 Ravasi, T., Reed, J.C., Reid, J., Ring, B.Z., Ringwald, M.,  
 Sandelin, A., Schneider, C., Semple, C.A., Setou, M., Shimada, K.,  
 Sultana, R., Takenaka, Y., Taylor, M.S., Teasdale, R.D., Tomita, M.,  
 Vekardo, R., Wagner, L., Wahlestedt, C., Wang, Y., Watanabe, Y.,  
 Wells, C., Wilming, L.G., Wynshaw-Boris, A., Yanagisawa, M., Yang, I.,  
 Yang, L., Yuan, Z., Zavolan, M., Zhu, Y., Zimmer, A., Carninci, P.,  
 Hayatsu, N., Hirozane-Kishikawa, T., Konno, H., Nakamura, M.,  
 Sakazume, N., Sato, K., Shiraki, T., Waki, K., Kawai, J., Aizawa, K.,  
 Arakawa, T., Fukuda, S., Hara, A., Hashizume, W., Imotani, K., Ishii, Y.,  
 Itoh, M., Kagawa, I., Miyazaki, A., Sakai, K., Sasaki, D., Shibata, K.,  
 Shinagawa, A., Yasunishi, A., Yoshino, M., Waterston, R., Lander, E.S.,  
 Rogers, J., Birney, E. and Hayashizaki, Y.  
 ANALYSIS of the mouse transcriptome based on functional annotation  
 of 60,770 full-length cDNAs  
 Nature 420, 563-573 (2002)  
 22354683

TITLE  
 ANALYSIS of the mouse transcriptome based on functional annotation  
 of 60,770 full-length cDNAs  
 JOURNAL  
 Nature 420, 563-573 (2002)  
 MEDLINE  
 22354683



Dd	187	GGCAAGGCGAACCCAAAGATGCCACAGACTGGTGTCTCAGAAGCATGAITTTGCTAT	246
Qy	242	GACCACCTGAAGACCCAGGGGTGC GGSCATCTACAAGGACTATTACAGATACAACTTTTCC	301
Dd	247	GCCCACCTGAAGATCGATGGATGCAAGGCCTGCAGACAACTACAATAACAGCATCTCC	306
Qy	302	CAGGGGRACATCCACTGCTCTGACAAAGGAGAGCTGGTGTAGCAGCAGCTGTGTGCTGT	361
Dd	307	CAGGCGCACTATCCAGTGTCTGTGACAAACGGGAGCTGGTGTGAAAGGCAACTGTGTGTCTGT	366
Qy	362	GACAAGGAGGTGGCTTCCTGCTGAAGCGCAACCTGGACACCTACAGAGCGACTGGT	421
Dd	367	GACAAGGAGGTGGCTTGTGTTTAAGCAAACCTGGATAGCTACAATAAGCGCTGGT	426
Qy	422	TTCCTACTGGCGCCCCACTGCGCGGGCGAGACCCCTGGTGCTAGAAGCCACACCCCTCT	481
Dd	427	TACTACTGGCGCCCCGTTGCAAGGCAAGACTCCAGCATGCTAAGGGAGTCCACTCTGT	486
RESULT	10		
AY417053			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			

REFERENCE	1	(bases 1 to 438)	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS	Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Perriera, S., Wang, G., Zheng, X.H., White, T.J., Shinsky, J.J., Adams, M.D. and Cargill, M.		
TITLE	Inferring nonneutral evolution from human-chimp-mouse orthologous gene trios		
JOURNAL	Science	302 (5652), 1960-1963 (2003)	
PUBMED	14671302		
REFERENCE	2	(bases 1 to 438)	
AUTHORS	Clark, A.G., Glanowski, S., Nielson, R., Thomas, P., Kejariwal, A., Todd, M.A., Tanenbaum, D.M., Civello, D.R., Lu, F., Murphy, B., Perriera, S., Wang, G., Zheng, X.H., White, T.J., Shinsky, J.J., Adams, M.D. and Cargill, M.		
TITLE	Direct Submission		
JOURNAL	Submitted (18-NOV-2003)	Celera Genomics, 45 West Gude Drive, Rockville, MD 20850, USA	
COMMENT	This sequence was made by sequencing genomic exons and ordering them based on alignment.		
FEATURES	Location/Qualifiers		
Source	1. .438		

```

/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
<!.>438
/gene="PLA2G2D"
/locus_tag="HCM6095"

ORIGIN
Query Match          49.0%; Score 289.8; DB 29; Length 438;
Best Local Similarity 78.9%; Pred. No. 1.7e-60;
Matches 345; Conservative 0; Mismatches 92; Indels 0; Gaps 0;

QY      29  ATGGAAC TTGCAC TCTGT GTGGG CTGGT GTGAT GGCTGG TGTTG ATTCC AATCC AGGGC 88
       |||   |||   |||   |||   |||   |||   |||   |||   |||   |||   |||
ddb     1  ATGAGACTCG CCCTCT GCTGT GTGGG CTGCT GTCTG GCGCG TGGTAA CTCGCA CCCCAG GA 60

QY      89  GGGATCTTCG AACCTCAA CAAGATG TCACAAG CTAAGTCA CTGGG AAAATGCC CATCTCT CCTC 148
       |||   |||   |||   |||   |||   |||   |||   |||   |||   |||
ddb    61  GGGCTCTCTG AACCTCAA CAAGATG TCACAAC ATGACG GGGGAAA GAAGCC TTCCTT CAGC 120

```

149 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACG 208  
121 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACA 180  
209 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 268  
181 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 240  
269 ATCTACAGGAGCTATTACAGATACAACTTTTCCAGGGGACATCCACTGCTGCAAG 328  
241 AGCCCTGACAGACCACTACAAATACAGATCTCCAGGGGCACTATCCAGTGTCTGACAC 300  
329 GGAAGCTGGTGGAGCAGCAGCTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 388  
301 GGGAGCTGGTGGAGGCAACTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 360  
389 CGCAACCTGGACACCTACAGAGGAGCTGGGTTTCTACTGGCGGCCCACTGGCGGGG 448  
361 CAAACCTGGATAGTACAATAAGCGCTGCTTACTACTGGCGGCCCGCTTGCAAGGC 420  
449 CAGACCCCTGGTGTCTA 465  
421 AAGACTCCAGCATGCTA 437

RESULT 11  
A1430241  
LOCUS  
DEFINITION  
IMAGE:1225779 5', similar to SW:PA2M CAVPO P47711 PHOSPHOLIPASE A2,  
MEMBRANE ASSOCIATED PRECURSOR ;, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

149 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACG 208  
121 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACA 180  
209 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 268  
181 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 240  
269 ATCTACAGGAGCTATTACAGATACAACTTTTCCAGGGGACATCCACTGCTGCAAG 328  
241 AGCCCTGACAGACCACTACAAATACAGATCTCCAGGGGCACTATCCAGTGTCTGACAC 300  
329 GGAAGCTGGTGGAGCAGCAGCTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 388  
301 GGGAGCTGGTGGAGGCAACTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 360  
389 CGCAACCTGGACACCTACAGAGGAGCTGGGTTTCTACTGGCGGCCCACTGGCGGGG 448  
361 CAAACCTGGATAGTACAATAAGCGCTGCTTACTACTGGCGGCCCGCTTGCAAGGC 420  
449 CAGACCCCTGGTGTCTA 465  
421 AAGACTCCAGCATGCTA 437

RESULT 11  
A1430241  
LOCUS  
DEFINITION  
IMAGE:1225779 5', similar to SW:PA2M CAVPO P47711 PHOSPHOLIPASE A2,  
MEMBRANE ASSOCIATED PRECURSOR ;, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

149 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACG 208  
121 TACTGGCCCTACGGCTGCTCACTGGGACTAGGTGGGAGAGGCCAACCAAGATGCCACA 180  
209 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 268  
181 GACTGGTGGTCCAGACCCATGCTGCTGCTATGACCACTGAAGCCAGCCAGGGGTGGCGC 240  
269 ATCTACAGGAGCTATTACAGATACAACTTTTCCAGGGGACATCCACTGCTGCAAG 328  
241 AGCCCTGACAGACCACTACAAATACAGATCTCCAGGGGCACTATCCAGTGTCTGACAC 300  
329 GGAAGCTGGTGGAGCAGCAGCTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 388  
301 GGGAGCTGGTGGAGGCAACTGTGCTGTGACAGGAGGTGGCCTTCTGCTGAAG 360  
389 CGCAACCTGGACACCTACAGAGGAGCTGGGTTTCTACTGGCGGCCCACTGGCGGGG 448  
361 CAAACCTGGATAGTACAATAAGCGCTGCTTACTACTGGCGGCCCGCTTGCAAGGC 420  
449 CAGACCCCTGGTGTCTA 465  
421 AAGACTCCAGCATGCTA 437

RESULT 11  
A1430241  
LOCUS  
DEFINITION  
IMAGE:1225779 5', similar to SW:PA2M CAVPO P47711 PHOSPHOLIPASE A2,  
MEMBRANE ASSOCIATED PRECURSOR ;, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

rounds of normalization, and was constructed by Bento  
Soares and M.Fatima Bonaldo."

ORIGIN

Query Match 45.4%; Score 268.8; DB 9; Length 460;  
Best Local Similarity 77.7%; Pred. No. 2.5e-55;  
Matches 324; Conservative 0; Mismatches 93; Indels 0; Gaps 0;

QY 65 GCTGGTGTGATTCATTCAGAGGGGGATCCTGAACCTGACCAAGATGGTCAACAAGTG 124  
DB 1 GCCGGTATACTGCAACCCAGGAGGGCTCTGAACCTGACCAAGATGGTCAACAAGTG 60  
QY 125 ACTGGGAAATGCCCCCTCTCTTACTGGCCCTACCGCTGCTCACTGGGACTAGGTGGC 184  
DB 61 ACGGGGAAGAAGCCTTCTTCAGCTACTGGCCCTACCGCTGCTCACTGGGACTAGGTGGC 120  
QY 185 AGAGGCCAACCAAGATGCCAGGATGCCAGGATGGTGTGTCAGACCCATGACTGCTGTATGAC 244  
DB 121 AAGGGCAACCAAGATGCCAGGATGCCAGGATGGTGTGTCAGACCCATGACTGCTGTATGAC 180  
QY 245 CACCTGAAGACCCAGGGGTGGGATCTACAAAGGACTATTACAGATCAACTTTTCCAG 304  
DB 181 CACCTGAAGATCGATGATGCAAGAGCCTGACAGCAACTACAAATACAGCATCTCCAG 240  
QY 305 GGGAACTCCACTGCTCTGACAAAGGAGCTGGTGTGAGCAGCAGCTGTGCTGTGAC 364  
DB 241 GGCATATCCAGTGTCTGTGACAAAGGAGCTGGTGTGAAAGGCAACTGTGCTGTGAC 300  
QY 365 AAGGAGGTGGCTTCTGCTGAAAGGCAACTGTGACCACTGACCAAGGAGCTGTGCTTTC 424  
DB 301 AAGGAGGTGGCTTGTGCTTGTGAGCAAACTGATGATCAATAAGGCGCTGGGTTAC 360  
QY 425 TACTGGCGGCCCTACTGCGGGGGGAGCCCTGCTGGTGTGAGAGCCCACTCTCT 481  
DB 361 TACTGGCGGCCCTGCTGCAAGGCAAGCTCCAGCATGCTAGGAGGATCCACTCTGT 417

RESULT 12  
AA762051  
LOCUS  
DEFINITION  
IMAGE:1225779 5', similar to SW:PA2M CAVPO P47711 PHOSPHOLIPASE A2,  
MEMBRANE ASSOCIATED PRECURSOR ;, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

AA762051 501 bp mRNA linear EST 27-JAN-1998  
v49h02.r1 Soares thymus 2NBMt Mus musculus cDNA clone  
IMAGE:1225779 5', similar to SW:PA2M CAVPO P47711 PHOSPHOLIPASE A2,  
MEMBRANE ASSOCIATED PRECURSOR ;, mRNA sequence.

AA762051  
AA762051.1 GI:2811798  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 501)  
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,  
Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,  
Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,  
Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and  
Waterston, R.  
The WashU-HMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@watson.wustl.edu  
This clone is available royalty-free through LML; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:651371  
Seq primer: -28m13 rev2 ET from Amersham  
High quality sequence stop: 492.  
Location/Qualifiers  
1. .501  
/organism="Mus musculus"





cdNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.  
Please visit our web site (<http://genome.gsc.riken.go.jp>) for further details.

FEATURES  
Location/Qualifiers  
1..998  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL/6J"  
/db\_xref="taxon:10090"  
/clone="1110051K23"  
/tissue\_type="whole body"  
/dev\_stage="18-day embryo"  
/clone\_lib="RIKEN full-length enriched, 18-day embryo whole body"

ORIGIN  
Query Match 44.9%; Score 265.8; DB 13; Length 998;  
Best Local Similarity 79.3%; Pred. No. 2.1e-54;  
Matches 315; Conservative 0; Mismatches 82; Indels 0; Gaps 0;  
QY 69 GTGTGATCCCAATCCAGGGCGGGATCCTGGAACCTGGAACAGATGCTCAAGCAAGTGAATG 128  
Db 78 GTATAACTGCAACCCAGGGAGGGCTCTGGAACCTGGAACAGATGCTCAACATGACGG 137  
QY 129 GGAAATGCCCATCT 188  
Db 138 GGAGAAAGCCCTTCTTCT 197  
QY 189 GCCAACCCAAAGATGCCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 248  
Db 198 GSCAACCCAAAGATGCCAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 257  
QY 249 TGAAAGATCGATGGATGCAAGCCCTGACAGACCTGACAGACCTGACAGACCTGACAGAC 308  
Db 258 TGAAAGATCGATGGATGCAAGCCCTGACAGACCTGACAGACCTGACAGACCTGACAGAC 317  
QY 309 ACATCCACTGCTCTGCAAGGGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 368  
Db 318 CTATCCAGTGTCTGCAACGAGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 377  
QY 369 AGGTGGCCCTTCTGCTGGAAGCCCAACCTGGACACCTGACAGACCTGACAGACCTGACAG 428  
Db 378 AGGTGGCCCTTCTGCTGGAAGCCCAACCTGGATAGCTTACAAATGAAGCCCTGCGTTACT 437  
QY 429 GCGGGCCCTTCTGCTGGAAGCCCAACCTGGATAGCTTACAAATGAAGCCCTGCGTTACT 465  
Db 438 GCGGGCCCTTCTGCTGGAAGCCCAACCTGGATAGCTTACAAATGAAGCCCTGCGTTACT 474

RESULT 15  
AK004232 1206 bp mRNA linear HTC 20-SEP-2003  
LOCUS Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched library, clone:1110051K23 product:phospholipase A2, group IID, full insert sequence.  
DEFINITION  
ACCESSION AK004232  
VERSION AK004232.1 GI:12935341  
KEYWORDS HTC; CAP trapper.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
REFERENCE 1 Carninci P. and Hayashizaki Y.  
AUTHORS High-efficiency full-length cDNA cloning  
TITLE Meth. Enzymol. 303, 19-44 (1999)  
JOURNAL 99279253  
MEDLINE 10349636  
PUBMED  
REFERENCE 2

BY704474 998 bp mRNA linear EST 16-DEC-2002  
BY704474 RIKEN full-length enriched, 18-day embryo whole body Mus  
musculus cDNA clone 1110051K23 5', mRNA sequence.  
BY704474 1 GI:27115602  
EST.  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 998)  
Okazaki, Y., Furuno, M., Kasukawa, T., Adachi, J., Bono, H., Kondo, S.,  
Nikaido, I., Otsu, N., Saito, R., Suzuki, H., Yamaguchi, Y., Nogami, A.,  
Kiyosawa, H., Yagi, K., Tomaru, Y., Hasegawa, Y., Hasegawa, Y.,  
Schonbach, C., Gojohori, T., Baldarelli, R., Hill, D.P., Bult, C.,  
Hume, D.A., Quackenbush, J., Schriml, L.M., Kanapin, A., Matsuda, H.,  
Batalov, S., Beisel, K.W., Blake, J.A., Bradt, D., Brusic, V.,  
Ciothia, C., Corbani, L.E., Cousins, S., Dalla, E., Dragani, T.A.,  
Fletcher, C.F., Forrest, A., Frazer, K.S., Gaasterland, T.,  
Gariboldi, M., Glssi, C., Godzik, A., Gough, J., Grimmond, S.,  
Gustincich, S., Hirokawa, N., Jackson, I.J., Jarvis, B.D., Kanai, A.,  
Kawaji, H., Kawasawa, Y., Kedzierski, R.M., King, B.L., Konagaya, A.,  
Kurochkin, I.V., Lee, Y., Lenhard, B., Lyons, P.A., Maglott, D.R.,  
Maitais, L., Marchionni, D., McKenzie, L., Miki, H., Nagashima, T.,  
Numata, K., Okido, T., Pavan, W.J., Pertea, G., Pesole, G.,  
Petrovsky, N., Pillai, R., Pontius, J.U., Qi, D., Ramchandran, S.,  
Ravasi, T., Reed, J.C., Reed, D.J., Reid, J., Ring, B.Z., Ringwald, M.,  
Sandelin, A., Schneider, C., Semple, C.A., Setou, M., Shimada, K.,  
Sultana, R., Takenaka, Y., Taylor, M.S., Teasdale, R.D., Tomita, M.,  
Verardo, R., Wagner, L., Wahlestedt, C., Wang, Y., Watanabe, Y.,  
Wells, C., Wilming, L.G., Wynter-Borja, A., Yanagisawa, M., Yang, I.,  
Yang, L., Yuan, Z., Zavolan, M., Zhu, Y., Zimmer, A., Carninci, P.,  
Hayatsu, N., Hirozane-Kishikawa, T., Konno, H., Nakamura, M.,  
Sakazume, N., Sato, K., Shiraki, T., Waki, K., Kawai, J., Aizawa, K.,  
Arakawa, T., Fukuda, S., Hara, A., Hashizume, W., Imotani, K., Ishii, Y.,  
Itoh, M., Kagawa, I., Miyazaki, A., Sakai, K., Sasaki, D., Shibata, K.,  
Shinagawa, A., Yasunishi, A., Yoshino, M., Waterston, R., Lander, E.S.,  
Rogers, J., Birney, E. and Hayashizaki, Y.  
Analysis of the mouse transcriptome based on functional annotation  
of 60,770 full-length cDNAs  
Nature 420, 563-573 (2002)  
22354683  
12466851  
Contact: Yoshihide Hayashizaki  
Laboratory for Genome Exploration Research Group, RIKEN Genomic  
Sciences Center (GSC), Yokohama Institute  
The Institute of Physical and Chemical Research (RIKEN)  
1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan  
Tel: 81-45-503-9222  
Fax: 81-45-503-9216  
Email: genome.res@gsc.riken.go.jp/  
URL: <http://genome.gsc.riken.go.jp/>  
Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Carninci, P.,  
Fukuda, S., Hashizume, W., Hayashida, K., Hirozane, T., Hori, F.,  
Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kawai, J., Kojima, Y.,  
Kondo, S., Konno, H., Koya, S., Miyazaki, A., Murata, M., Nakamura, M.,  
Numura, K., Numazaki, R., Ohno, M., Ohsato, N., Saito, R., Sakazume, N.,  
Sano, H., Sasaki, D., Sato, K., Shibata, K., Shiraki, T., Tagami, M.,  
Takeda, Y., Waki, K., Watabiki, A., Muramatsu, M. and Hayashizaki, Y.  
Direct Submission  
Computational Analysis of Full-Length Mouse cDNAs Compared with  
Human Genome Sequences Mamm. Genome. 12, 673-677 (2001)  
Normalization and subtraction of cap-trapper-selected cDNAs to  
prepare full-length cDNA libraries for rapid discovery of new  
genes. Genome Res. 10 (10), 1617-1630 (2000)  
RIKEN integrated sequence analysis (RISA) system--384-Format  
sequencing pipeline with 384 multicapillary sequencer. Genome Res.  
10 (11), 1757-1771 (2000)  
Computer-based methods for the mouse full-length cDNA  
encyclopedia: real-time sequence clustering for construction of a  
nonredundant cDNA library. Genome Res. 11 (2), 281-289 (2001)



**This Page Blank (uspto)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 11:15:59 ; Search time 2398.28 Seconds  
(without alignments)  
10698.960 Million cell updates/sec

Title: US-09-830-321A-4  
Perfect score: 592  
Sequence: 1 tctgctccactgctctgtg.....ccagcctcccggaacc 592

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl.\*

- 1: gb.ba.\*
- 2: gb.htg.\*
- 3: gb.in.\*
- 4: gb.om.\*
- 5: gb.ov.\*
- 6: gb.pat.\*
- 7: gb.ph.\*
- 8: gb.pl.\*
- 9: gb.pr.\*
- 10: gb.ro.\*
- 11: gb.sts.\*
- 12: gb.sy.\*
- 13: gb.un.\*
- 14: gb.vi.\*
- 15: em.ba.\*
- 16: em.fun.\*
- 17: em.hum.\*
- 18: em.in.\*
- 19: em.mu.\*
- 20: em.om.\*
- 21: em.or.\*
- 22: em.ov.\*
- 23: em.pat.\*
- 24: em.ph.\*
- 25: em.pl.\*
- 26: em.ro.\*
- 27: em.sts.\*
- 28: em.un.\*
- 29: em.vi.\*
- 30: em.htg.hum.\*
- 31: em.htg.inv.\*
- 32: em.htg.other.\*
- 33: em.htg.mus.\*
- 34: em.htg.pln.\*
- 35: em.htg.rod.\*
- 36: em.htg.mam.\*
- 37: em.htg.vrt.\*
- 38: em.sy.\*
- 39: em.htgo.hum.\*
- 40: em.htgo.mus.\*
- 41: em.htgo.other.\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	592	100.0	878	9	AF112982	AF112982 Homo sapi
2	590.4	99.7	1938	9	AF188625	AF188625 Homo sapi
3	579.4	97.9	2747	9	BC025706	BC025706 Homo sapi
4	296	50.0	1233	6	E37214	E37214 Mouse secre
5	296	50.0	1233	10	AF112983	AF112983 Mus muscu
6	296	50.0	1975	10	AF169407	AF169407 Mus muscu
7	296	50.0	2166	10	AF169408	AF169408 Mus muscu
8	284.2	48.0	496	6	AX464400	AX464400 Sequence
9	284.2	48.0	496	6	AX697309	AX697309 Sequence
10	284.2	48.0	496	6	AX358606	AX358606 Homo sapi
11	282.8	47.8	904	10	AF124374	AF124374 Mus muscu
12	272	45.9	98743	9	AL158172	AL158172 Human DNA
13	268.8	45.4	501	6	E37202	E37202 Mouse secre
14	133.8	22.6	760	10	CP11PH42	X82631 C.porcellus
15	119.6	20.2	1016	6	AR274880	AR274880 Sequence
16	119.6	20.2	1016	9	HSU03090	U03090 Homo sapien
17	119.6	20.2	1155	9	BC036792	BC036792 Homo sapi
18	118	19.9	1014	6	AR081996	AR081996 Sequence
19	118	19.9	1014	6	AR198392	AR198392 Sequence
20	118	19.9	1871	9	AK097693	AK097693 Homo sapi
21	114.8	19.4	8439	10	AF188624	AF188624 Mus muscu
22	114.8	19.4	158310	2	BX294108	BX294108 Mus muscu
23	114.8	19.4	186608	10	AL844178	AL844178 Mouse DNA
24	114.4	19.3	690	10	SHA251361	AJ251361 Mesocrice
25	112.4	19.0	479	6	A23025	A23025 PLA2 HGH ge
26	112.4	19.0	479	6	I23845	I23845 Sequence 9
27	110.8	18.7	854	6	I09230	I09230 Sequence 34
28	110.8	18.7	854	6	AR380662	AR380662 Sequence
29	110.8	18.7	854	6	AX337559	AX337559 Sequence
30	110.8	18.7	854	6	AX587679	AX587679 Sequence
31	110.8	18.7	854	9	HUMRASAB	M22430 Human RASF-
32	110.8	18.7	997	9	BC005919	BC005919 Homo sapi
33	110.8	18.7	1116	6	AX015387	AX015387 Sequence
34	110.8	18.7	1116	6	BD194533	BD194533 Human nuc
35	110.8	18.7	1268	6	AX015532	AX015532 Sequence
36	110.8	18.7	1268	6	BD194580	BD194580 Human nuc
37	109.8	18.5	150638	2	AC129994	AC129994 Rattus no
38	109.8	18.5	222086	2	AC106106	AC106106 Rattus no
39	109.8	18.5	239739	2	AC116054	AC116054 Rattus no
40	109.8	18.5	282515	2	AC118094	AC118094 Rattus no
41	109.2	18.4	854	6	AX202112	AX202112 Sequence
42	105.4	17.8	758	10	RATPPLA2A	M25148 Rat phospho
43	105	17.7	906	10	AF166099	AF166099 Mus muscu
44	104.8	17.7	1445	10	MMU18119	U18119 Mus musculu
45	104.8	17.7	1480	10	BC029347	BC029347 Mus muscu

# ALIGNMENTS

RESULT 1  
AF112982  
LOCUS AF112982 Homo sapiens group IID secretory phospholipase A2 (PLA2) mRNA, PRI 30-AUG-1999  
DEFINITION AF112982 complete cds.  
ACCESSION AF112982  
VERSION AF112982.1 GI:5771419  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 878)  
AUTHORS Ishizaki,J., Suzuki,N., Higashino,K., Yokota,Y., Ono,T., Kawamoto,K., Fujii,N., Arita,H. and Hanasaki,K.

```

TITLE      Cloning and characterization of novel mouse and human secretory
JOURNAL    phospholipase A2(s), 24973-24979 (1999)
MEDLINE    J. Biol. Chem. 274 (35), 24973-24979 (1999)
PUBMED     99386983
REFERENCE  10455175
AUTHORS    2 (bases 1 to 878)
           Iahizaki,J., Suzuki,N., Higashino,K. and Hanaeaki,K.
TITLE      Direct Submission
JOURNAL    Submitted (11-DEC-1998) Shionogi Research Laboratories,
           Fukushima-ku, Sagisu 5-12-4, Osaka 553-0002, Japan
FEATURES   Location/Qualifiers
            source
              1..878
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
            gene
              1..878
            CDS
              29..466
                /gene="PLA2"
                /note="PLA2"
                /codon_start=1
                /product="group IID secretory phospholipase A2"
                /protein_id="AAD51390.1"
                /db_xref="GI:5771420"
                /translation="MELALLCGLVVMAGVPIQGGILNLMKVKQVTGRMPILSYWYP
                GCHCGLGGRGPKDATMCCOHDCCYDLKTKGGIVKDYRYNFSQGNHCSDKGS
                WCEQQLCACDREVAFLKRLNLTQKRLRFYWRPHCRGQTGPGC"
            variation
              266
                /gene="PLA2"
                /note="results in glycine to serine substitution"
                /replace="a"

ORIGIN
Query Match      100.0%; Score 592; DB 9; Length 878;
Best Local Similarity 100.0%; Pred. No. 2.3e-139;
Matches 592; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1  TCTGCCTCCACGCTGCTGTGGGATCATGAACTTGCACTGCTGTGTGGGCTGTGTGT 60
DB      1  TCTGCCTCCACGCTGCTGTGGGATCATGAACTTGCACTGCTGTGTGGGCTGTGTGT 60

QY      61  GATGGCTGTGTGATTCCAATCCAGGGCGGGATCTGAACTTGAACCAAGATGGTCAAGCA 120
DB      61  GATGGCTGTGTGATTCCAATCCAGGGCGGGATCTGAACTTGAACCAAGATGGTCAAGCA 120

QY      121  AGTGAATGGGAAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACCTGGGACTAGG 180
DB      121  AGTGAATGGGAAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACCTGGGACTAGG 180

QY      181  TGGCAGAGGCCAACCCAAAGATGCCAGACTGGTGTGCGAGACCCATGACTGTGCTTA 240
DB      181  TGGCAGAGGCCAACCCAAAGATGCCAGACTGGTGTGCGAGACCCATGACTGTGCTTA 240

QY      241  TGACCACTTGAAGACCCAGGGGTGGCGATCTACAAGGACTATTACAGATACAACTTTTC 300
DB      241  TGACCACTTGAAGACCCAGGGGTGGCGATCTACAAGGACTATTACAGATACAACTTTTC 300

QY      301  CCAGGGGAACATCCACTGCTCTGACAGGGGAAGCTGTGTGACAGCAGCTGTGCGCTTG 360
DB      301  CCAGGGGAACATCCACTGCTCTGACAGGGGAAGCTGTGTGACAGCAGCTGTGCGCTTG 360

QY      361  TGACAAGGAGGTGGCCCTTCTGCTTGAAGCGCAACCTTGAACCTTACCAGAAGCGACTGG 420
DB      361  TGACAAGGAGGTGGCCCTTCTGCTTGAAGCGCAACCTTGAACCTTACCAGAAGCGACTGG 420

QY      421  TTTCTACTGCGGCGCCCACTGCGGGGGAGAGCCCTGGTGTGTAGAGCCCAACCCCTC 480
DB      421  TTTCTACTGCGGCGCCCACTGCGGGGGAGAGCCCTGGTGTGTAGAGCCCAACCCCTC 480

QY      481  TACCTGTTCCTCAGCATGAGCTCTGGCATCCCCACCTCAGTATCTAACTGAACACGAG 540
DB      481  TACCTGTTCCTCAGCATGAGCTCTGGCATCCCCACCTCAGTATCTAACTGAACACGAG 540

```

```

QY      541  CTGCTTTTCAACACATCCCGGGGGAGGTAGTCCACGCTCCCGGAACCC 592
DB      541  CTGCTTTTCAACACATCCCGGGGGAGGTAGTCCACGCTCCCGGAACCC 592

RESULT 2
AF188625      1938 bp mRNA linear PRI 28-AUG-2000
LOCUS        Homo sapiens phospholipase A2 (SPLASH) mRNA, complete cds.
DEFINITION   AF188625
ACCESSION    AF188625
VERSION      AF188625.1 GI:6453792
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1938)
AUTHORS      Shakhov,A.N., Rubtsov,A.V., Lyakhov,I.G., Tumanov,A.V. and
              Nedospasov,S.A.
TITLE        SPLASH (PLA2IID), a novel member of phospholipase A2 family, is
              associated with lymphotoxin deficiency
JOURNAL      Genes Immun. 1 (3), 191-199 (2000)
MEDLINE      21040292
PUBMED       11196711
AUTHORS      Shakhov,A.N., Rubtsov,A.V., Lyakhov,I.G., Tumanov,A.V. and
              Nedospasov,S.A.
TITLE        Direct Submission
JOURNAL      Submitted (20-SEP-1999) Laboratory of Molecular Immunoregulation,
              IRSP, SAIC, NCI-FCRDC, P.O. Box B, Frederick, MD 21702, USA
FEATURES     Location/Qualifiers
              1..1938
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /chromosome="1"
                /map="1q35"
              1..1938
                /gene="SPLASH"
                /note="PLA2IID; similar to Mus musculus phospholipase A2"
              37..474
                /codon_start=1
                /product="phospholipase A2"
                /protein_id="AAF09020.1"
                /db_xref="GI:6453793"
                /translation="MELALLCGLVVMAGVPIQGGILNLMKVKQVTGRMPILSYWYP
                GCHCGLGGRGPKDATMCCOHDCCYDLKTKGGIVKDYRYNFSQGNHCSDKGS
                WCEQQLCACDREVAFLKRLNLTQKRLRFYWRPHCRGQTGPGC"

ORIGIN
Query Match      99.7%; Score 590.4; DB 9; Length 1938;
Best Local Similarity 99.8%; Pred. No. 5.7e-139;
Matches 591; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1  TCTGCCTCCACGCTGCTGTGGGATCATGAACTTGCACTGCTGTGTGGGCTGTGTGT 60
DB      9  TCTGCCTCCACGCTGCTGTGGGATCATGAACTTGCACTGCTGTGTGGGCTGTGTGT 68

QY      61  GATGGCTGTGTGATTCCAATCCAGGGCGGGATCTGAACTTGAACCAAGATGGTCAAGCA 120
DB      69  GATGGCTGTGTGATTCCAATCCAGGGCGGGATCTTGAACCTGAAACAGATGGTCAAGCA 128

QY      121  AGTGAATGGGAAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACCTGGGACTAGG 180
DB      129  AGTGAATGGGAAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACCTGGGACTAGG 188

QY      181  TGGCAGAGGCCAACCCAAAGATGCCAGACTGGTGTGCGAGACCCATGACTGTGCTTA 240
DB      189  TGGCAGAGGCCAACCCAAAGATGCCAGACTGGTGTGCGAGACCCATGACTGTGCTTA 248

QY      241  TGACCACTTGAAGACCCAGGGGTGGCGATCTACAAGGACTATTACAGATACAACTTTTC 300

```

```

Db      249 TGACCACCTGAAGACCCAGGGGTGACAGCTCTACAAGGACTATTACAGATACAACTTTTC 308
QY      301 CCAGGGGAACATCCACTGCTCTGACAGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTG 360
Db      309 CCAGGGGAACATCCACTGCTCTGACAGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTG 368
QY      361 TGACAGGAGGTGGCTTCTGCTGTAAGCGCAACCTGGACACCTTACCAGAAAGCGACTGCG 420
Db      369 TGACAGGAGGTGGCTTCTGCTGTAAGCGCAACCTGGACACCTTACCAGAAAGCGACTGCG 428
QY      421 TTCTACTGCGGCGCCCACTGCGGGGGGAGACCCCTGGTGTGTAGAGCCACACCTC 480
Db      429 TTCTACTGCGGCGCCCACTGCGGGGGGAGACCCCTGGTGTGTAGAGCCACACCTC 488
QY      481 TACCCTGTTCTCAGCATGAGCTCTGGCAATCCCACTCCAGTATCTAACTGAACAGC 540
Db      489 TACCCTGTTCTCAGCATGAGCTCTGGCAATCCCACTCCAGTATCTAACTGAACAGC 548
QY      541 CTGGCTTTTCAACACTCGGGGGGAGGTAGTCCAGCCCTCCCGGAACCC 592
Db      549 CTGGCTTTTCAACACTCGGGGGGAGGTAGTCCAGCCCTCCCGGAACCC 600

RESULT 3
LOCUS   BC025706
DEFINITION Homo sapiens phospholipase A2, group IID, mRNA (cdna clone
ACCESSION BC025706
VERSION    BC025706.1 GI:19344000
KEYWORDS   MGC.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE 1 (bases 1 to 2747)
AUTHORS   Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,
Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,
Altshuler,S.F., Zeeberg,B., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,
Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,
Diatchenko,L., Marusina,K., Farmer,A.A., Rubin,G.M., Hong,L.,
Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,
Schectt,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,
Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J.,
Abramson,R.D., Mullahy,S.J., Bosak,S.A., McEwan,P.J.,
McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,
Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Rulyk,S.W.,
Villalon,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,
Sanchez,A., Whiting,M., Madan,A., Young,A.C., Rodrigues,S.,
Bouffard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D.,
Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,
Butterfield,Y.S., Krzywinski,M.I., Skalska,U., Smallus,D.E.,
Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
JOURNAL   12477932
MEDLINE   2
PUBMED    2 (bases 1 to 2747)
AUTHORS   Strausberg,R.
DIRECT SUBMISSION
TITLE     Submitted (06-MAR-2002) National Institutes of Health, Mammalian
JOURNAL   Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK    NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT   Contact: MGC help desk
Email: cgabs-remail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: National Institutes of Health Intramural

```

Sequencing Center (NISC),  
Gaithersburg, Maryland;  
Web site: <http://www.nisc.nih.gov/>  
Contact: [nisc\\_mgc@nhri.nih.gov](mailto:nisc_mgc@nhri.nih.gov)  
Akhter, N., Ayele, K., Beckstrom-Sternberg, S.M., Benjamin, B.,  
Blakesley, R.W., Bouffard, G.G., Breen, K., Brinkley, C., Brooks, S.,  
Dietrich, N.L., Granite, S., Guan, X., Gupta, J., Haghighi, P.,  
Hansen, N., Ho, S.-L., Karlins, E., Kwong, P., Laric, P., Legaspi, R.,  
Maduro, Q.L., Masiello, C., Maskeri, B., Mastrian, S.D., McCloskey, J.C.,  
McDowell, J., Pearson, R., Stantripop, S., Thomas, P.J., Touchman, J.W.,  
Tsurgeon, C., Vogt, J.L., Walker, M.A., Wetherby, K.D., Wiggins, L.,  
Young, A., Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAC Plate: 49 Row: m Column: 9  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 21314652.

## FEATURES

```

Location/Qualifiers
1..2747
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:34386 IMAGE:5223912"
/tissue_type="Pancreas, Spleen, adult pooled"
/clone_lib="NIH_MGC_120"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"
Gene
1..2747
/gene="PLA2G2D"
/note="synonyms: SPLASH, SPLA2S"
/db_xref="LocusID:26279"
/db_xref="MIM:605630"
18..455
/codon_start=1
/product="phospholipase A2, group IID"
/protein_id="AAH25706.1"
/db_xref="GI:19344001"
/translation="MELALLGLVYVAGVIQGGILNKNMKVQVTRMPILSYWYF
GCHCLGGRQPKDATWCCTHDCYDLKTCGSIYKDYRYNFSQGNHCSKGS
WCEQLCACDKEVAFCLXRLNLDYQKRLFYWRPHCRQTGPG"
78..386
/note="Phoslip; Region: Phospholipase A2. Phospholipase A2
releases fatty acids from the second carbon group of
glycerol. Perhaps the best known members are secreted
snake venoms, but also found in secreted pancreatic and
membrane-associated forms. Structure is all-alpha, with
two core disulfide-linked helices and a calcium-binding
loop. This alignment represents the major family of PLA2s.
A second minor family, defined by the honeybee venom PLA2
PDB:1POC and related sequences from Gila monsters
(Heloderma), is not recognized. This minor family
conserves the core helix pair but is substantially
different elsewhere"
/db_xref="CDD:pfam00068"
misc_feature

```

## ORIGIN

```

Query Match      97.9%; Score 579.4; DB 9; Length 2747;
Best Local Similarity 99.8%; Pred. No. 3.5e-136;
Matches 580; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      12 TGCTCTGTCTGGGAATCATGGAATTGCATCTGTGTGGGCTGTGTGTGTGTGTGTGTGTGTG 71
Db      1  TGCTCTGTCTGTGGGATCATGGAATTGCATCTGTGTGGGCTGTGTGTGTGTGTGTGTGTG 60

QY      72 TGATTCCAATCCAGGGGGGAGTCTCTGACCTGAACAGATGGTCAAGCAAGTCAATGGGA 131
Db      61 TGATTCCAATCCAGGGGGGAGTCTCTGAACTGAACAGATGGTCAAGCAAGTCAATGGGA 120

QY      132 AAATGCCCATCTCTCTCTACTTGGCCCTACGCTCTGCTCGGACTAGGTGGCAGAGGCC 191
Db      121 AAATGCCCATCTCTCTCTACTTGGCCCTACGCTCTGCTCGGACTAGGTGGCAGAGGCC 180

```





```

ORIGIN
Query Match          50.0%; Score 296; DB 10; Length 1233;
Best Local Similarity 77.5%; Pred. No. 2.7e-64;
Matches 372; Conservative 0; Mismatches 105; Indels 3; Gaps 1;

QY 2 CTGCTCCACTGCTGTGTGGGATCATGGAACCTTGCACTGTGTGTGGCTGGTGGT 61
Db 9 CTGCTCGCTTGTCTCTGGGCTGGAACCTATGAGACTCGCCCTGTGTGTGGCTGTC-- 66
QY 62 ATGGCTGTGTGATTCATCCAGGGGGGATCCTGAACTCTGAACTGAAAGATGGTCAAGCAA 121
Db 67 -TGGCCGGTATAACTGCAACCCAGGGAGGCTCTGAACTGAACTGAAAGATGGTCAACAC 125
QY 122 GTGACTGGGAAAATGCCATCTCTCTACTGTGCCCTACGGCTGTCACTGCGGACTAGGT 191
Db 126 ATGACGGGGAAGAAAGCCCTTCTCAGTACTGTGCCCTACGGCTGTCACTGAGACTGGT 185
QY 182 GGCAGAGGCCAACCCCAAGATGCCAGGACTGTGTGCTGTCAGAACCTATGTTGCTAT 241
Db 186 GGCAGAGGCCAACCCCAAGATGCCAGGACTGTGTGCTGTCAGAACCTATGTTGCTAT 245
QY 242 GACCACTCAAGACCCAGGGGTGCGGCATCTCAAGGACTATTAAGATACAACTTTTCC 301
Db 246 GCCACCTCAAGATCGATGGATGCAAGAGCCTGACAGCAAACTTACAAATACAGCATCTCC 305
QY 302 CAGGGGAACATCCTGCTCTGACAGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTCT 361
Db 306 CAGGGCACTATCCAGTGTCTGACAAAGGAGCTGTGTGAGGCACTGTGTGCTCT 365
QY 362 GACAGAGGAGTGGCTTCTGCTGAGAGCGCAACCTGGACACCTTACCAGAGGAGTGGCT 421
Db 366 GACAGAGGAGTGGCTTCTGCTGAGAGCAAACTGGATAGCTACAAATAGCGCTGCT 425
QY 422 TTCTACTGCGGCCCACTGCGGGGAGAGCCCTGGGTGTAGAGCCCAACCTCT 481
Db 426 TACTACTGCGGCCCGGTGTCAGAGCAAGGAGTCCAGCATGCTTAAGGGAGTCCACTCTGT 485

RESULT 6
AF169407 1975 bp mRNA linear ROD 13-MAR-2000
Mus musculus phospholipase A2 (splash) mRNA, complete cds; nuclear
gene for mitochondrial product.
ACCESSION AF169407
VERSION AF169407.1 GI:7230429
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus (house mouse)
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Shakhov, A.N., Rubtsov, A.V., Lyakhov, I.G., Tumanov, A.V. and
Nedospasov, S.A.
TITLE SPLASH (PLA2iID), a novel member of phospholipase A2 family, is
JOURNAL associated with lymphotoxin deficiency
MEDLINE Genes Immun. 1 (3), 191-199 (2000)
PUBMED 11196711
REFERENCE 2 (bases 1 to 1975)
AUTHORS Shakhov, A.N., Rubtsov, A., Lyakhov, I.G. and Nedospasov, S.A.
TITLE Direct Submission
JOURNAL Submitted (16-JUL-1999) Laboratory of Molecular Immunoregulation,
IRSP, SAIC, NCI-PCRDC, Sultan Str. 560, Frederick, MD 21702, USA
FEATURES Location/Qualifiers
SOURCE 1..1975
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 x C57/B6"
/db_xref="taxon:10090"
/chromosome="4"
/map="between D4Mit158 and D4Mit283"

gene
CDS
1..1975
/gene="Splash"
80..514
/gene="Splash"
/note="SPLASH"
/codon_start=1
/product="phospholipase A2"
/db_xref="GI:7230430"
/db_xref="GI:7230430"
/translation="MRLALLCGLLLAGITATQGLLNLMNMVTHMTGKKAFFSYWYVG
CHCGLGGQPKDADTWCCQKHDCVVAHLKIDGCKSLTDNYKYSIQGTIQCDNSGW
CBRQLCACDKKVALCLKQLNDSYNKRLRYWRPRCKGKTPAC"
repeat_region 181..1975
/note="B1 repeat"

ORIGIN
Query Match          50.0%; Score 296; DB 10; Length 1975;
Best Local Similarity 77.5%; Pred. No. 2.6e-64;
Matches 372; Conservative 0; Mismatches 105; Indels 3; Gaps 1;

QY 2 CTGCTCCACTGCTGTGTGGGATCATGGAACCTTGCACTGTGTGTGGCTGGTGGT 61
Db 53 CTGCTCGCTTGTCTCTGGGCTGGAACCTATGAGACTCGCCCTGTGTGTGGCTGTC-- 110
QY 62 ATGGCTGTGTGATTCATCCAGGGGGGATCCTGAACTCTGAACTGAAAGATGGTCAAGCAA 121
Db 111 -TGGCCGGTATAACTGCAACCCAGGGAGGCTCTGAACTGAACTGAAAGATGGTCAACAC 169
QY 122 GTGACTGGGAAAATGCCATCTCTCTACTGTGCCCTACGGCTGTCACTGCGGACTAGGT 181
Db 170 ATGACGGGGAAGAAAGCCCTTCTCAGTACTGTGCCCTACGGCTGTCACTGAGACTGGT 229
QY 182 GGCAGAGGCCAACCCCAAGATGCCAGGACTGTGTGCTGTCAGAACCTATGTTGCTAT 241
Db 230 GGCAGAGGCCAACCCCAAGATGCCAGGACTGTGTGCTGTCAGAACCTATGTTGCTAT 289
QY 242 GACCACTCAAGACCCAGGGGTGCGGCATCTCAAGGACTATTAAGATACAACTTTTCC 301
Db 290 GCCACCTCAAGATCGATGGATGCAAGAGCCTGACAGCAAACTTACAAATACAGCATCTCC 349
QY 302 CAGGGGAACATCCTGCTCTGACAGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTCT 361
Db 350 CAGGGCACTATCCAGTGTCTGACAAAGGAGCTGTGTGAGGCACTGTGTGCTCT 409
QY 362 GACAGAGGAGTGGCTTCTGCTGAGAGCGCAACCTGGACACCTTACCAGAGGAGTGGCT 421
Db 410 GACAGAGGAGTGGCTTGTGTGAGGCAAACTGGATAGCTACAAATAGGGCTGCT 469
QY 422 TTCTACTGCGGCCCACTGCGGGGAGAGCCCTGGGTGTAGAGCCCAACCTCT 481
Db 470 TACTACTGCGGCCCGGTGTCAGAGCAAGGAGTCCAGCATGCTTAAGGGAGTCCACTCTGT 529

RESULT 7
AF169408 2166 bp mRNA linear ROD 13-MAR-2000
Mus musculus non-secreted phospholipase A2 (Splash) mRNA, complete
cds; nuclear gene for mitochondrial product.
ACCESSION AF169408
VERSION AF169408.1 GI:7230431
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus (house mouse)
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Shakhov, A.N., Rubtsov, A.V., Lyakhov, I.G., Tumanov, A.V. and
Nedospasov, S.A.
TITLE SPLASH (PLA2iID), a novel member of phospholipase A2 family, is
JOURNAL associated with lymphotoxin deficiency
MEDLINE Genes Immun. 1 (3), 191-199 (2000)
PUBMED 11196711

```

```

REFERENCE
AUTHORS 2 (bases 1 to 2166)
TITLE Shakhov A.N., Rubtsov A., Lyakhov, I.G. and Nedospasov, S.A.
JOURNAL Direct Submission
IRSP, SAIC, NCI-FCRDC, Sultan Str. 560, Frederick, MD 21702, USA
FEATURES
    Location/Qualifiers
        1..2166
            /organism="Mus musculus"
            /mol_type="mRNA"
            /strain="129 x C57/B6"
            /db_xref="taxon:10090"
            /chromosome="4"
            /map="between D4Mit158 and D4Mit283"
            1..2166
                /gene="Splash"
                /gene="Splash"
                /note="SPLASH"
                /codon_start=1
                /product="non-secreted phospholipase A2"
                /protein_id="AAFA2988.1"
                /db_xref="GI:7230432"
                /translation="MVHTMTGKKAPFFSWPGVCHGLGGKQPKDADTWCCQKHDDCY
                AHLKIDGCKSLTDNKKYSISQGTTCSDNGSWCERQLCACDKVALCDKQMLDSINKR
                LRYVWRPRCKGKTPAC"
ORIGIN
Query Match 50.0%; Score 296; DB 10; Length 2166;
Best Local Similarity 77.5%; Pred. No. 2.6e-64;
Matches 372; Conservative 0; Mismatches 105; Indels 3; Gaps 1;
QY 2 CTGCTCCACCTGCTGTGGGATCATGGAACCTGCACTGCTGTGGGCTGTGGTG 61
Db 53 CTGCTGCTGTGCTGTGGGCTGGAATGAGACTGCGCTGCTGTGGGCTGTGC-- 110
QY 62 ATGGCTGTGTGATTCATCAATCAGGCGGGATCTCTGAACCTGAAACAAGATGTCAAGCA 121
Db 111 -TGGCGGTATAACTGCAACCCAGGAGGGCTCTTGAACCTGAAACAAGATGTCAACAC 169
QY 122 GTGACTGGGAAATGCCCATCTCTTACTGGCCCTAGGCTGTCACCTGCGGACTAGT 181
Db 170 ATGACGGGGAAGAAAGCCCTTCTACGCTACTGGCCCTACGGCTGTCACCTGTGGT 229
QY 182 GGCAGAGGCAACCAAGATGCGAGCTGTGTCGACAGCCATGACTGCTGCTAT 241
Db 230 GSCAAGGCAACCAAGATGCCAGACTGGTGTGTCAGAGCATGATTGTGCTAT 289
QY 242 GACCACTGAAGACCAAGCGGGTGGGATCTTCAAGGACTATTACAGTACAACTTTCC 301
Db 290 GCCCACTGAAGATCGATGGATGCAAGAGCCTGACAGCAACTACAAATACAGCATCTCC 349
QY 302 CAGGGGAACATCCACTGCTTGCAGAGGAAGCTGTGAGCAGCTGTGCTGT 361
Db 350 CAGGGCACTATCCAGTGTCTGACAAACGGAGCTGTGTGAAGCACTGTGTGTGT 409
QY 362 GACAAAGAGTGGCTTCTGCTTGAAGCGCAACCTGCAACCTTACAGAGGCACTGCT 421
Db 410 GACAAAGAGTGGCTTGTGCTTGAAGCAACCTGATAGCTTACAAAGAGCTGTGCT 469
QY 422 TTCTACTGGCGGCCCACTGCGGGGGCAGACCCCTGGGTGTAGAGCCCAACCTCT 481
Db 470 TACTACTGGCGGCCCGCTTGCAAGGCAAGACTCCAGCATGCTTAAGGAGTCCACTCTGT 529
RESULT 8
AX464400
LOCUS Sequence 533 from Patent WO0140466. linear PAT 16-JUL-2002
DEFINITION
ACCESSION AX464400
VERSION AX464400.1 GI:21899216
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

```

```

REFERENCE
AUTHORS Rukaryota, Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Gao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0140466-A 533 07-JUN-2001;
Genentech Inc. (US)
FEATURES
    source
        1..496
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
ORIGIN
Query Match 48.0%; Score 284.2; DB 6; Length 496;
Best Local Similarity 97.3%; Pred. No. 2.7e-61;
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAATTCGACTGTGCTGTGGGCTGTGGT 60
Db 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAATTCGACTGTGCTGTGGGCTGTGGT 60
QY 61 GATGCTGTGTGATTCCAATCCAGGCGGATCTGAACTGAAACAAGATGGTCAAGCA 120
Db 61 GATGCTGTGTGATTCCAATCCAGGCGGATCTGAACTGAAACAAGATGGTCAAGCA 120
QY 121 AGTGCTGGGAAATGCCATCTCTTACTGCGCTTACGCTTACGCTTACGCTTACGCT 180
Db 121 AGTGCTGGGAAATGCCATCTCTTACTGCGCTTACGCTTACGCTTACGCTTACGCT 180
QY 181 TGGCAGAGGCGCAACCAAGATGCGAGCTGTGCTGCCAGACCCATGCTGTGCTA 240
Db 181 TGGCAGAGGCGCAACCAAGATGCGAGCTGTGCTGCCAGACCCATGCTGTGCTA 240
QY 241 TGACCACCTGAAGACCCAGGGGTGGGATCTTACAGGACTATTACAGTACACTT 297
Db 241 TGACCACCTGAAGACCCAGGGGTGGGATCTTACAGGACTATTACAGGACTATTAC 297
RESULT 9
AX697309
LOCUS Sequence 377 from Patent WO078961. linear PAT 02-APR-2003
DEFINITION
ACCESSION AX697309
VERSION AX697309.1 GI:29498451
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE
AUTHORS Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Desnoyers, L.,
Eaton, D.L., Gao, W.Q., Pan, J., Botstein, D., Fong, S., Goddard, A.,
Godowski, P.J., Gurney, A.L., Smith, V., Tumas, D., Wood, W.L.,
Grimaldi, C.J., Hillan, K.J., Paoni, N.F., Roy, M.A. and Watanabe, C.K.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
the same
JOURNAL Patent: WO 0078961-A 377 28-DEC-2000;
Genentech Inc. (US)
FEATURES
    source
        1..496
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
ORIGIN
Query Match 48.0%; Score 284.2; DB 6; Length 496;
Best Local Similarity 97.3%; Pred. No. 2.7e-61;
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```

QY 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAACATTGCACTGCTGTGCTGGCTGGTGGT 60  
 Db 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAACATTGCACTGCTGTGCTGGCTGGTGGT 60  
 QY 61 GATGGCTGGTGTGATTCCCAATCCAGGCGGGATCCCTGAACCTGAACAGATGCTCAAGCA 120  
 Db 61 GATGGCTGGTGTGATTCCCAATCCAGGCGGGATCCCTGAACCTGAACAGATGCTCAAGCA 120  
 QY 121 AGTGACTGGGAAATGCCCATCTCTCTACTGCGCCCTACGGCTGTCTACTGCGGACTAGG 180  
 Db 121 AGTGACTGGGAAATGCCCATCTCTCTACTGCGCCCTACGGCTGTCTACTGCGGACTAGG 180  
 QY 181 TGCGAGGCGCCACCAAGATGCCAGCTGGTGTGCTGCGACACCATGACTGTGCTGCTA 240  
 Db 181 TGCGAGGCGCCACCAAGATGCCAGCTGGTGTGCTGCGACACCATGACTGTGCTGCTA 240  
 QY 241 TGACCACTTGAGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACATT 297  
 Db 241 TGACCACTTGAGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACATT 297

RESULT 10  
 LOCUS AY358606 496 bp mRNA linear PRI 03-OCT-2003  
 DEFINITION Homo sapiens clone DNA76538 PLA2G2D (UNQ768) mRNA, complete cds.  
 ACCESSION AY358606  
 VERSION AY358606.1 GI:37182333  
 KEYWORDS FLI\_CDNA.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

REFERENCE  
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E., Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S., Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C., Stinson, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V., Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z., Goddard, A., Wood, W.I. and Godowski, P.

TITLE The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment  
 JOURNAL Genome Res. 13 (10), 2265-2270 (2003)  
 PUBMED 12975309  
 REFERENCE 2 (bases 1 to 496)  
 AUTHORS Clark, H.F.  
 TITLE Direct Submission  
 JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES  
 source  
 Location/Qualifiers  
 1..496  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="DNA76538"  
 1..496  
 /locus\_tag="UNQ768"  
 29..379  
 /locus\_tag="UNQ768"  
 /note="PRO1561"  
 /codon\_start=1  
 /product="PLA2G2D"  
 /protein\_id="AAQ88969.1"  
 /db\_xref="GI:37182334"  
 /translation="MELALLCGLVVMAGVPIQGGILNLNKNVQVTKGKPIISWYPY GCHGCGGKGPDKDATWCCTHDCYDHLKTQCGIYKONKSSIHCMDSIQYCLM AVFNVIYLENEDS"

gene  
 CDS  
 29..379  
 /locus\_tag="UNQ768"  
 /note="PRO1561"  
 /codon\_start=1  
 /product="PLA2G2D"  
 /protein\_id="AAQ88969.1"  
 /db\_xref="GI:37182334"  
 /translation="MELALLCGLVVMAGVPIQGGILNLNKNVQVTKGKPIISWYPY GCHGCGGKGPDKDATWCCTHDCYDHLKTQCGIYKONKSSIHCMDSIQYCLM AVFNVIYLENEDS"

ORIGIN  
 Query Match 48.0%; Score 284.2; DB 9; Length 496;

Best Local Similarity 77.3%; Pred. No. 6e-61;

Best Local Similarity 97.3%; Pred. No. 2.7e-61;  
 Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAACATTGCACTGCTGTGCTGGCTGGTGGT 60  
 Db 1 TCTGCTCCACTGCTGTGCTGGGATCATGGAACATTGCACTGCTGTGCTGGCTGGTGGT 60  
 QY 61 GATGGCTGGTGTGATTCCCAATCCAGGCGGGATCCCTGAACCTGAACAGATGCTCAAGCA 120  
 Db 61 GATGGCTGGTGTGATTCCCAATCCAGGCGGGATCCCTGAACCTGAACAGATGCTCAAGCA 120  
 QY 121 AGTGACTGGGAAATGCCCATCTCTCTACTGCGCCCTACGGCTGTCTACTGCGGACTAGG 180  
 Db 121 AGTGACTGGGAAATGCCCATCTCTCTACTGCGCCCTACGGCTGTCTACTGCGGACTAGG 180  
 QY 181 TGCGAGGCGCCACCAAGATGCCAGCTGGTGTGCTGCGACACCATGACTGTGCTGCTA 240  
 Db 181 TGCGAGGCGCCACCAAGATGCCAGCTGGTGTGCTGCGACACCATGACTGTGCTGCTA 240  
 QY 241 TGACCACTTGAGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACATT 297  
 Db 241 TGACCACTTGAGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACATT 297

RESULT 11  
 LOCUS AF124374 904 bp mRNA linear ROD 06-JUL-1999  
 DEFINITION Mus musculus group IID secreted phospholipase A2 (Pla2a2) mRNA, complete cds.  
 ACCESSION AF124374  
 VERSION AF124374.1 GI:5359707  
 KEYWORDS  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus

REFERENCE  
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 Valentini, E., Koduri, R.S., Scimeca, J.C., Carle, G., Gelb, M.H., Lazdunski, M. and Lambeau, G.

TITLE Cloning and recombinant expression of a novel mouse-secreted phospholipase A2  
 JOURNAL J. Biol. Chem. 274 (27), 19152-19160 (1999)  
 PUBMED 99315857  
 REFERENCE 2 (bases 1 to 904)

AUTHORS Valentini, E., Koduri, R.S., Scimeca, J.C., Carle, G., Gelb, M.H., Lazdunski, M. and Lambeau, G.  
 TITLE Direct Submission  
 JOURNAL Submitted (28-JAN-1999) CNRS, IPMC, Sophia Antipolis, 660 route des Lucioles, Valbonne 06560, France

FEATURES  
 source  
 Location/Qualifiers  
 1..904  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:10090"  
 /chromosome="4"  
 1..904  
 /gene="Pla2a2"  
 10..444  
 /gene="Pla2a2"  
 /EC\_number="3.1.1.4"  
 /note="Ca2+-dependent secreted phospholipase A2"  
 /product\_start=1  
 /product="group IID secreted phospholipase A2"  
 /protein\_id="AA042773.1"  
 /db\_xref="GI:5359708"  
 /translation="MRLALLCGLLAGITATQGLLNLNKNVHTMTGKKAFFSWPYG CHGCGGKGPDKDATWCCTHDCYDHLKTQCGIYKONKSSIQGTTICSDNGSW CERQLCACDKEVALCLKQNLDSYNKRLRYRPRCKGKTAC"

gene  
 CDS  
 1..904  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:10090"  
 /chromosome="4"  
 1..904  
 /gene="Pla2a2"  
 10..444  
 /gene="Pla2a2"  
 /EC\_number="3.1.1.4"  
 /note="Ca2+-dependent secreted phospholipase A2"  
 /product\_start=1  
 /product="group IID secreted phospholipase A2"  
 /protein\_id="AA042773.1"  
 /db\_xref="GI:5359708"  
 /translation="MRLALLCGLLAGITATQGLLNLNKNVHTMTGKKAFFSWPYG CHGCGGKGPDKDATWCCTHDCYDHLKTQCGIYKONKSSIQGTTICSDNGSW CERQLCACDKEVALCLKQNLDSYNKRLRYRPRCKGKTAC"

ORIGIN  
 Query Match 47.8%; Score 282.8; DB 10; Length 904;

Best Local Similarity 77.3%; Pred. No. 6e-61;





```

FEATURES             source
FT                  Location/Qualifiers
                     1..501
                     /organism="Mus musculus"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:10090"

ORIGIN
Query Match          45.4%; Score 268.8; DB 6; Length 501;
Best Local Similarity 77.7%; Pred. No. 2.2e-57;
Matches 324; Conservative 0; Mismatches 93; Indels 0; Gaps 0;

Qy 65 GCTGGTGTATCAATCCAGGGGGGATCTGTAACCTGAACAGAGAGGTCAAGATG 124
Db 1 GCGGNTATTAATCTGCAACCCAGGGGGGCTCTGAACCTGAACAGAGAGGTCAACATG 60

Qy 125 ACTGGGAAATGCCCATCTCTCTTACTGCGCCCTAGCGCTCTACTGCGGACTAGTGGC 184
Db 61 ACGGGGAAGAAGCCTTCTTCACTACTGCGCCCTACGGCTGTCACTGTGGACTTGGTGGC 120

Qy 185 AGAGGCCAACCAAGATGCCAGGACTGTGCTGCCAGACCCATGACTGTGCTATGAC 244
Db 121 AAAGGGCAACCAAGATGCCAGGACTGTGCTGCCAGACCCATGACTGTGCTATGAC 180

Qy 245 CACCTGAAGACCCAGGGGTGGGCACTTACAGAGACTATTACAGATACAACTTTTCCAG 304
Db 181 CACCTGAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 240

Qy 305 GGGAACTCCATCTCTGACAAAGGAAGCTGGTGTGAGCAGCAGCTGTGCTGCTGAC 364
Db 241 GGCACATCCAGTCTCTGACAAAGGAAGCTGGTGTGAGCAGCAGCTGTGCTGCTGAC 300

Qy 365 AAGGAGTGGCTTCTGCTGAGCGCAACCTGACACTTACCAGAGGAGCTGGCTTTC 424
Db 301 AAGGAGTGGCTTCTGCTGAGCGCAACCTGACACTTACCAGAGGAGCTGGCTTTC 360

Qy 425 TACTGCGCGCCCACTGCGGGGGGAGACCCCTGGGTGTAGAGCCCAACCCCTCT 481
Db 361 TACTGCGGGCCCCGTGTGAAAGCAGACTCCAGCATGCTAAGGGAGTCCACTCTGT 417

RESULT 14
CPIIPHA2          760 bp mRNA linear ROD 25-FEB-2003
LOCUS             C.porcillus mRNA for typeII phospholipase A2.
DEFINITION        X82631
ACCESSION          X82631
VERSION            GI:951010
KEYWORDS           phospholipase a2.
SOURCE             Cavia porcellus (domestic guinea pig)
ORGANISM           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE          Mammalia; Eutheria; Rodentia; Hystricognathi; Caviidae; Cavia.
AUTHORS            Vial,D., Senorale-Pose,M., Havet,N., Molio,L., Vargaftig,B.B. and
                    Touqui,L.
TITLE              Expression of the type-II phospholipase A2 in alveolar macrophages.
JOURNAL            Down-regulation by an inflammatory signal
MEDLINE            J. Biol. Chem. 270 (29), 17327-17332 (1995)
PUBMED            95340522
REFERENCE          2 (bases 1 to 760)
AUTHORS            Vial,D.
TITLE              Direct Submission
JOURNAL            Submitted (10-NOV-1994) D. Vial, Institut Pasteur, 25 rue du Dr.
                    Roux, 75015 Paris, FRANCE
                    Location/Qualifiers
                    1..760
                    /organism="Cavia porcellus"
                    /mol_type="mRNA"
                    /strain="Hartley"
                    /db_xref="taxon:10141"
                    /cell_type="alveolar macrophage"
                    /dev_stage="adult"

FEATURES             source
FT                  Location/Qualifiers
                     1..1016
                     /organism="unknown"

ORIGIN
Query Match          22.6%; Score 133.8; DB 10; Length 760;
Best Local Similarity 55.5%; Pred. No. 3.7e-23;
Matches 258; Conservative 0; Mismatches 207; Indels 0; Gaps 0;

Qy 26 ATCATGAACCTTGACACTGCTGTGGGCTGTGGTGTGATGGTGTGATTCATTCATCCAG 85
Db 51 AGCATGAAGCTCTCTCTGCTCTTCTGTGTGTGATGGCTCTGACTTGTCTCAAGCCAC 110

Qy 86 GCGGGATCTCGAATCTGAACCAAGATGTCTCAAGCAAGTGAAGTGGGAAATGCCATCCTC 145
Db 111 GGACACTTTGAAGCAATTCACAGAAATGATCAAGCTCACGACAGGAAAGATGGACTTACA 170

Qy 146 TCCTACTGGCCCTAGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 205
Db 171 AGTTATGGCCCTAGGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 230

Qy 206 ACGGACTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 265
Db 231 ACAGATAGTGTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 290

Qy 266 GGCATCTACAGGACTATTACAGATACAACTTTCCAGGGGAAACATCCACTGCTCTGAC 325
Db 291 GGCACGAAATTTCTGAACTTACCGCTTACCCATAAGGGGAGCTCGATCACTGCTGTA 350

Qy 326 AAGGGAAGCTGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 385
Db 351 AAGCAGAACTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 410

Qy 386 AAGCGCAACTCGACACCTTACCAGAGCGACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 445
Db 411 GCTGCAAACTGAAAGTTATAGCAGAAGTACCAGTTTATTATACAAATGGACTGTGCGC 470

Qy 446 GGCAGACCCCTGGGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 490
Db 471 GGGAGACCCCGAGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 515

RESULT 15
AR274880          1016 bp DNA linear PAT 10-APR-2003
LOCUS             Sequence 17 from patent US 6506607.
DEFINITION        AR274880
ACCESSION          AR274880
VERSION            AR274880.1 GI:29707430
KEYWORDS           Unknown.
SOURCE             Unclassified.
ORGANISM           Unidentified.
REFERENCE          1 (bases 1 to 1016)
AUTHORS            Shyjan,A.W.
TITLE              Methods and compositions for the identification and assessment of
                    prostate cancer therapies and the diagnosis of prostate cancer
JOURNAL            Patent: US 6506607-A 17 14-JAN-2003;
FEATURES             Location/Qualifiers
                    1..1016
                    /organism="unknown"

```

```

ORIGIN /mol_type="genomic DNA"
Query Match 20.2%; Score 119.6; DB 6; Length 1016;
Best Local Similarity 58.0%; Pred. No. 1.5e-19;
Matches 231; Conservative 0; Mismatches 164; Indels 3; Gaps 1;

QY 67 TGGTGTGATTCCAAATCCAGGCGGGATCTCTGAACCTGAACAAGATGGTCAAGCAAGTGAC 126
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
171 TAGTGTGCCTGCTGTGCAAGGAGGCTTGTGGACCTAAATCAATGATCGAGAAGTGAC 230
QY 127 TGGGAAATGCCCATCTCTCTACTTGGCCCTAGGCTGTCACTGCGGACTAGGTGGCAG 186
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
231 AGGGAAGAACGCCCTGACAAACTACGGCTTCTACGGCTGTACTGCGGCTGGGGCGGCCG 290
QY 187 AGGCCAACCCAAAGATGCCACGACTGGTGTGCCAGACCCATGACTGTGCTATGACCA 246
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
291 AGGAACCCCNAGGATGGCACCGATTGGTGTCTTGGGCGCATGACCACTGTCTATGGGCG 350
QY 247 CCTGAAGACCCAGGGGTGGGATCTCAAGGACTATTACAGATACAACTTTTCCCAAGG 306
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
351 GCTGGAGGAGAGGGGTGCAACATTCGCACACAGTCTCTACAAATACAGATTCGCGTGGGG 410
QY 307 GAACATCCACTGCTCTGACAAGGAGAGCTGGTGTGAGCAGCAGCTGTGTGCTGTGACAA 366
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
411 CGTGTACCTGC---GAGCCCGGGCCCTTCTGCCATGTGAACCTCTGTGCCTGTGACCG 467
QY 367 GGAGGTGGCCTTCTGCTGAAGCGCAACCTGGACACCTACCAAGACGACTGGTTTCTA 426
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
468 GAAGCTCGTCTACTGCTCAAGAGAAACCTACGGAGCTAACACCCACAGTACCAATACTT 527
QY 427 CTGGGGGCCCCACTGCGGGGGGACAGCCCTGGGTGCT 464
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
528 TCCCAACATCCTCTGCTCTAGGCCCTCCCGAGAGCT 565

```

Search completed: October 7, 2004, 16:43:29  
Job time : 2407.28 secs

**This Page Blank (uspio)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 11:14:15 ; Search time 251.748 Seconds  
(without alignments)  
9989.875 Million cell updates/sec

Title: US-09-830-321A-4  
Perfect score: 592  
Sequence: 1 ttgtcctccactgctctgtg.....ccagcctccccggaaccc 592

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues  
Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N Geneseq\_29Jan04.\*  
1: Geneseqn1980s.\*  
2: Geneseqn1990s.\*  
3: Geneseqn2000s.\*  
4: Geneseqn2001as.\*  
5: Geneseqn2001bs.\*  
6: Geneseqn2002s.\*  
7: Geneseqn2003as.\*  
8: Geneseqn2003bs.\*  
9: Geneseqn2003cs.\*  
10: Geneseqn2004s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	592	100.0	592	3	AAA53269
2	592	100.0	878	3	AAA60878
3	579.4	97.9	2747	7	ACC72857
4	575.4	97.2	854	4	AA514884
5	568.8	96.1	1927	4	AAH98759
6	568.8	96.1	1927	4	AAH99768
7	567.4	95.8	1931	5	AAH19218
8	296	50.0	1233	3	AAA60866
9	296	50.0	1233	3	AAA72076
10	284.2	48.0	496	3	AAA77684
11	284.2	48.0	496	4	AAF54466
12	284.2	48.0	496	4	AA521510
13	284.2	48.0	496	7	ACD24119
14	284.2	48.0	496	7	ACA67260
15	284.2	48.0	496	7	ACA03869
16	284.2	48.0	496	7	ASX89407
17	284.2	48.0	496	7	ACD42061
18	284.2	48.0	496	7	ACA04290
19	284.2	48.0	496	8	ADA46052
20	284.2	48.0	496	8	ADA76483
21	284.2	48.0	496	8	ADA19133
22	284.2	48.0	496	8	ADA61756
23	284.2	48.0	496	8	ADB19541

# ALIGNMENTS

RESULT 1  
AAA53269  
ID AAA53269 standard; cDNA; 592 BP.  
XX  
AC AAA53269;  
XX  
DT 05-OCT-2000 (first entry)  
XX  
DE Human phospholipase 1 HPPL1 coding sequence.  
XX  
KW Human; phospholipase 1; HPPL1; cancer; autoimmune disorder;  
KW inflammatory disorder; reproductive disorder; infection; ss.  
XX  
OS Homo sapiens.

Key Location/Qualifiers

CDS 29..466

FT /tag= a

FT /product= "HPPL1"

FT 29..91

FT /tag= b

FT /note= "this is a putative signal peptide"

FT 29..76

FT /tag= c

FT /note= "this is a putative signal peptide"

FT 77..463

FT /tag= d

FT /note= "this is a putative mature HPPL1"

FT 92..463

FT /tag= e

FT /note= "this is a putative mature HPPL1"

XX WO200024911-A2.

XX 04-MAY-2000.

XX 27-OCT-1999; 99WO-USQ25021.

XX 27-OCT-1998; 98US-00181317.

XX 21-JAN-1999; 99US-00234726.

XX (INCY-) INCYTE PHARM INC.

XX Hillman JL, Bandman O, Guegler KJ, Corley NC, Baughn MR;

XX Azimzai Y, Lal P, Lu DAM;

XX

24	284.2	48.0	496	8	ADB28082	Adb28082	cdna	enco
25	284.2	48.0	496	8	ADA86561	Ada86561	Novel	hum
26	284.2	48.0	496	8	ADB16125	Adb16125	Human	PRO
27	284.2	48.0	496	8	ADA47911	Ada47911	Human	PRO
28	284.2	48.0	496	8	ACD68505	Ac68505	Novel	hum
29	284.2	48.0	496	8	ADA67706	Ada67706	Human	PRO
30	284.2	48.0	496	8	ADB30713	Adb30713	cdna	enco
31	284.2	48.0	496	8	ADA86009	Ada86009	Novel	hum
32	284.2	48.0	496	8	ADA97221	Ada97221	Human	PRO
33	284.2	48.0	496	8	ADA79525	Ada79525	Human	PRO
34	284.2	48.0	496	8	ADA87664	Ada87664	Novel	hum
35	284.2	48.0	496	8	ADB16866	Adb16866	Human	PRO
36	284.2	48.0	496	8	ADA91958	Ada91958	Novel	hum
37	284.2	48.0	496	8	ADB15021	Adb15021	Human	PRO
38	284.2	48.0	496	8	ADA18982	Ada18982	Novel	hum
39	284.2	48.0	496	8	ADA94197	Ada94197	Human	PRO
40	284.2	48.0	496	8	ADB20093	Adb20093	Novel	hum
41	284.2	48.0	496	8	ADB13405	Adb13405	Human	PRO
42	284.2	48.0	496	8	ACD98690	Ac98690	Novel	hum
43	284.2	48.0	496	8	ADA74659	Ada74659	Human	PRO
44	284.2	48.0	496	8	ADB24892	Adb24892	Human	PRO
45	284.2	48.0	496	8	ADA82416	Ada82416	Human	PRO

DR WPI; 2000-350750/30.  
XX P-PSDB; AAB03627.

DR Human phospholipase genes and proteins useful to diagnose, prevent or  
XX treat cancer, autoimmune or inflammatory or reproductive disorders.  
PT  
PT  
XX  
PS Claim 9; Page 74; 80pp; English.

XX The present sequence is the coding sequence of human phospholipase 1  
CC (HPLI). The protein produced from this sequence is involved in the  
CC hydrolysis of membrane phospholipids. The protein and its coding sequence  
CC can be used to diagnose and treat the following: cancers such as  
CC prostate, breast and testicular cancers, autoimmune and inflammatory  
CC disorders, such as AIDS, allergies, anaemia, asthma, atherosclerosis,  
CC Crohn's disease, diabetes mellitus, emphysema, Graves' disease, irritable  
CC bowel syndrome, multiple sclerosis, myasthenia gravis, psoriasis, caused  
CC rheumatoid arthritis and systemic lupus erythematosus, infection caused  
CC by viruses, fungi, bacteria, parasites and protozoa, and reproductive  
CC disorders including infertility, disruptions of the menstrual cycle,  
CC polycystic ovary syndrome, ectopic pregnancies, disruptions of  
CC spermatogenesis, cancers within the reproductive tract and impotence.  
CC This coding sequence was obtained from clone no.2641779, which was  
XX constructed using lung tumour tissue

XX Sequence 592 BP; 126 A; 182 C; 165 G; 119 T; 0 U; 0 Other;  
XX  
XX Query Match 100.0%; Score 592; DB 3; Length 592;  
XX Best Local Similarity 100.0%; Pred. No. 2.9e-149;  
XX Matches 592; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGTCTGTCTGTGGATCATGGAACATTGCAGTTCGTGGTGTTGGT 60  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 1 TCTGCTCCACTGTCTGTCTGTGGATCATGGAACATTGCAGTTCGTGGTGTTGGT 60  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 61 GATGGCTGGTGTGANTCCATCCAGCGGGGATCCTGAACCTCAACAAGATGTCACGCA 120  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 61 GATGGCTGGTGTGANTCCATCCAGCGGGGATCCTGAACCTCAACAAGATGTCACGCA 120  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 121 AGTGACTGGGAAATGCCATCTCTCTACTGGCCCTACGGTGTCTACGGGACTAGG 180  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 121 AGTGACTGGGAAATGCCATCTCTCTACTGGCCCTACGGTGTCTACGGGACTAGG 180  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTCCAGACCACCATGCTGTCTA 240  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTCCAGACCACCATGCTGTCTA 240  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTTTC 300  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTTTC 300  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 301 CCAGGGGAACATCCACTGTCTGACAGGGAAGTGTGTGAGCAGCAGTGTGTGCTG 360  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 301 CCAGGGGAACATCCACTGTCTGACAGGGAAGTGTGTGAGCAGCAGTGTGTGCTG 360  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 361 TGACAGGAGGTGGCTTCTGCTTGAAGCGCAACTGGACACCTTACAGAGGAGCTGG 420  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 361 TGACAGGAGGTGGCTTCTGCTTGAAGCGCAACTGGACACCTTACAGAGGAGCTGG 420  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 421 TTCTTACTGGGGCCCCACTGCGGGGGGACAGCCCTGGGTGTAGAGGCCACACCTC 480  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 421 TTCTTACTGGGGCCCCACTGCGGGGGGACAGCCCTGGGTGTAGAGGCCACACCTC 480  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 481 TACCTGTTCCTCAGCATGGAGCTCTGGCATCCCACCTCAGTATCTAACTGAACCCAG 540  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 481 TACCTGTTCCTCAGCATGGAGCTCTGGCATCCCACCTCAGTATCTAACTGAACCCAG 540  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 541 CTGGCTTTTCAAACACTCCGGGGGAGTAGTCCAGGCTTCCCGGAAACC 592  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 541 CTGGCTTTTCAAACACTCCGGGGGAGTAGTCCAGGCTTCCCGGAAACC 592  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

AAA60878 standard; CDNA; 878 BP.

AAA60878;

02-NOV-2000 (first entry)

Human secretory phospholipase A2 nucleotide sequence SEQ ID NO:36.

Secretory phospholipase A2; PLA2; antiallergic; antiinflammatory;  
antibacterial; immunosuppressive; tranquiliser; vulnerary; antirheumatic;  
antiarthritic; septic shock; trauma; pancreatitis; allergic rhinitis;  
chronic rheumatoid arthritis, BS.

Homo sapiens.

Key Location/Qualifiers  
CDS 29..466 /\*tag= a /product= "secretory phospholipase A2 (PLA2) "  
sig\_peptide 29..88 /\*tag= b  
mat\_peptide 89..463 /\*tag= c

WO200034486-A1.

15-JUN-2000.

07-DEC-1999; 99WO-JP006844.

09-DEC-1998; 98JP-00349608.

(SHIO ) SHIONOGI & CO LTD.

Ishizaki J, Suzuki N, Hanasaki K;  
WPI; 2000-423429/36.  
P-PSDB; AAB12537.

Human secretory phospholipase A2 (PLA2) and its encoded gene for  
diagnosis and treatment of secretory PLA2-associated diseases e.g. septic  
shock, trauma, pancreatitis, allergic rhinitis and chronic rheumatoid  
arthritis.

Claim 5; Page 39-40; 45pp; Japanese.

The present invention describes human secretory phospholipase A2 (PLA2).  
PLA2 has antiallergic, antiinflammatory, antibacterial, tranquiliser,  
immunosuppressive, vulnerary, antirheumatic and antiarthritic activities  
Human secretory phospholipase A2 (PLA2), the gene encoding it and  
antibodies against it are useful for the diagnosis and treatment of  
secretory PLA2-associated diseases e.g. septic shock, trauma,  
pancreatitis, allergic rhinitis and chronic rheumatoid arthritis. The  
present sequence encodes human PLA2

Sequence 878 BP; 206 A; 257 C; 238 G; 177 T; 0 U; 0 Other;

Query Match 100.0%; Score 592; DB 3; Length 878;  
Best Local Similarity 100.0%; Pred. No. 3.3e-149;  
Matches 592; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGTCTGTCTGTGGATCATGGAACATTGCAGTTCGTGGTGTTGGT 60  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 1 TCTGCTCCACTGTCTGTCTGTGGATCATGGAACATTGCAGTTCGTGGTGTTGGT 60  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 61 GATGGCTGGTGTGANTCCATCCAGCGGGGATCCTGAACCTCAACAAGATGTCACGCA 120  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 61 GATGGCTGGTGTGANTCCATCCAGCGGGGATCCTGAACCTCAACAAGATGTCACGCA 120  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 121 AGTGACTGGGAAATGCCATCTCTCTACTGGCCCTACGGTGTCTACGGGACTAGG 180  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 121 AGTGACTGGGAAATGCCATCTCTCTACTGGCCCTACGGTGTCTACGGGACTAGG 180  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTCCAGACCACCATGCTGTCTA 240  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTCCAGACCACCATGCTGTCTA 240  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTTTC 300  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTTTC 300  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 301 CCAGGGGAACATCCACTGTCTGACAGGGAAGTGTGTGAGCAGCAGTGTGTGCTG 360  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 301 CCAGGGGAACATCCACTGTCTGACAGGGAAGTGTGTGAGCAGCAGTGTGTGCTG 360  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 361 TGACAGGAGGTGGCTTCTGCTTGAAGCGCAACTGGACACCTTACAGAGGAGCTGG 420  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 361 TGACAGGAGGTGGCTTCTGCTTGAAGCGCAACTGGACACCTTACAGAGGAGCTGG 420  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 421 TTCTTACTGGGGCCCCACTGCGGGGGGACAGCCCTGGGTGTAGAGGCCACACCTC 480  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
QY 421 TTCTTACTGGGGCCCCACTGCGGGGGGACAGCCCTGGGTGTAGAGGCCACACCTC 480  
Db | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

QY 481 TACCTGTTCCTCAGCATGGAGCTCTGGCATCCCACCTCAGTATCTAACTGAACCCAG 540  
Db | | | | | | |

QY 181 TGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCCAGACCATGACTGTGCTA 240  
Db |||||  
QY 181 TGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCCAGACCATGACTGTGCTA 240  
Db |||||  
QY 241 TGACCACTGAAGACCCAGGGTGGCGATCTACAGGACTATTACAGATACAACTTTTC 300  
Db |||||  
QY 241 TGACCACTGAAGACCCAGGGTGGCGATCTACAGGACTATTACAGATACAACTTTTC 300  
Db |||||  
QY 301 CCAGGGGAACATCCACTGCTCTGACAAGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTG 360  
Db |||||  
QY 301 CCAGGGGAACATCCACTGCTCTGACAAGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTG 360  
Db |||||  
QY 361 TGACAGAGGAGTGGCTTCTGCTGAGGAGCAACCTGGACACCTACCAAGACGACTGGG 420  
Db |||||  
QY 361 TGACAGAGGAGTGGCTTCTGCTGAGGAGCAACCTGGACACCTACCAAGACGACTGGG 420  
Db |||||  
QY 421 TTCTACTGGCGGCCCACTGCGGGGGCAGACCCCTGGTGTGAGCAGCAGCTGTGTGCTG 480  
Db |||||  
QY 421 TTCTACTGGCGGCCCACTGCGGGGGCAGACCCCTGGTGTGAGCAGCAGCTGTGTGCTG 480  
Db |||||  
QY 481 TACCCTGTCTCAGCATGGAGCTCTGGCATCCCACTCAGTATCTAACCTGAACACG 540  
Db |||||  
QY 481 TACCCTGTCTCAGCATGGAGCTCTGGCATCCCACTCAGTATCTAACCTGAACACG 540  
Db |||||  
QY 541 CTGGCTTTTCAACACTCGGGGGGAGGTAGTCCAGCCTCCCGGAAACCC 592  
Db |||||  
QY 541 CTGGCTTTTCAACACTCGGGGGGAGGTAGTCCAGCCTCCCGGAAACCC 592  
Db |||||

RESULT 3

ACCT2857  
ID ACCT2857 standard; cDNA; 2747 BP.  
XX  
AC ACCT2857;  
XX  
DT 09-JUL-2003 (first entry)  
XX  
DE Human cancer related protein encoding cDNA SEQ ID NO:195.  
XX  
KW Human; cancer; diagnosis; screening; modulator; leukaemia; ischaemia;  
KW heart disease; atherosclerosis; endometriosis; gene; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025138-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-US029560.  
XX  
PR 17-SEP-2001; 2001US-0323469P.  
PR 20-SEP-2001; 2001US-0323887P.  
PR 13-NOV-2001; 2001US-0350666P.  
PR 08-FEB-2002; 2002US-0355145P.  
PR 08-FEB-2002; 2002US-0355257P.  
PR 12-APR-2002; 2002US-0372246P.  
XX  
PA (EOSB-) EOS BIOTECHNOLOGY INC.  
XX  
PI Afar D, Aziz N, Gish KC, Hevezi PA, Mack DH, Wilson KE;  
PI Zlotnik A;  
XX  
XX WPI; 2003-354600/33.  
DR P-ESDB; ABR58706.  
XX

New Genes that are up-regulated or down-regulated in cancers, useful as markers for diagnosing e.g. cancer, ischemia or heart diseases, or as therapeutic targets for screening drugs for treating these diseases.

Claim 8; Page 733; 767pp; English.

The present invention describes an isolated nucleic acid molecule, which comprises the sequence of any of the genes that are up-regulated or down-

regulated in specific cancers (e.g. about 1031 genes up-regulated in acute lymphocytic leukemia). ACC72641 to ACC72860 represent cancer related gene nucleotide sequences which encode the proteins given in ABR58706. Also described: (1) determining the presence or absence of a pathological cell in a patient; (2) an expression vector comprising a nucleic acid molecule described above; (3) a host cell comprising the vector; (4) an isolated polypeptide, which is encoded by the nucleic acid; (5) an antibody that specifically binds the polypeptide of (4); (6) specifically targeting a compound to a pathological cell in a patient by administering to the patient the antibody above; and (7) a drug screening assay. The nucleic acid is useful as diagnostic markers or therapeutic targets. In particular, the nucleic acid is useful for diagnosing a pathology, e.g. cancer (e.g. cancer of the bone marrow, bladder, brain, breast, cervix, colon/rectum, kidney, lung, ovary, pancreas, prostate, skin and uterus), wounds, ischaemia, heart diseases, atherosclerosis and endometriosis. The nucleic acid is also useful in drug screening, particularly for identifying agents for treating these pathologies

XX  
SQ Sequence 2747 BP; 719 A; 762 C; 668 G; 598 T; 0 U; 0 Other;

Query Match 97.9%; Score 579.4; DB 7; Length 2747;  
Best Local Similarity 99.8%; Pred. No. 1.2e-145;  
Matches 580; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 12 TGCTCTGTGCTGGGATCATGGAACTTGCACTGCTGTGGGCTGGTGTGATGGTGTG 71  
Db 1 TGGCTCTGTGCTGGGATCATGGAACTTGCACTGCTGTGGGCTGGTGTGATGGTGTG 60  
QY 72 TGATTCCAAATCCAGGGGGGATCCCTGAACCTGAAAGATGCTCAAGCAAGTCTGGGA 131  
Db 61 TGATTCCAAATCCAGGGGGGATCCCTGAACCTGAAAGATGCTCAAGCAAGTCTGGGA 120  
QY 132 AAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGTGTGAGAGGCC 191  
Db 121 AAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGTGTGAGAGGCC 180  
QY 192 AACCCAAAGATGCCAGGACTGGTGTGCGAGACCCATGACTGTGCTATGACACCTGA 251  
Db 181 AACCCAAAGATGCCAGGACTGGTGTGCGAGACCCATGACTGTGCTATGACACCTGA 240  
QY 252 AGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGAACA 311  
Db 241 AGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGAACA 300  
QY 312 TCCACTGTCTTGACAAGGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTGTGACAAGGAGG 371  
Db 301 TCCACTGTCTTGACAAGGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTGTGACAAGGAGG 360  
QY 372 TGGCCTCTGCTGCTGAGCGCAACCTGGACACTTACCAGAGGACTGGTGTGCTGCTGCTGC 431  
Db 361 TGGCCTCTGCTGCTGAGAGCGCAACCTGGACACTTACCAGAGGACTGGTGTGCTGCTGCTGC 420  
QY 432 GGCCCCACTGCGGGGGCAGACCCCTGGTGTGCTAGAGCCCAACACCTCTACCCGTGCTCC 491  
Db 421 GGCCCCACTGCGGGGGCAGACCCCTGGTGTGCTAGAGCCCAACACCTCTACCCGTGCTCC 480  
QY 492 TCAGATGGAGCTCTGGCATCCCACTCAGTATCTAACCTGAACACGCTGGCTTTTCA 551  
Db 481 TCAGATGGAGCTCTGGCATCCCACTCAGTATCTAACCTGAACACGCTGGCTTTTCA 540  
QY 552 AACACTCGGGGGGAGGTAGTCCAGCCTCCCGGAAACCC 592  
Db 541 AACACTCGGGGGGAGGTAGTCCAGCCTCCCGGAAACCC 581

RESULT 4

AAS14884  
ID AAS14884 standard; cDNA; 854 BP.  
XX  
AC AAS14884;  
XX  
DT 20-DEC-2001 (first entry)



PN	WO200154477-A2.	
XX		
PD	02-AUG-2001.	
XX		
PF	25-JAN-2001; 2001WO-US002687.	
XX		
XX	25-JAN-2000; 2000US-00491404.	
PR	17-JUL-2000; 2000US-00617746.	
PR	03-AUG-2000; 2000US-00631451.	
PR	15-SEP-2000; 2000US-00663870.	
XX		
PA	(HYSE-) HYSEQ INC.	
XX		
XX	Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;	
PI	Cao Y, Drmanac RA, Zhang J, Werhman T;	
PI		
XX	WPI; 2001-476164/51.	
DR	P-PSDB; AAM24100.	
DR		
XX	Isolated polypeptide for treatment of diseases, diagnostics, raising	
PT	antibodies and research use.	
PT		
PS	Claim 1; Page 599-600; 1275pp; English.	
XX		
CC	The present invention provides the protein and coding sequences of novel	
CC	proteins from a variety of organisms, including human, dog, cat, horse,	
CC	cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea	
CC	urchin and tomato. These were derived from expressed sequence tags (ESTs)	
CC	from the organism of interest. They can be used in diagnostic,	
CC	forensics, gene mapping, identification of mutations, to assess	
CC	biodiversity and for nutritional purposes. The present sequence is a cDNA	
CC	of the invention	
XX		
SQ	Sequence 1927 BP; 413 A; 598 C; 480 G; 436 T; 0 U; 0 Other;	
	Query Match	
	Best Local Similarity 96.1%; Score 568.8; DB 4; Length 1927;	
	Matches 573; Conservative 0; Mismatches 7; Indels 0; Gaps 0;	
QY	13 GCTGTGCTGGGATCATGGAACCTTGCATCTGTGTGGCTGGTGGTGGTGGTGT 72	
DB	2 GCGGTGGAATTCGATCATGGAACCTTGCATCTGTGTGGCTGGTGGTGGTGT 61	
QY	73 GATTCATTCAGGGCGGAGTCTGAACCTGAACAGATGTCAAGCAAGTCACTGGGAA 132	
DB	62 GATTCATTCAGGGCGGAGTCTGAACCTGAACAGATGTCAAGCAAGTCACTGGGAA 121	
QY	133 AATGCCCATCTCTCTACTGCGCTTACGGCTGTCTACTCGGATAGTGGAGGGCCA 192	
DB	122 AATGCCCATCTCTCTACTGCGCTTACGGCTGTCTACTCGGATAGTGGAGGGCCA 181	
QY	193 ACCCAAGATGCCAGGACTGGTGTGCGCAGACCCATGACTGCTATGACCCCTGAA 252	
DB	182 ACCCAAGATGCCAGGACTGGTGTGCGCAGACCCATGACTGCTATGACCCCTGAA 241	
QY	253 GACCCAGGGTGGCGCATCTCAAGGACTATTACAGATACAACTTTTCCAGGGGAACAT 312	
DB	242 GACCCAGGGTGGCGCATCTCAAGGACTATTACAGATACAACTTTTCCAGGGGAACAT 301	
QY	313 CCATGCTCTCACAAGGAGGAGTGTGTGACAGCAGCTGTGTGCTGTGCAAGGAGGT 372	
DB	302 CCATGCTCTCACAAGGAGGAGTGTGTGACAGCAGCTGTGTGCTGTGCAAGGAGGT 361	
QY	373 GGCTTTCTGCTGAAGGCGCACTTCAAGGACCTTACAGAGGAGTGTGTGCTGTGCTGCG 432	
DB	362 GGCTTTCTGCTGAAGGCGCACTTCAAGGACCTTACAGAGGAGTGTGTGCTGTGCTGCG 421	
QY	433 GCCCATCTGCGGGGCGAGCCCTTGGTGTCTAGAGCCACACCTCTACCTCTTCTCT 492	
DB	422 GCCCATCTGCGGGGCGAGCCCTTGGTGTCTAGAGCCACACCTCTACCTCTTCTCT 481	
QY	493 CAGCATGAGCTCGCATCCCACTTCTAGTATCTTAACCTGAACACGCTGGCTTTTCAA 552	

Db	482 CAGCATGGAGCTCTGGCATCCCACTCAGTATCTAACCTGAACACGACCTGGCTTTTCAA 541
QY	553 ACACCTCGGGGGAGGTAGTCCAGCCTCCCGGGAACCC 592
Db	542 ACACCTCGGGGGAGGTAGTCCAGCCTCCCGGGAACCC 581
RESULT 6	
AAH99768	
ID	AAH99768 standard; cDNA; 1927 BP.
XX	AAH99768;
XX	
DT	16-OCT-2001 (first entry)
XX	
DE	Human protein encoding cDNA sequence SEQ ID NO:603.
XX	
KW	Human; cancer; ulcer; HIV infection; human immunodeficiency virus;
KW	antiinflammatory; antirheumatic; antiarthritic; immunosuppressive;
KW	antibacterial; endocrine; cardiant; cardiant; central nervous system; virucide;
KW	anti-HIV; fungicide; antimutagen; cardiovascular; antianaemic; anaemia;
KW	antiaggregant; haemostatic; vulnary; antidiabetic; osteopathic; eczema;
KW	dermatological; antiallergic; antiasthmatic; antidiabetic; cytostatic;
KW	neuroprotective; antidepressant; nootropic; antiparkinsonian; infection;
KW	immunostimulant; gene therapy; antisense therapy; vaccine; inflammation;
KW	antianaphylactic; rheumatoid arthritis; septic shock; pancreatitis;
KW	cardiac dysfunction; neuropathology; cardiac anaphylaxis; autoimmunity;
KW	genetic disease; haematopoietic disorder; platelet disorder; asthma;
KW	thrombocytopaenia; diabetes; osteoporosis; severe combined immunodeficiency;
KW	allergic rhinitis; diabetes; multiple sclerosis; depression;
KW	Alzheimer's disease; Parkinson's disease; neurodegenerative disorder;
KW	neurological disorder; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO200153455-A2.
XX	
PD	26-JUL-2001.
XX	
PF	22-DEC-2000; 2000WO-US035017.
XX	
PR	23-DEC-1999; 99US-00471275.
PR	21-JAN-2000; 2000US-00488725.
XX	25-APR-2000; 2000US-00552317.
PA	(HYSE-) HYSEQ INC.
XX	
PI	Tang YT, Liu C, Drmanac RT;
XX	
DR	WPI; 2001-457603/49.
XX	P-PSDB; AAM25827.
PT	Isolated human polynucleotides encoding polypeptides, useful for the
XX	treatment and diagnosis of e.g. cancer, ulcers and HIV infection.
PS	Claim 1; Page 636; 1217pp; English.
XX	
CC	AAH99166 to AAH99904 encode the human proteins given in AAM25225 to
CC	AAM25963. The proteins can have activities based on the tissues and cells
CC	they are expressed in, such as: antiinflammatory; antirheumatic;
CC	antiarthritic; immunosuppressive; antibacterial; endocrine; cardiant;
CC	central nervous system; virucide; anti-HIV; fungicide; antimutagen;
CC	cardiovascular; antianaemic; antiaggregant; haemostatic; vulnary;
CC	antidiabetic; cytostatic; dermatological; antiallergic; antiasthmatic;
CC	antiparkinsonian; and immunostimulant. The proteins and polynucleotides
CC	encoding them can be used in gene therapy, antisense therapy and vaccine
CC	production. The proteins and polynucleotides are useful for screening for
CC	agonists or antagonists of a protein and for the treatment and diagnosis
CC	of disorders associated with the activity of a protein e.g. inflammation,
CC	rheumatoid arthritis, septic shock, pancreatitis, cardiac dysfunction,
CC	neuropathology, cardiac anaphylaxis, viral, bacterial, HIV and fungal
CC	infections, autoimmunity, genetic diseases, haematopoietic disorders,

	CC	anaemia, platelet disorders, thrombocytopaenia, wounds, burns, ulcers,
	CC	osteoporosis, severe combined immunodeficiency, eczema, allergic
	CC	rhinitis, asthma, diabetes, cancer, multiple sclerosis, depression,
	CC	Alzheimer's disease, Parkinson's disease, neurodegenerative and
	CC	neurological disorders
XX	CC	
Sequence	1927 BP; 413 A; 598 C; 480 G; 436 T; 0 U; 0 Other;	
Query Match	96.1%; Score 568.8; DB 4; Length 1927;	
Best Local Similarity	98.8%; Pred. No. 7.4e-143;	
Matches	573; Conservative 0; Mismatches 7; Indels 0; Gaps 0;	
QY	13	GCTCTGTCTGGGATCATGGAACTTGCACTGCTGTGTGGCTGTGGTGATGGCTGGTGT 72
Db	2	CGGTGGAAATTCGATCATGGAATTCGACTCTGTGTGGCTGTGGTGATGGCTGGTGT 61
QY	73	GATTCCAAATCAGGGCGGGATCTCTGAACCTGAAACAAGATGTCGAAGCAAGTGCATGGGAA 132
Db	62	GATTCCAAATCAGGGCGGGATCTCTGAACCTGAAACAAGATGTCGAAGCAAGTGCATGGGAA 121
QY	133	AATGCCATCTCTCTACTTGGCCCTACGGCTGTTCACCTGCCGACTAGGTGGCAGAGGCCA 192
Db	122	AATGCCATCTCTCTCTACTTGGCCCTACGGCTGTTCACCTGGCAGTAGTGGCAGAGGCCA 181
QY	193	ACCCAAAGATGCCACGGACTGTGTCTGCCAGACCATGACTGTCTGTATGACCACTGAA 252
Db	192	ACCCAAAGATGCCACGGACTGTGTCTGCCAGACCATGACTGTCTATGACCACTGAA 241
QY	253	GAACCCAGGGTGGGATCTCAAGGACTATTACAGATACACTTTTCCAGGGGAAACAT 312
Db	242	GAACCCAGGGTGGGATCTCAAGGACTATTACAGATACACTTTTCCAGGGGAAACAT 301
QY	313	CCACTGTCTGACAGGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTGTGACAAGAGGT 372
Db	302	CCACTGTCTGACAGGGGAAGCTGTGTGAGCAGCAGCTGTGTGCTGTGACAAGAGGT 361
QY	373	GGCCTTCTGCCTGAAGCGCAACTGTGACACCTACCAAGACGACTCGGTTTCTACTGGCG 432
Db	362	GGCCTTCTGCCTGAAGCGCAACTGTGACACCTACCAAGACGACTCGGTTTCTACTGGCG 421
QY	433	GCCCCACTCGCGGGGCGAGCCCTCGGTTGTAGAGCCCAACCTCTACCCCTGTTCCT 492
Db	422	GCCCCACTCGCGGGGCGAGCCCTCGGTTGTAGAGCCCAACCTCTACCCCTGTTCCT 481
QY	493	CAGCATGGAGCTCTGGCATCCCCACCTCAGTATCTAACTGAACACGCTGGCTTTTCAA 552
Db	482	CAGCATGGAGCTCTGGCATCCCCACCTCAGTATCTAACTGAACACGCTGGCTTTTCAA 541
QY	553	ACACTCGGGGGGAGGTAGTCCAGGCTTCCCCGGAAACC 592
Db	542	ACACTCGGGGGGAGGTAGTCCAGGCTTCCCCGGAAACC 581

RESULT 7  
AAD19218

AA  
AC  
AAD19218;

XX  
DT 18-DEC-2001 (first entry)

XX  
DE  
RUMANOCOE (or C870) linase DNA

XX Human, apolipoprotein; lipase; lipoprotein receptor; ALLx; angina;  
KW cardiovascular disease; lipid metabolism; myocardial infarction;  
KW cerebral ischaemia; arterial thrombosis; thrombolytic; antilipaeamic;  
KW coronary artery thrombosis; cerebral artery thrombosis; stroke;  
KW intracardiac thrombosis; gene therapy; cardiovascular; vasodilator;  
KW neuroprotectant; cerebroprotective; ds.  
ZW

XX Homo sapiens.

XX	Key	Location/Qualifiers
EH		

FN, Key

[illegible]

Db 133 TCTCTACTGGCCCTACGGTGTACACTGCGGACTAGGTGGCAGAGGCCAACCAAGATG 192  
QY 204 CCACGGACTGGTGTGTCGACAGACCATGACTGCTGTATGACCCCTGAAGACCCAGGGGT 263  
Db 193 CCACGGACTGGTGTGTCGACAGACCATGACTGCTGTATGACCCCTGAAGACCCAGGGGT 252  
QY 264 GCGCATCTACAGGACTATTACAGATACAACTTTTCCAGGGGAAACATCCACTGCTCTG 323  
Db 253 GCGGCATCTACAGGACTATTACAGATACAACTTTTCCAGGGGAAACATCCACTGCTCTG 312  
QY 324 ACAAGGAACTGGTGTGACAGCAGCTGTGTGCTGTGACAGAGGTGGCTTTCGCC 383  
Db 313 ACAAGGAACTGGTGTGACAGCAGCTGTGTGCTGTGACAGAGGTGGCTTTCGCC 372  
QY 384 TGAAGCGCACTGGACACCTACAGAGCAGCTGCGTTTCTACTGCGGCCCCACTGCC 443  
Db 373 TGAAGCGCACTGGACACCTACAGAGCAGCTGCGTTTCTACTGCGGCCCCACTGCC 432  
QY 444 GGGGGCAGACCCCTGGGTGCTAGAGCCACACCCCTTACCCCTGTTCCTCAGCATGGAGC 503  
Db 433 GGGGGCAGACCCCTGGGTGCTAGAGCCACACCCCTTACCCCTGTTCCTCAGCATGGAGC 492  
QY 504 TCTGGCATCCCACTCAGTATCTACCTGAACAGCCTGGCTTTTCAACACTCCGGGG 563  
Db 493 TCTGGCATCCCACTCAGTATCTACCTGAACAGCCTGGCTTTTCAACACTCCGGGG 552  
QY 564 GGAGGTAGTCCAGCCTCCCGGGAACCC 592  
Db 553 GGAGGTAGTCCAGCCTCCCGGGAACCC 581

RESULT 8  
AAA60866  
ID AAA60866 standard; cDNA; 1233 BP.  
AC AAA60866;  
DT 02-NOV-2000 (first entry)  
DE Mouse secretory phospholipase A2 nucleotide sequence SEQ ID NO:13.  
KW Secretory phospholipase A2; PLA2; antiallergic; antiinflammatory;  
KW antibacterial; immunosuppressive; tranquiliser; antirheumatic;  
KW antiarthritic; septic shock; trauma; pancreatitis; allergic rhinitis;  
KW chronic rheumatoid arthritis; ss.  
OS Mus musculus.

Key Location/Qualifiers  
CDS 36..470  
FT /\*tag= a  
FT /product= "secretory phospholipase A2 (PLA2)"  
FT sig\_peptide 36..92  
FT /\*tag= b  
FT mat\_peptide 93..467  
FT /\*tag= c  
XX  
XX WO200034486-A1.  
XX  
XX 15-JUN-2000.  
XX  
XX 07-DEC-1999; 99WO-JP006844.  
XX  
XX 09-DEC-1998; 98JP-00349608.  
XX (SHIO ) SHIONOGI & CO LTD.  
XX  
XX Ishizaki J, Suzuki N, Hanasaki K;  
XX WPI; 2000-423429/36.  
XX P-PSDB; AAB12536.  
XX

PT Human secretory phospholipase A2 (PLA2) and its encoded gene for  
PT diagnosis and treatment of secretory PLA2-associated diseases e.g. septic  
PT shock, trauma, pancreatitis, allergic rhinitis and chronic rheumatoid  
PT arthritis.  
PS Example 3; Page 35-36; 45pp; Japanese.  
XX  
XX The present invention describes human secretory phospholipase A2 (PLA2).  
XX PLA2 has antiallergic, antiinflammatory, antibacterial, tranquiliser,  
XX immunosuppressive, vulnerary, antirheumatic and antithratic activities.  
XX Human secretory phospholipase A2 (PLA2), the gene encoding it and  
XX antibodies against it are useful for the diagnosis and treatment of  
XX secretory PLA2-associated diseases e.g. septic shock, trauma,  
XX pancreatitis, allergic rhinitis and chronic rheumatoid arthritis. The  
XX present sequence encodes mouse PLA2, which is used in an example from the  
XX present invention  
SQ Sequence 1233 BP; 279 A; 337 C; 307 G; 310 T; 0 U; 0 Other;  
Query Match 50.0%; Score 296; DB 3; Length 1233;  
Best Local Similarity 77.5%; Pred. No. 1.7e-69;  
Matches 372; Conservative 0; Mismatches 105; Indels 3; Gaps 1;  
QY 2 CTGCTCCACTGCTGTGCTGCGATCATGGAACCTGCACTGCTGTGTGGCTGTGGT 61  
Db 9 CTGCTCCCTTGTCTGTGGCTGGAACCTATGAGACTGCGCTGTGTGGCTGTGTC-- 66  
QY 62 ATGGCTGGTGTGATTCCAAATCCAGGCGGGGATCTTGAACCTGAAACAAGATGTCAGCAA 121  
Db 67 -TGGCGGTATAACTGCAACCCAGGAGGGCTCTTGAACCTGAAACAAGATGTCACAC 125  
QY 122 GTGACTGGGAAAATGCCATCTCTTCTACTGGCCCTACGGCTGTCACTGCGGACTAGGT 181  
Db 126 ATGACGGGGAGAAAGACCTTCTTCTACTGCTGCTGCTGCTGCTGCTGCTGCT 185  
QY 182 GGCAGAGGCCAACCCAAAGATGCCAGGACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 241  
Db 186 GGCAGAGGCCAACCCAAAGATGCCAGGACTGCTGCTGCTGCTGCTGCTGCTGCTGCT 245  
QY 242 GACCACTGGAAGACCCAGGGGTGCGGCATCTTACAAGGACTATTACAGATACAACTTTCC 301  
Db 246 GCGCCACTGGAAGATCGATGGATGCAAGAGCCCTGACAGCACTACAATACAGATCTCC 305  
QY 302 CAGGGGAACATCCACTGCTCTGCAAGGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTGT 361  
Db 306 CAGGGCACTATCCAGTGTCTGTGACAAACGGGAGCTGGTGTGAAAGGCAACTGTGTCTGT 365  
QY 362 GACAAGGAGGTGGCTTCTGCTGAGCGCAACCTGGAACCTTACCAAGGAGTCCAGAGGACTGCGT 421  
Db 366 GACAAGGAGGTGGCTTGTGCTTGAAGCAAAACCTGGATAGCTACATAAGGCGCTGCGT 425  
QY 422 TTCTACTGGCGGCCCACTGCGGGGGCAGACCCCTGCGGTGCTAGAGCCCAACCCCTCT 481  
Db 426 TACTACTGGCGGCCCGTTTGAAGGCAAGACTCCAGCATGCTAAGGAGTCCACTCTGT 485  
RESULT 9  
AAA72076  
ID AAA72076 standard; cDNA; 1233 BP.  
AC AAA72076;  
XX  
XX 24-NOV-2000 (first entry)  
XX cDNA encoding mouse secreted phospholipase A2.  
XX Secreted phospholipase A2; PLA2; mouse; murine; recombinant production;  
XX antibody; diagnosis; expressed sequence tag; EST; drug screening; ss.  
XX Mus musculus.  
XX  
XX Key Location/Qualifiers  
XX CDS 36..470  
XX





CC nucleotide and protein sequences used in the exemplification of the  
 CC present invention  
 XX  
 SQ Sequence 496 BP; 200 A; 95 C; 104 G; 95 T; 0 U; 2 Other;  
 Query Match 48.0%; Score 284.2; DB 3; Length 496;  
 Best Local Similarity 97.3%; Pred. No. 1.9e-66;  
 Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
 QY 1 TCTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 60  
 Db 1 TCTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 60  
 QY 61 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCTTGAACCTGAACAAGATGTCGAAGCA 120  
 Db 61 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCTTGAACCTGAACAAGATGTCGAAGCA 120  
 QY 121 AGTGACTGGGAAATGCCCCATCTCTCTACTGGCCCTAGCGCTGTGCTGCGGACTAGG 180  
 Db 121 AGTGACTGGGAAATGCCCCATCTCTCTACTGGCCCTAGCGCTGTGCTGCGGACTAGG 180  
 QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCATGACTGTGCTA 240  
 Db 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCATGACTGTGCTA 240  
 QY 241 TGACCACTTGAGACCCAGGCGGTGGCGATCTTACAAGGACTATTACAGATACAACTT 297  
 Db 241 TGACCACTTGAGACCCAGGCGGTGGCGATCTTACAAGGACTATTACAGATACAACTT 297  
 RESULT 11  
 AAF54466  
 ID AAF54466 standard; DNA; 496 BP.  
 XX  
 AC AAF54466;  
 XX  
 DT 02-APR-2001 (first entry)  
 XX  
 DE DNA encoding protein of the invention #109.  
 XX  
 KW Secreted; transmembrane; gene therapy; ss.  
 XX  
 OS Unidentified.  
 XX  
 OS WO200078961-A1.  
 XX  
 PN 28-DEC-2000.  
 XX  
 PF 18-FEB-2000; 2000WO-US004342.  
 XX  
 PF 23-JUN-1999; 99US-0141037P.  
 XX  
 PF 20-JUL-1999; 99US-0144758P.  
 XX  
 PF 26-JUL-1999; 99US-0145698P.  
 XX  
 PF 01-SEP-1999; 99WO-US020111.  
 XX  
 PF 29-OCT-1999; 99US-0162506P.  
 XX  
 PF 30-NOV-1999; 99WO-US028313.  
 XX  
 PF 02-DEC-1999; 99WO-US028551.  
 XX  
 PF 16-DEC-1999; 99WO-US030095.  
 XX  
 PF 05-JAN-2000; 2000WO-US000219.  
 XX  
 PF 06-JAN-2000; 2000WO-US000376.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;  
 PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;  
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;  
 PI Williams PM, Wood WI;  
 XX  
 DR WPI; 2001-071395/08.  
 XX  
 XX Secreted and transmembrane proteins and nucleic acids designated PRO,  
 FT useful as hybridization probes, in chromosome and gene mapping and gene  
 PT therapy.

XX  
 PS Claim 2; Fig 217; 787pp; English.  
 XX  
 CC The present invention relates to secreted and transmembrane proteins.  
 CC These proteins and the DNA encoding them may be used as hybridization  
 CC probes, in chromosome and gene mapping and in the generation of anti-  
 CC sense RNA and DNA. They may also be used to generate either  
 CC transgenic animals or knockout animals which are in turn useful for  
 CC development and screening of therapeutically useful reagents. The nucleic  
 CC acids may also be used in gene therapy  
 XX  
 SQ Sequence 496 BP; 200 A; 95 C; 104 G; 95 T; 0 U; 2 Other;  
 Query Match 48.0%; Score 284.2; DB 4; Length 496;  
 Best Local Similarity 97.3%; Pred. No. 1.9e-66;  
 Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
 QY 1 TCTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 60  
 Db 1 TCTGCTCCACTGCTCTGTGCTGGGATCATGGAATTCGACTGCTGTGGCTGGTGGT 60  
 QY 61 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCTTGAACCTGAACAAGATGTCGAAGCA 120  
 Db 61 GATGGCTGGTGTGATTCGAATCCAGGCGGGATCTTGAACCTGAACAAGATGTCGAAGCA 120  
 QY 121 AGTGACTGGGAAATGCCCCATCTCTCTACTGGCCCTAGCGCTGTGCTGCGGACTAGG 180  
 Db 121 AGTGACTGGGAAATGCCCCATCTCTCTACTGGCCCTAGCGCTGTGCTGCGGACTAGG 180  
 QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCATGACTGTGCTA 240  
 Db 181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGCTGCGAGACCATGACTGTGCTA 240  
 QY 241 TGACCACTTGAGACCCAGGCGGTGGCGATCTTACAAGGACTATTACAGATACAACTT 297  
 Db 241 TGACCACTTGAGACCCAGGCGGTGGCGATCTTACAAGGACTATTACAGATACAACTT 297  
 RESULT 12  
 AAS21510  
 ID AAS21510 standard; cDNA; 496 BP.  
 XX  
 AC AAS21510;  
 XX  
 DT 24-OCT-2001 (first entry)  
 XX  
 DE Human cDNA sequence encoding for PRO1561 polypeptide.  
 XX  
 KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;  
 KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;  
 KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;  
 XX A-peptide; factor VIIa; gene therapy; ss.  
 OS Homo sapiens.  
 XX  
 PN WO200140466-A2.  
 XX  
 XX 07-JUN-2001.  
 XX  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX  
 XX 01-DEC-1999; 99WO-US028301.  
 XX  
 XX 01-DEC-1999; 99WO-US028634.  
 XX  
 XX 02-DEC-1999; 99WO-US028551.  
 XX  
 XX 02-DEC-1999; 99WO-US028564.  
 XX  
 XX 09-DEC-1999; 99US-0170262P.  
 XX  
 XX 16-DEC-1999; 99WO-US030095.  
 XX  
 XX 20-DEC-1999; 99WO-US030911.  
 XX  
 XX 20-DEC-1999; 99WO-US030999.  
 XX  
 XX 30-DEC-1999; 99WO-US031243.  
 XX  
 XX 30-DEC-1999; 99WO-US031274.  
 XX  
 XX 05-JAN-2000; 2000WO-US000219.

1 TCTGCTCCACTGCTCTGTGCTGGGATCATGGAACTTGCACTGCTGTGTGGGCTGGTGGT 60

61 GATGGCTGGTGTGATTCCCAATCCAGGGCGGGATCCTGAACCTGAACAAGATGGTCAAGCA 120

61 GATGGCTGGTGTGATTCCCAATCCAGGGCGGGATCCTGAACCTGAACAAGATGGTCAAGCA 120

121 AGTGACTGGGAAATGCCATCCTCTCTACTGSCCCTACGGCTGTCACTGCGGACTAGG 180

121 AGTGACTGGGAAATGCCATCCTCTCTACTGSCCCTACGGCTGTCACTGCGGACTAGG 180

181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGTCAGACCCCATGACTGCTGCTA 240

181 TGGCAGAGGCCAACCCAAAGATGCCAGGACTGGTGTGTCAGACCCCATGACTGCTGCTA 240

241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTT 297

241 TGACCACCTGAAGACCCAGGGGTGCGGCATCTACAAGACTATTACAGATACAACTT 297

RESULT 13

ACD24119

ID ACD24119 standard; cDNA; 496 BP.

XX AC

XX ACD24119;

DT 26-AUG-2003 (first entry)

XX DE

XX Novel human secreted and transmembrane protein PRO1561 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; antiinflammatory;

XX KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;

XX KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;

XX KW TNF-alpha release; cell proliferation; cell differentiation;

XX KW gene expression modulator; proteoglycan release; cytokine release;

XX KW tumour; inflammatory disease; organ failure; atherosclerosis;

XX KW cardiac injury; infertility; birth defect; premature aging; AIDS;

XX KW acquired immunodeficiency syndrome; cancer; diabetic complication;

XX KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;

XX KW bioreactor; tissue typing; gene; ss.

OS Homo sapiens.

XX

XX US20030321156-A1.

XX

XX 13-FEB-2003.

PD

XX

XX 06-MAY-2002; 2002US-00140474.

XX

XX 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 16-SEP-1998; 98WO-US019177.

PR 17-SEP-1998; 98WO-US019330.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

06-JAN-2000; 2000WO-US000277.  
06-JAN-2000; 2000WO-US000376.  
11-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
18-FEB-2000; 2000WO-US004342.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
01-MAR-2000; 2000WO-US005601.  
02-MAR-2000; 2000WO-US005841.  
03-MAR-2000; 2000US-018702P.  
10-MAR-2000; 2000WO-US006319.  
15-MAR-2000; 2000WO-US006884.  
20-MAR-2000; 2000WO-US007377.  
21-MAR-2000; 2000WO-US007532.  
30-MAR-2000; 2000WO-US008439.  
17-MAY-2000; 2000WO-US013705.  
22-MAY-2000; 2000WO-US014042.  
30-MAY-2000; 2000WO-US014941.  
02-JUN-2000; 2000WO-US015264.  
05-JUN-2000; 2000US-0209832P.  
28-JUL-2000; 2000WO-US020710.  
11-AUG-2000; 2000WO-US022031.  
23-AUG-2000; 2000WO-US023522.  
24-AUG-2000; 2000WO-US023328.  
08-NOV-2000; 2000WO-US030952.  
10-NOV-2000; 2000WO-US030873.  
XX  
FA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Geriensen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;  
PI  
XX WPI; 2001-408281/43.  
DR P-PSDB; AAU12438.  
DR  
XX Isolated , secretory and transmembrane PRO polypeptide used to detect  
XX other PRO polypeptides, link bioactive molecules to cells expressing PRO  
PT polypeptides, and detect the presence of mammalian tumors e.g. lung,  
PT breast, prostate, cervical.  
XX  
XX Claim 3; Fig 533; 813pp; English.  
PS  
XX AAS21244-AAS21518 encode for novel human secretory and transmembrane PRO  
XX polypeptides. The PRO polypeptides are useful to detect other PRO  
CC polypeptides, to link bioactive molecules to cells expressing PRO  
CC polypeptides, to modulate biological activities of cells expressing PRO  
CC polypeptides, and to detect the presence of mammalian lung, colon,  
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO  
CC polypeptide expression in a cell sample to that in a control sample. Some  
CC of the 275 sequences are also useful to stimulate the release of tumour  
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or  
CC differentiation of chondrocytes, the proliferation or gene expression in  
CC pericyte cells, the release of proteoglycans from cartilage, the  
CC proliferation of inner ear utricular supporting cells or of T-  
CC lymphocytes, the release of a cytokine from peripheral blood monocytes  
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO  
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal  
CC muscle cells or adipocytes; or inhibit binding of A-peptide to factor  
CC VIIA. The PRO polypeptides can be used in assays to identify molecules  
CC involved in binding interactions. The polynucleotides encoding PRO  
CC polypeptides can be used to generate probes, antisense RNA/DNA,  
CC transgenic or knock out animals and can be used in gene therapy  
XX  
XX Sequence 496 BP; 200 A; 95 C; 104 G; 95 T; 0 U; 2 Other;  
SQ  
Query Match 48.0%; Score 284.2; DB 4; Length 496;  
Best Local Similarity 97.3%; Pred. No. 1.9e-66;  
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps  
1 TCTGCCTCCACTGCTCTGCTGGGATCATCGAACTTGCACCTGCTGTGTGGCTGTGGT 60  
QY

```

PR 15-SEP-1999; 99WO-US021547.
PR 03-OCT-1999; 99WO-US0223089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001WO-US019692.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001WO-US020116.
PR 09-JUL-2001; 2001WO-US021066.
PR 18-JUL-2001; 2001WO-US021735.
PR 06-AUG-2001; 2001US-00908827.
PR 09-AUG-2001; 2001US-00924419.
PR 16-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.

PR 19-DEC-2001; 2001US-00028072.
PR (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-341980/32.
DR P-PSDB; ABO17882.
XX
XX New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 2; Fig 533; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression.
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This sequence encodes a novel human secreted and transmembrane PRO
CC polypeptide
XX
SQ Sequence 496 BP; 200 A; 95 C; 104 G; 95 T; 0 U; 2 Other;

Query Match 48.0%; Score 284.2; DB 7; Length 496;
Best Local Similarity 97.3%; Pred. No. 1.9e-66;
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGCTGTGTGGGATCATGGAACCTGCACTGCTGTGGCTGGTGGT 60
Db |||||
QY 61 GATGGCTGGTGTGATTCCAATCCAGGGCGGGATCCTGAACCTGAACAGATGGTCAAGCA 120
Db |||||
QY 121 AGTGACTGGGAAAATGCCATTCCTTCTACTGCGCCCTACGGCTGTCACTCGGACTAGG 180
Db |||||
QY 181 TGGCAGAGGGCCCAACCCAAAGATGCCAGGACTGGTGTGCCAGCCCATGACTCTGCTA 240
Db |||||
QY 241 TGACCCACTGAAGACCCAGGGGTGGCGCATCTTACAAGACTATTACAGATACACTT 297
Db |||||

RESULT 14
ACA67260
ID ACA67260 standard; cDNA; 496 BP.
XX
AC ACA67260;

```

Fri Oct 8 10:22:34 2004

us-09-830-321a-4.rng

XX	23-JUN-2003	(first entry)	98WO-US017888.
DT			98WO-US018824.
XX			98WO-US019093.
DE			98WO-US019094.
XX			98WO-US019177.
XX			98WO-US019330.
KW			98WO-US019437.
KW			98WO-US021141.
KW			98WO-US022991.
KW			98WO-US022992.
KW			98WO-US024855.
KW			98WO-US025108.
KW			98WO-US000106.
XX			98WO-US005028.
OS			98WO-US005190.
XX			98WO-US008615.
XX			98WO-US010733.
XX			98WO-US012252.
XX			98WO-US020111.
XX			98WO-US020594.
XX			98WO-US020944.
XX			98WO-US021090.
XX			98WO-US021547.
XX			98WO-US023089.
XX			98WO-US028214.
XX			98WO-US028313.
XX			98WO-US028409.
XX			98WO-US028301.
XX			98WO-US028634.
XX			98WO-US028551.
XX			98WO-US028564.
XX			98WO-US028565.
XX			98WO-US030095.
XX			98WO-US030911.
XX			98WO-US030999.
XX			98WO-US031243.
XX			98WO-US031274.
XX			2000WO-US000219.
XX			2000WO-US000277.
XX			2000WO-US000376.
XX			2000WO-US003565.
XX			2000WO-US004341.
XX			2000WO-US004342.
XX			2000WO-US004414.
XX			2000WO-US004914.
XX			2000WO-US005004.
XX			2000WO-US005601.
XX			2000WO-US005746.
XX			(GETH ) GENENTECH INC.
XX			Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX			Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX			Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX			WPI; 2003-352836/33.
XX			P-PSDB; ABU81136.
XX			New isolated PRO polypeptide useful for treating diabetes, rheumatoid
XX			arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
XX			heart attack.
XX			Claim 2; Fig 533; 643pp; English.
XX			The present invention relates to the isolation of novel human PRO
XX			polypeptides, and the polynucleotide sequences encoding them. The PRO
XX			polypeptides are secreted and transmembrane proteins. The PRO
XX			polypeptides and polynucleotides are useful for preparing a medicament
XX			useful in the treatment of diabetes, bone and/or cartilage disorders
XX			(e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
XX			hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
XX			(e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
XX			assays for PRO, by detecting its expression in specific cells, tissues or

23-JUN-2003 (first entry)

cDNA encoding human PRO polypeptide #267.

Human; PRO polypeptide; secreted and transmembrane protein;

anti-PRO antibody; diagnostic assay; gene expression; diabetes;

bone disorder; cartilage disorder; rheumatoid arthritis; obesity;

sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;

hearing loss; coagulation disorder; stroke; heart attack; cardiac;

antidiabetic; anorectic; vulnary; antiarthritic; osteopathic;

antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.

Homo sapiens.

US2003004311-A1.

02-JAN-2003.

19-DEC-2001; 2001US-00028072.

18-JUN-1997; 97US-0049911P.

26-AUG-1997; 97US-0056974P.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

19-SEP-1997; 97US-0059352P.

19-SEP-1997; 97US-0059588P.

24-SEP-1997; 97US-0059836P.

17-OCT-1997; 97US-0062250P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

17-OCT-1997; 97US-0063755P.

24-OCT-1997; 97US-0062814P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063082P.

24-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063350P.

28-OCT-1997; 97US-0063561P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063733P.

29-OCT-1997; 97US-0063735P.

29-OCT-1997; 97US-0063738P.

03-NOV-1997; 97US-0064248P.

07-NOV-1997; 97US-0064809P.

12-NOV-1997; 97US-0065186P.

17-NOV-1997; 97US-0065946P.

21-NOV-1997; 97US-0066364P.

24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066770P.

11-DEC-1997; 97US-0069212P.

11-DEC-1997; 97US-0069278P.

11-DEC-1997; 97US-0069334P.

16-DEC-1997; 97US-0069694P.

23-JAN-1998; 98US-0072320P.

04-FEB-1998; 98US-0073612P.

09-FEB-1998; 98US-0074086P.

09-FEB-1998; 98US-0074092P.

12-FEB-1998; 98US-0077791P.

20-MAR-1998; 98US-0078910P.

25-MAR-1998; 98US-0079294P.

27-MAR-1998; 98US-0079663P.

27-MAR-1998; 98US-0079728P.

31-MAR-1998; 98US-0080165P.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

CC serum, and for affinity purification of PRO from recombinant cell culture  
 CC or natural sources. ACA6994-ACA67268 represent cDNA sequences encoding  
 CC the human PRO polypeptides of the invention. Note: The sequence data for  
 CC this patent was obtained in electronic format directly from the USPTO web  
 CC site at seqdata.uspto.gov/psipsDIDEntry.html  
 XX  
 SQ Sequence 496 BP; 200 A; 95 C; 104 G; 95 T; 0 U; 2 Other;

Query Match 48.0%; Score 284.2; DB 7; Length 496;  
 Best Local Similarity 97.3%; Pred. No. 1.9e-66;  
 Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 TCTGCTCCACCTCTGCTGGGATCATGGAACCTGCACTGTGGGCTGTGGT 60  
 Db 1 TCTGCTCCACCTCTGCTGGGATCATGGAACCTGCACTGTGGGCTGTGGT 60  
 QY 61 GATGCTGTGTGATTCCTCAATCCAGGCGGGATCTTGAACCTGAAAGATGTCAAGCA 120  
 Db 61 GATGCTGTGTGATTCCTCAATCCAGGCGGGATCTTGAACCTGAAAGATGTCAAGCA 120  
 QY 121 AGTGACTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180  
 Db 121 AGTGACTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180  
 QY 181 TGGCAGAGCCCAACCAAGATGCCACGACTGTGCTGCCAGACCCATGACTGTGCTA 240  
 Db 181 TGGCAGAGCCCAACCAAGATGCCACGACTGTGCTGCCAGACCCATGACTGTGCTA 240  
 QY 241 TGACACCTGAGACCCAGGCTGGGATCTTACAGGACTATTACAGATCAACTT 297  
 Db 241 TGACACCTGAGACCCAGGCTGGGATCTTACAGGACTATTACAGATCAACTT 297

RESULT 15

ACA03869  
 ID ACA03869 standard; cDNA; 496 BP.  
 XX  
 AC ACA03869;  
 XX  
 DT 23-MAY-2003 (first entry)  
 XX  
 DE cDNA encoding human PRO polypeptide #267.  
 XX  
 KW Human; PRO polypeptide; secreted and transmembrane protein;  
 KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;  
 KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic; gene;  
 KW ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003036180-A1.  
 XX  
 ED 20-FEB-2003.  
 XX  
 PF 09-MAY-2002; 2002US-00143114.  
 XX  
 PP 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US0008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 02-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001US-00874503.  
 PR 05-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.

PR	21-JUN-2001; 2001US-00887879.	
PR	22-JUN-2001; 2001WO-US020116.	
PR	29-JUN-2001; 2001WO-US021066.	
PR	09-JUL-2001; 2001WO-US021735.	
PR	18-JUL-2001; 2001US-00908827.	
PR	06-AUG-2001; 2001US-00924419.	
PR	09-AUG-2001; 2001US-00927796.	
PR	16-AUG-2001; 2001US-00931836.	
PR	19-DEC-2001; 2001US-00028072.	
XX		
XX	(GETH ) GENENTECH INC.	
PA		
XX	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PI	Garritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
PI		
XX		
XX	WPI; 2003-332040/31.	
DR	P-PSDB; ABU66836.	
DR		
XX		
XX	New secreted and transmembrane PRO nucleic acids, useful for gene	
PT	therapy, in chromosome and gene mapping, as chromosome markers, in tissue	
PT	typing, and in chromosome identification.	
PT		
XX	Claim 2; Fig 533; 660pp; English.	
XX		
PS		

	Query Match	48.0%;	Score 284.2;	DB 7;	Length 496;
	Best Local Similarity	97.3%;	Prod. No. 1.9e-66;		
	Matches 289;	Conservative	0; Mismatches 8;	Indels 0;	Gaps 0;
QY	1	TCTGCTCCACGCTCTGTGCTGGGATCATGAACTTGCACTGCTGTGTGGCTGGTGGT	60		
Db	1	TCTGCTCCACGCTCTGTGCTGGGATCATGAACTTGCACTGCTGTGTGGCTGGTGGT	60		
QY	61	GATGGCTGGTGTGATTCGAATCAGGGGGGATCCTGAACTGGACAGATGCTCAAGCA	120		
Db	61	GATGGCTGGTGTGATTCGAATCAGGGGGGATCCTGAACTGGACAGATGCTCAAGCA	120		
QY	121	AGTGACTGGGAAAATGCCCATCTCTCTACTTGGCCCTACGGCTGTCTACTCGGACTAGG	180		
Db	121	AGTGACTGGGAAAATGCCCATCTCTCTACTTGGCCCTACGGCTGTCTACTCGGACTAGG	180		
QY	181	TGGCAGAGCCCAACCCAAAGATGCCACGACTGGTGTGCCAGACCCCATGCTGCTGTA	240		
Db	181	TGGCAGAGCCCAACCCAAAGATGCCACGACTGGTGTGCCAGACCCCATGCTGCTGTA	240		
QY	241	TGACCACTTGAAGACCCAGGGGTGGCGCATCTACAGGACTATTACAGATACAACTT	297		
Db	241	TGACCACTTGAAGACCCAGGGGTGGCGCATCTACAGGACTATTACAGATACAAAGCAGAT	297		

Search completed: October 7, 2004, 13:34:27  
Job time : 258.748 secs







```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 131..544
; PCT-US94-07926-31

Query Match      19.9%; Score 118; DB 5; Length 1014;
Best Local Similarity 57.8%; Pred. No. 2.8e-23;
Matches 230; Conservative 0; Mismatches 165; Indels 3; Gaps 1;

QY 67 TGGTGTGATTCCAAATCCAGGCGCGGATCCCTGAACCTGAACAAGATGCTCAAGCAAGTGAC 126
Db 169 TAGTGTGCTGTGTGCAAGAGGCTTGCTGGACCTAAATCAATGATCGAAGAGTGAC 228

QY 127 TGGGAAAATGCCCATCTCTCTTACTGGCCCTACGGCTGTCACTGGCGGACTAGTGGCAG 186
Db 229 AGGGAAGAAGCGCCCTGACAAACTACGGCTTCTACGGCTGTACTGCGGCTGGGCGGCGC 288

QY 187 AGGCCAACCCAAAGATGCCAGGACTGGTCTGCCACACCATGACTGCTGTCTATGACCA 246
Db 289 AGGAACCCCAAGATGGCCAGGATGGTGTCTTGGGCGCATGACCACTGCTATGGCGC 348

QY 247 CCTGAAGACCCAGGGGTGCGGCATCTACAAGGACTATTACAGATACAACTTTTCCCGAGG 306
Db 349 GCTGGAGGAGAGGGCTGCAACATTCGCACACAGTCTCTACAATACAGATCGGTGGGG 408

QY 307 GAACATCCATGCTGTGACAAGGAGAGTGGTGTGAGCAGCAGCTGTGTGCTGTGACAA 366
Db 409 CGTGGTCACCTGC---GAGCCCGGGCCCTTCTGCCATGTCAACCTCTGTGCTGTGACCG 465

QY 367 GGAGGTGGCCCTCTGCTGAAGCGCACTGGACACTTACCAGAAGGACTGGTTTCTA 426
Db 466 GAAGCTGCTCTACTGCTCTCAAGAGAACCCTACGGAGCTACACCCAGTACCAATACTT 525

QY 427 CTGCGCGCCCACTGCGCGGGGCGAGCCCTCTGGTGCT 464
Db 526 TCCCAACATCTCTGCTCTTAGGCCTCCCGAGCGAGCT 563

RESULT 5
US-08-186-895-9
; Sequence 9, Application US/08186895
; Patent No. 553885
; GENERAL INFORMATION:
; APPLICANT: Hollis, Melvyn
; APPLICANT: Needham, Maurice R.C.
; APPLICANT: Gooding, Clare
; APPLICANT: Grosveld, Franklin G.
; TITLE OF INVENTION: Expression Systems
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cushman, Darby & Cushman
; STREET: 1615 L Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20036-5601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/186.895
; FILING DATE: 27-JAN-1994
; CLASSIFICATION: 435
; PRIORITY INFORMATION:
; APPLICATION NUMBER: US/08/046.383
; FILING DATE: 09-APR-1993
; APPLICATION NUMBER: US/07/810.414

```





Fri Oct 8 10:22:35 2004

CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &  
 ADDRESSEE: Russell PA  
 STREET: 200 East Broward Boulevard  
 CITY: Fort Lauderdale  
 STATE: FL  
 COUNTRY: USA  
 ZIP: 33301  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.25  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/362,230  
 FILING DATE:  
 CLASSIFICATION:  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 08/888,497  
 FILING DATE:  
 APPLICATION NUMBER: US 08/097,354  
 FILING DATE: 26-JUL-1993  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Manso, Peter J.  
 REGISTRATION NUMBER: 32,264  
 REFERENCE/DOCKET NUMBER: IN21044-5  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 305-527-2498  
 TELEFAX: 305-764-4996  
 INFORMATION FOR SEQ ID NO: 29:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1828 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: cDNA  
 FEATURE:  
 NAME/KEY: CDS  
 LOCATION: 233..643  
 US-09-362-230-29

Query Match 16.6%; Score 98.4; DB 4; Length 1828;  
 Best Local Similarity 57.6%; Pred. No. 9e-18;  
 Matches 196; Conservative 0; Mismatches 141; Indels 3; Gaps 1;  
 QY 69 GTGTGATTCCTCAATCCAGGCGGGATCCTGAACTGAACCAAGATGGTCAAGCAAGTCACTG 128  
 Db 273 GTGTGCTCGAGTCCAGGCGGGCTTGCTAGAACTGAAGTCCATGATTGAGAAGGTGACTG 332  
 QY 129 GGAATATGCCATCTCTCTACTGSCCTTACGGCTGTCACTGCGGACTAGGTGGCAGAG 188  
 Db 333 GGAAGAAATGCCGTAAGAACTATGGCTTCTACGGCTGTCTACTGTGGCGGGCGCCAG 392  
 QY 189 GCCAACCCCAAGATGCCAGGACTGGTGTGTCGAGACCCATGACTGTCTATGACACACC 248  
 Db 393 GGACCCCTAAGATGGCACTGATTTGGTGTGTCGGATGACGACCGTGTATGGGCTAC 452  
 QY 249 TGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGA 308  
 Db 453 TGGAGGAGAAACACTGTGCCATCCGACCCAGTCTTATGACTACAGATTACACAGG-- 509  
 QY 309 ACATCCACTCTGTGACAGGAGCTGGTGTGAGCAGAGCTGTGCTGTGACAAAGG 368  
 Db 510 ACTTAGTCACTGTGCAACAGCACTCTCTTCTGTCCAGTGGGCTTTGTGTTGTGACCGGA 569  
 QY 369 AGGTGGGCTTCTGCTGAAGCGCAACCTGGACACCTACCA 408

RESULT 10  
 PCT-US94-07926-29  
 ; Sequence 29, Application PC/TUS9407926

GENERAL INFORMATION:  
 APPLICANT: Tischfield, Jay A.  
 APPLICANT: Seilhamer, Jeffrey J.  
 TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide  
 TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences  
 TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide  
 TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites  
 NUMBER OF SEQUENCES: 44  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &  
 ADDRESSEE: Russell PA  
 STREET: 200 East Broward Boulevard  
 CITY: Fort Lauderdale  
 STATE: FL  
 COUNTRY: USA  
 ZIP: 33301  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.25  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: PCT/US94/07926  
 FILING DATE: 15-JUL-1994  
 CLASSIFICATION:  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/097,354  
 FILING DATE: 26-JUL-1993  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Manso, Peter J.  
 REGISTRATION NUMBER: 32,264  
 REFERENCE/DOCKET NUMBER: IN21044-5  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 305-527-2498  
 TELEFAX: 305-764-4996  
 INFORMATION FOR SEQ ID NO: 29:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 1828 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: cDNA  
 FEATURE:  
 NAME/KEY: CDS  
 LOCATION: 233..643  
 PCT-US94-07926-29

Query Match 16.6%; Score 98.4; DB 5; Length 1828;  
 Best Local Similarity 57.6%; Pred. No. 9e-18;  
 Matches 196; Conservative 0; Mismatches 141; Indels 3; Gaps 1;  
 QY 69 GTGTGATTCCTCAATCCAGGCGGGATCCTGAACTGAACCAAGATGGTCAAGCAAGTCACTG 128  
 Db 273 GTGTGCTCGAGTCCAGGCGGGCTTGCTAGAACTGAAGTCCATGATTGAGAAGGTGACTG 332  
 QY 129 GGAATATGCCATCTCTCTACTGSCCTTACGGCTGTCACTGCGGACTAGGTGGCAGAG 188  
 Db 333 GGAAGAAATGCCGTAAGAACTATGGCTTCTACGGCTGTCTACTGTGGCGGGCGCCAG 392  
 QY 189 GCCAACCCCAAGATGCCAGGACTGGTGTGTCGAGACCCATGACTGTCTATGACACACC 248  
 Db 393 GGACCCCTAAGATGGCACTGATTTGGTGTGTCGGATGACGACCGTGTATGGGCTAC 452  
 QY 249 TGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACTTTTCCAGGGGA 308  
 Db 453 TGGAGGAGAAACACTGTGCCATCCGACCCAGTCTTATGACTACAGATTACACAGG-- 509  
 QY 309 ACATCCACTCTGTGACAGGAGCTGGTGTGAGCAGAGCTGTGCTGTGACAAAGG 368  
 Db 510 ACTTAGTCACTGTGCAACAGCACTCTCTTCTGTCCAGTGGGCTTTGTGTTGTGACCGGA 569  
 QY 369 AGGTGGGCTTCTGCTGAAGCGCAACCTGGACACCTACCA 408

Db 570 AGCTGGTCTACTGCTGAGGAGAAACCTCTGAGTTACAA 609

RESULT 11

US-08-888-497-21

; Sequence 21, Application US/08888497

; Patent No. 5972677

; GENERAL INFORMATION:

; APPLICANT: Tischfield, Jay A.

; APPLICANT: Seilhamer, Jeffrey J.

; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide

; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences

; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide

; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites

; NUMBER OF SEQUENCES: 44

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &

; ADDRESSEE: Russell PA

; STREET: 200 East Broward Boulevard

; CITY: Fort Lauderdale

; STATE: FL

; COUNTRY: USA

; ZIP: 33301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/888,497

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US/08/651,405

; FILING DATE:

; APPLICATION NUMBER: US 08/097,354

; FILING DATE: 26-JUL-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Manso, Peter J.

; REGISTRATION NUMBER: 32,264

; REFERENCE/DOCKET NUMBER: IN21044-5

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 305-527-2498

; TELEFAX: 305-764-4996

; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 4325 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 722..1195

US-08-888-497-21

Query Match 15.6%; Score 92.6; DB 2; Length 4325;

Best Local Similarity 56.9%; Pred. No. 4.9e-16;

Matches 195; Conservative 0; Mismatches 139; Indels 9; Gaps 1;

Qy 78 CAATCCAGGGGGGATCTCTGAACCTGAAGAGTGGTCAAGCAAGTGAAGTGGGAAATGC 137

Db 795 CCACCTCAGCAGCTCTTCCAGAGATGGTCAACACATCACGGGGCGCAGCG 854

Qy 138 CCATCTCTCTACTGCGCCCTACGCTCTACTGCGGACTAGGTGGGAGAGGCCAACCCCA 197

Db 855 CTTCTCTCTCTATACGATATGCTGCTACTGTGGGCTTGGGGCGGAGGATCCCTG 914

Qy 198 AAGATGCCACGAGTGGTGTGCCAGACCCATGCTGCTGTATGACCACTGAAGACCC 257

Db 915 TGGAGCCACAGACAGGTGCTGCTGGGCTCATGCTGTGTGTACCAAGCTTAAAGAA 974

Qy 258 AGGGGTGGGCACTTACAAAGGACTATTACAGATACAACTTTTCCAGGGGAAATCCACT 317

Db 975 ATGGCTGCCAGCCATCTTGAATGCCATATCAGTTTGCATTTGCAACGGGACCGTGACCT 1034

Qy 318 G-----CTCTGACAAAGGAAGCTGGTGTGAGCAGCAGCTGTGTGCTGTGACAAAGG 368

Db 1035 GTGATGCACCATGGGTGGCGGCTGTTGTGCGGGCAGAAAGCTGTGAGTGTGACAAAC 1094

Qy 369 AGTGGCTTCTCCCTGAAGCGCAACCTGGACACCTTACCAGAA 411

Db 1095 TGTCTGTGACTCTTCAAGGAGAACCTGGCCACCTACGAGAA 1137

RESULT 12

US-09-362-230-21

; Sequence 21, Application US/09362230

; Patent No. 6352849

; GENERAL INFORMATION:

; APPLICANT: Tischfield, Jay A.

; APPLICANT: Seilhamer, Jeffrey J.

; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide

; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences

; TITLE OF INVENTION: Encoded Thereby, Antisense Sequences and Nucleotide

; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites

; NUMBER OF SEQUENCES: 44

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &

; ADDRESSEE: Russell PA

; STREET: 200 East Broward Boulevard

; CITY: Fort Lauderdale

; STATE: FL

; COUNTRY: USA

; ZIP: 33301

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/362,230

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/888,497

; FILING DATE:

; APPLICATION NUMBER: US 08/097,354

; FILING DATE: 26-JUL-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Manso, Peter J.

; REGISTRATION NUMBER: 32,264

; REFERENCE/DOCKET NUMBER: IN21044-5

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 305-527-2498

; TELEFAX: 305-764-4996

; INFORMATION FOR SEQ ID NO: 21:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 4325 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; FEATURE:

; NAME/KEY: CDS

; LOCATION: 722..1195

US-09-362-230-21

Query Match 15.6%; Score 92.6; DB 4; Length 4325;

Best Local Similarity 56.9%; Pred. No. 4.9e-16;

Matches 195; Conservative 0; Mismatches 139; Indels 9; Gaps 1;

Qy 78 CAATCCAGGGGGGATCTCTGAACCTGAAGAGTGGTCAAGCAAGTGAAGTGGGAAATGC 137

Db 795 CCACCTCAGCAGCTCTTCCAGAGATGGTCAACACATCACGGGGCGCAGCG 854

Matches 195; Conservative 0; Mismatches 139; Indels 9; Gaps 1;  
QY 78 CAATCCAGGCGGATCCTGAACCTGAACAGATGTCACAGTGAAGTGGGAAATGC 137  
Db 795 CCACCTCAGCAGCTTCTGCAGTTCCAGAGGATGGTCAACACATCACGGGCGCAGCG 854  
QY 138 CAATCCTCTCTACTGCGCCCTACGGCTGTCACTGGGACTAGGTGGCAGAGGCCAACCCCA 197  
Db 855 CCTCTCTCTCTACTGCGCCCTACGGCTGTCACTGGGACTAGGTGGCAGAGGCCAACCCCA 914  
QY 198 AAGATGCCAGGACTGCTGCTGCGCAGACCCATGCTGCTATGACACCTGAAGACCC 257  
Db 915 TGGACGCCACAGACAGGTGCTGCTGGGCTCATGACTGTGTACCAAGCTTAAGGAAT 974  
QY 258 AGGCGTGGGCTGCTGCTGAAGCGCAACCTGGACACCTACCGAA 411  
Db 975 ATGGCTGCCGCCCATCTTGAATGCTTATGCTTGCCTTGTCAACGGGACCGTGACCT 1034  
QY 318 G-----CTCTGACAAAGGAAAGCTGCTGAGCAGCAGCTGTGCTGCTGTGACAAAGG 368  
Db 1035 GTGATGCCACCATGGTGGCGGCTGCTTGTGGGCGCAGAAAGCCTGTGAGTGTGACAAAC 1094  
QY 369 AGTGGCCTTCTGCTGAAAGCGCAACCTGGACACCTACCGAA 411  
Db 1095 TGCTGTGCTACTGCTTCAAGGAGAACCTGGCCACCTACGAGAA 1137  
RESULT 14  
US-08-966-317-2  
; Sequence 2, Application US/08966317  
; Patent No. 6103469  
; GENERAL INFORMATION:  
; APPLICANT: Hawkins, Phillip R.  
; APPLICANT: Bandman, Olga  
; APPLICANT: Guegler, Karl J.  
; APPLICANT: Shah, Purvi  
; APPLICANT: Corley, Neil C.  
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 PROTEIN  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Incyte Pharmaceuticals, Inc.  
; STREET: 3174 Porter Dr.  
; CITY: Palo Alto  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94304  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: DOS  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/966,317  
; FILING DATE: Filed Herewith  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Billings, Lucy J.  
; REGISTRATION NUMBER: 36,749  
; REFERENCE/DOCKET NUMBER: PF-0403 US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650-855-0555  
; TELEFAX: 650-845-4166  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 742 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; LIBRARY: OVARTUT01  
; CLONE: 816403

QY 138 CCATCCTCTCTACTGCGCCCTACGGCTGTCACTGCGGACTAGGTGGCAGAGGCCAACCCCA 197  
Db 855 CCTCTCTCTCTACTGCGCCCTACGGCTGTCACTGCGGACTAGGTGGCAGAGGCCAACCCCA 914  
QY 198 AAGATGCCAGGACTGCTGCTGCGCAGACCCATGCTGCTATGACACCTGAAGACCC 257  
Db 915 TGGACGCCACAGACAGGTGCTGCTGGGCTCATGACTGTGTACCAAGCTTAAGGAAT 974  
QY 258 AGGCGTGGGCTGCTGCTGAAGCGCAACCTGGACACCTACCGAA 411  
Db 975 ATGGCTGCCGCCCATCTTGAATGCTTATGCTTGCCTTGTCAACGGGACCGTGACCT 1034  
QY 318 G-----CTCTGACAAAGGAAAGCTGCTGAGCAGCAGCTGTGCTGCTGTGACAAAGG 368  
Db 1035 GTGATGCCACCATGGTGGCGGCTGCTTGTGGGCGCAGAAAGCCTGTGAGTGTGACAAAC 1094  
QY 369 AGTGGCCTTCTGCTGAAAGCGCAACCTGGACACCTACCGAA 411  
Db 1095 TGCTGTGCTACTGCTTCAAGGAGAACCTGGCCACCTACGAGAA 1137  
RESULT 13  
PCT-US94-07926-21  
; Sequence 21, Application PC/TUS9407926  
; GENERAL INFORMATION:  
; APPLICANT: Tischfield, Jay A.  
; APPLICANT: Seilhamer, Jeffrey J.  
; TITLE OF INVENTION: Mammalian Phospholipase A2 Nucleotide  
; TITLE OF INVENTION: Sequences and Low Molecular Weight Amino Acid Sequences  
; TITLE OF INVENTION: Encoded Therapy, Antisense Sequences and Nucleotide  
; TITLE OF INVENTION: Sequences Having Internal Ribosome Binding Sites  
; NUMBER OF SEQUENCES: 44  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Ruden, Barnett, McClosky, Smith, Schuster &  
; ADDRESSEE: Russell PA  
; STREET: 200 East Broward Boulevard  
; CITY: Fort Lauderdale  
; STATE: FL  
; COUNTRY: USA  
; ZIP: 33301  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US94/07926  
; FILING DATE: 15-JUL-1994  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/097,354  
; FILING DATE: 28-JUL-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Manso, Peter J.  
; REGISTRATION NUMBER: 32,264  
; REFERENCE/DOCKET NUMBER: IN21044-5  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 305-527-2498  
; TELEFAX: 305-764-4996  
; INFORMATION FOR SEQ ID NO: 21:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4325 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 722..1195  
PCT-US94-07926-21  
Query Match 15.6%; Score 92.6; DB 5; Length 4325;  
Best Local Similarity 56.9%; Pred. No. 4.9e-16;

Query Match	10.7%	Score 63.2;	DB 4;	Length 742;
Best Local Similarity	51.8;	Pred. No. 3.5e-08;		
Matches 143;	Conservative 0;	Mismatches 133;	Indels 0;	Gaps 0;

  

QY	138	CCATCCTCTCCTACTGGCCCTACGGCTGTGCAC	TGCGGACTAGGTGGCAGAGGCCAACCCCA	197
Db	197	CCCCATCGCTATATGAATATAGTTTGCTTTTGTG	CGCTTGGGAGGCCATGGCCAGGCCCC	256
QY	198	AAGATGCCAGGACTGGTGTGCCAGACCCATGACT	CTGCTATGACCACTCGAAGACCC	257
Db	257	GCGATGCCATTGACTGGTGTGCTGCATGGCCACG	ACTGTTGTACACTCGAGCTGAGGAGG	316
QY	258	AGGGGTGCGCATCTCAAGGACTATTACAGATACA	ACTTTTCCAGGGGAACATCCACT	317
Db	317	CCGGCTGCAGCCCAAGACAGACGCGTACTCTCT	GGCAGTGGCTCAATCAGAGCGTCTCTGT	376
QY	318	GCTCTGACAGGGAAGCTGGTGTGAGCAGCAGCT	GTGTGCTCTGTGACAAGAGGTGCCT	377
Db	377	CGCGACGGGACAGAACAAATGCCAAGACTGTT	TGCAAGTGTGACCGAGGATTGCTA	436
QY	378	TTTGCTCGAAGCGCAACCTGGACACCTACCAGA	AAGC	413
Db	437	ACTGCTTAGCCCAAACTGAGTGACAACTTAAAG	TACC	472

Search completed: October 7, 2004, 18:59:22  
Job time : 49.7926 secs

is Page Blank (uspto)



QY 136 GCCCATCCTCTCCTACTGGCCCTACGGCTG



```

RESULT 4
US - 09-946-374-377
Sequence 377, Application US/09946374
Publication No. US20030073129A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnuyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Smith, Victoria
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Watanabe, Colin K.
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secured and Transmitted Data
TITLE OF INVENTION: Acids Encoding and Methods of Synthesis
FILE REFERENCE: P2830P1C1
CURRENT APPLICATION NUMBER: US/09-946-374-377
CURRENT FILING DATE: 2001-09-04
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 2001-09-04

```

; PRIOR APPLICATION NUMBER: 60/101068  
 ; PRIOR FILING DATE: 1998-09-18  
 ; PRIOR APPLICATION NUMBER: 60/101071  
 ; PRIOR FILING DATE: 1998-09-18  
 ; PRIOR APPLICATION NUMBER: 60/101279  
 ; PRIOR FILING DATE: 1998-09-22  
 ; PRIOR APPLICATION NUMBER: 60/101471  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101472  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101474  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101475  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101476  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101477  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101479  
 ; PRIOR FILING DATE: 1998-09-23  
 ; PRIOR APPLICATION NUMBER: 60/101738  
 ; PRIOR FILING DATE: 1998-09-24  
 ; PRIOR APPLICATION NUMBER: 60/101915  
 ; PRIOR FILING DATE: 1998-09-24  
 ; PRIOR APPLICATION NUMBER: 60/101916  
 ; PRIOR FILING DATE: 1998-09-24  
 ; PRIOR APPLICATION NUMBER: 60/102207  
 ; PRIOR FILING DATE: 1998-09-29  
 ; PRIOR APPLICATION NUMBER: 60/102240  
 ; PRIOR FILING DATE: 1998-09-29  
 ; PRIOR APPLICATION NUMBER: 60/102307  
 ; PRIOR FILING DATE: 1998-09-29  
 ; PRIOR APPLICATION NUMBER: 60/102330  
 ; PRIOR FILING DATE: 1998-09-29  
 ; PRIOR APPLICATION NUMBER: 60/102331  
 ; PRIOR FILING DATE: 1998-09-29  
 ; PRIOR APPLICATION NUMBER: 60/102484  
 ; PRIOR FILING DATE: 1998-09-30  
 ; PRIOR APPLICATION NUMBER: 60/102487  
 ; PRIOR FILING DATE: 1998-09-30  
 ; PRIOR APPLICATION NUMBER: 60/102570  
 ; PRIOR FILING DATE: 1998-09-30  
 ; PRIOR APPLICATION NUMBER: 60/102571  
 ; PRIOR FILING DATE: 1998-09-30  
 ; PRIOR APPLICATION NUMBER: 60/102684  
 ; PRIOR FILING DATE: 1998-10-01  
 ; PRIOR APPLICATION NUMBER: 60/102687  
 ; PRIOR FILING DATE: 1998-10-01  
 ; PRIOR APPLICATION NUMBER: 60/102965  
 ; PRIOR FILING DATE: 1998-10-02  
 ; PRIOR APPLICATION NUMBER: 60/103258  
 ; PRIOR FILING DATE: 1998-10-06  
 ; PRIOR APPLICATION NUMBER: 60/103314  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103315  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103328  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103395  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103396  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103401  
 ; PRIOR FILING DATE: 1998-10-07  
 ; PRIOR APPLICATION NUMBER: 60/103449  
 ; PRIOR FILING DATE: 1998-10-06  
 ; PRIOR APPLICATION NUMBER: 60/103633  
 ; PRIOR FILING DATE: 1998-10-08  
 ; PRIOR APPLICATION NUMBER: 60/103678

; PRIOR FILING DATE: 1998-10-08  
 ; PRIOR APPLICATION NUMBER: 60/103679  
 ; PRIOR FILING DATE: 1998-10-08  
 ; PRIOR APPLICATION NUMBER: 60/103711  
 ; PRIOR FILING DATE: 1998-10-08  
 ; PRIOR APPLICATION NUMBER: 60/104257  
 ; PRIOR FILING DATE: 1998-10-14  
 ; PRIOR APPLICATION NUMBER: 60/104987  
 ; PRIOR FILING DATE: 1998-10-20  
 ; PRIOR APPLICATION NUMBER: 60/105000  
 ; PRIOR FILING DATE: 1998-10-20  
 ; PRIOR APPLICATION NUMBER: 60/105002  
 ; PRIOR FILING DATE: 1998-10-20  
 ; PRIOR APPLICATION NUMBER: 60/105104  
 ; PRIOR FILING DATE: 1998-10-21  
 ; PRIOR APPLICATION NUMBER: 60/105169  
 ; PRIOR FILING DATE: 1998-10-22  
 ; PRIOR APPLICATION NUMBER: 60/105266  
 ; PRIOR FILING DATE: 1998-10-22  
 ; PRIOR APPLICATION NUMBER: 60/105693  
 ; PRIOR FILING DATE: 1998-10-26  
 ; PRIOR APPLICATION NUMBER: 60/105694  
 ; PRIOR FILING DATE: 1998-10-26  
 ; PRIOR APPLICATION NUMBER: 60/105807

Query Match 48.0%; Score 284.2; DB 10; Length 496;  
 Best Local Similarity 97.3%; Pred. No. 4.4e-79;  
 Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY	1	TCTGCCTCCACTGCTCTGTGTGGGATCATGGAATGACCTGCTGTGTGGGCTGTGGT	60
Db	1	TCTGCCTCCACTGCTCTGTGTGGGATCATGGAATGACCTGCTGTGTGGGCTGTGGT	60
QY	61	GATGGCTGTGTGATTCCAAATCCAGGGGGGATCTGAACTGAAACAAGATGTCAGCA	120
Db	61	GATGGCTGTGTGATTCCAAATCCAGGGGGGATCTGAACTGAAACAAGATGTCAGCA	120
QY	121	AGTGACTGGGAAATGCCCATCTCTCTACTGCGCTACGGCTGCTACTGGGACTAGG	180
Db	121	AGTGACTGGGAAATGCCCATCTCTCTACTGCGCTACGGCTGCTACTGGGACTAGG	180
QY	181	TGGCAGAGGCCAACCCCAAGATGCCAGGATGTGTGTGCCAGACCCATGCTGTGCTA	240
Db	181	TGGCAGAGGCCAACCCCAAGATGCCAGGATGTGTGTGCCAGACCCATGCTGTGCTA	240
QY	241	TGACCACCTGAGACCCAGGGGTGGGCATCTCAAGGACTATTACAGATACAACTT	297
Db	241	TGACCACCTGAGACCCAGGGGTGGGCATCTCAAGGACTATTACAGATACAACTT	297

RESULT 5  
 US-10-015-395A-377  
 ; Sequence 377, Application US/10015395A  
 ; Publication No. US20040073015A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Baker, Kevin P.  
 ; APPLICANT: Botstein, David  
 ; APPLICANT: Desnoyers, Luc  
 ; APPLICANT: Eaton, Dan L.  
 ; APPLICANT: Ferrara, Napoleone  
 ; APPLICANT: Fong, Sherman  
 ; APPLICANT: Gao, Wei-Qiang  
 ; APPLICANT: Goddard, Audrey  
 ; APPLICANT: Godowski, Paul J.  
 ; APPLICANT: Grimaldi, Christopher J.  
 ; APPLICANT: Gurney, Austin L.  
 ; APPLICANT: Hillan, Kenneth J.  
 ; APPLICANT: Pan, James  
 ; APPLICANT: Paoni, Nicholas F.  
 ; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
 ; TITLE OF INVENTION: Acids Encoding the Same  
 ; FILE REFERENCE: F2830PIC57  
 ; CURRENT APPLICATION NUMBER: US/10/015,395A



Db 1 TCTGCTCCACTGCTCTGTCTGGGATCATGGAACTTGCACTGCTGTGGGCTGGTGT 60  
QY 61 GATGGCTGGTGTGATTCCAATCCAGGCGGGATCTTGAACTTGACAGATGGTCAAGCA 120  
Db 61 GATGGCTGGTGTGATTCCAATCCAGGCGGGATCTTGAACTTGACAGATGGTCAAGCA 120  
QY 121 AGTGAAGTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGGGACTAGG 180  
Db 121 AGTGAAGTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGGGACTAGG 180  
QY 181 TGGCAGAGGCCAACCCAAAGATGCCAGGATGGTGTGCTGCCAGACCCATGCTGTGCTA 240  
Db 181 TGGCAGAGGCCAACCCAAAGATGCCAGGATGGTGTGCTGCCAGACCCATGCTGTGCTA 240  
QY 241 TGACCACCTGAGACCCAGGGGTGGGCATCTACAGGACTATTACAGATACAATT 297  
Db 241 TGACCACCTGAGACCCAGGGGTGGGCATCTACAGGACTATTACAGATACAATT 297

## RESULT 8

US-10-160-503-533

; Sequence 533, Application US/10160503

; Publication No. US20040033559A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Beresini, Maureen

; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc

; APPLICANT: Filvaroff, Ellen

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Sherwood, Steven

; APPLICANT: Smith, Victoria

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K

; APPLICANT: Wood, William

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

; FILE REFERENCE: P3330R1C446

; CURRENT APPLICATION NUMBER: US/10/160,503

; CURRENT FILING DATE: 2002-05-30

; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 533

; LENGTH: 496

; TYPE: DNA

; ORGANISM: Homo Sapien

; FEATURE:

; NAME/KEY: unsure

; LOCATION: 396

; OTHER INFORMATION: unknown base

US-10-160-503-533

Query Match 48.0%; Score 284.2; DB 13; Length 496;

Best Local Similarity 97.3%; Pred. No. 4.4e-79;

Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1 TCTGCTCCACTGCTGTGTGGGATCATGGAACTTGCACTGCTGTGGGCTGGTGT 60  
Db 1 TCTGCTCCACTGCTGTGTGGGATCATGGAACTTGCACTGCTGTGGGCTGGTGT 60  
QY 61 GATGGCTGGTGTGATTCCAATCCAGGCGGGATCTTGAACTTGACAGATGGTCAAGCA 120  
Db 61 GATGGCTGGTGTGATTCCAATCCAGGCGGGATCTTGAACTTGACAGATGGTCAAGCA 120  
QY 121 AGTGAAGTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGGGACTAGG 180  
Db 121 AGTGAAGTGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGGGACTAGG 180

## RESULT 10

US-10-144-993-533  
; Sequence 533, Application US/10144993  
; Publication No. US20040038336A1  
; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura  
; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3330R1C261

; CURRENT APPLICATION NUMBER: US/10/144,993  
; CURRENT FILING DATE: 2002-05-13

; Prior Application removed - See File Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 550

; SEQ ID NO 533  
; LENGTH: 496

; TYPE: DNA  
; ORGANISM: Homo Sapien

; FEATURE:  
; NAME/KEY: unsure

; LOCATION: 396  
; OTHER INFORMATION: unknown base

US-10-144-993-533

Query Match 48.0%; Score 284.2; DB 13; Length 496;

Best Local Similarity 97.3%; Pred. No. 4.4e-79;

Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY	1	TCCTGCTCCACTGCTGCTGGGATCATGGAACCTTGCACTGCTGTGGGGCTGTGGT	60
Db	1	TCCTGCTCCACTGCTGCTGTGGGATCATGGAACCTTGCACTGCTGTGGGGCTGTGGT	60
QY	61	GATGCTGGTGTGATTCCTCAATCCAGGGCGGGATCCTGAACTGAACTGAACTGCTCAAGCA	120
Db	61	GATGCTGGTGTGATTCCTCAATCCAGGGCGGGATCCTGAACTGAACTGAACTGCTCAAGCA	120
QY	121	AGTGACTGGGAAATGCCCAATCCAGGATGCCAGGATGCTGCTGCCAGCCATGCTGTGCTA	180
Db	121	AGTGACTGGGAAATGCCCAATCCAGGATGCCAGGATGCTGCTGCCAGCCATGCTGTGCTA	180
QY	181	TGGCAGAGCCCAACCCAAAGATGCCAGGATGCCAGGATGCTGCTGCCAGCCATGCTGTGCTA	240
Db	181	TGGCAGAGCCCAACCCAAAGATGCCAGGATGCCAGGATGCTGCTGCCAGCCATGCTGTGCTA	240
QY	241	TGACCACTGGAAGACCCAGGGGTGGGCATCTTACAAGGACTATTACAGATACAACCTT	297
Db	241	TGACCACTGGAAGACCCAGGGGTGGGCATCTTACAAGGACTATTACAGATACAACCTT	297

## RESULT 11

US-10-158-787-533

; Sequence 533, Application US/10158787  
; Publication No. US20040039164A1  
; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.  
; APPLICANT: Beresini, Maureen  
; APPLICANT: DeForge, Laura

; APPLICANT: Desnoyers, Luc  
; APPLICANT: Filvaroff, Ellen  
; APPLICANT: Gao, Wei-Qiang  
; APPLICANT: Gerritsen, Mary E.  
; APPLICANT: Goddard, Audrey  
; APPLICANT: Godowski, Paul J.  
; APPLICANT: Gurney, Austin L.  
; APPLICANT: Sherwood, Steven  
; APPLICANT: Smith, Victoria  
; APPLICANT: Stewart, Timothy A.  
; APPLICANT: Tumas, Daniel  
; APPLICANT: Watanabe, Colin K  
; APPLICANT: Wood, William  
; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC  
; FILE REFERENCE: P3330R1C449

; CURRENT APPLICATION NUMBER: US/10/158,787  
; CURRENT FILING DATE: 2003-04-03

; Prior Application Number: 60/049911  
; Prior Application Number: 60/056974

; Prior Application Number: 60/059113  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

; Prior Application Number: 60/059117  
; Prior Application Number: 60/059117

```

Db      241 TGACCACCTGAAGACCCAGGGGTGGGCATCTACAAGGACAAACAACAAAGCAGCAT 297

RESULT 12
US-10-140-024-533
; Sequence 533, Application US/10140024
; Publication No. US20040058424A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C69
; CURRENT APPLICATION NUMBER: US/10/140,024
; CURRENT FILING DATE: 2002-05-06
; Prior Application removed - See Palm or File Wrapper
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 533
; LENGTH: 496
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 396
; OTHER INFORMATION: unknown base
;
US-10-140-024-533

Query Match      48.0%; Score 284.2; DB 13; Length 496;
Best Local Similarity 97.3%; Pred. No. 4.4e-79;
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY      1 TCTGCCTCCACTGCTCTGTGCTGGGATCATGGAACCTTGCACTGCTGTGTGGGCTGGTGT 60
Db      1 TCTGCCTCCACTGCTCTGTGCTGGGATCATGGAACCTTGCACTGCTGTGTGGGCTGGTGT 60

QY      61 GATGCTGTGTGATTCCAAATCCAGGGGGGATCTTGAACCTTGAACAGATGCTCAAGCA 120
Db      61 GATGCTGTGTGATTCCAAATCCAGGGGGGATCTTGAACCTTGAACAGATGCTCAAGCA 120

QY      121 AGTGAATGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180
Db      121 AGTGAATGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180

QY      181 TGGCAGAGGCCAACCCAAAGATGCCACGGACTGGTGTGCTGCCAGACCCATGACTGTGCTA 240
Db      181 TGGCAGAGGCCAACCCAAAGATGCCACGGACTGGTGTGCTGCCAGACCCATGACTGTGCTA 240

QY      241 TGACCACCTGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACATT 297
Db      241 TGACCACCTGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACATT 297

RESULT 13
US-10-140-808-533
; Sequence 533, Application US/10140808
; Publication No. US20030017563A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.

```

```

; APPLICANT: Beresini, Maureen
; APPLICANT: DeForge, Laura
; APPLICANT: Desnoyers, Luc
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Sherwood, Steven
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K
; APPLICANT: Wood, William
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3330R1C182
; CURRENT APPLICATION NUMBER: US/10/140,808
; CURRENT FILING DATE: 2002-05-07
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 550
; SEQ ID NO 533
; LENGTH: 496
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 396
; OTHER INFORMATION: unknown base
;
US-10-140-808-533

Query Match      48.0%; Score 284.2; DB 13; Length 496;
Best Local Similarity 97.3%; Pred. No. 4.4e-79;
Matches 289; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY      1 TCTGCCTCCACTGCTCTGTGCTGGGATCATGGAACCTTGCACTGCTGTGTGGGCTGGTGT 60
Db      1 TCTGCCTCCACTGCTCTGTGCTGGGATCATGGAACCTTGCACTGCTGTGTGGGCTGGTGT 60

QY      61 GATGCTGTGTGATTCCAAATCCAGGGGGGATCTTGAACCTTGAACAGATGCTCAAGCA 120
Db      61 GATGCTGTGTGATTCCAAATCCAGGGGGGATCTTGAACCTTGAACAGATGCTCAAGCA 120

QY      121 AGTGAATGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180
Db      121 AGTGAATGGGAAATGCCCATCTCTCTACTGGCCCTACGGCTGTCACTGCGGACTAGG 180

QY      181 TGGCAGAGGCCAACCCAAAGATGCCACGGACTGGTGTGCTGCCAGACCCATGACTGTGCTA 240
Db      181 TGGCAGAGGCCAACCCAAAGATGCCACGGACTGGTGTGCTGCCAGACCCATGACTGTGCTA 240

QY      241 TGACCACCTGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACATT 297
Db      241 TGACCACCTGAAGACCCAGGGGTGGGCATCTACAAGGACTATTACAGATACAACATT 297

RESULT 14
US-10-006-485A-377
; Sequence 377, Application US/10006485A
; Publication No. US20030064062A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.

```



APPLICANT: Gurney, Austin L.  
APPLICANT: Hillan, Kenneth J.  
APPLICANT: Pan, James  
APPLICANT: Paoni, Nicholas F.  
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic  
ACIDS Encoding the Same  
FILE REFERENCE: P2830P1C9  
CURRENT APPLICATION NUMBER: US/10/006,485A  
CURRENT FILING DATE: 2001-12-06  
PRIOR APPLICATION NUMBER: 60/098716  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098723  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098749  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098750  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: 60/098803  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/098821  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/098843  
PRIOR FILING DATE: 1998-09-02  
PRIOR APPLICATION NUMBER: 60/099536  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099596  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099598  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099602  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099642  
PRIOR FILING DATE: 1998-09-09  
PRIOR APPLICATION NUMBER: 60/099741  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099754  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099763  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099792  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099808  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099812  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099815  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/099816  
PRIOR FILING DATE: 1998-09-10  
PRIOR APPLICATION NUMBER: 60/100385  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100388  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100390  
PRIOR FILING DATE: 1998-09-15  
PRIOR APPLICATION NUMBER: 60/100584  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100627  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100661  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100662  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100664  
PRIOR FILING DATE: 1998-09-16  
PRIOR APPLICATION NUMBER: 60/100683  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100684  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100710  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100711  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100848  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/100849  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/100919  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/100930  
PRIOR FILING DATE: 1998-09-17  
PRIOR APPLICATION NUMBER: 60/101014  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101068  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101071  
PRIOR FILING DATE: 1998-09-18  
PRIOR APPLICATION NUMBER: 60/101279  
PRIOR FILING DATE: 1998-09-22  
PRIOR APPLICATION NUMBER: 60/101471  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101472  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101474  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101475  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101476  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101477  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101479  
PRIOR FILING DATE: 1998-09-23  
PRIOR APPLICATION NUMBER: 60/101738  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101741  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101743  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101915  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/101916  
PRIOR FILING DATE: 1998-09-24  
PRIOR APPLICATION NUMBER: 60/102207  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102240  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102307  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102330  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102331  
PRIOR FILING DATE: 1998-09-29  
PRIOR APPLICATION NUMBER: 60/102484  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102487  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102570  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102571  
PRIOR FILING DATE: 1998-09-30  
PRIOR APPLICATION NUMBER: 60/102684  
PRIOR FILING DATE: 1998-10-01  
PRIOR APPLICATION NUMBER: 60/102687  
PRIOR FILING DATE: 1998-10-01  
PRIOR APPLICATION NUMBER: 60/102965  
PRIOR FILING DATE: 1998-10-02  
PRIOR APPLICATION NUMBER: 60/103258  
PRIOR FILING DATE: 1998-10-06  
PRIOR APPLICATION NUMBER: 60/103314  
PRIOR FILING DATE: 1998-10-07  
PRIOR APPLICATION NUMBER: 60/103315  
PRIOR FILING DATE: 1998-10-07  
PRIOR APPLICATION NUMBER: 60/103328  
PRIOR FILING DATE: 1998-10-07  
PRIOR APPLICATION NUMBER: 60/103395

1	PRIOR FILING DATE: 1998-10-07	
2	PRIOR APPLICATION NUMBER: 60/103396	
3	PRIOR FILING DATE: 1998-10-07	
4	PRIOR APPLICATION NUMBER: 60/103401	
5	PRIOR FILING DATE: 1998-10-07	
6	PRIOR APPLICATION NUMBER: 60/103449	
7	PRIOR FILING DATE: 1998-10-06	
8	PRIOR APPLICATION NUMBER: 60/103633	
9	PRIOR FILING DATE: 1998-10-08	
10	PRIOR APPLICATION NUMBER: 60/103678	
11	PRIOR FILING DATE: 1998-10-08	
12	PRIOR APPLICATION NUMBER: 60/103679	
13	PRIOR FILING DATE: 1998-10-08	
14	PRIOR APPLICATION NUMBER: 60/103711	
15	PRIOR FILING DATE: 1998-10-08	
16	PRIOR APPLICATION NUMBER: 60/104257	
17	PRIOR FILING DATE: 1998-10-14	
18	PRIOR APPLICATION NUMBER: 60/104987	
19	PRIOR FILING DATE: 1998-10-20	
20	PRIOR APPLICATION NUMBER: 60/105000	
21	PRIOR FILING DATE: 1998-10-20	
22	PRIOR APPLICATION NUMBER: 60/105002	
23	PRIOR FILING DATE: 1998-10-20	
24	PRIOR APPLICATION NUMBER: 60/105104	
25	PRIOR FILING DATE: 1998-10-21	
26	PRIOR APPLICATION NUMBER: 60/105169	
27	PRIOR FILING DATE: 1998-10-22	
28	PRIOR APPLICATION NUMBER: 60/105266	
29	PRIOR FILING DATE: 1998-10-22	
30	PRIOR APPLICATION NUMBER: 60/105693	
31	PRIOR FILING DATE: 1998-10-26	
32	PRIOR APPLICATION NUMBER: 60/105694	
33	PRIOR FILING DATE: 1998-10-26	
34	PRIOR APPLICATION NUMBER: 60/105807	
35	PRIOR FILING DATE: 1998-10-27	
36	PRIOR APPLICATION NUMBER: 60/105881	
37	PRIOR FILING DATE: 1998-10-27	
38	PRIOR APPLICATION NUMBER: 60/105882	
39	PRIOR FILING DATE: 1998-10-27	
40	PRIOR APPLICATION NUMBER: 60/106023	
41	PRIOR FILING DATE: 1998-10-28	

```

; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Inc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC34
; CURRENT APPLICATION NUMBER: US/10/013,907A
; CURRENT FILING DATE: 2001-12-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 377
; LENGTH: 496
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: unsure
; LOCATION: 396
; OTHER INFORMATION: unknown base
US-10-013-907A-377

```

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 11:14:15 ; Search time 937.252 Seconds  
(without alignments)  
9989.875 Million cell updates/sec

Title: US-09-830-321A-5  
Perfect score: 2204  
Sequence: 1 catggttggggcgcagaga.....actcatcaaaaaaaaaaaaaa 2204

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : N Geneseq 29Jan04:\*

- 1: Geneseqn1980s:\*
- 2: Geneseqn1980s:\*
- 3: Geneseqn2000s:\*
- 4: Geneseqn2001as:\*
- 5: Geneseqn2001bs:\*
- 6: Geneseqn2002s:\*
- 7: Geneseqn2003as:\*
- 8: Geneseqn2003bs:\*
- 9: Geneseqn2003cs:\*
- 10: Geneseqn2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2202	99.9	2204	3	AA53270 Human pho
2	1816.8	82.4	3085	3	Aaz88757 Human PLA
3	1816.8	82.4	3085	3	Aaz88758 Human PLA
4	1816.8	82.4	3085	4	Aaf74999 Phospholi
5	1816.8	82.4	3085	4	Aaf75000 Phospholi
6	1816.8	82.4	3085	4	Aaf90489 Human pho
7	1816.8	82.4	3085	4	Aaf90488 Human pho
8	1806.2	82.0	2699	6	AA517363 cDNA enco
9	1806.2	82.0	2699	7	ABX11884 Human cDN
10	1806.2	82.0	4183	6	AA517362 Partial c
11	1806.2	82.0	4183	7	ABX11883 Human par
12	1788.8	81.2	1925	2	AAV34229 Human sec
13	1788.8	81.2	1925	7	ACD08100 cDNA enco
14	1777.8	80.7	1926	2	AAV34164 Human sec
15	1777.8	80.7	1926	7	ACD08035 cDNA enco
16	1676.6	76.1	1818	2	AAV34230 Human sec
17	1676.6	76.1	1818	7	ACD08101 cDNA enco
18	1432.2	65.0	3419	5	AA584341 DNA enco
19	1408.6	63.9	8517	3	Aaz88756 Human PLA
20	1408.6	63.9	8517	4	Aaf74998 Phospholi
21	1408.6	63.9	8517	4	Aaf90487 Human pho
22	1388.8	63.0	3068	5	AA570058 DNA enco
23	728.8	33.1	5241	5	AA570056 DNA enco

24	602	27.3	2409	6	AA36478 Human pho
25	602	27.3	3138	9	AD10173 Human NOV
26	602	27.3	3197	6	AB94700 Human lip
27	602	27.3	3587	8	ADB6164 Human DNA
28	539.4	24.5	4499	5	AA84340 DNA enco
29	483.8	22.0	1915	9	AA34883 cDNA enco
30	483.8	22.0	1915	9	AD46041 Human neo
31	451.4	20.5	567	5	AA84337 DNA enco
32	439	19.9	494	8	ACH45352 Human foe
33	429.6	19.5	3879	6	ABV72127 Nucleotid
34	415.6	18.9	4049	9	AD93423 Human lip
35	398.2	18.1	3418	9	AD07210 Novel cod
36	398.2	18.1	3460	6	ABL51334 Human pho
37	393.4	17.8	4803	4	AD11574 Human pho
38	393.4	17.8	4820	4	AD11388 Human pho
39	385.8	17.5	2547	6	AB94697 Human lip
40	365	16.6	2694	6	ABL51366 Mouse pho
41	358.6	16.3	3112	6	ABL51352 Mouse pho
42	342.8	15.6	369	3	AAA44804 Human sec
43	336.2	15.3	2397	6	AA36905 Human pho
44	324	14.7	4875	4	AD11386 Human pho
45	321.4	14.6	1317	5	AA84338 DNA enco

ALIGNMENTS

RESULT 1  
AA53270  
ID AA53270 standard; cDNA; 2204 BP.  
XX  
AC AA53270;  
XX  
DT 05-OCT-2000 (first entry)  
XX  
DE Human phospholipase 2 HPPL2 coding sequence.  
XX  
KW Human; phospholipase 2; HPPL2; cancer; autoimmune disorder;  
KW inflammatory disorder; reproductive disorder; infection; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT CDS 95..1912  
FT /tag= a  
FT /product= "HPPL2"  
XX  
PN WO200024911-A2.  
XX  
PD 04-MAY-2000.  
XX  
PF 27-OCT-1999; 99WO-US025021.  
XX  
PR 27-OCT-1998; 98US-00181317.  
PR 21-JAN-1999; 99US-00234726.  
XX  
PA (INCY-) INCYTE PHARM INC.  
XX  
PI Hillman JL, Bardman O, Guegler KJ, Corley NC, Baughn MR,  
PI Azimzai Y, Lal P, Lu DAM;  
XX  
DR WPI; 2000-350750/30.  
DR P-PSDB; AAB03628.  
XX  
PT Human phospholipase genes and proteins useful to diagnose, prevent or  
PT treat cancer, autoimmune or inflammatory or reproductive disorders.  
XX  
PS Claim 9; Page 74-75; 80pp; English.  
XX  
CC The present sequence is the coding sequence of human phospholipase 2  
CC (HPPL2). The protein produced from this sequence is involved in the  
CC hydrolysis of membrane phospholipids. The protein and its coding sequence  
CC can be used to diagnose and treat the following: cancers such as

CC prostate, breast and testicular cancers, autoimmune and inflammatory  
 CC disorders such as AIDS, allergies, anaemia, asthma, atherosclerosis,  
 CC Crohn's disease, diabetes mellitus, emphysema, Graves' disease, irritable  
 CC bowel syndrome, multiple sclerosis, myasthenia gravis, psoriasis,  
 CC rheumatoid arthritis and systemic lupus erythematosus, infection caused  
 CC by viruses, fungi, bacteria, parasites and protozoa, and reproductive  
 CC disorders including infertility, disruptions of the menstrual cycle,  
 CC polycystic ovary syndrome, ectopic pregnancies, disruptions of  
 CC spermatogenesis, cancers within the reproductive tract and impotence. The  
 CC present sequence was obtained from clone no.1430683, which was  
 CC constructed using ileum tissue  
 XX  
 SQ

Sequence 2204 BP; 429 A; 686 C; 625 G; 462 T; 0 U; 2 Other;

Query Match 99.9%; Score 2202; DB 3; Length 2204;

Best Local Similarity 100.0%; Pred. No. 0;

Matches 2204; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CATGGTTGGGGCGCAGAGGGCAGGNANACCAAGGGAGAGAGGGGAAATTGCGCC	60
DB	1	CATGGTTGGGGCGCAGAGGGCAGGNANACCAAGGGAGAGAGGGGAAATTGCGCC	60
QY	61	CTTTTGGGTGAAGCTGTTATGCTGAGCTTAAATGATCTTCGTAGAGTGTGCGCCAC	120
DB	61	CTTTTGGGTGAAGCTGTTATGCTGAGCTTAAATGATCTTCGTAGAGTGTGCGCCAC	120
QY	121	CCTGGCCCTCTGTCTTGGAGAGTGGCTTCTACCTCACAGACACAGGATTAATGGTCT	180
DB	121	CCTGGCCCTCTGTCTTGGAGAGTGGCTTCTACCTCACAGACACAGGATTAATGGTCT	180
QY	181	TTTTTGGCCGCGCCCTGGCCCTTTTTTTTTTTTTTTTGGATGGAGTCTCTCTGTGC	240
DB	181	TTTTTGGCCGCGCCCTGGCCCTTTTTTTTTTTTTTTTGGATGGAGTCTCTCTGTGC	240
QY	241	CCAGGCTGAGTGCATGCGGTGATCTGCTCACTGCAACCTCCGCTCTGGGTTCAA	300
DB	241	CCAGGCTGAGTGCATGCGGTGATCTGCTCACTGCAACCTCCGCTCTGGGTTCAA	300
QY	301	GGGATTCCTGCTCAGCTCCCGAGTAGCTGGGATTACAGACTGAGGAGCTGGCCGT	360
DB	301	GGGATTCCTGCTCAGCTCCCGAGTAGCTGGGATTACAGACTGAGGAGCTGGCCGT	360
QY	361	GGGATTCCTGCTCAGCTCCCGAGTAGCTGGGATTACAGACTGAGGAGCTGGCCGT	420
DB	361	GGGATTCCTGCTCAGCTCCCGAGTAGCTGGGATTACAGACTGAGGAGCTGGCCGT	420
QY	421	GGTGGCCGCGCTTGGAGCAGGCTGAGTGGATGAGACCTGCGAGGAGGATGAGAT	480
DB	421	GGTGGCCGCGCTTGGAGCAGGCTGAGTGGATGAGACCTGCGAGGAGGATGAGAT	480
QY	481	CCAGTGGTAGCTATTATGGCCACTGGTGGTGGATCCGGGCAATGACTTCCCTGTATGG	540
DB	481	CCAGTGGTAGCTATTATGGCCACTGGTGGTGGATCCGGGCAATGACTTCCCTGTATGG	540
QY	541	CGAGCTGGCTGCTGAGGAGCTGGCTCTTGGATTGCGTCTCTATACATCACCAGGCG	600
DB	541	CGAGCTGGCTGCTGAGGAGCTGGCTCTTGGATTGCGTCTCTATACATCACCAGGCG	600
QY	601	CTGGGCTTCCACTGGGCTTGGCCAACTTTATGAGGACCCAGAGTGGTCTCAGAAGGA	660
DB	601	CTGGGCTTCCACTGGGCTTGGCCAACTTTATGAGNACCCAGAGTGGTCTCAGAAGGA	660
QY	661	CCTGGCAGGCGCCACTGAGTGTCTGAAGACCCAGGTGACCAAGTGGTGTGCT	720
DB	661	CCTGGCAGGCGCCACTGAGTGTCTGAAGACCCAGGTGACCAAGTGGTGTGCT	720
QY	721	GSCCCCGCAGCTGCGAGCTGACCGAGAGCTGGCCGAGCGTCCCGCTTGGGCTA	780
DB	721	GSCCCCGCAGCTGCGAGCTGACCGAGAGCTGGCCGAGCGTCCCGCTTGGGCTA	780
QY	781	CCCAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGGCGTGTGCTGATGAGCC	840
DB	781	CCCAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGGCGTGTGCTGATGAGCC	840

QY	841	CCATGATCAAGCTCTCAGATCAACGGGAGGCGCTGAGTCAATGCGCAGAACCTCTGCC	900
DB	841	CCATGATCAAGCTCTCAGATCAACGGGAGGCGCTGAGTCAATGCGCAGAACCTCTGCC	900
QY	901	CATCTACTGTGCGCTCAACACCAAGGGAGAGCTGACCACTTTTGAATTTGGGAGTG	960
DB	901	CATCTACTGTGCGCTCAACACCAAGGGAGAGCTGACCACTTTTGAATTTGGGAGTG	960
QY	961	GTGCGAGTCTCTCCCTAAGAGTTCGCTTCCCAAGTAGCGGGGCTTCAATCCCTCTGA	1020
DB	961	GTGCGAGTCTCTCCCTAAGAGTTCGCTTCCCAAGTAGCGGGGCTTCAATCCCTCTGA	1020
QY	1021	GCTCTTTTGGCTCGAGTCTTTTATGGGGAGCTGATGAAGAGGCTTCTGAGTCCGCGAT	1080
DB	1021	GCTCTTTTGGCTCGAGTCTTTTATGGGGAGCTGATGAAGAGGCTTCTGAGTCCGCGAT	1080
QY	1081	CTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGAGCAACCTCCAGACAGCTTATA	1140
DB	1081	CTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGAGCAACCTCCAGACAGCTTATA	1140
QY	1141	CTGGGCTCAGAGCCAGCCAGTCTTGGGACCGCTGGTCAAGAACAGGCCAACTCTGGA	1200
DB	1141	CTGGGCTCAGAGCCAGCCAGTCTTGGGACCGCTGGTCAAGAACAGGCCAACTCTGGA	1200
QY	1201	CAAGGAGAGGTCCTCCCTTCTGAAGATAGAAGAACACCTCAACAGCCGGCAGATAGC	1260
DB	1201	CAAGGAGAGGTCCTCCCTTCTGAAGATAGAAGAACACCTCAACAGCCGGCAGATAGC	1260
QY	1261	TGAGTTTTTACCGATCTTCTGACGTGGGTCCACCTGGGCCAGGCCACATAATTTCT	1320
DB	1261	TGAGTTTTTACCGATCTTCTGACGTGGGTCCACCTGGGCCAGGCCACATAATTTCT	1320
QY	1321	GGTGGCTCCATTTCCAAAGACTACTTTTTCAGATCTCTCACTTCCACATGGAAGC	1380
DB	1321	GGTGGCTCCATTTCCAAAGACTACTTTTTCAGATCTCTCACTTCCACATGGAAGC	1380
QY	1381	TACCACTCTGGATGGCTCCCAACAGCTGACACCTCGAGGCCACCTGTCCTGCT	1440
DB	1381	TACCACTCTGGATGGCTCCCAACAGCTGACACCTCGAGGCCACCTGTCCTGCT	1440
QY	1441	GGATGTGGCTACCTCATCAATACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	1500
DB	1441	GGATGTGGCTACCTCATCAATACAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	1500
QY	1501	GGACCTCATCTCTGATGGACTAACAACCTCCACAGGAGCTTCCAGCAGTTCAGTCT	1560
DB	1501	GGACCTCATCTCTGATGGACTAACAACCTCCACAGGAGCTTCCAGCAGTTCAGTCT	1560
QY	1561	GGGCGGCTTCTGCGAGGAGCAGGGATCCCGTTCCACCCATCTCGCCAGCCCGAAGA	1620
DB	1561	GGGCGGCTTCTGCGAGGAGCAGGGATCCCGTTCCACCCATCTCGCCAGCCCGAAGA	1620
QY	1621	GGAGCTCAGGCTCGGAGTGCCACACTTTCGACCCCACTCTGCGGAGCCCTGTC	1680
DB	1621	GGAGCTCAGGCTCGGAGTGCCACACTTTCGACCCCACTCTGCGGAGCCCTGTC	1680
QY	1681	GGTGTGCTGCTTCTCTGCGGTCGGGGGACACCGGAGGCGGAGCTGGGAGGT	1740
DB	1681	GGTGTGCTGCTTCTCTGCGGTCGGGGGACACCGGAGGCGGAGCTGGGAGGT	1740
QY	1741	GAACCTGTCTTCTCATCGGACTCTCCCTACCACTACAGAAAGTGAATACAGCAGGAGA	1800
DB	1741	GAACCTGTCTTCTCATCGGACTCTCCCTACCACTACAGAAAGTGAATACAGCAGGAGA	1800
QY	1801	CGTGAAGAAGCTGTGCACTGACATTAATGCTGTGCAACAACAGGAGCAGTGT	1860
DB	1801	CGTGAAGAAGCTGTGCACTGACATTAATGCTGTGCAACAACAGGAGCAGTGT	1860
QY	1861	GGAGCTCTGCGCCAGGAGTGACGAGGCGGAGCGGCGGCGGCGGCGGCGGCGG	1920
DB	1861	GGAGCTCTGCGCCAGGAGTGACGAGGCGGAGCGGCGGCGGCGGCGGCGGCGGCGG	1920

QY 1921 GCCCTGCCACCCCTAACTCTCATTCATTCCTCGGCTGCTGAGTTCAGGTGGAACTGT 1980  
 Db 1921 GCCCTGCCACCCCTAACTCTCATTCATTCCTCGGCTGCTGAGTTCAGGTGGAACTGT 1980  
 QY 1981 CATCAGCGAGTGTTCAGAGCCTCGGCTCAGTGGCACTGTCAGGGTCCAGGCTGAG 2040  
 Db 1981 CATCAGCGAGTGTTCAGAGCCTCGGCTCAGTGGCACTGTCAGGGTCCAGGCTGAG 2040  
 QY 2041 GGTGTGGAGTCCCTTGGCCCTCAGCAGTTTGCAAGTGGGTAAAGAGGCCAAGCCCATTT 2100  
 Db 2041 GGTGTGGAGTCCCTTGGCCCTCAGCAGTTTGCAAGTGGGTAAAGAGGCCAAGCCCATTT 2100  
 QY 2101 GTGTAAATCAACCAACCCCGGCTGTGCTGTTTCCCTTTCGCTGCTGAGTA 2160  
 Db 2101 GTGTAAATCAACCAACCCCGGCTGTGCTGTTTCCCTTTCGCTGCTGAGTA 2160  
 QY 2161 GTTGGAGCACTTGATACATCAGAGCTCATACAAAAA 2204  
 Db 2161 GTTGGAGCACTTGATACATCAGAGCTCATACAAAAA 2204

RESULT 2

AAZ88757  
 ID AAZ88757 standard; cDNA; 3085 BP.  
 AC AAZ88757;  
 XX 18-MAY-2000 (first entry)  
 DT 18-MAY-2000 (first entry)  
 DE Human PLA2 cDNA.  
 KW PLA2; phospholipase A2; phosphatide 2-acyl hydrolase; human; therapy;  
 KW arachidonic acid; lysophospholipid; Alzheimer's disease; ss.  
 XX Homo sapiens.

OS Location/Qualifiers  
 XX 48..2789  
 FT /\*tag= a  
 FT /product= "PLA2"

PN US6025178-A.

PD 15-FEB-2000.

PF 28-MAR-1997; 97US-00827208.

PR 29-MAR-1996; 96US-0014608P.

PS (ELIL ) LILLY & CO ELI.

PI Sharp JD, Strifler BA, Choiu XC, Kramer RM, Pickard RT;

PP WPI; 2000-181816/16.

PT P-PSDB; AAY51557.

PT An isolated amino acid having phospholipase (PL)A2 activity is useful in  
 PT assays to identify inhibitors having a therapeutic benefit, such as  
 PT inhibiting the central role of PLA2 in the inflammatory component of  
 PT Alzheimer's disease.

PS Example 5; Col 47-54; 32pp; English.

XX This invention describes a novel human phospholipase A2 (PLA2) protein  
 CC (I) and its encoding nucleic acid. The amino acid (I) releases  
 CC arachidonic acid in specific tissues characterized by unique membrane  
 CC phospholipids, by generating lysophospholipid species which are  
 CC deleterious to membrane integrity or by remodeling of unsaturated species  
 CC of membrane phospholipids through deacylation/reacylation mechanisms. The  
 CC amino acid is useful in assays to identify inhibitors having a  
 CC therapeutic benefit, such as inhibiting the central role of PLA2 in the  
 CC inflammatory component of Alzheimer's disease. The amino acid (I) allows  
 CC sensitive and rapid screening and identification of inhibitors of

CC phospholipase A2. This sequence encodes the human PLA2 protein (also  
 CC known as phosphatide 2-acyl hydrolase)  
 XX Sequence 3085 BP; 607 A; 959 C; 907 G; 612 T; 0 U; 0 Other;  
 SQ  
 Query Match 82.4%; Score 1816.8; DB 3; Length 3085;  
 Best Local Similarity 98.2%; Pred. No. 0;  
 Matches 1861; Conservative 0; Mismatches 2; Indels 33; Gaps 1;  
 QY 342 GACTGAGGAGTGGCCGTGCGACTTGGCTTGGGCGCTTGCAGAGGAGCGGCTTCC 401  
 Db 1186 GACTGAGGAGTGGCCGTGCGACTTGGCTTGGGCGCTTGCAGAGGAGCGGCTTCC 1245  
 QY 402 TCAGCAGGAGGAGGAGTGGTGGCGGCGCTTGCAGGAGCGGCTTGCAGTGGATGAG 461  
 Db 1246 TCAGCAGGAGGAGGAGTGGTGGCGGCGCTTGCAGGAGCGGCTTGCAGTGGATGAG 1305  
 QY 462 ACCTGCAGGAGGATGAGATCCCGAGTGGTAGCTATTATGSCCACTGGTGGTGGATCCGG 521  
 Db 1306 ACCTGCAGGAGGATGAGATCCCGAGTGGTAGCTATTATGSCCACTGGTGGTGGATCCGG 1365  
 QY 522 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCTTTCGATGG 581  
 Db 1366 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCTTTCGATGG 1425  
 QY 582 TCTCCTACATCACCGGGCGCTGGGCTTCACTGGGCGCTTGGCCCAACCTTTATGAGGACC 641  
 Db 1426 TCTCCTACATCACCGGGCGCTGGGCTTCACTGGGCGCTTGGCCCAACCTTTATGAGGACC 1485  
 QY 642 CAGAGTGGTCTCAGAAAGAGACCTGGCAGGCGCCACTGAGTTCGTGAAGACCCAGGTGACCA 701  
 Db 1486 CAGAGTGGTCTCAGAAAGAGACCTGGCAGGCGCCACTGAGTTCGTGAAGACCCAGGTGACCA 1545  
 QY 702 AGAACAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACCGGAGGAGCTGGCGG 761  
 Db 1546 AGAACAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACCGGAGGAGCTGGCGG 1605  
 QY 762 AGCGTGGCGGCTTGGGCTACCCAGAGCTGCTTCCAGAACCTTGGGCGCTTATCAACGAGG 821  
 Db 1606 AGCGTGGCGGCTTGGGCTACCCAGAGCTGCTTCCAGAACCTTGGGCGCTTATCAACGAGG 1665  
 QY 822 CGCTGCTGCATGATGAGCCCCCATCATCAAGCTCTCAGATCAACGAGGAGCGGCTGAGTC 881  
 Db 1666 CGCTGCTGCATGATGAGCCCCCATCATCAAGCTCTCAGATCAACGAGGAGCGGCTGAGTC 1725  
 QY 882 ATGCCAGAACCTTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGCGGCTGACCA 941  
 Db 1726 ATGCCAGAACCTTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGCGGCTGACCA 1785  
 QY 942 CTTTGTGAATTTGGGAGTGGTGGAGTTCCTCCCTAGGAGTGGCTTCCCAAGTACG 1001  
 Db 1786 CTTTGTGAATTTGGGAGTGGTGGAGTTCCTCCCTAGGAGTGGCTTCCCAAGTACG 1845  
 QY 1002 GGGCTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAGA 1061  
 Db 1846 GGGCTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAGA 1905  
 QY 1062 GGGTTCCTGAGTCCCGCATCTGCTTTTGAAGGTATCTGGAGCAACTGTATGACGCA 1121  
 Db 1906 GGGTTCCTGAGTCCCGCATCTGCTTTTGAAGGTATCTGGAGCAACTGTATGACGCA 1965  
 QY 1122 ACCTCCAGGAGAGCTTATCTGGGCTCAGAGCCAGCCAGTTCCTGGGACCGTGGGTCA 1181  
 Db 1966 ACCTCCAGGAGAGCTTATCTGGGCTCAGAGCCAGCCAGTTCCTGGGACCGTGGGTCA 2025  
 QY 1182 GGAACCCAGGCAACCTTGGCAAGAGCAGTCCCGCTTCTGAGATAGAGAGACCCCT 1241  
 Db 2026 GGAACCCAGGCAACCTTGGCAAGAGCAGTCCCGCTTCTGAGATAGAGAGACCCCT 2085  
 QY 1242 CAACCCCGGCAAGATGCTGAGTTCCTTCCCGATCTTCTGAGCTGGCGTCCACTGGCCC 1301  
 Db 2086 CAACCCCGGCAAGATGCTGAGTTCCTTCCCGATCTTCTGAGCTGGCGTCCACTGGCCC 2145

1302 AGGCGACATATATTTCTGCTGGCTCCATTTTCCAAAGAACTACTTTTTCAGCATCCTC 1361  
1361  
2146 AGGCCACACATATATTTCTGCTGGCTCCATTTTCCAAAGAACTACTTTTTCAGCATCCTC 2205  
2205  
1362 ACTTCTCCACATGAAAGCTTACCATCTGTGATGGGTCCCAACACAGCTGACACCTCTCG 1421  
1421  
2206 ACTTCTCCACATGAAAGCTTACCATCTGTGATGGGTCCCAACACAGCTGACACCTCTCG 2265  
2265  
1422 AGCCCACTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1481  
1481  
2266 AGCCCACTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2325  
2325  
1482 TGAGGCCACTGCGGAGCTGAGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1541  
1541  
2326 TGAGGCCACTGCGGAGCTGAGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2385  
2385  
1542 TCAGAGCTTGCAGCTCCTGCGGCGGTTCTGCCAGGAGCGGGATCCCGTTCCACCCCA 1601  
1601  
2386 TCAGAGCTTGCAGCTCCTGCGGCGGTTCTGCCAGGAGCGGGATCCCGTTCCACCCCA 2445  
2445  
1602 TCTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1661  
1661  
2446 TCTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2505  
2505  
1662 CTTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1693  
1693  
2506 CTTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2565  
2565  
1694 TCTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1748  
1748  
2566 ACTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2625  
2625  
1749 CTTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1808  
1808  
2626 CTTGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2685  
2685  
1809 AGCTGCTGCAGCTGACATACATGCTGCAACACAGGAGCTGCTGAGGCTC 1868  
1868  
2686 AGCTGCTGCAGCTGACATACATGCTGCAACACAGGAGCTGCTGAGGCTC 2745  
2745  
1869 TGCGCCAGGAGCTGAGCGAGGCGGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAG 1928  
1928  
2746 TGCGCCAGGAGCTGAGCGAGGCGGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAGCGAG 2805  
2805  
1929 CACCCCTAACTCTCATTTATTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1988  
1988  
2806 CACCCCTAACTCTCATTTATTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2865  
2865  
1989 AGTGCTTCAGAGCTTCGGGCTCAGCTGCGACTGTCCAGGGTCCAGGGTCCAGGGTCCAG 2048  
2048  
2866 AGTGCTTCAGAGCTTCGGGCTCAGCTGCGACTGTCCAGGGTCCAGGGTCCAGGGTCCAG 2925  
2925  
2049 GCTCCCTTCGGCTTCAGAGCTTCGGGCTCAGCTGCGACTGTCCAGGGTCCAGGGTCCAG 2108  
2108  
2926 GCTCCCTTCGGCTTCAGAGCTTCGGGCTCAGCTGCGACTGTCCAGGGTCCAGGGTCCAG 2985  
2985  
2109 ACCCAAAACCCCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTC 2168  
2168  
2986 ACCCAAAACCCCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTCGGCTTC 3045  
3045  
2169 ACTTGATACATACAGACTCATACAAAAA 2204  
2204  
3046 ACTTGATACATACAGACTCATACAAAAA 3081  
3081

RESULT 3  
AAZ88758  
ID AAZ88758 standard; DNA; 3085 BP.  
XX  
XX AAZ88758;  
AC  
XX 18-MAY-2000 (first entry)  
DT  
XX

DE Human PLA2 mRNA.  
KW PLA2; phospholipase A2; phosphatide 2-acyl hydrolase; human; therapy;  
KW arachidonic acid; lysophospholipid; Alzheimer's disease; ss.  
OS Homo sapiens.  
PN US6025178-A.  
XX 15-FEB-2000.  
XX 28-MAR-1997; 97US-00827208.  
XX 29-MAR-1996; 96US-0014608P.  
XX (ELIL ) LILLY & CO ELI.  
XX Sharp JD, Strifler BA, Choiu XC, Kramer RM, Pickard RT;  
XX WPI; 2000-181816/16.  
XX  
XX An isolated amino acid having phospholipase (PL)A2 activity is useful in  
XX assays to identify inhibitors having a therapeutic benefit, such as  
XX inhibiting the central role of PLA2 in the inflammatory component of  
XX Alzheimer's disease.  
XX Disclosure; Col 57-62; 32pp; English.  
XX This invention describes a novel human phospholipase A2 (PLA2) protein  
XX (I) and its encoding nucleic acid. The amino acid (I) releases  
XX arachidonic acid in specific tissues characterized by unique membrane  
XX phospholipids, by generating lysophospholipid species which are  
XX deleterious to membrane integrity or by remodeling of unsaturated species  
XX of membrane phospholipids through deacylation/reacylation mechanisms. The  
XX amino acid is useful in assays to identify inhibitors having a  
XX therapeutic benefit, such as inhibiting the central role of PLA2 in the  
XX inflammatory component of Alzheimer's disease. The amino acid (I) allows  
XX sensitive and rapid screening and identification of inhibitors of  
XX phospholipase A2. This sequence encodes the human PLA2 protein (also  
XX known as phosphatide 2-acyl hydrolase  
XX Sequence 3085 BP; 607 A; 959 C; 907 G; 0 T; 612 U; 0 Other;  
SQ  
Query Match 82.4%; Score 1816.8; DB 3; Length 3085;  
Best Local Similarity 78.9%; Pred. No. 0;  
Matches 1496; Conservative 365; Mismatches 2; Indels 33; Gaps 1;  
QY 342 GACTCAGGAGCTGGCCCTGCGACTGGCTTGGGCTTGGGCTTGGGCTTGGGCTTGGGCTTGG 401  
1186 GACUGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1245  
QY 402 TGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 461  
1246 UGACGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1305  
QY 462 ACCTCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 521  
1306 ACCUGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1365  
QY 522 CAATGACTTCCCTGATGATGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 581  
1366 CAUUGACUCCUGUAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1425  
QY 582 TCTCTTACATCACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 641  
1426 UCUCUUAUACUACCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1485  
QY 642 CAGAGTGGTCTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 701  
1486 CAGAGGUGGUCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1545  
QY 702 AGAACAAAGCTGGGTGCTTGGGCTTGGGCTTGGGCTTGGGCTTGGGCTTGGGCTTGGGCTTGG 761

1546 AGAACAAGCUGGUGUGUGGCGCCGCCAGCAGCUGCAGCGGUAACCGCAGGAGCUGGCGCG 1605  
 762 AGCGTCCCGCTGGGCTACCAAGCTGCTTACCAACCTGTGGGCGCTCATCAACAGG 821  
 1606 AGGUGCGCGUGGCUACCAAGCUGUUCACCAACCGUGGCGCCUACUACAGG 1665  
 822 CGGTGTGATGATGAGCCCAATGATCAACAAGCTTCAGATCAACGGGAGGCGCTGATC 881  
 1666 CGCUGCUGAUGAAGGCGCCAGUAUCAACAAGCUCUGAUAACAAGGAGGCCUGAGUC 1725  
 882 ATGGCCAGAAACCTCTGCGCCATCTACTGTGCGCTCAACACCAAGGCGAGGCTGACCA 941  
 1726 AUGGCGAGAACCCUCUGCCCAUCUACUGUGCCUACCAACCAAGGCGAGCGUAGCA 1785  
 942 CTTTGAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTTCGGCTTCCCACTAGC 1001  
 1786 CUUUGAAUUGGGAGUGGUGGAGUUCUUCUACAGGUGGCGUCCUCCAGUAGC 1845  
 1002 GGGCCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGCGAGCTGATGAAG 1061  
 1846 GGGCCUUAUCCUUGAGCUCUUGGUCGAGUUCUUAUUGGGCGAGCUGAUGAAG 1905  
 1062 GGCCTTCTGAGTCCGCTCTGCTTCTTAGAGGTATCTGGAGCAACCTGTATGAGCA 1121  
 1906 GGCUCUGAGGCCGCAUCUGCUCUUAAGAGGUAUCUGGAGCAACUUGAUGCAGCA 1965  
 1122 ACCTCCAGGACAGTTATCTAGTGGGCTCAGAGCCAGCCAGTTCGGGACCGCTGGTCA 1181  
 1966 ACCUCCAGGACAGUUAUACUGGCGCUCAGAGCCAGCCAGCAGUUCUGGAGCCCGGUGCA 2025  
 1182 GGAACAGGCGAAGCTGGAGAGGAGGAGTCCCTCTTGAAGATAGAAGAACCACTCT 1241  
 2026 GGAACAGGCGAAGCTGGAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2085  
 1242 CAACAGCGGCGAGATAGTGTGTTTCAACGATCTTCTGAGTGGGCTGCGTCCAGTGGCC 1301  
 2086 CAACAGCGGCGAGAAUGAGUAGUUAUACCGAUCUUGAGCUGGCGGCGGCGGCGGCG 2145  
 1302 AGGCCACACATAATTTCTGCGTGGCTCCATTTCCACAAAGACTACTTTTCTGAGTCTCTC 1361  
 2146 AGGCCACACAAUUAUUCUGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG 2205  
 1362 ACTTCTCAGATGGAAGTACCACTGTGATGGGCTCCCAACAGAGTGCAGACCCCTCGG 1421  
 2206 ACUUCUCCACUAGGAAGCAUACUUGGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG 2265  
 1422 AGCCCCACCTGCTGCTGATGTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1481  
 2266 AGCCCCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2325  
 1482 TGCAGCCACTCGGACGCTGAGCTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1541  
 2326 UGCAGCCACUAGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAG 2385  
 1542 TCCAGCAGTTCGAGTCTGCGGCGGCTTCTGCGAGGAGCAGGAGGATCCGTTTCCACCCA 1601  
 2386 UCCAGCAGUUGCAGCUCUGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCG 2445  
 1602 TCTGCGCCAGCCCGAGAGAGAGTCCAGCTCGGAGTTCGAGTTCGAGTTCGAGTTCGAG 1661  
 2446 UCUGGCCAGCCCGAGAGAGAGTCCAGCTCGGAGTTCGAGTTCGAGTTCGAGTTCGAG 2505  
 1662 CCGCCCGGAGCCCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1693  
 2506 CCUGCCCGGAGCCCGGAGAGAGTTCGAGTTCGAGTTCGAGTTCGAGTTCGAGTTCGAG 2565  
 1694 -----TCTCTGGGTCCGCGGAGACCCGAGGAGGCGGAGTTCGAGTTCGAGTTCGAG 1748  
 2566 ACUGGCGCGCGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2625  
 1749 CTTTCAGTCTCTCTTACCACTACAGAGGAGTTCGAGTTCGAGTTCGAGTTCGAGTTCGAG 1808  
 2626 CUUACUGGAGCUCUCCUACCAUACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2685

1809 AGCTGCTGCACCTGACACATTACATCTGCAACAACAGGAGAGAGCTGCTGGAGGCTC 1868  
 2686 AGCUGUGCAGCUGACACAUACAUGUCUGAACCAACAGGAGCAGCUGCUGGAGGCGC 2745  
 1869 TCGCGCAGCAGCTGACGCGAGGCGGAGCGAGGCGGAGGCGGAGGCGGAGGCGGAGGCG 1928  
 2746 UGCGCAGGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2805  
 1929 CACCCCTAATCTCATTCATTCCCTGGCTGCTGAGTTGAGTTGAGTTGAGTTGAGTTGAG 1988  
 2806 CACCCCAACACUCUACUACUCCUGGCGUGAGUUGCAGGUGGAGGAGGAGGAGGAGGAG 2865  
 1989 AGTGTCTCAGAGCTTGGGCTCAGTGGCAGTGTCCAGGTCAGGTCAGGTCAGGTCAGG 2048  
 2866 AGUGCUUCAGAGCCCGGCGCAGGUGGCAUGUCCAGGCGGAGGCGGAGGCGGAGGCGG 2925  
 2049 GCTCCCTTGGGCTCAGAGTTTTCAGTGGGTTAGGAGGCGGAGGCGGAGGCGGAGGCGG 2108  
 2926 GCUCCUUGGCGTUCAGAGUUGCAGGUGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2985  
 2109 ACCCAAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2168  
 2986 ACCCAAAACCCCGGCGCUGGCGUUCUCCUGGCGUACCUAGUAGUAGGAGGAGGAGGAG 3045  
 2169 ACTTGATATACATCAGACTCATACAAAAA 2204  
 3046 ACUUGAUAUACACAGACUCUACAAAAA 3081

RESULT 4

AAAF74999 standard; cDNA; 3085 BP.

XX AAF74999;

XX 23-MAY-2001 (first entry)

XX Phospholipase A2 (PLA2) encoding cDNA SEQ ID NO:2.

XX Phospholipase A2; PLA2; antiinflammatory; inflammatory condition; rheumatoid arthritis; psoriasis; asthma; cytosolic PLA2; cPLA2; ss.

XX Homo sapiens.

XX US6197569-B1.

XX 06-MAR-2001.

XX 07-FEB-2000; 2000US-00500358.

XX 29-MAR-1996; 96US-0014608P.

XX 19-MAR-1997; 97US-0041264P.

XX 28-MAR-1997; 97US-00827208.

XX (EJIL ) LILLY & CO ELI.

XX Choiu XC, Kramer RM, Pickard RT, Sharp JD, Strifler BA;

XX WPI; 2001-256372/26.

XX P-PSDB; AAB74635.

XX Novel nucleic acid molecules encoding phospholipase A2 enzyme, useful in screening assays for identifying compounds that inhibit or block phospholipase A2 enzyme activity.

XX Claim 1; Col 47-54; 32pp; English.

XX The present invention describes an isolated polynucleotide (I), comprising a 3085 base pair phospholipase A2 (PLA2) sequence (given in AAF74999), encoding a 913 residue phospholipase A2 protein sequence (given in AAB74635), or a nucleotide sequence which hybridises under stringent conditions to the above mentioned nucleotide sequence. Also

22.0%

described are: (1) an isolated polynucleotide (II) comprising an 8517 base pair sequence, given in AAF7498; (2) an expression vector (III) comprising (I) and an expression control sequence; (3) a host cell transformed with (III); (4) an expression vector (IV) comprising (II) operably linked to an expression control sequence; and (5) a host cell transformed with (IV). (I) is useful for screening compounds which inhibit or block cytosolic PLA2 (cPLA2) enzyme activity. The host cells transformed or transfected with cPLA2 enzymes in large quantities which are useful in screening assays for discovering agents that inhibit PLA2. The inhibitors identified are useful for treating inflammatory conditions such as rheumatoid arthritis, psoriasis, or asthma. (I) is also useful in the detection of mutant genomic DNA which has been digested with restriction enzymes and run on an electrophoretic gel by hybridising to the genomic DNA.

Sequence 3085 BP; 607 A; 959 C; 907 G; 612 T; 0 U; 0 Other; XX

Query Match

**Query Match**

Seq. ID	Accession	Length	Score	E-value	Identical	Similarity	Freq. NO.	Mismatches	Indels	Gaps
1	U00096.1	1861	100.0	0.0	100	100.0	0	0	2	33
2	U00096.1	1861	100.0	0.0	100	100.0	0	0	2	33

Qy	342	GA	CTGAGGGAGCTGGCGCTGGCTGGACTGGGCTTCGGGCCCTCTGTG	CAGAGGACGAGCGCTTCC	401
Db	1186	GA	CTGAGGAGCTGGCGCTGGCTGGACTGGGCTTCGGGCCCTCTGTG	CAGAGGACGAGCGCTTCC	1245
Qy	402	TG	ACGACGAGGAGACGAGGTGGTGGCGCGCGCTTTGAGGCAGGCGCC	CTGCACTGGATGGATGAG	461
Db	1246	TG	ACGACGAGGAGGACGAGGTGGTGGCGCGCGCTTTGAGGCAGGCGCC	CTGCACTGGATGGATGAG	1305
Qy	462	AC	CTGCAAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACT	CTGGTGGATCGGG	521
Db	1306	AC	CTGCAAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACT	CTGGTGGATCGGG	1365
Qy	522	CA	ATGACTTCCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGCC	CTTTGGATTGGG	581
Db	1366	CA	ATGACTTCCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGCC	CTTTGGATTGGG	1425
Qy	582	TCT	CCTACATACCGGGGCTCGGGCTCCACCTGGCGCTTGGCCAACT	TTATGAGGACC	641
Db	1426	TCT	CCTACATACCGGGGCTCGGGCTCCACCTGGCGCTTGGCCAACT	TTATGAGGACC	1485
Qy	642	CAG	AGTGGTCTCACAAGGACCTGGCAGGGGCCACTGAGTTGCTG	AAGACCAGGTGACCA	701
Db	1486	CAG	AGTGGTCTCACAAGGACCTGGCAGGGGCCACTGAGTTGCTG	AAGACCAGGTGACCA	1545
Qy	702	AGA	ACAAGCTGGGTGTGTGGCCCCCAGCAGCTGACGGGTACCGG	CAGGAGCTGGCGG	761
Db	1546	AGA	ACAAGCTGGGTGTGTGGCCCCCAGCAGCTGACGGGTACCGG	CAGGAGCTGGCGG	1605
Qy	762	AG	CTGCCCGCTTGGGCTACCAAGCTGCTTCAACCACTGGGCCCT	CATCAACGAGG	821
Db	1606	AG	CTGCCCGCTTGGGCTACCAAGCTGCTTCAACCACTGGGCCCT	CATCAACGAGG	1665
Qy	822	CG	TGCTCATGATCAGCCCCCATCATCAAGCTCTCAGATCAACG	GGAGGCCCTGAGTC	881
Db	1666	CG	TGCTCATGATGAGCCCCCATCATCAAGCTCTCAGATCAACG	GGAGGCCCTGAGTC	1725
Qy	882	AT	GCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACAA	AGGGCAGAGCTGACCA	941
Db	1726	AT	GCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACAA	AGGGCAGAGCTGACCA	1785
Qy	942	CT	TTTGAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGGTGG	CTTCCCAAGTACG	1001
Db	1786	CT	TTTGAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGGTGG	CTTCCCAAGTACG	1845
Qy	1002	GG	CGCTTCAATCCCTCTCAGCTCTTTGGCTCCGAGTTCTTTAT	TGGGGCAGCTGATGAAGA	1061
Db	1846	GG	CGCTTCAATCCCTCTCAGCTCTTTGGCTCCGAGTTCTTTAT	TGGGGCAGCTGATGAAGA	1905
Qy	1062	GG	CTTCCTGAGTCCGCAATCTGCTTCTTTAGAAGGTATCTGG	AGCAACTGTATGACGCCA	1121
Db	1906	GG	CTTCCTGAGTCCGCAATCTGCTTCTTTAGAAGGTATCTGG	AGCAACTGTATGACGCCA	1965







```

Db      1666  CGCUGCUGAUGAUGAGCCCAUGAUCACAAAGCUCUCAGAUCAACGGAGGAGCGCCUGAGUC 1725
QY      882  ATGGCCAGAAACCTCTCCCATCTACTGTGCTCTCAACACCAAGGAGGAGGAGCTGACCA 941
Db      1726  AUGGCCAGAAACCTCUCUGCCCAUCUACUGUGCCUCCAAACCAAGGAGGAGGAGCTGACCA 1785
QY      942  CTTTGTGAAATTTGGGAGTGTGGAGTTCTCTCCCTACGAGGTGCGCTTCCCAAGTACG 1001
Db      1786  CUUUGAAUUTGGGAGUGUGGAGUUCUCUCCUACGAGGUGCGCUUCCCAAGUAGC 1845
QY      1002  GGGCCCTTCATCCCTCTGAGCTCTTTGGCTCCAGTCTTTATGGGAGAGCTGATGAAGA 1061
Db      1846  GGGCUUUAUCCCUUGAGCUCUUGUGGCUCCGAGUUCUUAUAGGGGAGGAGUAGGA 1905
QY      1062  GGGTCTCTGAGTCCCGCATCTGCTTTCTTAGAAGGTATCTGAGCAACCTGTATGAGGCCA 1121
Db      1906  GGGUUCUGAGUCCCGCAUCUGCUCUUAAGAGGUAUUGGAGCAACCCUGUAUGAGCCA 1965
QY      1122  ACTCTCAGGACAGCTTATCTAGTGGGCTCTAGAGCCAGCCAGTTCTGGGACCGCTGGGTCA 1181
Db      1966  ACCUCAGGACAGCUUAUACUGGGCCUCAGAGCCAGCCAGCAGUUCUGGAGCCGUGGGUCA 2025
QY      1182  GGAACAGGACCAACCTGGCAAGGAGCAGTCCCTCTCTGAAGATAGAAAGAACCACTT 1241
Db      2026  GGAACAGGACCAACCTGGCAAGGAGCAGTCCCTCTCTGAAGATAGAAAGAACCACTT 2085
QY      1242  CAAACAGGCGGAGAAATAGCTGAGTTTTCACCGATCTCTGAGCTGGGCTCCACCTGGCC 1301
Db      2086  CAAACAGGCGGAGAAATAGCTGAGTTTTCACCGATCTCTGAGCTGGGCTCCACCTGGCC 2145
QY      1302  AGGCCACACATATTTCTGCTGGGCTGCTCATTTCCAAAGACTACTTTTCAGCATCTCT 1361
Db      2146  AGGCCACACAAUUAUUCUGGCGGCUCCAUUCCAAAGAGUACUUAUCCAGCAUCCUC 2205
QY      1362  ACTTCTCAGATGAAAGTACCTACTCTGAGTGGGCTCCCAACAGCTGACACCTCGG 1421
Db      2206  ACUUCUCCAGAGAAAGUACCUUGGAGUGGCGUCCCAACAGCTGACACCTCGG 2265
QY      1422  AGCCCACTGTGCTGTGATGTGTGCTACTCATCAATACAGCTGCTGCTGCCCTCC 1481
Db      2266  AGCCCACTGTGCTGTGATGTGTGCTACTCATCAATACAGCTGCTGCTGCCCTCC 2325
QY      1482  TGCAGGCCACTCGGAGCTGAGACTCACTCTGATGAGTGTGCTGATGAGTGTGAGTGT 1541
Db      2326  UGCAGGCCACUUGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2385
QY      1542  TCCAGCAGTTGACGCTCTGCGGCGGTTCTGCGAGGAGGAGGAGGAGGAGGAGGAGGAG 1601
Db      2386  UCCAGCAGUUGCAGCUCUGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2445
QY      1602  TCTGCGCCAGCCCGAAGAGAGCTCCAGCTCTGAGCTGCGGAGTGCACACTTCTCCGAGCCCA 1661
Db      2446  UCUGGCCAGCCCGAAGAGAGCAGCUCAGCUCUGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2505
QY      1662  CTTGCCCGGAGCGGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1693
Db      2506  CUUGCCCGGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 2565
QY      1694  -----TCTCTGCGGCTCGGCGGAGACCCGAGGAGGCGGAGGAGGAGGAGGAGGAGGAG 1748
Db      2566  ACUGGCGGCGGCGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2625
QY      1749  CTTCTGCGGAGTCTGCTTACCACTACAGAGTGTGCTTACAGCAGGAGGAGGAGGAGGAGGAG 1808
Db      2626  CUUACUGGAGCUCUCCUACCAUACAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2685
QY      1809  AGCTGTGACCTGACATTAATGCTGTGAAACCAACGAGGAGGAGGAGGAGGAGGAGGAGGAG 1868
Db      2686  AGCUGGAGCAGCAGUACAUUAUAGUUGCUGCAACCAACGAGGAGGAGGAGGAGGAGGAGGAG 2745
QY      1869  TGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1928

```

```

Db      2746  UGCGCCAGGAGCAGUGCAGCGGAGGCGGAGCGGCCCAUCAGUAGCCCGGGCGCCCGC 2805
QY      1929  CACCCCTAACTCTCAITTCATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1988
Db      2806  CACCCUUAUCUCUUAUCCUGGCTGUCAGUUGCAGGUGGAGGAGGAGGAGGAGGAGGAGGAG 2865
QY      1989  AGTGTCTCAGAGCTCGGCTCAGGTGGCACTGTCCAGGCTCCAGGCTCAGGCTGAGGCTGGGA 2048
Db      2866  AGUGCUUACAGCUCUGGCGCUCAGGUGGACUCUGUCCAGGUCUCCAGGUCUCCAGGCTUGGA 2925
QY      2049  GCTCCCTTGGGCTCAGCAGTGTGGGTAAAGAGGCCAAGCCCATTTGTGTAATC 2108
Db      2926  GCUCCUUGGCGCUCAGCAGUUGGAGGUGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2985
QY      2109  ACCCAAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2168
Db      2986  ACCCAAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 3045
QY      2169  ACTTGATACATCACAGCTCATCAAAACCAAAACCAAAACCAAAACCAAAACCAAAACCAAA 2204
Db      3046  ACTUGAUAUCAACAGACACUACAAACCAAAACCAAAACCAAAACCAAAACCAAAACCAAA 3081

```

## RESULT 7

AAF90488

ID AAF90488 standard; cDNA; 3085 BP.

XX AAF90488;

XX 06-AUG-2001 (first entry)

XX Human phospholipase A2 cDNA.

XX Phospholipase A2; PLA2; bPLA2; PLA2-beta; inhibitor; screening;  
 antiinflammatory; human; Alzheimer's disease; therapy; ss.

XX Homo sapiens.

Key Location/Qualifiers  
 CDS 48..2789  
 FT /\*tag= a  
 FT /EC\_number= "3.1.1.4"

XX US6242206-B1.

XX 05-JUN-2001.

XX 07-FEB-2000; 2000US-00498809.

XX 29-MAR-1996; 96US-0014608P.

XX 19-MAR-1997; 97US-0041264P.

XX 28-MAR-1997; 97US-00827208.

XX (BLIL ) LILLY &amp; CO ELI.

XX Chou XC, Kramer RM, Pickard RT, Sharp JD, Strifler BA;  
 WPI; 2001-366537/38.  
 P-PSDB; AAB82415.

XX Assays to evaluate the effectiveness of inhibitors of phospholipase A2,  
 used to screen candidate compounds, comprise recombinant expression of a  
 novel phospholipase A2.  
 Claim 1(a); Col 47-54; 32pp; English.

XX The present sequence is that of human cDNA encoding a novel phospholipase  
 A2 (PLA2, also referred to bPLA2 or PLA2-beta). PLA2 liberates  
 arachidonic acid from phospholipids, leading to the production of  
 eicosanoids involved in inflammatory reaction. A claimed assay for  
 evaluating the effectiveness of a compound as an inhibitor of  
 phospholipase A2 (PLA2) involves culturing a cell transfected with an  
 expression vector comprising PLA2 genomic DNA or cDNA, isolating the

CC	PLA2, contacting it with a candidate compound, and determining whether
CC	the PLA2 activity has been inhibited. The assay provides rapid and
CC	efficient screening for new anti-inflammatory drugs that inhibit the
CC	arachidonic acid cascade. These may be especially useful in the treatment
CC	of the inflammatory component of Alzheimer's disease
XX	
SQ	Sequence 3085 BP; 607 A; 959 C; 907 G; 612 T; 0 U; 0 Other;
	Query Match 82.4%; Score 1816.8; DB 4; Length 3085;
	Best local Similarity 98.2%; Pred. No. 0;
	Matches 1861; Conservative 0; Mismatches 2; Indels 33; Gaps 1;
QY	342 GACTGAGGAGCTGGCGCTGCGAGTGGGCTTCGGGCGCTGTGAGAGGAGCAGGCTTCC 401
DB	1186 GACTGAGGAGCTGGCGCTGCGAGTGGGCTTCGGGCGCTGTGAGAGGAGCAGGCTTCC 1245
QY	402 TGAGCAGGAGGAGAGAGAGTGGTGGCGCGCTTGAAGCAGGCGCTTGAGCTGGATGGAG 461
DB	1246 TGAGCAGGAGGAGAGAGTGGTGGCGCGCTTGAAGCAGGCGCTTGAGCTGGATGGAG 1305
QY	462 ACCTGCAGGAGGATGAGATCCAGTGTAGTATATGAGGAGCTGGGCTCTTGGATGGG 521
DB	1306 ACCTGCAGGAGGATGAGATCCAGTGTAGTATATGAGGAGCTGGGCTCTTGGATGGG 1365
QY	522 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAGAGGAGCTGGGCTCTTGGATGGG 581
DB	1366 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAGAGGAGCTGGGCTCTTGGATGGG 1425
QY	582 TCTCTCATACACCGGCGCTCGGGCTCCACTTGGGCGCTTGGCCAACTTTATGAGGACC 641
DB	1426 TCTCTCATACACCGGCGCTCGGGCTCCACTTGGGCGCTTGGCCAACTTTATGAGGACC 1485
QY	642 CAGAGTGTCTCAGAAGGACCTGCGAGGGCCCACTGAGTGTGAGACCCAGGTGACCA 701
DB	1486 CAGAGTGTCTCAGAAGGACCTGCGAGGGCCCACTGAGTGTGAGACCCAGGTGACCA 1545
QY	702 AGAACAGCTGGGTGTGTCGCCCCCAGCGAGCTGACGGGTACCGGAGAGCTGGCGG 761
DB	1546 AGAACAGCTGGGTGTGTCGCCCCCAGCGAGCTGACGGGTACCGGAGAGCTGGCGG 1605
QY	762 AGCGTGCCGCTTGGGCTTACCAAGCTGCTTCAACCACTGTGGGCGCTTCAACAGAGG 821
DB	1606 AGCGTGCCGCTTGGGCTTACCAAGCTGCTTCAACCACTGTGGGCGCTTCAACAGAGG 1665
QY	822 CGCTGCTGCATGATGAGGAGCCCATGATCAAGCTCTCAGATCAACGAGGCGGCTGAGTC 881
DB	1666 CGCTGCTGCATGATGAGGAGCCCATGATCAAGCTCTCAGATCAACGAGGCGGCTGAGTC 1725
QY	882 ATGGCCAGNACCTCTGCCATCTACTGTGCCCTCAACACCAAGGCGAGAGCTGACCA 941
DB	1726 ATGGCCAGNACCTCTGCCATCTACTGTGCCCTCAACACCAAGGCGAGAGCTGACCA 1785
QY	942 CTTTGTGAATTTGGGAGTGGTGGAGTCTCTCCCTACGAGGTGGGCTTCCCAAGTAGC 1001
DB	1786 CTTTGTGAATTTGGGAGTGGTGGAGTCTCTCCCTACGAGGTGGGCTTCCCAAGTAGC 1845
QY	1002 GGCGCTTCAATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1061
DB	1846 GGCGCTTCAATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1905
QY	1062 GGCTTCTGAGTCCCGCATCTGCTTCTAGAAGTATCTGAGCAACCTGTATGAGGCCA 1121
DB	1906 GGCTTCTGAGTCCCGCATCTGCTTCTAGAAGTATCTGAGCAACCTGTATGAGGCCA 1965
QY	1122 ACCTCCAGGACAGCTTATCTGGGCGCTCAGAGCCAGGCGAGTCTGGGACCGTGGGTCA 1181
DB	1966 ACCTCCAGGACAGCTTATCTGGGCGCTCAGAGCCAGGCGAGTCTGGGACCGTGGGTCA 2025
QY	1182 GGAAACAGGCAACCTGGAACAAGGAGAGTCCCGCTTCTGAAGATAGAAGAACCCCT 1241
DB	2026 GGAAACAGGCAACCTGGAACAAGGAGAGTCCCGCTTCTGAAGATAGAAGAACCCCT 2085
QY	1242 CAACAGCGCGCAGAATAGCTGAGTTTTTACCCGATCTTCTGACGTGGGCTCCACTGGGCC 1301

RESULT 8  
AAS17363  
ID AAS17363 standard; cDNA; 2699 BP.  
XX  
AC AAS17363;

2086	CAACAGCGCGCAGAAATAGCTGAGTTTTTTCACCGATCTTCTGACGTGGCTCCACTGGGCC 2145
1302	AGGCCACACATATTTCTCGCTGGCTCCATTTCCAAAGAGCTACTTTGAGCATCTTC 1361
2146	AGGCCACACATATTTCTCGCTGGCTCCATTTCCAAAGAGCTACTTTGAGCATCTTC 2205
1362	ACTTCTCCACATGGAAGCTACACTCTGGATGGGCTCCCAACAGCTGACACCTCGG 1421
2206	ACTTCTCCACATGGAAGCTACACTCTGGATGGGCTCCCAACAGCTGACACCTCGG 2265
1422	AGCCCCACCTGTGCTGCTGGATGTTGGTCACTCATCAATACAGCTGCTGCCCTTC 1481
2266	AGCCCCACCTGTGCTGCTGGATGTTGGTCACTCATCAATACAGCTGCTGCCCTTC 2325
1482	TGACAGCCCACTCGGGAGCTGGACCTCATCTGTCTATTTGGACTCAACCTCCAGGACCT 1541
2326	TGACAGCCCACTCGGGAGCTGGACCTCATCTGTCTATTTGGACTCAACCTCCAGGACCT 2385
1542	TCACAGAGTTGAGCTCTCGGCGCGGTTCTGCCAGGAGCAGGGATCCCGTTCCACCCA 1601
2386	TCACAGAGTTGAGCTCTCGGCGCGGTTCTGCCAGGAGCAGGGATCCCGTTCCACCCA 2445
1602	TCTCGCCAGCCCGAAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCGACCCCA 1661
2446	TCTCGCCAGCCCGAAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCGACCCCA 2505
1662	CCTGCCCCGAGGCGCTTGGCGTGTGCACTTT----- 1693
2506	CCTGCCCCGAGGCGCTTGGCGTGTGCACTTTCTGTCAGCGACTCTCTTCGGGAGT 2565
1694	-----TCTCTGCGGCTCGGGCGGACACCGGAGGCGGAGCTGGGAGGTGAACCTGT 1748
2566	ACTCGGCGCTTGGGCTCGGGCGGACACCGGAGGAGCGGAGCTGGGAGGTGAACCTGT 2625
1749	CTTCATCGGACTCTCCCTTACCCTACACGAAGGTGACCTACAGCCAGAGGAGCTGGACA 1808
2626	CTTCATCGGACTCTCCCTTACCCTACACGAAGGTGACCTACAGCCAGAGGAGCTGGACA 2685
1809	AGCTGCTGCACCTGACACATTTACAATGCTGCAACCAACAGGAGCAGCTGTGGAGGCTC 1868
2686	AGCTGCTGCACCTGACACATTTACAATGCTGCAACCAACAGGAGCAGCTGTGGAGGCTC 2745
1869	TGCGCCAGGAGTGCAGCGGAGGCGGAGCGGCGGAGCTGATGGCGGGGCGGCTTGC 1928
2746	TGCGCCAGGAGTGCAGCGGAGGCGGAGCGGCGGAGCTGATGGCGGGGCGGCTTGC 2805
1929	CACCCCTAACTCTCATTTCACTTCCCTGGCTGTGAGTTGAGGTGGGAACTGTCAACGC 1988
2806	CACCCCTAACTCTCATTTCACTTCCCTGGCTGTGAGTTGAGGTGGGAACTGTCAACGC 2865
1989	AGTGTCTTCAGAGCTCGGCTCAGGTGGCACTGTCCAGGCTCCAGGCTGAGGCTGGGA 2048
2866	AGTGTCTTCAGAGCTCGGCTCAGGTGGCACTGTCCAGGCTCCAGGCTGAGGCTGGGA 2925
2049	GCTCCCTTCGGCTCAGCAGTTTTCAGTGGGTTAGGAGGCGCAAGCCCACTTTGTGAATC 2108
2926	GCTCCCTTCGGCTCAGCAGTTTTCAGTGGGTTAGGAGGCGCAAGCCCACTTTGTGAATC 2985
2109	ACCCAAACCCCGGCGCTGTGCTTTTCCCTTCTGCGCTACCTTGTAGTGTGGAGC 2168
2986	ACCCAAACCCCGGCGCTGTGCTTTTCCCTTCTGCGCTACCTTGTAGTGTGGAGC 3045
2169	ACTTGTATACATCACAGCTCATCAAAAAAAAAAAAAA 2204
3046	ACTTGTATACATCACAGCTCATCAAAAAAAAAAAAAA 3081





Db	1529	GGCTTCTCTGAGTCCCGCATCTCTCTTTAGAGGTATCTGAGCAACCTGTATGACCCA	1588
QY	1122	ACCTCCAGGACAGCTTATCTGGGCTCAGAGCCAGCCAGTCTCTGGACCGCTGGGTCA	1181
Db	1589	ACCTCCAGGACAGCTTATCTGGGCTCAGAGCCAGCCAGTCTCTGGACCGCTGGGTCA	1648
QY	1182	GGAACTGAGCCAACTGGACAAGGAGCAGGTCCCCCTTCTGAAGATAGAAGAACACCT	1241
Db	1649	GGAACTGAGCCAACTGGACAAGGAGCAGGTCCCCCTTCTGAAGATAGAAGAACACCT	1708
QY	1242	CAACAGCGGACAGATAGCTGAGTTTTCACCGATCTTCTGACGTGGGTCCACTGSCCC	1301
Db	1709	CAACAGCGGACAGATAGCTGAGTTTTCACCGATCTTCTGACGTGGGTCCACTGSCCC	1768
QY	1302	AGGCCACACATAAATTCCTGGGTGGCCTCCATTTCCAAAGACTACTTTGAGATCTC	1361
Db	1769	AGGCCACACATAAATTCCTGGGTGGCCTCCATTTCCAAAGACTACTTTGAGATCTC	1828
QY	1362	ACTTCTCCACATGGAAGCTACCACTCTGGATGGCTCCCCAACGACTGACACCCCTCGG	1421
Db	1829	ACTTCTCCACATGGAAGCTACCACTCTGGATGGCTCCCCAACGACTGACACCCCTCGG	1888
QY	1422	AGCCCCACTGTGCTGCTGATGTTGGTACTCTCATTAFAACGACTGCTGCCCTCC	1481
Db	1889	AGCCCCACTGTGCTGCTGATGTTGGTACTCTCATTAFAACGACTGCTGCCCTCC	1948
QY	1482	TGACGCCACTCGGACCTGACCTCATCTGTCTATTGGACTACACTCCACGAGGCT	1541
Db	1949	TGACGCCACTCGGACCTGACCTCATCTGTCTATTGGACTACACTCCACGAGGCT	2008
QY	1542	TCCAGCAGTTGAGCTCTGGGCGGTTCTGCCAGGAGCAGGGGATCCCGTTCACACCA	1601
Db	2009	TCCAGCAGTTGAGCTCTGGGCGGTTCTGCCAGGAGCAGGGGATCCCGTTCACACCA	2068
QY	1602	TCTGCCCCAGCCCCGAGAGCAGCTCAGCCTCGGAGTGCCACACTTCTCGACCCCA	1661
Db	2069	TCTGCCCCAGCCCCGAGAGCAGCTCAGCCTCGGAGTGCCACACTTCTCGACCCCA	2128
QY	1662	CCTGCCCGGAGCCCTCGCGGTGTCGACTTT-----	1693
Db	2129	CCTGCCCGGAGCCCTCGCGGTGTCGACTTTCTCTGTGTCAGCGACTCTTCCGGAGT	2188
QY	1694	-----TCTCTGGGTCGCGGACACCCGAGGAGCGGAGCTGGGGAGGTGAACCTGT	1748
Db	2189	ACTCGGCCCTCGGGTCGCGGACACCCGAGGAGCGGAGCTGGGGAGGTGAACCTGT	2248
QY	1749	CTTCATCGGACTCTCCCTACCACTACAGNAGTGACTTACAGCCAGGAGCAGTGGA	1808
Db	2249	CTTCATCGGACTCTCCCTACCACTACAGNAGTGACTTACAGCCAGGAGCAGTGGA	2308
QY	1809	AGTGTCTGACCTGACACATTACATGTCTGCAACCAACAGAGCAGCTGCTGGAGGCTC	1868
Db	2309	AGTGTCTGACCTGACACATTACATGTCTGCAACCAACAGAGCAGCTGCTGGAGGCTC	2368
QY	1869	TGGCCAGGAGTGACGAGCGGCGCAGCGAGGCCCACTGATGGCGGGGCCCTTCG	1928
Db	2369	TGGCCAGGAGTGACGAGCGGCGCAGCGAGGCCCACTGATGGCGGGGCCCTTCG	2428
QY	1929	CACCCCTAACTCTCATTTCTCCCTGGCTGTGATGTTGAGTGGGAACCTGTCTACGC	1988
Db	2429	CACCCCTAACTCTCATTTCTCCCTGGCTGTGATGTTGAGTGGGAACCTGTCTACGC	2488
QY	1989	AGTGTCTCAGAGCTCGGGCTCAGGTGGCACTGTCCCGAGGTCACAGGCTGAGGCTGGA	2048
Db	2489	AGTGTCTCAGAGCTCGGGCTCAGGTGGCACTGTCCCGAGGTCACAGGCTGAGGCTGGA	2548
QY	2049	GCTCCCTTGCAGCTAGAGTTTGACGTGGGTTAAGAGGCCCAAGCCCACTTGTGTAATC	2108
Db	2549	GCTCCCTTGCAGCTAGAGTTTGACGTGGGTTAAGAGGCCCAAGCCCACTTGTGTAATC	2608
QY	2109	ACCCAAAACCCCGGCTGTGCTGTTTCCCTTCTGCGCTACCTGAGTAGTGGAGC	2168

Db	2609	ACCCAAAACCCCGCCCTGTCCTGTTTCCCTTCTCGCTACTCTGAGTAGTTGGAGC	2668
Qy	2169	ACTTGATACATCACAGACTCATACAAA	2195
Db	2669	ACTTGATACATCACAGACTCATACAAA	2695
RESULT 10			
ID	AA517362	standard; cDNA; 4183 BP.	
XX	AA517362;		
XX	25-FEB-2002	(first entry)	
XX	Partial cDNA encoding human cPLA2-beta enzyme.		
XX	Calcium-independent cytosolic phospholipase A2-beta; cPLA2-beta;		
KW	U937 cell; membrane phospholipid turnover; intracellular signalling;		
KW	arachidonic acid cascade; inflammatory disorder; rheumatoid arthritis;		
KW	psoriasis; asthma; inflammatory bowel disease; antiinflammatory; ss.		
XX	Homo sapiens.		
XX	Key	Location/Qualifiers	
FH	CDS	1560..3896	
FT		/*tag= a	
FT		/partial	
FT		/product= "cPLA2-beta enzyme"	
FT		/note= "This sequence lacks a start codon"	
XX	US6287838-B1.		
PN	XX		
PD	11-SEP-2001.		
XX	13-DEC-1999;	99US-00460145.	
PF	24-JAN-1997;	97US-00788975.	
PR	(GEMY ) GENETICS INST INC.		
XX	Kriz R, Song C;		
PI	WPI; 2002-054342/07.		
DR	P-PSDB; AAU10696.		
XX	Novel cytosolic phospholipase A2-beta enzyme encoding polynucleotide,		
PT	useful for producing the enzyme for use in assays to discover enzyme		
PT	antagonists.		
XX	Claim 1; Col 11-15; 19pp; English.		
PS	The present invention relates to a novel calcium-independent cytosolic		
CC	phospholipase A2 (cPLA2)-beta enzyme and the cDNA sequence encoding it.		
CC	The cDNA clone is isolated from U937 cells. The cPLA2 enzyme is active in		
CC	membrane phospholipid turnover and in regulation of intracellular		
CC	signalling mediated by the arachidonic acid cascade. The invention		
CC	describes a method for producing phospholipase enzymes which can be used		
CC	to identify inhibitors of their function. The inhibitors can be used		
CC	treat inflammatory disorders such as rheumatoid arthritis, psoriasis,		
CC	asthma, and inflammatory bowel disease. The present sequence represents a		
CC	partial cDNA sequence which encodes for human cPLA2-beta enzyme		
XX	Sequence 4183 BP; 983 A; 1177 C; 1168 G; 850 T; 0 U; 5 Other;		
XX	Query Match	82.0%; Score 1806.2; DB 6; Length 4183;	
XX	Best Local Similarity	98.1%; Pred. No. 0;	
XX	Matches 1851; Conservative	0; Mismatches 3; Indels 33; Gaps 1;	
Qy	342	GACTGAGGAGCTGGCCGTGCGACTGGCTTCGGGCCCTGTGCAGAGCAGCGCCTTC	401
Db	2293	GACTGAGGAGCTGGCCGTGCGACTGGCCCTTCGGGCCCTGTGCAGAGCAGCGCCTTC	2352



QY	402	TGAGCAGGAGGAACAGGTGGTGGCGCGCCCTTGAGGCAGGCCCTTGACGCTGGATGGAG	461
Db	2353	TGAGCAGGAGGAACAGGTGGTGGCGCGCCCTTGAGGCAGGCCCTTGACGCTGGATGGAG	2412
QY	462	ACCTGCAGGAGATGAGATCCAGTGGTAGCTATTATATGSCCACTGGTGGTGGGATCCGGG	521
Db	2413	ACCTGCAGGAGATGAGATCCAGTGGTAGCTATTATATGSCCACTGGTGGTGGGATCCGGG	2472
QY	522	CAATGACTCCCTGTATGGCGCAGCTGGCTGGCCTGAAGGAGCTGGGCCCTTTGGAATTCG	581
Db	2473	CBAATGACTCCCTGTATGGCGCAGCTGGCTGGCCTGAAGGAGCTGGGCCCTTTGGAATTCG	2532
QY	582	TCTCTTACAATCACCGGGGCGCTCGGGCTCAACTGGGCGCTTGGSCCAACCTTTATGAGAAC	641
Db	2533	TCTCTTACAATCACCGGGGCGCTCGGGCTCAACTGGGCGCTTGGSCCAACCTTTATGAGAAC	2592
QY	642	CAGAGTGGTCTCAGAAGGACCTGCGCAGGGGCCACTGAGTTGCTGAAGACCAGGTGACCA	701
Db	2593	CAGAGTGGTCTCAGAAGGACCTGCGCAGGGGCCACTGAGTTGCTGAAGACCAGGTGACCA	2652
QY	702	AGAAACAAGCTGGGTGTCTTGGCCCCCAGCCAGCTGCAGCGGTACCGGCAGAGCTGGCG	761
Db	2653	AGAAACAAGCTGGGTGTCTTGGCCCCCAGCCAGCTGCAGCGGTACCGGCAGAGCTGGCG	2712
QY	762	AGCGTCCCGCTTGGGCTACCCAGAGCTGCTTCAACCACTGTGGGCCCTCATCAACAGG	821
Db	2713	AGCGTCCCGCTTGGGCTACCCAGAGCTGCTTCAACCACTGTGGGCCCTCATCAACAGG	2772
QY	822	CGCTGTCTGATGATGAGCCCCCATGATCACAGCTCTCAGATCAAACGAGAGCCCTGAGTC	881
Db	2773	CGCTGTCTGATGATGAGCCCCCATGATCACAGCTCTCAGATCAAACGAGAGCCCTGAGTC	2832
QY	882	ATGGCCAGAACCCCTCTGCCCATCTAATCTGCGCCCTCAACCAAGGCGAGGCTGACCA	941
Db	2833	ATGGCCAGAACCCCTCTGCCCATCTAATCTGCGCCCTCAACCAAGGCGAGGCTGACCA	2892
QY	942	CTTTTGAAATTTGGGAGTGGTGCAGTTCTCTCCCTACAGGTGGGCTTCCCAGTAGC	1001
Db	2893	CTTTTGAAATTTGGGAGTGGTGCAGTTCTCTCCCTACAGGTGGGCTTCCCAGTAGC	2952
QY	1002	GGGCTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGGCAGCTGATAAGA	1061
Db	2953	GGGCTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGGCAGCTGATAAGA	3012
QY	1062	GCGTTCCTGAGTCGGCATCTGCTTCTTAGAGGTATCTGGAGCAACCTGTATGACCCA	1121
Db	3013	GCGTTCCTGAGTCGGCATCTGCTTCTTAGAGGTATCTGGAGCAACCTGTATGACCCA	3072
QY	1122	ACCTCCAGGACAGCTTATCTAGCTGGGCTCAGAGCCAGCCAGTTCCTGGGACCGCTGGTCA	1181
Db	3073	ACCTCCAGGACAGCTTATCTAGCTGGGCTCAGAGCCAGCCAGTTCCTGGGACCGCTGGTCA	3132
QY	1182	GGAAACCAAGGCCAACTCGAACAAAGGACGAGTCCCGCTTCTGAAGATAGNAGAACCCCT	1241
Db	3133	GGAAACCAAGGCCAACTCGAACAAAGGACGAGTCCCGCTTCTGAAGATAGNAGAACCCCT	3192
QY	1242	CAA GAGCGCGCAGATAGCTGAGTTTTTCACCGATCTTCTGACGTGGCGCTCCACTGGCCC	1301
Db	3193	CAA GAGCGCGCAGGATAGCTGAGTTTTTCACCGATCTTCTGACGTGGCGCTCCACTGGCCC	3252
QY	1302	AGGCCACACATAAATTTCCCTGGCGCTCCATTTCCAAAAGACTACTTTTCAGCATCTCTC	1361
Db	3253	AGGCCACACATAAATTTCCCTGGCGCTCCATTTTCAAAAGACTACTTTTCAGCATCTCTC	3312
QY	1362	ACTTCTCACATGGAAGTACCACTCTGGATGGGCTCCCCAACCAAGCTGACACCCCTCGG	1421
Db	3313	ACTTCTCACATGGAAGTACCACTCTGGATGGGCTCCCCAACCAAGCTGACACCCCTCGG	3372
QY	1422	AGCCCCACTGTGCGCTGCTGGATGTTGGCTACCTCATTAATACCAAGCTGACACCCCTCG	1481
Db	3373	AGCCCCACTGTGCGCTGCTGGATGTTGGCTACCTCATTAATACCAAGCTGACACCCCTCG	3432
QY	1482	TGCAGGCCACTCGGAGCTGGGACCTCATCTCTGCTATTGGACTACCAACCTCCACGGAGCCT	1541

Db	3433	TCGAGCCCACTCGGAGCTGGACCTCATCTGCTCATTTGCACTACAACTCCACGAGCT	3492
Qy	1542	TTCCAGAGTTGACGCTCCCTGGGCGCGTCTGCGCAGGACAGGGGATCCGGTTCCACCCCA	1601
Db	3493	TCAGCAGTTGACGCTCTCGGCGCGTCTGCGCAGGACAGGGGATCCGGTTCCACCCCA	3552
Qy	1602	TCCTGCCCCAGCCCGAAGACGAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCCA	1661
Db	3553	TTCTGCCCCAGCCCGAAGACGAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCCA	3612
Qy	1662	CTCTGCCCGGAGCCCTCGCGTCTGCACTTT-----	1693
Db	3613	CTTGCCCCGAGGCCCTCGCGTCTGCACTTTCTCTGCTCAGCGACTCTCTTCGCGAGT	3672
Qy	1694	-----TCCTCTGGGTCCTCGGCGGACACCGAGGAGCGGACGTGGGAGGTGAACCTGT	1748
Db	3673	ACTCGGCCCTCGGGTCCGCGGACACCGAGGAGCGGACGTGGGAGGTGAACCTGT	3732
Qy	1749	CTTCACTCGACTCTCCCTACCACTACACGAAGGTGACCTACAGCCAGGAGGACGTGGACA	1808
Db	3733	CTTCACTCGACTCTCCCTACCACTACACGAAGGTGACCTACAGCCAGGAGGACGTGGACA	3792
Qy	1809	AGCTGTCTGACCTGCACACATTACAATGTCTGCAACAAACAGGAGAGCTGCTGGAGCTC	1868
Db	3793	AGCTGTCTGACCTGCACACATTACAATGTCTGCAACAAACAGGAGAGCTGCTGGAGCTC	3852
Qy	1869	TGCGCCAGGACGTGCAGCGAGGCGGACGCGAGGCCCACTCATGGCCGGGCCCCCTGC	1928
Db	3853	TGCGCCAGGACGTGCAGCGAGGCGGACGCGAGGCCCACTCATGGCCGGGCCCCCTGC	3912
Qy	1929	CACCCCTAACTTCATTCATTCTCCCTGGCTGCTCAGTTGCAAGTGGGAACCTGTCAACGC	1988
Db	3913	CACCCCTAACTTCATTCATTCTCCCTGGCTGCTCAGTTGCAAGTGGGAACCTGTCAACGC	3972
Qy	1989	AGTGCTTCAGAGCCTCGGGCTCAGTGGCACTGTGCCAGGCTCAGAGCTGAGGCTGGGA	2048
Db	3973	AGTGCTTCAGAGCCTCGGGCTCAGTGGCACTGTGCCAGGCTCAGAGCTGAGGCTGGGA	4032
Qy	2049	GCTCCCTTGGCCCTCAGCAGTTTGCAGTGGGTAAAGGAGGCCAAGCCCATTTGTGTAATC	2108
Db	4033	GCTCCCTTGGCCCTCAGCAGTTTGCAGTGGGTAAAGGAGGCCAAGCCCATTTGTGTAATC	4092
Qy	2109	ACCCAAACCCCGCGCTGTGCTGCTTTTCCCTCTTCGCGTACCTTGAGTAGTGGAGC	2168
Db	4093	ACCCAAACCCCGCGCTGTGCTGCTTTTCCCTCTTCGCGTACCTTGAGTAGTGGAGC	4152
Qy	2169	ACTTGATACATCACAGACTATACAAA	2195
Db	4153	ACTTGATACATCACAGACTATACAAA	4179
RESULT 11			
ABX11883			
ID	ABX11883 standard; cDNA; 4183 BP.		
XX	AC ABX11883;		
XX			
DT	10-MAY-2003 (first entry)		
XX	Human partial cDNA for cytosolic phospholipase A2-beta, cPLA2-beta.		
DE	Human; ss; calcium independent cytosolic phospholipase A2-beta;		
XX	cPLA2-beta; antiinflammatory; arachidonic acid cascade;		
KW	inflammatory condition.		
KW	Homo sapiens.		
XX			
XX			
FH	Key	Location/Qualifiers	
FT	CDS	1560..3896	
FT		/tag= a	
FT		/product= "Partial cPLA2-beta"	
FT		/partial	



/note= "No start codon shown"

ET	/note= "No start codon shown"
XX	
PN	US6482625-B1.
XX	
PD	19-NOV-2002.
XX	
PF	29-JUN-2001; 2001US-00895547.
XX	
PR	24-JAN-1997; 97US-00788975.
PR	13-DEC-1999; 99US-00460145.
XX	
PA	(GEMY ) GENETICS INST LLC.
XX	
PI	Kriz R, Song C;
XX	
XX	WPI, 2003-287361/28.
DR	P-PSDB; ABG76482.
DR	
XX	
PT	Novel purified calcium-independent cytosolic phospholipase A2-beta
PT	enzyme, useful for screening compounds having antiinflammatory activity
PT	mediated by the arachidonic acid cascade.
XX	
PS	Claim 1; Col 11-14; 19pp; English.
XX	
CC	The invention relates to a purified phospholipase enzyme (calcium-
CC	independent cytosolic phospholipase A <sub>2</sub> -beta enzyme) peptide appearing as
CC	ABG76482 encoded by a polynucleotide appearing as ABX118983. The protein
CC	has an enzymatic activity in a mixed micelle assay (MMA) with 1-palmitoyl
CC	-2-( <sup>14</sup> C)-arachidonyl- phosphatidylcholine. cPLA2-beta is useful for
CC	assaying chemical agents for antiinflammatory activity mediated by the
CC	various components of the arachidonic acid cascade. cPLA2-beta is also
CC	useful in the development of polyclonal and monoclonal antibodies which
CC	are useful as research or diagnostic tools, and to study phospholipase
CC	A <sub>2</sub> activity and inflammatory conditions. The present sequence encodes a
CC	partial cPLA2-beta protein
XX	
SQ	Sequence 4183 BP; 983 A; 1177 C; 1168 G; 850 T; 0 U; 5 Other;
Query Match	
Best Local Similarity 82.0%; Score 1806.2; DB 7; Length 4183;	
Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;	
QY	342 GACTGAGGAGCTGGCGTGCAGCTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCTTCC 401
Db	
QY	2293 GACTGAGGAGCTGGCGCTGCAGCTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCTTCC 2352
Db	
QY	402 TGAGCAGGAGGAGACAGGTGGTGGCGCGGCTTGAGCAGGCCCTCGAGCTGGATGGAG 461
Db	
QY	2353 TGAGCAGGAGGAGACAGGTGGTGGCGCGGCTTGAGCAGGCCCTCGAGCTGGATGGAG 2412
Db	
QY	462 ACCTGCAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACTGGTGGGATCCGGG 521
Db	
QY	2413 ACCTGCAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACTGGTGGGATCCGGG 2472
Db	
QY	522 CAATGACTTCCCTGTATGGCAGCTGGCTGGCCTGAAGAGAGCTGGGCCTCTTGGATTGCG 581
Db	
QY	2473 CAATGACTTCCCTGTATGGCAGCTGGCTGGCCTGAAGAGAGCTGGGCCTCTTGGATTGCG 2532
Db	
QY	582 TCTCTTACATCACCGGGGCTTCGGGCTCCACCTGGGCTTGGCCAACTTTATGAGAGCC 641
Db	
QY	2533 TCTCTTACATCACCGGGGCTTCGGGCTCCACCTGGGCTTGGCCAACTTTATGAGAGCC 2592
Db	
QY	642 CAGAGTGGTCTCAGAAGGACCTGGCAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCA 701
Db	
QY	2593 CAGAGTGGTCTCAGAAGGACCTGGCAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCA 2652
Db	
QY	702 AGAACAAAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACCGGCAGGAGCTGGCCG 761
Db	
QY	2653 AGAACAAAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACCGGCAGGAGCTGGCCG 2712
Db	
QY	762 AGCGTCCCGCTTGGGTACCCAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG 821
Db	
QY	2713 AGCGTCCCGCTTGGGTACCCAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG 2772
Db	

[illegible]



QY	1933	CCTAACTCTCATTCATTCCTCGGCTGCTGAGTTGCAGGTGGGAACTGTTCATCACGAGTG	1992
Db	1626	CCTAACTCTCATTCATTCCTCGGCTGCTGAGTTGCAGGTGGGAACTGTTCATCACGAGTG <td>1685</td>	1685
QY	1993	CTTCAGAGCCTCGGGCTCAGGTGGCACTGTCCACGGGTCACGGCTGAGGGCTGGGAGCTC	2052
Db	1686	CTTCAGAGCCTCGGGCTCAGGTGGCACTGTCCACGGGTCACGGCTGAGGGCTGGGAGCTC	1745
QY	2053	CCTTCGGGCTCAGCAGTTTGACGTGGGTAAAGGAGGCCAAGCCCACTTGTGTAATCACCC	2112
Db	1746	CCTTCGGGCTCAGCAGTTTGACGTGGGTAAAGGAGGCCAAGCCCACTTGTGTAATCACCC	1805
QY	2113	AAAAACCCCGCGCTGCTGCTGTTTCCCTCTCTCGCTACCTTTGAGTAGTTGGAGCACTT	2172
Db	1806	AAAAACCCCGCGCTGCTGCTGTTTCCCTCTCTCGCTACCTTTGAGTAGTTGGAGCACTT	1865
QY	2173	GATACATCACAGACTCATACAAA	2195
Db	1866	GATACATCACAGACTCATACAAA	1888
RESULT 13			
ACD08100			
ID	ACD08100	standard; cDNA; 1925 BP.	
XX	ACD08100;		
XX	12-AUG-2003	(first entry)	
XX	cDNA encoding novel human secreted protein #76.		
XX	Human; immunoglobulin G; IgG; fragment of crystallisation; Fc;		
KW	immune system disorder; haematopoietic cell disorder;		
KW	immunologic deficiency disorder; ataxia telangiectasia; HIV infection;		
KW	Wiskott-Aldrich disorder; thrombocytopenia; haemoglobinuria;		
KW	blood coagulation disorder; blood platelet disorder; autoimmune disorder;		
KW	Addison's disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;		
KW	glomerulonephritis; Grave's disease; allergic reaction;		
KW	grat-versus-host disease; hyperproliferative disorder; neoplasm;		
KW	infectious disease; nervous system disease; spinal cord disorder;		
KW	head trauma; stroke; tissue regeneration; congenital defect; trauma;		
KW	wound; burn; incision; ulcer; age disease; osteoporosis;		
KW	periodontal disease; liver failure; catabolism; anabolism; metabolism;		
KW	food additive; preservative; secreted protein; gene; ss.		
XX	Homo sapiens.		
XX	US2003027132-A1.		
XX	06-FEB-2003.		
XX	04-SEP-1998;	98US-00148545.	
XX	07-MAR-1997;	97US-0038621P.	
PR	07-MAR-1997;	97US-0040161P.	
PR	07-MAR-1997;	97US-0040162P.	
PR	07-MAR-1997;	97US-0040163P.	
PR	07-MAR-1997;	97US-0040333P.	
PR	07-MAR-1997;	97US-0040334P.	
PR	07-MAR-1997;	97US-0040335P.	
PR	07-MAR-1997;	97US-0040626P.	
PR	11-APR-1997;	97US-0043311P.	
PR	11-APR-1997;	97US-0043312P.	
PR	11-APR-1997;	97US-0043313P.	
PR	11-APR-1997;	97US-0043314P.	
PR	11-APR-1997;	97US-0043315P.	
PR	11-APR-1997;	97US-0043568P.	
PR	11-APR-1997;	97US-0043569P.	
PR	11-APR-1997;	97US-0043576P.	
PR	11-APR-1997;	97US-0043578P.	
PR	11-APR-1997;	97US-0043580P.	
PR	11-APR-1997;	97US-0043669P.	
PR	11-APR-1997;	97US-0043670P.	
PR	11-APR-1997;	97US-0043671P.	
PR	11-APR-1997;	97US-0043672P.	
PR	11-APR-1997;	97US-0043673P.	
PR	11-APR-1997;	97US-0043674P.	
PR	23-MAY-1997;	97US-0047492P.	
PR	23-MAY-1997;	97US-0047500P.	
PR	23-MAY-1997;	97US-0047501P.	
PR	23-MAY-1997;	97US-0047502P.	
PR	23-MAY-1997;	97US-0047503P.	
PR	23-MAY-1997;	97US-0047581P.	
PR	23-MAY-1997;	97US-0047582P.	
PR	23-MAY-1997;	97US-0047583P.	
PR	23-MAY-1997;	97US-0047584P.	
PR	23-MAY-1997;	97US-0047585P.	
PR	23-MAY-1997;	97US-0047586P.	
PR	23-MAY-1997;	97US-0047587P.	
PR	23-MAY-1997;	97US-0047588P.	
PR	23-MAY-1997;	97US-0047589P.	
PR	23-MAY-1997;	97US-0047590P.	
PR	23-MAY-1997;	97US-0047592P.	
PR	23-MAY-1997;	97US-0047593P.	
PR	23-MAY-1997;	97US-0047594P.	
PR	23-MAY-1997;	97US-0047595P.	
PR	23-MAY-1997;	97US-0047596P.	
PR	23-MAY-1997;	97US-0047597P.	
PR	23-MAY-1997;	97US-0047598P.	
PR	23-MAY-1997;	97US-0047599P.	
PR	23-MAY-1997;	97US-0047600P.	
PR	23-MAY-1997;	97US-0047612P.	
PR	23-MAY-1997;	97US-0047613P.	
PR	23-MAY-1997;	97US-0047614P.	
PR	23-MAY-1997;	97US-0047615P.	
PR	23-MAY-1997;	97US-0047617P.	
PR	23-MAY-1997;	97US-0047618P.	
PR	23-MAY-1997;	97US-0	

The invention describes an isolated human secreted HODAD50 polypeptide (I) comprising a sequence at least 95% identical to a sequence selected from polypeptide fragment of any one of the 123 polypeptide sequences (PS) fully defined in the specification and having biological activity, polypeptide domain or epitope of PS, secreted form of PS, full-length polypeptide of PS, or variant, allelic variant or species homologue of PS. (I) or a polynucleotide (II) encoding (I) is useful for preventing, treating, or ameliorating a medical condition in a mammalian subject. (I) or (II) is also useful for diagnosing a pathological condition or a susceptibility to a pathological condition in a subject. (I) is useful for identifying a binding partner which involves contacting the polypeptide with the binding partner and determining whether the binding partner affects the activity of the polypeptide. (I) or (II) is useful for diagnosing or treating deficiencies or disorders of the immune system, deficiencies or disorders of haematopoietic cells, to treat immunologic deficiency disorders, ataxia telangiectasia, to treat coagulation disorders, thrombocytopenia or haemoglobinuria, blood disorders, Addison's disease, haemolytic anaemia, autoimmune disorders (e.g., Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid arthritis, Grave's disease), allergic reactions, graft-versus-host disease, hyperproliferative disorders (e.g., neoplasms located in the abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands), infectious diseases (e.g., viral, bacterial, fungal or parasitic infection), central and peripheral nervous system diseases (e.g., spinal cord disorders, head trauma or stroke), to differentiate, proliferate and attract cells leading to the regeneration of tissues to repair, replace or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers) age disease (e.g., osteoporosis, periodontal disease, liver failure) or surgery. (I) or (II) is useful to modulate mammalian characteristics, to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilisation, and storage of energy, to change a mammal's mental state or physical state, or as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components. This

CC	sequence encodes a novel human secreted protein					
XX						
SQ	Sequence	1925 BP; 388 A; 613 C; 545 G; 377 T; 0 U; 2 Other;				
	Query Match	81.2%; Score 1788.8; DB 7; Length 1925;				
	Best Local Similarity	97.9%; Pred. No. 0;				
	Matches 1844; Conservative	1; Mismatches 4; Indels 34; Gaps 2				
QY	347	AGGGAGCTTGGCGTCGCACTGGGCCTTCGGGCCCTGTG-CAGAGGAGCAGGCTTCCTCTGAG	405			
Db	6	AGGGAGCTGGCGTCGCACTGGGCCTTCGGGCCCTGTGCCAGAGGACGANGCTTCCTCTGAG	65			
QY	406	CAGGAGGAAGCAGGTGTGTGGCCGCGGCCTTGAGGCAGGCCCTGCAGCTGGATGGAGACCT	465			
Db	66	CAGGAGGAAGCAGGTGTGTGGCCGCGGCCTTGAGGCAGGCCCTGCAGCTGGATGGAGACCT	125			
QY	466	GCAGGAGATGAGATCCCACTGGTAGCTATTATGGCCACTGGTGGTGGGATCCGGGCAAT	525			
Db	126	GCAGGAGATGAGATCCCACTGGTAGCTATTATGGCCACTGGTGGTGGGATCCGGGCAAT	185			
QY	526	GACTTCCCCTGTATGGCAGCTGGCTGAAGAGCTGGGCTTCAAAGAGCTGGGCTCTTTGGATTGCGTCTC	585			
Db	186	GACTTCCCCTGTATGGCAGCTGGCTGGCCTGAAGAGCTGGGCTCTTTGGATTGCGTCTC	245			
QY	586	CTAATCATCCGGGCGCTGGGCTCCAGCTGGGCCCTTGCCCAACCTTTATGAGGACCAGA	645			
Db	246	CTAATCATCCGGGCGCTGGGCTCCAGCTGGGCCCTTGCCCAACCTTTATGAGGACCAGA	305			
QY	646	GTGCTCTCAGAAGACCTTGGCAGGGCCCCACTGAGTTGCTGAAGACCCAGGTGACAAGAA	705			
Db	306	GTGCTCTCAGAAGACCTTGGCAGGGCCCCACTGAGTTGCTGAAGACCCAGGTGACAAGAA	365			
QY	706	CAAGCTGGGTGTGTGGGCCCCCAAGCCAGCTGCACGGTACCGGCAGGAGCTGGCCGAGCG	765			
Db	366	CAAGCTGGGTGTGTGGGCCCCCAAGCCAGCTGCACGGTACCGGCAGGAGCTGGCCGAGCG	425			
QY	766	TGCCCGCTTGGGCTATCCCAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGGCGCT	825			
Db	426	TGCCCGCTTGGGCTATCCCAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGGCGCT	485			
QY	826	GCTGCATGATGAGCCCCATGATCACAGCTCTCAGATCAACGGGAGGCCCTGAGTGTATGG	885			
Db	486	GCTGCATGATGAGCCCCATGATCACAGCTCTCAGATCAACGGGAGGCCCTGAGTGTATGG	545			
QY	886	CCAGAACCCCTTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCACTTT	945			
Db	546	CCAGAACCCCTTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCACTTT	605			
QY	946	TGAATTTGGGGAGTGTGCGAGTTCTCTCCCTACGAGGTGCGCTTCCCCAAGTACGGGGC	1005			
Db	606	TGAATTTGGGGAGTGTGCGAGTTCTCTCCCTACGAGGTGCGCTTCCCCAAGTACGGGGC	665			
QY	1006	CTTCACTCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGAGGCT	1065			
Db	666	CTTCACTCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGAGGCT	725			
QY	1066	TCCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTCGAGCAACTCTGTATGCGACCAACCT	1125			
Db	726	TCCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTCGAGCAACTCTGTATGCGACCAACCT	785			
QY	1126	CCAGGACAGTTATCTGGGCCCTCAGAGCCACGCAAGTTCTTGCGACCGCTGGGTCAAGAA	1185			
Db	786	CCAGGACAGTTATCTGGGCCCTCAGAGCCACGCAAGTTCTTGCGACCGCTGGGTCAAGAA	845			
QY	1186	CCAGGCCAACCTTGGACAAAGGACGAGTCCCCCTTCTGAAGATAGAAGAACCAACCTTCAAC	1245			
Db	846	CCAGGCCAACCTTGGACAAAGGACGAGTCCCCCTTCTGAAGATAGAAGAACCAACCTTCAAC	905			
QY	1246	AGCCGGCAGAAATAGCTGAGTTTTTTCACCGATCTCTGAGTGGCGTCCACTGGCCAGGC	1305			
Db	906	AGCCGGCAGAAATAGCTGAGTTTTTTCACCGATCTCTGAGTGGCGTCCACTGGCCAGGC	965			
QY	1306	CACACATAATTTCTGCGTGGGCTCCATTTCCACAAAGACTACTTTGACATCTCTCACTT	1365			

Db	966	CACACATAATTTCCCTGGTGGCTCCATTTCACAAAGACTACTTTACGATCCTCACTT	1025
Qy	1366	CTCCACATGAAAGCTACACACTCTGATGGGTCCCAACACAGCTGACACCTCTGGAGCC	1425
Db	1026	CTCCACATGAAAGCTACACACTCTGATGGGTCCCAACACAGCTGACACCTCTGGAGCC	1085
Qy	1426	CCACCTGTGCTCTGCTGGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCTCTGCA	1485
Db	1086	CCACCTGTGCTCTGCTGGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCTCTGCA	1145
Qy	1486	GCCCACTCGGAGCGTGGACCTCATTCCTGTTCATTGGACTACCACTTCCAGGAGCCTTCCA	1545
Db	1146	GCCCACTCGGAGCGTGGACCTCATTCCTGTTCATTGGACTACCACTTCCAGGAGCCTTCCA	1205
Qy	1546	GCAAGTTCAGCTCCTGGGCGGTCTTGCCAGGAGCAGGGATCCCGTTCCCAACCCATCTC	1605
Db	1206	GCAAGTTCAGCTCCTGGGCGGTCTTGCCAGGAGCAGGGATCCCGTTCCCAACCCATCTC	1265
Qy	1606	GCCCAGCCCCGAAGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCGACCCGACCTG	1665
Db	1266	GCCCAGCCCCGAAGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCGACCCGACCTG	1325
Qy	1666	CCCCGGAGCCCTGCGGTCTGCACATTT-----	1693
Db	1326	CCCCGGAGCCCTGCGGTCTGCACATTTCTCTGTTCAGCGACTCTTTCGGGAGTACTC	1385
Qy	1694	-TCTCTTGGGGTCCGGCGGACACCCGAGGAGCGGCAGCTGGGAGGTGAACCTGTCTTC	1752
Db	1386	GGCCCTTGGGGTCCGGCGGACACCCGAGGAGCGGCAGCTGGGAGGTGAACCTGTCTTC	1445
Qy	1753	ATCGGACTCTCCCTAACCACTACATACGAAGGTGACCTACAGCCAGGAGACCTGCACAAGCT	1812
Db	1446	ATCGGACTCTCCCTAACCACTACATACGAAGGTGACCTACAGCCAGGAGACCTGCACAAGCT	1505
Qy	1813	GCTGCACCTGCACATTAACAATGCTGCAACAAACAGGAGCAGCTGCTGGAGGCTCTGCG	1872
Db	1506	GCTGCACCTGCACATTAACAATGCTGCAACAAACAGGAGCAGCTGCTGGAGGCTCTGCG	1565
Qy	1873	CCAGCAGTGCAGCGGAGCGGCAGCGCAGGCCCACTGATGGCCGGGGCCCTGCGCACC	1932
Db	1566	CCAGCAGTGCAGCGGAGCGGCAGCGCAGGCCCACTGATGGCCGGGGCCCTGCGCACC	1625
Qy	1933	CCTAACTCTCATTCATTCCTTCCCTGGCTGCTGAGTTCAGGTGGAACTGTTCATCAGCAGTG	1992
Db	1626	CCTAACTCTCATTCATTCCTTCCCTGGCTGCTGAGTTCAGGTGGAACTGTTCATCAGCAGTG	1685
Qy	1993	CTTTCAGAGCCTCGGGCTCAGGTGGCACTGTCTCCAGGGTCCAGGCTGAGGGCTGGAGCTC	2052
Db	1686	CTTTCAGAGCCTCGGGCTCAGGTGGCACTGTCTCCAGGGTCCAGGCTGAGGGCTGGAGCTC	1745
Qy	2053	CCTTCGGCTCAGCAGTTTGAGTGGGTAAAGGAGGCCAAGCCCATTTGTGTATACACC	2112
Db	1746	CCTTCGGCTCAGCAGTTTGAGTGGGTAAAGGAGGCCAAGCCCATTTGTGTATACACC	1805
Qy	2113	AAAACCCCCGGCTGTGCTGTTTCCCTTCTGGCTTACCTTGAGTAGTTGGAGCACTT	2172
Db	1806	AAAACCCCCGGCTGTGCTGTTTCCCTTCTGGCTTACCTTGAGTAGTTGGAGCACTT	1865
Qy	2173	GATACATCACAGACTCATACAAA	2195
Db	1866	GATACATCACAGACTCATACAAA	1888

RESULT 14  
AAV34164  
ID AAV34164 standard; DNA; 1926 BP.

XX	25-MAR-2003	(revised)
DT	28-JAN-1999	(first entry)
DT		
XX		

Human secreted protein gene 11 clone HCENJ40.

Human; secreted protein; fusion protein; gene therapy; protein therapy; diagnosis; tissue; cancer; tumour; neurodegenerative disorder; leukaemia; developmental abnormality; foetal deficiency; blood; allergy; renal; ds; immune system; asthma; lymphocytic disease; brain; hepatic; lymphoma; inflammation; ischaemic shock; Alzheimer's disease; reterosias; AIDS; cognitive disorder; schizophrenia; prostate; obesity; osteoclast; thymus; osteoporosis; arthritis; testis; lung; thyroiditis; thyroid; digestion; regulation; malabsorption; colitis; arthritis; neoplasm.

[illegible]



Fri Oct 8 10:22:36 2004

us-09-830-321a-5.rng

1366 CTCACATGGAAGCTACCACTCTGATGGCTCCCAACCACTGACACCCCTCGAGCC 1425  
1026 CTCACATGGAAGCTACCACTCTGATGGCTCCCAACCACTGACACCCCTCGAGCC 1085  
1426 CCACTGTGCTCTGATGGCTTGGCTACCTCATCAATACAGCTGCTGCCCTCTGCA 1485  
1086 CCACTGTGCTCTGATGGCTTGGCTACCTCATCAATACAGCTGCTGCCCTCTGCA 1145  
1486 GCCACTTCGGGACGCTGAGACCTCATCTGTCAATTGGACTCAACCTTCACGGAGCTTCCA 1545  
1146 GCCACTTCGGGACGCTGAGACCTCATCTGTCAATTGGACTCAACCTTCACGGAGCTTCCA 1205  
1546 GCAGTTGCAGCTCTGGGCGGCTTCCAGGAGCAGGGATCCCGTTCACCCATCTC 1605  
1206 GCAGTTGCAGCTCTGGGCGGCTTCCAGGAGCAGGGATCCCGTTCACCCATCTC 1265  
1606 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGGAGTGCCACACCTTTCGACCCACCTG 1665  
1266 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGGAGTGCCACACCTTTCGACCCACCTG 1325  
1666 CCCCAGAGCCCTCGGCTGCTGCACTTT----- 1693  
1326 CCCCAGAGCCCTCGGCTGCTGCACTTTCTCTGTCAGCGACTCTTCGGGAGTACTC 1385  
1694 -TCTCTGGGTCGCGGGACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTC 1752  
1386 GGCCCTCTGGGTCGCGGGACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTC 1445  
1753 ATCGGACTCTCCCTACCACTACAGAAAGGTGAACCTACAGCCAGGAGCAGTGGACAGCT 1812  
1446 ATCGGACTCTCCCTACCACTACAGAAAGGTGAACCTACAGCCAGGAGCAGTGGACAGCT 1505  
1813 GCTGCACCTGACATTAATGTCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGCG 1872  
1506 GCTGCACCTGACATTAATGTCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGCG 1565  
1873 CCAGGAGTGCAGGAGGCGGAGCAGGAGCCCACTGATGGCGGGGCCCCCTGCCACC 1932  
1566 CCAGGAGTGCAGGAGGCGGAGCAGGAGCCCACTGATGGCGGGGCCCCCTGCCACC 1625  
1933 CCTAACTCTCATTCCTCGGCTGTGAGTGCAGTGGGAACTGTCATCAGCAGTG 1992  
1626 CCTAACTCTCATTCCTCGGCTGTGAGTGCAGTGGGAACTGTCATCAGCAGTG 1685  
1993 CTT-CAGAGCTCGGCTCAGTGGCACTTCCAGGCTCCAGGCTGAGGCTGGAGCT 2051  
1686 CTTTCAGAGCTCGGCTCAGTGGCACTTCCAGGCTCCAGGCTGAGGCTGGAGCT 1745  
2052 CCCTTGGCCCTCAGCAGTTTGCAGTGGGTAAAGGAGGCGCAAGCCCACTTGTGTAATCACC 2111  
1746 CCCTTGGCCCTCAGCAGTTTGCAGTGGGTAAAGGAGGCGCAAGCCCACTTGTGTAATCACC 1805  
2112 CAAACCCCGGCTGTGCTGTTTCCCTTCTGGCTACCTGAGTAGTTGGAGCACT 2171  
1806 CAAACCCCGGCTGTGCTGTTTCCCTTCTGGCTACCTGAGTAGTTGGAGCACT 1865  
2172 TGATATCATCAGACTCATACAA 2195  
1866 TGATATCATCAGACTCATACAA 1889

RESULT 15

ACD08035 standard; cDNA; 1926 BP.

XX  
AC ACD08035;

DT 12-AUG-2003 (first entry)

XX cDNA encoding novel human secreted protein #11.

XX Human; immunoglobulin G; IgG; fragment of crystallisation; Fc;

XX immune system disorder; haematopoietic cell disorder;

immunologic deficiency disorder; ataxia telangiectasia; HIV infection;  
Wiskott-Aldrich disorder; thrombocytopenia; haemoglobinuria;  
blood coagulation disorder; blood platelet disorder; autoimmune disorder;  
Addison's disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;  
glomerulonephritis; Grave's disease; allergic reaction;  
graft-versus-host disease; hyperproliferative disorder; neoplasm;  
infectious disease; nervous system disease; spinal cord disorder;  
head trauma; stroke; tissue regeneration; congenital defect; trauma;  
wound; burn; incision; ulcer; age disease; osteoporosis;  
periodontal disease; liver failure; catabolism; anabolism; metabolism;  
food additive; preservative; secreted protein; gene; ss.

Homo sapiens.

US2003027132-A1.

06-FEB-2003.

04-SEP-1998; 98US-00148545.

07-MAR-1997; 97US-0038621P.  
07-MAR-1997; 97US-0040161P.  
07-MAR-1997; 97US-0040162P.  
07-MAR-1997; 97US-0040163P.  
07-MAR-1997; 97US-0040333P.  
07-MAR-1997; 97US-0040334P.  
07-MAR-1997; 97US-0040336P.  
07-MAR-1997; 97US-0040626P.  
11-APR-1997; 97US-0043311P.  
11-APR-1997; 97US-0043312P.  
11-APR-1997; 97US-0043313P.  
11-APR-1997; 97US-0043314P.  
11-APR-1997; 97US-0043315P.  
11-APR-1997; 97US-0043568P.  
11-APR-1997; 97US-0043569P.  
11-APR-1997; 97US-0043576P.  
11-APR-1997; 97US-0043578P.  
11-APR-1997; 97US-0043580P.  
11-APR-1997; 97US-0043669P.  
11-APR-1997; 97US-0043670P.  
11-APR-1997; 97US-0043671P.  
11-APR-1997; 97US-0043672P.  
11-APR-1997; 97US-0043674P.  
23-MAY-1997; 97US-0047492P.  
23-MAY-1997; 97US-0047500P.  
23-MAY-1997; 97US-0047501P.  
23-MAY-1997; 97US-0047502P.  
23-MAY-1997; 97US-0047503P.  
23-MAY-1997; 97US-0047581P.  
23-MAY-1997; 97US-0047582P.  
23-MAY-1997; 97US-0047583P.  
23-MAY-1997; 97US-0047584P.  
23-MAY-1997; 97US-0047585P.  
23-MAY-1997; 97US-0047586P.  
23-MAY-1997; 97US-0047587P.  
23-MAY-1997; 97US-0047588P.  
23-MAY-1997; 97US-0047589P.  
23-MAY-1997; 97US-0047590P.  
23-MAY-1997; 97US-0047592P.  
23-MAY-1997; 97US-0047593P.  
23-MAY-1997; 97US-0047594P.  
23-MAY-1997; 97US-0047595P.  
23-MAY-1997; 97US-0047596P.  
23-MAY-1997; 97US-0047597P.  
23-MAY-1997; 97US-0047598P.  
23-MAY-1997; 97US-0047599P.  
23-MAY-1997; 97US-0047600P.  
23-MAY-1997; 97US-0047601P.  
23-MAY-1997; 97US-0047612P.  
23-MAY-1997; 97US-0047613P.  
23-MAY-1997; 97US-0047614P.  
23-MAY-1997; 97US-0047615P.  
23-MAY-1997; 97US-0047617P.





Fri Oct 8 10:22:36 2004

Db 366 CAAGTGGGTGTGTGGCCCCAGCAGCTGACGGGTACCGGACGAGCTGGCCGAGCG 425  
QY 766 TGCCCGCTTGGGCTACCCAAAGTGTCTTCAACAACTGTGGGCCCTTATCAACAGAGCGCT 825  
Db 426 TGCCCGCTTGGGCTACCCAAAGTGTCTTCAACAACTGTGGGCCCTTATCAACAGAGCGCT 485  
QY 826 GGTGATGATGAGCCCCATGATCAAGCTCTCAGATCAACGGGAGGCGCTCAGTCATGG 885  
Db 486 GGTGATGATGAGCCCCATGATCAAGCTCTCAGATCAACGGGAGGCGCTCAGTCATGG 545  
QY 886 CGAGAACCTCTGCCATCTACTGTGCGCTCAACAAAGGCGAGAGCTGACCACTTT 945  
Db 546 CCAGAACCTCTGCCATCTACTGTGCGCTCAACAAAGGCGAGAGCTGACCACTTT 605  
QY 946 TGAATTTGGGAGTGTGGAGTTCCTCTCCCTACGAGGTGGCTTCCCAAGTACGGGCG 1005  
Db 606 TGAATTTGGGAGTGTGGAGTTCCTCTCCCTACGAGGTGGCTTCCCAAGTACGGGCG 665  
QY 1006 CTTTATCCCTCTGAGCTCTTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAAGAGGCT 1065  
Db 666 CTTTATCCCTCTGAGCTCTTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAAGAGGCT 725  
QY 1066 TCCGTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGAGCAACCTGTATGACGCCAACCT 1125  
Db 726 TCCGTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGAGCAACCTGTATGACGCCAACCT 785  
QY 1126 CCAGGACAGCTTATCTGSGCCTCAGAGCCGAGCCAGTTCGAGACCGCTGGGTGAGGAA 1185  
Db 786 CCAGGACAGCTTATCTGSGCCTCAGAGCCGAGCCAGTTCGAGACCGCTGGGTGAGGAA 845  
QY 1186 CAGAGCCAACTGAGACAGAGAGGAGTCCCGCTTCAAGATAGAAAGCAACCCACTCAAC 1245  
Db 846 CAGAGCCAACTGAGACAGAGAGGAGTCCCGCTTCAAGATAGAAAGCAACCCACTCAAC 905  
QY 1246 AGCCGCGAGATAGCTGAGTTTTTACCGATCTTCTGACGTGGCTCCACTGGGCCAGGC 1305  
Db 906 AGCCGCGAGATAGCTGAGTTTTTACCGATCTTCTGACGTGGCTCCACTGGGCCAGGC 965  
QY 1306 CACACATAATTTCTGCGTGGCTCCATTTCCAAAGACTACTTTCAGCATCTCACTT 1365  
Db 966 CACACATAATTTCTGCGTGGCTCCATTTCCAAAGACTACTTTCAGCATCTCACTT 1025  
QY 1366 CTCACATGGAAGTACACTCTGGATGGCTCCCAACAGCTGACACCTCGGAGCC 1425  
Db 1026 CTCACATGGAAGTACACTCTGGATGGCTCCCAACAGCTGACACCTCGGAGCC 1085  
QY 1426 CCACCTGTGCTGCTGATGTGGCTACCTCATCAATACCAAGCTGCCCTGCCCTCTGCA 1485  
Db 1086 CCACCTGTGCTGCTGATGTGGCTACCTCATCAATACCAAGCTGCCCTGCCCTCTGCA 1145  
QY 1486 GCCCACTCGGACGTGGACCTCATCTGTGATGAGTACAACTTCCAGGAGGCTTCCA 1545  
Db 1146 GCCCACTCGGACGTGGACCTCATCTGTGATGAGTACAACTTCCAGGAGGCTTCCA 1205  
QY 1546 GAGTTGAGCTCTTGGGCGGCTTCTGCCAGAGAGGAGTCCCGTTCACCCCATCTC 1605  
Db 1206 GAGTTGAGCTCTTGGGCGGCTTCTGCCAGAGAGGAGTCCCGTTCACCCCATCTC 1265  
QY 1606 GCCCAGCCCCGAGAGAGCTCCAGCTCGGAGTGCACACCTTCCGACCCCACTG 1665  
Db 1266 GCCCAGCCCCGAGAGAGCTCCAGCTCGGAGTGCACACCTTCCGACCCCACTG 1325  
QY 1666 CCCCGAGCCCCGCGGTGCTGACTTT----- 1693  
Db 1326 CCCCGAGCCCCGCGGTGCTGACTTTCTCTGGTACGACTCTCTTCCGGAGTACTC 1385  
QY 1694 -TCTCTGGGTCGGGCGGACCCCGAGGAGGCGGAGCTGGGGAGGTGAACCTGTCTC 1752  
Db 1386 GGGCCCTTGGGGTCCGGCGGACACCCGAGGAGGCGGAGCTGGGGAGGTGAACCTGTCTC 1445  
QY 1753 ATCGGACTCTCCCTTACCACTACAGAGGTGACCTACAGCAGGAGAGCTGGACAGCT 1812  
Db 1446 ATCGGACTCTCCCTTACCACTACAGAGGTGACCTACAGCAGGAGAGCTGGACAGCT 1505

QY 1813 GCTGCACTGACACATTATCAATGTCTGCAACAACGAGGAGAGCTGCTGGAGGCTCTGCG 1872  
Db 1506 GCTGCACTGACACATTATCAATGTCTGCAACAACGAGGAGAGCTGCTGGAGGCTCTGCG 1565  
QY 1873 CCAGGCACTGACGCGAGGCGGCGAGCGCAGGCGCCCACTGATGGCGGGGCCCTTCCACC 1932  
Db 1566 CCAGGCACTGACGCGAGGCGGCGAGCGCAGGCGCCCACTGATGGCGGGGCCCTTCCACC 1625  
QY 1933 CCTAACTCTCATTTCAATTCCTTGGCTGCTGAGTTGAGTTGAGTTGAGTTGAGTTGAGTTG 1992  
Db 1626 CTTAACTCTCATTTCAATTCCTTGGCTGCTGAGTTGAGTTGAGTTGAGTTGAGTTGAGTTG 1685  
QY 1993 CTTT-CAGAGCCTCGGCTCAGGTGGCACTGTCCAGGGTCCAGGGTCCAGGGTCCAGGGT 2051  
Db 1686 CTTTNCAGAGCCTCGGCTCAGGTGGCACTGTCCAGGGTCCAGGGTCCAGGGTCCAGGGT 1745  
QY 2052 CCGTTGGGCTCAGCAAGTTTGCAGTGGGTAAAGGAGGCCAAGCCCAATTTGTGTAATCAAC 2111  
Db 1746 CCGTTGGGCTCAGCAAGTTTGCAGTGGGTAAAGGAGGCCAAGCCCAATTTGTGTAATCAAC 1805  
QY 2112 CAAAACCCCGGCTGTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2171  
Db 1806 CAAAACCCCGGCTGTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1865  
QY 2172 TGATACATCACAGACTCATACAAA 2195  
Db 1866 TGATACATCACAGACTCATACAAA 1889

Search completed: October 7, 2004, 13:34:49  
Job time : 959.252 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 11:15:59 ; Search time 8928.72 Seconds  
(without alignments)  
10698.960 Million cell updates/sec

Title: US-09-830-321A-5  
Perfect score: 2204  
Sequence: 1 catggtttggggcgcagaga.....actcatcaaaaaaaaaa 2204

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues  
Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : GenEmbl:\*

- 1: gb\_ba:\*
- 2: gb\_htg:\*
- 3: gb\_in:\*
- 4: gb\_om:\*
- 5: gb\_ov:\*
- 6: gb\_pat:\*
- 7: gb\_ph:\*
- 8: gb\_pl:\*
- 9: gb\_pr:\*
- 10: gb\_ro:\*
- 11: gb\_sts:\*
- 12: gb\_sy:\*
- 13: gb\_un:\*
- 14: gb\_vi:\*
- 15: em\_ba:\*
- 16: em\_fun:\*
- 17: em\_hum:\*
- 18: em\_in:\*
- 19: em\_mu:\*
- 20: em\_om:\*
- 21: em\_or:\*
- 22: em\_ov:\*
- 23: em\_pat:\*
- 24: em\_ph:\*
- 25: em\_pl:\*
- 26: em\_ro:\*
- 27: em\_sts:\*
- 28: em\_un:\*
- 29: em\_vi:\*
- 30: em\_htg\_hum:\*
- 31: em\_htg\_inv:\*
- 32: em\_htg\_other:\*
- 33: em\_htg\_mus:\*
- 34: em\_htg\_pln:\*
- 35: em\_htg\_rtd:\*
- 36: em\_htg\_mam:\*
- 37: em\_htg\_vrt:\*
- 38: em\_sy:\*
- 39: em\_htgo\_hum:\*
- 40: em\_htgo\_mus:\*
- 41: em\_htgo\_other:\*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	2118.6	96.1	3038	9	AK124489	AK124489 Homo sapi
2	1816.8	82.4	3085	6	AR137923	AR137923 Sequence
3	1816.8	82.4	3085	6	AR137924	AR137924 Sequence
4	1816.8	82.4	3085	6	AR156370	AR156370 Sequence
5	1816.8	82.4	3085	6	AR156371	AR156371 Sequence
6	1816	82.4	3352	9	AF065215	AF065215 Homo sapi
7	1814	82.3	3193	9	BC013415	BC013415 Homo sapi
8	1806.2	82.0	2699	6	AR168355	AR168355 Sequence
9	1806.2	82.0	2699	6	AR255869	AR255869 Sequence
10	1806.2	82.0	3339	9	AF121908	AF121908 Homo sapi
11	1806.2	82.0	4183	6	AR168354	AR168354 Sequence
12	1806.2	82.0	4183	6	AR255868	AR255868 Sequence
13	1788.8	81.2	1925	6	AR352679	AR352679 Sequence
14	1788.8	81.2	1925	6	BD195624	BD195624 70 human
15	1777.8	80.7	1926	6	AR352614	AR352614 Sequence
16	1777.8	80.7	1926	6	BD195559	BD195559 70 human
17	1676.6	76.1	1818	6	AR352680	AR352680 Sequence
18	1676.6	76.1	1818	6	BD195625	BD195625 70 human
19	1422	64.5	7252	9	AF065216	AF065216 Homo sapi
20	1408.6	63.9	8517	6	AR137922	AR137922 Sequence
21	1408.6	63.9	8517	6	AR156369	AR156369 Sequence
22	1320.2	59.9	3775	9	HSN808466	HSN808466 Homo sapi
23	918.4	41.7	1712	10	BC042758	BC042758 Mus muscu
24	602	27.3	2409	6	AX417785	AX417785 Sequence
25	602	27.3	3197	6	AX402962	AX402962 Sequence
26	602	27.3	3587	9	AB090876	AB090876 Homo sapi
27	509.2	23.1	168413	2	AC009877	AC009877 Homo sapi
28	507.6	23.0	139376	9	AC020659	AC020659 Homo sapi
29	507.6	23.0	180304	2	AC012541	AC012541 Homo sapi
30	494.8	22.5	58152	2	AC087582	AC087582 Homo sapi
31	444.2	20.2	3998	9	HSN808630	HSN808630 Homo sapi
32	441	20.0	4066	9	AK127558	AK127558 Homo sapi
33	429.6	19.5	3879	6	AX512947	AX512947 Sequence
34	399.8	18.1	3370	9	BC035335	BC035335 Homo sapi
35	398.2	18.1	3460	6	BD141861	BD141861 Polypepti
36	393.2	17.8	3032	9	AK122623	AK122623 Homo sapi
37	385.8	17.5	2547	6	AX402959	AX402959 Sequence
38	380.2	17.3	4459	10	BC060600	BC060600 Mus muscu
39	365	16.6	2694	6	BD141893	BD141893 Polypepti
40	358.6	16.3	3006	10	BC039947	BC039947 Mus muscu
41	358.6	16.3	3112	6	BD141879	BD141879 Polypepti
42	336.2	15.3	2397	6	AX490840	AX490840 Sequence
43	261.6	11.9	1269	6	AX417778	AX417778 Sequence
44	217	9.8	421	11	G23044	G23044 human STS W
45	184.8	8.4	237806	2	AC097746	AC097746 Rattus no

ALIGNMENTS

RESULT 1  
AK124489  
LOCUS  
DEFINITION  
Homo sapiens cDNA FLJ2498 fis, clone BRACE203381, highly similar  
to Homo sapiens phospholipase A2, group IIV (cytosolic) (FLA2G4B).  
ACCESSION  
AK124489.1 GI:34530282  
VERSION  
AK124489.1  
KEYWORDS  
oligo capping; fis (full insert sequence).  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS  
Tanigami,A., Fujiwara,T., Shibahara,T., Goto,Y., Hirao,M., Ozaki,K.,  
Shimizu,F., Wakebe,H., Ono,T., Hishigaki,H., Watanabe,T.,



```
Db 2430 AAGAGCAGCTCCAGGCTCGGAGTGCCACACCTTCTCCGAGCCACCTGCCCCGAGGCC 2489
Qy 1677 CTGCGGTGCTGCACTTT-----TCTCTGCGG 1703
Db 2490 CTGCGGTGCTGCACTTTCTCTGTCGAGCAGCTCTCCGAGGAGTCTGCGGCCCTGCGG 2549
Qy 1704 TCCGCGGACACCCGAGGAGGCGGAGCTGCGGAGGTGAACCTGCTTTCATCGGACTCTC 1763
Db 2550 TCCGCGGACACCCGAGGAGGCGGAGCTGCGGAGGTGAACCTGCTTTCATCGGACTCTC 2609
Qy 1764 CTTACCACTACAGAAAGTGACTTACAGCAGGAGGAGCTGCAAGCTGTCACCTGA 1823
Db 2610 CTTACCACTACAGAAAGTGACTTACAGCAGGAGGAGCTGCAAGCTGTCACCTGA 2669
Qy 1824 CACATTACAACTCTGCAACACAGGAGGAGCTGCTGGAGGCTCTGGCAGGAGTGC 1883
Db 2670 CACATTACAACTCTGCAACACAGGAGGAGCTGCTGGAGGCTCTGGCAGGAGTGC 2729
Qy 1884 AGCGAGGCGGAGCGGAGGCGGAGCTGATGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 1943
Db 2730 AGCGAGGCGGAGCGGAGGCGGAGCTGATGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 2789
Qy 1944 TTCAATCCCTGCTGCTGAGTTGCAAGTGGAGGAGCTGTCATCAGCAGTGTTCAGAGCCT 2003
Db 2790 TTCAATCCCTGCTGCTGAGTTGCAAGTGGAGGAGCTGTCATCAGCAGTGTTCAGAGCCT 2849
Qy 2004 CGGGCTCAGGTGGCACTGTCAGGAGTCCAGGCTGAGGCTGAGGCTGAGGCTGAGGCTG 2063
Db 2850 CGGGCTCAGGTGGCACTGTCAGGAGTCCAGGCTGAGGCTGAGGCTGAGGCTGAGGCTG 2909
Qy 2064 AGCAGTTGCACTGGGTTAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2123
Db 2910 AGCAGTTGCACTGGGTTAAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2969
Qy 2124 GCCTGTGCTGTTTCCCTTCTGCGCTACCTTGTAGTGTGAGTGTGAGTGTGAGTGTGAGT 2183
Db 2970 GCCTGTGCTGTTTCCCTTCTGCGCTACCTTGTAGTGTGAGTGTGAGTGTGAGTGTGAGT 3029
Qy 2184 GACTCATAC 2192
Db 3030 GACTCATAC 3038

RESULT 2
AR137923
LOCUS AR137923 3085 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 2 from patent US 6197569.
ACCESSION AR137923
VERSION AR137923.1 GI:14479432
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 3085)
Choiu,X.-C.C., Kramer,R.M., Pickard,R.T., Sharp,J.D. and
Striffler,B.A.
TITLE Human phospholipase A2 and related nucleic acid compounds
JOURNAL Patent: US 6197569-A 2 06-MAR-2001;
FEATURES
location/Qualifiers
1..3085
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 82.4%; Score 1816.8; DB 6; Length 3085;
Best Local Similarity 98.2%; Pred. No. 0;
Matches 1861; Conservative 0; Mismatches 2; Indels 33; Gaps 1;

Qy 342 GACTGAGGAGCTGGCCGTGCACTGGGCTTGGGCGCTTGGCAGAGCAGGCGCTTCC 401
Db 1186 GACTGAGGAGCTGGCCGTGCACTGGGCTTGGGCGCTTGGCAGAGCAGGCGCTTCC 1245
```

```
Qy 402 TGAGCAGGAGGAGCAGTGTGTGGCGCGGCTTGGAGCAGGCGCTTGGAGCTGGATGGAG 461
Db 1246 TGAGCAGGAGGAGCAGTGTGTGGCGCGGCTTGGAGCAGGCGCTTGGAGCTGGATGGAG 1305
Qy 462 ACCTCCAGGAGGAGATCAGATCCAGTGTGTAGCTATTATGGCCACTGTGTGGTGGATCCGGG 521
Db 1306 ACCTCCAGGAGGAGATCAGATCCAGTGTGTAGCTATTATGGCCACTGTGTGGTGGATCCGGG 1365
Qy 522 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAAGAGCTGGGCTCTTTGGATTTGG 581
Db 1366 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAAGAGCTGGGCTCTTTGGATTTGG 1425
Qy 582 TCTCCTACATCACCGGGCGCTCGGCTCCACTCGGCGCTTGGCCAACTTTATAGAGGACC 641
Db 1426 TCTCCTACATCACCGGGCGCTCGGCTCCACTCGGCGCTTGGCCAACTTTATAGAGGACC 1485
Qy 642 CAGAGTGTCTCAGAAGGAGCTGGCAGGCGGCGGCTGAGTGTCTGAAGACCCAGGAGTGA 701
Db 1486 CAGAGTGTCTCAGAAGGAGCTGGCAGGCGGCGGCTGAGTGTCTGAAGACCCAGGAGTGA 1545
Qy 702 AGAACAACTGGGTGTCTGGGCGGCGGCGGCTGAGTGTCTGAAGACCCAGGAGTGA 761
Db 1546 AGAACAACTGGGTGTCTGGGCGGCGGCGGCTGAGTGTCTGAAGACCCAGGAGTGA 1605
Qy 762 AGCGTGCGGCTTGGGCTTACCAAGCTGCTTCAACCACTGTGGGCGGCTTCAACAGGAG 821
Db 1606 AGCGTGCGGCTTGGGCTTACCAAGCTGCTTCAACCACTGTGGGCGGCTTCAACAGGAG 1665
Qy 822 CGCTGCTCATGATGAGCGGCGGCGGCTGAGTGTCTGAGATCAACCGGAGGCGGCTGAGT 881
Db 1666 CGCTGCTCATGATGAGCGGCGGCGGCTGAGTGTCTGAGATCAACCGGAGGCGGCTGAGT 1725
Qy 882 ATGGCCAGAACCTCTGCGGCTTACTGTGGCTCAACCAACAAAGGAGGAGGAGGAGGAG 941
Db 1726 ATGGCCAGAACCTCTGCGGCTTACTGTGGCTCAACCAACAAAGGAGGAGGAGGAGGAG 1785
Qy 942 CTTTGAATTTGGGAGTGTGGAGTGTCTCTCCCTAGAGGTGGCTTCCCAAGTACG 1001
Db 1786 CTTTGAATTTGGGAGTGTGGAGTGTCTCTCCCTAGAGGTGGCTTCCCAAGTACG 1845
Qy 1002 GGGCGCTTCACTCCCTCTGAGCTCTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1061
Db 1846 GGGCGCTTCACTCCCTCTGAGCTCTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1905
Qy 1062 GGCTTCTGAGTCCGCGATCTGCTTCTTAGAAGTATCTGGAGCAACTGTATGAGGCA 1121
Db 1906 GGCTTCTGAGTCCGCGATCTGCTTCTTAGAAGTATCTGGAGCAACTGTATGAGGCA 1965
Qy 1122 ACCTCCAGGACAGCTTATCTGGGCGCTCAGAGCGGCGGAGTCTTGGGACCGCTGGTCA 1181
Db 1966 ACCTCCAGGACAGCTTATCTGGGCGCTCAGAGCGGCGGAGTCTTGGGACCGCTGGTCA 2025
Qy 1182 GGAAACCGAGGCGAACTGGGAGGAGGAGTGGGCTTCTGAAGATGAAGAAGCAACCCCT 1241
Db 2026 GGAAACCGAGGCGAACTGGGAGGAGGAGTGGGCTTCTGAAGATGAAGAAGCAACCCCT 2085
Qy 1242 CAACAGCGGCGGAGATAGTGTGAGTGTTCACCGATCTTCTGAGTGGGCTGCACTGGGCG 1301
Db 2086 CAACAGCGGCGGAGATAGTGTGAGTGTTCACCGATCTTCTGAGTGGGCTGCACTGGGCG 2145
Qy 1302 AGGCGCACACATAATTTCTGCGTGGCGCTTCCATTTCCAAAGAGCTACTTTTTCAGCATCTC 1361
Db 2146 AGGCGCACACATAATTTCTGCGTGGCGCTTCCATTTCCAAAGAGCTACTTTTTCAGCATCTC 2205
Qy 1362 ACTTCTCCACATGGAAGAGTACCACTCTGGATGGGCTTCCCAACAGCTGACACCCCTCGG 1421
Db 2206 ACTTCTCCACATGGAAGAGTACCACTCTGGATGGGCTTCCCAACAGCTGACACCCCTCGG 2265
Qy 1422 AGCCCGCACTGTGCTGCTGATGTGGCTACCTCATCATATACAGCTGCTGCGGCTTCC 1481
Db 2266 AGCCCGCACTGTGCTGCTGATGTGGCTACCTCATCATATACAGCTGCTGCGGCTTCC 2325
Qy 1482 TGCAGCCCACTCGGAGCGTGGAGCTCATCTCTGTCATTTGAGCTACAACTCCCAAGGAGCT 1541
```

Db	2326	TGCAGCCACCTCGGAGCTGACCTCATCTCTGTCATTGGACTACAACTCCACGAGCCT	2385
Qy	1542	TCCAGCAGTTTCAGCTCTCGGCGGTTCTCCAGGAGCAGGGATCCCGTTCACACCA	1601
Db	2386	TCCAGCAGTTTCAGCTCTCGGCGGTTCTCCAGGAGCAGGGATCCCGTTCACACCA	2445
Qy	1602	TCTCGCCAGCCCGAGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCCA	1661
Db	2446	TCTCGCCAGCCCGAGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCCA	2505
Qy	1662	CCTCGCCGAGCCCTCGGCTGCTGCACTTT-----	1693
Db	2506	CCTCGCCGAGCCCTCGGCTGCTGCACTTTCTCTGCTCAGCAGCTCTCTCCGAGT	2565
Qy	1694	-----TCTCTGCGGTCGCGGACACCCGAGGAGGCGGAGCTGGGAGGTGAACCTGT	1748
Db	2566	ACTCGGCCCTCGGCTGCGGAGACCCGAGGAGGCGGAGCTGGGAGGTGAACCTGT	2625
Qy	1749	CTTCATCGGACTCTCCCTTACCCTACACGAGGTGACCTACAGCCAGGAGCAGTGGACA	1808
Db	2626	CTTCATCGGACTCTCCCTTACCCTACACGAGGTGACCTACAGCCAGGAGCAGTGGACA	2685
Qy	1809	AGCTGCTGCACTGACACATTACATTAATGTCTGCAACACAGGAGCAGCTGTGAGGCTC	1868
Db	2686	AGCTGCTGCACTGACACATTACATTAATGTCTGCAACACAGGAGCAGCTGTGAGGCTC	2745
Qy	1869	TGCGCCAGGAGTGCAGGAGGCGGAGCCAGCCAGCCCTCATGTGCGGCGGCCCTGTC	1928
Db	2746	TGCGCCAGGAGTGCAGGAGGCGGAGCCAGCCAGCCCTCATGTGCGGCGGCCCTGTC	2805
Qy	1929	CACCCCTAACTCTCATTCATTCCTGCTGCTGCTGAGTTGCAGTGGGAACTGTCTACGC	1988
Db	2806	CACCCCTAACTCTCATTCATTCCTGCTGCTGAGTTGCAGTGGGAACTGTCTACGC	2865
Qy	1989	AGTGTCTCAGAGCTCTGGGCTCAGTGCGACATGTCCTCAGAGGTCCAGGCTGAGGGCTGGA	2048
Db	2866	AGTGTCTCAGAGCTCTGGGCTCAGTGCGACATGTCCTCAGAGGTCCAGGCTGAGGGCTGGA	2925
Qy	2049	GCTCCCTGCGCTCAGCAGTTGTCAGTGGGTGAGGAGGCGCCAGCCATTGTGTATC	2108
Db	2926	GCTCCCTGCGCTCAGCAGTTGTCAGTGGGTGAGGAGGCGCCAGCCATTGTGTATC	2985
Qy	2109	ACCCAAAACCCCGGCTGTGCTGTTTCCCTTCTCGGCTACCTTCAGTAGTTGGAGC	2168
Db	2986	ACCCAAAACCCCGGCTGTGCTGTTTCCCTTCTCGGCTACCTTCAGTAGTTGGAGC	3045
Qy	2169	ACTTGATACATCAGACTCATACAAAAA	2204
Db	3046	ACTTGATACATCAGACTCATACAAAAA	3081

RESULT 3  
 AR137924  
 LOCUS 3085 bp DNA linear PAT 16-JUN-2001  
 DEFINITION Sequence 4 from patent US 6197569.  
 ACCESSION AR137924  
 VERSION AR137924.1 GI:14479433  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 3085)  
 AUTHORS Chou,X.-C., Kramer,R.M., Pickard,R.T., Sharp,J.D. and Striffler,B.A.  
 TITLE Human phospholipase A2 and related nucleic acid compounds  
 JOURNAL Patent: US 6197569-A 4 06-MAR-2001;  
 FEATURES Location/Qualifiers  
 1..3085 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 ORIGIN

Query Match		82.4%;	Score 1816.8;	DB 6;	Length 3085;
Best Local Similarity		98.2%;	Pred. No. 0;		
Matches 1861;		Conservative	0;	Mismatches	2;
				Indels	33;
				Gaps	1;
Qy	342	GACTGAGGAGCTGGCCGTCGCACTGGGCTTCGGGCCCTGTGCAGAGAGCAGGCTTC	401		
Db	1186	GACTGAGGAGCTGGCCGTCGCACTGGGCTTCGGGCCCTGTGCAGAGAGCAGGCTTC	1245		
Qy	402	TGACAGGAGGAACAGGTGTGTCGCGGCTTTGAGCAGGCGCTGTCAGCTGGATGGAG	461		
Db	1246	TGACAGGAGGAACAGGTGTGTCGCGGCTTTGAGCAGGCGCTGTCAGCTGGATGGAG	1305		
Qy	462	ACCTGAGGAGGATGAGATCCAGTGTAGCTATTATGGCCACTGTGGTGGGATCCGGG	521		
Db	1306	ACCTGAGGAGGATGAGATCCAGTGTAGCTATTATGGCCACTGTGGTGGGATCCGGG	1365		
Qy	522	CAATGACTTCCCTGTATGGGAGCTGGCTGCGCTTGAGGAGCTGGCTCTTGGATTGCG	581		
Db	1366	CAATGACTTCCCTGTATGGGAGCTGGCTGCGCTTGAGGAGCTGGCTCTTGGATTGCG	1425		
Qy	582	TCTCTTACATCACCGGGGCTTCGGGCTCCACTGGGCTTGGCCAACTTTATGAGGACC	641		
Db	1426	TCTCTTACATCACCGGGGCTTCGGGCTCCACTGGGCTTGGCCAACTTTATGAGGACC	1485		
Qy	642	CAGAGTGTCTCAAGAGGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACA	701		
Db	1486	CAGAGTGTCTCAAGAGGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACA	1545		
Qy	702	AGAACAGCTGGGTGCTGTCGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGCTGGCG	761		
Db	1546	AGAACAGCTGGGTGCTGTCGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGCTGGCG	1605		
Qy	762	AGCGTGCCCGCTTGGGCTTACCCAAAGCTCTTCAACCACTGTGGGCCCTCATCAACGAGG	821		
Db	1606	AGCGTGCCCGCTTGGGCTTACCCAAAGCTCTTCAACCACTGTGGGCCCTCATCAACGAGG	1665		
Qy	822	CGCTGTGCATGATGAGCCCAATGATCAAGCTCTCAGATCAACGAGGAGCCCTGAGTC	881		
Db	1666	CGCTGTGCATGATGAGCCCAATGATCAAGCTCTCAGATCAACGAGGAGCCCTGAGTC	1725		
Qy	882	ATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGGAGGAGCTGACCA	941		
Db	1726	ATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGGAGGAGCTGACCA	1785		
Qy	942	CTTTTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACGAGGTGCGCTTCCCAAGTAGC	1001		
Db	1786	CTTTTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACGAGGTGCGCTTCCCAAGTAGC	1845		
Qy	1002	GGGCTTTCATCCCTCTGAGCTCTTTGGCTCGGAGTTCTTTATGGGAGCTGATGAAGA	1061		
Db	1846	GGGCTTTCATCCCTCTGAGCTCTTTGGCTCGGAGTTCTTTATGGGAGCTGATGAAGA	1905		
Qy	1062	GGCTTCTGAGTCCCGCATCTGTTCTTAGAGGTATCTGGAGCAACCTGTATGACCA	1121		
Db	1906	GGCTTCTGAGTCCCGCATCTGTTCTTAGAGGTATCTGGAGCAACCTGTATGACCA	1965		
Qy	1122	ACCTCCAGGACAGCTTATCTAGTGGGCTCAGAGCCCGCAGCTTCTGGGACCGCTGGTCA	1181		
Db	1966	ACCTCCAGGACAGCTTATCTAGTGGGCTCAGAGCCCGCAGCTTCTGGGACCGCTGGTCA	2025		
Qy	1182	GGACACGGCCAACTCGGACAGGAGGAGTCCCGCTTCTGAAGATAGAAGAACACCCCT	1241		
Db	2026	GGACACGGCCAACTCGGACAGGAGGAGTCCCGCTTCTGAAGATAGAAGAACACCCCT	2085		
Qy	1242	CAACAGCGCGCAGATAGCTGAGTTTTCACGATCTTCTGACGTGGCGTCCACTGGGCC	1301		
Db	2086	CAACAGCGCGCAGATAGCTGAGTTTTCACGATCTTCTGACGTGGCGTCCACTGGGCC	2145		
Qy	1302	AGGCCACACATAATTTCTCGGTGCGCTCCCAATTTCCAAAAGACTACTTTTCAGATTC	1361		
Db	2146	AGGCCACACATAATTTCTCGGTGCGCTCCCAATTTCCAAAAGACTACTTTTCAGATTC	2205		
Qy	1362	ACTTCTCCACATGGAAGACTACCACTCTGGATGGGCTCCCCAACCCAGCTGACACCCCTCG	1421		





Db 2086 CAACAGCGGCGAATAGCTAGTTCAGTTTTCACCGATCTTCAGGTGGGTCCACTGGCC 2145  
Qy 1302 AGGCCACATATAATTTCTCGTGGCTCCATTTCCACAAAGACTACTTTTTCAGATCTTC 1361  
Db 2146 AGGCCACATATAATTTCTCGTGGCTCCATTTCCACAAAGACTACTTTTTCAGATCTTC 2205  
Qy 1362 ACTTCTCCACATGAAGTACCACTCTGATGGCTCCCAACAGCTGACACCTCGG 1421  
Db 2206 ACTTCTCCACATGAAGTACCACTCTGATGGCTCCCAACAGCTGACACCTCGG 2265  
Qy 1422 AGCCCACTGTGCTGTGATGTGCTACCTCATCAATACCAAGCTGCTGCCCTCC 1481  
Db 2266 AGCCCACTGTGCTGTGATGTGCTACCTCATCAATACCAAGCTGCTGCCCTCC 2325  
Qy 1482 TGCAGCCCACTGGGAGCTGACCTCATCTGTGCTATGGAATGGAATGGAAGCTT 1541  
Db 2326 TGCAGCCCACTGGGAGCTGACCTCATCTGTGCTATGGAATGGAAGCTT 2385  
Qy 1542 TCCAGCAGTTCAGCTCTGCTGGGCGGTTCGACAGGAGCGGATCCGTTCCACCCA 1601  
Db 2386 TCCAGCAGTTCAGCTCTGCTGGGCGGTTCGACAGGAGCGGATCCGTTCCACCCA 2445  
Qy 1602 TCTCCGCCAGCCGCAAGAGCAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCA 1661  
Db 2446 TCTCCGCCAGCCGCAAGAGCAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCA 2505  
Qy 1662 CTTGCCCGGAGCCCTCGGCTGTGCACTTT----- 1693  
Db 2506 CTTGCCCGGAGCCCTCGGCTGTGCACTTTCTTGTGACGCACTCTTCCGGAGT 2565  
Qy 1694 -----TCCCTCGGGTCCGGCGGACACCGAGGCGGACCTGGGAGGTGAACCTGT 1748  
Db 2566 ACTCGGCCCTCGGGTCCGGCGGACACCGAGGCGGACCTGGGAGGTGAACCTGT 2625  
Qy 1749 CTTTCATCGGACTCTCCCTACCACTACACGAAGGTGACCTACAGCCAGGAGGACGTTGACA 1808  
Db 2626 CTTTCATCGGACTCTCCCTACCACTACACGAAGGTGACCTACAGCCAGGAGGACGTTGACA 2685  
Qy 1809 AGCTGTGACCTGACACATTACATGTCTGAAACACAGAGAGAGCTGCTGGAGGCTC 1868  
Db 2686 AGCTGTGACCTGACACATTACATGTCTGAAACACAGAGAGAGCTGCTGGAGGCTC 2745  
Qy 1869 TGGCCAGGAGTGCAGCGGAGCGGACGAGCGCCCACTGATGGCGGGGCCCTGC 1928  
Db 2746 TGGCCAGGAGTGCAGCGGAGCGGACGAGCGCCCACTGATGGCGGGGCCCTGC 2805  
Qy 1929 CACCCCTAACTCTCAATTCCTTCCCTGGCTGCTGAGTTGAGGTGGAACTGTCAATCACGC 1988  
Db 2806 CACCCCTAACTCTCAATTCCTTCCCTGGCTGCTGAGTTGAGGTGGAACTGTCAATCACGC 2865  
Qy 1989 AGTGCTTACAGGCTCGGCTCAGGTGGCACTGCTCCAGGCTCAGGCTGAGGCTGGGA 2048  
Db 2866 AGTGCTTACAGGCTCGGCTCAGGTGGCACTGCTCCAGGCTCAGGCTGAGGCTGGGA 2925  
Qy 2049 GTCCTCTCGCTCAGCAGTTTGAGTGGGGTAAGGAGGCCAAGCCCAATTTGTGAATC 2108  
Db 2926 GTCCTCTCGCTCAGCAGTTTGAGTGGGGTAAGGAGGCCAAGCCCAATTTGTGAATC 2985  
Qy 2109 ACCCAAAACCCCGGCTGTGCTGCTTTTCCCTTCTGGCTACCTTGAGTAGTTGGAGC 2168  
Db 2986 ACCCAAAACCCCGGCTGTGCTGCTTTTCCCTTCTGGCTACCTTGAGTAGTTGGAGC 3045  
Qy 2169 ACTTGATACATCAGACTCATCAAAAAA 2204  
Db 3046 ACTTGATACATCAGACTCATCAAAAAA 3081

RESULT 5  
AR156371  
LOCUS  
DEFINITION Sequence 4 from patent US 6242206.  
ACCESSION AR156371

AR156371.1 GI:15125075  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 3085)  
AUTHORS Chou, X.-C.C., Kramer, R.M., Pickard, R.T., Sharp, J.D. and Striffler, B.A.  
TITLE Human phospholipase A2 and related nucleic acid compounds  
JOURNAL Patent: US 6242206-A 4 05-JUN-2001;  
FEATURES Location/Qualifiers  
          1..3085  
          /organism="unknown"  
          /mol\_type="unassigned DNA"  
  
ORIGIN  
Query Match 82.4%; Score 1816.8; DB 6; Length 3085;  
Best Local Similarity 98.2%; Pred. No. 0;  
Matches 1861; Conservative 0; Mismatches 2; Indels 33; Gaps 1;  
  
Qy 342 GACTGAGGAGCTGGCCGCTGGGACTGGGCTTCGGGCCCTGTGCAGAGGAGCGCTTCC 401  
Db 1186 GACTGAGGAGCTGGCCGCTGGGACTGGGCTTCGGGCCCTGTGCAGAGGAGCGCTTCC 1245  
Qy 402 TGAGCAGAGGAAGCAGGTGTGGCCGCGCTTGAGGAGGCCCTGCAGCTGGATGGAG 461  
Db 1246 TGAGCAGAGGAAGCAGGTGTGGCCGCGCTTGAGGAGGCCCTGCAGCTGGATGGAG 1305  
Qy 462 ACCTCAGAGGATGAGATCCCAAGTGTAGTATTTATGCCACTGGTGGGATCCGG 521  
Db 1306 ACCTCAGAGGATGAGATCCCAAGTGTAGTATTTATGCCACTGGTGGGATCCGG 1365  
Qy 522 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCCCTCTTGGATTGG 581  
Db 1366 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCCCTCTTGGATTGG 1425  
Qy 582 TCTCTCATATCAACCGGGGCTCGGGCTCCACCTGGGGCTTGGCCAACTTTATGAGGAC 641  
Db 1426 TCTCTCATATCAACCGGGGCTCGGGCTCCACCTGGGGCTTGGCCAACTTTATGAGGAC 1485  
Qy 642 CAGAGTGGTCTCAGAGGAGCTGGGAGGCGCCACCTGAGTTGCTGAAGACCCAGGTGACCA 701  
Db 1486 CAGAGTGGTCTCAGAGGAGCTGGGAGGCGCCACCTGAGTTGCTGAAGACCCAGGTGACCA 1545  
Qy 702 AGAAACAAGCTGGTGTGCTGGCCCGCCAGCAGCTGCAGCGGTACCGGAGGAGCTGGCCG 761  
Db 1546 AGAAACAAGCTGGTGTGCTGGCCCGCCAGCAGCTGCAGCGGTACCGGAGGAGCTGGCCG 1605  
Qy 762 AGCGTCCCGCTTGGGCTACCCAAAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG 821  
Db 1606 AGCGTCCCGCTTGGGCTACCCAAAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG 1665  
Qy 822 CGCTGTGATGATGAGCCCATGATCAAGCTCTCAGATCAACCGGAGGCGCTCAGTTC 881  
Db 1666 CGCTGTGATGATGAGCCCATGATCAAGCTCTCAGATCAACCGGAGGCGCTCAGTTC 1725  
Qy 882 ATGGCCAGAAACCTCTCTGCCCATCTACTGTGCCCTCAACCAAGGCGAGAGCTGACCA 941  
Db 1726 ATGGCCAGAAACCTCTCTGCCCATCTACTGTGCCCTCAACCAAGGCGAGAGCTGACCA 1785  
Qy 942 CTTTGAATTTGGGAGTGGTGGAGTTCCTCCCTACGAGTCCGCTTCCCAAGTACG 1001  
Db 1786 CTTTGAATTTGGGAGTGGTGGAGTTCCTCCCTACGAGTCCGCTTCCCAAGTACG 1845  
Qy 1002 GGGCCCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1061  
Db 1846 GGGCCCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGA 1905  
Qy 1062 GGCTTCTGAGTCCCGCATCTGCTTTAGAAAGGTATCTGGAGCAACCTGTATGAGGCCA 1121  
Db 1906 GGCTTCTGAGTCCCGCATCTGCTTTAGAAAGGTATCTGGAGCAACCTGTATGAGGCCA 1965  
Qy 1122 ACCTCCAGGACAGCTTATCTAGTGGGCTCAGAGCCAGCGGAGTTCGGGACCGCTGGGTCA 1181



Db 1966 ACCTCAGGACGCTTATCTAGGCGCTCAGAGCCAGCCAGCTTCTGGAGCCGCTGGGTCA 2025  
 QY 1182 GGAAACAGGCAACCTGGCAAGAGCAGTCCCTCTCTGAAGATAGAGACACCCCT 1241  
 Db 2026 GGAAACAGGCAACCTGGCAAGAGCAGTCCCTCTCTGAAGATAGAGACACCCCT 2085  
 QY 1242 CAACAGCCGCGCAATAGCTAGTGTGATTTTCAACCGATCTTCTGACGTGGCGTCCACTGGCCC 1301  
 Db 2086 CAACAGCCGCGCAATAGCTAGTGTGATTTTCAACCGATCTTCTGACGTGGCGTCCACTGGCCC 2145  
 QY 1302 AGSCCACAATAATTTCTGCGTGGCTCCATTTCCAAAAGACTACTTTTCAGCATCTC 1361  
 Db 2146 AGSCCACAATAATTTCTGCGTGGCTCCATTTCCAAAAGACTACTTTTCAGCATCTC 2205  
 QY 1362 ACTTCTCCACATGGAAGCTACCACTCTGATGGCTCCCAACACAGCTGACACCCCTCG 1421  
 Db 2206 ACTTCTCCACATGGAAGCTACCACTCTGATGGCTCCCAACACAGCTGACACCCCTCG 2265  
 QY 1422 AGSCCACAATGCTGCTGGATGTTGGCTACCTCAATACAGCTGCTGCCCTCC 1481  
 Db 2266 AGSCCACAATGCTGCTGGATGTTGGCTACCTCAATACAGCTGCTGCCCTCC 2325  
 QY 1482 TGCAGCCACTCGGACCTGGACCTCATCTGCTGATTTGACTTACAACTCCAGAGCTC 1541  
 Db 2326 TGCAGCCACTCGGACCTGGACCTCATCTGCTGATTTGACTTACAACTCCAGAGCTC 2385  
 QY 1542 TGCAGAGTTGAGCTCTCGGCGGCTTCTGCGAGGAGGAGGATCCGTTCCCAACCA 1601  
 Db 2386 TGCAGAGTTGAGCTCTCGGCGGCTTCTGCGAGGAGGAGGATCCGTTCCCAACCA 2445  
 QY 1602 TCTGCGCCAGCCGAGAGAGCTCAGCTCGGAGTGCACACCTTCTCGACCCCA 1661  
 Db 2446 TCTGCGCCAGCCGAGAGAGCTCAGCTCGGAGTGCACACCTTCTCGACCCCA 2505  
 QY 1662 CTGCGCCGAGCCCTCGGCTGCTGCTGCTT----- 1693  
 Db 2506 CTGCGCCGAGCCCTCGGCTGCTGCTGCTT----- 2565  
 QY 1694 -----TCTCTCGGCTCGGCGGAGCAGCCGAGGAGGCGGAGTGAACCTGT 1748  
 Db 2566 ACTCGGCGCTCGGCTCGGCGGAGCAGCCGAGGAGGCGGAGTGAACCTGT 2625  
 QY 1749 TTTCATCGGACTCTCCCTACCACTACAGAGGTGACCTACAGCCAGGAGGAGCTGGACA 1808  
 Db 2626 TTTCATCGGACTCTCCCTACCACTACAGAGGTGACCTACAGCCAGGAGGAGCTGGACA 2685  
 QY 1809 AGCTCTGACCTGACATTAATGCTGCAACAAACAGGAGAGCTGCTGGAGGCTC 1868  
 Db 2686 AGCTCTGACCTGACATTAATGCTGCAACAAACAGGAGAGCTGCTGGAGGCTC 2745  
 QY 1869 TCGCGCAGGAGCTGAGCGGAGGCGGAGCGGAGCCGAGCCGAGCTGAGTGGAGTGGAACTGTCAACGC 1928  
 Db 2746 TCGCGCAGGAGCTGAGCGGAGGCGGAGCGGAGCCGAGCCGAGCTGAGTGGAGTGGAACTGTCAACGC 2805  
 QY 1929 CACCCCTAACTCTCAATCATTCCTCGGCTGCTGAGTGGAGTGGAACTGTCAACGC 1988  
 Db 2806 CACCCCTAACTCTCAATCATTCCTCGGCTGCTGAGTGGAGTGGAACTGTCAACGC 2865  
 QY 1989 AGTGTTCAGAGCTCGGCTCAGTGGAGCTGTCAGAGGTCAGGCTGAGGCTGGGA 2048  
 Db 2866 AGTGTTCAGAGCTCGGCTCAGTGGAGCTGTCAGAGGTCAGGCTGAGGCTGGGA 2925  
 QY 2049 GCTCCCTTGGCGCTCAGCAGTTTTCAGTGGGTAAGGAGGCGCAAGCCATTTGTGTAATC 2108  
 Db 2926 GCTCCCTTGGCGCTCAGCAGTTTTCAGTGGGTAAGGAGGCGCAAGCCATTTGTGTAATC 2985  
 QY 2109 ACCCAAAACCCCGGCTGCTGCTGTTTCCCTTCTGCTGCTTACCTTCTGAGTAGTGGAGC 2168  
 Db 2986 ACCCAAAACCCCGGCTGCTGCTGTTTCCCTTCTGCTGCTTACCTTCTGAGTAGTGGAGC 3045  
 QY 2169 ACTTGATACATCAGACTCATCAAAAAA 2204

Db 3046 ACTTGATACATCAGAGCTCATCAAAAAA 3081  
 RESULT 6  
 AF065215 3352 bp mRNA linear PRI 23-MAR-1999  
 LOCUS Homo sapiens cytosolic phospholipase A2 beta (cPLA2 beta) mRNA, complete cds.  
 DEFINITION  
 AF065215  
 ACCESSION  
 AF065215  
 VERSION  
 AF065215.1 GI:3811346  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 3352)  
 AUTHORS Pickard,R.T., Striffler,B.A., Kramer,R.M. and Sharp,J.D.  
 TITLE Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A2  
 JOURNAL J. Biol. Chem. 274 (13), 8823-8831 (1999)  
 MEDLINE 99185108  
 PUBMED 10085124  
 REFERENCE 2 (bases 1 to 3352)  
 AUTHORS Pickard,R.T., Striffler,B.A., Kramer,R.M. and Sharp,J.D.  
 TITLE Direct Submission  
 JOURNAL Submitted (15-MAY-1998) Lilly Research Laboratory, Lilly Corporate Center, Indianapolis, IN 46285, USA  
 FEATURES  
 Location/Qualifiers  
 1..3352  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /chromosome="15"  
 /note="spliced mRNA is rare in all tissues examined, and was obtained by PCR; more abundant unspliced RNA form can be found in GenBank Accession Number AF065216"  
 gene 1..3352  
 /gene="cPLA2 beta"  
 CDS 16..3054  
 /gene="cPLA2 beta"  
 /codon\_start=1  
 /product="cytosolic phospholipase A2 beta"  
 /protein\_id="AAC78836.1"  
 /db\_xref="GI:3811347"  
 /translation="MAEAALEAVSELSREFFPAARELCVLAIVPLDKPPELPHYRD  
 WVCNRPCLIRNALQHWPAQKSLPYFRATVSTGVAVTPDGYADAVRGDRPMP  
 AERLPLSVLDVLEGRAQHPGVLYQKCSNLSPELQQLPDLESHPVMAEALGKM  
 PDVNFVLEAAAVTSLHKHYENLYCVSGEKHFLPHPPSDRPFIPVELYTPATYQ  
 TEBGTFKVDDEAMEKAEVSTCLTVRVLOAHLRPSKDIATPSDCYVTLMLPTACSH  
 RLQRTVKNSSPVNQSFPHIRHQLKNWELKVDQDLVTGDDPVLVLFADGTLR  
 AGEFRRESFSLSPQSGRLEVEFRQLSADRGEWLVNGLVARELSCLHVOLEETGD  
 QKSEHRVQLVVPSCGEGFQASVGTGTFPHCFACWQELSIQLQDAPEEQALPLS  
 ALPQGVVRLVPTTSQEPIMRVLEKAGRELAVLFGFCAEPAQLFSRRKQVAA  
 ALRQALQDGLQDEIPVVAIMATGGIRAMTSLYGLQAGLKEGLDLCVSYIYGS  
 STWALNLYEDPWSOKDLAGTELLKTQVTKNKLGVLAQSLQRYQLAERARLIG  
 YPSCFTNLWALINEALHDEPHDKLSQREALSQGNPLPIYCAINTGQSLITFEF  
 GEWCESFYEGFPIGAFIPSELFSEFFQMLKLPESRIQCELEGISNLYAANL  
 QDSLYASBSQSFQWDRVNRNANLDKEQVPLKIEEPESTAGRIAEFTDLITWRPLA  
 QATNIFLGRHFHFDHPHFSTKATLTDGLNQLTPSPHCLLDVGLINTPSCL  
 PLLQPTRDVLDLILSLYNLHGAFQOLGRFCOEQIPFPPIPSPEQQLPQRECHT  
 FSDPTCPGAVLHPLVSDSFREYSAGVPTPEEAAAGSEVNLSSSPHYTKVY  
 SQEDVDKLLHLTHVNCNNQQLLEALRQAVRRRRQRPH"  
 ORIGIN  
 Query Match 82.4%; Score 1816; DB 9; Length 3352;  
 Best Local Similarity 98.0%; Pred. No. 0;  
 Matches 1859; Conservative 2; Mismatches 2; Indels 33; Gaps 1;  
 QY 342 GACTGAGGAGCTGGCGCTGCGACTGGGCTTCGGGCGCTGTGCAAGAGGAGGAGGCTTCC 401  
 Db 1451 GACTGAGGAGCTGGCGCTGCGACTGGGCTTCGGGCGCTGTGCAAGAGGAGGAGGCTTCC 1510  
 QY 402 TGAGCAGGAGGAGGAGGAGGCTGTGGCGGCGCTTGAGGAGGAGGCGCTGAGCTGATGGAG 461

Db 1511 TGACAGGAGGAGCAGGTGTGGCCGCGCTTTGAGGCAGGCCCTGCGAGCTGATGGAG 1570  
 Qy 462 ACCTGCGAGGAGATGAGATCCAGTGTAGTATATATGCGCCACTGTGGTGGATCCGGG 521  
 Db 1571 ACCTGCGAGGAGATGAGATCCAGTGTAGTATATATGCGCCACTGTGGTGGATCCGGG 1630  
 Qy 522 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAGGAGCTGGCCCTTTGATTGCG 581  
 Db 1631 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAGGAGCTGGCCCTTTGATTGCG 1690  
 Qy 582 TCTCTCATCATCACCGGGCCCTCGGGCTCCACTGGGCCCTTGGCCAACTTTATGAGGACC 641  
 Db 1691 TCTCTCATCATCACCGGGCCCTCGGGCTCCACTGGGCCCTTGGCCAACTTTATGAGGACC 1750  
 Qy 642 CAGAGTGTCTCAGAGAGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCA 701  
 Db 1751 CAGAGTGTCTCAGAGAGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCA 1810  
 Qy 702 AGAACAGCTGGGTGTGCTGGCCCGCCAGCAGCTGACGGGTACCGGAGAGCTGGCGG 761  
 Db 1811 AGAACAGCTGGGTGTGCTGGCCCGCCAGCAGCTGACGGGTACCGGAGAGCTGGCGG 1870  
 Qy 762 AGCGTGGCCGCTTGGGCTACCCAAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGG 821  
 Db 1871 AGCGTGGCCGCTTGGGCTACCCAAAGCTGCTTCAACCACTGTGGGCCCTCATCAACGAGG 1930  
 Qy 822 CGTGTCTGATGATGAGCCCATGATCAAGCTCTGATCAACGGGAGGCCCTGAGTC 881  
 Db 1931 CGTGTCTGATGAGCCCATGATCAAGCTCTGATCAACGGGAGGCCCTGAGTC 1990  
 Qy 882 ATGGCCAGAACCCCTGCGCCCTACTGTGCCCTCAACACAAAGGGCAGAGCCCTGACCA 941  
 Db 1991 ATGGCCAGAACCCCTGCGCCCTACTGTGCCCTCAACACAAAGGGCAGAGCCCTGACCA 2050  
 Qy 942 CTTTGTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACAGAGTCCGGCTTCCCAAGTAGC 1001  
 Db 2051 CTTTGTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACAGAGTCCGGCTTCCCAAGTAGC 2110  
 Qy 1002 GGGCCCTCATCCCTCTGAGCTCTTTGGCTCGAGTTCTTTATGGGAGCTGATGAAGA 1061  
 Db 2111 GGGCCCTCATCCCTCTGAGCTCTTTGGCTCGAGTTCTTTATGGGAGCTGATGAAGA 2170  
 Qy 1062 GGTCTCTGAGTCCGCGATCTGCTTTAGAGAGTATCTGAGCAACCTGTATGACGCA 1121  
 Db 2171 GGTCTCTGAGTCCGCGATCTGCTTTAGAGAGTATCTGAGCAACCTGTATGACGCA 2230  
 Qy 1122 ACCTCCAGGACAGCTTATATCTGGGCTCAGAGCCAGCCAGTTCCTGGACCCGCTGGTCA 1181  
 Db 2231 ACCTCCAGGACAGCTTATATCTGGGCTCAGAGCCAGCCAGTTCCTGGACCCGCTGGTCA 2290  
 Qy 1182 GGAACCGGCCAACCTGGACAGGAGCAGGTCCCTCTGAGATAGAGAACCACTCT 1241  
 Db 2291 GGAACCGGCCAACCTGGACAGGAGCAGGTCCCTCTGAGATAGAGAACCACTCT 2350  
 Qy 1242 CAACAGCCGCGAGATAGCTGAGTTTTCACCGATCTTCTGAGCTGGCGCTCCACTGGCCC 1301  
 Db 2351 CAACAGCCGCGAGATAGCTGAGTTTTCACCGATCTTCTGAGCTGGCGCTCCACTGGCCC 2410  
 Qy 1302 AGGCCACACATAATTTCTCGGTGGCCCTCAATTCACAAAGACTACTTTTCAGCATCTCTC 1361  
 Db 2411 AGGCCACACATAATTTCTCGGTGGCCCTCAATTCACAAAGACTACTTTTCAGCATCTCTC 2470  
 Qy 1362 ACTTCTCCACATGGAAGCTACCACTCTGATGGGCTCCCAACAGAGCTGACACCCCTCGG 1421  
 Db 2471 ACTTCTCCACATGGAAGCTACCACTCTGATGGGCTCCCAACAGAGCTGACACCCCTCGG 2530  
 Qy 1422 AGCCCCACCTGTGCTGCTGATGTTGGTACTCATCAATACCAAGCTGCTGCCCTCTCC 1481  
 Db 2531 AGCCCCACCTGTGCTGCTGATGTTGGTACTCATCAATACCAAGCTGCTGCCCTCTCC 2590  
 Qy 1482 TGAGGCCACTCGGAGCTGGAGCTCATCTGTCTGACTGACATCAACCTCCAGGAGCTT 1541

Db 2591 TGACAGCCACTCTGGGACGTGGACCTCATCTCTGTTCAATTGGGACTACAACCTCCAGGAGCCT 2650  
 Qy 1542 TCACAGCAGTTTGCACTCTCTGGCCCGGTTCTGCCAGAGGACAGGGATCCCGTTCCACCCCA 1601  
 Db 2651 TCACAGCAGTTTGCACTCTCTGGCCCGGTTCTGCCAGAGGACAGGGATCCCGTTCCACCCCA 2710  
 Qy 1602 TCTCGCCAGCCCGAAGAGAGCAGTCCAGCCTCTGGGAGTGCACACCTTCTCCGACCCCA 1661  
 Db 2711 TCTCGCCAGCCCGAAGAGAGCAGTCCAGCCTCTGGGAGTGCACACCTTCTCCGACCCCA 2770  
 Qy 1662 CTTGCCCCGAGCCCTCGGCTGCTGCACCTTT----- 1693  
 Db 2771 CTTGCCCCGAGCCCTCGGCTGCTGCACCTTTCTCTGCTCAGGCACTCTCTTCGGGAGT 2830  
 Qy 1694 -----TCTCTCTGGGCTCGGCGGACACCCGAGGAGGCGGAGCTGGGAGAGTGAACCTGT 1748  
 Db 2831 ACTCGGCCCTTGGGTCGGGCGGACACCCGAGGAGGCGGAGCTGGGAGAGTGAACCTGT 2890  
 Qy 1749 CTTCATCGGACTCTCCCTACCACTACAGAAAGGTGACCTACAGCAGAGGACGTTGGACA 1808  
 Db 2891 CTTCATCGGACTCTCCCTACCACTACAGAAAGGTGACCTACAGCAGAGGACGTTGGACA 2950  
 Qy 1809 AGCTGCTGCACTGACACATTACATCTCTGCAACACACAGAGCAGCTGTTGGAGGCTC 1868  
 Db 2951 AGCTGCTGCACTGACACATTACATCTCTGCAACACACAGAGCAGCTGTTGGAGGCTC 3010  
 Qy 1869 TGCGCCAGCAGTGCAGCGGAGGCGGACAGCGAGGCCCTCACTGATGGCGGGCCCTTGC 1928  
 Db 3011 TGCGCCAGCAGTGCAGCGGAGGCGGACAGCGAGGCCCTCACTGATGGCGGGCCCTTGC 3070  
 Qy 1929 CACCCCTAACTCTCATTTCCCTGGCTGCTGAGTTGAGTTGAGGAACTGTCTATCAGCG 1988  
 Db 3071 CACCCCTAACTCTCATTTCCCTGGCTGCTGAGTTGAGTTGAGGAACTGTCTATCAGCG 3130  
 Qy 1989 AGTGTCTCAGAGCCTCGGCTCAGTGGCACTGTCCAGGGTCCAGGCTGAGGCTGGGA 2048  
 Db 3131 AGTGTCTCAGAGCCTCGGCTCAGTGGCACTGTCCAGGGTCCAGGCTGAGGCTGGGA 3190  
 Qy 2049 GCTCCCTTTCGCGCTCAGCAGTTTTCAGTGGGTTAGAGGAGCCCAACCCATTTGTGTAATC 2108  
 Db 3191 GCTCCCTTTCGCGCTCAGCAGTTTTCAGTGGGTTAGAGGAGCCCAACCCATTTGTGTAATC 3250  
 Qy 2109 ACCCAAAAACCCCGGCTGCTGCTTTTCCCTTCTGCGCTACCTTGTAGTGTGGAGC 2168  
 Db 3251 ACCCAAAAACCCCGGCTGCTGCTTTTCCCTTCTGCGCTACCTTGTAGTGTGGAGC 3310  
 Qy 2169 ACTTGATATACAGACCTCATACAAAAA 2204  
 Db 3311 ACTTGATATACAGACCTCATACAAAAA 3346

RESULT 7

LOCUS BC013415 3193 bp mRNA linear PRI 19-AUG-2003  
 DEFINITION Homo sapiens phospholipase A2, group IVB (cytosolic), mRNA (cdna  
 clone IMAGE:3528417), partial cds.

ACCESSION

BC013415

VERSION

BC013415.2 GI:33604011

KEYWORDS

Source

ORGANISM

Homo sapiens (human)

REFERENCE

1 (bases 1 to 3193)

AUTHORS

Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,  
 Hopkins, R.P., Jordan, H., Moore, I., Max, S.I., Wang, J., Hsieh, F.,  
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
 Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L.,  
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
 Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,  
 Abramson, R.D., Mullaly, S.J., Bosak, S.A., McEwan, P.J.,

McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzyzanski, M.I., Skalska, U., Smalish, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.  
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
22386257  
12477932  
2 (bases 1 to 3193)  
Straussberg, R.  
Direct Submission  
Submitted (31-AUG-2001) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA  
NIH-MGC Project URL: <http://mgc.ncl.nih.gov>  
On Aug 12, 2003 this sequence version replaced gi:16807142.  
Contact: MGC help desk  
Email: [cgapsb-remail.nih.gov](mailto:cgapsb-remail.nih.gov)  
Tissue Procurement: ATCC  
cDNA Library Preparation: Rubin Laboratory  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Institute for Systems Biology  
<http://www.systemsbio.org>  
contact: [amadansystemsbio.org](mailto:amadansystemsbio.org)  
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettelman, Anuradha Madan, Stephanie Rodriguez, Amy Sanchez and Michelle Whiting  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAL Plate: 11 Row: a Column: 11  
This clone was selected for full length sequencing because it passed the following selection criteria: Hexamer frequency ORF analysis.  
FEATURES  
source  
1..3193  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:3528417"  
/tissue\_type="Muscle, rhabdomyosarcoma"  
/clone\_lib="NIH\_MGC\_17"  
/lab\_host="DH10B-R"  
/note="Vector: pOTB7"  
ORIGIN  
Query Match 82.3%; Score 1814; DB 9; Length 3193;  
Best Local Similarity 98.0%; Pred. No. 0;  
Matches 1860; Conservative 0; Mismatches 5; Indels 33; Gaps 1;  
Qy 340 CAGACTGAGGAGCTGGCCGCTCGCACTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCCTT 399  
Db 1290 CAGACTGAGGAGCTGGCCGCTCGCACTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCCTT 1349  
Qy 400 CTTGAGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 459  
Db 1350 CTTGAGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1409  
Qy 460 AGACTGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 519  
Db 1410 AGACTGCGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1469  
Qy 520 GGCAATGACTTCCCTGTATGGGCGAGCTGGCTGGCTGAAGGAGCTGGGCCCTCTTGGATTG 579  
Db 1470 GGCAATGACTTCCCTGTATGGGCGAGCTGGCTGGCTGAAGGAGCTGGGCCCTCTTGGATTG 1529  
Qy 580 CGTCTCTACATACACCGGGGCGCTCGGGCTCCACCTGGGCGCTTGGCCAACTTTATGAGGA 639

Db 1530 CGTCTCTACATACACCGGGGCGCTCGGGCTCCACCTGGGCGCTTGGCCAACTTTATGAGGA 1589  
Qy 640 CCCAGAGTGGTCTCAAGAGGACCTGGCAGGGCCCACTGAGTTGCTGAAGACCCAGGTGAC 699  
Db 1590 CCCAGAGTGGTCTCAAGAGGACCTGGCAGGGCCCACTGAGTTGCTGAAGACCCAGGTGAC 1649  
Qy 700 CAAGAACAGCTGGGTGTGCTGGGCCCCAGCCAGCTGCGAGCGGTACCCGCGAGAGCTGGC 759  
Db 1650 CAAGAACAGCTGGGTGTGCTGGGCCCCAGCCAGCTGCGAGCGGTACCCGCGAGAGCTGGC 1709  
Qy 760 CGAGCGTGGCCGCTTGGGCTACCCAAAGTGTCTTCAACCACTGTGGGCCCTCATCAACGA 819  
Db 1710 CGAGCGTGGCCGCTTGGGCTACCCAAAGTGTCTTCAACCACTGTGGGCCCTCATCAACGA 1769  
Qy 820 GCGCGTGTGATGATGAGCCCAATGATCAACAAGTCTCAGATCAACGGGAGGCCCTGAG 879  
Db 1770 GCGCGTGTGATGATGAGCCCAATGATCAACAAGTCTCAGATCAACGGGAGGCCCTGAG 1829  
Qy 880 TCATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACCAAGGGCAGAGCTGAC 939  
Db 1830 TCATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACCAAGGGCAGAGCTGAC 1889  
Qy 940 CACTTTTGAATTTGGGAGTGTGGAGTCTCTCCCTACGAGTCTGGCTTCCCAAGTA 999  
Db 1890 CACTTTTGAATTTGGGAGTGTGGAGTCTCTCCCTACGAGTCTGGCTTCCCAAGTA 1949  
Qy 1000 CGGGGCCCTTCAATCCCTCTGAGCTCTTTGGCTCGAGTCTTTATGGGGCAGCTGATGA 1059  
Db 1950 CGGGGCCCTTCAATCCCTCTGAGCTCTTTGGCTCGAGTCTTTATGGGGCAGCTGATGA 2009  
Qy 1060 GAGGCTTCTCAGTCCCGCATCTGCTCTTAGAAGGTATCTGGACCACTGTATGCGAC 1119  
Db 2010 GAGGCTTCTCAGTCCCGCATCTGCTCTTAGAAGGTATCTGGACCACTGTATGCGAC 2069  
Qy 1120 CAACCTCCAGGACAGCTTATATCTGGGCTCAGAGCCAGCCAGTCTCTGGACCGCTGGT 1179  
Db 2070 CAACCTCCAGGACAGCTTATATCTGGGCTCAGAGCCAGCCAGTCTCTGGACCGCTGGT 2129  
Qy 1180 CAGGAACAGGCCAACCTGGACAAGGACAGGTCCCTCTCTGAAGATAGAGAACCCACC 1239  
Db 2130 CAGGAACAGGCCAACCTGGACAAGGACAGGTCCCTCTCTGAAGATAGAGAACCCACC 2189  
Qy 1240 CTCACAGCCGCGAGATAGCTGAGTCTTTCACCGATCTTCTGAGCGTGGCGTCCACTGGC 1299  
Db 2190 CTCACAGCCGCGAGATAGCTGAGTCTTTCACCGATCTTCTGAGCGTGGCGTCCACTGGC 2249  
Qy 1300 CCAGGCCACACATAATTTCTCGCTGGGCTCCATTTCCACAAAGACTACTTTTTCAGCATCC 1359  
Db 2250 CCAGGCCACACATAATTTCTCGCTGGGCTCCATTTCCACAAAGACTACTTTTTCAGCATCC 2309  
Qy 1360 TCACCTTCTCAGTGAAGCTACACTCTGGATGGGCTCCCAACCCAGCTGACACCCCTC 1419  
Db 2310 TCACCTTCTCAGTGAAGCTACACTCTGGATGGGCTCCCAACCCAGCTGACACCCCTC 2369  
Qy 1420 GGAGCCCACTGTGCGCTGGATGTGCTACTCATCAATCCAGCTGCTGCTGCCCT 1479  
Db 2370 GGAGCCCACTGTGCGCTGGATGTGCTACTCATCAATCCAGCTGCTGCTGCCCT 2429  
Qy 1480 CCTCAGCCCACTCGGACAGTGGACCTCATCTCTGCTATTGGACTTACACCTCCAGCGAGC 1539  
Db 2430 CCTCAGCCCACTCGGACAGTGGACCTCATCTCTGCTATTGGACTTACACCTCCAGCGAGC 2489  
Qy 1540 CTTCCAGAGTTGAGCTCTTGGCCGCGTTCTGCCAGGAGCGGGGATCCCGTTTCCACCC 1599  
Db 2490 CTTCCAGAGTTGAGCTCTTGGCCGCGTTCTGCCAGGAGCGGGGATCCCGTTTCCACCC 2549  
Qy 1600 CATCTCGCCAGCCCCGAGAGGAGCTCCAGCTTCGGGAGTGCCACACCTTCTCCGAGCC 1659  
Db 2550 CATCTCGCCAGCCCCGAGAGGAGCTCCAGCTTCGGGAGTGCCACACCTTCTCCGAGCC 2609  
Qy 1660 CACTGCGCCGAGCCCTCGGCTGCTGCACTTT----- 1693





QY	1482	TGACGACCACTCGGAGCTGGACCTCATCTGTCTATTTGGACTACAACTCCACGAGCCT	1541
Db	1949	TGACGACCACTCGGAGCTGGACCTCATCTGTCTATTTGGACTACAACTCCACGAGCCT	2008
QY	1542	TCCAGCAGTTGACGCTCTCGGCGGCTTCTCCAGGAGCAGGGATCCGTTCCACCCCA	1601
Db	2009	TCCAGCAGTTGACGCTCTCGGCGGCTTCTCCAGGAGCAGGGATCCGTTCCACCCCA	2068
QY	1602	TCTGCGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGGAGTGCACACCTTCTCCGACCCCA	1661
Db	2069	TCTGCGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGGAGTGCACACCTTCTCCGACCCCA	2128
QY	1662	CCTGCGCCAGCCCGGAGCTCGGCTGCTGCACTTT-----	1693
Db	2129	CCTGCGCCAGCCCGGAGCTCGGCTGCTGCACTTTCTCTGTCAGCAGCTCCTTCCGGAGT	2188
QY	1694	-----TCCTCTGGGTCGCGGCGGACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGT	1748
Db	2189	ACTGCGCCCTGGGTCGCGGCGGACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGT	2248
QY	1749	CTTATCGGAGCTCTCCCTACCACTACAGAGGTGACCTACAGCAGGAGGAGCTGGACA	1808
Db	2249	CTTATCGGAGCTCTCCCTACCACTACAGAGGTGACCTACAGCAGGAGGAGCTGGACA	2308
QY	1809	AGCTGCTGCACTGACATTAATGCTGCAACACAGGAGCAGCTGCTGGAGGCTC	1868
Db	2309	AGCTGCTGCACTGACATTAATGCTGCAACACAGGAGCAGCTGCTGGAGGCTC	2368
QY	1869	TGCGCCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAG	1928
Db	2369	TGCGCCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAG	2428
QY	1929	CACCCCTAATCTCATTTATTCCTGCTGCTGAGTTCAGTGGAGTGCATCAGC	1988
Db	2429	CACCCCTAATCTCATTTATTCCTGCTGCTGAGTTCAGTGGAGTGCATCAGC	2488
QY	1989	AGTGCTTCAGAGCTTCGGGCTCAGTGGACGCTGCCAGGCTCCAGGCTCAGGCTGGGA	2048
Db	2489	AGTGCTTCAGAGCTTCGGGCTCAGTGGACGCTGCCAGGCTCCAGGCTCAGGCTGGGA	2548
QY	2049	GCTCCCTTCGCTCAGCAGTTTGCAGTGGGTAAGAGGCGCAAGCCCATTTGTGTAATC	2108
Db	2549	GCTCCCTTCGCTCAGCAGTTTGCAGTGGGTAAGAGGCGCAAGCCCATTTGTGTAATC	2608
QY	2109	ACCCAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	2168
Db	2609	ACCCAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT	2668
QY	2169	ACTTGATACATCAGACACTCATAAAA	2195
Db	2669	ACTTGATACATCAGACACTCATAAAA	2695
RESULT 10			
AF121908			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
MEDLINE			
PUBMED			
REFERENCE			
AUTHORS			

Kriz, R.W.		Direct Submission	
Submitted (21-JAN-1999)		Genetics Institute, 87 Cambridge Park	
Drive, Cambridge, MA 02140, USA			
Location/Qualifiers			
1. 3339			
/organism="Homo sapiens"			
/mol_type="mRNA"			
/db_xref="taxon:9606"			
8_3046			
/note="cPIA2beta"			
/codon_start=1			
/product="cytosolic phospholipase A2 beta"			
/protein_id="AAD32135.1"			
/db_xref="GI:4886978"			
/translation="MARAALAEVSELREFPAAARELCVPLAVPLDKPPTPLHFRD			
WVNRFCILIRNALQHPALQKSLPYERATVSGTSTVAVTPDGYADAVGDRFMP			
AENRPLFVLIDLEAGHPGVLYVQKSNLSELPOLLPLDLESHVPMASEALGKM			
PDVNFVIGAAAVTSLKHDIENLYCVSGEKHFLHPPSDRPFIPYELTYPTAYQL			
TEEGTFKVIDEAMEKAEVSTCLTTLVRVQLHRLPSKDLVTPSDVYVTLPTACSH			
RLQRTVKNSSPVNQSFPHRIHQKLVNMLKVFQDLVTDGDPVLSVLFDAETLR			
AGEFRRSFSLSPQEGRLVEFRLQSLADRGWFWNVGLVARELSLHAPQLKAPLS			
QKSEHVLVLPVPGSCGPOEASVGTGTFHCPACWEOELSLQADAPQLKAPLS			
ALPQGVVRLVLPFSPQELMRVELKXZAGLRELAVRLGFGPCBEQAFLSRRKQVAA			
ALRQALQDLQDLEIPVVAIMATGGIRANTSLYQGLAGLKEGLDLCVSYITGAS			
GSTWALNLYEDPEWSQDLAGPTTELLKTQVKNLGLVLPSPQVLRQVLAERLUG			
YPSCTNLWALINEALLHDEPHDKLSDREALSHGNPLFIYCALNTKGSGLTFEF			
GECFESPEYEVGPKYGAFIPELPGSEFFQMLKMLPESRICTFLEIGNLYAANL			
ODSLYWAESPQFQWVNRVNOANLDKQVPLKIEEPPSTAGRIAEFTDLLTWRLA			
QATNFRGLHFKDYFOHPHFSTWKTLLDGLNQLTPSEPHLLDVLVLYINTSL			
PLQPTRDVDLILSLDYNLHGAFOQLQLLGRFCQGGIPFPFSPSPREQLQPRECHT			
FSDTFCGAPVHLHPLVLSDFREYSPAGVRRTPFEEAAGVLESSDPSHYTKVTY			
SQEDVDKLLHLTHYVNCNNQQLLEALRQAVRRRRRRPH"			
ORIGIN			
Query Match		82.0%; Score 1806.2; DB 9; Length 3339;	
Best Local Similarity		98.1%; Pred. No. 0;	
Matches 1851; Conservative		0; Mismatches	
		3; Indels 33; Gaps 1;	
QY	342	GACTCAGGAGCTGGCGCTGCGACTTGGGCTTCGGGCTTGCAGGAGCAGGCGCTTCC	401
Db	1443	GACTCAGGAGCTGGCGCTGCGACTTGGGCTTGCAGGAGCAGGCGCTTCC	1502
QY	402	TGAGCAGGAGGAGCAGGTGGTGGCGGCTTGCAGGAGCAGGCGCTTGCAGTGGAG	461
Db	1503	TGAGCAGGAGGAGCAGGTGGTGGCGGCTTGCAGGAGCAGGCGCTTGCAGTGGAG	1562
QY	462	ACCTCAGGAGGATCAGATCCAGTGGTAGCTATTATGGCCACTGGTGGGATCCGG	521
Db	1563	ACCTCAGGAGGATCAGATCCAGTGGTAGCTATTATGGCCACTGGTGGGATCCGG	1622
QY	522	CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCTTGGGATTCG	581
Db	1623	CAATGACTTCCCTGTATGGGAGCTGGCTGAGGAGCTGGGCTTGGGATTCG	1682
QY	582	TCTCTACATACCGGGGCTCGGCTCCACTGGGCTTGGCCAACTTATGAGGACC	641
Db	1683	TCTCTACATACCGGGGCTCGGCTCCACTGGGCTTGGCCAACTTATGAGGACC	1742
QY	642	CAGAGTGGTCTCAGAGGAGCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCA	701
Db	1743	CAGAGTGGTCTCAGAGGAGCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCA	1802
QY	702	AGAACAAAGCTGGGTGTGCTGGGCGCCCGCAGCAGCTCAGCGGTACCGGAGGAGCTGGCG	761
Db	1803	AGAACAAAGCTGGGTGTGCTGGGCGCCCGCAGCAGCTCAGCGGTACCGGAGGAGCTGGCG	1862
QY	762	AGCGTCCCGCTGGGCTACCCAAAGCTGTTACCAAACTGGGCGCTCATCAACGAGG	821
Db	1863	AGCGTCCCGCTGGGCTACCCAAAGCTGTTACCAAACTGGGCGCTCATCAACGAGG	1922
QY	822	CGCTGCTGATGATGAGCCCATGATCACAAGCTCTCAGATCAACGAGGAGGCGCTCAGTC	881

```
Db 1923 CCGTCTGCTGATGATGAGCCCATGATCAAGAAGTCTCAGATCAACGGGAGGCGCTGAGTC 1982
QY 882 ATGGCCAGAACCCCTCTGCCCCATCTACTGTGCCCTCAACACCAAGAGGAGAGCCCTGACCA 941
Db 1983 ATGGCCAGAACCCCTCTGCCCCATCTACTGTGCCCTCAACACCAAGAGGAGAGCCCTGACCA 2042
QY 942 CTTTGTGAATTTGGGAGTGGTGCAGTTCCTCTCCCTACGAGTCCGCTTCCCAAGTAGC 1001
Db 2043 CTTTGTGAATTTGGGAGTGGTGCAGTTCCTCTCCCTACGAGTCCGCTTCCCAAGTAGC 2102
QY 1002 GGGCCCTTCATCCCTCTGAGCTCTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAAGA 1061
Db 2103 GGGCCCTTCATCCCTCTGAGCTCTTGGCTCCGAGTTCCTTATGGGCGAGCTGATGAAGA 2162
QY 1062 GGGCTTCCTGAGTCCCGCATCTCTCTTTAGAAAGTATCTGGAGCAACCTGTATGAGCCA 1121
Db 2163 GGGCTTCCTGAGTCCCGCATCTCTCTTTAGAAAGTATCTGGAGCAACCTGTATGAGCCA 2222
QY 1122 ACCTCCAGGACAGCTTATCTAGGCTCAGAGCCAGCCAGTTCCTGGGACCGCTGGGTCA 1181
Db 2223 ACCTCCAGGACAGCTTATCTAGGCTCAGAGCCAGCCAGTTCCTGGGACCGCTGGGTCA 2282
QY 1182 GGAACCAAGCCCAACCTGGACAGGAGGAGTCCCTCTTCTGAAGATAGAAGAACACCT 1241
Db 2283 GGAACCAAGCCCAACCTGGACAGGAGGAGTCCCTCTTCTGAAGATAGAAGAACACCT 2342
QY 1242 CAACAGCGGCGAGATAGTGAATTTTTCACCGATCTTCTGACGTGGCGTCCACCTGGGCC 1301
Db 2343 CAACAGCGGCGAGATAGTGAATTTTTCACCGATCTTCTGACGTGGCGTCCACCTGGGCC 2402
QY 1302 AGGCCACACATAATTTCTGGGTGGCTCCATTTCCACAAAGACTACTTTTCAGCATCCTC 1361
Db 2403 AGGCCACACATAATTTCTGGGTGGCTCCATTTCCACAAAGACTACTTTTCAGCATCCTC 2462
QY 1362 ACTTCTCCACATGGAAGACTACCTCTGGATGGCTCCCAACAGCTGACACCTCGG 1421
Db 2463 ACTTCTCCACATGGAAGACTACCTCTGGATGGCTCCCAACAGCTGACACCTCGG 2522
QY 1422 AGCCCCACCTGTGCTGTGGATGTGGCTACCTCATCAATACCAAGCTGCCGTGCCCTCC 1481
Db 2523 AGCCCCACCTGTGCTGTGGATGTGGCTACCTCATCAATACCAAGCTGCCGTGCCCTCC 2582
QY 1482 TGCAGCCCACTCGGGACCTGGAACCTCATCTGTCAATGGACTACAACTTCTCCACGGAGCCT 1541
Db 2583 TGCAGCCCACTCGGGACCTGGAACCTCATCTGTCAATGGACTACAACTTCTCCACGGAGCCT 2642
QY 1542 TCCAGCAGTTTCAGCTCTGCGGCGGTTCTGCGAGGACAGGGATCCGTTTCCACCCCA 1601
Db 2643 TCCAGCAGTTTCAGCTCTGCGGCGGTTCTGCGAGGACAGGGATCCGTTTCCACCCCA 2702
QY 1602 TCTCGCCCGAGCCCGAAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCCGACCCCA 1661
Db 2703 TCTCGCCCGAGCCCGAAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCCGACCCCA 2762
QY 1662 CTTGCGCGGAGCCCTGCGGTGTGCACTTTT----- 1693
Db 2763 CTTGCGCGGAGCCCTGCGGTGTGCACTTTT----- 1693
QY 1694 -----TCTCTCGGGTCCGGGACACCCGAGGCGGAGCTGGGAGGTGAACCTGT 2822
Db 2823 ACTCGGCCCCCTGGGGTCCGGGACACCCGAGGCGGAGCTGGGAGGTGAACCTGT 2882
QY 1749 CTTTCATCGGACTCTCCCTACCCTACACGAAGGTGACCTACAGCAGGAGACCTGGACA 1808
Db 2883 CTTTCATCGGACTCTCCCTACCCTACACGAAGGTGACCTACAGCAGGAGACCTGGACA 2942
QY 1809 AGCTGCTGCACTTGCACATTAATGTCTCAACAAACAGGAGCAGCTGCTGGAGGCTC 1868
Db 2943 AGCTGCTGCACTTGCACATTAATGTCTCAACAAACAGGAGCAGCTGCTGGAGGCTC 3002
QY 1869 TGGCCAGGAGCTGACGGAGGCGGAGCCAGCCAGGCCCTCATGTATGGCCGGGGCCCTGC 1928
Db 3003 TGGCCAGGAGCTGACGGAGGCGGAGCCAGCCAGGCCCTCATGTATGGCCGGGGCCCTGC 3062
```

```
QY 1929 CACCCCTAACTCTCATTTCAATCCCTGGCTGTGAGTTGAGGTGGAACTGTCAATCACGC 1988
Db 3063 CACCCCTAACTCTCATTTCAATCCCTGGCTGTGAGTTGAGGTGGAACTGTCAATCACGC 3122
QY 1989 AGTGCTTTCAGAGCCTCGGGCTCAGGTGGCACTGTCCAGGGTCCAGGCTGAGGCTGGGA 2048
Db 3123 AGTGCTTTCAGAGCCTCGGGCTCAGGTGGCACTGTCCAGGGTCCAGGCTGAGGCTGGGA 3182
QY 2049 GCTCCCTTTCAGGCTCAGCAGTTTTCAGTGGGTAAAGAGGCCAAAGCCCATTTGTGTAAATC 2108
Db 3183 GCTCCCTTTCAGGCTCAGCAGTTTTCAGTGGGTAAAGAGGCCAAAGCCCATTTGTGTAAATC 3242
QY 2109 ACCCAAAACCCCGGCTGTGCTGTTTCCCTTCTGGCTACCTTGAGTAGTTGGAGC 2168
Db 3243 ACCCAAAACCCCGGCTGTGCTGTTTCCCTTCTGGCTACCTTGAGTAGTTGGAGC 3302
QY 2169 ACTTGATACATCAGACTCATACAAA 2195
Db 3303 ACTTGATACATCAGACTCATACAAA 3329

RESULT 11
AR168354
LOCUS AR168354 4183 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 1 from patent US 6287838.
ACCESSION AR168354
VERSION AR168354.1 GI:17904226
KEYWORDS SOURCE
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 4183)
AUTHORS Kriz, R. and Song, C.
TITLE Cytosolic phospholipase A2-Beta enzymes
JOURNAL Patent: US 6287838-A 1 11-SEP-2001;
FEATURES Location/Qualifiers
source 1. 4183
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN
Query Match 82.0%; Score 1806.2; DB 6; Length 4183;
Best Local Similarity 98.1%; Pred. No. 0;
Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;

QY 342 GACTGAGGAGCTGGCGCTGCGACTGGGCTTCGGGCCCTGTGCAGAGAGCAGGCTTCC 401
Db 2293 GACTGAGGAGCTGGCGCTGCGACTGGGCTTCGGGCCCTGTGCAGAGAGCAGGCTTCC 2352
QY 402 TGAGCAGGAGGAACAGAGTGTGGCCGGGCTTGAAGCAGGCGCTGAGCTGGATGGAG 461
Db 2353 TGAGCAGGAGGAACAGAGTGTGGCCGGGCTTGAAGCAGGCGCTGAGCTGGATGGAG 2412
QY 462 ACCTGACAGGAGATGAGATCCAGTGTGTAGCTATTATGGCCACCTGGTGGTGGATCCGGG 521
Db 2413 ACCTGACAGGAGATGAGATCCAGTGTGTAGCTATTATGGCCACCTGGTGGTGGATCCGGG 2472
QY 522 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGCTGAAGAGAGCTGGGCCCTCTTGGATTGCG 581
Db 2473 CAATGACTTCCCTGTATGGGAGCTGGCTGAGGCTGAAGAGAGCTGGGCCCTCTTGGATTGCG 2532
QY 582 TCTCTACATCACGGGGCTTCGGGCTTCACCTGGGCTTGGGCCAACTTTATGAGGACC 641
Db 2533 TCTCTACATCACGGGGCTTCGGGCTTCACCTGGGCTTGGGCCAACTTTATGAGGACC 2592
QY 642 CAGAGTGTCTCAGAAGGAGCTGCGACGGCCCACTGAGTTGCTGAAGACCCAGGTGACCA 701
Db 2593 CAGAGTGTCTCAGAAGGAGCTGCGACGGCCCACTGAGTTGCTGAAGACCCAGGTGACCA 2652
QY 702 AGAACAGCTGGGTGTCTGTGGCCCCCAGCCAGCTGACAGCGGTACCGGAGGAGCTGGCCG 761
Db 2653 AGAACAGCTGGGTGTCTGTGGCCCCCAGCCAGCTGACAGCGGTACCGGAGGAGCTGGCCG 2712
```



```
Qy 762 AGCGTGCCTGGGCTACCCAGCTGCTTCAACCAACCTGTGGGCCCTCATCAACGAGG 821
Db 2713 AGCGTGCCTGGGCTACCCAGCTGCTTCAACCAACCTGTGGGCCCTCATCAACGAGG 2772
Qy 822 CGTGTGTCATGATGAGCCCATGATCAACAGCTCTCAGATCAACGGGAGGCCCTGAGTC 881
Db 2773 CGTGTGTCATGATGAGCCCATGATCAACAGCTCTCAGATCAACGGGAGGCCCTGAGTC 2832
Qy 882 ATGCGCAGAACCTCTGCGCCATCTACTGTGCGCCCTCAACCAAGGGGAGAGCCTGACCA 941
Db 2833 ATGCGCAGAACCTCTGCGCCATCTACTGTGCGCCCTCAACCAAGGGGAGAGCCTGACCA 2892
Qy 942 CTTTGTGAATTTGGGAGTGGTGGAGTCTCTCCCTACGAGTGGCTTCCCAAGTACG 1001
Db 2893 CTTTGTGAATTTGGGAGTGGTGGAGTCTCTCCCTACGAGTGGCTTCCCAAGTACG 2952
Qy 1002 GGGCTTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGGCAGCTGATGAAGA 1061
Db 2953 GGGCTTTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGGCAGCTGATGAAGA 3012
Qy 1062 GGCTTCTGAGTCCCGCATCTGCTTTTAGAGGTATCTGAGCAACCTGTATGAGGCCA 1121
Db 3013 GGCTTCTGAGTCCCGCATCTGCTTTTAGAGGTATCTGAGCAACCTGTATGAGGCCA 3072
Qy 1122 ACCTCCAGGACAGCTTATCTAGTGGGCTCAGAGCCAGCCAGTCTTGAGCACCGCTGGGTCA 1181
Db 3073 ACCTCCAGGACAGCTTATCTAGTGGGCTCAGAGCCAGCCAGTCTTGAGCACCGCTGGGTCA 3132
Qy 1182 GGAACACAGGCCAACCTGGACAGGAGCAGGTCCCTTTCTGAAGATAGAAGAACCAACCT 1241
Db 3133 GGAACACAGGCCAACCTGGACAGGAGCAGGTCCCTTTCTGAAGATAGAAGAACCAACCT 3192
Qy 1242 CAACAGCGGCGAGAACTAGCTGAGTCTTTCAGGATCTTCTGACGTGGGGTCCACTGGGCC 1301
Db 3193 CAACAGCGGCGAGGATAGCTGAGTCTTTCAGGATCTTCTGACGTGGGGTCCACTGGGCC 3252
Qy 1302 AGGCCACACATAATTTCTGTGGTGGCTCCATTTCCACAAAGACTACTTTTCAGATCTCTC 1361
Db 3253 AGGCCACACATAATTTCTGTGGTGGCTCCATTTCCACAAAGACTACTTTTCAGATCTCTC 3312
Qy 1362 ACTTCTCCACATGAAAGCTACCACTGTGATGGGCTCCCAACAGCTGACACCTCGG 1421
Db 3313 ACTTCTCCACATGAAAGCTACCACTGTGATGGGCTCCCAACAGCTGACACCTCGG 3372
Qy 1422 AGCCCCACCTGTGCTGTGATGTGCTGATCTTCAATACAGCTGCTGCTGCTGCTCC 1481
Db 3373 AGCCCCACCTGTGCTGTGATGTGCTGATCTTCAATACAGCTGCTGCTGCTGCTCC 3432
Qy 1482 TGACGCCCACTCGGAGCTGGACCTCATCTGTGATTTGACCTTACAACTCCACGGAGCT 1541
Db 3433 TGACGCCCACTCGGAGCTGGACCTCATCTGTGATTTGACCTTACAACTCCACGGAGCT 3492
Qy 1542 TCCAGCAGTTGAGCTCTCTGGGCGCGTCTTGCCAGGAGCAGGGATCCCGTTCCACCCA 1601
Db 3493 TCCAGCAGTTGAGCTCTCTGGGCGCGTCTTGCCAGGAGCAGGGATCCCGTTCCACCCA 3552
Qy 1602 TCTGGCCACGCCCGAAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCA 1661
Db 3553 TCTGGCCACGCCCGAAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCA 3612
Qy 1662 CTGCGCCCGGAGCCCTCGGTGCTGCACTTTT----- 1693
Db 3613 CTGCGCCCGGAGCCCTCGGTGCTGCACTTTTCTCTGTGTGCTGCTGCTTCTCGGGAGT 3672
Qy 1694 -----TCTCTGGGTCCGGGAGCAACCGAGAGGCGGACCTGGGAGGTGAACCTGT 1748
Db 3673 ACTCGGCCCTTGGGTCCGGGAGCAACCGAGAGGCGGACCTGGGAGGTGAACCTGT 3732
Qy 1749 CTTTCATCGGACTCTCCCTACCACTACAGAGGTGACCTFACAGCCAGGAGGAGCTGGACA 1808
Db 3733 CTTTCATCGGACTCTCCCTACCACTACAGAGGTGACCTFACAGCCAGGAGGAGCTGGACA 3792
```

```
Qy 1809 AGCTGTGCACCTGACACATTACAATGTCTGCACAAACACAGGAGCAGCTGCTGAGGCTC 1868
Db 3793 AGCTGTGCACCTGACACATTACAATGTCTGCACAAACACAGGAGCAGCTGCTGAGGCTC 3852
Qy 1869 TGGCCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAG 1928
Db 3853 TGGCCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAG 3912
Qy 1929 CACCCCTTAACCTCTCATTTCTCCTGCTGCTGAGTTGCGAGTGGGAACTGTCTATCAGC 1988
Db 3913 CACCCCTTAACCTCTCATTTCTCCTGCTGCTGAGTTGCGAGTGGGAACTGTCTATCAGC 3972
Qy 1989 AGTGTCTCAGAGCCTCGGCTCAGGTGGCACTGTCCAGGGTCCAGGTCAGGGCTGGGA 2048
Db 3973 AGTGTCTCAGAGCCTCGGCTCAGGTGGCACTGTCCAGGGTCCAGGTCAGGGCTGGGA 4032
Qy 2049 GCTCCCTTGGCCTCAGCAGTTTGCAGTGGGTTAAGAGGCCCAAGCCATTTGTGTAATC 2108
Db 4033 GCTCCCTTGGCCTCAGCAGTTTGCAGTGGGTTAAGAGGCCCAAGCCATTTGTGTAATC 4092
Qy 2109 ACCCAAAACCCCGGCTGTGCTGCTTTTCCCTTCTGCGCTACTCTTGAGTAGTTGGAGC 2168
Db 4093 ACCCAAAACCCCGGCTGTGCTGCTTTTCCCTTCTGCGCTACTCTTGAGTAGTTGGAGC 4152
Qy 2169 ACTTGATACATCAAGACTCATACAA 2195
Db 4153 ACTTGATACATCAAGACTCATACAA 4179

RESULT 12
LOCUS AR255868 4183 bp mRNA linear PAT 20-DEC-2002
DEFINITION Sequence 1 from patent US 6482625.
ACCESSION AR255868
VERSION AR255868.1 GI:27305098
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 4183)
Krishna, R. and Song, C.
TITLE Cytosolic phospholipase A2-beta enzymes
JOURNAL Patent: US 6482625-A 1 19-NOV-2002;
FEATURES Location/Qualifiers
1..4183
source /organism="unknown"
/mol_type="mRNA"

ORIGIN
Query Match 82.0%; Score 1806.2; DB 6; Length 4183;
Best Local Similarity 98.1%; Pred. No. 0;
Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;

Qy 342 GACTGAGGAGCTGGCCCTGCGACTGGGCTTCGGGCTTCGGGCTTCGGGCTTCGGGCTTC 401
Db 2293 GACTGAGGAGCTGGCCCTGCGACTGGGCTTCGGGCTTCGGGCTTCGGGCTTCGGGCTTC 2352
Qy 402 TGACGAGGAGGAGCAGGTGTGGCGCGGCTTCGAGCAGGCGCTTCGAGCTGGATGGAG 461
Db 2353 TGACGAGGAGGAGCAGGTGTGGCGCGGCTTCGAGCAGGCGCTTCGAGCTGGATGGAG 2412
Qy 462 ACCTGAGGAGGATGAGATCCAGTGTGATTTATGGCCACTGGTGGTGGATCCGGG 521
Db 2413 ACCTGAGGAGGATGAGATCCAGTGTGATTTATGGCCACTGGTGGTGGATCCGGG 2472
Qy 522 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAAGAGCTGGGCTCTTGGATTTGG 581
Db 2473 CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGAAGAGCTGGGCTCTTGGATTTGG 2532
Qy 582 TCTCTCATACACCGGGGCTTCGGGCTCCACTGGGCTTCAGCCAACTTTATGAGGACC 641
Db 2533 TCTCTCATACACCGGGGCTTCGGGCTCCACTGGGCTTCAGCCAACTTTATGAGGACC 2592
```



```
QY 542 CAGAGTGGTCTCAGAAAGCACTGGCAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCA 701
Db 2593 CAGAGTGGTCTCAGAAAGCACTGGCAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCA 2652
QY 702 AGAACAGCTGGGTGCTGGCCCCCAGCAGCTGACGCGGTACCGCAGGAGCTGGCCG 761
Db 2653 AGAACAGCTGGGTGCTGGCCCCCAGCAGCTGACGCGGTACCGCAGGAGCTGGCCG 2712
QY 762 AGCGTGCCCGCTTGGGCTACCAAGCTGCTTCAACCACTGTGGGCCCTCATCAAGGAGG 821
Db 2713 AGCGTGCCCGCTTGGGCTACCAAGCTGCTTCAACCACTGTGGGCCCTCATCAAGGAGG 2772
QY 822 CGCTGCTGATGATGAGCCCCCATGATCAAAAGCTCTCAGATCAACGAGGAGGCCCTGAGTC 881
Db 2773 CGCTGCTGATGATGAGCCCCCATGATCAAAAGCTCTCAGATCAACGAGGAGGCCCTGAGTC 2832
QY 882 ATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCA 941
Db 2833 ATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCA 2892
QY 942 CTTTGAATTGGGAGTGGTGGAGTTCTCTCCCTACGAGGTGGCTTCCCAAGTACG 1001
Db 2893 CTTTGAATTGGGAGTGGTGGAGTTCTCTCCCTACGAGGTGGCTTCCCAAGTACG 2952
QY 1002 GGGCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA 1061
Db 2953 GGGCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA 3012
QY 1062 GGGCTTCAGTCCCGCATCTGCTTCTAGAGGTATCTGGAGCAACCTGTATGACGCCA 1121
Db 3013 GGGCTTCAGTCCCGCATCTGCTTCTAGAGGTATCTGGAGCAACCTGTATGACGCCA 3072
QY 1122 ACTTCAGGACAGCTTATCTGGGCTCAGAGCCAGCCAGTTCTGGAGCCGCTGGGTCA 1181
Db 3073 ACTTCAGGACAGCTTATCTGGGCTCAGAGCCAGCTGCTTCTGGAGCCGCTGGGTCA 3132
QY 1182 GGAACAGGCCAACCTGGACAGGAGCAGGTGCTTCTGAAGATAGAAGAACCAACCTC 1241
Db 3133 GGAACAGGCCAACCTGGACAGGAGCAGGTGCTTCTGAAGATAGAAGAACCAACCTC 3192
QY 1242 CAACAGCGGAGAGTAGCTGAGTTTTCACCGATCTTCTGAGTGGCGTCCACTGGCCC 1301
Db 3193 CAACAGCGGAGAGTAGCTGAGTTTTCACCGATCTTCTGAGTGGCGTCCACTGGCCC 3252
QY 1302 AGGCCACACATAATTTCTCGTGGGCTCCATTTCCACAAAGACTACTTTTCAGGATCCTC 1361
Db 3253 AGGCCACACATAATTTCTCGTGGGCTCCATTTCCACAAAGACTACTTTTCAGGATCCTC 3312
QY 1362 ACTTCTCCATGGAAGTACACCTCTGGATGGGTCCCCAACAGCTGACACCCCTCGG 1421
Db 3313 ACTTCTCCATGGAAGTACACCTCTGGATGGGTCCCCAACAGCTGACACCCCTCGG 3372
QY 1422 AGCCCCACTGTGCTGCTGGATGTTGGTACTCATCAATACCAAGCTGCTGCCCTCC 1481
Db 3373 AGCCCCACTGTGCTGCTGGATGTTGGTACTCATCAATACCAAGCTGCTGCCCTCC 3432
QY 1482 TGCAGCCCACTCGGACGTGGACCTCATCTGCTGATTTGGACTTACAACTTCCACGAGCT 1541
Db 3433 TGCAGCCCACTCGGACGTGGACCTCATCTGCTGATTTGGACTTACAACTTCCACGAGCT 3492
QY 1542 TCCAGCAGTTGAGCTCTCTGGCCCGGTGCTGCGAGAGAGGGATCCGTTTCCACCCA 1601
Db 3493 TCCAGCAGTTGAGCTCTCTGGCCCGGTGCTGCGAGAGAGGGATCCGTTTCCACCCA 3552
QY 1602 TCTGCCCCAGCCCCAGAGAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCA 1661
Db 3553 TCTGCCCCAGCCCCAGAGAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCA 3612
QY 1662 CTGCCCCCGAGCCCCCTCGGCTGCTGCACTTT----- 1693
Db 3613 CTGCCCCCGAGCCCCCTCGGCTGCTGCACTTTCTCTGCTCAGCGACTCTCTTCGGGAGT 3672
QY 1694 -----TCCTCTGGGGTCCGGCGGACACCCGAGAGGCGGCGAGCTGGGAGGTGAACCTGT 1748
```

```
Db 3673 ACTCGGCCCTGGGTTCCGGCGGACACCCGAGAGGGCGGAGCTGGGGAGGTGAACCTGT 3732
QY 1749 CTTTCATCGGACTCTCCCTACCACTACACGAAAGTGTACCTACAGCCAGGAGGACCTGGACA 1808
Db 3733 CTTTCATCGGACTCTCCCTACCACTACACGAAAGTGTACCTACAGCCAGGAGGACCTGGACA 3792
QY 1809 AGCTGCTGCACCTGCACACATTACAAATGTCTGCAACAAACCCAGGAGCAGCTGCTGGAGGCTC 1868
Db 3793 AGCTGCTGCACCTGCACACATTACAAATGTCTGCAACAAACCCAGGAGCAGCTGCTGGAGGCTC 3852
QY 1869 TGGCCGAGGCGAGTGCAGCGAGGCGGCGAGCGAGGCGGCGAGGCGGCGGCGGCGGCGGCGGCGG 1928
Db 3853 TGGCCGAGGCGAGTGCAGCGAGGCGGCGAGCGAGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 3912
QY 1929 CACCCCTAACTCTCATTCATTCCCTGGCTGCTGAGTTGCGAGTGGGAACCTGTCTATCACGC 1988
Db 3913 CACCCCTAACTCTCATTCATTCCCTGGCTGCTGAGTTGCGAGTGGGAACCTGTCTATCACGC 3972
QY 1989 AGTGTCTCAGGCGCTCGGCTCAGGTGGCACTGTGCCAGGTTCCAGGCTCAGGCGTGGGA 2048
Db 3973 AGTGTCTCAGGCGCTCGGCTCAGGTGGCACTGTGCCAGGTTCCAGGCTCAGGCGTGGGA 4032
QY 2049 GTTCCCTTGGCGCTCAGCAGTTTGCAGTGGGTAAAGGAGGCGGCGGCGGCGGCGGCGGCGG 2108
Db 4033 GTTCCCTTGGCGCTCAGCAGTTTGCAGTGGGTAAAGGAGGCGGCGGCGGCGGCGGCGGCGG 4092
QY 2109 ACCCAAAACCCCGGCTGTGCTGTTTTCCTTCTCGGCTACCTTGTAGTGTGGAGC 2168
Db 4093 ACCCAAAACCCCGGCTGTGCTGTTTTCCTTCTCGGCTACCTTGTAGTGTGGAGC 4152
QY 2169 ACTTGATACATCACAGCTCATACAAA 2195
Db 4153 ACTTGATACATCACAGCTCATACAAA 4179

RESULT 13
AR352679
LOCUS AR352679 1925 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 86 from patent US 6590075.
ACCESSION AR352679
VERSION AR352679.1 GI:33757937
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1925)
AUTHORS Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,
Bednarek,D.P., Endress,G.A., Yu,G.-L., Ni,J., Peng,P., Young,P.E.,
Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.-S., Florence,K.A.,
Olsen,H.S., Ebner,K., Brewer,L.A. and Shi,Y.
TITLE Secreted protein H0DAZ50
JOURNAL Patent: US 6590075-A 86 08-JUL-2003;
FEATURES Location/Qualifiers
source 1..1925
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN
Query Match 81.2%; Score 1788.8; DB 6; Length 1925;
Best Local Similarity 97.9%; Pred. No. 0;
Matches 1844; Conservative 1; Mismatches 4; Indels 34; Gaps 2;

QY 347 AGGAGCTGGCCGCTGCGACTGGGTTGGGCCCTGTG- CAGAGGAGCAGGCTTCTCTGAG 405
Db 6 AGGAGCTGGCCGCTGCGACTGGGTTGGGCCCTGTG- CAGAGGAGCAGGCTTCTCTGAG 65
QY 406 CAGAGGAGCAGGCTGGTGGCGGCGCTTTCAGGAGCGCCCTGCGAGCTGAGTGGAGACT 465
Db 66 CAGAGGAGCAGGCTGGTGGCGGCGCTTTCAGGAGCGCCCTGCGAGCTGAGTGGAGACT 125
QY 466 GCAGAGGATGAGATCCAGTGGTAGCTATTATGSCCACTGGTGGATCCGGGCAAT 525
```

Db 126 GCAGGAGGATGAGATCCAGTGGTAGCTATTATGCGCACTGGTGGTGGATCCGGGCAAT 185  
 Qy 526 GACTTCCTGTATGGGAGCTGGTGGCTCAAGAGCTGGGCTCTTGGATTGCGTCTC 585  
 Db 186 GACTTCCTGTATGGGAGCTGGTGGCTGAAGAGCTGGGCTCTTGGATTGCKTCTC 245  
 Qy 586 CTACATCACCGGGGCTCTGGGCTCCACTGGGCTCTGGCCAACTTTATGAGGACCCAGA 645  
 Db 246 CTACATCACCGGGGCTCTGGGCTCCACTGGGCTCTGGCCAACTTTATAGGACCCAGA 305  
 Qy 646 GTGGTCTCAGAAGGACTGGGAGGCTGGGCTCAAGTGGTGAAGAGCCAGGTTGAACAAGAA 705  
 Db 306 GTGGTCTCAGAAGGACTGGGAGGCTGGGCTCAAGTGGTGAAGAGCCAGGTTGAACAAGAA 365  
 Qy 706 CAAGCTGGGTGTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGG 765  
 Db 366 CAAGCTGGGTGTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGG 425  
 Qy 766 TGCCCGCTTGGGCTACCCAACTGTTTCCAACTGTTGGGCTTCAATCAACGAGGCGCT 825  
 Db 426 TGCCCGCTTGGGCTACCCAACTGTTTCCAACTGTTGGGCTTCAATCAACGAGGCGCT 485  
 Qy 826 GCTGATGATGAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 885  
 Db 486 GCTGATGATGAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 545  
 Qy 886 CCAGAACCTCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCG 945  
 Db 546 CCAGAACCTCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCG 605  
 Qy 946 TGAATTTGGGAGTGGTGGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGG 1005  
 Db 606 TGAATTTGGGAGTGGTGGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGG 665  
 Qy 1006 TTCTATCCCTCTGAGCTGTTGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTG 1065  
 Db 666 TTCTATCCCTCTGAGCTGTTGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTG 725  
 Qy 1066 TCCTGAGTCCCGCATCTGCTTCTAGAGGTATCTGGAGCACTGTATGAGCAACCT 1125  
 Db 726 TCCTGAGTCCCGCATCTGCTTCTAGAGGTATCTGGAGCACTGTATGAGCAACCT 785  
 Qy 1126 CCAGGACAGCTTATCTGGGCTCAGAGCCAGGCTGCTGGGACCGCTGGGTGAGGAA 1185  
 Db 786 CCAGGACAGCTTATCTGGGCTCAGAGCCAGGCTGCTGGGACCGCTGGGTGAGGAA 845  
 Qy 1186 CCAGGACAGCTTATCTGGGCTCAGAGCCAGGCTGCTGGGACCGCTGGGTGAGGAA 1245  
 Db 846 CCAGGACAGCTTATCTGGGCTCAGAGCCAGGCTGCTGGGACCGCTGGGTGAGGAA 905  
 Qy 1246 AGCCGGCAGATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 1305  
 Db 906 AGCCGGCAGATGAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 965  
 Qy 1306 CACACATATTTCTGGCTGGCTCCATTTCCAAAGACTACTTTGAGCATCTTCACTTT 1365  
 Db 966 CACACATATTTCTGGCTGGCTCCATTTCCAAAGACTACTTTGAGCATCTTCACTTT 1025  
 Qy 1366 CTCCATGAGAAAGTACACCTCTGGATGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1425  
 Db 1026 CTCCATGAGAAAGTACACCTCTGGATGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1085  
 Qy 1426 CCACCTGTGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1485  
 Db 1086 CCACCTGTGCTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGG 1145  
 Qy 1486 GCCACTCGGAGGTGGAGCTCATCTGCTCATTTGAGCTCAACCTCCAGGAGCTTTCCA 1545  
 Db 1146 GCCACTCGGAGGTGGAGCTCATCTGCTCATTTGAGCTCAACCTCCAGGAGCTTTCCA 1205  
 Qy 1546 GCAGTTGACCTCTGGGCGGTTCTGCCAGGAGGAGGATCCCTTCCACCCATCTC 1605  
 Db 1206 GCAGTTGACCTCTGGGCGGTTCTGCCAGGAGGAGGATCCCTTCCACCCATCTC 1265

Qy 1606 GCCCAGCCCCGAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCCGACCCCACTG 1665  
 Db 1266 GCCCAGCCCCGAGAGCAGCTCCAGCTCGGGAGTGCACACCTTCTCCGACCCCACTG 1325  
 Qy 1666 CCCCAGAGCCCTCGGGTGTGCACTTT----- 1693  
 Db 1326 CCCCAGAGCCCTCGGGTGTGCACTTT----- 1385  
 Qy 1694 -TCCTCTGGGTCGGGCGGACACCCGAGGAGCGGCGAGCTGGGAGGTGAACCTGTCTTC 1752  
 Db 1386 GGGCCCTTGGGTCGGGCGGACACCCGAGGAGCGGCGAGCTGGGAGGTGAACCTGTCTTC 1445  
 Qy 1753 ATCGGACTCTCCCTACCACTACAGAAAGTGCCTACAGCCAGGAGGAGCTGGACAAGCT 1812  
 Db 1446 ATCGGACTCTCCCTACCACTACAGAAAGTGCCTACAGCCAGGAGGAGCTGGACAAGCT 1505  
 Qy 1813 GCTGCACCTGACATACATACATATGCTGCAACACAGGAGCAGCTGCTGGAGGCTCTCG 1872  
 Db 1506 GCTGCACCTGACATACATACATATGCTGCAACACAGGAGCAGCTGCTGGAGGCTCTCG 1565  
 Qy 1873 CCAGGAGTGCAGCGGAGCGGCGAGCGCAGGCGCCCACTGATGCGCGGGCGCCCTGCCACC 1932  
 Db 1566 CCAGGAGTGCAGCGGAGCGGCGAGCGCAGGCGCCCACTGATGCGCGGGCGCCCTGCCACC 1625  
 Qy 1933 CCTAACTCTCATTCATTCCTGCTGCTGAGTTGAGGTGGGAACTGTCAACGCACTG 1992  
 Db 1626 CCTAACTCTCATTCATTCCTGCTGCTGAGTTGAGGTGGGAACTGTCAACGCACTG 1685  
 Qy 1993 CTTGAGAGCTCGGGCTCAGGTGCGACCTGCTCCAGGCTCCAGGCTGAGGCTGGGAGCTC 2052  
 Db 1686 CTTGAGAGCTCGGGCTCAGGTGCGACCTGCTCCAGGCTCCAGGCTGAGGCTGGGAGCTC 1745  
 Qy 2053 CTTGCGGCTCAGCAGATTTGAGTGGGTAAAGAGGCGCAAGCCCACTTTGTGTAAATCACCC 2112  
 Db 1746 CTTGCGGCTCAGCAGATTTGAGTGGGTAAAGAGGCGCAAGCCCACTTTGTGTAAATCACCC 1805  
 Qy 2113 AAAACCCCGGCTGCTGCTGCTTTTCCCTTCTGCGCTACCTTGTAGTAGTTGGAGCACTT 2172  
 Db 1806 AAAACCCCGGCTGCTGCTGCTTTTCCCTTCTGCGCTACCTTGTAGTAGTTGGAGCACTT 1865  
 Qy 2173 GATACATCACAGACTCATACAAA 2195  
 Db 1866 GATACATCACAGACTCATACAAA 1888

BD195624 1925 bp DNA linear PAT 17-JUL-2003  
 70 human secreted proteins.  
 DEFINITION  
 ACCESSION BD195624  
 VERSION BD195624.1 GI:33005394  
 KEYWORDS JP 200251990-A/85.  
 SOURCE unidentified  
 ORGANISM unidentified  
 1 (bases 1 to 1925)  
 Ruben, S.M., Rosen, C.A., Fischer, C.L., Soppet, D.R., Carter, K.C.,  
 Bednarek, D.P., Endress, G.A., Yu, G.L., N.J., Feng, P., Young, P.E.,  
 Greene, J.M., Ferrie, A.M., Duan, R., Hu, J.S., Florence, K.A.,  
 Olsen, H.S., Ebner, R., Brewer, L.A., Moore, P.A., Shi, Y.,  
 Lafleur, D.W., Li, Y., Zeng, Z. and Kyaw, H.  
 70 human secreted proteins  
 Patent: JP 200251990-A 85 02-JUL-2002;  
 HUMAN GENOME SCIENCES INC  
 OS Unidentified  
 PN JP 200251990-A/85  
 PD 02-JUL-2002  
 PF 06-MAR-1998 JP 1998538875  
 PR 07-MAR-1997 US 60/040162, 07-MAR-1997 US 60/040333 PR  
 07-MAR-1997 US 60/038621, 07-MAR-1997 US 60/040161 PR  
 07-MAR-1997 US 60/040626, 07-MAR-1997 US 60/040334 PR  
 07-MAR-1997 US 60/040336, 07-MAR-1997 US 60/040163 PR  
 RESULT 14  
 BD195624  
 LOCUS  
 DEFINITION  
 ACCESSION BD195624  
 VERSION BD195624.1 GI:33005394  
 KEYWORDS JP 200251990-A/85.  
 SOURCE unidentified  
 ORGANISM unidentified  
 1 (bases 1 to 1925)  
 Ruben, S.M., Rosen, C.A., Fischer, C.L., Soppet, D.R., Carter, K.C.,  
 Bednarek, D.P., Endress, G.A., Yu, G.L., N.J., Feng, P., Young, P.E.,  
 Greene, J.M., Ferrie, A.M., Duan, R., Hu, J.S., Florence, K.A.,  
 Olsen, H.S., Ebner, R., Brewer, L.A., Moore, P.A., Shi, Y.,  
 Lafleur, D.W., Li, Y., Zeng, Z. and Kyaw, H.  
 70 human secreted proteins  
 Patent: JP 200251990-A 85 02-JUL-2002;  
 HUMAN GENOME SCIENCES INC  
 OS Unidentified  
 PN JP 200251990-A/85  
 PD 02-JUL-2002  
 PF 06-MAR-1998 JP 1998538875  
 PR 07-MAR-1997 US 60/040162, 07-MAR-1997 US 60/040333 PR  
 07-MAR-1997 US 60/038621, 07-MAR-1997 US 60/040161 PR  
 07-MAR-1997 US 60/040626, 07-MAR-1997 US 60/040334 PR  
 07-MAR-1997 US 60/040336, 07-MAR-1997 US 60/040163 PR



QY 1426 CCACCTGTGCTGCTGGATGTTGGTACCTCATCAATACAGCTGCTGCTGCCCTCTCGCA 1485  
Db 1086 CCACCTGTGCTGCTGGATGTTGGTACCTCATCAATACAGCTGCTGCTGCCCTCTCGCA 1145  
QY 1486 GCCACTTCGGGACGTGGACCTCATCTGTTGATGGACTACAACCTCCACGAGCTTCCA 1545  
Db 1146 GCCACTTCGGGACGTGGACCTCATCTGTTGATGGACTACAACCTCCACGAGCTTCCA 1205  
QY 1546 GCAGTTGACGCTCCTGGGCGGTTCTGCCAGGAGCAGGAGATCCGTTCCACCCCACTC 1605  
Db 1206 GCAGTTGACGCTCCTGGGCGGTTCTGCCAGGAGCAGGAGATCCGTTCCACCCCACTC 1265  
QY 1606 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCCACTG 1665  
Db 1266 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGAGTGCCACACCTTCTCCGACCCCACTG 1325  
QY 1666 CCCCGAGCCCCCTCGGTTGCTGCACTTT----- 1693  
Db 1326 CCCCGAGCCCCCTCGGTTGCTGCACTTTCTCTGCTCAGCGACTCTTCCGGGAGTACTC 1385  
QY 1694 -TCCTCTGGGTCGGGCGGACACCGGAGGCGGACGCTGGGAGGTGAACCTGTCTTC 1752  
Db 1386 GGGCCCTCGGGTCCGGCGGACACCGGAGGCGGACGCTGGGAGGTGAACCTGTCTTC 1445  
QY 1753 ATCGGACTCTCCCTACCACTACAGAGGTGACCTTACAGCCAGGAGGACGTGGCAAGCT 1812  
Db 1446 ATCGGACTCTCCCTACCACTACAGAGGTGACCTTACAGCCAGGAGGACGTGGCAAGCT 1505  
QY 1813 GCTGACCTGACACATTAATGCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGCG 1872  
Db 1506 GCTGACCTGACACATTAATGCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGCG 1565  
QY 1873 CCAGGAGTCCAGCGGAGCGGACGCGAGCCGCTGATGGCGGGCCCTGCCACC 1932  
Db 1566 CCAGGAGTCCAGCGGAGCGGACGCGAGCCGCTGATGGCGGGCCCTGCCACC 1625  
QY 1933 CTTAACTCTCATTCCTCGGCTGCTGAGTTGAGGTGGGAACTGTCAACGACGTG 1992  
Db 1626 CTTAACTCTCATTCCTCGGCTGCTGAGTTGAGGTGGGAACTGTCAACGACGTG 1685  
QY 1993 CTTAGAGCTTCGGGCTCAGTGGGCACTGTGCTCCAGGGTCCAGGCTGGAGGCTGGAGCTC 2052  
Db 1686 CTTAGAGCTTCGGGCTCAGTGGGCACTGTGCTCCAGGGTCCAGGCTGGAGGCTGGAGCTC 1745  
QY 2053 CTTGCGGCTCAGCAGTTTGAGTGCGGTGAGGAGCCAGCCCAATTTGTGAATCACCC 2112  
Db 1746 CTTGCGGCTCAGCAGTTTGAGTGCGGTGAGGAGCCAGCCCAATTTGTGAATCACCC 1805  
QY 2113 AAAACCCCGGCTGTGCTGCTTTTCCCTTCTGCGCTACCTTGAGTGGAGCACTT 2172  
Db 1806 AAAACCCCGGCTGTGCTGCTTTTCCCTTCTGCGCTACCTTGAGTGGAGCACTT 1865  
QY 2173 GATACATCACAGACTCATACAAA 2195  
Db 1866 GATACATCACAGACTCATACAAA 1888

RESULT 15  
AR352614  
LOCUS 1926 bp DNA linear PAT 17-AUG-2003  
DEFINITION Sequence 21 from patent US 6590075.  
ACCESSION AR352614  
VERSION AR352614.1 GI:33757872  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 1926)  
AUTHORS Ruben,S.M., Rosen,C.A., Fischer,C.L., Soppet,D.R., Carter,K.C.,  
Bednarek,D.P., Endress,G.A., Yu,G.-L., Ni,J., Feng,P., Young,P.E.,  
Greene,J.M., Ferrie,A.M., Duan,R., Hu,J.-S., Florence,K.A.,  
Olsen,H.S., Emer,R., Brewer,L.A. and Shi,Y.  
TITLE Secreted protein HODA250

JOURNAL FEATURES

Patent: US 6590075-A 21 08-JUL-2003;  
Location/Qualifiers  
1. .1926  
/organism="unknown"  
/mol\_type="genomic DNA"

source

ORIGIN

Query Match 80.7%; Score 1777.8; DB 6; Length 1926;  
Best Local Similarity 97.9%; Pred. No. 0;  
Matches 1844; Conservative 1; Mismatches 4; Indels 35; Gaps 3;

QY 347 AGGAGCTGCGCGCTGCGACTGGGCTTCGGGCCCTGTG-CAGAGGAGCAGGCGCTTCCTGAG 405  
Db 6 AGGAGCTGCGCGCTGCGACTGGGCTTCGGGCCCTGTG-CAGAGGAGCAGGCGCTTCCTGAG 65  
QY 406 CAGGAGGAAGCAGGTGCTGGCGCGGCTTTCAGGAGCGGCCCTGTGAGTGGATGAGACCT 465  
Db 66 CAGGAGGAAGCAGGTGCTGGCGCGGCTTTCAGGAGCGGCCCTGTGAGTGGATGAGACCT 125  
QY 466 GCAGGAGGATGAGATCCAGTGGTAGCTATTATATGGCCACTGCTGGTGGGATCCGGGCAAT 525  
Db 126 GCAGGAGGATGAGATCCAGTGGTAGCTATTATATGGCCACTGCTGGTGGGATCCGGGCAAT 185  
QY 526 GACTTCCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGGCTCTTGGATTGCTCTC 585  
Db 186 GACTTCCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGGCTCTTGGATTGCTCTC 245  
QY 586 CTACATCACCGGGGCTTCGGGCTCCACTGCGGCTTCGCAACCTTTATAGGAGCCCAAGA 645  
Db 246 CTACATCACCGGGGCTTCGGGCTCCACTGCGGCTTCGCAACCTTTATAGGAGCCCAAGA 305  
QY 646 GTGCTCTCAGAAAGCACTGGCAGGCGCCACTGTAGTTGCTGAAGACCCAGGTGACCAAGAA 705  
Db 306 GTGCTCTCAGAAAGCACTGGCAGGCGCCACTGTAGTTGCTGAAGACCCAGGTGACCAAGAA 365  
QY 706 CAAGCTGGGCTGCTGGCGCCCGGAGCTGAGCGGTACCGGAGGAGCTGGCGGAGCG 765  
Db 366 CAAGCTGGGCTGCTGGCGCCCGGAGCTGAGCGGTACCGGAGGAGCTGGCGGAGCG 425  
QY 766 TGCCGCTTGGGCTACCCAAAGCTGTTTCAACAACTGTGGGCGCTCATCAAGAGGCGCT 825  
Db 426 TGCCGCTTGGGCTACCCAAAGCTGTTTCAACAACTGTGGGCGCTCATCAAGAGGCGCT 485  
QY 826 GCTGATGATGAGCCCATGATCAAGCTCTCAGATCAACGGGAGGCGCTGAGTCATGG 885  
Db 486 GCTGATGATGAGCCCATGATCAAGCTCTCAGATCAACGGGAGGCGCTGAGTCATGG 545  
QY 886 CCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGCTGACCACTTT 945  
Db 546 CCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGCTGACCACTTT 605  
QY 946 TGAATTTGGGAGTGGTGGAGTTCTCTCCCTACAGGTTCGGCTTCCCAAGTACGGGCG 1005  
Db 606 TGAATTTGGGAGTGGTGGAGTTCTCTCCCTACAGGTTCGGCTTCCCAAGTACGGGCG 665  
QY 1006 CTTCAATCCCTCTGAGCTCTTGGCTCCGAGTTCTTTATGGGCGAGCTGATCAAGAGGCT 1065  
Db 666 CTTCAATCCCTCTGAGCTCTTGGCTCCGAGTTCTTTATGGGCGAGCTGATCAAGAGGCT 725  
QY 1066 TCCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGACGCAACCT 1125  
Db 726 TCCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGACGCAACCT 785  
QY 1126 CCAGGACAGCTTTATATCTGGGCTCTCAGAGCCAGCAGTTCCTGGGACCGCTGGGTGAGAA 1185  
Db 786 CCAGGACAGCTTTATATCTGGGCTCTCAGAGCCAGCAGTTCCTGGGACCGCTGGGTGAGAA 845  
QY 1186 CCAGGCAACCTTCGACAGGAGCAGGTCCCGCTTCTGAGATAGAGAACCCACCTTCAAC 1245  
Db 846 CCAGGCAACCTTCGACAGGAGCAGGTCCCGCTTCTGAGATAGAGAACCCACCTTCAAC 905  
QY 1246 AGCGGCGAGATAGCTGAGTTTTCACCGATCTTCTGACGTGGCGTCCACTGCGCCAGGC 1305

Db 906 AGCCGGCAGAAATAGCTGAGTTTTTCCACCGATCTTCTGACGTGGCGTCCACTGGCCAGGC 965  
QY 1306 CACACATAATTTCTCGTGGCCCTCCATTTCCACAAAGACTACTTTTCAGATCCTCACATT 1365  
Db 966 CACACATAATTTCTCGTGGCCCTCCATTTCCACAAAGACTACTTTTCAGATCCTCACATT 1025  
QY 1366 CTCACATGGAAGCTACCACTCTGGATGGGTCCCAACCAAGCTGACACCCCTCGGAGCC 1425  
Db 1026 CTCACATGGAAGCTACCACTCTGGATGGGTCCCAACCAAGCTGACACCCCTCGGAGCC 1085  
QY 1426 CCACCTGTGCCTGCTGGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCCTGCA 1485  
Db 1086 CCACCTGTGCCTGCTGGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCCTGCA 1145  
QY 1486 GCCCACTCGGGAGCTGGACCTCATCTGTCTATTGGACTACAACCTCCACGGAGCCTTCCA 1545  
Db 1146 GCCCACTCGGGAGCTGGACCTCATCTGTCTATTGGACTACAACCTCCACGGAGCCTTCCA 1205  
QY 1546 GCAGTTGCACTCTCTGGGCGGTTCTGCCAGGACAGGGGATCCCGTTCCCAACCATCTC 1605  
Db 1206 GCAGTTGCACTCTCTGGGCGGTTCTGCCAGGACAGGGGATCCCGTTCCCAACCATCTC 1265  
QY 1606 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGAGTGCCACACTTCTCCAGCCCCACCTG 1665  
Db 1266 GCCCAGCCCCGAGAGCAGCTCCAGCCTCGGAGTGCCACACTTCTCCAGCCCCACCTG 1325  
QY 1666 CCCCAGGCCCTCGGGTCTGCACCTT----- 1693  
Db 1326 CCCCAGGCCCTCGGGTCTGCACCTTCTCTGTGCTCAGGACTCCTTCCGGGAGTACTC 1385  
QY 1694 -TCCCTCTGGGTCGCGCGGACACCCGAGGACGCGCAGCTGGGGAGGTGAACCTGTCTTC 1752  
Db 1386 GGCCCTCTGGGTCGCGCGGACACCCGAGGACGCGCAGCTGGGGAGGTGAACCTGTCTTC 1445  
QY 1753 ATCGGACTCTCCCTACCACTACACGAGGTGACCTACAGCCAGGAGGAGCTGGACAAGCT 1812  
Db 1446 ATCGGACTCTCCCTACCACTACACGAGGTGACCTACAGCCAGGAGGAGCTGGACAAGCT 1505  
QY 1813 GCTGCACTTGACACATTAATGTCTGCAACCAACAGGAGCAGCTGCTGGAGGCTCTGCG 1872  
Db 1506 GCTGCACTTGACACATTAATGTCTGCAACCAACAGGAGCAGCTGCTGGAGGCTCTGCG 1565  
QY 1873 CCAGCAGTGACGCGGAGCGCAGCGAGGCCCACTGATGGCCGGGGCCCCCTGCCACC 1932  
Db 1566 CCAGCAGTGACGCGGAGCGCAGCGAGGCCCACTGATGGCCGGGGCCCCCTGCCACC 1625  
QY 1933 CCTAATCTCATTTCAATCCCTGGCTGCTGAGTTGAGGTGGGAACTGTCAACGCACTG 1992  
Db 1626 CCTAATCTCATTTCAATCCCTGGCTGCTGAGTTGAGGTGGGAACTGTCAACGCACTG 1685  
QY 1993 CTT-CAGAGCCTCGGGCTCAGGTGGCACTGTCCAGGGTCCAGGCTGAGGGCTGGAGCT 2051  
Db 1686 CTTNCAGAGCCTCGGGCTCAGGTGGCACTGTCCAGGGTCCAGGCTGAGGGCTGGAGCT 1745  
QY 2052 CCCTTGGCCCTCAGCAGTTTGGAGTGGGGTAAGGAGGCCAAGCCCATTTGTATATCACC 2111  
Db 1746 CCCTTGGCCCTCAGCAGTTTGGAGTGGGGTAAGGAGGCCAAGCCCATTTGTATATCACC 1805  
QY 2112 CAAAACCCCGGCTGTGCTGTTTCCCTTCTGCGCTACCTGAGTAGTTGGAGCACT 2171  
Db 1806 CAAAACCCCGGCTGTGCTGTTTCCCTTCTGCGCTACCTGAGTAGTTGGAGCACT 1865  
QY 2172 TGATACATCAGAGCTCATACAAA 2195  
Db 1866 TGATACATCAGAGCTCATACAAA 1889

Search completed: October 7, 2004, 16:44:04  
Job time : 8963.72 secs

Page Blank (uspio)

Result No.	Score	Query Match	Length	DB	ID	Description	
1	1816.8	82.4	3085	3	US-08-827-208-2	Sequence 2, Appli	
2	1816.8	82.4	3085	3	US-08-827-208-4	Sequence 4, Appli	
3	1816.8	82.4	3085	3	US-09-500-358-2	Sequence 2, Appli	
4	1816.8	82.4	3085	3	US-09-500-358-4	Sequence 4, Appli	
5	1816.8	82.4	3085	3	US-09-498-809-2	Sequence 2, Appli	
6	1816.8	82.4	3085	3	US-09-498-809-4	Sequence 4, Appli	
7	1806.2	82.0	2699	3	US-09-460-145-3	Sequence 3, Appli	
8	1806.2	82.0	2699	4	US-09-895-547-3	Sequence 3, Appli	
9	1806.2	82.0	4183	3	US-09-460-145-1	Sequence 1, Appli	
10	1806.2	82.0	4183	4	US-09-895-547-1	Sequence 1, Appli	
11	1788.8	81.2	1925	4	US-09-148-545-86	Sequence 1, Appli	
12	1777.8	80.7	1926	4	US-09-148-545-21	Sequence 86, Appli	
13	1676.6	76.1	1818	4	US-09-148-545-21	Sequence 21, Appli	
14	1408.6	63.9	8517	3	US-08-827-208-1	Sequence 87, Appli	
15	1408.6	63.9	8517	3	US-09-500-358-1	Sequence 1, Appli	
16	1408.6	63.9	8517	3	US-09-498-809-1	Sequence 1, Appli	
17	128.8	5.8	74962	4	US-09-685-853A-3	Sequence 1, Appli	
18	127.6	5.8	4668	3	US-09-045-301-1	Sequence 3, Appli	
19	127.6	5.8	81001	4	US-09-750-580-1	Sequence 1, Appli	
20	126.2	5.7	1001	4	US-09-641-638-629	Sequence 1, Appli	
21	126.2	5.7	1001	4	US-09-641-638-630	Sequence 629, App	
22	126.2	5.7	20674	4	US-09-641-638-651	Sequence 630, App	
23	125.8	5.7	2932	4	US-09-016-434-1419	Sequence 651, App	
24	125.6	5.7	1656	4	US-08-324-465-2	Sequence 1419, App	
25	125.6	5.7	1856	2	US-08-465-981-2	Sequence 2, Appli	
26	125.6	5.7	1856	5	PT-0893-11915-2	Sequence 2, Appli	
27	125.6	5.7	1725	1	US-08-324-465-5	Sequence 5, Appli	





Query Match	82.4%	Score 1816.8	DB 3	Length 3085
Best Local Similarity	78.9%	Pred. No. 0		
Matches 1496	Conservative 365	Mismatches 2	Indels 33	Gaps 1
QY	342	GACTGAGGAGCTGGCCGTCGACTGGGCTTCGGGCCCTTCGACAGAGCAGCGCTTCC	401	
Db	1186	GACUGAGGAGCUGGCCUGCGACUGGGCUUGCGGCCUUGGACAGAGCAGCGCTUCC	1245	
QY	402	TGAGCAGGAGGAAGCAGGTGGTGGCCGCGCTTGTAGGCGAGGCGCTTCAGCTGGATGGAG	461	
Db	1246	UGAGCAGGAGGAAGCAGGUGUGGCCGCGCCUUGAGGCGAGGCCUGCACGUGGAG	1305	
QY	462	ACCTGCAGGAGGATGATCCCACTGGTAGCTATTATGGCCACTGTGTGGATCCGGG	521	
Db	1306	ACCUGCAGGAGGAUGAGAUCCGAGUGGUAUCUAUUGGCCACUUGGUGUGGGAUCCGGG	1365	
QY	522	CAATGACTTCCCTGTATGGGCAGCTGGCTGGCCCTGAAGGAGCTGGGCGCTCTTCGATTGCG	581	
Db	1366	CAUAGCAUUCUUGUAUUGGACGACUGGCGGCCUGAAGGAGCUGGGCCUUCUGGAUUGCG	1425	
QY	582	TCCTCTACATCACGGGGGCTCGGGCTCGACCTGGGCGCTTGGCCAACTTTATGAGGACC	641	
Db	1426	UCUCCUAUAUCACGGGGCCUUGGGGCUCCACCUUGGGCCUUGGGCAACCUUAUAGGAGACC	1485	
QY	642	CAGAGTGGTCTCAGAAGGACCTGGCAGGGGCCCACTGAGTTGCTGAAGACCCAGGTGACCA	701	
Db	1486	CAGAGUGUUCUAGAAGGACUUGGCGAGGGGCCACUGAGUUGCUGAAGACCAGGUGACCA	1545	
QY	702	AGAACAGCTGGGTGTGGGCCCCAGCCAGCTGCAGCGGTACCGGCAAGGAGCTGGCCG	761	
Db	1546	AGAACAGCTGGGTGTGGGCCCCAGCCAGCTGCAGCGGTACCGGCAAGGAGCTGGCCG	1605	

```

QY 1809 AGCTGCTGCACCTGACACATTACATCTGTGCAACACACAGGAGCAGCTGCTGAGGCTC 1868
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2686 AGUGGUGGACCUUGACACAUUACAUUUGUGCAACACACAGGAGCAGCUGUGAGGCUU 2745
QY 1869 TGGCCACAGGAGTGACGAGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGG 1928
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2746 UGGCCACAGGAGUGACGAGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGG 2805
QY 1929 CACCCCTAACCTCTCATTCATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1988
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2806 CACCCCTAACCTCTCATTCATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2865
QY 1989 AGTCTTCAGAGCTCGGCTCAGTGGCAGTGTCCAGGCTCCAGGCTGAGGCTGCGGA 2048
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2866 AGUGGUGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGG 2925
QY 2049 GCTCCCTTGGGCTCAGCAGTTCAGTGGGTAAGGAGGCGGAGGCGGAGGCGGAGGCG 2108
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2926 GCUCCUUGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGG 2985
QY 2109 ACCCAAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2168
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
2986 ACCCAAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3045
QY 2169 ACTTGATACATCAGACTCATACAAAAA 2204
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
3046 ACUGAUAUCACAGACUCUAACAAAAA 3081

```

```

RESULT 3
US-09-500-358-2
; Sequence 2, Application US/09500358
; Patent No. 6197569
; GENERAL INFORMATION:
; APPLICANT: Chiou, Xue-Chiou C.
; APPLICANT: Kramer, Ruth M.
; APPLICANT: Pickard, Richard T.
; APPLICANT: Sharp, John D.
; APPLICANT: Striffler, Beth A.
; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Eli Lilly and Company
; STREET: Lilly Corporate Center
; CITY: Indianapolis
; STATE: Indiana
; COUNTRY: United States of America
; ZIP: 46285
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/500,358
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/827,208
; FILING DATE: 28-MAR-1997
; APPLICATION NUMBER: US 60/014,608
; FILING DATE: 29-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/041,264
; FILING DATE: 19-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaylo, Paul J.
; REGISTRATION NUMBER: 36,808
; REFERENCE/DOCKET NUMBER: X-10610
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (317) 276-0756
; TELEFAX: (317) 276-3861

```

```

; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 3085 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 48..2786
US-09-500-358-2

Query Match      82.4%; Score 1816.8; DB 3; Length 3085;
Best Local Similarity 98.2%; Pred. No. 0;
Matches 1861; Conservative 0; Mismatches 2; Indels 33; Gaps 1;

QY 342 GACTGAGGAGCTGGCGTGGAGCTGGGCTTCGGGCTTCGAGAGGAGGAGGAGGAGGAGG 401
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1186 GACTGAGGAGCTGGCGTGGAGCTGGGCTTCGGGCTTCGAGAGGAGGAGGAGGAGGAGG 1245
QY 402 TGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 461
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1246 TGAGCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1305
QY 462 ACCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 521
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1306 ACCTGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1365
QY 522 CAATGACTTCCTGTATGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 581
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1366 CAATGACTTCCTGTATGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1425
QY 582 TCTCCTCATCATCACCGGGGCTCGGCTCCACTGGGCTCCACTGGGCTCCACTGGGCTCC 641
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1426 TCTCCTCATCATCACCGGGGCTCGGCTCCACTGGGCTCCACTGGGCTCCACTGGGCTCC 1485
QY 642 CAGAGTGTCTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 701
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1486 CAGAGTGTCTCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1545
QY 702 AGAACAAGCTGGTGTCTGGGCTCCAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG 761
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1546 AGAACAAGCTGGTGTCTGGGCTCCAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG 1605
QY 762 AGCGTGGCGGCTTGGGCTACCCAAAGCTGCTTCCAAAGCTGCTTCCAAAGCTGCTTCC 821
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1606 AGCGTGGCGGCTTGGGCTACCCAAAGCTGCTTCCAAAGCTGCTTCCAAAGCTGCTTCC 1665
QY 822 CGCTGCTGATGATGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 881
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1665 CGCTGCTGATGATGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1725
QY 882 ATGGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 941
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1726 ATGGCCAGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1785
QY 942 CTTTGTGAATTTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1001
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1786 CTTTGTGAATTTGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1845
QY 1002 GGGGCTTCATCCGCTGAGCTGCTTGGCTCCGAGTTCCTTATGGGAGGAGGAGGAGGAGG 1061
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1846 GGGGCTTCATCCGCTGAGCTGCTTGGCTCCGAGTTCCTTATGGGAGGAGGAGGAGGAGG 1905
QY 1062 GGGCTTCCTGAGTCCGCTGAGCTGCTTGGCTCCGAGTTCCTTATGGGAGGAGGAGGAGG 1121
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1906 GGGCTTCCTGAGTCCGCTGAGCTGCTTGGCTCCGAGTTCCTTATGGGAGGAGGAGGAGG 1965
QY 1122 ACCTCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1181
Db |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1966 ACCTCCAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 2025
QY 1182 GGAACACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 1241

```





```

/ FILING DATE: 19-MAR-1997
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Gaylo, Paul J.
/ REGISTRATION NUMBER: 36,8
/ REFERENCE/DOCKET NUMBER:
/ TELECOMMUNICATION INFORMATION
/ TELEPHONE: (317) 276-0756
/ TELEFAX: (317) 276-3861
/ INFORMATION FOR SEQ ID NO: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 3085 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cdna
/ FEATURE:
/ NAME/KEY: CDS
/ LOCATION: 48..2786
/ US-09-498-809-2

```

Query Match	82.4%	Score 1816.8	DB 3	Length 3085
Best Local Similarity	98.2%	Pred. No. 0		
Matches 1861	Conservative 0	Mismatches 2	Indels 33	Gaps 1
QY	342	GACTGAGGGAGCTGGCCGCTGGCACTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCCTTCC	401	
Db	1186	GACTGAGGGAGCTGGCCGCTGGCACTGGGCTTCGGGCCCTGTGCAGAGGACGAGCCCTTCC	1245	
QY	402	TGAGCAGAGGAAAGCAGGTGGTGGCCGCGCCCTTGAGGCGAGGCCCTGCAGCTGGATGGAG	461	
Db	1246	TGAGCAGAGGAAAGCAGGTGGTGGCCGCGCCCTTGAGGCGAGGCCCTGCAGCTGGATGGAG	1305	
QY	462	ACCTGCAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACTGTGGTGGGATCCGGG	521	
Db	1306	ACCTGCAGGAGGATGAGATCCCACTGGTAGCTATTATGGCCACTGTGGTGGGATCCGGG	1365	
QY	522	CAATGACTTCCCTGTATGGCAGCTGGCTGGCCCTGAAGGAGCTGGGCCCTCTTCGATTCGG	581	
Db	1366	CAATGACTTCCCTGTATGGCAGCTGGCTGGCCCTGAAGGAGCTGGGCCCTCTTCGATTCGG	1425	
QY	582	TCTCCTACATCACCGGGGCCCTCGGGCTCACCTGGGCCCTTGGCCAACTTTATGAGGACC	641	
Db	1426	TCTCCTACATCACCGGGGCCCTCGGGCTCACCTGGGCCCTTGGCCAACTTTATGAGGACC	1485	
QY	642	CAGAGTGGTCTCAGAGGACCTGGCAGGGCCCACTGAGTTGCTGAAGACCGAGGTGACCA	701	
Db	1486	CAGAGTGGTCTCAGAGGACCTGGCAGGGCCCACTGAGTTGCTGAAGACCGAGGTGACCA	1545	
QY	702	AGAACAAAGCTGGGTGTGCTGGCCCCACGCCAGCTGCAGCGGTATCCGCGAGGAGCTGGCCG	761	
Db	1546	AGAACAAAGCTGGGTGTGCTGGCCCCACGCCAGCTGCAGCGGTATCCGCGAGGAGCTGGCCG	1605	
QY	762	AGGTCGCCGCTGGGCTACCCAAAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG	821	
Db	1606	AGGTCGCCGCTGGGCTACCCAAAGCTGCTTCAACAACTGTGGGCCCTCATCAACGAGG	1665	
QY	822	CGCTGTGATGATGAGCCCAATGATCAAGCTCTCAGATCAACGGGAGGCCCTGAGTC	881	
Db	1666	CGCTGTGATGATGAGCCCAATGATCAAGCTCTCAGATCAACGGGAGGCCCTGAGTC	1725	
QY	882	ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGCGAGAGCCTGACCA	941	
Db	1726	ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGCGAGAGCCTGACCA	1785	
QY	942	CTTTTGAAATTGGGGAGTGGTGGAGTTCTCTCCCTACCAGTCCGCTTCCCCAGTAGC	1001	
Db	1786	CTTTTGAAATTGGGGAGTGGTGGAGTTCTCTCCCTACCAGTCCGCTTCCCCAGTAGC	1845	
QY	1002	GGGCCCTTATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA	1061	
Db	1846	GGGCCCTTATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA	1905	
QY	1062	GGCTTCCTGAGTCCCGCATCTCGTCTCTTAAAGGATATCGGAGCAACCTGTATGACGCCA	1121	







Db 1589 ACCTCAGGACACCTTATCTGGGCTCAGAGCCAGCCAGTTCTGGGACCGCTGGTCA 1648  
QY 1182 GGAACACGCGCAACCTGGACAAGAGAGAGTCCCTTCTGAAGATAGAAGAACCCCT 1241  
Db 1649 GGAACACGCGCAACCTGGACAAGAGAGAGTCCCTTCTGAAGATAGAAGAACCCCT 1708  
QY 1242 CAACAGCGCGAGATAGCTGAGTTTTCACCGATCTTTCAGTGGCGTCCACTGGGCC 1301  
Db 1709 CAACAGCGCGAGATAGCTGAGTTTTCACCGATCTTTCAGTGGCGTCCACTGGGCC 1768  
QY 1302 AGGCAACACATATTTCTCGGTGGCTCCATTTCCAAAGACTACTTTTCAGCATCTC 1361  
Db 1769 AGGCAACACATATTTCTCGGTGGCTCCATTTCCAAAGACTACTTTTCAGCATCTC 1828  
QY 1362 ACTTCTCCACATGAAGACTACACTCTGGANGGGTCCCAACAGCTGACACCCCTGG 1421  
Db 1829 ACTTCTCCACATGAAGACTACACTCTGGANGGGTCCCAACAGCTGACACCCCTGG 1888  
QY 1422 AGCCGACCTGTGCTGTGATGTTGGTACCTCATCATACAGCTGCTGCGCCCTCC 1481  
Db 1889 AGCCGACCTGTGCTGTGATGTTGGTACCTCATCATACAGCTGCTGCGCCCTCC 1948  
QY 1482 TGACGACCACTCGGGAAGTGAACCTCATCTGTCAATTTGGAACCACTCCACGAGCCT 1541  
Db 1949 TGACGACCACTCGGGAAGTGAACCTCATCTGTCAATTTGGAACCACTCCACGAGCCT 2008  
QY 1542 TCCAGAGTTCAGCTCTCGGCGGTTCTGCCAGGAGCAGGGATCCCTTCCACCCA 1601  
Db 2009 TCCAGAGTTCAGCTCTCGGCGGTTCTGCCAGGAGCAGGGATCCCTTCCACCCA 2068  
QY 1602 TCTGCGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1661  
Db 2069 TCTGCGCCAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2128  
QY 1662 CTGCGCCGAGCCCTCGGTGTGTGCACTTT----- 1693  
Db 2129 CTGCGCCGAGCCCTCGGTGTGTGCACTTTCTCTGTGTGCTCAGGACTCTTCCGGAGT 2188  
QY 1694 -----TCTGTGGGTTCGGGGACACCGAGAGCGGAGCTGGGAGTGAACCTGT 1748  
Db 2189 ACTCGGCCCTTGGGTTCGGGGACACCGAGAGCGGAGCTGGGAGTGAACCTGT 2248  
QY 1749 CTTCATCGGACTCTCCCTACCACTACAGAGTGAACCTACAGCAGAGAGAGCTGGACA 1808  
Db 2249 CTTCATCGGACTCTCCCTACCACTACAGAGTGAACCTACAGCAGAGAGAGCTGGACA 2308  
QY 1809 AGCTGCTGCACCTGACATTAACAATGTGTGCAACAACAGAGAGAGCTGTGGAGGCTC 1868  
Db 2309 AGCTGCTGCACCTGACATTAACAATGTGTGCAACAACAGAGAGAGCTGTGGAGGCTC 2368  
QY 1869 TGGCCAGGAGCTGAGAGAGCGGAGCAGCAGGCGCCACTGATGGCGGGGCGCCCTGC 1928  
Db 2369 TGGCCAGGAGCTGAGAGAGCGGAGCAGCAGGCGCCACTGATGGCGGGGCGCCCTGC 2428  
QY 1929 CACCCCTAATCTCATTCATTCCTCGCTGTGAGTTGAGTGGGAACTGTATCACGC 1988  
Db 2429 CACCCCTAATCTCATTCATTCCTCGCTGTGAGTTGAGTGGGAACTGTATCACGC 2488  
QY 1989 AGTGTCTCAGAGCTCGGCTCAGGTGGCACTGTGCCAGGGTCCAGGCTGAGGGCTGGGA 2048  
Db 2489 AGTGTCTCAGAGCTCGGCTCAGGTGGCACTGTGCCAGGGTCCAGGCTGAGGGCTGGGA 2548  
QY 2049 GCTCCCTTGGCTCAGAGTTTGCAGTGGGTAAAGAGGCCAAGCCCAATTTGTGAATC 2108  
Db 2549 GCTCCCTTGGCTCAGAGTTTGCAGTGGGTAAAGAGGCCAAGCCCAATTTGTGAATC 2608  
QY 2109 ACCCAAAACCCCGGCTGTGCTGCTTTTCTGCTTCTGCGCTACCTTGTAGTAGTGGAGC 2168  
Db 2609 ACCCAAAACCCCGGCTGTGCTGCTTTTCTGCTTCTGCGCTACCTTGTAGTAGTGGAGC 2668  
QY 2169 ACTTGATACATCAGACTCATCAAA 2195

Db 2669 ACTTGATACATCAGACTCATCAAA 2695  
RESULT 8  
US-09-895-547-3  
; Sequence 3, Application US/09895547  
; Patent No. 6482625  
; GENERAL INFORMATION:  
; APPLICANT: Križ, Ron  
; Song, Chuanzheng  
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute, Inc.  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/895,547  
; FILING DATE: 29-Jun-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/460,145  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brown, Scott A.  
; REGISTRATION NUMBER: 32,724  
; REFERENCE/DOCKET NUMBER: G15289  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 498-8224  
; TELEFAX: (617) 876-5851  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 2699 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
US-09-895-547-3  
Query Match 82.0%; Score 1806.2; DB 4; Length 2699;  
Best Local Similarity 98.1%; Pred. No. 0;  
Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;  
QY 342 GACTCAGGAGCTGGCGCTTGCAGCTGGGCTTCGGGCCCTGTGCAGAGGAGGAGGCTTCC 401  
Db 809 GACTCAGGAGCTGGCGCTTGCAGCTGGGCTTCGGGCCCTGTGCAGAGGAGGAGGCTTCC 868  
QY 402 TCAGCAGGAGGAAGCAGGTGGTGGCGGCGCTTCAGGAGCCCTTCAGCTGGATGGAG 461  
Db 869 TCAGCAGGAGGAAGCAGGTGGTGGCGGCGCTTCAGGAGCCCTTCAGCTGGATGGAG 928  
QY 462 ACTCTCAGGAGATCAGATCCAGTGTAGTATTATGCGCACTGGTGGTGGATCCGGG 521  
Db 929 ACTCTCAGGAGATCAGATCCAGTGTAGTATTATGCGCACTGGTGGTGGATCCGGG 988  
QY 522 CAATGACTTCCCTGTATGGGAGCTGGTGGCTGAAGAGCTGGGCTCTTGGATGGG 581  
Db 989 CAATGACTTCCCTGTATGGGAGCTGGTGGCTGAAGAGCTGGGCTCTTGGATGGG 1048  
QY 582 TCTCTTACATCACCGGGGCTCGGCTCCACCTGGGCTTGGCAACCTTTATGAGACC 641  
Db 1049 TCTCTTACATCACCGGGGCTCGGCTCCACCTGGGCTTGGCAACCTTTATGAGACC 1108  
QY 642 CAGAGTGGTCTCAGAGGAGCCCTGGCAGGGGCCCACTGAGTTGCTGAAGACCCAGGTGACCA 701



1109 CAGAGTGGTCTCAGAGGACCTGGCAGGGCCCACTGAGTTGCTCAAGACCCAGGTGACCA 1168  
702 AGAACAGCTGGGTGTGCTGGCCGCCAGCAGCTGCAGCGGTACCCGCGAGGAGCTGGCCG 761  
1169 AGAACAGCTGGGTGTGCTGGCCGCCAGCAGCTGCAGCGGTACCCGCGAGGAGCTGGCCG 1228  
762 AGGTGCGCCCTGGGCTACCCAGGTGCTTACCAACCTGTGGGCCCTCATCAACGAGG 821  
1229 AGGTGCGCCCTGGGCTACCCAGGTGCTTACCAACCTGTGGGCCCTCATCAACGAGG 1288  
822 CGTGTGCTGATGAGCCCGATGATCAAGCTCTCAGATCAAGCGGAGGCGCTGAGTC 881  
1289 CGTGTGCTGATGAGCCCGATGATCAAGCTCTCAGATCAAGCGGAGGCGCTGAGTC 1348  
882 ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGCGAGGCTGACCA 941  
1349 ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGCGAGGCTGACCA 1408  
942 CTTTGGAAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTTCGGCTTCCCAAGTACG 1001  
1409 CTTTGGAAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTTCGGCTTCCCAAGTACG 1468  
1002 GGCCCTTCTATCCCTCTGAGCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA 1061  
1469 GGCCCTTCTATCCCTCTGAGCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA 1528  
1062 GGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGACGCCA 1121  
1529 GGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGGAGCAACCTGTATGACGCCA 1588  
1122 ACTTCAGAGACCTTATCTGGGCTCAGAGCCAGCAGTTCTGGGACCGCTGGGTCA 1181  
1589 ACTTCAGAGACCTTATCTGGGCTCAGAGCCAGCAGTTCTGGGACCGCTGGGTCA 1648  
1182 GGAACAGCCCACTGGACAGGAGCAGTCCCTCTTGAAGATAGAAAGAACCACTT 1241  
1649 GGAACAGCCCACTGGACAGGAGCAGTCCCTCTTGAAGATAGAAAGAACCACTT 1708  
1242 CAACAGCCGCGCAAGATAGTGGAGTTTTCACCGATCTTCTGACGTGGCGTCCACTGGGCC 1301  
1709 CAACAGCCGCGCAAGATAGTGGAGTTTTCACCGATCTTCTGACGTGGCGTCCACTGGGCC 1768  
1302 AGGCCACACATAATTTCCCTGGCTGCTCCATTTCCACAAAGCTACTTTTCAAGCATCTTC 1361  
1769 AGGCCACACATAATTTCCCTGGCTGCTCCATTTCCACAAAGCTACTTTTCAAGCATCTTC 1828  
1362 ACTTCTCAGATGGAAGCTACCTCTGGATGGCTCCCAACAGCTGACACCCCTGG 1421  
1829 ACTTCTCAGATGGAAGCTACCTCTGGATGGCTCCCAACAGCTGACACCCCTGG 1888  
1422 AGCCCACTGTGCTGCTGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCC 1481  
1889 AGCCCACTGTGCTGCTGATGTTGGCTACCTCATCAATACAGCTGCTGCCCTCC 1948  
1482 TGCAGCCACTCGGAGCTGAGCTATCTGTGATGAGCTTACAACTTCCACGAGGCT 1541  
1949 TGCAGCCACTCGGAGCTGAGCTATCTGTGATGAGCTTACAACTTCCACGAGGCT 2008  
1542 TCCAGCAGTTCAGCTCTGGCGGCTTCTGCGAGGAGCAGGGATCCGTTCCACCCCA 1601  
2009 TCCAGCAGTTCAGCTCTGGCGGCTTCTGCGAGGAGCAGGGATCCGTTCCACCCCA 2068  
1602 TCTCGCCAGCCCGGAGAGCAGCTTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 1661  
2069 TCTCGCCAGCCCGGAGAGCAGCTTCCAGCTCGGAGTGCACACCTTCTCCGACCCCA 2128  
1662 CTTGCCCGGAGCCCTCGGTGTGCACTTT----- 1693  
2129 CTTGCCCGGAGCCCTCGGTGTGCACTTT----- 2188  
1694 -----TCTCTGGGTCCGGCGGACCCGAGGAGCGGAGCTGGGAGGTGAACCTGT 1748

2189 ACTCGGCCCTGGGTCCGGCGGACACCCAGAGGCGGCGAGCTGGGGAGGTGAACCTGT 2248  
1749 CTTTATCGGACTCTCCCTACCACTACAGAAAGTGAACCTACAGCCAGGAGACGTGGACA 1808  
2249 CTTTATCGGACTCTCCCTACCACTACAGAAAGTGAACCTACAGCCAGGAGACGTGGACA 2308  
1809 AGTGTGTGCACTTGCACACATTAATGTCTGCAACACAGGAGGAGCAGCTGCTGGAGGCTC 1868  
2309 AGTGTGTGCACTTGCACACATTAATGTCTGCAACACAGGAGGAGCAGCTGCTGGAGGCTC 2368  
1869 TGGCCAGGAGCTGCAAGCGGAGCGGCGAGCGAGGCGCCCACTCATGGCCGGGCCCTGTC 1928  
2369 TGGCCAGGAGCTGCAAGCGGAGCGGCGAGCGAGGCGCCCACTCATGGCCGGGCCCTGTC 2428  
1929 CACCCCTAATCTCATATTCCTGCTGCTGAGTTGAGTTGGAACCTGTATCACGC 1988  
2429 CACCCCTAATCTCATATTCCTGCTGCTGAGTTGAGTTGGAACCTGTATCACGC 2488  
1989 AGTGTGTGCAAGCTCGGCTCAGGCTGAGGCTGAGTTGAGTTGGAACCTGTATCACGC 2048  
2489 AGTGTGTGCAAGCTCGGCTCAGGCTGAGGCTGAGTTGAGTTGGAACCTGTATCACGC 2548  
2049 GCTCCCTTCAGGCTCAGCAGTTTTCAGTGGGCTAAGGAGGCGCAAGCCCATTTGTGTAATC 2108  
2549 GCTCCCTTCAGGCTCAGCAGTTTTCAGTGGGCTAAGGAGGCGCAAGCCCATTTGTGTAATC 2608  
2109 ACCCAAAACCCCGGCTGCTGCTGCTTTCCTTCTGCTGCTACCTTGAGTTGAGGCT 2168  
2609 ACCCAAAACCCCGGCTGCTGCTGCTTTCCTTCTGCTGCTACCTTGAGTTGAGGCT 2668  
2169 ACTTGATACATCACAGCTCATACAA 2195  
2669 ACTTGATACATCACAGCTCATACAA 2695

## RESULT 9

US-09-460-145-1  
; Sequence 1, Application US/09460145  
; Patent No. 6287838  
; GENERAL INFORMATION:  
; APPLICANT: Kriz, Ron  
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute, Inc.  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/788,975  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brown, Scott A.  
; REGISTRATION NUMBER: 32,724  
; REFERENCE/DOCKET NUMBER: G15289  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 498-8224  
; TELEFAX: (617) 876-5851  
; INFORMATION FOR SEQ ID NO: 1:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 4183 base pairs

```

; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-09-460-145-1

```

Query Match 82.0%; Score 1806.2; DB 3; Length 4183;  
Best Local Similarity 98.1%; Pred. No. 0;  
Matches 1851: Conservative 0; Mismatches 3; Indels 33;

QY	342	GACTGAGGAGCTGGCGTGGCGACTGGCTGGCGCTGGCGCCCTGTCAGAGGACGACGCTTCC	401
DB	2293	GACTGAGGAGCTGGCGTGGCGACTGGCTGGCGCTGGCGCCCTGTCAGAGGACGACGCTTCC	2352
QY	402	TGACGAGGAGAACACAGTGGTGGCCCGCTTTGAGCGAGGCCCTGCAGCTGGATGGAG	461
DB	2353	TGACGAGGAGAACACAGTGGTGGCCCGCTTTGAGCGAGGCCCTGCAGCTGGATGGAG	2412
QY	462	ACCTGACGAGGATGAGATCCAGTGGTAGCTATTATATGGCCACTGCTGGTGGGATCCGGG	521
DB	2413	ACCTGACGAGGATGAGATCCAGTGGTAGCTATTATATGGCCACTGCTGGTGGGATCCGGG	2472
QY	522	CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGGAAGGAGCTGGGCTCTTGGATTGGC	581
DB	2473	CAATGACTTCCCTGTATGGGAGCTGGCTGGCTGGAAGGAGCTGGGCTCTTGGATTGGC	2532
QY	582	TCTCTACATCAACGGGGCTTGGGCTCCACCTGGGCTTGGCCAACTTTATGAGAGCC	641
DB	2533	TCTCTCTACATCAACGGGGCTTGGGCTCCACCTGGGCTTGGCCAACTTTATGAGAGCC	2592
QY	642	CAGAGTGGTCTCAGAAGGACCTGGCAGGGCCCATGAGTTGCTGAAGACCCAGGTGACCA	701
DB	2593	CAGAGTGGTCTCAGAAGGACCTGGCAGGGCCCATGAGTTGCTGAAGACCCAGGTGACCA	2652
QY	702	AGAAACAAGCTGGGTGTGGCCCGCCAGCAGCTGCAGCGTACCGGACGAGCTGGCCG	761
DB	2653	AGAAACAAGCTGGGTGTGGCCCGCCAGCAGCTGCAGCGTACCGGACGAGCTGGCCG	2712
QY	762	AGCGTCCCGCTTGGGCTACCCAGCTGCTTACCACCTCTGGGCCCTCATCAACGAGG	821
DB	2713	AGCGTCCCGCTTGGGCTACCCAGCTGCTTACCACCTCTGGGCCCTCATCAACGAGG	2772
QY	822	CGCTGCTGATGATCAGCCCATGATCAAGCTCTCAGATCAACGGGAGGCCCTTGATGC	881
DB	2773	CGCTGCTGATGATCAGCCCATGATCAAGCTCTCAGATCAACGGGAGGCCCTTGATGC	2832
QY	882	ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCA	941
DB	2833	ATGGCCAGAACCCCTCTGCCCATCTACTGTGCCCTCAACACCAAGGGCAGAGCTGACCA	2892
QY	942	CTTTTGAATTTGGGAGTGGTCCGAGTTCTCTCCCTACGAGTCCGGCTTCCCAAGTACG	1001
DB	2893	CTTTTGAATTTGGGAGTGGTCCGAGTTCTCTCCCTACGAGTCCGGCTTCCCAAGTACG	2952
QY	1002	GGGCTTCTATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA	1061
DB	2953	GGGCTTCTATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGGCAGCTGATGAAGA	3012
QY	1062	GGCTTCCCTGAGTCCCGCATCTCTCTTTAGAAAGGTATCTGGAGCAACTGTATGAGCA	1121
DB	3013	GGCTTCCCTGAGTCCCGCATCTCTCTTTAGAAAGGTATCTGGAGCAACTGTATGAGCA	3072
QY	1122	ACCTCCAGACAGCTTATCTGGGCTCTAGAGCCAGCCAGTCTTGGGACCGCTGGGTCA	1181
DB	3073	ACCTCCAGACAGCTTATCTGGGCTCTAGAGCCAGCCAGTCTTGGGACCGCTGGGTCA	3133
QY	1182	GGAAACAGGCCAACCCTGGACAGGAGCAGGTCCGCCCTTCTGAAGATAGAAGAACCACTC	1241
DB	3133	GGAAACAGGCCAACCCTGGACAGGAGCAGGTCCGCCCTTCTGAAGATAGAAGAACCACTC	3193
QY	1242	CAACAGCCGCGAGAATAGCTGAGTTTTTCAACCGATCTTCTGACGTGGGCGTCCACTGGGCC	1301
DB	3193	CAACAGCCGCGAGAATAGCTGAGTTTTTCAACCGATCTTCTGACGTGGGCGTCCACTGGGCC	3253

RESULT 10  
US-09-895-547-1  
; Sequence 1, Application US/09895547  
; Patent No. 6492625  
; GENERAL INFORMATION:  
; APPLICANT: Kriiz, Ron  
; Song, Chuanzheng

TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES

NUMBER OF SEQUENCES: 9  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Genetics Institute, Inc.  
 STREET: 87 CambridgePark Drive  
 CITY: Cambridge  
 STATE: MA  
 COUNTRY: USA  
 ZIP: 02140  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/09/895,547  
 FILING DATE: 29-Jun-2001  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 09/460,145  
 FILING DATE: <Unknown>  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Brown, Scott A.  
 REGISTRATION NUMBER: 32,724  
 REFERENCE/DOCKET NUMBER: G15289  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (617) 498-8224  
 TELEFAX: (617) 876-5851  
 INFORMATION FOR SEQ ID NO: 1:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 4183 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: double  
 TOPOLOGY: linear  
 MOLECULE TYPE: cDNA  
 SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
 US-09-895-547-1

Query Match 82.0%; Score 1806.2; DB 4; Length 4183;  
 Best Local Similarity 98.1%; Pred. No. 0;  
 Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;

QY	822	CGCTGCTGCATGATGAGCCCATGATCAAGCTCTCAGATCAACCGGAGGCGCTGAGTC	881
DB	2773	CGCTGCTGCATGATGAGCCCATGATCAAGCTCTCAGATCAACCGGAGGCGCTGAGTC	2832
QY	882	ATGGCCAGAAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGAGCTGACCA	941
DB	2833	ATGGCCAGAAACCTCTGCCCATCTACTGTGCCCTCAACACCAAGGAGGAGAGCTGACCA	2892
QY	942	CTTTTGAATTTGGGAGTGGTCCGAGTTCTCTCCCTACGAGTCCGCTTCCCCAACTAGC	1001
DB	2893	CTTTTGAATTTGGGAGTGGTCCGAGTTCTCTCCCTACGAGTCCGCTTCCCCAACTAGC	2952
QY	1002	GGGCGCTTCATCCCTCTGAGCTCTTTGGCTCGAGTCTTTTATGGGCGAGCTGATGAAG	1061
DB	2953	GGGCGCTTCATCCCTCTGAGCTCTTTGGCTCGAGTCTTTTATGGGCGAGCTGATGAAG	3012
QY	1062	GGCTTCTGAGTCCCGCATCTCTTTAGAAAGTATCTGGAGCAACCTGTATGAGCCA	1121
DB	3013	GGCTTCTGAGTCCCGCATCTCTTTAGAAAGTATCTGGAGCAACCTGTATGAGCCA	3072
QY	1122	ACCTCAGGACAGCTTATCTGGGCTCAGAGCCAGCTTCTGGGACCGCTGGGTCA	1181
DB	3073	ACCTCAGGACAGCTTATCTGGGCTCAGAGCCAGCTTCTGGGACCGCTGGGTCA	3132
QY	1182	GGAAACCGGCAACCTGGACAGGAGAGTCCCTTCTGAAGATAGAAGAACCACTCT	1241
DB	3133	GGAAACCGGCAACCTGGACAGGAGAGTCCCTTCTGAAGATAGAAGAACCACTCT	3192
QY	1242	CAACAGCGGCGAGATAGCTGAGTTTTCACCGATCTTCTGACGTGGCGTCCACTGGCC	1301
DB	3193	CAACAGCGGCGAGATAGCTGAGTTTTCACCGATCTTCTGACGTGGCGTCCACTGGCC	3252
QY	1302	AGGCCACACATAATTTCTGCTGGTCCCTCCATTTCCACAAAGACTACTTTTCAGCAT	1361
DB	3253	AGGCCACACATAATTTCTGCTGGTCCCTCCATTTCCACAAAGACTACTTTTCAGCAT	3312
QY	1362	ACTTCTCCACATGGAAGCTACCTACCTGATGGCTCCCAACAGGTGACACCTCGG	1421
DB	3313	ACTTCTCCACATGGAAGCTACCTACCTGATGGCTCCCAACAGGTGACACCTCGG	3372
QY	1422	AGCCCGACCTGTGCTGTGATGTTGGCTACCTCATATACAGCTGCGTCCCTCC	1481
DB	3373	AGCCCGACCTGTGCTGTGATGTTGGCTACCTCATATACAGCTGCGTCCCTCC	3432
QY	1482	TGAGCCCTCTGGGACGTGACCTCATCTCTGTCTATTGGACTACAACTCCACGGAGCT	1541
DB	3433	TGAGCCCTCTGGGACGTGACCTCATCTCTGTCTATTGGACTACAACTCCACGGAGCT	3492
QY	1542	TCCAGCAGTTGACCTCTGGGCGGTTCTGCCAGGAGCAGGGATCCCGTTCCACCCA	1601
DB	3493	TCCAGCAGTTGACCTCTGGGCGGTTCTGCCAGGAGCAGGGATCCCGTTCCACCCA	3552
QY	1602	TCTCGCCAGCCCCGAAAGAGCAGCTCCAGCTCCGGAGTGCACACCTTCTCCGCCCA	1661
DB	3553	TCTCGCCAGCCCCGAAAGAGCAGCTCCAGCTCCGGAGTGCACACCTTCTCCGCCCA	3612
QY	1662	CTTCCCGGAGCCCCCTGCGGTGCTGCACTTT	1693
DB	3613	CTTCCCGGAGCCCCCTGCGGTGCTGCACTTT	3672
QY	1694	-----TCTCTGGGCTCGGGGACACCCGAGGAGGCGGAGTGGGAGGAGTGAACCTGT	1748
DB	3673	ACTCGGCCCCCTGGGGTCCGGCGGACACCCGAGGAGGCGGAGTGGGAGGAGTGAACCTGT	3732
QY	1749	CTTCATCGACTCTCCCTTACCTACCTACAGAGGTGACCTACAGCAGGAGGAGTGGACA	1808
DB	3733	CTTCATCGACTCTCCCTTACCTACCTACAGAGGTGACCTACAGCAGGAGGAGTGGACA	3792
QY	1809	AGCTGTGCACTTGACACATTACAATGTCTGCAACCAACAGGAGCAGCTGCTGAGGCTC	1868
DB	3793	AGCTGTGCACTTGACACATTACAATGTCTGCAACCAACAGGAGCAGCTGCTGAGGCTC	3852





Fri Oct 8 10:22:37 2004

us-09-830-321a-5.rni

1246 AGCGGCGAATAGCTGAGTCTTTTACCGATCTTCTGAGTGGCGTCCACTGGCCGAGGC 1305  
1306 CACACATAATTTCTGGTGGCTTCCATTTCCAAAGACTACTTTTCCAGCATCTCTCACTT 1365  
966 CACACATAATTTCTGGTGGCTTCCATTTCCAAAGACTACTTTTCCAGCATCTCTCACTT 1025  
1366 CTCACATGAAAGCTACCACTCTGGATGGCTTCCCAACAGCTGACACCTCTGGAGCC 1425  
1026 CTCACATGAAAGCTACCACTCTGGATGGCTTCCCAACAGCTGACACCTCTGGAGCC 1085  
1426 CCACTGTGCTGCTGATGTTGGCTACCTCATCAATACAGCTGCTGCTGCTCCCTCTGCA 1485  
1086 CCACTGTGCTGCTGATGTTGGCTACCTCATCAATACAGCTGCTGCTGCTCCCTCTGCA 1145  
1486 GCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1545  
1146 GCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1205  
1546 GCAGTTGAGCTCTGGGCGGTTCTGCGAGGAGCGGGATCCGTTTCCACCATCTC 1605  
1206 GCAGTTGAGCTCTGGGCGGTTCTGCGAGGAGCGGGATCCGTTTCCACCATCTC 1265  
1606 GCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1665  
1266 GCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1325  
1666 CCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1693  
1326 CCGGCTGCGGCTGAGCTCATCTCTGTCTATGAGCTTCAACCTTCCACGAGGCTTCCA 1385  
1694 -TCCTCTGGGCTGCGGCGGACCGGAGGCGGCTGCGGAGGCTGGAACCTCTCTTC 1752  
1386 GCGGCTGCGGCTGCGGCGGACCGGAGGCGGCTGCGGAGGCTGGAACCTCTCTTC 1445  
1753 ATCGGACTCTCCCTACCACTACCAAGTGTGACCTACAGCAGGAGGAGCTGGAAGCT 1812  
1446 ATCGGACTCTCCCTACCACTACCAAGTGTGACCTACAGCAGGAGGAGCTGGAAGCT 1505  
1813 GCTGACCTGACACATTAATGTTCTGCAACCAAGGAGGAGCTGCTGAGGCTCTGG 1872  
1506 GCTGACCTGACACATTAATGTTCTGCAACCAAGGAGGAGCTGCTGAGGCTCTGG 1565  
1873 CAGGAGTGTAGGAGGCGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCG 1932  
1566 CAGGAGTGTAGGAGGCGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCGGAGGCG 1625  
1933 CCTAATCTCTATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1992  
1626 CCTAATCTCTATTCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1685  
1993 CTTTCAAGCTCTGCGGCTCAGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2052  
1686 CTTTCAAGCTCTGCGGCTCAGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1745  
2053 CTTTCAAGCTCTGCGGCTCAGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2112  
1746 CTTTCAAGCTCTGCGGCTCAGGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1805  
2113 AAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2172  
1806 AAAACCCCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1865  
2173 GATACATCAGACTCATACAAA 2195  
1866 GATACATCAGACTCATACAAA 1888

RESULT 12  
US-09-148-545-21  
; Sequence 21, Application US/09148545  
; Patent No. 6590075

GENERAL INFORMATION:  
APPLICANT: Rosen et al.  
TITLE OF INVENTION: 70 Human Secreted Proteins  
FILE REFERENCE: P2001P1  
CURRENT APPLICATION NUMBER: US/09/148,545  
CURRENT FILING DATE: 1998-09-04  
EARLIER APPLICATION NUMBER: PCT/US98/04482  
EARLIER FILING DATE: 1998-03-06  
EARLIER APPLICATION NUMBER: 60/040,162  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,333  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/038,621  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,161  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,626  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,334  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,336  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/040,163  
EARLIER FILING DATE: 1997-03-07  
EARLIER APPLICATION NUMBER: 60/047,615  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,600  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,597  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,502  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,633  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,583  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,503  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,592  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,581  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,584  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,500  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,587  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,492  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,598  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,613  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,582  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,596  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,612  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,632  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/047,601  
EARLIER FILING DATE: 1997-05-23  
EARLIER APPLICATION NUMBER: 60/043,580  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,568  
EARLIER FILING DATE: 1997-04-11  
EARLIER APPLICATION NUMBER: 60/043,314

; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,569  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,311  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,671  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,674  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,669  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,312  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,313  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,672  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,315  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/048,974  
; EARLIER FILING DATE: 1997-06-06  
; EARLIER APPLICATION NUMBER: 60/056,886  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,877  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,889  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,893  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,630  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,878  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,662  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,872  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,882  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,637  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,903  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,888  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,879  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,880  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,894  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,911  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,636  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,874  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,910  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,864  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,631  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,845  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,892  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/047,595  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/057,761  
; EARLIER FILING DATE: 05-Sep-1997  
; EARLIER APPLICATION NUMBER: 60/047,599  
; EARLIER FILING DATE: 1997-05-23

; EARLIER APPLICATION NUMBER: 60/047,588  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,585  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,586  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,590  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,594  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,589  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,593  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,614  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/043,578  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/043,576  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/047,501  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/043,670  
; EARLIER FILING DATE: 1997-04-11  
; EARLIER APPLICATION NUMBER: 60/056,632  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,664  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,876  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,881  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,909  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,875  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,862  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,887  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/056,908  
; EARLIER FILING DATE: 1997-08-22  
; EARLIER APPLICATION NUMBER: 60/048,964  
; EARLIER FILING DATE: 1997-06-06  
; EARLIER APPLICATION NUMBER: 60/057,650  
; EARLIER FILING DATE: 1997-09-05  
; EARLIER APPLICATION NUMBER: 60/056,884  
; EARLIER FILING DATE: 1997-08-22  
; NUMBER OF SEQ ID NOS: 280  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 21  
; LENGTH: 1926

Query Match 80.7%; Score 1777.8; DB 4; Length 1926;  
Best Local Similarity 97.9%; Pred. No. 0;  
Matches 1844; Conservative 1; Mismatches 4; Indels 35; Gaps 3;

Qy	347	AGGAGCTGGCCGCTGGACCTGGGCTTCGGGCCCTGTG-CAGAGGAGCAGCCCTTCCTGAG	405
Db	6	AGGAGCTGGCCGCTGGACCTGGGCTTCGGGCCCTGTG-CAGAGGAGCAGCCCTTCCTGAG	65
Qy	406	CAGAGGAGCAGCTGGTGGCCCGGCGCTTGTAGGAGGCGCCCTGCAGCTGGATGGAGACCT	465
Db	66	CAGAGGAGCAGCTGGTGGCCCGGCGCTTGTAGGAGGCGCCCTGCAGCTGGATGGAGACCT	125
Qy	466	GCAGGAGGATGAGATCCAGTGGTATTTATGGCCACTGGTGGTGGGATCCGGGCAAT	525
Db	126	GCAGGAGGATGAGATCCAGTGGTATTTATGGCCACTGGTGGTGGGATCCGGGCAAT	185
Qy	526	GACTTCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGGCTCTTGGATTGGCTTC	585
Db	186	GACTTCCTGTATGGGAGCTGGCTGGCCCTGAAGGAGCTGGGCTCTTGGATTGGCTTC	245



586 CTACATCAACGGGGGCTCGGGCTCCACCTGGGGCTTGGCCAACTTTATGAGGACCCAGA 645  
246 CTACATCAACGGGGGCTCGGGCTCCACCTGGGGCTTGGCCAACTTTATGAGGACCCAGA 305  
646 GTGGTCTCAGAAAGACTGCGAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCAAGAA 705  
306 GTGGTCTCAGAAAGACTGCGAGGGGCCACTGAGTTGCTGAAGACCCAGGTGACCAAGAA 365  
706 CAAGCTGGGGTGTGTGGCCCCCAGCCAGCTGCGACCGGTACCGGAGAGCTGGCCGAGCG 765  
366 CAAGCTGGGGTGTGTGGCCCCCAGCCAGCTGCGACCGGTACCGGAGAGCTGGCCGAGCG 425  
766 TGCCCGCTTGGGTACCCAGCTGCTTACCAACCTGTGGCCCTCATCAACGAGGGGCT 825  
426 TGCCCGCTTGGGTACCCAGCTGCTTACCAACCTGTGGCCCTCATCAACGAGGGGCT 485  
826 GCTGCATGATGAGCCCATGATCAACAAGCTCTCAGATCAACGGGAGGCCCTGAGTCAATGG 885  
486 GCTGCATGATGAGCCCATGATCAACAAGCTCTCAGATCAACGGGAGGCCCTGAGTCAATGG 545  
886 CCAGAACCTCTGCCCCATCTACTGTGCGCTCAACCAAGGGGAGAGCCCTGACCACTTT 945  
546 CCAGAACCTCTGCCCCATCTACTGTGCGCTCAACCAAGGGGAGAGCCCTGACCACTTT 605  
946 TGAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTCCGGCTTCCCAAGTACGGGGC 1005  
606 TGAATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTCCGGCTTCCCAAGTACGGGGC 665  
1006 CTTTCATCCCTCTGAGCTCTTGGCTCCGAGTTCTTTATGGGGGAGCTGATGAAGAGGCT 1065  
666 CTTTCATCCCTCTGAGCTCTTGGCTCCGAGTTCTTTATGGGGGAGCTGATGAAGAGGCT 725  
1066 TCCTGAGTCCCGCATCTGCTTTCTTAGAAGGTATCTGGAGCAACCTGTATGAGCCCACT 1125  
726 TCCTGAGTCCCGCATCTGCTTTCTTAGAAGGTATCTGGAGCAACCTGTATGAGCCCACT 785  
1126 CCAGAGAGCTTATCTGGGCTCAGCCAGCCAGCTTCTGGGACCGCTGGGTGAGGAA 1185  
786 CCAGAGAGCTTATCTGGGCTCAGAGCCAGCCAGCTTCTGGGACCGCTGGGTGAGGAA 845  
1186 CCAGGCCAATCTGGAAGGAGAGCTCCCTCTCTGAAGATAGAGAACCAACCTCAAC 1245  
846 CCAGGCCAATCTGGAAGGAGAGCTCCCTCTCTGAAGATAGAGAACCAACCTCAAC 905  
1246 AGCCGGCAGAAATAGTGTGTTTTCACCGATCTTCTGAGTGGCTCCACTGGCCGAGGC 1305  
906 AGCCGGCAGAAATAGTGTGTTTTCACCGATCTTCTGAGTGGCTCCACTGGCCGAGGC 965  
1306 GACACATAATTTCTGGCTGGCTCCATTTCCACAAAGACTACTTTTCAGCATCTCTCACTT 1365  
966 GACACATAATTTCTGGCTGGCTCCATTTCCACAAAGACTACTTTTCAGCATCTCTCACTT 1025  
1366 CTTCCATGGAAGTACCACTCTGGATGGGCTCCCAACCAAGCTGACACCTTCGGAGCC 1425  
1026 CTTCCATGGAAGTACCACTCTGGATGGGCTCCCAACCAAGCTGACACCTTCGGAGCC 1085  
1426 CCACTGTGCTGCTGATGTTGGTACCTCATCAATCAACAGCTGACACCTTCCTGGA 1145  
1086 CCACTGTGCTGCTGATGTTGGTACCTCATCAATCAACAGCTGACACCTTCCTGGA 1145  
1486 GCGGCTCGGAGGCTGAGCTCATCTGTCATTGGACTACAACTCCAGGAGCCCTTCCA 1545  
1146 GCGGCTCGGAGGCTGAGCTCATCTGTCATTGGACTACAACTCCAGGAGCCCTTCCA 1205  
1546 GCAATTTGAGCTCCTGGGCGGTTCTGCCAGGAGAGGGGATCCCGTTCACCAACCATCTC 1605  
1206 GCAATTTGAGCTCCTGGGCGGTTCTGCCAGGAGAGGGGATCCCGTTCACCAACCATCTC 1265  
1606 GCGGAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGAGCCCACTG 1665  
1266 GCGGAGCCCGAAGAGAGCTCCAGCTCGGAGTGCACACCTTCTCCGAGCCCACTG 1325  
1666 CCGGAGGAGCCCTGGGCTGTGCACTTT----- 1693

1326 CCCCAGAGCCCTTGGCGTCTGCACCTTCTCTGGTCAGGACTCTTCTCGGAGTACTC 1385  
1694 -TCCTCTGGGTCCGGCGGACACCCGAGAGGCGGAGCTGGGAGGTGAACCTGTCTTC 1752  
1386 GGGCCCTGGGTCCGGCGGACACCCGAGGAGGCGGAGCTGGGAGGTGAACCTGTCTTC 1445  
1753 ATCGGACTCTTCCCTTACCCTACACGAAAGTGAACCTACGACGAGGAGGACCTGACAGCT 1812  
1446 ATCGGACTCTTCCCTTACCCTACACGAAAGTGAACCTACGACGAGGAGGACCTGACAGCT 1505  
1813 GCTGCACCTGACACATTTACAAATGTCTGCAACCAACGAGGAGGACCTGCTGAGGCTCTGCG 1872  
1506 GCTGCACCTGACACATTTACAAATGTCTGCAACCAACGAGGAGGACCTGCTGAGGCTCTGCG 1565  
1873 CCAGGAGTGCAGCGAGGCGGAGCGAGGCGGCCCACTGATGGCGGGGCCCTTGCACAC 1932  
1566 CCAGGAGTGCAGCGAGGCGGAGCGAGGCGGCCCACTGATGGCGGGGCCCTTGCACAC 1625  
1933 CCTAAGCTCTCATTCATTCCTGGCTGCTGAGTTGCGAGTGGGAACTGTCTACGCGAGTG 1992  
1626 CCTAAGCTCTCATTCATTCCTGGCTGCTGAGTTGCGAGTGGGAACTGTCTACGCGAGTG 1685  
1993 CTT-CAGAGCTCGGGCTCAGGTGGCACTGTCCAGGCTCCAGGCTCAGGCTCGGAGCT 2051  
1686 CTTNCAGAGCTCGGGCTCAGGTGGCACTGTCCAGGCTCCAGGCTCAGGCTCGGAGCT 1745  
2052 CCCTTGGCGCTCAGCAGTTTGCAGTGGGTTAAGGAGGCGCAAGCCCACTTGTGTAATCACC 2111  
1746 CCCTTGGCGCTCAGCAGTTTGCAGTGGGTTAAGGAGGCGCAAGCCCACTTGTGTAATCACC 1805  
2112 CAAACCCCGGCTGTGCTGCTTCCCTTCTGCGTACTCTTGGAGTGGAGCACT 2171  
1806 CAAACCCCGGCTGTGCTGCTTCCCTTCTGCGTACTCTTGGAGTGGAGCACT 1865  
2172 TGATACATCAGACTCATACAA 2195  
1866 TGATACATCAGACTCATACAA 1889

RESULT 13  
US-09-148-545-87/c  
; Sequence 87, Application US/09148545  
; Patent No. 6590075  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 70 Human Secreted Proteins  
; FILE REFERENCE: PZ001PI  
; CURRENT APPLICATION NUMBER: US/09/148,545  
; CURRENT FILING DATE: 1998-09-04  
; EARLIER APPLICATION NUMBER: PCT/US98/04482  
; EARLIER FILING DATE: 1998-03-06  
; EARLIER APPLICATION NUMBER: 60/040,162  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,333  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/038,621  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,161  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,626  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,334  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,336  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,163  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/047,615  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,600  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,597



1	EARLIER APPLICATION NUMBER: 60/056,630
2	EARLIER FILING DATE: 1997-08-22
3	EARLIER APPLICATION NUMBER: 60/056,878
4	EARLIER FILING DATE: 1997-08-22
5	EARLIER APPLICATION NUMBER: 60/056,662
6	EARLIER FILING DATE: 1997-08-22
7	EARLIER APPLICATION NUMBER: 60/056,872
8	EARLIER FILING DATE: 1997-08-22
9	EARLIER APPLICATION NUMBER: 60/056,882
10	EARLIER FILING DATE: 1997-08-22
11	EARLIER APPLICATION NUMBER: 60/056,637
12	EARLIER FILING DATE: 1997-08-22
13	EARLIER APPLICATION NUMBER: 60/056,903
14	EARLIER FILING DATE: 1997-08-22
15	EARLIER APPLICATION NUMBER: 60/056,888
16	EARLIER FILING DATE: 1997-08-22
17	EARLIER APPLICATION NUMBER: 60/056,879
18	EARLIER FILING DATE: 1997-08-22
19	EARLIER APPLICATION NUMBER: 60/056,880
20	EARLIER FILING DATE: 1997-08-22
21	EARLIER APPLICATION NUMBER: 60/056,894
22	EARLIER FILING DATE: 1997-08-22
23	EARLIER APPLICATION NUMBER: 60/056,911
24	EARLIER FILING DATE: 1997-08-22
25	EARLIER APPLICATION NUMBER: 60/056,636
26	EARLIER FILING DATE: 1997-08-22
27	EARLIER APPLICATION NUMBER: 60/056,874
28	EARLIER FILING DATE: 1997-08-22
29	EARLIER APPLICATION NUMBER: 60/056,910
30	EARLIER FILING DATE: 1997-08-22
31	EARLIER APPLICATION NUMBER: 60/056,864
32	EARLIER FILING DATE: 1997-08-22
33	EARLIER APPLICATION NUMBER: 60/056,631
34	EARLIER FILING DATE: 1997-08-22
35	EARLIER APPLICATION NUMBER: 60/056,845
36	EARLIER FILING DATE: 1997-08-22
37	EARLIER APPLICATION NUMBER: 60/056,892
38	EARLIER FILING DATE: 1997-08-22
39	EARLIER APPLICATION NUMBER: 60/047,595
40	EARLIER FILING DATE: 1997-05-23
41	EARLIER APPLICATION NUMBER: 60/057,761
42	EARLIER FILING DATE: 05-Sep-1997
43	EARLIER APPLICATION NUMBER: 60/047,599
44	EARLIER FILING DATE: 1997-05-23
45	EARLIER APPLICATION NUMBER: 60/047,588
46	EARLIER FILING DATE: 1997-05-23
47	EARLIER APPLICATION NUMBER: 60/047,585
48	EARLIER FILING DATE: 1997-05-23
49	EARLIER APPLICATION NUMBER: 60/047,586
50	EARLIER FILING DATE: 1997-05-23
51	EARLIER APPLICATION NUMBER: 60/047,590
52	EARLIER FILING DATE: 1997-05-23
53	EARLIER APPLICATION NUMBER: 60/047,594
54	EARLIER FILING DATE: 1997-05-23
55	EARLIER APPLICATION NUMBER: 60/047,589
56	EARLIER FILING DATE: 1997-05-23
57	EARLIER APPLICATION NUMBER: 60/047,593
58	EARLIER FILING DATE: 1997-05-23
59	EARLIER APPLICATION NUMBER: 60/047,614
60	EARLIER FILING DATE: 1997-05-23
61	EARLIER APPLICATION NUMBER: 60/043,578
62	EARLIER FILING DATE: 1997-04-11
63	EARLIER APPLICATION NUMBER: 60/043,576
64	EARLIER FILING DATE: 1997-04-11
65	EARLIER APPLICATION NUMBER: 60/047,501
66	EARLIER FILING DATE: 1997-05-23
67	EARLIER APPLICATION NUMBER: 60/043,670
68	EARLIER FILING DATE: 1997-04-11
69	EARLIER APPLICATION NUMBER: 60/056,632
70	EARLIER FILING DATE: 1997-08-22
71	EARLIER APPLICATION NUMBER: 60/056,664
72	EARLIER FILING DATE: 1997-08-22
73	EARLIER APPLICATION NUMBER: 60/056,876





8205 CGCAGCCCACTGATGGCGGGCCCTGCGACCCCTAACTCTCATTTCCCTGGCT 8264  
 1958 GCTGAGTTGAGTGGGAACTGTCAFCAGCAGTGTTCAGAGCCTCGGGCTCAGGTGGC 2017  
 8265 GCTGAGTTGAGTGGGAACTGTCAFCAGCAGTGTTCAGAGCCTCGGGCTCAGGTGGC 8324  
 2018 ACTGTCCAGGTTCCAGGCTGAGGCTGGAGCTCCCTTGGCCTCAGCAGTTTGCAGTG 2077  
 8325 ACCTGCCAGGTTCCAGGCTGAGGCTGGAGCTCCCTTGGCCTCAGCAGTTTGCAGTG 8384  
 2078 GGTATAGGAGCCCAAGCCATTTGTGTATCAACCCCAAAACCCCGGCTGTGCTGTTT 2137  
 8385 GGTATAGGAGCCCAAGCCATTTGTGTATCAACCCCAAAACCCCGGCTGTGCTGTTT 8444  
 2138 TCCTCTTTCGCTACCTTGTGTATCAACCCCAAAACCCCGGCTGTGCTGTTT 2197  
 8445 TCCTCTTTCGCTACCTTGTGTATCAACCCCAAAACCCCGGCTGTGCTGTTT 8504  
 2198 AAAAAA 2204  
 8505 AAAAAA 8511

RESULT 15  
 US-09-500-358-1  
 ; Sequence 1, Application US/09500358  
 ; Patent No. 6197569  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Chiou, Xue-Chiou C.  
 ; APPLICANT: Kramer, Ruth M.  
 ; APPLICANT: Pickard, Richard T.  
 ; APPLICANT: Sharp, John D.  
 ; APPLICANT: Striffler, Beth A.  
 ; TITLE OF INVENTION: HUMAN PHOSPHOLIPASE A2 AND RELATED  
 ; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS  
 ; NUMBER OF SEQUENCES: 4  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Eli Lilly and Company  
 ; STREET: Lilly Corporate Center  
 ; CITY: Indianapolis  
 ; STATE: Indiana  
 ; COUNTRY: United States of America  
 ; ZIP: 46285  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/500,358  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/827,208  
 ; FILING DATE: 28-MAR-1997  
 ; APPLICATION NUMBER: US 60/014,608  
 ; FILING DATE: 29-MAR-1996  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 60/041,264  
 ; FILING DATE: 19-MAR-1997  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Gaylo, Paul J.  
 ; REGISTRATION NUMBER: 36,808  
 ; REFERENCE/DOCKET NUMBER: X-10610  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (317) 276-0756  
 ; TELEFAX: (317) 276-3861  
 ; INFORMATION FOR SEQ ID NO: 1:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 8517 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear

7125 CTTTCAATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGACCTGATGAGAGGCT 7184  
 1066 TCTGAGTCCCGCATCTGCTCTTTAGAGGTATCTGAGCAACCTGTATGAGCAGCAACCT 1125  
 7185 TCTGAGTCCCGCATCTGCTCTTTAGAGGTATCTGAGCAACCTGTATGAGCAGCAACCT 7244  
 1126 CAGGACAGTTTATCTGAGGCTCAGAGCCAGCAGTCTGAGGACCGCTGGGTGAGGAA 1185  
 7245 CAGGACAGTTTATCTGAGGCTCAGAGCCAGCAGTCTGAGGACCGCTGGGTGAGGAA 7304  
 1186 CAGGACCAACCTG----- 1198  
 7305 CAGGACCAACCTGGTGAAGTCTCCGGGCCCTTCATAAGGGTGCCAGGGGCGAGCAGCT 7364  
 1199 ----- 1198  
 7365 GGGGCTGCACACCGGGGGGGGTTTCAACCTCTTCCCTCCAGGCTCACCACCAAGG 7424  
 1199 -----GACAAGGAGCAG 1210  
 7425 TGGGATTAAGGTGACAGAGTCCCATTTTCCCACTTGGCTGTGAGACAGGAGCAG 7484  
 1211 GTCCCTCTCTGAAGATAGAAACCAACCTTCAACAGCGCGCAGAGTGTGATTTTTC 1270  
 7485 GTCCCTCTCTGAAGATAGAAACCAACCTTCAACAGCGCGCAGAGTGTGATTTTTC 7544  
 1271 ACCGATCTTCTGAGTGGCTGCTACTGCGCCAGGCGCACATATTTCTGCGTGGCTC 1330  
 7545 ACCGATCTTCTGAGTGGCTGCTACTGCGCCAGGCGCACATATTTCTGCGTGGCTC 7604  
 1331 CATTTCCACAAAGACTTTTCAGCATCTTCCATCTTCCATGGAAGCTTACCACTGTG 1390  
 7605 CATTTCCACAAAGACTTTTCAGCATCTTCCATCTTCCATGGAAGCTTACCACTGTG 7664  
 1391 GATGGCTCCCAACAGCTGACCTTCCGAGCCCACTGTGCTGCTGCTGCTGCTGCTGCTG 1450  
 7665 GATGGCTCCCAACAGCTGACCTTCCGAGCCCACTGTGCTGCTGCTGCTGCTGCTGCTG 7724  
 1451 TACCTCATTAATACAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1510  
 7725 TACCTCATTAATACAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 7784  
 1511 CTGCTATTTGGACTACAACCTCAGAGGCTTCCAGAGCTTCCAGCTCTTGGGCGGCTTC 1570  
 7785 CTGCTATTTGGACTACAACCTCAGAGGCTTCCAGAGCTTCCAGCTCTTGGGCGGCTTC 7844  
 1571 TGCCAGGAGCAGGGGATCCCGTTCCCAACCCATCTCGCCAGCCCGGAGAGAGCTCCAG 1630  
 7845 TGCCAGGAGCAGGGGATCCCGTTCCCAACCCATCTCGCCAGCCCGGAGAGAGCTCCAG 7904  
 1631 CTTGGAGTGCACACCTTTCCGACCCCACTGCGCCGAGCCCTGCGGTGCTGCAC 1690  
 7905 CTTGGAGTGCACACCTTTCCGACCCCACTGCGCCGAGCCCTGCGGTGCTGCAC 7964  
 1691 TTTT-----CCTCTGGGCTCCGCGGACACCC 1717  
 7965 TTTTCTCTGTCAGCAGCTCTTCCGAGGAGTACTCGGCCCTTGGGCTCGCGGACACCC 8024  
 1718 GAGGAGCGCGAGCTGGGAGGTGAACCTGTCTCATCGGACTCTCCCTACCACTACAG 1777  
 8025 GAGGAGCGCGAGCTGGGAGGTGAACCTGTCTCATCGGACTCTCCCTACCACTACAG 8084  
 1778 AGGTGACCTACAGCAGGAGCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1837  
 8085 AAGGTGACCTACAGCAGGAGCTGGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 8144  
 1838 TGCAACAAACAGGAGCAGCTGCTGGAGGCTCTGCGCCAGGAGCTGAGCGGAGCGGAG 1897  
 8145 TGCAACAAACAGGAGCAGCTGCTGGAGGCTCTGCGCCAGGAGCTGAGCGGAGCGGAG 8204  
 1898 CGCAGGCGCCACTGATGGCGGGGGCCCTGCGCACCTCTCACTTCTTCTTCTTCTTCTTCT 1957

MOLECULE TYPE:	DNA (genomic)
FEATURE:	
NAME/KEY:	exon
LOCATION:	1611..2063
FEATURE:	
NAME/KEY:	exon
LOCATION:	5315..6045
FEATURE:	
NAME/KEY:	exon
LOCATION:	6143..6758
FEATURE:	
NAME/KEY:	exon
LOCATION:	7075..7317
FEATURE:	
NAME/KEY:	exon
LOCATION:	7473..8499
US-09-500-358-1	
Query Match	63.9%; Score 1408.6; DB 3; Length 8517;
Best Local Similarity	79.3%; Pred. No. 0;
Matches 1957; Conservative	0; Mismatches 4; Indels 506; Gaps 4;
QY	244 GGCTGAGTGCATATGCGCGATCTTGGCTCACTGCAACCTCGCCTCTGGGTTCAAGCG 303
Db	6045 GGCTGAGTGCATATGCGCGATCTTGGCTCACTGCAACCTCGCCTCTGGGTTCAAGCG 6104
QY	304 ATTCTCTGCTCAGCCTCCCGAGTAGCTGGGATTTACAGACTGAGGAGCTGGCGTGGC 363
Db	6105 ATTCTCTGCTCAGCCTCCCGAGTAGCTGGGATTTACAGACTGAGGAGCTGGCGTGGC 6164
QY	364 ACTGGGCTTCGGGCGCTGTGCAGAGGACGAGCCCTTCTGAGCAGGAGGAACAGAGTGGT 423
Db	6165 ACTGGGCTTCGGGCGCTGTGCAGAGGACGAGCCCTTCTGAGCAGGAGGAACAGAGTGGT 6224
QY	424 GGCCCGGGCCTTGAAGCAGGCGCTTCAGCTGGATGGAGACCTGAGCAGGAGGATGAT-CC 482
Db	6225 GGCCCGGGCCTTGAAGCAGGCGCTTCAGCTGGATGGAGACCTGAGCAGGAGGATGAT-CC 6284
QY	483 CAGTGGTAGCTATTATGCCCACCTGGTGGTGGGATCCGGGCAATGACTTCCTGTATGGGC 542
Db	6285 CAGTGGTAGCTATTATGCCCACCTGGTGGTGGGATCCGGGCAATGACTTCCTGTATGGGC 6344
QY	543 AGCTGGCTGGCCTGAAGAGCTGGGCTCTTGGATTCGCTCTCCTACATCACCGGGCCCT 602
Db	6345 AGCTGGCTGGCCTGAAGAGCTGGGCTCTTGGATTCGCTCTCCTACATCACCGGGCCCT 6404
QY	603 CGGCTCCACTCGGCTTCGGCCAACTTTATGAGGACCCAGAGTGCTGTCAAGAGGACC 662
Db	6405 CGGCTCCACTCGGCTTCGGCCAACTTTATGAGGACCCAGAGTGCTGTCAAGAGGACC 6464
QY	663 TGGCAGGGCCCACTAGTTGCTGAAGACCCAGGTGACCAAGAACAGCTGGGTGTCTGG 722
Db	6465 TGGCAGGGCCCACTAGTTGCTGAAGACCCAGGTGACCAAGAACAGCTGGGTGTCTGG 6524
QY	723 CCCCCAGCCAGCTGCACGGGTACCGGAGAGCTGGCCGAGCGTGCCTGGGCTACC 782
Db	6525 CCCCCAGCCAGCTGCACGGGTACCGGAGAGCTGGCCGAGCGTGCCTGGGCTACC 6584
QY	783 CAAGCTGCTTCAACCAACTCTGGGCGCTCATCAACAGGCGCTGTGCATGATGAGCGCC 842
Db	6585 CAAGCTGCTTCAACCAACTCTGGGCGCTCATCAACAGGCGCTGTGCATGATGAGCGCC 6644
QY	843 ATGATCAAGCTCTCAGATCAACGGGAGCCCTGAGTCATGGCCAGAACCTCTGGCCA 902
Db	6645 ATGATCAAGCTCTCAGATCAACGGGAGCCCTGAGTCATGGCCAGAACCTCTGGCCA 6704
QY	903 TCTACTGTGCCCTCAACCAAGGGGAGCGCTGACCACTTTTGAATTTGGG----- 955
Db	6705 TCTACTGTGCCCTCAACCAAGGGGAGCGCTGACCACTTTTGAATTTGGGGTGAGT 6764
QY	956 ----- 955
Db	6765 GGCCCAAGAGCTGAGACCTGTGCCCTTGCAGTTGGTGAATTAAGGGGAGAACGAGGACTG 6824

Fri Oct 8 10:22:37 2004

QY	1631	CCTCGGGAGTGCACACACCTTCTCCGACCCACCTGCGCGAGCCCTGCGGTGCTGCAC	1690
Db	7905	CCTCGGGAGTGCACACACCTTCTCCGACCCACCTGCGCGAGCCCTGCGGTGCTGCAC	7964
QY	1691	TTTTT-----CCTCTGGGTCCGGGGACACCC	1717
Db	7965	TTTTCTCTGGTACGCACTCCTTCCGGGAGTACTCGGCCCTTGGGTCCGGCGGACACCC	8024
QY	1718	GAGGAGCGGCAGCTGGGAGGTGAACCTGTCTTCATTCGGACTCTCCCTACCACTACAG	1777
Db	8025	GAGGAGCGGCAGCTGGGAGGTGAACCTGTCTTCATTCGGACTCTCCCTACCACTACAG	8084
QY	1778	AAGGTGACCTACAGCCAGGAGGACGTGGACAAGCTGTGCACCTGCACATTACAAATGTC	1837
Db	8085	AAGGTGACCTACAGCCAGGAGGACGTGGACAAGCTGTGCACCTGCACATTACAAATGTC	8144
QY	1838	TGCAACAACAGGAGCAAGCTGTGGAGGCTCTGCGCCAGGACGTGCAGCGGAGGCGGCAG	1897
Db	8145	TGCAACAACAGGAGCAAGCTGTGGAGGCTCTGCGCCAGGACGTGCAGCGGAGGCGGCAG	8204
QY	1898	CGCAGGCCCACTGATGGCGGGGCCCTGCGCACCCCTAACTCTCATTTCCCTGGCT	1957
Db	8205	CGCAGGCCCACTGATGGCGGGGCCCTGCGCACCCCTAACTCTCATTTCCCTGGCT	8264
QY	1958	GCTGAGTTCAGGTGGGAACTGTCTATCAGCAGTGTTCAGAGCTCGGGCTCAGGTGGC	2017
Db	8265	GCTGAGTTCAGGTGGGAACTGTCTATCAGCAGTGTTCAGAGCTCGGGCTCAGGTGGC	8324
QY	2018	ACTGTCCAGGGTCCAGGCTGAGGGCTGGGAGCTCCCTTGGCGCTCAGCAGTTTGCAGTG	2077
Db	8325	ACGGTCCAGGGTCCAGGCTGAGGGCTGGGAGCTCCCTTGGCGCTCAGCAGTTTGCAGTG	8384
QY	2078	GGGTAAGAGGCCAAGCCCTTTGTGTAATCACCCAAACCCCGGCTGTGCTGTTT	2137
Db	8385	GGGTAAGAGGCCAAGCCCTTTGTGTAATCACCCAAACCCCGGCTGTGCTGTTT	8444
QY	2138	TCCCTTCTGCGCTACCTTGTAGTGTGAGACATTGATACATCAGAGACTCATACAAAA	2197
Db	8445	TCCCTTCTGCGCTACCTTGTAGTGTGAGACATTGATACATCAGAGACTCATACAAAA	8504
QY	2198	AAAAAA 2204	
Db	8505	AAAAAA 8511	

Search completed: October 7, 2004, 18:59:56  
Job time : 208.207 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 7, 2004, 16:44:09 ; Search time 1131.17 Seconds  
(without alignments)  
9877.707 Million cell updates/sec

Title: US-09-830-321A-5  
Perfect score: 2204  
Sequence: 1 catggttggggcgcagaga.....actcatcaaaaaaaaaa 2204

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 3340653 seqs, 2534783454 residues

Total number of hits satisfying chosen parameters: 6681306

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published Applications NA.\*  
1: /cgn2\_6/ptodata/2/pubpna/US07\_PUBCOMB.seq.\*  
2: /cgn2\_6/ptodata/2/pubpna/US06\_NEW\_PUB.seq.\*  
3: /cgn2\_6/ptodata/2/pubpna/US06\_PUBCOMB.seq.\*  
4: /cgn2\_6/ptodata/2/pubpna/US06\_PUBCOMB.seq.\*  
5: /cgn2\_6/ptodata/2/pubpna/US07\_NEW\_PUB.seq.\*  
6: /cgn2\_6/ptodata/2/pubpna/US07\_PUBCOMB.seq.\*  
7: /cgn2\_6/ptodata/2/pubpna/US08\_NEW\_PUB.seq.\*  
8: /cgn2\_6/ptodata/2/pubpna/US08\_PUBCOMB.seq.\*  
9: /cgn2\_6/ptodata/2/pubpna/US09A\_PUBCOMB.seq.\*  
10: /cgn2\_6/ptodata/2/pubpna/US09B\_PUBCOMB.seq.\*  
11: /cgn2\_6/ptodata/2/pubpna/US09C\_PUBCOMB.seq.\*  
12: /cgn2\_6/ptodata/2/pubpna/US09C\_PUBCOMB.seq.\*  
13: /cgn2\_6/ptodata/2/pubpna/US09\_NEW\_PUB.seq.\*  
14: /cgn2\_6/ptodata/2/pubpna/US10A\_PUBCOMB.seq.\*  
15: /cgn2\_6/ptodata/2/pubpna/US10B\_PUBCOMB.seq.\*  
16: /cgn2\_6/ptodata/2/pubpna/US10C\_PUBCOMB.seq.\*  
17: /cgn2\_6/ptodata/2/pubpna/US10\_NEW\_PUB.seq.\*  
18: /cgn2\_6/ptodata/2/pubpna/US60\_NEW\_PUB.seq.\*  
19: /cgn2\_6/ptodata/2/pubpna/US60\_PUBCOMB.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1806.2	82.0	2699	15	US-10-266-388-3
2	1806.2	82.0	4183	15	US-10-266-388-1
3	1788.8	81.2	1925	9	US-09-981-876-86
4	1788.8	81.2	1925	10	US-09-148-545-86
5	1777.8	80.7	1926	9	US-09-981-876-21
6	1777.8	80.7	1926	10	US-09-148-545-21
7	1676.6	76.1	1818	9	US-09-981-876-87
8	1676.6	76.1	1818	10	US-09-148-545-87
9	602	27.3	3197	13	US-10-332-426-14
10	483.8	22.0	1915	15	US-10-103-313-127
11	439	19.9	494	10	US-09-918-995-32564
12	429.6	19.5	3879	17	US-10-467-248-10
13	398.2	18.1	3460	16	US-10-380-873B-2
14	385.8	17.5	2547	13	US-10-332-426-11

15	365	16.6	2694	16	US-10-380-873B-39	Sequence 39, Appl
16	358.6	16.3	3112	16	US-10-380-873B-23	Sequence 23, Appl
17	235.6	10.7	554	10	US-09-918-995-28234	Sequence 28234, A
18	172.4	7.8	174	9	US-09-880-107-3899	Sequence 3899, Ap
19	166.6	7.6	556	13	US-10-296-115-178	Sequence 178, App
20	150	6.8	1519	16	US-10-380-873B-4	Sequence 4, Appli
21	136.8	6.2	323	13	US-10-027-632-13940	Sequence 13940, A
22	136.8	6.2	323	16	US-10-027-632-13940	Sequence 13940, A
23	132.8	6.0	24741	13	US-10-087-192-1042	Sequence 1042, Ap
24	131.8	6.0	31868	17	US-10-444-795B-808	Sequence 808, App
25	131.8	6.0	300000	15	US-10-262-553-33	Sequence 33, Appl
26	131.8	6.0	300000	17	US-10-703-210-33	Sequence 33, Appl
27	130.8	5.9	11853	16	US-10-074-024-739	Sequence 739, App
28	130.6	5.9	9474	9	US-09-764-878-372	Sequence 372, App
29	130.6	5.9	9474	15	US-10-079-854-372	Sequence 372, App
30	130.4	5.9	60381	13	US-10-087-192-970	Sequence 970, App
31	130.2	5.9	14103	16	US-10-242-355-1114	Sequence 1114, Ap
32	130.2	5.9	186391	13	US-10-087-192-136	Sequence 136, App
33	129.8	5.9	32433	12	US-10-052-482-136	Sequence 136, App
34	129.8	5.9	154817	16	US-10-085-117-334	Sequence 334, App
35	129.8	5.9	186957	15	US-10-085-117-334	Sequence 334, App
36	129.8	5.9	201986	13	US-10-087-192-874	Sequence 874, App
37	129.6	5.9	201	17	US-10-741-601-12145	Sequence 12145, A
38	129.6	5.9	1245	13	US-10-027-632-252450	Sequence 252450, A
39	129.6	5.9	1245	16	US-10-027-632-252450	Sequence 252450, A
40	129.6	5.9	46649	10	US-09-805-456-3	Sequence 3, Appli
41	129.6	5.9	77992	15	US-10-225-810-11	Sequence 11, Appl
42	129.6	5.9	86081	17	US-10-741-601-5640	Sequence 5640, Ap
43	129.6	5.9	250000	15	US-10-225-810-26	Sequence 26, Appl
44	129.4	5.9	3124	16	US-10-108-260A-568	Sequence 568, App
45	129.4	5.9	3318	13	US-10-027-632-113926	Sequence 113926,

## ALIGNMENTS

RESULT 1  
US-10-266-388-3  
; Sequence 3, Application US/10266388  
; Publication NO. US20030124702A1  
; GENERAL INFORMATION:  
; APPLICANT: Kriz, Ron  
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute, Inc.  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/266,388  
; FILING DATE: 07-Oct-2002  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/895,547  
; FILING DATE: 29-Jun-2001  
; APPLICATION NUMBER: 09/460,145  
; FILING DATE: <Unknown>  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Brown, Scott A.  
; REGISTRATION NUMBER: 32,724  
; REFERENCE/DOCKET NUMBER: G15289  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 498-8224  
; TELEFAX: (617) 876-5851





; Publication No. US20030124702A1					
; GENERAL INFORMATION:					
; APPLICANT: Kriz, Ron					
; Invention Title: Song, Chuanzheng					
; TITLE OF INVENTION: CYTOSOLIC PHOSPHOLIPASE A2-BETA ENZYMES					
; NUMBER OF SEQUENCES: 9					
; CORRESPONDENCE ADDRESS:					
; ADDRESSEE: Genetics Institute, Inc.					
; STREET: 87 CambridgePark Drive					
; CITY: Cambridge					
; STATE: MA					
; COUNTRY: USA					
; ZIP: 02140					
; COMPUTER READABLE FORM:					
; MEDIUM TYPE: Floppy disk					
; OPERATING SYSTEM: IBM PC compatible					
; SOFTWARE: PatentIn Release #1.0, Version #1.30					
; CURRENT APPLICATION DATA:					
; APPLICATION NUMBER: US/10/266,388					
; FILING DATE: 07-Oct-2002					
; CLASSIFICATION: <Unknown>					
; PRIOR APPLICATION DATA:					
; APPLICATION NUMBER: US/09/895,547					
; FILING DATE: 29-Jun-2001					
; APPLICATION NUMBER: 09/460,145					
; FILING DATE: <Unknown>					
; ATTORNEY/AGENT INFORMATION:					
; NAME: Brown, Scott A.					
; REGISTRATION NUMBER: 32,724					
; REFERENCE/DOCKET NUMBER: GI5289					
; TELECOMMUNICATION INFORMATION:					
; TELEPHONE: (617) 498-8224					
; TELEFAX: (617) 876-5851					
; INFORMATION FOR SEQ ID NO: 1:					
; SEQUENCE CHARACTERISTICS:					
; LENGTH: 4183 base pairs					
; TYPE: nucleic acid					
; STRANDEDNESS: double					
; TOPOLOGY: linear					
; MOLECULE TYPE: cDNA					
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:					
US-10-266-388-1					
Query Match 82.0%; Score 1806.2; DB 15; Length 4183;					
Best Local Similarity 98.1%; Pred. No. 0;					
Matches 1851; Conservative 0; Mismatches 3; Indels 33; Gaps 1;					
QY	342	GACTGAGGGAGCTGGCGGTGCAGTCCGACCTTCGGGCCCTTGAGCAGGCGCCCTGCAGAGGACGAGCCCTTC	401		
DB	2293	GACTGAGGGAGCTGGCGGTGCAGTCCGACCTTCGGGCCCTTGAGCAGGCGCCCTGCAGAGGACGAGCCCTTC	2352		
QY	402	TGAGCAGGAGGAGCAGGTGGTGGCGCGCTTGAGCAGGCGCCCTGCAGTGGATGGAG	461		
DB	2353	TGAGCAGGAGGAGCAGGTGGTGGCGCGCTTGAGCAGGCGCCCTGCAGTGGATGGAG	2412		
QY	462	ACCTGCAGGAGGATGAGATCCCAGTGTAGCTATTATGGCACTGTGGGCTTTGGATTTGG	521		
DB	2413	ACCTGCAGGAGGATGAGATCCCAGTGTAGCTATTATGGCACTGTGGGCTTTGGATTTGG	2472		
QY	522	CAATGACTTCCCTGTATGGCAGCTGGCTGGCTGAAGGAGCTGGGCCCTTTGGATTTGG	581		
DB	2473	CAATGACTTCCCTGTATGGCAGCTGGCTGGCTGAAGGAGCTGGGCCCTTTGGATTTGG	2532		
QY	582	TCCTCCATCATCACCGGGGCTTCGGCTCCACCTGGGCTTTGGCCAACTTTATGAGGACC	641		
DB	2533	TCCTCCATCATCACCGGGGCTTCGGCTCCACCTGGGCTTTGGCCAACTTTATGAGGACC	2592		
QY	642	CAGAGTGGTCTCAGAAGGACCTGGCAGGCGCCACTCAGTTGCTGAGACCCAGGTGACCA	701		
DB	2593	CAGAGTGGTCTCAGAAGGACCTGGCAGGCGCCACTCAGTTGCTGAGACCCAGGTGACCA	2652		
QY	702	AGAACAAAGCTGGGTGTGCTGGCCCCCAGCCAGCAGCTGCAGCGGTACCGGAGGAGCTGGCGG	761		



;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,637  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,903  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,888  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,879  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,880  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,894  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,911  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,636  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,874  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,910  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,864  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,631  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,845  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,892  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,761  
;; PRIOR FILING DATE: 05-Sep-1997  
;; PRIOR APPLICATION NUMBER: 60/047,599  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,588  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,585  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,586  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,590  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,594  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,589  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,593  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/047,614  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/043,578  
;; PRIOR FILING DATE: 1997-04-11  
;; PRIOR APPLICATION NUMBER: 60/043,576  
;; PRIOR FILING DATE: 1997-04-11  
;; PRIOR APPLICATION NUMBER: 60/047,501  
;; PRIOR FILING DATE: 1997-05-23  
;; PRIOR APPLICATION NUMBER: 60/043,670  
;; PRIOR FILING DATE: 1997-04-11  
;; PRIOR APPLICATION NUMBER: 60/056,632  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,664  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,876  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,881  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,909  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,875  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,862  
;; PRIOR FILING DATE: 1997-08-22

;; PRIOR APPLICATION NUMBER: 60/056,887  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/056,908  
;; PRIOR FILING DATE: 1997-08-22  
;; PRIOR APPLICATION NUMBER: 60/048,964  
;; PRIOR FILING DATE: 1997-06-06  
;; PRIOR APPLICATION NUMBER: 60/057,650  
;; PRIOR FILING DATE: 1997-09-05  
;; PRIOR APPLICATION NUMBER: 60/056,884  
;; PRIOR FILING DATE: 1997-08-22  
;; NUMBER OF SEQ ID NOS: 280  
;; SOFTWARE: PatentIn Ver. 2.0  
;; SEQ ID NO 86  
;; LENGTH: 1925

## Query Match

Best Local Similarity 81.2%; Score 1788.8; DB 9; Length 1925;

Matches 1844; Conservative 1; Mismatches 4; Indels 34; Gaps 2;

QY	347	AGGAGCTGGCCGCTGGACTGGGCTTCGGGCGCTGTG-CAGAGGACAGGCTTCCTGAG	405
Db	6	AGGAGCTGGCCGCTGGACTGGGCTTCGGGCGCTGTG-CAGAGGACAGGCTTCCTGAG	65
QY	406	CAGGAGGAAGCAGGTGGTGGCGCGCTTGAGGCAGGCGCTTGACAGTGGAGACT	465
Db	66	CAGGAGGAAGCAGGTGGTGGCGCGCTTGAGGCAGGCGCTTGACAGTGGAGACT	125
QY	466	GCAGGAGATGAGATCCAGTGGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	585
Db	126	GCAGGAGATGAGATCCAGTGGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	245
QY	526	GACTTCCCTGATGGGAGCTGGCTGAGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	585
Db	186	GACTTCCCTGATGGGAGCTGGCTGAGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	245
QY	586	CTACATCACCGGGGCTCGGGCTCCACTGGGCTTCAGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	645
Db	246	CTACATCACCGGGGCTCGGGCTCCACTGGGCTTCAGTGGCTGAAAGAGTGGGCTTCCTGGATTGGCTCTC	305
QY	646	GTGTCTCAGAAAGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCAAGAA	705
Db	306	GTGTCTCAGAAAGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACCAAGAA	365
QY	706	CAAGCTGGGTGCTGGCCCGCCAGCAGCTGCAGCGTACCGGAGGAGCTGGCGGAGCG	765
Db	366	CAAGCTGGGTGCTGGCCCGCCAGCAGCTGCAGCGTACCGGAGGAGCTGGCGGAGCG	425
QY	766	TGCCCGCTTGGGCTACCCAAAGCTGCTTCCAAAGCTGCTGGGCTTCATCAACGAGGCGCT	825
Db	426	TGCCCGCTTGGGCTACCCAAAGCTGCTTCCAAAGCTGCTGGGCTTCATCAACGAGGCGCT	485
QY	826	GCTGCATGATGAGCCCATGATCACAGCTCTCAGATCAACGGGAGCGCTTCATGATGG	885
Db	486	GCTGCATGATGAGCCCATGATCACAGCTCTCAGATCAACGGGAGCGCTTCATGATGG	545
QY	886	CCAGAACCTCTGCCATCTACTGTGCTCCAAACAAAGGCGAGCGCTTCATGATGG	945
Db	546	CCAGAACCTCTGCCATCTACTGTGCTCCAAACAAAGGCGAGCGCTTCATGATGG	605
QY	946	TGAATTTGGGAGTGGGAGTTCCTCCCTACGAGGTGGCTTCCTCCAAAGTACGGGGC	1005
Db	606	TGAATTTGGGAGTGGGAGTTCCTCCCTACGAGGTGGCTTCCTCCAAAGTACGGGGC	665
QY	1006	CTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGCGAGCTGATGAGGCT	1065
Db	666	CTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTTATGGGCGAGCTGATGAGGCT	725
QY	1066	TCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGAGCAACCTGTATGACCAACCT	1125
Db	726	TCTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGAGCAACCTGTATGACCAACCT	785
QY	1126	CCAGGACAGCTTATCTGGGCTCAGAGCCAGCGTCTGGGACCGTGGTCAAGAA	1185

Fri Oct 8 10:22:37 2004

us-09-830-321a-5.rnbp

Db 786 CCAGGACAGCTTATCTGGGCTCAGAGCCAGCCAGCTTCTGGGACCGCTGGGTGAGAA 845  
QY 1186 CCAGGCCAACCTGGACAAAGAGAGGTCCTCCCTTCTGAAGATAGAACACCTCAAC 1245  
Db 846 CCAGGCCAACCTGGACAAAGAGAGGTCCTCCCTTCTGAAGATAGAACACCTCAAC 905  
QY 1246 AGCCGGCAAGATAGCTAGCTTTTACCGCATCTTCTGACGTGGCGTCCACTGGCCGAGGC 1305  
Db 906 AGCCGGCAAGATAGCTAGCTTTTACCGCATCTTCTGACGTGGCGTCCACTGGCCGAGGC 965  
QY 1306 CACACATAATTTCTCGTGGCTTCCATTTCACAAAGACTACTTTTCAGATCCTCACTT 1365  
Db 966 CACACATAATTTCTCGTGGCTTCCATTTCACAAAGACTACTTTTCAGATCCTCACTT 1025  
QY 1366 CTCACATGAAAGCTACCACTCTGATGGCTCCCAACCACTGACACCCCTCGAGCC 1425  
Db 1026 CTCACATGAAAGCTACCACTCTGATGGCTCCCAACCACTGACACCCCTCGAGCC 1085  
QY 1426 CGACCTGTGCTGCTGATGTTGGTACCTCATCAATACAGCTGCTGCCCTCTCTGCA 1485  
Db 1086 CGACCTGTGCTGCTGATGTTGGTACCTCATCAATACAGCTGCTGCCCTCTCTGCA 1145  
QY 1486 GCGCACTCGGAGCTGACCTCATCTGTCAATTGGACTACAACTCCACGAGCTTCCA 1545  
Db 1146 GCGCACTCGGAGCTGACCTCATCTGTCAATTGGACTACAACTCCACGAGCTTCCA 1205  
QY 1546 GCACTTCAGCTCTCGGCGGTTCTGCGAGGAGCGGATCCGTTCCACCCATCTC 1605  
Db 1206 GCACTTCAGCTCTCGGCGGTTCTGCGAGGAGCGGATCCGTTCCACCCATCTC 1265  
QY 1606 GCGGAGCCCGAGAGAGAGCTCCAGCTCGGAGTGCCACACCTTCTCCGACCCCACTG 1665  
Db 1266 GCGGAGCCCGAGAGAGAGCTCCAGCTCGGAGTGCCACACCTTCTCCGACCCCACTG 1325  
QY 1666 CCGGAGCCCGCTCGGCTGTGCACTTT----- 1693  
Db 1326 CCGGAGCCCGCTCGGCTGTGCACTTTCTCTGTGAGCAGCTCTTCCGGGAGTACTC 1385  
QY 1694 -TCTCTGGGTCTCGGCGGACACCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTC 1752  
Db 1386 GCGCCCTCGGCTCGGCGGACACCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTC 1445  
QY 1753 ATCGGACTCTCCCTACCACTACGAAGTGAACCTACAGCCAGGAGGAGCTGGAACAAGCT 1812  
Db 1446 ATCGGACTCTCCCTACCACTACGAAGTGAACCTACAGCCAGGAGGAGCTGGAACAAGCT 1505  
QY 1813 GCTGACCTGACATTAATGTCTGCAACCAAGAGAGCTGCTGGAGGCTCTGG 1872  
Db 1506 GCTGACCTGACATTAATGTCTGCAACCAAGAGAGCTGCTGGAGGCTCTGG 1565  
QY 1873 CCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCTGATGCGGCGGCGGCTCCACC 1932  
Db 1566 CCAGGAGTGCAGCGGAGCGGAGCGGAGCGGAGCGGAGCTGATGCGGCGGCGGCTCCACC 1625  
QY 1933 CTTACTCTCATTCATCTCTCGCTGCTGAGTGGAGTGGAACTGTATCAGCAGTG 1992  
Db 1626 CTTACTCTCATTCATCTCTCGCTGCTGAGTGGAGTGGAACTGTATCAGCAGTG 1685  
QY 1993 CTTGAGAGCTCGGCTCAGGTGGCACTCTCCAGGGTCCAGGCTGAGGCTGGAGCTC 2052  
Db 1686 CTTGAGAGCTCGGCTCAGGTGGCACTCTCCAGGGTCCAGGCTGAGGCTGGAGCTC 1745  
QY 2053 CTTGCGGCTCAGCAGTTTGCATGGGTGAAGAGCGGAGCGGAGCTTGTGTAATCACCC 2112  
Db 1746 CTTGCGGCTCAGCAGTTTGCATGGGTGAAGAGCGGAGCGGAGCTTGTGTAATCACCC 1805  
QY 2113 AAAACCCCGGCTCTGCTGCTGTTTCCCTTCTGCGCTACCTTGTAGTGTGAGCACTT 2172  
Db 1806 AAAACCCCGGCTCTGCTGCTGTTTCCCTTCTGCGCTACCTTGTAGTGTGAGCACTT 1865  
QY 2173 GATACATCAGACTCATACAAA 2195  
Db 1866 GATACATCAGACTCATACAAA 1888

RESULT 4  
US-09-148-545-86  
; Sequence 86, Application US/09148545  
; Publication No. US20030027132A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 70 Human Secreted Proteins  
; FILE REFERENCE: P2001P1  
; CURRENT APPLICATION NUMBER: US/09/148,545  
; CURRENT FILING DATE: 1998-09-04  
; EARLIER APPLICATION NUMBER: PCT/US98/04482  
; EARLIER FILING DATE: 1998-03-06  
; EARLIER APPLICATION NUMBER: 60/040,162  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,333  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/038,621  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,161  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,626  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,334  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,336  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/040,163  
; EARLIER FILING DATE: 1997-03-07  
; EARLIER APPLICATION NUMBER: 60/047,615  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,600  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,597  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,502  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,633  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,583  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,617  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,618  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,503  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,592  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,581  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,584  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,500  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,587  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,492  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,598  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,613  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,582  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,596  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,612  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,632  
; EARLIER FILING DATE: 1997-05-23  
; EARLIER APPLICATION NUMBER: 60/047,601

	Query Match	81.2%;	Score 1788.8;	DB 10;	Length 1925;
	Best Local Similarity	97.9%;	Pred. No. 0;		
	Matches 1844;	Conservative	1;	Mismatches	4;
				Indels	34;
				Gaps	2;
QY	347	AGGGAGCTGGCCGTCGCACTGGGCTTCGGGCCCCCTGTG-CAGAGGAGCAGGCCCTTCCTGAG	405		
db	6	AGGGAGCTGGCCGTCGCACTGGGCTTCGGGCCCCCTGTGCCAGGAGCAGGCCCTTCCTGAG	65		
QY	406	CAGGAGGAAGCAGGTGTGTGGCCCGGCCCTTTGAGGCAAGGCCCTGCAGCTGGATGGAGACCT	465		
db	66	CAGGAGGAAGCAGGTGTGTGGCCCGGCCCTTTGAGGCAAGGCCCTGCAGCTGGATGGAGACCT	125		
QY	466	GCAGGAGGATGAGATCCCACTGGTGGTATTTATGGCCACTGTGTGGGATCGGGCAAT	525		



✓	PRIOR APPLICATION NUMBER:	60/056,877
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,889
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,893
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,630
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,878
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,662
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,872
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,882
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,637
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,903
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,888
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,879
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,880
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,894
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,911
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,636
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,874
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,910
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,864
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,631
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,845
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/056,892
✓	PRIOR FILING DATE:	1997-08-22
✓	PRIOR APPLICATION NUMBER:	60/047,595
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/057,761
✓	PRIOR FILING DATE:	05-Sep-1997
✓	PRIOR APPLICATION NUMBER:	60/047,599
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,588
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,585
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,586
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,590
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,594
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,589
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,593
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/047,614
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/043,578
✓	PRIOR FILING DATE:	1997-04-11
✓	PRIOR APPLICATION NUMBER:	60/043,576
✓	PRIOR FILING DATE:	1997-04-11
✓	PRIOR APPLICATION NUMBER:	60/047,501
✓	PRIOR FILING DATE:	1997-05-23
✓	PRIOR APPLICATION NUMBER:	60/043,670







Query Match		80.7%;	Score 1777.8;	DB 10;	Length 1926;
Best Local Similarity		97.9%;	Pred. No. 0;		
Matches 1844;		Conservative	1;	Mismatches	4;
				Indels	35;
				Gaps	3;
QY	347	AGGGAGCTGGCGCTGGAGCTGGGCTTCGGGCGCTGTG-CAGAGGAGCAGGCTTCCTTGAG	405		
DB	6	AGGGAGCTGGCGCTGGAGCTGGGCTTCGGGCGCTGTG-CAGAGGAGCAGGCTTCCTTGAG	65		
QY	406	CAGGAGGAGCAGGTGGTGGCGCGCTTTGAGCGAGGCGCTGCAGCTGATGAGACCT	465		
DB	66	CAGGAGGAGCAGGTGGTGGCGCGCTTTGAGCGAGGCGCTGCAGCTGATGAGACCT	125		
QY	466	GCAGGAGGATGAGATCCAGTGTAGCTATTATATGGCCACTGGTGGATCCGGGCAAT	525		
DB	126	GCAGGAGGATGAGATCCAGTGTAGCTATTATATGGCCACTGGTGGATCCGGGCAAT	185		
QY	526	GACTTCCCTGTATGGGCGCTTCACCTGGGCGCTTCAGTGGGCTTCCTTGATTCGCTC	585		
DB	186	GACTTCCCTGTATGGGCGCTTCACCTGGGCGCTTCAGTGGGCTTCCTTGATTCGCTC	245		
QY	586	CTACATCACCGGGCGCTTCGGGCTTCACCTGGGCGCTTCAGTGGGCTTCCTTGATTCGCTC	645		
DB	246	CTACATCACCGGGCGCTTCGGGCTTCACCTGGGCGCTTCAGTGGGCTTCCTTGATTCGCTC	305		
QY	646	GTGGTCTCAGAGGACCTGGCAGGCGCTTCAGTGGGCTTCAGTGGGCTTCCTTGATTCGCTC	705		
DB	306	GTGGTCTCAGAGGACCTGGCAGGCGCTTCAGTGGGCTTCAGTGGGCTTCCTTGATTCGCTC	365		
QY	706	CAAGCTGGGCTGTGCTGGCGCGCTTCAGTGGGCTTCAGTGGGCTTCCTTGATTCGCTC	765		
DB	366	CAAGCTGGGCTGTGCTGGCGCGCTTCAGTGGGCTTCAGTGGGCTTCCTTGATTCGCTC	425		
QY	766	TGCGCGCTTGGGCTTACCCAGCTGCTTCAACCTGTGGGCGCTTCATCAAGGCGCT	825		
DB	426	TGCGCGCTTGGGCTTACCCAGCTGCTTCAACCTGTGGGCGCTTCATCAAGGCGCT	485		
QY	826	GCTGATGATGAGCGCGCTTATGATCAAGCTCTCAGATCAAGCGGAGGCGCTTGAAGTGG	885		
DB	486	GCTGATGATGAGCGCGCTTATGATCAAGCTCTCAGATCAAGCGGAGGCGCTTGAAGTGG	545		
QY	886	CCAGAACCTCTGCCATCTACTGTGCGCTCAACCAACCAAGGCGAGCTGACCACTTT	945		
DB	546	CCAGAACCTCTGCCATCTACTGTGCGCTCAACCAACCAAGGCGAGCTGACCACTTT	605		
QY	946	TGAATTTGGGAGTGGTGGGCTTCTCCCTTACAGGTGGGCTTCCCAAGTACGGGC	1005		
DB	606	TGAATTTGGGAGTGGTGGGCTTCTCCCTTACAGGTGGGCTTCCCAAGTACGGGC	665		
QY	1006	CTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGGCT	1065		
DB	666	CTTCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGCGAGCTGATGAAGGCT	725		
QY	1066	TCCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGGAGCAACCTGTATGAGCAACCT	1125		
DB	726	TCCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGGAGCAACCTGTATGAGCAACCT	785		
QY	1126	CCAGGACAGCTTATATCTGGGCTTCAGAGCCCGAGGCTTCTGGGCGCTGGTCAAGAA	1185		
DB	786	CCAGGACAGCTTATATCTGGGCTTCAGAGCCCGAGGCTTCTGGGCGCTGGTCAAGAA	845		
QY	1186	CCAGGCAACCTGGAGCAAGGAGGCTCCCGCTTCTGAGAGTATCTGGAGCAACCTCAAC	1245		
DB	846	CCAGGCAACCTGGAGCAAGGAGGCTCCCGCTTCTGAGAGTATCTGGAGCAACCTCAAC	905		
QY	1246	AGCGGCGAGATGAGTGGTGGTTCACCGATCTTCTGAGTGGGCTTCCAGTGGGCGG	1305		
DB	906	AGCGGCGAGATGAGTGGTGGTTCACCGATCTTCTGAGTGGGCTTCCAGTGGGCGG	965		
QY	1306	CACACATAATTTCTGGTGGGCTTCCATTTCCAGAGTACTTTCAGCATCTCTCACTT	1365		
DB	966	CACACATAATTTCTGGTGGGCTTCCATTTCCAGAGTACTTTCAGCATCTCTCACTT	1025		

EARLIER FILING DATE: 1997-08-22	60/056,636
EARLIER APPLICATION NUMBER: 60/056,636	
EARLIER FILING DATE: 1997-08-22	60/056,874
EARLIER APPLICATION NUMBER: 60/056,874	
EARLIER FILING DATE: 1997-08-22	60/056,910
EARLIER APPLICATION NUMBER: 60/056,910	
EARLIER FILING DATE: 1997-08-22	60/056,864
EARLIER APPLICATION NUMBER: 60/056,864	
EARLIER FILING DATE: 1997-08-22	60/056,631
EARLIER APPLICATION NUMBER: 60/056,631	
EARLIER FILING DATE: 1997-08-22	60/056,845
EARLIER APPLICATION NUMBER: 60/056,845	
EARLIER FILING DATE: 1997-08-22	60/056,892
EARLIER APPLICATION NUMBER: 60/056,892	
EARLIER FILING DATE: 1997-08-22	60/047,595
EARLIER APPLICATION NUMBER: 60/047,595	
EARLIER FILING DATE: 1997-05-23	60/057,761
EARLIER APPLICATION NUMBER: 60/057,761	
EARLIER FILING DATE: 05-Sep-1997	60/047,599
EARLIER APPLICATION NUMBER: 60/047,599	
EARLIER FILING DATE: 1997-05-23	60/047,586
EARLIER APPLICATION NUMBER: 60/047,586	
EARLIER FILING DATE: 1997-05-23	60/047,590
EARLIER APPLICATION NUMBER: 60/047,590	
EARLIER FILING DATE: 1997-05-23	60/047,594
EARLIER APPLICATION NUMBER: 60/047,594	
EARLIER FILING DATE: 1997-05-23	60/047,589
EARLIER APPLICATION NUMBER: 60/047,589	
EARLIER FILING DATE: 1997-05-23	60/047,593
EARLIER APPLICATION NUMBER: 60/047,593	
EARLIER FILING DATE: 1997-05-23	60/047,614
EARLIER APPLICATION NUMBER: 60/047,614	
EARLIER FILING DATE: 1997-05-23	60/043,578
EARLIER APPLICATION NUMBER: 60/043,578	
EARLIER FILING DATE: 1997-04-11	60/043,576
EARLIER APPLICATION NUMBER: 60/043,576	
EARLIER FILING DATE: 1997-04-11	60/047,501
EARLIER APPLICATION NUMBER: 60/047,501	
EARLIER FILING DATE: 1997-05-23	60/043,670
EARLIER APPLICATION NUMBER: 60/043,670	
EARLIER FILING DATE: 1997-04-11	60/056,632
EARLIER APPLICATION NUMBER: 60/056,632	
EARLIER FILING DATE: 1997-08-22	60/056,664
EARLIER APPLICATION NUMBER: 60/056,664	
EARLIER FILING DATE: 1997-08-22	60/056,876
EARLIER APPLICATION NUMBER: 60/056,876	
EARLIER FILING DATE: 1997-08-22	60/056,881
EARLIER APPLICATION NUMBER: 60/056,881	
EARLIER FILING DATE: 1997-08-22	60/056,909
EARLIER APPLICATION NUMBER: 60/056,909	
EARLIER FILING DATE: 1997-08-22	60/056,875
EARLIER APPLICATION NUMBER: 60/056,875	
EARLIER FILING DATE: 1997-08-22	60/056,862
EARLIER APPLICATION NUMBER: 60/056,862	
EARLIER FILING DATE: 1997-08-22	60/056,887
EARLIER APPLICATION NUMBER: 60/056,887	
EARLIER FILING DATE: 1997-08-22	60/056,908
EARLIER APPLICATION NUMBER: 60/056,908	
EARLIER FILING DATE: 1997-08-22	60/048,964
EARLIER APPLICATION NUMBER: 60/048,964	
EARLIER FILING DATE: 1997-06-06	60/057,650
EARLIER APPLICATION NUMBER: 60/057,650	
EARLIER FILING DATE: 1997-09-05	60/056,884
EARLIER APPLICATION NUMBER: 60/056,884	
EARLIER FILING DATE: 1997-08-22	
NUMBER OF SEQ ID NOS: 280	
SOFTWARE: PatentIn ver. 2.0	
SEQ ID NO 21	
LENGTH: 1926	

QY	1366	CTCCACATGGAAAGCTACCACTCTGATGGGTCCCAACACAGTGACACCTCGAGGCC	1425	;	PRIOR APPLICATION NUMBER: 60/040,162
Db	1026	CTCCACATGGAAAGCTACCACTCTGATGGGTCCCAACACAGTGACACCTCGAGGCC	1085	;	PRIOR FILING DATE: 1997-03-07
QY	1426	CCACCTGTGCTCTCTGATGTTGGTCTACCTCATCAATACCACTGCTGCTGCTCTGCA	1485	;	PRIOR APPLICATION NUMBER: 60/040,333
Db	1086	CCACCTGTGCTCTCTGATGTTGGTCTACCTCATCAATACCACTGCTGCTGCTCTGCA	1145	;	PRIOR FILING DATE: 1997-03-07
QY	1486	GCCCACTCGGAGCTGGAGCTCATCTCTGTCATTTGAGTACAACTCCACGAGGCCCTTCCA	1545	;	PRIOR APPLICATION NUMBER: 60/040,161
Db	1146	GCCCACTCGGAGCTGGAGCTCATCTCTGTCATTTGAGTACAACTCCACGAGGCCCTTCCA	1205	;	PRIOR FILING DATE: 1997-03-07
QY	1546	GCAGTTGCACTCTCTGGCGGGTCTGCCAGGAGAGGGATCCCGTTCACCACTCTC	1605	;	PRIOR APPLICATION NUMBER: 60/040,334
Db	1206	GCAGTTGCACTCTCTGGCGGGTCTGCCAGGAGAGGGATCCCGTTCACCACTCTC	1265	;	PRIOR FILING DATE: 1997-03-07
QY	1606	GCCAGCCCCGAGAGCAGCTCCAGCCTCGGGAGTGCACACTTTCGACCCCACTTG	1665	;	PRIOR APPLICATION NUMBER: 60/040,163
Db	1266	GCCAGCCCCGAGAGCAGCTCCAGCCTCGGGAGTGCACACTTTCGACCCCACTTG	1325	;	PRIOR FILING DATE: 1997-03-07
QY	1666	CCCCGAGCCCCCTGGGGTCTGCACCTT	1693	;	PRIOR APPLICATION NUMBER: 60/047,615
Db	1326	CCCCGAGCCCCCTGGGGTCTGCACCTT	1385	;	PRIOR FILING DATE: 1997-05-23
QY	1694	-TCCCTCTGGGTCGCGCGACACCCGAGGCGGAGTGGGAGGTGAACCTGTCTTC	1752	;	PRIOR APPLICATION NUMBER: 60/047,600
Db	1386	GGCCCCCTGGGGTCCGCGCGACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTC	1445	;	PRIOR FILING DATE: 1997-05-23
QY	1753	ATCGACTCTCCCTACCACTACACGAAGTGACCTACAGCAGGAGGAGCGTGAAGCT	1812	;	PRIOR APPLICATION NUMBER: 60/047,583
Db	1446	ATCGACTCTCCCTACCACTACACGAAGTGACCTACAGCAGGAGGAGCGTGAAGCT	1505	;	PRIOR FILING DATE: 1997-05-23
QY	1813	GCTGACCTGACACATTAAATGTTCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGG	1872	;	PRIOR APPLICATION NUMBER: 60/047,618
Db	1506	GCTGACCTGACACATTAAATGTTCTGCAACACAGGAGCAGCTGCTGGAGGCTCTGG	1565	;	PRIOR FILING DATE: 1997-05-23
QY	1873	CCAGGAGTGCAGGAGGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	1932	;	PRIOR APPLICATION NUMBER: 60/047,503
Db	1566	CCAGGAGTGCAGGAGGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGGAGCGG	1625	;	PRIOR FILING DATE: 1997-05-23
QY	1933	CCTAACTCTCAATTCCTCGCTGCTGAGTGCAGCTGGGAGTGTATCATCAGCAGTG	1992	;	PRIOR APPLICATION NUMBER: 60/047,592
Db	1626	CCTAACTCTCAATTCCTCGCTGCTGAGTGCAGCTGGGAGTGTATCATCAGCAGTG	1685	;	PRIOR FILING DATE: 1997-05-23
QY	1993	CTT-CAGAGCTCGGGCTCAGTGTCGACTGTCAGGCTCCAGGCTGAGGCTGGAGCT	2051	;	PRIOR APPLICATION NUMBER: 60/047,581
Db	1686	CTT-CAGAGCTCGGGCTCAGTGTCGACTGTCAGGCTCCAGGCTGAGGCTGGAGCT	1745	;	PRIOR FILING DATE: 1997-05-23
QY	2052	CCCTTGGGCTCAGCAGTTTCAGTGGGTAAGAGGCGCAAGCCATTGTGTATCACC	2111	;	PRIOR APPLICATION NUMBER: 60/047,584
Db	1746	CCCTTGGGCTCAGCAGTTTCAGTGGGTAAGAGGCGCAAGCCATTGTGTATCACC	1805	;	PRIOR FILING DATE: 1997-05-23
QY	2112	CAAAACCCCGGCTGTGCTGTTTCCCTTCTGCGCTACCTTGAGTGTGAGCAGCT	2171	;	PRIOR APPLICATION NUMBER: 60/047,596
Db	1806	CAAAACCCCGGCTGTGCTGTTTCCCTTCTGCGCTACCTTGAGTGTGAGCAGCT	1865	;	PRIOR FILING DATE: 1997-05-23
QY	2172	TGATACATCAGACTCATACAAA	2195	;	PRIOR APPLICATION NUMBER: 60/047,612
Db	1866	TGATACATCAGACTCATACAAA	1889	;	PRIOR FILING DATE: 1997-05-23

RESULT 7

US-09-981-876-87/c  
; Sequence 87, Application US/09981876  
; Patent No. US20020164669A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: 70 Human Secreted Proteins  
; FILE REFERENCE: P2001P1  
; CURRENT APPLICATION NUMBER: US/09/981,876  
; CURRENT FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: 09/148,545  
; PRIOR FILING DATE: 1998-09-04

Fri Oct 8 10:22:37 2004

```

; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,669
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,312
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,313
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,672
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,315
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/048,974
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/056,886
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,877
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,889
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,893
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,630
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,878
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,662
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,872
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,882
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,637
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,903
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,888
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,879
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,880
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,894
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,911
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,636
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,874
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,910
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,864
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,631
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,845
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,892
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/047,595
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/057,761
; PRIOR FILING DATE: 05-Sep-1997
; PRIOR APPLICATION NUMBER: 60/047,599
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,588
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,585
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,586
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,590
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,594
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,589
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,593
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/047,614
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,578
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/043,576
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/047,501
; PRIOR FILING DATE: 1997-05-23
; PRIOR APPLICATION NUMBER: 60/043,670
; PRIOR FILING DATE: 1997-04-11
; PRIOR APPLICATION NUMBER: 60/056,632
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,664
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,876
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,881
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,909
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,875
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,862
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,887
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/056,908
; PRIOR FILING DATE: 1997-08-22
; PRIOR APPLICATION NUMBER: 60/048,964
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: 60/057,650
; PRIOR FILING DATE: 1997-09-05
; PRIOR APPLICATION NUMBER: 60/056,884
; PRIOR FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 280
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 87
; LENGTH: 1818

Query Match      76.1%; Score 1676.6; DB 9; Length 1818;
Best Local Similarity 97.4%; Pred. No. 0;
Matches 1745; Conservative 3; Mismatches 7; Indels 36; Gaps 3;

QY 450 AGCTGGATGGAGACCTGCGAGGAGATGAGATCCCAAGTGGTAGCTATTTATGGCCACTGGTG 509
Db 1818 AGCTGGATGGAGACCTGCGAGGAGATGAGATCCCAAGTGGTAGCTATTTATGGCCACTGGTG 1759
QY 510 GTGGGATCCGGCAATGACTTCCCTGTATGGGAGATGAGATCCCAAGTGGTAGCTATTTATGGCCACTGGTG 567
Db 1758 GTGGGATCCGGCAATGACTTCCCTGTATGGGAGATGAGATCCCAAGTGGTAGCTATTTATGGCCACTGGTG 1699
QY 568 CCTCTTGATTCGCTCTCTCATACACCGGGGCTCGGGCTCCACTGGGCTTGGCCAA 827
Db 1698 CCTCTTGATTCGCTCTCTCATACACCGGGGCTCGGGCTCCACTGGGCTTGGCCAA 1639
QY 628 CTTTATGAGGACCCAGAGTGTCTCAGAGGAGCTGGGAGGAGCTGGGAGGAGCTGGGAGGAGCTGGTGA 687
Db 1638 CTTTATGAGGACCCAGAGTGTCTCAGAGGAGCTGGGAGGAGCTGGGAGGAGCTGGTGA 1579
QY 688 GACCCAGGTGACCAAGAAAGCTGGGTGTCTGGGCCCCCAGCCAGCTCAGCGGTACCG 747
Db 1578 GACCCAGGTGACCAAGAAAGCTGGGTGTCTGGGCCCCCAGCCAGCTCAGCGGTACCG 1519
QY 748 GCAGGAGCTGGCGAGCGGTGCCCGTGGGCTACCCAAAGTGTGGGCTACCCAAAGTGTGGGCTGGGC 807
Db 1518 GCAGGAGCTGGCGAGCGGTGCCCGTGGGCTACCCAAAGTGTGGGCTACCCAAAGTGTGGGCTGGGC 1459
```



[illegible][illegible]

```

;   EARLIER FILING DATE: 1997-09-05
;   EARLIER APPLICATION NUMBER: 60/056,884
;   EARLIER FILING DATE: 1997-08-22
;   NUMBER OF SEQ ID NOS: 280
;   SOFTWARE: PatentIn Ver. 2.0
;   SEQ ID NO 87
;   LENGTH: 1818

```

Query Match									
Best Local Similarity 97.4%;			Score 1676.6;		DB 10;		Length 1818;		
Matches 1745;			Conservative 3;		Mismatches 7;		Indels 36; Gaps 3;		
QY	450	AGCTGATGGAGACCTGCAGAGAGATGATCCCGAGTGGTACGTATTATAGCCCATGCTGTG	509						
Db	1818	AGCTGATGGAGACCTGCAGAGAGATGATCCCGAGTGGTACGTATTATAGCCCATGCTGTG	1759						
QY	510	GTGGATCCGGCAATGACTCCCTGTATGGCAGCTGCTGGCCTGAA--GGAGCTGGG	567						
Db	1758	GTGGATCCGGCAATGACTCCCTGTATGGCAGCTGCTGGCCTGAAAGAGCTGGGG	1699						
QY	568	CCTCTTGATTCGCTCTCTATACACCGGGCTTCGGGCTCCACCTGGGCTTTGGCCAA	627						
Db	1638	CCTCTTGATTCGCTCTCTATACACCGGGCTTCGGGCTCCACCTGGGCTTTGGCCAA	1639						
QY	628	CCTTTATCAGGACCCAGAGTGGTCTCAGAAGGACTGCAGGGGCCCACTGAGTTCGTAA	687						
Db	1638	CCTTTATCAGGACCCAGAGTGGTCTCAGAAGGACTGCAGGGGCCCACTGAGTTCGTAA	1579						
QY	688	GACCCAGGTGACCAAGAACAAAGCTGGGTGTCTGGCCCCCAGCCAGCTGCAGCGGTACCG	747						
Db	1578	GACCCAGGTGACCAAGAACAAAGCTGGGTGTCTGGCCCCCAGCCAGCTGCAGCGGTACCG	1519						
QY	748	GCAGAGCTGCCAGCGTGCCTTGGGCTACCCAAAGCTGTTTACAAACCTGTGGGC	807						
Db	1518	GCAGAGCTGCCAGCGTGCCTTGGGCTACCCAAAGCTGTTTACAAACCTGTGGGC	1459						
QY	808	CCTCATCAACGAGCGCTGCTGCATGATGAGCCCCCATGATCAAGCTCTCAGATCAACG	867						
Db	1458	CCTCATCAACGAGCGCTGCTGCATGATGAGCCCCCATGATCAAGCTCTCAGATCAACG	1399						
QY	868	GGAGCCCTGAGTCATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAAGG	927						
Db	1398	GGAGCCCTGAGTCATGGCCAGAACCTCTGCCCATCTACTGTGCCCTCAACACCAAAGG	1339						
QY	928	GCAGAGCTGCACCACTTTTGAATTTGGGAGTGGTGGAGTTCTCTCCCTACAGATCGG	987						
Db	1338	GCAGAGCTGCACCACTTTTGAATTTGGGAGTGGTGGAGTTCTCTCCCTACAGATCGG	1279						
QY	988	CTTCCCCAAGTACGGGCTTCATCCCTCTGAGCTCTTTGGTCCGAGTTCTTTATGGG	1047						
Db	1278	CTTCCCCAAGTACGGGCTTCATCCCTCTGAGCTCTTTGGTCCGAGTTCTTTATGGG	1219						
QY	1048	GCAGCTGATCAAGAGGCTTCTCAGTCCCGCATCTGTTCTTAGAAGGTATCTGGAGCAA	1107						
Db	1218	GCAGCTGATCAAGAGGCTTCTCAGTCCCGCATCTGTTCTTAGAAGGTATCTGGAGCAA	1159						
QY	1108	CCTGTATGCAGCCAACTCCAGGACAGCTTATACTGGGCTCAGAGCCACGACCTTCG	1167						
Db	1158	CCTGTATGCAGCCAACTCCAGGACAGCTTATACTGGGCTCAGAGCCACGACCTTCG	1099						
QY	1168	GGACCGCTGGTCAGGAAACGAGCCAACTTCGACAAAGGAGCAGGTCCCTCTCTGAAGAT	1227						
Db	1098	GGACCGCTGGTCAGGAAACGAGCCAACTTCGACAAAGGAGCAGGTCCCTCTCTGAAGAT	1039						
QY	1228	AGAAGAACCACTTCAACAGCGGCAAGTACTGAGTTTTTACCGATCTTCTGACGTG	1287						
Db	1038	AGAAGAACCACTTCAACAGCGGCAAGTACTGAGTTTTTACCGATCTTCTGACGTG	979						
QY	1288	GGTTCACCTGGGCCAGGCCACACATAATTTCTCGGTGGCTCCATTTCCCAAAAGCTA	1347						
Db	978	GGTTCACCTGGGCCAGGCCACACATAATTTCTCGGTGGCTCCATTTCCCAAAAGCTA	919						
QY	1348	CTTTCAGCATCTCACTTCTCCATATGGAAAGCTACCACTCTCGATGGGCTCCCCAACCA	1407						

APPLICANT: LAL, Preeti.; RAMKUMAR, Jayalaxmi;  
APPLICANT: NGUYEN, Dannie B.; BAUGHN, Mariah R.  
TITLE OF INVENTION: LIPID METABOLISM MOLECULES  
FILE REFERENCE: PI-0152 USN  
CURRENT APPLICATION NUMBER: US/10/332,426  
CURRENT FILING DATE: 2003-01-06  
PRIOR APPLICATION NUMBER: US 60/216,803  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 60/216,801  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 60/218,233  
PRIOR FILING DATE: 2000-07-14  
PRIOR APPLICATION NUMBER: US 60/220,046  
PRIOR FILING DATE: 2000-07-21  
PRIOR APPLICATION NUMBER: US 60/220,739  
PRIOR FILING DATE: 2000-07-26  
PRIOR APPLICATION NUMBER: US 60/222,824  
PRIOR FILING DATE: 2000-08-04  
NUMBER OF SEQ ID NOS: 16  
SOFTWARE: PERL Program  
SEQ ID NO 14  
LENGTH: 3197  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc\_feature  
OTHER INFORMATION: Incyte ID No. US20040029136A1 7477093CB1  
US-10-332-426-14

Query Match 27.3%; Score 602; DB 13; Length 3197;  
Best Local Similarity 62.2%; Pred. No. 5,4e-152;  
Matches 1012; Conservative 0; Mismatches 565; Indels 51; Gaps 2;

QY 315 TCAGCCTCCGAGTAGCTGGGATACAGACTGAGGAGCTGCCCTGAGGAGCTGCCCTGACCTGGGCTTCA 1477  
Db 1418 TGAGCTCAGCTCAAGCAGCAGAGGCTGCCCTGAGGAGCTGCCCTGACCTGGGCTTCA 1477

QY 375 GGCCCTGTGAGAGAGCAGGCTTCTGAGCAGGAGAGCAGCTGGTGGCCGGGCT 434  
Db 1478 ATCTGTGTCAGAGAGCAGGCTTCTGAGCAGGAGAGCAGCTGGTGGCCAAAGGCC 1537

QY 435 TGAGCAGGCTCAGCTGAGTGGAGCTCAGAGGAGTGGAGTCCAGTGGTGGT 494  
Db 1538 TGAAGCAGGCTCAGCTGAGTGGAGAGCTCAGAGGAGTGGAGTACCCTGTGGGCA 1597

QY 495 TTATGGCCACTGGTGGTGGATCCGGGCAATGACTTCCCTGTATGGGAGCTGGCTGGCC 554  
Db 1598 TCATGGCCACAGAGAGGAGTGGCCGGGCCATGACCTCACTTACGGCCACCTATTGGGCT 1657

QY 555 TGAAGAGCTGGGCTTCTGGATGGCTTCTGATCCTACATACCGGGGCTCGGCTCCACCT 614  
Db 1658 TGCAGAAGCTGGGCTTCTGAGCTGTGTGACCTTCTGATGGCTTCTGCTTACGT 1717

QY 615 GGGCTTGGCCACCTTTATGAGGAGCCAGAGTGGTCTCAGAGGAGCCTGGCAGGCCCCA 674  
Db 1718 GGAATATGCCCCCTGTAGCGGAGCTTGTGAGTGGTTCGAGAGGAGCCTGGAGGACCTA 1777

QY 675 CTGAGTGTCTGAAGACCCAGGTGACCAAGAAAGCTGGGTGTGTCGGCCCCCAGCCAGC 734  
Db 1778 TCAGATACGCCCGGAGCAGCTGGCCAGAGAAAGCTGGAGGTCTTTCCTCCAGAGCGCC 1837

QY 735 TGCAGCGGTACCGCAGGAGCTGGCCGAGCTGGCCGCTTGGGCTACCCAAAGTGTCTCA 794  
Db 1838 TGGCAGAGTACCCCGGAGCTGGAGCTGGGCTGAGCAGGCGCCACCCACGACCTTGG 1897

QY 795 CCAACTGTGGGCTTCATCAACAGGCGGTGTGTGATGATGAGCCCATGATCAAGC 854  
Db 1898 TGAACCTGTGGGCTGTGCTGAGTCCATGCTGACCGCCAGGTGATGGATCAGAAGC 1957

QY 855 TCTCAGATCAACGGGAGGCTGAGTTCATGGCCAGAACCTCTGCCCATCTACTGTGCC 914  
Db 1958 TGTTCAGACAGAGCGGCTTGGAAACGGGGTTCAGAACCTCTGCCCTCTACTTGGACC 2017

QY 915 TCACACCAAGGAGAGAGCTGACCACTTTTGAATTTGGGAGTGGTGGAGTTCTCTC 974  
Db 2018 TCAATGTCAAAGAGAACTTCTGGAGACACTGGACTTCAAGGAGTGGTGGTGGTCTCCC 2077

QY 975 CTTACAGAGTGGCTTCCCAAGTACGGGCTTTCATCCCTCTGAGCTCTTTGGTCCG 1034  
Db 2078 CCTATGAGGTGGTTCCTTGAAGTACGGGCTTCTGCTCTCTGAGCTCTTGGCTCCG 2137

QY 1035 AGTTCTTTATGGGCGAGCTGATGAAGAGGCTTCTGAGTCCCGCATCTCTTTAGAG 1094  
Db 2138 AGTTCTTCATGGAGCGCTGATGAGGAGTATCCGGAGCCCGGATCTGCTTTCTGGAAG 2197

QY 1095 GTATCTGAGCAACCTGTATGAGCCAACTTCAGGACACTTATCTATGGGCTCAGAGC 1154  
Db 2198 CCATCTGGAGCAACATTTCTCCCTGAACTGCTGGATGCTGATGACCTCACAGTT 2257

QY 1155 CCAGCCAGTTCTGGAGCGCTGGTTCAGGAACACAGGCA-----ACC 1196  
Db 2258 CTGGGAGTCTTGGAAACAGCANCTAAGGACAGACAGGAGCTTAGAAGAGAGCCCC 2317

QY 1197 TGGACAAAGGAGCAGGCTCCCTCTTGAAGATAGAGAACCACTCTCAACAGCCGGAGAA 1256  
Db 2318 TGACCACCTCGGAGACTCTCGCGGCTGGAGGCTCTGGCTGACGACGACGCGC 2377

QY 1257 TAGCTGAGTTTTCACCGATCTTCTGAGCTGGCTCCACTGGGCCAGGCCACACATAAT 1316  
Db 2378 TGGCCAGGCAATTTAAAGGCTTCTGACAGCAGGCCCCCTCCACAGGAGCCCCAACT 2437

QY 1317 TCCTGGCTGGCTCCATTTCCACAAAGACTACTTTTCAGCACTCTCTCTCCACATGGA 1376  
Db 2438 TCTTCCAGGGCTTCCAGTGCACAGGACTACTGTAGCCACAAAGACTTCTCCACCTGG 2497

QY 1377 AAGCTACCACTCTGGATGGGCTCCCAACCAAGCTGACACCTCGGAGCCCCACCTGTCC 1436  
Db 2498 CAGACTACCACTTGACTCCATGCCAGCAGCTGACCCCAAGAGAGCCCCGGCTCTGCC 2557

QY 1437 TGCTGAGTGGCTTACCTCATCATACAGCTGCTGCCCTCTCTCGAGCCCACTCGGG 1496  
Db 2558 TGGTGGAGCGGCTTACTTCAACACCACTCTCCCTCATGTTTCGGCCAGCCGCA 2617

QY 1497 ACGTGGACTCATCTCTGTCATTGGACTACAACCTCCAGGAGCTTCCAGCAGTTGCGAGC 1556  
Db 2618 GGCTGGAGCTCATCTCTCTCTGACTACTCCCTATCTGCGGCTTTCGAGGCACTGCGAGC 2677

QY 1557 TCCTGGGCGGTTTTCGAGGAGCAGGAGTCCCTTCCCACTCTGCGGAGCTCTGCGGAGCCCG 1616  
Db 2678 AGACGAGCTGTACTTGGCGGCGCGGGGCTGCCCTTTCCTCCGGGTGGAAACCAAGCCCTC 2737

QY 1617 AAGAGCAGCTCCAGCTCGGAGTGGCAGACCTTCTCGAGCCCACTGCCCCGGAGCCCC 1676  
Db 2738 AGGACAGCAGCAGCAGGGAATGCCACCTCTTCTCAGACCCCGCTGCCCCGAGGCC 2797

QY 1677 CTGCGGTGCTGCATTT-----TTCTCTTGGGG 1703  
Db 2798 CGATCTGCTGACTTCTCCGCTGGTCAATGCTCTTCAAGGACCACTCAGGCCCGGCTG 2857

QY 1704 TCCGGCGGACACCCGAGGAGGCGAGCTGGGAGAGGTGAACCTGTCTTCTCATCGGACTCTC 1763  
Db 2858 TCCAGCGAGCCCGCAGAGCTCCAGGCTGGCGCAAGTGGATCTCACCGGGGCGACCTGCC 2917

QY 1764 CTTACCACTACAGAGGTGACTTACAGCCAGGAGGAGCTGGACAGAGTGTGTCACCTGA 1823  
Db 2918 CTTACACCTGTCCACATGACCTTCAAGAGAGAGACTTCAGAGCCCTGTGTCGGCTCA 2977

QY 1824 CACATTACAACTGTCTCAACCAACAGGAGCAGCTGCTGGAGGCTCTGCGCCAGGAGTGC 1883  
Db 2978 GTGACTACAACTGTGACAGCCAGGCTGCTGAGGCTTCTGAGGAGCCGCTGAGAGCCGCTGA 3037

QY 1884 AGCGGAG 1891  
Db 3038 AGCACCGG 3045



```

US-09-918-995-32564
; Sequence 32564, Application US/09918995
; Publication NO. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20

```

```

US-10-467-248-10
; Sequence 10, Application US/10467248
; Publication No. US20040086905A1
; GENERAL INFORMATION:
; APPLICANT: DAS, Debopriya; YAO, Monique G.;
; APPLICANT: ARVIZU, Chandra S.; BAUGHN, Mariah R.;
; APPLICANT: LU, Yan; HAFALIA, April J.A.;
; APPLICANT: CHAWLA, Narinder K.; GRIFFIN, Jennifer A.;
; APPLICANT: LU, Dyung Aina M.; YUE, Henry;
; APPLICANT: DING, Li; ELLIOTT, Vicki S.;
; APPLICANT: FORTSYTHE, Ian J.; RAMKOMAR, Jayalaxmi;
; APPLICANT: GANDHI, Ameena R.; ISON, Craig H.;
; APPLICANT: WARREN, Bridget A.; TANG, Y. Tom;
; APPLICANT: EMERLING, Brooke M.; HONCHELL, Cynthia D.;
; APPLICANT: LYNE, Michael; BARROSO, Ines
; TITLE OF INVENTION: LIPID-ASSOCIATED MOLECULES
; FILE REFERENCE: PI-0358 USN
; CURRENT APPLICATION NUMBER: US/10/467,248
; CURRENT FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: PCT/US02/03813
; PRIOR FILING DATE: 2002-02-06
; PRIOR APPLICATION NUMBER: US 60/266,910
; PRIOR FILING DATE: 2001-02-06

```

PRIOR APPLICATION NUMBER: US 60/276,891  
PRIOR FILING DATE: 2001-03-16  
PRIOR APPLICATION NUMBER: US 60/276,855  
PRIOR FILING DATE: 2001-03-16  
PRIOR APPLICATION NUMBER: US 60/279,760  
PRIOR FILING DATE: 2001-03-28  
PRIOR APPLICATION NUMBER: US 60/283,818  
PRIOR FILING DATE: 2001-04-13  
PRIOR APPLICATION NUMBER: US 60/285,405  
PRIOR FILING DATE: 2001-04-20  
NUMBER OF SEQ ID NOS: 18  
SOFTWARE: PERL Program  
SEQ ID NO 10  
LENGTH: 3879  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: misc feature  
OTHER INFORMATION: Incyte ID No: 7472774CB1  
US-10-467-248-10

Query Match 19.5%; Score 429.6; DB 17; Length 3879;  
Best Local Similarity 56.2%; Pred. No. 1.9e-105;  
Matches 909; Conservative 0; Mismatches 644; Indels 63; Gaps 3;

Qy 353 CTGGCCGTGCGAGTGGGCTTCGGCCCTGTCAGAGGAGGAGGCTTCCTGAGCAGGAGG 412  
Db 1681 CTGACGCTGGCGCTGGGCTTCAGCCTGTGCCAGAGAGCTGGAGTTCTTCAGAGCGG 1740

Qy 413 AAGCAGGTGGTGGCGCGGCTTGGAGCAGGCTTGCAGCTGGATGGAGACCTGCAGGAG 472  
Db 1741 AAGTGTGTGGTGGCGAGGCTTGAAGCAGGTGCTGCAGCTGGAGGAGAGCCTGCAGGAG 1800

Qy 473 GATGAGATCCAGTGGTATATATGAGCTATGATGAGCTGAGTGGATCCGGGCAATGACTCC 532  
Db 1801 GACGAGGTGGCGCTGATAGCCATATGCGCCTGAGGCTGGGGTGAACAAGATCCATGACCTCC 1860

Qy 533 CTGTATGGCAGCTGGCTGGCTGAGGAGCTGGGCTTCTGGATGGTCTCTTACATC 592  
Db 1861 ATGTATGGCCACCTGCTGGGCTGCAGAGCTGAACCTTCCTGGATGCTGCAGCTACATC 1920

Qy 593 ACCGGGGCTCGGGCTCCACCTGGGCTTGGCCAACTTTATGAGACCCAGAGTGGTCT 652  
Db 1921 ACTGTCTATCAGGGGCCACCTGGACCATGGCTACTTGTACCGTGAACCTGACTGGTCC 1980

Qy 653 CAGAGGACCTGGCAGGCGCCACTGAGTTGCTGAAGACCCAGGTGACAGAGAGAGCTG 712  
Db 1981 TCCAAAAACTTGGAGCTGCTATCTTTGAGGCTCGGAGACATGTGTAAAGACAAGCTA 2040

Qy 713 GGTGTGTCGGCCCGCAGCCAGCTGCAGCGGTACCGGAGGAGCTGGCCGAGGCTGCCCG 772  
Db 2041 CCTCCCTGTTCCAGACAGCTCCGCAATTCAGGAGAGCTCCGGCAGCGCCAG 2100

Qy 773 TTGGGCTACCCAACTGCTTCCAACTGTGGGCCCTCATCAAGAGCGGTGTGTGCAT 832  
Db 2101 GAAGGCTACAGGCTCACCTTTACAGACTTCTGGGGCTGCTGATAGAGACCTGCCTGGGG 2160

Qy 833 GATGAGCCCATGATCAAGCTCTCAGATCAACGGAGGCGCTTGAATCATGCCAGAAC 892  
Db 2161 GACGAGAGAAATGAATGCAAACTGTGAGTCAAGCTGCTGTGAGTGGCGCCAGAAC 2220

Qy 893 CCTCTGCCATCTACTGTGCTCCCTCAACACCAAGGCGAGGCTGTACCACTTTTGAATTT 952  
Db 2221 CCCCCCTCATCTA-----CCTCACCATCATGTCAAGATGATGATGACCAACAGGAT 2274

Qy 953 GGGGAGTGTGCGAGTTCTCTCCCTACGAGTGGCTTCCCCAAGTACGGGGCTTCAATC 1012  
Db 2275 GTGAGTGTTCAGTTCTCCCCCTACGAGTGGGCTTCAGAGATGATGGGGCTTCAATC 2334

Qy 1013 CCTCTGAGCTTTTGGCTCGAGTTCTTTATGGGCGAGCTGATGAAGGCTTCTCTGAG 1072  
Db 2335 CCTCTGAGCTTTTGGCTCGAGTTCTTTATGGGCGGCTGTTGAGAGGATCCCGGAG 2394

Qy 1073 TCCCGCATCTGCTTCTTAGAGGTATCTGGAGCAACCTGTATGACGCCAACCTCCAGGAC 1132  
Db 2395 TCTCGAATCTGCTACATGCTTAGGCTGTGGAGCAGCATCTTCTCCCTGAACCTGCTGGAT 2454

Qy 1133 AGCTTATCTGGGCTTCAGAGCCAGCCAGTTCCTGGGACCGCTGGGTGAGAACCCAGGCC 1192  
Db 2455 GCTTGAACCTGTTCACACACCTCGGAGGAGTTTTCACAGGTGGACAAGGGAGAAAGTG 2514

Qy 1193 AACCTGGACAAGGAGCAGGTCCCTTCTGAAGATAGAAGAACCCCTCAA----- 1244  
Db 2515 CAGGACATCGAAGACGAGCGGATCTCTGCTGAAATCCCAATGTGATGTAAACATCTG 2574

Qy 1245 -----CAGCGGCGAGATAGTGTGAGTTTTCACCGATCTTCTGACG 1285  
Db 2575 GAGACCAAGGTAGTATCCAGGCTATGCTGTCAAATCTTTCCGAGAAATCTTTACC 2634

Qy 1286 TGGGCTCCACTGGCCAGGCGCACATAATTTCTGCTGGTGGCTTCCATTTTCCAAAGAC 1345  
Db 2635 CATCGTCTTCTGCTGAGTTTCAAACTTCTCTAGGTGGAAGACACAGTGTAGATGTTTCCAAAC 2694

Qy 1346 TACTTTCAGCATCTCTCTTCCACATGGAAGACTACCACTCTGGATGGGCTCCCAAC 1405  
Db 2695 TACCTCCAGAATGGCCAGTTCTCTAGGTGGAAGACACAGTGTAGATGTTTCCAAAC 2754

Qy 1406 CAGCTGACACCTCGGAGCCCACTGCTGCTGCTGATGTTGGTACCTCATCAATACC 1465  
Db 2755 CAGCTGACGAGTCCGGAACCACTGCTGCTGCTGCACTGCTGTTTGTGCACTCC 2814

Qy 1466 AGCTGCTGCTCCCTCTGAGCCCACTCGGAGCTGGACCTCATCTGTCAATGGACTAC 1525  
Db 2815 AGCTACCGCCCTCTCTCAGGCGAGGAGGAAAGCCGATCTCATCATCCACTCAACTAC 2874

Qy 1526 AACCTCCAAGGAGCTTCCAGCAGTTGAGCTTCTGGGCGGCTTCTGCCAGGAGGAGG 1585  
Db 2875 TGTGCTGGGTCCTCCAGACAAAGCCCTGAAACAAACCTGTGAGTACTGCACTGTGAGAAC 2934

Qy 1586 ATCCGTTTCCC-----ACCATCTCGCCAGCCGCC 1615  
Db 2935 ATCCCTTTCCTCCAAATACAGCTGCCAGTCCAGATGAAATCTCAAGAAATGTACTCTG 2994

Qy 1616 GAAGAGCAGTCTCAGCTCGGAGTGCACACCTTCTCCGACCCCACTGCCCCGAGGCC 1675  
Db 2995 ATGGAGAACCCCGAGGAAACCGATGCCCATCTGTGACTTTTCTCCACTCATCAATGAC 3054

Qy 1676 COTGGGTGCTGCACTTTTCTGCTGGGTCCGGGACACCCGAGGAGGCGGAGCTGGG 1735  
Db 3055 ACTTCCGAAATAACAAGGCACCAAGTGTAGAGCGAAGCCCTGAGGAGCTGGAGCGGCG 3114

Qy 1736 GAGGTGAACCTGCTTCTATCGGACTCTCCCTACCACTACCAAGGTGACCTACAGCCAG 1795  
Db 3115 CAGGTGGACATTTATGGTCCCAAACTCCCTATGCAACCAAGGAGCTGACATACAGAG 3174

Qy 1796 GAGGACGTGGACAAGCTGTCACCTGACATTAATGCTGCTGCAACCAAGGAGGAG 1855  
Db 3175 GCCACTTTGACAGCTGTGAACTCTCAGAGTATAACATCTGAAATAAAGGACACT 3234

Qy 1856 CTGCTGGAGGCTTCTGCGCCAGGAGCTGACGCGGAGGCGGAGGAGGCGGAGGCTG 1911  
Db 3235 CTCTCCAGGCTCTCGGCTCGAGTGGAGAAAGAGCGCTGAGGCGGCGAGTG 3290

RESULT 13  
US-10-380-873B-2  
; Sequence 2, Application US/10380873B  
; Publication No. US20040014089A1  
; GENERAL INFORMATION:  
; APPLICANT: Hiromasa MIYAJI, et al.  
; TITLE OF INVENTION: Polypeptide having phospholipase A2 activity  
; FILE REFERENCE: 2139.34  
; CURRENT APPLICATION NUMBER: US/10/380,873B  
; CURRENT FILING DATE: 2003-07-09  
; PRIOR APPLICATION NUMBER: JP 00/146466  
; PRIOR FILING DATE: 2000-09-19





Query Match	16.6%	Score 365;	DB 16;	Length 2694;
Best Local Similarity	54.3%;	Pred. No. 4.7e-88;		
Matches 882;	Conservative 0;	Mismatches 665;	Indels 78;	Gaps 4;
QY	348	GGGAGCTGGCGCTGCGACTGGCTTCGGGCTTCGGGAGGAGCAGGCCTTCCTGACGA	407	
Db	968	GGGACTTGGACCTGCGCCTTGTTTTCACCTCTGTGATGGAGAGCAGGAATTTCTGGACA	1027	
QY	408	GGAGGAACAGAGTGGTGGCCCGCGCTTGAGGCAGGCGCTTCGCAGCTGGATGGAGACCTGC	467	
Db	1028	AGAGGAACAGAGTGGCGTCCAGGCCCTCGACGGGTGATGGGATTGAGTGAGGCTCTGC	1087	
QY	468	AGAGGATGAGATCCCAAGTGTAGCTATTATGCCACTGTGTGTGGGATCCGGGCATGA	527	
Db	1088	ACTGTGACCAAGGTACCTGTGTAGCCGTGTTAGGCTCTGGGGTGGAAACAGAGCCATGA	1147	
QY	528	CTTCCCTGTATGGCAGCTGGCTGGCTTGAAGAGCTGGGCTCTTGGATGGCTCTCCCT	587	
Db	1148	CTTCCCTGTACGGAGCCTGGCTGGGCTGCAGAGAGCTTGGTCTTCTGTGATGCCGTGACCT	1207	
QY	588	ACATCAACCGGGGCTTCGGGCTCCACCTGGGCCCTTGGCCACCTTTATGAGGCCACAGT	647	
Db	1208	ACCTGAGTGGGGTCTCTGGGTCTTCTGTGTGATCTTACACTCTACAGGATGCCATCCT	1267	
QY	648	GGTCTCAGAAAGCACTGGCGAGGGCCCACTGAGTTGCTGAAAGACCCAGGTGACCAAGACA	707	
Db	1268	GGTCCACAGAGGCTTTGACAGGGCCCCATTAAATATGCCTCAGAGCGAGTCTGCAGCATG	1327	
QY	708	AGCTGGGTGTGCTGGCCCCCGCCAGCTGACGGGTGACCGGAGAGCTGGCCGAGCGTG	767	
Db	1328	AAATTGGGATGCTGTCTCCCAAGCAGTTTGAATACTACTCCCGGAAAAAGAGCGCTGG	1387	
QY	768	CCCGTCTGGGCTACCCAAGCTGCTTCAACCAACTGTGGGCCCTCATCAACAGGCGCTGC	827	
Db	1388	AGAGCAGGGGACACAGCATGTCTTCACTGACTGTGTGGGCTCATCATGTGATGATTTCC	1447	
QY	828	TGCATGATGAGCCCCATGATCAAAAGCTCTAGATCAACGGGAGGCCCTGAGTCATGGCC	887	
Db	1448	TGAACCCAGAGGAAAAACCTGCCAAGTGTGACAGCAGCAAGAGGTCAGCCAGGTC	1507	
QY	888	AGAAACCTCTGCCCATCTACTGTGGCTCAACACCAAGGGCAGAGCCTGACCACTTTTG	947	
Db	1508	AGAACCCATACCCCATCTA---TGGCAGCATTAATGTCCAAAAAATCATAGTGGGGACG	1564	
QY	948	AATTTGGGAGTGGTGGAGTTCTCTCCCTACGAGTGGCTTCCCAAGTACGGGGCT	1007	
Db	1565	ACTTTGCAGAGTGGTGGAGTTCACCCCCTATAGAGTGGTTTCCCCAAGTACGGGGCTT	1624	
QY	1008	TCATCCCTCTGAGCTCTTTGGCTCCGAGTCTTTATGGGGCAGCTGATGAAGGCTTC	1067	
Db	1625	ACGTTTCCACCGAACTCTTTGGCTCTGAATCTTTCATGGCCGGCTGCTGATTTCTGGC	1684	
QY	1068	CTGAGTCCCGCATCTGCTTCTTAGAAGGTATCTGGAGCAACTGTGATGACGCCAACCCTCC	1127	
Db	1685	CAGAGCCCGCATCTGTTTACCTGCAAGGTATGTGGGGAAGTGCTTTTGCAGCCAGCCTGT	1744	
QY	1128	AGGACAGCTTACTTGGGCTTCAGAGCCAGCCAGTCTTGGGACCGCTGGGTGAGGAACC	1187	
Db	1745	ATGAGATCTTCTGAGCTGGAGGCCCTTAGGCCGTGAGCTTTCTGGACTGGCACAGGGGGA	1804	

Search completed: October 7, 2004, 22:41:01  
Job time : 1150.17 secs

Search completed: October 7, 2004, 22:41:01  
Job time : 1150.17 secs

**This Page Blank (uspto)**

Result No.	Score	Query Match %	Length	DB	ID	Description
1	1129.8	51.3	4240	11	AK037218	Mus muscu
2	892.8	40.5	1131	12	BM928260	AGENCOURT
3	697	31.6	957	14	CA488226	CA488226 AGENCOURT
4	677.6	30.7	949	12	BI768993	BI768993 603058145

REFERENCE AUTHORS	3 Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P., Konno,H., Akiyama,J., Nishi,K., Katsunai,T., Tashiro,H., Itoh,M., Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A., Yanamoto,R., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kashiwagi,K., Fujiwaka,S., Inoue,K., Togawa,Y., Izawa,M., Ohata,E., Watahiki,M., Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsunura,S., Kawai,J., Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y. RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer Genome Res. 10 (11), 1757-1771 (2000) 20530913 11076861
TITLE	4 The RIKEN Genome Exploration Research Group Phase II Team and the PANTOM Consortium. Functional annotation of a full-length mouse cDNA collection Nature 409, 685-690 (2001)
JOURNAL MEDLINE PUBMED REFERENCE AUTHORS	5 The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs Nature 420, 563-573 (2002) 6 (bases 1 to 4240) Adachi,J., Aizawa,K., Akimura,T., Arakawa,T., Bono,H., Carninci,P., Fukuda,S., Furuno,M., Hanagaki,T., Hara,A., Hashizume,W., Hayashida,K., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hirozane,T., Hori,F., Imotani,K., Ishii,Y., Itoh,M., Kagawa,I., Kasukawa,T., Kato,H., Kawai,J., Kohji,Y., Kondo,S., Konno,H., Kouda,M., Koya,S., Kurihara,C., Matsuyama,T., Miyazaki,A., Murata,M., Nakamura,M., Nishi,K., Nomura,K., Numazaki,R., Ohno,M., Ohsato,N., Okazaki,Y., Saito,R., Saitoh,H., Sakai,C., Sakai,K., Sakazume,N., Sano,H., Sasaki,D., Shibata,K., Shinagawa,A., Shiraki,T., Sogabe,Y., Tagami,M., Tagawa,A., Takahashi,F., Takaku-Akahira,S., Takeda,Y., Tanaka,T., Tomaru,A., Toya,T., Yasunishi,A., Muramatsu,M. and Hayashizaki,Y. Direct Submission
TITLE JOURNAL	Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail:genome-res@gsr.riken.go.jp, URL:http://genome.gsc.riken.go.jp/, Tel:81-45-503-9222, Fax:81-45-503-9216)
COMMENT	cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. Please visit our web site for further details. URL:http://genome.gsc.riken.go.jp/ URL:http://fantom.gsc.riken.go.jp/.
FEATURES	Location/Qualifiers 1..4240 /organism="Mus musculus" /mol_type="mRNA" /strain="C57BL/6J" /db_xref="FANTOM DB:A030011C02" /db_xref="MGI:2401694" /db_xref="taxon:10090" /clone="A030011C02" /tissue_type="skin" /clone_lib="RIKEN full-length enriched mouse cDNA library" /dev_stage="6 days neonate"
misc_feature	1..4240 /note="similar to CYTOSOLIC PHOSPHOLIPASE A2 BETA [Homo sapiens] (SPR 095712, evidence: FASTY, 70.9%ID, 76.7%length, match=2694)"
ORIGIN	Query Match 51.3%; Score 1129.8; DB 11; Length 4240; Best Local Similarity 82.5%; Pred. No. 1.3e-215;
Matches 1321; Conservative 0; Mismatches 247; Indels 33; Gaps 1;	
334	GGATTACAGACTGAGGAGCTGGCCCTGGGACTGGGCTTTCGGCCCTTTCGGAGAGGACA 393
2270	GGAGNAGACCAAGAGAGCTGGCTGTGGGCTGGGCTGTGGGCTTTCGGAGGACA 2329
394	GGCTTTCCTGAGCAGAGAGAGAGCTGGTGGGCGGGCTTTCAGGAGAGGCGCTTCAGCT 453
2330	GGCTTTCCTAAGCAAGAGAGAGAGCTGGTGGGCTTTCAGGAGAGGCGCTTTCAGCT 2389
454	GGATGAGAGCTTCAGGAGAGAGAGAGCTGGTGGGCTTTCAGGAGAGGCGCTTTCAGCT 513
2390	GGACCAAGAGCTTCAGGAGAGAGAGAGCTGGTGGGCTTTCAGGAGAGGCGCTTTCAGCT 2449
514	GATCCGGGCAATGACTTCCCTGTATGGGAGAGCTGGTGGGCTTTCAGGAGAGGCGCTTTC 573
2450	GATCCGGGCAATGACTTCCCTGTATGGGAGAGCTGGTGGGCTTTCAGGAGAGGCGCTTTC 2509
574	GGATTGGCTTCCTACATACACCGGGGCTTCAGAGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 633
2510	CGACTGCATCTCCTATATACCGGGGCTTTCAGGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 2569
634	TGAGGAGAGAGAGAGAGAGCTGGGCTTCAGAGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 693
2570	TGAGGAGAGAGAGAGAGAGCTGGGCTTCAGAGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 2629
694	GGTGACCAAGAAAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 753
2630	GGTGACCAAGAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGGAGAGGCGCTTTC 2689
754	GCTGGGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 813
2690	GCTGGGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 2749
814	CAAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 873
2750	TAATGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 2809
874	CCTGAGTCAATGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 933
2810	CCTGAGTCAATGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 2869
934	CCTGAGTCAATGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 993
2870	CCTGAGTCAATGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 2929
994	CAAGTACGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 1053
2930	CAAGTACGGGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAG 2989
1054	GATGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCT 1113
2990	GATGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCT 3049
1114	TGAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCT 1173
3050	TGAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCT 3109
1174	CTGGGTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAG 1233
3110	CTGGGTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAG 3169
1234	ACCACCTCAACAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 1293
3170	GCCACCGAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAG 3229
1294	ACTGGGTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAG 1353
3230	CCTGGGTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTCAGAG 3289
1354	GCATCTCACTTTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 1413
3290	GAACTCTCACTTTCAGAGAGAGCTTTCAGAGAGAGCTGGGCTTTCAGAGAGAGCTGGGCTTTC 3349



/note=Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: EcoRV (destroyed); RNA source anonymous pool of 3 fetal brains, female age 20 weeks, female age 24 weeks, and male age 26 weeks. Library is oligo-dT primed and directionally cloned (EcoRV site is destroyed upon cloning). Average insert size 1.7 kb, insert size range 0.7-3.5 kb. Library is normalized and enriched for full-length clones and was constructed by C. Gruber (Invitrogen). Research Genetics tracking code 017. Note: this is a NIH MGC Library."

Query Match	40.5%;	Score 892.8;	DB 12;	Length 1131;
Best Local Similarity	93.4%;	Pred. No. 3.8e-168;		
Matches 998;	Conservative 0;	Mismatches 60;	Indels 11;	Gaps 6;
QY	627	ACCTTTATGAGGACCCACAGTGGTCTCAGAAAGACCTGGCAGGGCCCATGAGTTCTCTGA	686	
Db	18	ATCTTTATGAGACCCAGAGTGGTCTCAGAAAGACCTGGCAGGGCCCATGAGTTCTCTGA	77	
QY	687	AGACCACAGGTACCAAGAAACAAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACC	746	
Db	78	AGACCACAGGTACCAAGAAACAAGCTGGGTGTGCTGGCCCCCAGCCAGCTGCAGCGGTACC	137	
QY	747	GGCAGGAGCTGGCCGAGGGTGCCCGCTTGGGCTACCCAACTGCTTACCAACCTGTGGG	806	
Db	138	GGCAGGAGCTGGCCGAGGGTGCCCGCTTGGGCTACCCAACTGCTTACCAACCTGTGGG	197	
QY	807	CCCTCATCAAGAGGCGCTGCTGCATCATAGAGCCCATGATCAAGGCTCTCAGATCAAC	866	
Db	198	CCCTCATCAAGAGGCGCTGCTGCATCATAGAGCCCATGATCAAGGCTCTCAGATCAAC	257	
QY	867	GGGAGGCCCTGAGTCATGGCCAGAAACCTCTGCCCATCTACTGTGCCCTCAACACCAAG	926	
Db	258	GGGAGGCCCTGAGTCATGGCCAGAAACCTCTGCCCATCTACTGTGCCCTCAACACCAAG	317	
QY	927	GGCAGAGCTGACCACTTTTGAATTTGGGAGTGGTGCAGATTCTCTCCCTACGAGGTCTG	986	
Db	318	GGCAGAGCTGACCACTTTTGAATTTGGGAGTGGTGCAGATTCTCTCCCTACGAGGTCTG	377	
QY	987	GCTTCCCCAAAGTACGGGCGCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGG	1046	
Db	378	GCTTCCCCAAAGTACGGGCGCTTCATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGG	437	
QY	1047	GGCAGCTGATGAAGAGGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGGAGCA	1106	
Db	438	GGCAGCTGATGAAGAGGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGGAGCA	497	
QY	1107	ACCTGTATGAGGCAACCTCTCAGGACAGCTTATATGGGCTCTCAGAGCCACGAGTTCT	1166	
Db	498	ACCTGTATGAGGCAACCTCTCAGGACAGCTTATATGGGCTCTCAGAGCCACGAGTTCT	557	
QY	1167	GGGACCGCTGGGTACGGAACACGAGCCACCTGGACAGCTTATCTGGGCTCAGAGCCAGGAGTCT	1226	
Db	558	GGGACCGCTGGGTACGGAACACGAGCCACCTGGACAGCTTATCTGGGCTCAGAGCCAGGAGTCT	617	
QY	1227	TAGAAGAACCACTCAACAGCGCGCAGAAATGCTAGTTTTTACCAGTATCTCTGAGCT	1286	
Db	618	TAGAAGAACCACTCAACAGCGCGCAGGATAGCTAGTTTTTACCAGTATCTCTGAGCT	677	
QY	1287	GGCGTCCATGGCCAGGCCACACATAATTTCTGCGTGGCGCTCAATTTCCACAAAGACT	1346	
Db	678	GGCGTCCATGGCCAGGCCACACATAATTTCTGCGTGGCGCTCAATTTCCACAAAGACT	737	
QY	1347	ACTTTTCAGCATCTCACTTCTCCATCGAAAGCTACCACTCTGGATGGGTCCCCAAC	1406	
Db	738	ACTTTTCAGCATCTCACTTCTCCATCGAAAGCTACCACTCTGGATGGGTCCCCAAC	797	
QY	1407	AGCTGACACCTCTCGAGGCCACCTGTGCCCTGCTGGATGTGGTACTCATATACCA	1466	
Db	798	AGCTGACACCTCTCGAGGCCACCTGTGCCCTGCTGGATGTGGTACTCATATACCA	857	
QY	1467	GCTGCTGCCCTCTCTGAGGCCACTCGGAGCTGGACC-TCATCTGTGATTTGGACTAC	1525	

```

RESULT 2
BM928260
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BM928260
AGENCOURT_6699873 NIH_MGC_121 Homo sapiens cDNA clone IMAGE:5770097
5', mRNA sequence.
BM928260
BM928260.1 GI:19378639
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
NIH-MGC http://mgc.nci.nih.gov/
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgabbs@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM12832 row: j column: 18
High quality sequence stop: 629.
Location/Qualifiers
1..1131
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5770097"
/lab_host="DH10B"
/clone_lib="NIH MGC 121"

FEATURES
source

```

```

FEATURES
  high quality sequence stop: 629.
  Location/Qualifiers
    1..1131
      organism="Homo sapiens"
      mol_type="mrna"
      db_xref="taxon:9606"
      clone="IMAGE:5770097"
      lab_host="DH10B"
      clone_lib="NIH MGC 121"

```



QY	1711	GACA-CCGAGGAGCGGACGTGGGAGGTGAACCTGT--CTTCATCGGACTCTCCCTA	1767
D5	720	GACACCCGAGGAGCGGAGCTGGGAGGTGAACCTGTCTTCATCGGACTCTCCCTA	779
QY	1768	CCACTACACG-AAGGTGACCTACAGCCAGGAGG---ACGTGGACAAGCTCTGCACCTGA	1823
D5	780	CCACTACACGAATGTGACTTACAGCCAGGAGGACCGTGGACCAAGCTGTGCACTGAA	839
QY	1824	CACATTACATGTCTGCAACAACAGGAGCAGCTGTGGAGGTCTTCGCGCCAGGCAGTGC	1883
D5	840	CACATTACAAATGTCTGCAAAACCA-GAGCAAGTGTCTAAGGCTCTG-GCCAGGCAGTGC	897
QY	1884	AGCGAGGCGCGCAGCGCAGGCCCCACTGTATGGCGCGGGCC	1923
D5	898	AGGAGGCCAAAGC---AGGCCCTTGTATGGCGCGGGCC	934
RESULT 5	BU688449/c		
LOCUS	BU688449	759 bp	linear
DEFINITION	UI-CF-EC1-aea-j-17-0-UI.s1 UI-CF-EC1 Homo sapiens cDNA clone		EST 07-OCT-2002
ACCESSION	UI-CF-EC1-aea-j-17-0-UI 3', mRNA sequence.		
VERSION	BU688449		
KEYWORDS	EST.		
SOURCE	BU688449.1 GI:23545244		
ORGANISM	Homo sapiens (human)		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
AUTHORS	Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.		
TITLE	Bonaldi,M.F., Lennon,G. and Soares,M.B.		
JOURNAL	Normalization and subtraction: two approaches to facilitate gene		
MEDLINE	discovery		
PUBMED	Genome Res. 6 (9), 791-806 (1996)		
COMMENT	97044477		
	8889548		
	Contact: McCray, PB		
	McCray Lab		
	University of Iowa		
	2024 University of Iowa Med Labs, Iowa City, IA 52242, USA		
	Tel: 319 356 4866		
	Fax: 319 356 7171		
	Email: paul-mccray@uiowa.edu		
	Tissue Procurement: Dr. M. J. Welsh, University of Iowa		
	cDNA Library preparation: Dr. M. Bento Soares, University of Iowa		
	cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa		
	CNA Sequencing by: Dr. M. Bento Soares, University of Iowa		
	Clone Distribution: Researchers may obtain clones from Research		
	Genetics (www.resgen.com) or from Open Biosystems		
	(www.openbiosystems.com).		
	Seq primer: M13 FORWARD		
	POLYA=Yes.		
FEATURES	Location/Qualifiers		
Source	1..759		
	/organism="Homo sapiens"		
	/mol_type="mRNA"		
	/db_xref="taxon:9606"		
	/clone="UI-CF-EC1-aea-j-17-0-UI"		
	/tissue_type="Lung"		
	/dev_stages="Adult and Fetal"		
	/lab_host="DH10B (Life Technologies) (T1 phage resistant)"		
	/clone_lib="UI-CF-EC1"		
	/note="Organ: Lung; Vector: pT7T3-Pac (Pharmacia) with a		
	modified polylinker; Site_1: EcoR I; Site_2: Not I;		
	UI-CF-EC1 is a normalized cDNA library containing the		
	following tissue(s): Normal lung from adult and from fetal		
	day 64, day 87, week 19 and week 42. The library was		
	constructed according to Bonaldi, Lennon and Soares,		
	Genome Research, 6:791-806, 1996. First strand cDNA		
	synthesis was primed with an oligo-dT primer containing a		
	Not I site. Double stranded cDNA was ligated to an EcoR I		
	adaptor, digested with Not I, and cloned directionally		
	into pT7T3-Pac vector. The oligonucleotide used to prime		

the synthesis of first-strand cDNA contains a library tag sequence that is located between the Not I site and the (dT)18 tail. The sequence tag for this library is AAGTGTCTTAC. TAG TISSUE=Normal Lung Epithelial Cells Tissue nos 369-371 and 380-383 TAG LIB=UI-CF-EC1 TAG\_SEQ=AAGTGTCTTAC"

ORIGIN

Query Match 30.0%; Score 661.4; DB 13; Length 759;  
Best Local Similarity 94.2%; Pred. No. 7.9e-122;  
Matches 711; Conservative 0; Mismatches 11; Indels 33; Gaps 1;  
QY 1483 GCAGCCCACTCGGACGTGACCTCATCTCTGATTTGGACTACAACTCCACGAGCCTT 1542  
Db |||||||  
QY 1543 CCAGCAGTTGAGCTCTGGCGGTTCGCGAGCAGCGGATCCGTTCCACCCAT 1602  
Db |||||||  
QY 699 CCAGCAGTTGAGCTCTGGCGGTTCGCGAGCAGCGGATCCGTTCCACCCAT 640  
Db |||||||  
QY 1603 CTGCCCCAGCCCCGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCAC 1662  
Db |||||||  
QY 639 CTGCCCCAGCCCCGAGCAGCTCCAGCCTCGGAGTGCACACCTTCTCCGACCCAC 580  
Db |||||||  
QY 1663 CTGCCCCGAGCCCTCGGCTGCTGCACTTT----- 1693  
Db |||||||  
QY 579 CTGCCCCGAGCCCTCGGCTGCTGCACTTTCTCTGCTCAGCGACTCTTCCGGGAGTA 520  
Db |||||||  
QY 1694 ----TCTCTCGGCTCGGCGGACACCGAGCGCGCAGCTGGGAGGTGAACCTGTCT 1749  
Db |||||||  
QY 519 CTGCGCCCTCGGCTCGGAGACACCGAGAGCGGCAGCTGGGAGGTGAACCTGTCT 460  
Db |||||||  
QY 1750 TTCAATCGACTCTCCCTACCTACACGAGGTGACCTACAGCCAGGAGGACGTTGACAA 1809  
Db |||||||  
QY 459 TTCAATCGACTCTCCCTACCTACACGAGGTGACCTACAGCCAGGAGGACGTTGACAA 400  
Db |||||||  
QY 1810 GCTGCTGACCTGACACATTACATGCTGCAACACGAGCAGCTGCTGGAGGCTCT 1869  
Db |||||||  
QY 399 GCTGCTGACCTGACACATTACATGCTGCAACACGAGCAGCTGCTGGAGGCTCT 340  
Db |||||||  
QY 1870 GCGCAGCAGTGACGCGGAGCGCAGCGAGGCCCACTGATGCGCGGCGCCCTGCC 1929  
Db |||||||  
QY 339 GCGCAGCAGTGACGCGGAGCGCAGCGAGGCCCACTGATGCGCGGCGCCCTGCC 280  
Db |||||||  
QY 1930 ACCCTTAACCTCTCAATTCCTCGCTGCTGAGTTGAGGTGGAACTGTATCAGCA 1989  
Db |||||||  
QY 279 ACCCTTAACCTCTCAATTCCTCGCTGCTGAGTTGAGGTGGAACTGTATCAGCA 220  
Db |||||||  
QY 1990 GTGCTTCAGAGCTCGGGCTCAGGTGGCACTGTCGCCAGGCTCCAGGCTGAGGCTGGGAG 2049  
Db |||||||  
QY 219 GTGCTTCAGAGCTCGGGCTCAGGTGGCACTGTCGCCAGGCTCCAGGCTGAGGCTGGGAG 160  
Db |||||||  
QY 2050 CTCCTCTGCGCTCAGCAGTTTTCAGTGGGGTAAGGAGCCCAAGCCCAATTTGTATCA 2109  
Db |||||||  
QY 159 CTCCTCTGCGCTCAGCAGTTTTCAGTGGGGTAAGGAGCCCAAGCCCAATTTGTATCA 100  
Db |||||||  
QY 2110 CCAAAACCCCGGCTCTGCTGCTTTTCCCTTCTGCTGCTACCTTGTAGTTGAGCA 2169  
Db |||||||  
QY 99 CCAAAACCCCGGCTCTGCTGCTTTTCCCTTCTGCTGCTACCTTGTAGTTGAGCA 40  
Db |||||||  
QY 2170 CTTGATACATCAGACTCATACAAAAA 2204  
Db |||||||  
QY 39 CTTGATACATCAGACTCATACAAAAA 5  
Db |||||||

RESULT 6  
BM718675  
LOCUS  
DEFINITION  
UI-E-EO1-ajc-i-21-0-UI.r1 UI-E-EO1 Homo sapiens cDNA clone  
UI-E-EO1-ajc-i-21-0-UI 5', mRNA sequence.  
ACCESSION  
BM718675

VERSION

KEYWORDS  
SOURCE  
ORGANISM

REFERENCE

AUTHORS  
TITLE  
JOURNAL  
MEDLINE  
PUBMED  
COMMENT

BM718675.1 GI:19037020  
EST.  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 647)  
Bonaldo,M.F., Lennon,G. and Soares,M.B.  
Normalization and subtraction: two approaches to facilitate gene  
discovery  
Genome Res. 6 (9), 791-806 (1996)  
97044477  
8889548  
Contact: Soares, MB  
Coordinated Laboratory for Computational Genomics  
University of Iowa  
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA  
Tel: 319 335 8250  
Fax: 319 335 9565  
Email: Bento-soares@uiowa.edu  
Tissue Procurement: Dr. Gregg Hageman  
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa  
cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa  
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa  
Clone Distribution: Researchers may obtain clones from Research  
Genetics (www.resgen.com).  
Seq primer: M13 Reverse.  
Location/Qualifiers  
1. .647  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="UI-E-EO1-ajc-i-21-0-UI"  
/tissue\_type="fetal eye"  
/dev\_stage="fetal"  
/lab\_host="DH10B (Life Technologies) (T1 phage resistant)"  
/clone\_lib="UI-E-EO1"  
/note="Organ: eye; Vector: p773-Pac (Pharmacia) with a  
modified polylinker; Site 1: EcoR I; Site 2: Not I;  
UI-E-EO1 is a normalized cDNA library containing the  
following tissue(s): fetal eye. The library was  
constructed according to Bonaldo, Lennon and Soares,  
Genome Research, 6:791-806, 1996. First strand cDNA  
synthesis was primed with an oligo-dT primer containing a  
Not I site. Double stranded cDNA was ligated to an EcoR I  
adaptor, digested with Not I, and cloned directionally  
into p773-Pac vector. The oligonucleotide used to prime  
the synthesis of first-strand cDNA contains a library tag  
sequence that is located between the Not I site and the  
(dT)18 tail. The sequence tag for this library is  
CGCGTATACC. This library was created for the program, Gene  
Discovery in the Visual System, supported by National Eye  
Institute (NEI)."

FEATURES

source

ORIGIN

Query Match 28.7%; Score 633.2; DB 12; Length 647;  
Best Local Similarity 99.4%; Pred. No. 3.5e-116;  
Matches 635; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 470 GAGGATGAGATCCCAGTGTAGCTATTATGGCCACTGTGTGGGATCCGGCAATGACT 529  
Db |||||||  
QY 530 TCCCTGTATGGCAGCTGGCTCGCTGAAGAGAGCTGGGCTCTTGGATTGCTCTCTAC 589  
Db |||||||  
QY 590 ATCAGCGGGCTCGGGCTCCACCTGGGCTTGGCCACCTTTATCAGCACCCAGAGTGG 649  
Db |||||||  
QY 121 ATCAGCGGGCTCGGGCTCCACCTGGGCTTGGCCACCTTTATGAGGACCCAGAGTGG 180  
Db |||||||  
QY 650 TCTCAGAAGACCTGGCAGGCGCCACTGATGTTCTGAAGACCCAGGTGACCAAGAACAG 709  
Db |||||||

```

Db      181 TCTCAGAGACCTGGCAGGGGCCCATGAGTTGCTGAAGACCCAGGTGACCAAGAAACAAG 240
QY      710 CTGGGTGTGCTGGCCGCCACCCAGCTGCGAGCGGTACCGGAGGAGTGGCCGAGCGTGCC 769
Db      241 CTGGGTGTGCTGGCCGCCACCCAGCTGCGAGCGGTACCGGAGGAGTGGCCGAGCGTGCC 300
QY      770 CGCTTGGGTACCAAGCTGCTTACCAACCTGTGGGCCCTCATCAATGAGGCGCTGCTG 829
Db      301 CGCTTGGGTACCAAGCTGCTTACCAACCTGTGGGCCCTCATCAATGAGGCGCTGCTG 360
QY      830 CATGATGAGCCCATCATCATCAGAGCTCTCAGATCAACGAGGAGGCGCTGATCATGCCAG 889
Db      361 CATGATGAGCCCATCATCATCAGAGCTCTCAGATCAACGAGGAGGCGCTGATCATGCCAG 420
QY      890 AACCTCTGCCATCTACTGTGCTTCAACACCAAGGAGGAGGCGCTGACCACTTTTGA 949
Db      421 AACCTCTGCCATCTACTGTGCTTCAACACCAAGGAGGAGGCGCTGACCACTTTTGA 480
QY      950 TTTGGGGAGTGTGGAGTTCTCTCCCTACGAGGTGGCTTCCCAAGTACGGGGCTTC 1009
Db      481 TTTGGGGAGTGTGGAGTTCTCTCCCTACGAGGTGGCTTCCCAAGTACGGGGCTTC 540
QY      1010 ATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGCGAGCTGATGAAGGCTTCT 1069
Db      541 ATCCCTCTGAGCTCTTTGGCTCCGAGTTCTTTATGGGCGAGCTGATGAAGGCTTCT 600
QY      1070 GAGTCCCGCATCTGCTTCTTAGAAGTATCTGGAGCAAC 1108
Db      601 GAGTCTCGCATCTGCTTCTTANAAGTATCTGGAGCACC 639

```

## RESULT 7

```

BM982475/c
LOCUS      BM982475.1 701 bp mRNA linear EST 21-FEB-2003
DEFINITION UI-CF-EN1-acq-e-01-0-UI-s1 UI-CF-EN1 Homo sapiens cDNA clone
            UI-CF-EN1-acq-e-01-0-UI-3', mRNA sequence.
ACCESSION  BM982475
VERSION     BM982475.1 GI:19606011
KEYWORDS    EST.
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 701)
AUTHORS     Bonaldo,M.F., Lennon,G. and Soares,M.B.
TITLE       Normalization and subtraction: two approaches to facilitate gene
            discovery
JOURNAL     Genome Res. 6 (9), 791-806 (1996)
MEDLINE    97044477
PUBMED     8889548
COMMENT     Contact: McCray, PB
            McCray Lab
            University of Iowa
            2024 University of Iowa Med Labs, Iowa City, IA 52242, USA
            Tel: 319 356 4866
            Fax: 319 356 7171
            Email: paul-mccray@uiowa.edu
            Tissue Procurement: Dr. M. J. Welsh, University of Iowa
            cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
            DNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
            DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
            Clone Distribution: Researchers may obtain clones from Research
            Genetics (www.resgen.com) or from Open Biosystems
            (www.openbiosystems.com).
            Seq primer: M13 FORWARD
            POLYA=Yes
            Location/Qualifiers
                1..701
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /clone="UI-CF-EN1-acq-e-01-0-UI"
                /tissue_type="Primary Lung Cystic Fibrosis Epithelial

```

## FEATURES

```

source
Query Match      27.9%; Score 615.2; DB 12; Length 701;
Best Local Similarity 94.7%; Pred. No. 1.4e-112;
Matches 660; Conservative 0; Mismatches 4; Indels 33; Gaps 1;
QY      1541 TTCCAGCAGTTGTCAGCTCTCTGGCCCGGTTCTGCCAGGAGCAGCGGATCCCGTTCCACCCC 1600
Db      701 TTCCAGCAGTTGTCAGCTCTCTGGCCCGGTTTNGCAGGAGCAGCGGATCCCGTTCCACCCC 642
QY      1601 ATCTCGCCAGCCCGAAGAGAGCAGCTCAGGCTCGGAGTGCCACACCTTCTCCGACCCC 1660
Db      641 ATCTCGCCAGCCCGAAGAGAGCAGCTCAGGCTCGGAGTGCCACACCTTCTCCGACCCC 582
QY      1661 ACCTGCCCGGAGCCCTCGCGTGTGCACATT----- 1693
Db      581 ACCTGCCCGGAGCCCTCGCGTGTGCACATTCTCTGTGTCAGCGACTCTCTCCGGAG 522
QY      1694 -----TCCTCTGGGTCGCGCGGACACCCGAGAGCGCGCAGCTGGGGAGTGAACCTG 1747
Db      521 TACTCGGCCCTCGGGTCCGCGGACACCCGAGAGCGCGCAGCTGGGGAGTGAACCTG 462
QY      1748 TCTTCATCGGACTCTCCCTACCACTACACGAAAGTGACTACAGCCAGGAGGACGTGGAC 1807
Db      461 TCTTCATCGGACTCTCCCTACCACTACACGAAAGTGACTACAGCCAGGAGGACGTGGAC 402
QY      1808 AAGCTGTGTGACCTGACACATTACATGTCTGCAACACACGAGGAGCAGCTGCTGGAGGCT 1867
Db      401 AAGCTGTGTGACCTGACACATTACATGTCTGCAACACACGAGGAGCAGCTGCTGGAGGCT 342
QY      1868 CTGCGCCAGGAGTGCAGCGGAGCGCGCAGCGAGGCCCACTGATGCCCGGGGCCCTG 1927
Db      341 CTGCGCCAGGAGTGCAGCGGAGCGCGCAGCGAGGCCCACTGATGCCCGGGGCCCTG 282
QY      1928 CCACCCCTAATCTCATTTTCCTGGCTGCTGAGTTGAGTTGAGGAACTGTTCATCAG 1987
Db      281 CCACCCCTAATCTCATTTTCCTGGCTGCTGAGTTGAGTTGAGGAACTGTTCATCAG 222
QY      1988 CAGTGCTTCAGAGCTCGGGCTCAGTGCGCACTGTCCCGAGGTTCCAGCTGAGGCTGGG 2047
Db      221 CAGTGCTTCAGAGCTCGGGCTCAGTGCGCACTGTCCCGAGGTTCCAGCTGAGGCTGGG 162
QY      2048 AGCTCCCTTGGCCTCAGCAGTTTTCAGTGGGGTAAGGAGGCCAAGCCCACTTGTGTAAT 2107
Db      161 AGCTCCCTTGGCCTCAGCAGTTTTCAGTGGGGTAAGGAGGCCAAGCCCACTTGTGTAAT 102
QY      2108 CACCCAAAACCCCGGCTGTGCCTGTTTTCCTTCTCGGCTACCTTGTAGTAGTGGAG 2167
Db      101 CACCCAAAACCCCGGCTGTGCCTGTTTTCCTTCTCGGCTACCTTGTAGTAGTGGAG 42
QY      2168 CACTTGATACATCACAGACTCATACAAAAA 2204

```

## Cells"

```

/dev_stage="Adult"
/lab_host="DH10B (Life Technologies) (T1 phage resistant)"
/clone_lib="UI-CF-EN1"
/notes="Organ: Lung; Vector: pT73-Pac (Pharmacia) with a
modified polylinker; Site 1: EcoR I; Site 2: Not I;
UI-CF-EN1 is a normalized cDNA library containing the
following tissue(s): Primary Lung Cystic Fibrosis
Epithelial Cells. The library was constructed according to
Bonaldo, Lennon and Soares, Genome Research, 6:791-806,
1996. First strand cDNA synthesis was primed with an
oligo-dT primer containing a Not I site. Double stranded
cDNA was ligated to an EcoR I adaptor, digested with Not
I, and cloned directionally into pT73-Pac vector. The
oligonucleotide used to prime the synthesis of
first-strand cDNA contains a library tag sequence that is
located between the Not I site and the (dT)18 tail. The
sequence tag for this library is CTGCTCAGCT.
TAG TISSUE=Human Lung Epithelial Cell Lines untreated LPS
Chr to LPS 24h
TAG LIB=UI-CF-EN1
TAG_SEQ=CTGCTCAGGT"

```

```

|||||
41 CACTGTATACATCAGACACTATACAAAAA 5

Db
CD252554 869 bp mRNA linear EST 22-MAY-2003
AGENCOURT 14161855 NIH_MGC_181 Homo sapiens cDNA clone
IMAGE:30374934 5', mRNA sequence.
CD252554
ACCESSION CD252554.1 GI:31013020
VERSION Homo sapiens (human)
KEYWORDS EST.
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 869)
JOURNAL NIH-MGC http://mgc.nci.nih.gov/.
COMMENT National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Daniela S. Gerhard, Ph.D.
Office of Cancer Genomics
National Cancer Institute / NIH
Bldg. 31 Rm10A07 Bethesda, MD 20892
Email: cgapbs-re@mail.nih.gov
Tissue Procurement: Dr. Michael Brownstein
cDNA Library Preparation: Invitrogen Corp
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: ND4W435 row: c column: 07
High quality sequence start: 6
High quality sequence stop: 549.
FEATURES
Location/Qualifiers
1..869
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:30374934"
/tissue_type="White Matter"
/dev_status="Unknown"
/lab_host="DH10B-Ton A (T1 and T5 phage resistances)"
/clone_lib="NIH_MGC_181"
/note="Vector: pCMV-SPORT6.1; Site_1: NotI; Site_2: EcoRV
(destroyed); Library is oligo-dr primed and directionally
cloned (EcoRV site is destroyed upon cloning). Average
insert size 1.42 kb. Library was constructed by
(Invitrogen). Note: this is a NIH_MGC Library."

ORIGIN
source
Query Match 27.6%; Score 608; DB 14; Length 869;
Best Local Similarity 99.0%; Pred. No. 3.8e-111;
Matches 622; Conservative 0; Mismatches 5; Indels 1; Gaps 1;

QY 879 GTCTATGGCCAGAACCTCTGCCACTACTGTGCGCTCAACACCAAGGCGAGCGCTCA 938
Db 5 GTCTATGGCCAGAACCTCTGCCCTCTACTGTGCGCTCAACACCAAGGCGAGCGCTCA 63
QY 939 CCACCTTTTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACGAGTGTGCGCTTCCCAAGT 998
Db 64 CCACCTTTTGAATTTGGGAGTGTGCGAGTTCTCTCCCTACGAGTGTGCGCTTCCCAAGT 123
QY 999 ACGGGCCCTATCCCTCTGAGCTTTGGTCCGAGTTCTTATGGGGCAGCTGATCA 1058
Db 124 ACGGGCCCTATCCCTCTGAGCTTTGGTCCGAGTTCTTATGGGGCAGCTGATCA 183
QY 1059 AGAGGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGAGCAACCTGTATGCGAG 1118
Db 184 AGAGGCTTCTGAGTCCCGCATCTGCTTCTTAGAAGTATCTGAGCAACCTGTATGCGAG 243
QY 1119 CCAACCTCCAGGACAGCTTATCTACTGGGCTCAGAGCCCGAGCCCGCTGGG 1178

|||||
244 CCAACCTCCAGGACAGCTTATCTACTGGGCTTACAGAGCCCGAGCTTCTGGACCGCTGGG 303
1179 TCAGGAACAGGCAACCTCGACCAAGAGCAGGTCCCGCTTCTGAAGATAGAAGAACAC 1238
304 TCAGGAACAGGCAACCTCGACCAAGAGCAGGTCCCGCTTCTGAAGATAGAAGAACAC 363
1239 CCTCAACAGCGCGCAGATAGCTGAGTTTTTTCACCGATCTTCTGACGTGGCTCCACTGG 1298
364 CCTCAACAGCGCGCAGATAGCTGAGTTTTTTCACCGATCTTCTGACGTGGCTCCACTGG 423
1299 CCAGGCGCACACATAATTTCTCGGTGGCTCCATTTCCACAAGAGTACTTTTCAGCATC 1358
424 CCAGGCGCACACATAATTTCTCGGTGGCTCCATTTCCACAAGAGTACTTTTCAGCATC 483
1359 CTCACTTCTCACATGGAAGCTACCACTCTGGATGGGCTCCCGCAACAGCTGACACCT 1418
484 CTCACTTCTCACATGGAAGCTACCACTCTGGATGGGCTCCCGCAACAGCTGACACCT 543
1419 CGAGGCGCGCAGCTGCTGCTGATGTTGGTACCTCACTCAATACAGCTGCTGCGCC 1478
544 CGAGGCGCGCAGCTGCTGCTGATGTTGGTACCTCACTCAATACAGCTGCTGCGCC 603
1479 TCCTGAGCGCCACTCGGAGCGTGACCT 1506
604 TCCTGCAACCCACTCAGGAGTGAACT 631

RESULT 9
BG696408 935 bp mRNA linear EST 07-MAY-2001
LOCUS 602659504F1 NCI_CGAP_Skn3 Homo sapiens cDNA clone IMAGE:4802713 5',
DEFINITION mRNA sequence.
ACCESSION BG696408
VERSION BG696408.1 GI:13961522
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 935)
JOURNAL NIH-MGC http://mgc.nci.nih.gov/.
COMMENT National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished (1999)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-re@mail.nih.gov
Tissue Procurement: James Cleaver, M.D.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA
Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: LLAM10697 row: g column: 02
High quality sequence stop: 707.
FEATURES
Location/Qualifiers
1..935
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4802713"
/lab_host="DH10B (T1 phage-resistant)"
/clone_lib="NCI_CGAP_Skn3"
/note="Organ: skin; Vector: pCMV-SPORT6; Site_1: NotI;
Site_2: SalI; Cloned unidirectionally. Primer: Oligo dr.
Average insert size 1.5kb. Library constructed by Life
Technologies. Note: this is a NCI_CGAP Library."

ORIGIN
Query Match 27.0%; Score 594; DB 12; Length 935;
Best Local Similarity 86.8%; Pred. No. 2.4e-108;
Matches 799; Conservative 0; Mismatches 65; Indels 56; Gaps 11;

```

1062 GGCTTCTCAGTCCCGCATCTGCTTTCTTAGAGGTATCTGGAGCAACCTGTATGACGCCA 1121  
 1 GGCTTCTCAGTCCCGCATCTGCTTTCTTAGAGGTATCTGGAGCAACCTGTATGACGCCA 60  
 1122 ACTCTCAGACAGCTTATCTAGTGGCTCAGAGCCAGCAGTCTGGAGCCGTGGGTCA 1181  
 61 ACTCTCAGACAGCTTATCTAGTGGCTCAGAGCCAGCAGTCTGGAGCCGTGGGTCA 120  
 1182 GGAAACAGCCCACTTGGCAAGGAGCAGTCCCTCTCTGAAGATAGAGAACCACTCT 1241  
 121 GGAAACAGCCCACTTGGCAAGGAGCAGTCCCTCTCTGAAGATAGAGAACCACTCT 180  
 1242 CAACAGCCGCGAATAGTGTGATTTTACCGATCTTCTGAGTGTGCGTCCACTGGCCC 1301  
 181 CAACAGCCGCGAATAGTGTGATTTTACCGATCTTCTGAGTGTGCGTCCACTGGCCC 240  
 1302 AGGCCACACATAATTTCTCTGCTGCTCCATTTCCACAAAGACTACTTTGAGATCTCTC 1361  
 241 AGGCCACACATAATTTCTCTGCTGCTCCATTTCCACAAAGACTACTTTGAGATCTCTC 300  
 1362 ACTTCTCCACATGGAAGCTACCACTCTGGATGGGTCCCAACAGCTGACACCTCTGG 1421  
 301 ACTTCTCCACATGGAAGCTACCACTCTGGATGGGTCCCAACAGCTGACACCTCTGG 360  
 1422 AGCCCACTCTGCTGCTGATGTTGGTACCTCATCAATACCACTGCTGCTGCTCTCC 1481  
 361 AGCCCACTCTGCTGCTGATGTTGGTACCTCATCAATACCACTGCTGCTGCTCTCC 420  
 1482 TGCAGCCCACTCGGACGCTGACCTCATCTGATGGGTCCCAACAGCTGACACCTCTGG 1541  
 421 TGCAGCCCACTCGGACGCTGACCTCATCTGATGGGTCCCAACAGCTGACACCTCTGG 480  
 1542 TCCAGAGTGTGAGCTCTCTGGCCGGTCTTGCAGGAGCAGGGATCCGTTCCCAACCA 1601  
 481 TCCAGAGTGTGAGCTCTCTGGCCGGTCTTGCAGGAGCAGGGATCCGTTCCCAACCA 540  
 1602 TCTGCCAGCCCGGAGAGAGCAGC-TCAGGCTGGG-AGTGCCACACCTT--CTCCGAC 1657  
 541 TCTGCCAGCCCGGAGAGAGCAGC-TCAGGCTGGG-AGTGCCACACCTT--CTCCGAC 600  
 1658 CCCACCTGCCCGGAGCCCTCGGTGCTGACATTTTCTCTC----- 1698  
 601 ACCAACTGCCCGGAGCCCTGAGTGTGACATTTTCTCTCTGCTGAGCGACTCTCTCCG 660  
 1699 -----TGGGGTCCGCGGACACCCGAGGAGCGGCGAGCTG-GGGAGGT 1740  
 661 GGAGTACTCGGACCCCATGGGTCCGCGGACACCCGAGGAGCGGCGAGCTGAGGGAGT 720  
 1741 GAACCTG---TCTTCATCGACTCTCCCTACCACTA--CAGGAAGGTGACTACAGCCAG 1795  
 721 GAACCTGGAATCCATACGAGATCTCCCTACCAATAGCAGGAAGGTGACCTACAGACAG 780  
 1796 GAGGAGCTGGACAAAG---CTGCTCAGCTGACACATTTACAT--GTCTGACACACAGGA 1851  
 781 GAGGAGCTGGACAAAG---CTGCTCAGCTGACACATTTACAT--GTCTGACACACAGGA 840  
 1852 GCAGCTGCT-----GGAGGTCTGCGCAGGAGCTGAGCGGAGGC--GGCAGCGCAGGCC 1905  
 841 AGACACGCTGATGGAGGGAATGAGCAGGAGGGAACAGAGGAGGAGGAGGAGGAGGAGG 900  
 1906 CCATGATGCGCGGGCCCC 1925  
 901 ACATAGAAATGGCCGAGGCC 920

RESULT 10  
 BM906397  
 LOCUS  
 DEFINITION  
 AGENCOURT\_6620095 NIH\_MGC\_125 Homo sapiens cDNA clone IMAGE:5590352  
 5', mRNA sequence.  
 ACCESSION  
 BM906397  
 VERSION  
 BM906397.1 GI:19356776  
 EST.

SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 1149)  
 AUTHORS NIH-MGC http://mgi.nci.nih.gov/  
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
 JOURNAL Unpublished (1999)  
 COMMENT Contact: Robert Strausberg, Ph.D.  
 Email: cgabbs-remail.nih.gov  
 Tissue Procurement: Invitrogen  
 cDNA Library Preparation: Life Technologies, Inc.  
 DNA Sequencing by: Agencourt Bioscience Corporation  
 Clone distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 Plate: LLAM12364 row: i column: 09  
 High quality sequence stop: 568.  
 FEATURES  
 Location/Qualifiers  
 1..1149  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:5590352"  
 /lab\_host="DH10B"  
 /clone\_lib="NIH\_MGC\_125"  
 /note="Organ: ovary (pool of 3); Vector: pCMV-SPORT6;  
 Site 1: EcoRV (destroyed); Site 2: NotI; RNA source pool  
 of three ovaries, from females ranging in age from 38 to  
 49 yo. Library is oligo-dT primed and directionally cloned  
 (EcoRV site is destroyed upon cloning). Average insert  
 size 2.1 kb, insert size range 1-3.5 kb. Library is  
 normalized and enriched for full-length clones and was  
 constructed by C. Gruber (Invitrogen). Research Genetics  
 tracking code 036."  
 ORIGIN  
 Query Match 26.1%; Score 574.4; DB 12; Length 1149;  
 Best Local Similarity 92.0%; Pred. No. 2e-104;  
 Matches 653; Conservative 0; Mismatches 21; Indels 36; Gaps 3;  
 QY 1492 TCAGGAGCTGACCTCATCTGCTGATGGATCACTCACTCCAGGAGCTTCCAGAGCTT 1551  
 Db 11 TCAGGAGCTGACCTCATCTGCTGATGGATCACTCACTCCAGGAGCTTCCAGAGCTT 70  
 QY 1552 GCAGCTCTGCGGCGGTTCGCCAGGAGCAGGGATCCCGTTCCACCCATCTCGCCAG 1611  
 Db 71 GCAGCTCTGCGGCGGTTCGCCAGGAGCAGGGATCCCGTTCCACCCATCTCGCCAG 130  
 QY 1612 CCCGAGAGAGCTTCAGGCTCGGGAGTGCCACACCTTTCGAGACCCCACTGCCCCGG 1671  
 Db 131 CCCGAGAGAGCTTCAGGCTCGGGAGTGCCACACCTTTCGAGACCCCACTGCCCCGG 190  
 QY 1672 AGCCCTCTGCGGTGCTGACCTT-----TCTC 1698  
 Db 191 AGCCCTCTGCGGTGCTGACCTTCTCTGTCAGCAGCTCTCTCGGGAGTACTCGGCC 250  
 QY 1699 TGGGCTTCGCGGACACCCGAGGAGCGGAGTGGGAGGTGAACCTGCTTCATCGGA 1758  
 Db 251 TGGGCTTCGCGGACACCCGAGGAGCGGAGTGGGAGGTGAACCTGCTTCATCGGA 310  
 QY 1759 CTCTCCCTACCTACACGAGGTGACCTACAGCCAGGAGCAGTGGACAAAGCTGTGCA 1818  
 Db 311 CTCTCCCTACCTACACGAGGTGACCTACAGCCAGGAGCAGTGGACAAAGCTGTGCA 370  
 QY 1819 CTGACACATTAATGCTGCAACACAGGAGCAGCTGCTGAGAGCTTGGCCAGGC 1878  
 Db 371 CTGACACATTAATGCTGCAACACAGGAGCAGCTGCTGAGAGCTTGGCCAGGC 430  
 QY 1879 AGTGACGAGGAGCGGAGCGAGCGAGGCCCACTGATGCGGGGCCCTGACCCCTAAC 1938  
 Db 431 AGTGACGAGGAGCGGAGCGAGCGAGGCCCACTGATGCGGGGCCCTGACCCCTAAC 490



sequence that is located between the Not I site and the (AT)18 tail. The sequence tag for this library is CCGGTATACC. This library was created for the program, Gene Discovery in the Visual System, supported by National Eye Institute (NEI).  
TAG\_TISSUE=human fetal eye  
TAG\_LIB=UI-E-E01  
TAG\_SEQ=CGCGTATACC"

ORIGIN

Query Match 25.9%; Score 569.8; DB 13; Length 653;  
Best Local Similarity 94.8%; Pred. No. 1.7e-103;  
Matches 614; Conservative 0; Mismatches 2; Indels 33; Gaps 1;

1589 CCCTTCCACCCCATCTGCGCCAGCCGCGGAGAGAGAGCTCCAGCTCGGGAGTGGCACC 1648  
653 CCGTTCACCCCATCTGCGCCAGCCGCGGAGAGAGAGCTCCAGCTCGGGAGTGGCACC 594  
1649 TTCTCCAGCCCATCTGCGCCAGCCGCGGAGAGAGAGCTCCAGCTCGGGAGTGGCACC 1693  
593 TTCTCCAGCCCATCTGCGCCAGCCGCGGAGAGAGAGCTCCAGCTCGGGAGTGGCACC 534  
1694 -----TCTCTGGGGTCTCGGCGGACACCCGAGGAGGCGGAGTGGCACC 474  
533 TCCTTCGGGAGTACTCGGCGGCGGAGAGAGAGCTCCAGCTCGGGAGTGGCACC 1735  
1736 GAGGTGAACCTGTCTTCATCGGACTCTCCCTACCTACAGAGAGTGGCACCAGCAG 1795  
473 GAGGTGAACCTGTCTTCATCGGACTCTCCCTACCTACAGAGAGTGGCACCAGCAG 414  
1796 GAGGACGTGACAGAGTCTGACCTGACATTCATTAATGTCTCAACAACAGCAGAGCAG 1855  
413 GAGGACGTGACAGAGTCTGACCTGACATTCATTAATGTCTCAACAACAGCAGAGCAG 354  
1856 CTGCTGGAGGCTCTGCGCCAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAG 1915  
353 CTGCTGGAGGCTCTGCGCCAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAG 294  
1916 CCGGGGCGCTGCGCCAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 1975  
293 CCGGGGCGCTGCGCCAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 234  
1976 ACTGTATCATGAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2035  
233 ACTGTATCATGAGGCTGAGGAGGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 174  
2036 CTGAGGGCTGGAGCTCCCTTGGCGCTCAGCAGTTCAGTGGGTAAAGGAGGCGCAAGCC 2095  
173 CTGAGGGCTGGAGCTCCCTTGGCGCTCAGCAGTTCAGTGGGTAAAGGAGGCGCAAGCC 114  
2096 CATTGTGTATATACCCAAACCCCGGCGCTGCGCTGCTTCCCTTCTGGGCTACCTT 2155  
113 CATTGTGTATATACCCAAACCCCGGCGCTGCGCTGCTTCCCTTCTGGGCTACCTT 54  
2156 GAGTGTGGAGCACTTGATATCATCAGAGCTCATACAAAAA 2204  
53 GAGTGTGGAGCACTTGATATCATCAGAGCTCATACAAAAA 5

RESULT 12

BQ887656

LOCUS

DEFINITION

5', mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

BQ887656 922 bp mRNA linear EST 16-AUG-2002  
AGENCY: NIH\_MGC\_129 Mus musculus cDNA clone IMAGE:6312998  
BQ887656  
BQ887656.1 GI:22279670  
EST.  
Mus musculus (house mouse)  
Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 922)  
NIH-MGC <http://mgc.nci.nih.gov/>.

1939 TCTCATTATTCCTCGCTGCTGAGTTGAGGTTGAGGAGTGTCTCATCAGCAGTGTCTCAG 1998  
491 TCTCATTATTCCTCGCTGCTGAGTTGAGGTTGAGGAGTGTCTCATCAGCAGTGTCTCAG 550  
1999 AGCTCGGGCTCAGGTGGCACTGTCACAGGCTCCAGGCTGAGGCTGGGAGTCCCTTGC 2058  
551 AGCTCGGGCTCAGGTGGCACTGTCACAGGCTCCAGGCTGAGGCTGGGAGTCCCTTGC 610  
2059 GCTCAGCAGTGTGAGTGGGTTAAGAGGCGCAAGCCCA-TTTGTGTAAATCACCRAAAC 2117  
611 GCCCAGCAGTGTGAGGCGGTTAAGAGGCGCGGAGGCGGAGGCGGAGTGTGAGTGG 670  
2118 CCCCAGCAGTGTGAGTGGGTTTCCCTTACAGGCGGAGGCGGAGTGTGAGTGG 2165  
671 CCCCAGCAGTGTGAGTGGGTTTCCCTTACAGGCGGAGGCGGAGTGTGAGTGG 720

RESULT 11

BU742347/c

LOCUS

DEFINITION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

MEDLINE

PUBMED

COMMENT

BU742347 653 bp mRNA linear EST 10-OCT-2002  
UI-E-E01-ajc-i-21-0-UI.s1 UI-E-E01 Homo sapiens cDNA clone  
BU742347  
BU742347.1 GI:23688719  
EST.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 653)  
Bonald, M.F., Lennon, G. and Soares, M.B.  
Normalization and subtraction: two approaches to facilitate gene  
discovery  
Genome Res. 6 (9), 791-806 (1996)  
97044477  
8889548  
Contact: Soares, MB  
Coordinated Laboratory for Computational Genomics  
University of Iowa  
375 Newton Road, 4156 MEBRF, Iowa City, IA 52242, USA  
Tel: 319 335 8250  
Fax: 319 335 9565  
Email: bento-soares@uiowa.edu  
Tissue Procurement: Dr. Gregg Hageman  
cDNA Library Preparation: Dr. M. Bento Soares, University of Iowa  
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa  
Clone Distribution: Researchers may obtain clones from Research  
Genetics (www.resgen.com).  
Seq primer: M13 FORWARD  
PolyA=yes.

FEATURES

source

1..653  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="UI-E-E01-ajc-i-21-0-UI"  
/tissue\_type="fetal eye"  
/dev\_stage="fetal"  
/lab\_host="PH10B (Life Technologies) (T1 phage resistant)"  
/clone\_lib="UI-E-E01"  
/note="Organ: eye; Vector: p7T3-Pac (Pharmacia) with a  
modified polylinker; Site 1: EcoR I; Site 2: Not I;  
UI-E-E01 is a normalized cDNA library containing the  
following tissue(s): fetal eye. The library was  
constructed according to Bonald, Lennon and Soares,  
Genome Research, 6:791-806, 1996. First strand cDNA  
synthesis was primed with an oligo-dT primer containing a  
Not I site. Double stranded cDNA was ligated to an EcoR I  
adaptor, digested with Not I, and cloned directionally  
into p7T3-Pac vector. The oligonucleotide used to prime  
the synthesis of first-strand cDNA contains a library tag



TITLE  
JOURNAL  
COMMENT

National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.  
Email: egapbs-x@mail.nih.gov  
cDNA Library Preparation: Susan L. Sullivan, PhD  
Tissue Procurement: Susan L. Sullivan, PhD  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Agencourt Bioscience Corporation  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at:  
http://image.llnl.gov  
Plate: LLAM13739 row: g column: 15  
High quality sequence stop: 622.

FEATURES  
source  
1. .922  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10090"  
/clone="IMAGE:631298"  
/lab\_host="DHI0B (phage-resistant)"  
/clone\_lib="NIH\_MGC\_129"  
/note="Organ: olfactory epithelium; Vector: pCMV-SPORT6.1; Site 1: EcoRV; Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 2.2 Kb. Constructed by ResGen, Invitrogen Corp. Note: this is a NIH\_MGC Library."

ORIGIN

Query Match 25.5%; Score 562; DB 13; Length 922;  
Best Local Similarity 83.6%; Pred. No. 6.2e-102;  
Matches 637; Conservative 0; Mismatches 125; Indels 0; Gaps 0;

QY 610 CACCTGGGCTTGGCCAACTTTATGAGCACCAGAGTGTCTCAGAAGGACCTGGCAGG 669  
DB |||  
2 CACAGAAGACCTGGCCAACTCTATGAGCACCAGAGTGTCTGCGAGAAGACCTGGCAGG 61  
QY 670 GCCCACTGAGTGTCTGAGACCCAGGTGACCAAGAACAAAGCTGGGTGTCTGGCCCCAG 729  
DB |||  
62 GCCCACTGAGTGTCTGAGACACAGGTGACCAAGAACAAAGCTGGGTGTCTGGCCCCAG 121  
QY 730 CCAGCTGCAGCGGTACCGGCAGGAGCTGGCCGAGCTGCCCTGGGTACCAAGCTG 789  
DB |||  
122 CCAACTTTGGCGGTACCGGCAGAGCTGGCTGAGGTGTCTGCCCTGGGGCACCAACCTG 181  
QY 790 CTTACCAACCTTGGGCGCTCATCAAGAGCGCTGTCTGATGATGAGCCCCATGATCA 849  
DB |||  
182 CTTACCAACCTTGGGCGCTCATTAATGAGCGCTTGTCTGCGACAGACCCCATGAACA 241  
QY 850 CAAGCTCTCAGATCAACGGGAGCGCTGAGTATGCGCCAGAACCTCTGCGCCATCTACTG 909  
DB |||  
242 CAAGCTCTCAGATCAACGGGAGCGCTGAGTATGCGCCAGAACCTCTGCGCCATCTACTG 301  
QY 910 TGCCCTCAACACCAAGGCGCAGAGCTGCACCACTTTTGAATTTGGGAGTGGTGGAGTT 969  
DB |||  
302 TGCCCTCAACAGCAGGAGCGGCTGAGTACCTTTGACCTTTGGGAGTGGTGGAGTT 361  
QY 970 CTCTCCCTACAGGTGGCTTCCCAAGTACGGGCGCTTATCCCTCTGAGCTTTGG 1029  
DB |||  
362 CTCTCCATATGAAGTGGCTTCCCAAGTATGAGCGCTTATCCCTCTGAGCTTTGG 421  
QY 1030 CTCCGAGTTCTTATGGGCGAGCTGATGAAGAGGCTTCTGAGTCCCGCATCTGCTTT 1089  
DB |||  
422 CTCCGAGTTCTTATGGGCGGCTGGTGAAGAGGCTTCCCGAGTCCCGCATCTGCTTCT 481  
QY 1090 AGAAGGTATCTGAGCAACCTGTATGACGCAACCTCCAGACAGCTTATATCTGGGCTC 1149  
DB |||  
482 GGAAGGATCTGGAGCAATCTGTTTGGCGCAGGCTCCAGACAGCTTGTACTGGTCTC 541  
QY 1150 AGACCCAGCAGTTCTGGGACCGCTGGGTGAGAACCGAGCCCACTGGACAAAGGAGCA 1209  
DB |||  
542 AGAAGCCAGCAGTTCTGGGACCGCTGGGCGCAGGATCAGGCGCAACCTGGACAAAGAGCA 601  
QY 1210 GGTCCCCCTTCTGAAGATAGNAGAACCCCTCAACAGCGCGGAGAAATAGCTGAGTTT 1269

Db 602 GGTCCCCCACTCTGAGATAGCAGAGCCACCGACAATGGCTGGCAAGATCGCCGAGCTCT 661  
QY 1270 CACGATCTTCTGACGTGGCTCCACTGGCCCGCCAGGCCACACATATTTCTCGCTGGCT 1329  
Db 662 CACTGACCTCTGACAAAGCGTCCCTCGCCCGCCAGCCACCACTTCAGCGAGGCT 721  
QY 1330 CCATTTCACAAAGACTACTTTTCAGATCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1371  
Db |||  
722 CCATTTCACAAAGGACTATTTTCAGAAACTCTCAACTCTC 763

RESULT 13  
AW959903  
LOCUS  
DEFINITION AW959903 666 bp mRNA linear EST 01-JUN-2000  
ACCESSION AW959903  
VERSION AW959903.1 GI:8149587  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 666)  
AUTHORS Hegde,P., Qi,R., Abernathy,K., Dharap,S., Gaspard,R., Gay,C.,  
Holt,I.E., Saeed,A.I., Sharov,V., Lee,N.H., Yeatman,T.J. and  
Quackenbush,J.  
TITLE Assessment of gene expression patterns in a model of colon tumor  
metastasis using a 19,200 element cDNA microarray  
JOURNAL Unpublished (2000)  
COMMENT Contact: John Quackenbush  
The Institute for Genomic Research  
9712 Medical Center Dr., Rockville, MD 20850, USA  
Tel: 301 838 3528  
Fax: 301 838 0208  
Email: johnq@tigr.org  
Plate: 139  
Seq primer: Reverse.  
Location/Qualifiers  
1. .666  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone\_lib="MAGE resequences, MAGP"  
/note="Vector: pBluescriptSKm"

ORIGIN

Query Match 25.3%; Score 558.2; DB 10; Length 666;  
Best Local Similarity 92.0%; Pred. No. 3.6e-101;  
Matches 612; Conservative 0; Mismatches 20; Indels 33; Gaps 1;

QY 1275 ATCTTCTGACGTGGCTCCACTGGCCCGCCAGGCCACACATAATTTCTCGCTGGCTCTCAAT 1334  
Db 1 ATCTTCTGACGTGGCTCCACTGGCCCGCCAGGCCACACATAATTTCTCGCTGGCTCTCAAT 60  
QY 1335 TCCCAAGAGACTTTTCAGCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1394  
Db 61 TCCCAAGAGACTTTTCAGCATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 120  
QY 1395 GGCTTCCCAACCCAGCTGACACCTCGGAGCCCACTGTGCTGCTGCTGCTGCTGCTGCTACC 1454  
Db 121 GGCTTCCCAACCCAGCTGACACCTCGGAGCCCACTGTGCTGCTGCTGCTGCTGCTGCTACC 180  
QY 1455 TCATCAATACAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1514  
Db 181 TCATCAATACAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240  
QY 1515 CATTGGACTCAACCTCCAGGAGCTTTCAGAGTTCAGAGTTCAGAGTTCAGAGTTCAGAGTTCAG 1574  
Db 241 CATTGGACTCAACCTCCAGGAGCTTTCAGAGTTCAGAGTTCAGAGTTCAGAGTTCAGAGTTCAG 300  
QY 1575 AGGAGCAGGGGATCCCTTCCCACTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1634

301 AGGAGCAGGGGATCCCGTTCCACCATCTGCGCCAGCCCGGAGAGCAGCTCAGCCCTC 360  
 1635 GGAAGTGCACACATCTCTCGGACCCACCTGCGCCGAGCCCTGCGGTCTGCACTTTT 1694  
 361 GGAAGTGCACACATCTCTCGGACCCACCTGCGCCGAGCCCTGCGGTCTGCACTTTT 420  
 1695 C-----CTCTGGGTCCGGCGGACACCCGAGG 1721  
 421 CTCTGTTCAGCGACTCTTTCGCGAGTACTGCGGCCCTTGGTCCGCGACACCCGAGG 480  
 1722 AGCGCGAGCTGGGAGGTGAACCTGTCTTATCGGACTCTCCCTACCACTACACGAAG 1781  
 481 AGCGCGAGCTGGGAGGTGAACCTGTCTTATCGGACTCTCCCTACCACTACACGAAG 540  
 1782 TGACCTACACCGAGGAGCTGTGACCAAGCTGTGCACTGACATTAATCTTCGCA 1841  
 541 TGACCTACACCGAGGAGCTGTGACCAAGCTGTGCACTGACATTAATCTTCGCG 600  
 1842 ACAACAGGAGCAGCTGTGAGGCTCTGCGCCAGGAGTGCAGCGGAGCGCGAGGCGCA 1901  
 601 ACAACAGGAGCAANTGCTTGAAGCTCTGCGCCAGGAGTGCAGCGGAGCGCGAGGCGCA 660  
 1902 GGCCC 1906  
 661 GGCCC 665

CA319426 810 bp mRNA linear EST 09-JUL-2003  
 UI-M-FW0-cbz-n-15-0-UI-r1 NIH\_BMAP\_FW0 Mus musculus cDNA clone  
 IMAGE:6816688 5', mRNA sequence.  
 CA319426  
 CA319426.1 GI:24537550  
 EST.  
 Mus musculus (house mouse)  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 810)  
 NIH-MGC http://mgi.nci.nih.gov/.  
 National Institutes of Health, Mammalian Gene Collection (MGC)  
 Unpublished (1999)  
 Contact: Robert Strausberg, Ph.D.  
 Email: cgaabs-r@mail.nih.gov  
 Tissue Procurement: Dr. Jim Lin, University of Iowa  
 cDNA Library preparation: Dr. M. Bento Soares, University of Iowa  
 cDNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa  
 DNA Sequencing by: Dr. M. Bento Soares, University of Iowa  
 Clone Distribution: MGC clone distribution information can be  
 found through the I.M.A.G.E. Consortium/LLNL at:  
 http://image.llnl.gov  
 This clone was contributed by the Brain Molecular Anatomy Project  
 (BMAP)

Seq primer: pYX-5.  
 Location/Qualifiers  
 1..810  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /strain="C57BL/6"  
 /db\_xref="taxon:10090"  
 /clone="IMAGE:6816688"  
 /tissue\_type="whole brain"  
 /dev\_stage="embryo.13.5,14.5,16.5,17.5dpc"  
 /lab\_host="PHIOB (71 phage resistant)"  
 /clone\_lib="NIH BMAP FW0"  
 /note="Organ: Brain; Vector: pYX-Asc; Site1: Ecor I;  
 Site 2: Not I; The library was constructed according  
 Bonaudo, Lennon and Soares, Genome Research, 6:791-806,  
 1996. Denatured RNA was size fractionated on a 1% agarose  
 gel. First strand cDNA synthesis was primed with oligo-dT  
 primer containing a Not I site. Double strand cDNA was  
 size selected according to mRNA size fraction, ligated

with Ecor I adaptor, digested with NotI and then cloned  
 directionally into pYX-Asc vector. The library tag  
 sequence located between the Not I site and the polyA tail  
 is AGGAGACAG. This library was created for the University  
 of Iowa Brain Anatomy Project (BMAP): 'Gene Discovery in the  
 Developing Mouse Nervous System', supported by National  
 Institute of Mental Health (NIMH), Hemin Chin, Ph.D.,  
 program coordinator."

ORIGIN

Query Match	25.2%;	Score	556.2;	DB 14;	Length	810;			
Best Local Similarity	82.4%;	Pred. No.	9e-101;						
Matches	672;	Conservative	0;	Mismatches	138;	Indels	6;	Gaps	3;

709 GCTGGGTGTCTGCTGGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGTGGCCGAGCGTGC 768  
 Db 1 GCTGGGTGTCTGCTGGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGTGGCCGAGCGTGC 60  
 769 CCGTGGGTGTCTGCTGGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGTGGCCGAGCGTGC 828  
 Db 61 TCGCTGGGTGTCTGCTGGCCGCCAGCCAGCTGCAGCGGTACCGGAGGAGTGGCCGAGCGTGC 120  
 829 GCATGATGAGCCCATCATCATCAAGCTCTCAGATCAACGCGGAGGAGTGGCCGAGCGTGC 888  
 Db 121 GCAGCAGAGCCCATCATCATCAAGCTCTCAGATCAACGCGGAGGAGTGGCCGAGCGTGC 180  
 889 GAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 948  
 Db 181 GAACCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 240  
 949 ATTTGGGAGTGTGCGAGTGTCTCTCCCTAGAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 1008  
 Db 241 CTTTGGGAGTGTGCGAGTGTCTCTCCATATGAAGTGTGCTGCTGCTGCTGCTGCTGCTGCT 300  
 1009 CATCCCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1068  
 Db 301 CATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 360  
 1069 TGAGTCCCGCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1128  
 Db 361 CGAGTCCCGCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 420  
 1129 GCAGCTTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1188  
 Db 421 AGACAGCTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 480  
 1189 GGCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1248  
 Db 481 GGCACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540  
 1249 CGGCAAGATAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1308  
 Db 541 TGGCAGGATGCGCGAGCTCTTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 600  
 1309 ACATTAATTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1368  
 Db 601 CCACAACTTACGCGAGGCTCCATTTCCAAAGGAGTATTTCCAGAACTCTCACTTCTC 660  
 1369 CACATGGAAGCTTACCATCTCTGATGGGCTCCCGAACCAAGCTGACACCTCTGGAGCCCA 1428  
 Db 661 TGCCTGGAAGCTTCCAACTTGAAGGCTCCCGAACCAAGCTGACACCTCTGGAGCCCA 719  
 1429 CTTGTGCT 1488  
 Db 720 CTTGTGCT 777  
 1489 CACTCGGAGCTGGAGCTCATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1524  
 Db 778 CAC---GGGATGTGAGTCTATCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 810

RESULT 15  
 BF769253/c

FEATURES  
 source

LOCUS B5769253 579 bp mRNA linear EST 12-JAN-2001  
 DEFINITION QV3-IT0008-111100-413-c05 IT0008 Homo sapiens cDNA, mRNA sequence.  
 ACCESSION BF769253  
 VERSION BF769253.1 GI:12117153  
 KEYWORDS EST.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,  
 Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.,  
 Goldman, G.H., Carvalho, A.F., Matsukuma, A., Baia, G.S., Simpson, D.H.,  
 Brunstein, A., deOliveira, P.S., Bucher, P., Jongeneel, C.V.,  
 O'Hare, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
 Simpson, A.J.  
 TITLE Shotgun sequencing of the human transcriptome with ORF expressed  
 sequence tags  
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)  
 MEDLINE 20202663  
 PUBMED 10737800  
 COMMENT Contact: Simpson A.J.G.  
 Laboratory of Cancer Genetics  
 Ludwig Institute for Cancer Research  
 Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,  
 Brazil  
 Tel: +55-11-2704922  
 Fax: +55-11-2707001  
 Email: asimpson@ludwig.org.br  
 This sequence was derived from the FAPESP/LICR Human Cancer Genome  
 Project. This entry can be seen in the following URL  
 (http://www.ludwig.org.br/scripts/gethtml2.pl?tl=QV3&t2=QV3-IT0008-  
 111100-413-c05&t3=2000-11-11&t4=1)  
 Seq primer: puc 18 forward  
 High quality sequence start: 9  
 High quality sequence stop: 558.  
 Location/Qualifiers  
 1..579  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /dev\_stage="Adult"  
 /clone\_lib="IT0008"  
 /note="Organ: epid tumor; Vector: puc18; Site 1: SmaI;  
 Site 2: SmaI; A mini-library was made by cloning products  
 derived from ORESTES PCR (U.S. Letters Patent application  
 No. 196,716 - Ludwig Institute for Cancer Research)  
 profiles into the pUC 18 vector. Reverse transcription of  
 tissue mRNA and cDNA amplification were performed under  
 low stringency conditions."

Query Match 23.3%; Score 514.4; DB 10; Length 579;  
 Best Local Similarity 96.2%; Pred. No. 2.1e-92;  
 Matches 560; Conservative 0; Mismatches 16; Indels 6; Gaps 3;

QY 723 CCCCAGCCAGCTCAGCGGTACCGGAGAGCTGGCGAGCGTCCCGCTTGGGCTACC 782  
 DB 579 CCCCAGCCATCTGCATCTGTTACCGGAGAGCTGTCGAGCGTCCCGCTTGGGCTACC 520  
 QY 783 CAGAGCTGTTACCAACCTGTGGGCGCTTCATCAACGAGGCGCTGTCATGATGAGCCCC 842  
 DB 519 CAGAGCTGTTACCAACCTGTGGGCGCTTCATCAACGAGGCGCTGTCATGATGAGCCCC 460  
 QY 843 ATGATCAAGAGCTCTCAGATCAACGAGGCGCTGAGTCATGGCCAGAACCTCTGGCCCA 902  
 DB 459 ATGATCAAGAGCTCTCAGATCAACGAGGCGCTGAGTCATGGCCAGAACCTCTGGCCCA 400  
 QY 903 TCTACTGTGCCCTCAACACCAAGGAGAGCCCTGACCACTTTTGAATTTGGGAGTGGT 962  
 DB 399 TCTACTGTGCCCTCAACACCAAGGAGAGCCCTGACCACTTTTGAATTTGGGAGTGGT 340  
 QY 963 GCGAGTTCTCTCCCTACGAGTGGGTTCGCCAAGTACGGGGCGCTTCATCCCTCTGAGC 1022

339 GCAGTTCTCTCCCTACGAGTGGGTTCGCCAAGTACGGGGCGCTTCATCCCTCTGAGC 280  
 1023 TCTTTGGCTCCGAGTCTCTTTATGGGGCAGCTGATGAAGAGGCTTCTCTGAGTCCCGCATCT 1082  
 279 TCTTTGGCTCCGAGTCTCTTTATGGGGCATCTGATGAAGAGGCTTCTGAGTCCCGCATCT 220  
 1083 GCTTCTTAGAAGTATCTGGAGCAACCTGTATGAGCAACCTCCAGGACAGCTTATACT 1142  
 219 GCTTCTTAGAAGTATCTGGAGCAACCTGTATGAGCAACCTCCAGGACAGCTTATACT 160  
 1143 GGGCCTCAGAGCCCA-GCCAGTTCTGGGACCGTGGTACGAAACAGGCAACCTGGAC 1201  
 159 GGGCCTCAGAGCCCATGCCAGTTCTGGGACCGCTGGGTACGAAACAGGCAACCTGGAC 100  
 1202 AAGGAGCA-GGTCCCCCTTCTGAAGATAGAAGAACCACTCAACAGCGGCGAGATAGC 1260  
 99 AAGGACCAAGTCCCTCTTCTGAGATAGAGAACCACTCAACAGCGGCGAGATAGC 40  
 1261 TGAGTTTTCACCGATCTTCTGACGTTGCGTCCACTGGGCCA 1302  
 39 TGA----TTCAACGATCTTCTGACGTTGCGTCCACTCTACCTA 2

Search completed: October 7, 2004, 18:55:46  
 Job time : 6248.42 secs

This Page Blank (uspto)